	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
).	O
•	O
WARNINGS	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
).	O
•	O
WARNINGS	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
).	O
•	O
WARNINGS	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
and	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)].	O
Meloxicam	B-D000077239
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	O
(4.2)	O
and	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)].	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
reactions	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.4)].	O
WARNING:	O
CARDIOVASCULAR	O
and	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1)	O
Meloxicam	B-D000077239
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(4.2,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1)	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
higher	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
(5.2)	O
Elevated	O
liver	O
enzymes,	O
and	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen.	O
(5.3)	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment.	O
(5.4)	O
Fluid	O
retention	O
and	O
edema.	O
Should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
(5.5)	O
Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long-term	O
use.	O
Use	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists.	O
The	O
use	O
of	O
meloxicam	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
is	O
not	O
recommended	O
(5.6)	O
Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning.	O
Discontinue	O
meloxicam	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions.	O
(5.8)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years’	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
CONTRAINDICATIONS	O
(4.2)].	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)].	O
5.2	O
Gastrointestinal	O
(GI)	O
Effects	O
-	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
meloxicam,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs,	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Prescribe	O
NSAIDs,	O
including	O
meloxicam,	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
for	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore,	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration.	O
Patients	B-D010361
and	O
physicians	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
meloxicam	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
This	O
should	O
include	O
discontinuation	O
of	O
meloxicam	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
For	O
high-risk	O
patients,	O
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs.	O
5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs	O
including	O
meloxicam.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
In	O
addition,	O
rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure,	O
some	O
of	O
them	O
with	O
fatal	O
outcomes	O
have	O
been	O
reported	O
[see	O
ADVERSE	O
REACTIONS	O
(6.1)].	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
evaluated	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
meloxicam.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
meloxicam	O
[see	O
USE	O
IN	O
SPECIFIC	O
POPULATIONS	O
(8.6)	O
AND	O
CLINICAL	O
PHARMACOLOGY	O
(12.3)].	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
meloxicam,	O
can	O
lead	O
to	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
NSAIDs,	O
including	O
meloxicam,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
(BP)	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
Patients	B-D010361
taking	O
ACE	O
inhibitors,	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs.	O
Use	O
meloxicam	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention,	O
hypertension,	O
or	O
heart	O
failure.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs,	O
including	O
meloxicam,	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis,	O
renal	O
insufficiency,	O
acute	O
renal	O
failure,	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
and	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
A	O
pharmacokinetic	O
study	O
in	O
patients	O
with	O
mild	O
and	O
moderate	O
renal	O
impairment	O
revealed	O
that	O
no	O
dosage	O
adjustments	O
in	O
these	O
patient	O
populations	O
are	O
required.	O
Patients	B-D010361
with	O
severe	O
renal	O
impairment	O
have	O
not	O
been	O
studied.	O
The	O
use	O
of	O
meloxicam	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
with	O
CrCl	O
less	O
than	O
20	O
mL/min	O
is	O
not	O
recommended.	O
A	O
study	O
performed	O
in	O
patients	O
on	O
hemodialysis	O
revealed	O
that	O
although	O
overall	O
Cmax	O
was	O
diminished	O
in	O
this	O
population,	O
the	O
proportion	O
of	O
free	O
drug	O
not	O
bound	O
to	O
plasma	O
was	O
increased.	O
Therefore	O
it	O
is	O
recommended	O
that	O
meloxicam	O
dosage	O
in	O
this	O
population	O
not	O
exceed	O
7.5	O
mg	O
per	O
day.	O
Closely	O
monitor	O
the	O
renal	O
function	O
of	O
patients	O
with	O
impaired	O
renal	O
function	O
who	O
are	O
taking	O
meloxicam	O
[see	O
DOSAGE	O
AND	O
ADMINISTRATION	O
(2.1),	O
USE	O
IN	O
SPECIFIC	O
POPULATIONS	O
(8.7)	O
AND	O
CLINICAL	O
PHARMACOLOGY	O
(12.3)].	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
meloxicam	O
in	O
patients	O
with	O
considerable	O
dehydration.	O
It	O
is	O
advisable	O
to	O
rehydrate	O
patients	O
first	O
and	O
then	O
start	O
therapy	O
with	O
meloxicam.	O
Caution	O
is	O
also	O
recommended	O
in	O
patients	O
with	O
pre-existing	O
kidney	O
disease.	O
The	O
extent	O
to	O
which	O
metabolites	O
may	O
accumulate	O
in	O
patients	O
with	O
renal	O
impairment	O
has	O
not	O
been	O
studied	O
with	O
meloxicam.	O
Because	O
some	O
meloxicam	O
metabolites	O
are	O
excreted	O
by	O
the	O
kidney,	O
monitor	O
patients	O
with	O
significant	O
renal	O
impairment	O
closely.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
meloxicam.	O
Meloxicam	B-D000077239
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
CONTRAINDICATIONS	O
(4.1)	O
AND	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.12)].	O
Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Adverse	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
meloxicam,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
Starting	O
at	O
30	O
weeks	O
gestation,	O
avoid	O
the	O
use	O
of	O
meloxicam,	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[see	O
USE	O
IN	O
SPECIFIC	O
POPULATIONS	O
(8.1)	O
AND	O
PATIENT	O
COUNSELING	O
INFORMATION	O
(17.8)].	O
5.10	O
Corticosteroid	O
Treatment	O
Meloxicam	B-D000077239
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
disease	O
exacerbation.	O
Slowly	O
taper	O
patients	O
on	O
prolonged	O
corticosteroid	O
therapy	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
meloxicam	O
in	O
reducing	O
fever	O
and	O
inflammation	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.12	O
Hematological	O
Effects	O
Anemia	B-D000740
may	O
occur	O
in	O
patients	O
receiving	O
NSAIDs,	O
including	O
meloxicam.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
including	O
meloxicam,	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia.	O
NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration,	O
and	O
reversible.	O
Carefully	O
monitor	O
patients	O
treated	O
with	O
meloxicam	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alterations	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants.	O
5.13	O
Use	O
in	O
Patients	B-D010361
with	O
Pre-existing	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
meloxicam	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
pre-existing	O
asthma.	O
5.14	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
their	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
or	O
renal	O
disease	O
develop,	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.)	O
or	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
meloxicam	O
should	O
be	O
discontinued.	O
6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
(≥5%	O
and	O
greater	O
than	O
placebo)	O
adverse	O
events	O
in	O
adults	O
are	O
diarrhea,	O
upper	O
respiratory	O
tract	O
infections,	O
dyspepsia,	O
and	O
influenza-like	O
symptoms	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Zydus	O
Pharmaceuticals	O
(USA)	O
Inc.	O
at	O
1-877-993-8779	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Cardiovascular	O
thrombotic	O
events	O
[	O
see	O
BOXED	O
WARNINGS	O
AND	O
WARNING	O
AND	O
PRECAUTIONS	O
(5.1)]	O
Gastrointestinal	O
effects	O
[	O
see	O
BOXED	O
WARNING	O
AND	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)]	O
Hepatic	O
effects	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.3)]	O
Hypertension	B-D006973
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.4)]	O
Congestive	O
heart	O
failure	O
and	O
edema	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.5)]	O
Renal	O
effects	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.6)]	O
Anaphylactoid	O
reaction	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.7)]	O
Adverse	O
skin	O
reaction	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.8)]	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Adult	B-D000328
s	O
Osteoarthritis	B-D010003
and	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
The	O
meloxicam	O
Phase	O
2/3	O
clinical	O
trial	O
database	O
includes	O
10,122	O
OA	O
patients	O
and	O
1012	O
RA	O
patients	O
treated	O
with	O
meloxicam	O
7.5	O
mg/day,	O
3,505	O
OA	O
patients	O
and	O
1351	O
RA	O
patients	O
treated	O
with	O
meloxicam	O
15	O
mg/day.	O
Meloxicam	B-D000077239
at	O
these	O
doses	O
was	O
administered	O
to	O
661	O
patients	O
for	O
at	O
least	O
6	O
months	O
and	O
to	O
312	O
patients	O
for	O
at	O
least	O
one	O
year.	O
Approximately	O
10,500	O
of	O
these	O
patients	O
were	O
treated	O
in	O
ten	O
placebo-	O
and/or	O
active-controlled	O
osteoarthritis	O
trials	O
and	O
2363	O
of	O
these	O
patients	O
were	O
treated	O
in	O
ten	O
placebo-	O
and/or	O
active-controlled	O
rheumatoid	O
arthritis	O
trials.	O
Gastrointestinal	O
(GI)	O
adverse	O
events	O
were	O
the	O
most	O
frequently	O
reported	O
adverse	O
events	O
in	O
all	O
treatment	O
groups	O
across	O
meloxicam	O
trials.	O
A	O
12-week	O
multicenter,	O
double-blind,	O
randomized	O
trial	O
was	O
conducted	O
in	O
patients	O
with	O
osteoarthritis	O
of	O
the	O
knee	O
or	O
hip	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
meloxicam	O
with	O
placebo	O
and	O
with	O
an	O
active	O
control.	O
Two	O
12-week	O
multicenter,	O
double-blind,	O
randomized	O
trials	O
were	O
conducted	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
meloxicam	O
with	O
placebo.	O
Table	O
1a	O
depicts	O
adverse	O
events	O
that	O
occurred	O
in	O
≥2%	O
of	O
the	O
meloxicam	O
treatment	O
groups	O
in	O
a	O
12-week	O
placebo-	O
and	O
active-controlled	O
osteoarthritis	O
trial.	O
Table	O
1b	O
depicts	O
adverse	O
events	O
that	O
occurred	O
in	O
≥2%	O
of	O
the	O
meloxicam	O
treatment	O
groups	O
in	O
two	O
12-week	O
placebo-	O
controlled	O
rheumatoid	O
arthritis	O
trials.	O
Table	O
1aAdverse	O
Events	O
(%)	O
Occurring	O
in	O
≥	O
2%	O
of	O
Meloxicam	B-D000077239
Patients	B-D010361
in	O
a	O
12-Week	O
Osteoarthritis	B-D010003
Placebo-	O
and	O
Active-Controlled	O
Trial	O
Placebo	O
Meloxicam	B-D000077239
7	O
.	O
5	O
mg	O
daily	O
Meloxicam	B-D000077239
15	O
mg	O
daily	O
Diclofenac	B-D004008
100	O
mg	O
daily	O
1WHO	O
preferred	O
terms	O
edema,	O
edema	O
dependent,	O
edema	O
peripheral	O
and	O
edema	O
legs	O
combined	O
2WHO	O
preferred	O
terms	O
rash,	O
rash	O
erythematous	O
and	O
rash	O
maculo-papular	O
combined	O
No	O
.	O
of	O
Patients	B-D010361
157	O
154	O
156	O
153	O
Gastrointestinal	O
17.2	O
20.1	O
17.3	O
28.1	O
Abdominal	B-D015746
Pain	I-D015746
2.5	O
1.9	O
2.6	O
1.3	O
Diarrhea	B-D003967
3.8	O
7.8	O
3.2	O
9.2	O
Dyspepsia	B-D004415
4.5	O
4.5	O
4.5	O
6.5	O
Flatulence	B-D005414
4.5	O
3.2	O
3.2	O
3.9	O
Nausea	B-D009325
3.2	O
3.9	O
3.8	O
7.2	O
Body	O
as	O
a	O
Whole	O
Accident	O
Household	O
1.9	O
4.5	O
3.2	O
2.6	O
Edema	B-D004487
1	O
2.5	O
1.9	O
4.5	O
3.3	O
Fall	O
0.6	O
2.6	O
0.0	O
1.3	O
Influenza-Like	O
Symptoms	O
5.1	O
4.5	O
5.8	O
2.6	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
3.2	O
2.6	O
3.8	O
2.0	O
Headache	B-D006261
10.2	O
7.8	O
8.3	O
5.9	O
Respiratory	O
Pharyngitis	B-D010612
1.3	O
0.6	O
3.2	O
1.3	O
Upper	O
Respiratory	O
Tract	O
Infection	O
1.9	O
3.2	O
1.9	O
3.3	O
Skin	B-D012867
Rash2	O
2.5	O
2.6	O
0.6	O
2.0	O
Table	O
1bAdverse	O
Events	O
(%)	O
Occurring	O
in	O
≥	O
2%	O
of	O
MELOXICAM	O
Patients	B-D010361
in	O
two	O
12-Week	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Placebo	O
Controlled	O
Trials	O
Placebo	O
Meloxicam	B-D000077239
7	O
.	O
5	O
mg	O
daily	O
Meloxicam	B-D000077239
15	O
mg	O
daily	O
1MedDRA	O
high	O
level	O
term	O
(preferred	O
terms):	O
dyspeptic	O
signs	O
and	O
symptoms	O
(dyspepsia,	O
dyspepsia	O
aggravated,	O
eructation,	O
gastrointestinal	O
irritation),	O
upper	O
respiratory	O
tract	O
infections-pathogen	O
unspecified	O
(laryngitis	O
NOS,	O
pharyngitis	O
NOS,	O
sinusitis	O
NOS),	O
joint	O
related	O
signs	O
and	O
symptoms	O
(arthralgia,	O
arthralgia	O
aggravated,	O
joint	O
crepitation,	O
joint	O
effusion,	O
joint	O
swelling)	O
2MedDRA	O
preferred	O
term:	O
nausea,	O
abdominal	O
pain	O
NOS,	O
influenza-like	O
illness,	O
headaches	O
NOS,	O
and	O
rash	O
NOS	O
No	O
.	O
of	O
Patients	B-D010361
469	O
481	O
477	O
Gastrointestinal	O
disorders	O
14.1	O
18.9	O
16.8	O
Abdominal	O
pain	O
NOS2	O
0.6	O
2.9	O
2.3	O
Dyspeptic	O
signs	O
and	O
symptoms1	O
3.8	O
5.8	O
4.0	O
Nausea	B-D009325
2	O
2.6	O
3.3	O
3.8	O
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
Influenza	O
like	O
illness2	O
2.1	O
2.9	O
2.3	O
Infection	O
and	O
infestations	O
Upper	O
respiratory	O
tract	O
infections-pathogen	O
class	O
unspecified1	O
4.1	O
7.0	O
6.5	O
Musculoskeletal	O
and	O
connective	O
tissue	O
disorders	O
Joint	O
related	O
signs	O
and	O
symptoms	O
1	O
1.9	O
1.5	O
2.3	O
Nervous	O
system	O
disorders	O
Headache	B-D006261
s	O
NOS2	O
6.4	O
6.4	O
5.5	O
Skin	B-D012867
and	O
subcutaneous	O
tissue	O
disorders	O
Rash	O
NOS2	O
1.7	O
1.0	O
2.1	O
The	O
adverse	O
events	O
that	O
occurred	O
with	O
meloxicam	O
in	O
≥2%	O
of	O
patients	O
treated	O
short-term	O
(4-6	O
weeks)	O
and	O
long-term	O
(6	O
months)	O
in	O
active-controlled	O
osteoarthritis	O
trials	O
are	O
presented	O
in	O
Table	O
2	O
Table	O
2Adverse	O
Events	O
(%)	O
Occurring	O
in	O
≥	O
2%	O
of	O
Meloxicam	B-D000077239
Patients	B-D010361
in	O
4	O
to	O
6	O
Weeksand	O
6	O
Month	O
Active-Controlled	O
Osteoarthritis	B-D010003
Trials	O
4	O
-	O
6	O
Weeks	O
Controlled	O
Trials	O
6	O
Month	O
Controlled	O
Trials	O
Meloxicam	B-D000077239
7	O
.	O
5	O
mg	O
daily	O
Meloxicam	B-D000077239
15	O
mg	O
daily	O
Meloxicam	B-D000077239
7	O
.	O
5	O
mg	O
daily	O
Meloxicam	B-D000077239
15	O
mg	O
daily	O
No	O
.	O
of	O
Patients	B-D010361
8955	O
256	O
169	O
306	O
Gastrointestinal	O
11.8	O
18.0	O
26.6	O
24.2	O
Abdominal	B-D015746
Pain	I-D015746
2.7	O
2.3	O
4.7	O
2.9	O
Constipation	B-D003248
0.8	O
1.2	O
1.8	O
2.6	O
Diarrhea	B-D003967
1.9	O
2.7	O
5.9	O
2.6	O
Dyspepsia	B-D004415
3.8	O
7.4	O
8.9	O
9.5	O
Flatulence	B-D005414
0.5	O
0.4	O
3.0	O
2.6	O
Nausea	B-D009325
2.4	O
4.7	O
4.7	O
7.2	O
Vomiting	B-D014839
0.6	O
0.8	O
1.8	O
2.6	O
Body	O
as	O
a	O
Whole	O
Accident	O
Household	O
0.0	O
0.0	O
0.6	O
2.9	O
Edema	B-D004487
WHO	O
preferred	O
terms	O
edema,	O
edema	O
dependent,	O
edema	O
peripheral,	O
and	O
edema	O
legs	O
combined	O
0.6	O
2.0	O
2.4	O
1.6	O
Pain	B-D010146
0.9	O
2.0	O
3.6	O
5.2	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
1.1	O
1.6	O
2.4	O
2.6	O
Headache	B-D006261
2.4	O
2.7	O
3.6	O
2.6	O
Hematologic	O
Anemia	B-D000740
0.1	O
0.0	O
4.1	O
2.9	O
Musculoskeletal	O
Arthralgia	B-D018771
0.5	O
0.0	O
5.3	O
1.3	O
Back	B-D001416
Pain	I-D001416
0.5	O
0.4	O
3.0	O
0.7	O
Psychiatric	O
Insomnia	O
0.4	O
0.0	O
3.6	O
1.6	O
Respiratory	O
Cough	B-D003371
ing	O
0.2	O
0.8	O
2.4	O
1.0	O
Upper	O
Respiratory	O
tract	O
Infection	O
0.2	O
0.0	O
8.3	O
7.5	O
Skin	B-D012867
Pruritus	B-D011537
0.4	O
1.2	O
2.4	O
0.0	O
RashWHO	O
preferred	O
terms	O
rash,	O
rash	O
erythematous,	O
and	O
rash	O
maculo-papular	O
combined	O
0.3	O
1.2	O
3.0	O
1.3	O
Urinary	O
Micturition	O
Frequency	O
0.1	O
0.4	O
2.4	O
1.3	O
Urinary	B-D014551
Tract	I-D014551
Infection	O
0.3	O
0.4	O
4.7	O
6.9	O
Higher	O
doses	O
of	O
meloxicam	O
(22.5	O
mg	O
and	O
greater)	O
have	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
GI	O
events;	O
therefore,	O
the	O
daily	O
dose	O
of	O
meloxicam	O
should	O
not	O
exceed	O
15	O
mg.	O
The	O
following	O
is	O
a	O
list	O
of	O
adverse	O
drug	O
reactions	O
occurring	O
in	O
<2%	O
of	O
patients	O
receiving	O
meloxicam	O
in	O
clinical	O
trials	O
involving	O
approximately	O
16,200	O
patients.	O
Body	O
as	O
a	O
Whole	O
allergic	O
reaction,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
malaise,	O
syncope,	O
weight	O
decrease,	O
weight	O
increase	O
Cardiovascular	O
angina	O
pectoris,	O
cardiac	O
failure,	O
hypertension,	O
hypotension,	O
myocardial	O
infarction,	O
vasculitis	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
convulsions,	O
paresthesia,	O
tremor,	O
vertigo	O
Gastrointestinal	O
colitis,	O
dry	O
mouth,	O
duodenal	O
ulcer,	O
eructation,	O
esophagitis,	O
gastric	O
ulcer,	O
gastritis,	O
gastroesophageal	O
reflux,	O
gastrointestinal	O
hemorrhage,	O
hematemesis,	O
hemorrhagic	O
duodenal	O
ulcer,	O
hemorrhagic	O
gastric	O
ulcer,	O
intestinal	O
perforation,	O
melena,	O
pancreatitis,	O
perforated	O
duodenal	O
ulcer,	O
perforated	O
gastric	O
ulcer,	O
stomatitis	O
ulcerative	O
Heart	B-D006339
Rate	I-D006339
and	O
Rhythm	O
arrhythmia,	O
palpitation,	O
tachycardia	O
Hematologic	O
leukopenia,	O
purpura,	O
thrombocytopenia	O
Liver	B-D008099
and	O
Biliary	O
System	O
ALT	O
increased,	O
AST	O
increased,	O
bilirubinemia,	O
GGT	O
increased,	O
hepatitis	O
Metabolic	O
and	O
Nutritional	O
dehydration	O
Psychiatric	O
abnormal	O
dreaming,	O
anxiety,	O
appetite	O
increased,	O
confusion,	O
depression,	O
nervousness,	O
somnolence	O
Respiratory	O
asthma,	O
bronchospasm,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
alopecia,	O
angioedema,	O
bullous	O
eruption,	O
photosensitivity	O
reaction,	O
pruritus,	O
sweating	O
increased,	O
urticaria	O
Special	O
Senses	O
abnormal	O
vision,	O
conjunctivitis,	O
taste	O
perversion,	O
tinnitus	O
Urinary	O
System	O
albuminuria,	O
BUN	O
increased,	O
creatinine	O
increased,	O
hematuria,	O
renal	O
failure	O
6.2	O
Post	O
Marketing	B-D040541
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
meloxicam.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Decisions	O
about	O
whether	O
to	O
include	O
an	O
adverse	O
event	O
from	O
spontaneous	O
reports	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
event,	O
(2)	O
number	O
of	O
reports,	O
or	O
(3)	O
strength	O
of	O
causal	O
relationship	O
to	O
the	O
drug.	O
Adverse	O
reactions	O
reported	O
in	O
worldwide	O
post	O
marketing	O
experience	O
or	O
the	O
literature	O
include:	O
acute	O
urinary	O
retention;	O
agranulocytosis;	O
alterations	O
in	O
mood	O
(such	O
as	O
mood	O
elevation);	O
anaphylactoid	O
reactions	O
including	O
shock;	O
erythema	O
multiforme;	O
exfoliative	O
dermatitis;	O
interstitial	O
nephritis;	O
jaundice;	O
liver	O
failure;	O
Stevens-Johnson	O
syndrome,	O
and	O
toxic	O
epidermal	O
necrolysis.	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Delayed	O
healing	O
(5.1)	O
Cross-sensitivity	O
or	O
hypersensitivity	O
(5.2)	O
Increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
thrombocyte	O
aggregation	O
(5.3)	O
Cornea	B-D003315
l	O
effects	O
including	O
keratitis	O
(5.4)	O
5.1	O
Delayed	O
Healing	O
Topical	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
slow	O
or	O
delay	O
healing.	O
Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing.	O
Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
steroids	O
may	O
increase	O
the	O
potential	O
for	O
healing	O
problems.	O
5.2	O
Cross-Sensitivity	O
or	O
Hypersensitivity	B-D006967
There	O
is	O
the	O
potential	O
for	O
cross-sensitivity	O
to	O
acetylsalicylic	O
acid,	O
phenylacetic	B-C025136
acid	I-C025136
derivatives,	O
and	O
other	O
NSAIDs.	O
There	O
have	O
been	O
reports	O
of	O
bronchospasm	O
or	O
exacerbation	O
of	O
asthma	O
associated	O
with	O
the	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solution	O
in	O
patients	O
who	O
have	O
either	O
a	O
known	O
hypersensitivity	O
to	O
aspirin/non-steroidal	O
anti-inflammatory	O
drugs	O
or	O
a	O
past	O
medical	O
history	O
of	O
asthma.	O
Therefore,	O
caution	O
should	O
be	O
used	O
when	O
treating	O
individuals	O
who	O
have	O
previously	O
exhibited	O
sensitivities	O
to	O
these	O
drugs.	O
5.3	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
With	O
some	O
NSAIDs,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
thrombocyte	O
aggregation.	O
There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
tissues	O
(including	O
hyphemas)	O
in	O
conjunction	O
with	O
ocular	O
surgery.	O
It	O
is	O
recommended	O
that	O
ketorolac	O
tromethamine	O
ophthalmic	O
solution	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
known	O
bleeding	O
tendencies	O
or	O
who	O
are	O
receiving	O
other	O
medications,	O
which	O
may	O
prolong	O
bleeding	O
time.	O
5.4	O
Cornea	B-D003315
l	O
Effects	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
keratitis.	O
In	O
some	O
susceptible	O
patients,	O
continued	O
use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
epithelial	O
breakdown,	O
corneal	O
thinning,	O
corneal	O
erosion,	O
corneal	O
ulceration,	O
or	O
corneal	O
perforation.	O
These	O
events	O
may	O
be	O
sight	O
threatening.	O
Patients	B-D010361
with	O
evidence	O
of	O
corneal	O
epithelial	O
breakdown	O
should	O
immediately	O
discontinue	O
use	O
of	O
topical	O
NSAIDs	O
and	O
should	O
be	O
closely	O
monitored	O
for	O
corneal	O
health.	O
Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
patients	O
with	O
complicated	O
ocular	O
surgeries,	O
corneal	O
denervation,	O
corneal	O
epithelial	O
defects,	O
diabetes	O
mellitus,	O
ocular	O
surface	O
diseases	O
(e.g.,	O
dry	O
eye	O
syndrome),	O
rheumatoid	O
arthritis,	O
or	O
repeat	O
ocular	O
surgeries	O
within	O
a	O
short	O
period	O
of	O
time	O
may	O
be	O
at	O
increased	O
risk	O
for	O
corneal	O
adverse	O
events	O
which	O
may	O
become	O
sight	O
threatening.	O
Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients.	O
Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
1	O
day	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
post-surgery	O
may	O
increase	O
patient	O
risk	O
for	O
the	O
occurrence	O
and	O
severity	O
of	O
corneal	O
adverse	O
events.	O
5.5	O
Contact	O
Lens	O
Wear	O
Ketorolac	B-D020910
tromethamine	O
ophthalmic	O
solution	O
should	O
not	O
be	O
administered	O
while	O
wearing	O
contact	O
lenses.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
elsewhere	O
in	O
the	O
labeling:	O
Delayed	O
Healing	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
Cross-Sensitivity	O
or	O
Hypersensitivity	B-D006967
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
Cornea	B-D003315
l	O
Effects	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)]	O
The	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
1	O
-	O
5%	O
of	O
patients	O
included	O
conjunctival	O
hyperemia,	O
corneal	O
infiltrates,	O
headache,	O
ocular	O
edema	O
and	O
ocular	O
pain.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Allergan	O
at	O
1-800-678-1605	O
or	O
the	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
for	O
ketorolac	O
tromethamine	O
ophthalmic	O
solution	O
occurring	O
in	O
approximately	O
1	O
to	O
5%	O
of	O
the	O
overall	O
study	O
population	O
were	O
conjunctival	O
hyperemia,	O
corneal	O
infiltrates,	O
headache,	O
ocular	O
edema,	O
and	O
ocular	O
pain.	O
The	O
most	O
frequent	O
adverse	O
reactions	O
reported	O
with	O
the	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
have	O
been	O
transient	O
stinging	O
and	O
burning	O
on	O
instillation.	O
These	O
reactions	O
were	O
reported	O
by	O
up	O
to	O
40%	O
of	O
patients	O
participating	O
in	O
clinical	O
trials.	O
Other	O
adverse	O
reactions	O
occurring	O
approximately	O
in	O
1	O
to	O
10%	O
of	O
the	O
time	O
during	O
treatment	O
with	O
other	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
included	O
allergic	O
reactions,	O
corneal	O
edema,	O
iritis,	O
ocular	O
inflammation,	O
ocular	O
irritation,	O
superficial	O
keratitis,	O
and	O
superficial	O
ocular	O
infections.	O
Other	O
adverse	O
reactions	O
reported	O
rarely	O
with	O
the	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
included:	O
corneal	O
ulcer,	O
eye	O
dryness,	O
and	O
visual	O
disturbance	O
(blurry	O
vision).	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postmarketing	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
in	O
clinical	O
practice.	O
Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size,	O
estimates	O
of	O
frequency	O
cannot	O
be	O
made.	O
The	O
reactions,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
bronchospasm	O
or	O
exacerbation	O
of	O
asthma,	O
corneal	O
erosion,	O
corneal	O
perforation,	O
corneal	O
thinning	O
and	O
corneal	O
melt,	O
and	O
epithelial	O
breakdown	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
,	O
5.4	O
)].	O
CARDIOVASCULAR	O
RISK	O
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(	O
s	O
ee	O
WARNINGS	O
).	O
Naproxen	B-D009288
as	O
NAPRELAN	O
®	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(	O
s	O
ee	O
WARNINGS	O
).	O
GASTROINTESTINAL	O
RISK	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
people	O
are	O
at	O
greater	O
risk	O
for	O
ser	O
i	O
ous	O
gastrointestinal	O
events.	O
(	O
s	O
ee	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
As	O
with	O
all	O
drugs	O
in	O
this	O
class,	O
the	O
frequency	O
and	O
severity	O
of	O
adverse	O
events	O
depends	O
on	O
several	O
factors:	O
the	O
dose	O
of	O
the	O
drug	O
and	O
duration	O
of	O
treatment;	O
the	O
age,	O
the	O
sex,	O
physical	O
condition	O
of	O
the	O
patient;	O
any	O
concurrent	O
medical	O
diagnoses	O
or	O
individual	O
risk	O
factors.	O
The	O
following	O
adverse	O
reactions	O
are	O
divided	O
into	O
three	O
parts	O
based	O
on	O
frequency	O
and	O
whether	O
or	O
not	O
the	O
possibility	O
exists	O
of	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
these	O
adverse	O
events.	O
In	O
those	O
reactions	O
listed	O
as	O
“Probable	O
Causal	O
Relationship”	O
there	O
is	O
at	O
least	O
one	O
case	O
for	O
each	O
adverse	O
reaction	O
where	O
there	O
is	O
evidence	O
to	O
suggest	O
that	O
there	O
is	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
the	O
reported	O
event.	O
The	O
adverse	O
reactions	O
reported	O
were	O
based	O
on	O
the	O
results	O
from	O
two	O
double-blind	O
controlled	O
clinical	O
trials	O
of	O
three	O
months	O
duration	O
with	O
an	O
additional	O
nine	O
month	O
open-label	O
extension.	O
A	O
total	O
of	O
542	O
patients	O
received	O
NAPRELAN®	O
Tablets	B-D013607
either	O
in	O
the	O
double-blind	O
period	O
or	O
in	O
the	O
nine	O
month	O
open-label	O
extension.	O
Of	O
these	O
542	O
patients,	O
232	O
received	O
NAPRELAN®	O
Tablets	B-D013607
,	O
167	O
were	O
initially	O
treated	O
with	O
Naprosyn®***	O
and	O
143	O
were	O
initially	O
treated	O
with	O
placebo.	O
Adverse	O
reactions	O
reported	O
by	O
patients	O
who	O
received	O
NAPRELAN®	O
Tablets	B-D013607
are	O
shown	O
by	O
body	O
system.	O
Those	O
adverse	O
reactions	O
observed	O
with	O
naproxen	O
but	O
not	O
reported	O
in	O
controlled	O
trials	O
with	O
NAPRELAN®	O
Tablets	B-D013607
are	O
italicized.	O
The	O
most	O
frequent	O
adverse	O
events	O
from	O
the	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
were	O
headache	O
(15%),	O
followed	O
by	O
dyspepsia	O
(14%),	O
and	O
flu	O
syndrome	O
(10%).	O
The	O
incidence	O
of	O
other	O
adverse	O
events	O
occurring	O
in	O
3%	O
-	O
9%	O
of	O
the	O
patients	O
are	O
marked	O
with	O
an	O
asterisk.	O
Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.	O
INCIDENCE	O
GREATER	O
THAN	O
1%	O
(PROBABLE	O
CAUSAL	O
RELATIONSHIP)	O
Body	O
as	O
a	O
Whole—Pain	O
(back)*,	O
pain*,	O
infection*,	O
fever,	O
injury	O
(accident),	O
asthenia,	O
pain	O
chest,	O
headache	O
(15%),	O
flu	O
syndrome	O
(10%).	O
Gastrointestinal—Nausea*,	O
diarrhea*,	O
constipation*,	O
abdominal	O
pain*,	O
flatulence,	O
gastritis,	O
vomiting,	O
dysphagia,	O
dyspepsia	O
(14%),	O
heartburn*,	O
stomatitis.	O
Hematologic—Anemia,	O
ecchymosis.	O
Respiratory—Pharyngitis*,	O
rhinitis*,	O
sinusitis*,	O
bronchitis,	O
cough	O
increased.	O
Renal—Urinary	O
tract	O
infection*,	O
cystitis.	O
Dermatologic—Skin	O
rash*,	O
skin	O
eruptions*,	O
ecchymoses*,	O
purpura.	O
Metabolic	O
and	O
Nutrition—Peripheral	O
edema,	O
hyperglycemia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Dizziness,	O
paresthesia,	O
insomnia,	O
drowsiness*,	O
lightheadedness.	O
Cardiovascular—Hypertension,	O
edema*,	O
dyspnea*,	O
palpitations.	O
Musculoskeletal—Cramps	O
(leg),	O
myalgia,	O
arthralgia,	O
joint	O
disorder,	O
tendon	O
disorder.	O
Special	O
Senses—Tinnitus*,	O
hearing	O
disturbances,	O
visual	O
disturbances.	O
General—Thirst.	O
INCIDENCE	O
LESS	O
THAN	O
1%	O
(PROBABLE	O
CAUSAL	O
RELATIONSHIP)	O
Body	O
as	O
a	O
Whole—Abscess,	O
monilia,	O
neck	O
rigid,	O
pain	O
neck,	O
abdomen	O
enlarged,	O
carcinoma,	O
cellulitis,	O
edema	O
general,	O
LE	O
syndrome,	O
malaise,	O
mucous	O
membrane	O
disorder,	O
allergic	O
reaction,	O
pain	O
pelvic.	O
Gastrointestinal—Anorexia,	O
cholecystitis,	O
cholelithiasis,	O
eructation,	O
GI	O
hemorrhage,	O
rectal	O
hemorrhage,	O
stomatitis	O
aphthous,	O
stomatitis	O
ulcer,	O
ulcer	O
mouth,	O
ulcer	O
stomach,	O
periodontal	O
abscess,	O
cardiospasm,	O
colitis,	O
esophagitis,	O
gastroenteritis,	O
GI	O
disorder,	O
rectal	O
disorder,	O
tooth	O
disorder,	O
hepatosplenomegaly,	O
liver	O
function	O
abnormality,	O
melena,	O
ulcer	O
esophagus,	O
hematemesis,	O
jaundice,	O
pancreatitis,	O
necrosis.	O
Renal—Dysmenorrhea,	O
dysuria,	O
kidney	O
function	O
abnormality,	O
nocturia,	O
prostate	O
disorder,	O
pyelonephritis,	O
carcinoma	O
breast,	O
urinary	O
incontinence,	O
kidney	O
calculus,	O
kidney	O
failure,	O
menorrhagia,	O
metrorrhagia,	O
neoplasm	O
breast,	O
nephrosclerosis,	O
hematuria,	O
pain	O
kidney,	O
pyuria,	O
urine	O
abnormal,	O
urinary	O
frequency,	O
urinary	O
retention,	O
uterine	O
spasm,	O
vaginitis,	O
glomerular	O
nephritis,	O
hyperkalemia,	O
interstitial	O
nephritis,	O
nephrotic	O
syndrome,	O
renal	O
disease,	O
renal	O
failure,	O
renal	O
papillary	O
necrosis.	O
Hematologic—Leukopenia,	O
bleeding	O
time	O
increased,	O
eosinophilia,	O
abnormal	O
RBC,	O
abnormal	O
WBC,	O
thrombocytopenia,	O
agranulocytosis,	O
granulocytopenia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Depression,	O
anxiety,	O
hypertonia,	O
nervousness,	O
neuralgia,	O
neuritis,	O
vertigo,	O
amnesia,	O
confusion,	O
co-ordination,	O
abnormal	O
diplopia,	O
emotional	O
lability,	O
hematoma	O
subdural,	O
paralysis,	O
dream	O
abnormalities,	O
inability	O
to	O
concentrate,	O
muscle	O
weakness.	O
Dermatologic:	O
Angiodermatitis,	O
herpes	O
simplex,	O
dry	O
skin,	O
sweating,	O
ulcer	O
skin,	O
acne,	O
alopecia,	O
dermatitis	O
contact,	O
eczema,	O
herpes	O
zoster,	O
nail	O
disorder,	O
skin	O
necrosis,	O
subcutaneous	O
nodule,	O
pruritus,	O
urticaria,	O
neoplasm	O
skin,	O
photosensitive	O
dermatitis,	O
photosensitivity	O
reactions	O
resembling	O
porphyria	O
cutaneous	O
tarda,	O
epidermolysis	O
bullosa.	O
Special	O
Senses—Amblyopia,	O
scleritis,	O
cataract,	O
conjunctivitis,	O
deaf,	O
ear	O
disorder,	O
keratoconjunctivitis,	O
lacrimation	O
disorder,	O
otitis	O
media,	O
pain	O
eye.	O
Cardiovascular—Angina	O
pectoris,	O
coronary	O
artery	O
disease,	O
myocardial	O
infarction,	O
deep	O
thrombophlebitis,	O
vasodilation,	O
vascular	O
anomaly,	O
arrhythmia,	O
bundle	O
branch	O
block,	O
abnormal	O
ECG,	O
heart	O
failure	O
right,	O
hemorrhage,	O
migraine,	O
aortic	O
stenosis,	O
syncope,	O
tachycardia,	O
congestive	O
heart	O
failure.	O
Respiratory—Asthma,	O
dyspnea,	O
lung	O
edema,	O
laryngitis,	O
lung	O
disorder,	O
epistaxis,	O
pneumonia,	O
respiratory	O
distress,	O
respiratory	O
disorder,	O
eosinophilic	O
pneumonitis.	O
Musculoskeletal—Myasthenia,	O
bone	O
disorder,	O
spontaneous	O
bone	O
fracture,	O
fibrotendinitis,	O
bone	O
pain,	O
ptosis,	O
spasm	O
general,	O
bursitis.	O
Metabolic	O
and	O
Nutrition—Creatinine	O
increase,	O
glucosuria,	O
hypercholesteremia,	O
albuminuria,	O
alkalosis,	O
BUN	O
increased,	O
dehydration,	O
edema,	O
glucose	O
tolerance	O
decrease,	O
hyperuricemia,	O
hypokalemia,	O
SGOT	O
increase,	O
SGPT	O
increase,	O
weight	O
decrease.	O
General—Anaphylactoid	O
reactions,	O
angioneurotic	O
edema,	O
menstrual	O
disorders,	O
hypoglycemia,	O
pyrexia	O
(chills	O
and	O
fevers).	O
INCIDENCE	O
LESS	O
THAN	O
1%	O
(CAUSAL	O
RELATIONSHIP	O
UNKNOWN)	O
Other	O
adverse	O
reactions	O
listed	O
in	O
the	O
naproxen	O
package	O
label,	O
but	O
not	O
reported	O
by	O
those	O
who	O
received	O
NAPRELAN®	O
Tablets	B-D013607
are	O
shown	O
in	O
italics.	O
These	O
observations	O
are	O
being	O
listed	O
as	O
alerting	O
information	O
to	O
the	O
physician.	O
Hematologic—Aplastic	O
anemia,	O
hemolytic	O
anemia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Aseptic	O
meningitis,	O
cognitive	O
dysfunction.	O
Dermatologic—Epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome.	O
Gastrointestinal—Non-peptic	O
GI	O
ulceration,	O
ulcerative	O
stomatitis.	O
Cardiovascular—Vasculitis.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Sumatriptan	B-D018170
And	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Cardiovascular	O
Thrombotic	O
Events:	O
Perform	O
cardiac	O
evaluation	O
in	O
patients	O
with	O
cardiovascular	O
risk	O
factors.	O
(5.1)	O
Arrhythmias:	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
if	O
occurs.	O
(5.3)	O
Chest,	O
Throat,	O
Neck	B-D009333
,	O
and/or	O
Jaw	B-D007568
Pain	B-D010146
/Tightness/Pressure:	O
Generally	O
not	O
associated	O
with	O
myocardial	O
ischemia;	O
evaluate	O
for	O
coronary	O
artery	O
disease	O
in	O
patients	O
at	O
high	O
risk.	O
(5.4)	O
Cerebrovascular	O
Events:	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
if	O
occurs.	O
(5.5)	O
Other	O
Vasospasm	O
Reactions:	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
if	O
non-coronary	O
vasospastic	O
reaction	O
occurs.	O
(5.6)	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop.	O
(5.7)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure.	O
(5.8)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure.	O
(5.9)	O
Medication	O
Overuse	O
Headache	B-D006261
:	O
Detoxification	O
may	O
be	O
necessary.	O
(5.10)	O
Serotonin	B-D020230
Syndrome	I-D020230
:	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
if	O
occurs.	O
(5.11)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
(5.12)	O
Anaphylactic	O
Reactions:	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
Seep	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.(5.13)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
at	O
first	O
sign	O
of	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity.	O
(5.14)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia.	O
(5.16)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity).	O
(5.17)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
The	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
ischemic	O
or	O
vasospastic	O
coronary	O
artery	O
disease	O
(CAD)	O
and	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
due	O
to	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
events	O
with	O
sumatriptan	O
and	O
NSAIDS	O
[see	O
Contraindications	B-D000075202
(4)].	O
Cardiovascular	O
Events	O
with	O
Sumatriptan	B-D018170
There	O
have	O
been	O
rare	O
reports	O
of	O
serious	O
cardiac	O
adverse	O
reactions,	O
including	O
acute	O
myocardial	O
infarction,	O
occurring	O
within	O
a	O
few	O
hours	O
following	O
administration	O
of	O
sumatriptan.	O
Some	O
of	O
these	O
reactions	O
occurred	O
in	O
patients	O
without	O
known	O
CAD.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
may	O
cause	O
coronary	O
artery	O
vasospasm	O
(Prinzmetal's	O
angina),	O
even	O
in	O
patients	O
without	O
a	O
history	O
of	O
CAD.	O
Cardiovascular	O
Thrombotic	O
Events	O
with	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
naproxen,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Perform	O
a	O
cardiovascular	O
evaluation	O
in	O
patients	O
who	O
have	O
multiple	O
cardiovascular	O
risk	O
factors	O
(e.g.,	O
increased	O
age,	O
diabetes,	O
hypertension,	O
smoking,	O
obesity,	O
strong	O
family	O
history	O
of	O
CAD)	O
prior	O
to	O
receiving	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
If	O
there	O
is	O
evidence	O
of	O
CAD	O
or	O
coronary	O
artery	O
vasospasm,	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated.	O
For	O
patients	O
with	O
multiple	O
cardiovascular	O
risk	O
factors	O
who	O
have	O
a	O
negative	O
cardiovascular	O
evaluation,	O
consider	O
administering	O
the	O
first	O
dose	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
in	O
a	O
medically	O
supervised	O
setting	O
and	O
performing	O
an	O
electrocardiogram	O
(ECG)	O
immediately	O
following	O
administration	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
For	O
such	O
patients,	O
consider	O
periodic	O
cardiovascular	O
evaluation	O
in	O
intermittent	O
long-term	O
users	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
cardiovascular	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
cardiovascular	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
cardiovascular	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
naproxen,	O
a	O
component	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
,	O
cause	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
1	O
in	O
5	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
gastrointestinal	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
gastrointestinal	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
appear	O
to	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
daily	O
for	O
3	O
to	O
6	O
months	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
1	O
year.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Among	O
3,302	O
adult	O
patients	O
with	O
migraine	O
who	O
received	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
in	O
controlled	O
and	O
uncontrolled	O
clinical	O
trials,	O
1	O
patient	O
experienced	O
a	O
recurrence	O
of	O
gastric	O
ulcer	O
after	O
taking	O
8	O
doses	O
over	O
3	O
weeks,	O
and	O
1	O
patient	O
developed	O
a	O
gastric	O
ulcer	O
after	O
treating	O
an	O
average	O
of	O
8	O
attacks	O
per	O
month	O
over	O
7	O
months.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
gastrointestinal	O
bleeding	O
compared	O
with	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
for	O
gastrointestinal	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
gastrointestinal	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients,	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
high	O
risk	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.3	O
Arrhythmias	O
Life	B-D019369
-threatening	O
disturbances	O
of	O
cardiac	O
rhythm,	O
including	O
ventricular	O
tachycardia	O
and	O
ventricular	O
fibrillation	O
leading	O
to	O
death,	O
have	O
been	O
reported	O
within	O
a	O
few	O
hours	O
following	O
the	O
administration	O
of	O
5-HT1	O
agonists.	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
if	O
these	O
disturbances	O
occur.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
Wolff-Parkinson-White	O
syndrome	O
or	O
arrhythmias	O
associated	O
with	O
other	O
cardiac	O
accessory	O
conduction	O
pathway	O
disorders.	O
5.4	O
Chest,	O
Throat,	O
Neck	B-D009333
,	O
and/or	O
Jaw	B-D007568
Pain	B-D010146
/Tightness/Pressure	O
Sensation	B-D012677
s	O
of	O
tightness,	O
pain,	O
pressure,	O
and	O
heaviness	O
in	O
the	O
precordium,	O
throat,	O
neck,	O
and	O
jaw	O
commonly	O
occur	O
after	O
treatment	O
with	O
sumatriptan	O
and	O
are	O
usually	O
non-cardiac	O
in	O
origin.	O
However,	O
perform	O
a	O
cardiac	O
evaluation	O
if	O
these	O
patients	O
are	O
at	O
high	O
cardiac	O
risk.	O
The	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
is	O
contraindicated	O
in	O
patients	O
with	O
CAD	O
and	O
those	O
with	O
Prinzmetal's	B-C536421
variant	I-C536421
angina	I-C536421
.	O
5.5	O
Cerebrovascular	O
Events	O
Cerebral	O
hemorrhage,	O
subarachnoid	O
hemorrhage,	O
and	O
stroke	O
have	O
occurred	O
in	O
patients	O
treated	O
with	O
5-HT1	O
agonists,	O
and	O
some	O
have	O
resulted	O
in	O
fatalities.	O
In	O
a	O
number	O
of	O
cases,	O
it	O
appears	O
possible	O
that	O
the	O
cerebrovascular	O
events	O
were	O
primary,	O
the	O
5-HT1	O
agonist	O
having	O
been	O
administered	O
in	O
the	O
incorrect	O
belief	O
that	O
the	O
symptoms	O
experienced	O
were	O
a	O
consequence	O
of	O
migraine	O
when	O
they	O
were	O
not.	O
Also,	O
patients	O
with	O
migraine	O
may	O
be	O
at	O
increased	O
risk	O
of	O
certain	O
cerebrovascular	O
events	O
(e.g.,	O
stroke,	O
hemorrhage,	O
TIA).	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
if	O
a	O
cerebrovascular	O
event	O
occurs.	O
Before	O
treating	O
headaches	O
in	O
patients	O
not	O
previously	O
diagnosed	O
as	O
migraineurs,	O
and	O
in	O
migraineurs	O
who	O
present	O
with	O
atypical	O
symptoms,	O
exclude	O
other	O
potentially	O
serious	O
neurological	O
conditions.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
a	O
history	O
of	O
stroke	O
or	O
TIA	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.6	O
Other	O
Vasospasm	O
Reactions	O
Sumatriptan	B-D018170
may	O
cause	O
non-coronary	O
vasospastic	O
reactions,	O
such	O
as	O
peripheral	O
vascular	O
ischemia,	O
gastrointestinal	O
vascular	O
ischemia	O
and	O
infarction	O
(presenting	O
with	O
abdominal	O
pain	O
and	O
bloody	O
diarrhea),	O
splenic	O
infarction,	O
and	O
Raynaud′s	O
syndrome.	O
In	O
patients	O
who	O
experience	O
symptoms	O
or	O
signs	O
suggestive	O
of	O
non-coronary	O
vasospasm	O
reaction	O
following	O
the	O
use	O
of	O
any	O
5-HT1	O
agonist,	O
rule	O
out	O
a	O
vasospastic	O
reaction	O
before	O
receiving	O
additional	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Reports	O
of	O
transient	O
and	O
permanent	O
blindness	O
and	O
significant	O
partial	O
vision	O
loss	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
5-HT1	O
agonists.	O
Since	O
visual	O
disorders	O
may	O
be	O
part	O
of	O
a	O
migraine	O
attack,	O
a	O
causal	O
relationship	O
between	O
these	O
events	O
and	O
the	O
use	O
of	O
5-HT1	O
agonists	O
have	O
not	O
been	O
clearly	O
established.	O
5.7	O
Hepatotoxicity	O
Borderline	O
elevations	O
of	O
1	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
who	O
take	O
NSAIDs	O
including	O
naproxen,	O
a	O
component	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Hepatic	O
abnormalities	O
may	O
be	O
the	O
result	O
of	O
hypersensitivity	O
rather	O
than	O
direct	O
toxicity.	O
These	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
essentially	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy.	O
Notable	O
(3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
elevations	O
of	O
SGPT	O
(ALT)	O
or	O
SGOT	O
(AST)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported	O
with	O
NSAIDs.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.7),	O
Clinical	O
Pharmacology	B-D010600
(12.3)].	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
evaluated	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
should	O
be	O
discontinued	O
if	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
or	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flulike"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.8	O
Hypertension	B-D006973
Significant	O
elevation	O
in	O
blood	O
pressure,	O
including	O
hypertensive	O
crisis	O
with	O
acute	O
impairment	O
of	O
organ	O
systems,	O
has	O
been	O
reported	O
on	O
rare	O
occasions	O
in	O
patients	O
treated	O
with	O
5-HT1	O
agonists,	O
including	O
sumatriptan,	O
a	O
component	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
This	O
occurrence	O
has	O
included	O
patients	O
without	O
a	O
history	O
of	O
hypertension.	O
NSAIDs,	O
including	O
naproxen,	O
a	O
component	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
,	O
can	O
also	O
lead	O
to	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
cardiovascular	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
angiotensin	O
receptor	O
blockers	O
(ARBs),	O
beta-blockers,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Monitor	O
blood	O
pressure	O
in	O
patients	O
treated	O
with	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
uncontrolled	O
hypertension	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.9	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
naproxen	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
Since	O
each	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
85/500	O
mg	O
tablet	O
contain	O
approximately	O
60	O
mg	O
of	O
sodium	O
and	O
each	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
10/60	O
mg	O
tablet	O
contain	O
approximately	O
20	O
mg	O
of	O
sodium,	O
this	O
should	O
be	O
considered	O
in	O
patients	O
whose	O
overall	O
intake	O
of	O
sodium	O
must	O
be	O
severely	O
restricted.	O
5.10	O
Medication	O
Overuse	O
Headache	B-D006261
Overuse	O
of	O
acute	O
migraine	O
drugs	O
(e.g.,	O
ergotamine,	O
triptans,	O
opioids,	O
or	O
a	O
combination	O
of	O
these	O
drugs	O
for	O
10	O
or	O
more	O
days	O
per	O
month)	O
may	O
lead	O
to	O
exacerbation	O
of	O
headache	O
(medication	O
overuse	O
headache).	O
Medication	O
overuse	O
headache	O
may	O
present	O
as	O
migraine-like	O
daily	O
headaches,	O
or	O
as	O
a	O
marked	O
increase	O
in	O
frequency	O
of	O
migraine	O
attacks.	O
Detoxification	O
of	O
patients,	O
including	O
withdrawal	O
of	O
the	O
overused	O
drugs,	O
and	O
treatment	O
of	O
withdrawal	O
symptoms	O
(which	O
often	O
includes	O
a	O
transient	O
worsening	O
of	O
headache)	O
may	O
be	O
necessary.	O
5.11	O
Serotonin	B-D020230
Syndrome	I-D020230
Serotonin	B-D012701
syndrome	O
may	O
occur	O
with	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
,	O
particularly	O
during	O
coadministration	O
with	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs),	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs),	O
tricyclic	O
antidepressants	O
(TCAs),	O
and	O
MAO	O
inhibitors	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Drug	B-D004347
Interactions	I-D004347
(7.1)].	O
Serotonin	B-D012701
syndrome	O
symptoms	O
may	O
include	O
mental	O
status	O
changes	O
(e.g.,	O
agitation,	O
hallucinations,	O
coma),	O
autonomic	O
instability	O
(e.g.,	O
tachycardia,	O
labile	O
blood	O
pressure,	O
hyperthermia),	O
neuromuscular	O
aberrations	O
(e.g.,	O
hyperreflexia,	O
incoordination),	O
and/or	O
gastrointestinal	O
symptoms	O
(e.g.,	O
nausea,	O
vomiting,	O
diarrhea).	O
The	O
onset	O
of	O
symptoms	O
usually	O
occurs	O
within	O
minutes	O
to	O
hours	O
of	O
receiving	O
a	O
new	O
or	O
a	O
greater	O
dose	O
of	O
a	O
serotonergic	O
medication.	O
Discontinue	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
if	O
serotonin	O
syndrome	O
is	O
suspected.	O
5.12	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
salt	O
depletion,	O
those	O
taking	O
diuretics	O
and	O
angiotensin-converting	O
enzyme	O
(ACE)	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
should	O
be	O
discontinued	O
if	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
renal	O
disease	O
develop	O
or	O
if	O
systemic	O
manifestations	O
occur.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
not	O
recommended	O
for	O
use	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
(creatinine	O
clearance	O
[CrCl]	O
<30	O
mL/min)	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.6),	O
Clinical	O
Pharmacology	B-D010600
(12.3)].	O
If	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
mild	O
(CrCl	O
=	O
60	O
to	O
89	O
mL/min)	O
or	O
moderate	O
(CrCl	O
=	O
30	O
to	O
59	O
mL/min)	O
renal	O
impairment,	O
preexisting	O
kidney	O
disease,	O
or	O
dehydration.	O
The	O
renal	O
effects	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
pre-existing	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.13	O
Anaphylactic	O
Reactions	O
Anaphylactic	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
either	O
component	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Such	O
reactions	O
can	O
be	O
life-threatening	O
or	O
fatal.	O
In	O
general,	O
anaphylactic	O
reactions	O
to	O
drugs	O
are	O
more	O
likely	O
to	O
occur	O
in	O
individuals	O
with	O
a	O
history	O
of	O
sensitivity	O
to	O
multiple	O
allergens	O
although	O
anaphylactic	O
reactions	O
with	O
naproxen	O
have	O
occurred	O
in	O
patient	O
without	O
known	O
hypersensitivity	O
to	O
naproxen	O
or	O
to	O
patients	O
with	O
aspirin	O
sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.17)].	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
patients	O
with	O
asthma	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
a	O
history	O
of	O
hypersensitivity	O
reaction	O
to	O
sumatriptan,	O
naproxen,	O
or	O
any	O
other	O
component	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
.	O
Naproxen	B-D009288
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
without	O
known	O
hypersensitivity	O
to	O
naproxen	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.17)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.14	O
Serious	O
Skin	B-D012867
Reactions	O
NSAID-containing	O
products	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.15	O
Prema	B-C070504
ture	O
Closure	O
of	O
the	O
Ductus	B-D004373
Arteriosus	I-D004373
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Contraindications	B-D000075202
(4),	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.16	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
gastrointestinal	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
has	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs),	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.17	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
are	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.18	O
Seizures	B-D012640
Seizures	B-D012640
have	O
been	O
reported	O
following	O
administration	O
of	O
sumatriptan.	O
Some	O
have	O
occurred	O
in	O
patients	O
with	O
either	O
a	O
history	O
of	O
seizures	O
or	O
concurrent	O
conditions	O
predisposing	O
to	O
seizures.	O
There	O
are	O
also	O
reports	O
in	O
patients	O
where	O
no	O
such	O
predisposing	O
factors	O
are	O
apparent.	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
a	O
history	O
of	O
epilepsy	O
or	O
conditions	O
associated	O
with	O
a	O
lowered	O
seizure	O
threshold.	O
5.19	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.20	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.7,	O
5.12)].	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
below	O
and	O
elsewhere	O
in	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Arrhythmias	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Chest,	O
Throat,	O
Neck	B-D009333
,	O
and/or	O
Jaw	B-D007568
Pain	B-D010146
/Tightness/Pressure	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Cerebrovascular	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Other	O
Vasospasm	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.8)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Medication	O
Overuse	O
Headache	B-D006261
[see	O
Warnings	O
and	O
Precautions	O
(5.10)]	O
Serotonin	B-D020230
Syndrome	I-D020230
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.12)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.13)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.14)]	O
Hematological	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.16)]	O
Exacerbation	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.17)]	O
Seizures	B-D012640
[see	O
Warnings	O
and	O
Precautions	O
(5.18)]	O
The	O
most	O
common	O
adverse	O
reactions	O
(incidence	O
≥2%)	O
were:	O
Adult	B-D000328
s:	O
Dizziness	B-D004244
,	O
somnolence,	O
nausea,	O
chest	O
discomfort/chest	O
pain,	O
neck/throat/jaw	O
pain/tightness/pressure,	O
paresthesia,	O
dyspepsia,	O
dry	O
mouth.	O
(6.1)	O
Pediatrics	B-D010372
:	O
Hot	O
flush	O
(i.e.,	O
hot	O
flash[es])	O
and	O
muscle	O
tightness.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Macoven	O
at	O
1-800-793-2145	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Adult	B-D000328
s	O
The	O
adverse	O
reactions	O
reported	O
below	O
are	O
specific	O
to	O
the	O
clinical	O
trials	O
with	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
85/500	O
mg.	O
See	O
also	O
the	O
full	O
prescribing	O
information	O
for	O
naproxen	O
and	O
sumatriptan	O
products.	O
Table	O
1	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
2	O
placebo-controlled	O
clinical	O
trials	O
(Study	O
1	O
and	O
2)	O
in	O
adult	O
patients	O
who	O
received	O
1	O
dose	O
of	O
study	O
drug.	O
Only	O
adverse	O
reactions	O
that	O
occurred	O
at	O
a	O
frequency	O
of	O
2%	O
or	O
more	O
in	O
any	O
group	O
treated	O
with	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
85/500	O
mg	O
and	O
that	O
occurred	O
at	O
a	O
frequency	O
greater	O
than	O
the	O
placebo	O
group	O
are	O
included	O
in	O
Table	O
1.	O
Table	O
1.	O
Adverse	O
Reactions	O
in	O
Pooled	O
Placebo-Controlled	O
Trials	O
in	O
Adult	B-D000328
Patients	B-D010361
with	O
Migraine	O
Adverse	O
Reactions	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
85/500	O
mg%(n	O
=	O
737)	O
Placebo%(n	O
=	O
752)	O
Sumatriptan	B-D018170
85	O
mg%(n	O
=	O
735)	O
Naproxen	B-D009288
Sodium	B-D012964
500	O
mg%(n	O
=	O
732)	O
Nervous	O
system	O
disorders	O
Dizziness	B-D004244
4	O
2	O
2	O
2	O
Somnolence	O
3	O
2	O
2	O
2	O
Paresthesia	B-D010292
2	O
<1	O
2	O
<1	O
Gastrointestinal	O
disorders	O
Nausea	B-D009325
3	O
1	O
3	O
<1	O
Dyspepsia	B-D004415
2	O
1	O
2	O
1	O
Dry	O
mouth	O
2	O
1	O
2	O
<1	O
Pain	B-D010146
and	O
other	O
pressure	O
sensations	O
Chest	O
discomfort/chest	O
pain	O
3	O
<1	O
2	O
1	O
Neck	B-D009333
/throat/jaw	O
pain/tightness/pressure	O
3	O
1	O
3	O
1	O
The	O
incidence	O
of	O
adverse	O
reactions	O
in	O
controlled	O
clinical	O
trials	O
was	O
not	O
affected	O
by	O
gender	O
or	O
age	O
of	O
the	O
patients.	O
There	O
were	O
insufficient	O
data	O
to	O
assess	O
the	O
impact	O
of	O
race	O
on	O
the	O
incidence	O
of	O
adverse	O
reactions.	O
Pediatric	O
Patients	B-D010361
12	O
to	O
17	O
Years	O
of	O
Age	O
In	O
a	O
placebo-controlled	O
clinical	O
trial	O
that	O
evaluated	O
pediatric	O
patients	O
12	O
to	O
17	O
years	O
of	O
age	O
who	O
received	O
1	O
dose	O
of	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
10/60	O
mg,	O
30/180	O
mg,	O
or	O
85/500	O
mg,	O
adverse	O
reactions	O
occurred	O
in	O
13%	O
of	O
patients	O
who	O
received	O
10/60	O
mg,	O
9%	O
of	O
patients	O
who	O
received	O
30/180	O
mg,	O
13%	O
who	O
received	O
85/500	O
mg,	O
and	O
8%	O
who	O
received	O
placebo.	O
No	O
patients	O
who	O
received	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
experienced	O
adverse	O
reactions	O
leading	O
to	O
withdrawal	O
from	O
the	O
trial.	O
The	O
incidence	O
of	O
adverse	O
reactions	O
in	O
pediatric	O
patients	O
12	O
to	O
17	O
years	O
of	O
age	O
was	O
comparable	O
across	O
all	O
3	O
doses	O
compared	O
with	O
placebo.	O
Table	O
2	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
a	O
placebo-controlled	O
trial	O
in	O
pediatric	O
patients	O
12	O
to	O
17	O
years	O
of	O
age	O
at	O
a	O
frequency	O
of	O
2%	O
or	O
more	O
with	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
and	O
were	O
more	O
frequent	O
than	O
the	O
placebo	O
group.	O
Table	O
2.	O
Adverse	O
Reactions	O
in	O
a	O
Placebo-Controlled	O
Trial	O
in	O
Pediatric	O
Patients	B-D010361
12	O
to	O
17	O
Years	O
of	O
Age	O
with	O
Migraine	O
Adverse	O
Reactions	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
S	B-C012009
10	I-C012009
/60	O
mg%	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
30/180	O
mg%	O
Sumatriptan	B-D018170
and	O
Naproxen	B-D009288
Sodium	B-D012964
Tablets	B-D013607
85/500	O
mg%	O
Placebo%	O
(n	O
=	O
96)	O
(n	O
=	O
97)	O
(n	O
=	O
152)	O
(n	O
=	O
145)	O
Vascular	O
Hot	O
flush	O
(i.e.,	O
hot	O
flash[es])	O
0	O
2	O
<1	O
0	O
Musculoskeletal	O
Muscle	O
tightness	O
0	O
0	O
2	O
0	O
ADVERSE	O
REACTIONS	O
Hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	O
was	O
administered	O
to	O
approximately	O
300	O
pain	O
patients	O
in	O
a	O
safety	O
study	O
that	O
employed	O
dosages	O
and	O
a	O
duration	O
of	O
treatment	O
sufficient	O
to	O
encompass	O
the	O
recommended	O
usage	O
(see	O
DOSAGE	O
AND	O
ADMINISTRATION).	O
Adverse	O
event	O
rates	O
generally	O
increased	O
with	O
increasing	O
daily	O
dose.	O
The	O
event	O
rates	O
reported	O
below	O
are	O
from	O
approximately	O
150	O
patients	O
who	O
were	O
in	O
a	O
group	O
that	O
received	O
one	O
tablet	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
an	O
average	O
of	O
three	O
to	O
four	O
times	O
daily.	O
The	O
overall	O
incidence	O
rates	O
of	O
adverse	O
experiences	O
in	O
the	O
trials	O
were	O
fairly	O
similar	O
for	O
this	O
patient	O
group	O
and	O
those	O
who	O
received	O
the	O
comparison	O
treatment,	O
acetaminophen	O
with	O
600	O
mg	O
codeine	O
60	O
mg.	O
The	O
following	O
lists	O
adverse	O
events	O
that	O
occurred	O
with	O
an	O
incidence	O
of	O
1%	O
or	O
greater	O
in	O
clinical	O
trials	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen,	O
without	O
regard	O
to	O
the	O
causal	O
relationship	O
of	O
the	O
events	O
to	O
the	O
drug.	O
To	O
distinguish	O
different	O
rates	O
of	O
occurrence	O
in	O
clinical	O
studies,	O
the	O
adverse	O
events	O
are	O
listed	O
as	O
follows:	O
name	O
of	O
adverse	O
event	O
=	O
less	O
than	O
3%	O
adverse	O
events	O
marked	O
with	O
an	O
asterisk*	O
=	O
3%	O
to	O
9%	O
adverse	O
event	O
rates	O
over	O
9%	O
are	O
in	O
parentheses.	O
Body	O
as	O
a	O
whole:	O
Abdominal	O
pain*,	O
Asthenia	B-D001247
*;	O
Fever	B-D005334
;	O
Flu	O
syndrome;	O
Headache	B-D006261
(27%),	O
Infection*,	O
Pain	B-D010146
.	O
Cardiovascular:	O
Palpitations;	O
Vasodilation	B-D014664
.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Anxiety	B-D001007
*;	O
Confusion	B-D003221
;	O
Dizziness	B-D004244
(14%);	O
Hypertonia;	O
Insomnia*;	O
Nervousness*;	O
Paresthesia	B-D010292
;	O
Somnolence	O
(22%);	O
Thinking	B-D013850
abnormalities.	O
Digestive:	O
Anorexia	B-D000855
,	O
Constipation	B-D003248
(22%);	O
Diarrhea	B-D003967
*;	O
Dry	O
Mouth	B-D009055
,	O
Dyspepsia	B-D004415
(12%);	O
Flatulence	B-D005414
,	O
Gastritis	B-D005756
;	O
Melena	B-D008551
;	O
Mouth	B-D009055
ulcers;	O
Nausea	B-D009325
(12%),	O
Thirst	B-D013894
;	O
Vomiting	B-D014839
*.	O
Metabolic	O
and	O
Nutritional	O
Disorders:	O
Edema	B-D004487
*.	O
Respiratory:	O
Dyspnea	B-D004417
;	O
Hiccup	B-D006606
s;	O
Pharyngitis	B-D010612
;	O
Rhinitis	B-D012220
.	O
Skin	B-D012867
and	O
Appendages:	O
Pruritus	B-D011537
*;	O
Sweating	B-D013546
*.	O
Special	O
Senses:	O
Tinnitus	B-D014012
.	O
Urogenital:	O
Urinary	O
frequency.	O
Incidence	B-D015994
less	O
than	O
1%	O
Body	O
as	O
a	O
Whole:	O
Allergic	O
reaction.	O
Cardiovascular:	O
Arrhythmia;	O
Hypotension	B-D007022
;	O
Tachycardia	B-D013610
.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Agitation;	O
Abnormal	O
dreams;	O
Decreased	O
libido;	O
Depression	B-D003863
;	O
Euphoria	B-D005059
;	O
Mood	O
changes;	O
Neuralgia	B-D009437
;	O
Slurred	O
speech;	O
Tremor	B-D014202
,	O
Vertigo	B-D014717
.	O
Digestive:	O
Chalky	O
stool;	O
“Clenching	O
teeth”;	O
Dysphagia;	O
Esophageal	O
spasm;	O
Esophagitis	B-D004941
;	O
Gastroenteritis	B-D005759
;	O
Glossitis	B-D005928
;	O
Liver	B-D008099
enzyme	O
elevation.	O
Metabolic	O
and	O
Nutritional:	O
Weight	O
decrease.	O
Musculoskeletal:	O
Arthralgia	B-D018771
;	O
Myalgia	B-D063806
.	O
Respiratory:	O
Asthma	B-D001249
;	O
Bronchitis	B-D001991
;	O
Hoarseness	B-D006685
;	O
Increased	O
cough;	O
Pulmonary	O
congestion;	O
Pneumonia	B-D011014
;	O
Shallow	O
breathing;	O
Sinusitis	B-D012852
.	O
Skin	B-D012867
and	O
Appendages:	O
Rash;	O
Urticaria	B-D014581
.	O
Special	O
Senses:	O
Altered	O
vision;	O
Bad	O
taste;	O
Dry	O
eyes.	O
Urogenital:	O
Cystitis	B-D003556
,	O
Glyosuria;	O
Impotence,	O
Urinary	O
incontinence;	O
Urinary	O
retention.	O
WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
RISK	O
EVALUATION	O
AND	O
MITIGATION	O
STRATEGY	O
(REMS);	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION;	O
ACCIDENTAL	O
INGESTION;	O
RISKS	O
FROM	O
CONCOMITANT	O
USE	O
WITH	O
BENZODIAZEPINES	O
OR	O
OTHER	O
CNS	O
DEPRESSANTS;	O
ULTRA-RAPID	O
METABOLISM	O
OF	O
CODEINE	O
AND	O
OTHER	O
RISK	O
FACTORS	O
FOR	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION	O
IN	O
CHILDREN;	O
NEONATAL	O
OPIOID	O
WITHDRAWL	O
SYNDROME;	O
and	O
INTERACTIONS	O
WITH	O
DRUGS	O
AFFECTING	O
CYTOCHROME	O
P450	O
ISOENZYMES	O
•	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
ASCOMP	O
with	O
CODEINE	O
exposes	O
patients	O
and	O
other	O
users	O
to	O
the	O
risks	O
of	O
opioid	O
addiction,	O
abuse,	O
and	O
misuse,	O
which	O
can	O
lead	O
to	O
overdose	O
and	O
death.	O
Assess	O
each	O
patient’s	O
risk	O
prior	O
to	O
prescribing	O
ASCOMP	O
with	O
CODEINE,	O
and	O
monitor	O
all	O
patients	O
regularly	O
for	O
the	O
development	O
of	O
these	O
behaviors	O
and	O
conditions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1	O
)].	O
•	O
Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
REMS	O
for	O
these	O
products	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)].	O
Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
educations	O
programs	O
available	O
to	O
healthcare	O
providers.	O
Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
do	O
all	O
of	O
the	O
following:	O
•	O
complete	O
a	O
REMS-compliant	O
education	O
program,	O
•	O
counsel	O
patients	O
and/or	O
their	O
caregivers,	O
with	O
every	O
prescription,	O
on	O
safe	O
use,	O
serious	O
risks,	O
storage,	O
and	O
disposal	O
of	O
these	O
products,	O
•	O
emphasize	O
to	O
patients	O
and	O
their	O
caregivers	O
the	O
importance	O
of	O
reading	O
the	O
Medication	O
Guide	O
every	O
time	O
it	O
is	O
provided	O
by	O
their	O
pharmacist,	O
and	O
•	O
consider	O
other	O
tools	O
to	O
improve	O
patient,	O
household,	O
and	O
community	O
safety.	O
•	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
may	O
occur	O
with	O
use	O
of	O
ASCOMP	O
with	O
CODEINE.	O
Monitor	O
for	O
respiratory	O
depression,	O
especially	O
during	O
initiation	O
of	O
ASCOMP	O
with	O
CODEINE	O
or	O
following	O
a	O
dose	O
increase	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)].	O
•	O
Accidental	O
Ingestion	O
Accidental	O
ingestion	O
of	O
even	O
one	O
dose	O
of	O
ASCOMP	O
with	O
CODEINE,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
a	O
fatal	O
overdose	O
of	O
ASCOMP	O
with	O
CODEINE	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)].	O
•	O
Risk	B-D012306
s	O
From	O
Concomitant	O
Use	O
With	O
Benzodiazepines	B-D001569
Or	O
Other	O
CNS	O
Depressants	O
Concomitant	O
use	O
of	O
opioids	O
with	O
benzodiazepines	O
or	O
other	O
central	O
nervous	O
system	O
(CNS)	O
depressants,	O
including	O
alcohol,	O
may	O
result	O
in	O
profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.4,	O
5.8),	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
•	O
Reserve	O
concomitant	O
prescribing	O
of	O
ASCOMP	O
with	O
CODEINE	O
and	O
benzodiazepines	O
or	O
other	O
CNS	O
depressants	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
treatment	O
options	O
are	O
inadequate.	O
•	O
Limit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required.	O
•	O
Follow	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
•	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
and	O
death	O
have	O
occurred	O
in	O
children	O
who	O
received	O
codeine.	O
Most	O
of	O
the	O
reported	O
cases	O
occurred	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy,	O
and	O
many	O
of	O
the	O
children	O
had	O
evidence	O
of	O
being	O
an	O
ultra-rapid	O
metabolizer	O
of	O
codeine	O
due	O
to	O
a	O
CYP2D6	O
polymorphism.	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)].	O
ASCOMP	O
with	O
CODEINE	O
is	O
contraindicated	O
in	O
children	O
younger	O
than	O
12	O
years	O
of	O
age	O
and	O
in	O
children	O
younger	O
than	O
18	O
years	O
of	O
age	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy	O
[see	O
Contraindications	B-D000075202
(	O
4	O
)].	O
Avoid	O
the	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
in	O
adolescents	O
12	O
to	O
18	O
years	O
of	O
age	O
who	O
have	O
other	O
risk	O
factors	O
that	O
may	O
increase	O
their	O
sensitivity	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine.	O
•	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
during	O
pregnancy	O
can	O
result	O
in	O
neonatal	O
opioid	O
withdrawal	O
syndrome,	O
which	O
may	O
be	O
life-threatening	O
if	O
not	O
recognized	O
and	O
treated,	O
and	O
requires	O
management	O
according	O
to	O
protocols	O
developed	O
by	O
neonatology	O
experts.	O
If	O
opioid	O
use	O
is	O
required	O
for	O
a	O
prolonged	O
period	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)].	O
•	O
Interactions	O
with	O
Drugs	O
Affect	B-D000339
ing	O
Cytochrome	O
P450	O
Isoenzymes	B-D007527
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
codeine	O
are	O
complex.	O
Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
ASCOMP	O
with	O
CODEINE	O
requires	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
codeine,	O
and	O
the	O
active	O
metabolite,	O
morphine	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.7,	O
5.8),	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
RISK	O
EVALUATION	O
AND	O
MITIGATION	O
STRATEGY	O
(REMS);	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION;	O
ACCIDENTAL	O
INGESTION;	O
RISKS	O
FORM	O
CONCOMITANT	O
USE	O
WITH	O
BENZODIAZEPINES	O
OR	O
OTHER	O
CNS	O
DEPRESSANTS;	O
ULTRA-RAPID	O
METABOLISM	O
OF	O
CODEINE	O
AND	O
OTHER	O
RISK	O
FACTORS	O
FOR	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION	O
IN	O
CHILDREN;	O
NEONATAL	O
OPIOID	O
WITHDRAWAL	O
SYNDROME;	O
and	O
INTERACTION	O
WITH	O
DRUGS	O
AFFECTING	O
CYTOCHROME	O
P450	O
ISOENZYMES	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
•	O
ASCOMP	O
with	O
CODEINE	O
exposes	O
users	O
to	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse,	O
which	O
can	O
lead	O
to	O
overdose	O
and	O
death.	O
Assess	O
patient’s	O
risk	O
before	O
prescribing	O
and	O
monitor	O
regularly	O
for	O
these	O
behaviors	O
and	O
conditions.	O
(	O
5.1	O
)	O
•	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
strategy	O
(REMS)	O
for	O
these	O
products.	O
(	O
5.2	O
)	O
•	O
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
may	O
occur.	O
Monitor	O
closely,	O
especially	O
upon	O
initiation	O
or	O
following	O
a	O
dose	O
increase.	O
(	O
5.3	O
)	O
•	O
Accidental	O
ingestion	O
of	O
ASCOMP	O
with	O
CODEINE,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
fatal	O
overdose.	O
(	O
5.3	O
)	O
•	O
Concomitant	O
use	O
of	O
opioids	O
or	O
a	O
barbiturate	O
with	O
benzodiazepines	O
or	O
other	O
central	O
nervous	O
system	O
(CNS)	O
depressants,	O
including	O
alcohol,	O
may	O
result	O
in	O
profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death.	O
Reserve	O
concomitant	O
prescribing	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
treatment	O
options	O
are	O
inadequate;	O
limit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required;	O
and	O
follow	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
(	O
5.4	O
,	O
5.8,	O
7)	O
•	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
and	O
death	O
have	O
occurred	O
in	O
children	O
who	O
received	O
codeine;	O
most	O
cases	O
followed	O
tonsillectomy	O
and/or	O
adenoidectomy,	O
and	O
many	O
of	O
the	O
children	O
had	O
evidence	O
of	O
being	O
an	O
ultra-rapid	O
metabolizer	O
of	O
codeine	O
due	O
to	O
a	O
CYP2D6	O
polymorphism.	O
(	O
5.5	O
)	O
ASCOMP	O
with	O
CODEINE	O
is	O
contraindicated	O
in	O
children	O
younger	O
than	O
12	O
years	O
of	O
age	O
and	O
in	O
children	O
younger	O
than	O
18	O
years	O
of	O
age	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy	O
(	O
4	O
).	O
Avoid	O
the	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
in	O
adolescents	O
12	O
to	O
18	O
years	O
of	O
age	O
who	O
have	O
other	O
risk	O
factors	O
that	O
may	O
increase	O
their	O
sensitivity	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine.	O
•	O
Prolonged	O
use	O
during	O
pregnancy	O
can	O
result	O
in	O
neonatal	O
opioid	O
withdrawal	O
syndrome,	O
which	O
may	O
be	O
life-threatening	O
if	O
not	O
recognized	O
and	O
treated.	O
If	O
prolonged	O
opioid	O
use	O
is	O
required	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available.	O
(	O
5.6	O
)	O
•	O
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
codeine	O
are	O
complex.	O
Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
ASCOMP	O
with	O
CODEINE	O
requires	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
codeine,	O
and	O
the	O
active	O
metabolite,	O
morphine.	O
(	O
5.7	O
,	O
5.8,	O
7	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
or	O
in	O
Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
:	O
Monitor	O
closely,	O
particularly	O
during	O
initiation	O
and	O
titration.	O
(5.8	O
)	O
•	O
Adrenal	B-D000309
Insufficiency	I-D000309
:	O
If	O
diagnosed,	O
treat	O
with	O
physiologic	O
replacement	O
of	O
corticosteroids,	O
and	O
wean	O
patient	O
off	O
the	O
opioid.	O
(	O
5.10	O
)	O
•	O
Severe	O
Hypotension	B-D007022
:	O
Monitor	O
during	O
dose	O
initiation	O
and	O
titration.	O
Avoid	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
in	O
patients	O
with	O
circulatory	O
shock.	O
(	O
5.11	O
)	O
•	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Increased	O
Intracranial	B-D007427
Pressure	I-D007427
,	O
Brain	B-D001921
Tumors,	O
Head	B-D006257
Injury,	O
or	O
Impaired	O
Consciousness	B-D003243
:	O
Monitor	O
for	O
sedation	O
and	O
respiratory	O
depression.	O
Avoid	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
in	O
patients	O
with	O
impaired	O
consciousness	O
or	O
coma.	O
(	O
5.12	O
)	O
5.1	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
ASCOMP	O
with	O
CODEINE	O
contains	O
codeine.	O
Codeine	B-D003061
in	O
combination	O
with	O
butalbital	B-C004470
,	O
aspirin,	O
and	O
caffeine	O
is	O
a	O
Schedule	O
III	O
controlled	O
substance.	O
As	O
ASCOMP	O
with	O
CODEINE	O
contains	O
butalbital	B-C004470
and	O
codeine,	O
it	O
exposes	O
users	O
to	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse	O
[see	O
Drug	O
Abuse	O
and	O
Dependence	O
(9)	O
].	O
Although	O
the	O
risk	O
of	O
addiction	O
in	O
any	O
individual	O
is	O
unknown,	O
it	O
can	O
occur	O
in	O
patients	O
appropriately	O
prescribed	O
ASCOMP	O
with	O
CODEINE.	O
Addiction	O
can	O
occur	O
at	O
recommended	O
dosages	O
and	O
if	O
the	O
drug	O
is	O
misused	O
or	O
abused.	O
Assess	O
each	O
patient’s	O
risk	O
for	O
addiction,	O
abuse,	O
or	O
misuse	O
prior	O
to	O
prescribing	O
ASCOMP	O
with	O
CODEINE,	O
and	O
monitor	O
all	O
patients	O
receiving	O
ASCOMP	O
with	O
CODEINE	O
for	O
the	O
development	O
of	O
these	O
behaviors	O
and	O
conditions.	O
Risk	B-D012306
s	O
are	O
increased	O
in	O
patients	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
substance	O
abuse	O
(including	O
drug	O
or	O
alcohol	O
abuse	O
or	O
addiction)	O
or	O
mental	O
illness	O
(e.g.,	O
major	O
depression).	O
The	O
potential	O
for	O
these	O
risks	O
should	O
not,	O
however,	O
prevent	O
the	O
proper	O
management	O
of	O
pain	O
in	O
any	O
given	O
patient.	O
Patients	B-D010361
at	O
increased	O
risk	O
may	O
be	O
prescribed	O
opioids	O
such	O
as	O
ASCOMP	O
with	O
CODEINE	O
but	O
use	O
in	O
such	O
patients	O
necessitates	O
intensive	O
counseling	O
about	O
the	O
risks	O
and	O
proper	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
along	O
with	O
intensive	O
monitoring	O
for	O
signs	O
of	O
addiction,	O
abuse,	O
and	O
misuse.	O
Opioids	O
and	O
barbiturates	O
are	O
sought	O
by	O
drug	O
abusers	O
and	O
people	O
with	O
addiction	O
disorders	O
and	O
are	O
subject	O
to	O
criminal	O
diversion.	O
Consider	O
these	O
risks	O
when	O
prescribing	O
or	O
dispensing	O
ASCOMP	O
with	O
CODEINE.	O
Strategies	O
to	O
reduce	O
these	O
risks	O
include	O
prescribing	O
the	O
drug	O
in	O
the	O
smallest	O
appropriate	O
quantity	O
and	O
advising	O
the	O
patient	O
on	O
the	O
proper	O
disposal	O
of	O
unused	O
drug	O
[see	O
Patient	O
Counseling	B-D003376
Information	O
(17)	O
].	O
Contact	O
local	O
state	O
professional	O
licensing	O
board	O
or	O
state	O
controlled	O
substances	O
authority	O
for	O
information	O
on	O
how	O
to	O
prevent	O
and	O
detect	O
abuse	O
or	O
diversion	O
of	O
this	O
product.	O
5.2	O
Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
for	O
these	O
products.	O
Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
education	O
programs	O
available	O
to	O
healthcare	O
providers.	O
Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
do	O
all	O
of	O
the	O
following:	O
•	O
Complete	O
a	O
REMS-compliant	O
education	O
program	O
offered	O
by	O
an	O
accredited	O
provider	O
of	O
continuing	O
education	O
(CE)	O
or	O
another	O
education	O
program	O
that	O
includes	O
all	O
the	O
elements	O
of	O
the	O
FDA	O
Education	B-D004493
Blueprint	O
for	O
Health	B-D006262
Care	O
Providers	O
Involved	O
in	O
the	O
Management	O
or	O
Support	O
of	O
Patients	B-D010361
with	O
Pain	B-D010146
.	O
•	O
Discuss	O
the	O
safe	O
use,	O
serious	O
risks,	O
and	O
proper	O
storage	O
and	O
disposal	O
of	O
opioid	O
analgesics	O
with	O
patients	O
and/or	O
their	O
caregivers	O
every	O
time	O
these	O
medicines	O
are	O
prescribed.	O
The	O
Patient	O
Counseling	B-D003376
Guide	O
(PCG)	O
can	O
be	O
obtained	O
at	O
this	O
link:	O
www.fda.gov/OpioidAnalgesicREMSPCG.	O
•	O
Emphasize	O
to	O
patients	O
and	O
their	O
caregivers	O
the	O
importance	O
of	O
reading	O
the	O
Medication	O
Guide	O
that	O
they	O
will	O
receive	O
from	O
their	O
pharmacist	O
every	O
time	O
an	O
opioid	O
analgesic	O
is	O
dispensed	O
to	O
them.	O
•	O
Consider	O
using	O
other	O
tools	O
to	O
improve	O
patient,	O
household,	O
and	O
community	O
safety,	O
such	O
as	O
patient-prescriber	O
agreements	O
that	O
reinforce	O
patient-prescriber	O
responsibilities.	O
To	O
obtain	O
further	O
information	O
on	O
the	O
opioid	O
analgesic	O
REMS	O
and	O
for	O
a	O
list	O
of	O
accredited	O
REMS	O
CME/CE,	O
call	O
1-800-503-0784,	O
or	O
log	O
on	O
to	O
www.opioidanalgesicrems.com	O
.	O
The	O
FDA	O
Blueprint	O
can	O
be	O
found	O
at	O
www.fda.gov/OpioidAnalgesicREMSBlueprint.	O
5.3	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
opioids,	O
even	O
when	O
used	O
as	O
recommended.	O
Respiratory	O
depression,	O
if	O
not	O
immediately	O
recognized	O
and	O
treated,	O
may	O
lead	O
to	O
respiratory	O
arrest	O
and	O
death.	O
Management	O
of	O
respiratory	O
depression	O
may	O
include	O
close	O
observation,	O
supportive	O
measures,	O
and	O
use	O
of	O
opioid	O
antagonists,	O
depending	O
on	O
the	O
patient’s	O
clinical	O
status	O
[see	O
Overdosage	O
(10)	O
].	O
Carbon	B-D002244
dioxide	O
(CO2)	O
retention	O
from	O
opioid-induced	O
respiratory	O
depression	O
can	O
exacerbate	O
the	O
sedatin	B-C493049
g	O
effects	O
of	O
opioids.	O
While	O
serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
can	O
occur	O
at	O
any	O
time	O
during	O
the	O
use	O
of	O
ASCOMP	O
with	O
CODEINE,	O
the	O
risk	O
is	O
greatest	O
during	O
the	O
initiation	O
of	O
therapy	O
or	O
following	O
a	O
dosage	O
increase.	O
Monitor	O
patients	O
closely	O
for	O
respiratory	O
depression,	O
especially	O
within	O
the	O
first	O
24-72	O
hours	O
of	O
initiating	O
therapy	O
with	O
and	O
following	O
dosage	O
increases	O
of	O
ASCOMP	O
with	O
CODEINE.	O
To	O
reduce	O
the	O
risk	O
of	O
respiratory	O
depression,	O
proper	O
dosing	O
and	O
titration	O
of	O
ASCOMP	O
with	O
CODEINE	O
are	O
essential	O
[see	O
Dosage	O
and	O
Administration	O
(2.1)].	O
Overestimating	O
the	O
ASCOMP	O
with	O
CODEINE	O
dosage	O
when	O
converting	O
patients	O
from	O
another	O
opioid	O
product	O
can	O
result	O
in	O
a	O
fatal	O
overdose	O
with	O
the	O
first	O
dose.	O
Accidental	O
ingestion	O
of	O
ASCOMP	O
with	O
CODEINE,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
respiratory	O
depression	O
and	O
death	O
due	O
to	O
an	O
overdose	O
of	O
codeine	O
and	O
butalbital	B-C004470
.	O
Opioids	O
can	O
cause	O
sleep-related	O
breathing	O
disorders	O
including	O
central	O
sleep	O
apnea	O
(CSA)	O
and	O
sleep-related	O
hypoxemia.	O
Opioid	O
use	O
increases	O
the	O
risk	O
of	O
CSA	O
in	O
a	O
dose-dependent	O
fashion.	O
In	O
patients	O
who	O
present	O
with	O
CSA,	O
consider	O
decreasing	O
the	O
opioid	O
dosage	O
using	O
best	O
practices	O
for	O
opioid	O
taper	O
[see	O
Dosage	O
and	O
Administration	O
(2.3)].	O
5.4	O
Risk	B-D012306
s	O
from	O
Concomitant	O
Use	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
Profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death	O
may	O
result	O
from	O
the	O
concomitant	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
with	O
benzodiazepines	O
or	O
other	O
CNS	O
depressants	O
(e.g.,	O
non-benzodiazepine	O
sedatives/hypnotics,	O
anxiolytics,	O
tranquilizers,	O
muscle	O
relaxants,	O
general	O
anesthetics,	O
antipsychotics,	O
other	O
opioids,	O
alcohol).	O
Because	O
of	O
these	O
risks,	O
reserve	O
concomitant	O
prescribing	O
of	O
these	O
drugs	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
treatment	O
options	O
are	O
inadequate.	O
Observation	B-D019370
al	O
studies	O
have	O
demonstrated	O
that	O
concomitant	O
use	O
of	O
opioid	O
analgesics	O
and	O
benzodiazepines	O
increases	O
the	O
risk	O
of	O
drug-related	O
mortality	O
compared	O
to	O
use	O
of	O
opioid	O
analgesics	O
alone.	O
Because	O
of	O
similar	O
pharmacological	O
properties,	O
it	O
is	O
reasonable	O
to	O
expect	O
similar	O
risk	O
with	O
the	O
concomitant	O
use	O
of	O
other	O
CNS	O
depressant	O
drugs	O
with	O
opioid	O
analgesics	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
If	O
the	O
decision	O
is	O
made	O
to	O
prescribe	O
a	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant	O
concomitantly	O
with	O
an	O
opioid	O
analgesic,	O
prescribe	O
the	O
lowest	O
effective	O
dosages	O
and	O
minimum	O
durations	O
of	O
concomitant	O
use.	O
In	O
patients	O
already	O
receiving	O
an	O
opioid	O
analgesic,	O
prescribe	O
a	O
lower	O
initial	O
dose	O
of	O
the	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant	O
than	O
indicated	O
in	O
the	O
absence	O
of	O
an	O
opioid,	O
and	O
titrate	O
based	O
on	O
clinical	O
response.	O
If	O
an	O
opioid	O
analgesic	O
is	O
initiated	O
in	O
a	O
patient	O
already	O
taking	O
a	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant,	O
prescribe	O
a	O
lower	O
initial	O
dose	O
of	O
the	O
opioid	O
analgesic,	O
and	O
titrate	O
based	O
on	O
clinical	O
response.	O
Follow	O
patients	O
closely	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
Advise	O
both	O
patients	O
and	O
caregivers	O
about	O
the	O
risks	O
of	O
respiratory	O
depression	O
and	O
sedation	O
when	O
ASCOMP	O
with	O
CODEINE	O
is	O
used	O
with	O
benzodiazepines	O
or	O
other	O
CNS	O
depressants	O
(including	O
alcohol	O
and	O
illicit	O
drugs).	O
Advise	O
patients	O
not	O
to	O
drive	O
or	O
operate	O
heavy	O
machinery	O
until	O
the	O
effects	O
of	O
concomitant	O
use	O
of	O
the	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant	O
have	O
been	O
determined.	O
Screen	O
patients	O
for	O
risk	O
of	O
substance	O
use	O
disorders,	O
including	O
opioid	O
abuse	O
and	O
misuse,	O
and	O
warn	O
them	O
of	O
the	O
risk	O
for	O
overdose	O
and	O
death	O
associated	O
with	O
the	O
use	O
of	O
additional	O
CNS	O
depressants	O
including	O
alcohol	O
and	O
illicit	O
drugs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
and	O
Patient	O
Counseling	B-D003376
Information	O
(17)	O
].	O
5.5	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
and	O
death	O
have	O
occurred	O
in	O
children	O
who	O
received	O
codeine.	O
Codeine	B-D003061
is	O
subject	O
to	O
variability	O
in	O
metabolism	O
based	O
upon	O
CYP2D6	O
genotype	O
(described	O
below),	O
which	O
can	O
lead	O
to	O
an	O
increased	O
exposure	O
to	O
the	O
active	O
metabolite	O
morphine.	O
Based	O
upon	O
postmarketing	O
reports,	O
children	O
younger	O
than	O
12	O
years	O
old	O
appear	O
to	O
be	O
more	O
susceptible	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine,	O
particularly	O
if	O
there	O
are	O
risk	O
factors	O
for	O
respiratory	O
depression.	O
For	O
example,	O
many	O
reported	O
cases	O
of	O
death	O
occurred	O
in	O
the	O
postoperative	O
period	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy,	O
and	O
many	O
of	O
the	O
children	O
had	O
evidence	O
of	O
being	O
ultra-rapid	O
metabolizers	O
of	O
codeine.	O
Furthermore,	O
children	O
with	O
obstructive	O
sleep	O
apnea	O
who	O
are	O
treated	O
with	O
codeine	O
for	O
post-tonsillectomy	O
and/or	O
adenoidectomy	O
pain	O
may	O
be	O
particularly	O
sensitive	O
to	O
its	O
respiratory	O
depressant	O
effect.	O
Because	O
of	O
the	O
risk	O
of	O
life-threatening	O
respiratory	O
depression	O
and	O
death:	O
•ASCOMP	O
with	O
CODEINE	O
is	O
contraindicated	O
for	O
all	O
children	O
younger	O
than	O
12	O
years	O
of	O
age	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
•ASCOMP	O
with	O
CODEINE	O
is	O
contraindicated	O
for	O
post-operative	O
management	O
in	O
pediatric	O
patients	O
younger	O
than	O
18	O
years	O
of	O
age	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
•Avoid	O
the	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
in	O
adolescents	O
12	O
to	O
18	O
years	O
of	O
age	O
who	O
have	O
other	O
risk	O
factors	O
that	O
may	O
increase	O
their	O
sensitivity	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine	O
unless	O
the	O
benefits	O
outweigh	O
the	O
risks.	O
Risk	B-D012306
factors	O
include	O
conditions	O
associated	O
with	O
hypoventilation,	O
such	O
as	O
postoperative	O
status,	O
obstructive	O
sleep	O
apnea,	O
obesity,	O
severe	O
pulmonary	O
disease,	O
neuromuscular	O
disease,	O
and	O
concomitant	O
use	O
of	O
other	O
medications	O
that	O
cause	O
respiratory	O
depression.	O
•As	O
with	O
adults,	O
when	O
prescribing	O
ASCOMP	O
with	O
CODEINE	O
for	O
adolescents,	O
healthcare	O
providers	O
should	O
choose	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
period	O
of	O
time	O
and	O
inform	O
patients	O
and	O
caregivers	O
about	O
these	O
risks	O
and	O
the	O
signs	O
of	O
morphine	O
overdose	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(	O
8.4	O
),	O
Overdosage	O
(	O
10	O
)]	O
Nursing	B-D009729
Mothers	B-D009035
At	O
least	O
one	O
death	O
was	O
reported	O
in	O
a	O
nursing	O
infant	O
who	O
was	O
exposed	O
to	O
high	O
levels	O
of	O
morphine	O
in	O
breast	O
milk	O
because	O
the	O
mother	O
was	O
an	O
ultra-rapid	O
metabolizer	O
of	O
codeine.	O
Breast	B-D001940
feeding	O
is	O
not	O
recommended	O
during	O
treatment	O
with	O
ASCOMP	O
with	O
CODEINE	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.2)	O
].	O
CYP2D6	O
Genetic	O
Variability:	O
Ultra-rapid	O
metabolizer	O
Some	O
individuals	O
may	O
be	O
ultra-rapid	O
metabolizers	O
because	O
of	O
a	O
specific	O
CYP2D6	O
genotype	O
(gene	O
duplications	O
denoted	O
as	O
*1/*1xN	O
or	O
*1/*2xN).	O
The	O
prevalence	O
of	O
this	O
CYP2D6	O
phenotype	O
varies	O
widely	O
and	O
has	O
been	O
estimated	O
at	O
1	O
to	O
10%	O
for	O
Whites	O
(European,	O
North	B-D009656
America	I-D009656
n),	O
3	O
to	O
4%	O
for	O
Blacks	O
(African	O
Americans),	O
1	O
to	O
2%	O
for	O
East	O
Asia	B-D001208
ns	O
(Chinese,	O
Japan	B-D007564
ese,	O
Korea	B-D007723
n),	O
and	O
may	O
be	O
greater	O
than	O
10%	O
in	O
certain	O
racial/ethnic	O
groups	O
(i.e.,	O
Oceania	B-D044349
n,	O
Northern	O
Africa	B-D000349
n,	O
Middle	B-D008877
East	I-D008877
ern,	O
Ashkenazi	O
Jews	B-D007585
,	O
Puerto	O
Rican).	O
These	O
individuals	O
convert	O
codeine	O
into	O
its	O
active	O
metabolite,	O
morphine,	O
more	O
rapidly	O
and	O
completely	O
than	O
other	O
people.	O
This	O
rapid	O
conversion	O
results	O
in	O
higher	O
than	O
expected	O
serum	O
morphine	O
levels.	O
Even	O
at	O
labeled	O
dosage	O
regimens,	O
individuals	O
who	O
are	O
ultra-rapid	O
metabolizers	O
may	O
have	O
life-threatening	O
or	O
fatal	O
respiratory	O
depression	O
or	O
experience	O
signs	O
of	O
overdose	O
(such	O
as	O
extreme	O
sleepiness,	O
confusion,	O
or	O
shallow	O
breathing)	O
[see	O
Overdosage	O
(10)	O
].	O
Therefore,	O
individuals	O
who	O
are	O
ultra-rapid	O
metabolizers	O
should	O
not	O
use	O
ASCOMP	O
with	O
CODEINE.	O
5.6	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
during	O
pregnancy	O
can	O
result	O
in	O
withdrawal	O
in	O
the	O
neonate.	O
Neon	B-D009356
atal	O
opioid	O
withdrawal	O
syndrome,	O
unlike	O
opioid	O
withdrawal	O
syndrome	O
in	O
adults,	O
may	O
be	O
life-threatening	O
if	O
not	O
recognized	O
and	O
treated,	O
and	O
requires	O
management	O
according	O
to	O
protocols	O
developed	O
by	O
neonatology	O
experts.	O
Observe	O
newborns	O
for	O
signs	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
manage	O
accordingly.	O
Advise	O
pregnant	O
women	O
using	O
opioids	O
for	O
a	O
prolonged	O
period	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(	O
8.1	O
,	O
8.2	O
),	O
Patient	O
Counseling	B-D003376
Information	O
(	O
17	O
)].	O
5.7	O
Risk	B-D012306
s	O
of	O
Interactions	O
with	O
Drugs	O
Affect	B-D000339
ing	O
Cytochrome	O
P450	O
Isoenzymes	B-D007527
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
codeine	O
are	O
complex.	O
Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
ASCOMP	O
with	O
CODEINE	O
requires	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
codeine	O
and	O
the	O
active	O
metabolite,	O
morphine.	O
Cytochrome	O
P450	O
3A4	O
Interaction	O
The	O
concomitant	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
with	O
all	O
cytochrome	O
P450	O
3A4	O
inhibitors,	O
such	O
as	O
macrolide	O
antibiotics	O
(e.g.,	O
erythromycin),	O
azole-antifungal	O
agents	O
(e.g.,	O
ketoconazole),	O
and	O
protease	O
inhibitors	O
(e.g.,	O
ritonavir)	O
or	O
discontinuation	O
of	O
a	O
cytochrome	O
P450	O
3A4	O
inducer	O
such	O
as	O
rifampin,	O
carbamazepine,	O
and	O
phenytoin,	O
may	O
result	O
in	O
an	O
increase	O
in	O
codeine	O
plasma	O
concentrations	O
with	O
subsequently	O
greater	O
metabolism	O
by	O
cytochrome	O
P450	O
2D6,	O
resulting	O
in	O
greater	O
morphine	O
levels,	O
which	O
could	O
increase	O
or	O
prolong	O
adverse	O
reactions	O
and	O
may	O
cause	O
potentially	O
fatal	O
respiratory	O
depression.	O
The	O
concomitant	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
with	O
all	O
cytochrome	O
P450	O
3A4	O
inducers	O
or	O
discontinuation	O
of	O
a	O
cytochrome	O
P450	O
3A4	O
inhibitor	O
may	O
result	O
in	O
lower	O
codeine	O
levels,	O
greater	O
norcodeine	B-C010414
levels,	O
and	O
less	O
metabolism	O
via	O
2D6	O
with	O
resultant	O
lower	O
morphine	O
levels.	O
This	O
may	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
efficacy,	O
and	O
in	O
some	O
patients,	O
may	O
result	O
in	O
signs	O
and	O
symptoms	O
of	O
opioid	O
withdrawal.	O
Follow	O
patients	O
receiving	O
ASCOMP	O
with	O
CODEINE	O
and	O
any	O
CYP3A4	O
inhibitor	O
or	O
inducer	O
for	O
signs	O
and	O
symptoms	O
that	O
may	O
reflect	O
opioid	O
toxicity	O
and	O
opioid	O
withdrawal	O
when	O
ASCOMP	O
with	O
CODEINE	O
is	O
used	O
in	O
conjunction	O
with	O
inhibitors	O
and	O
inducers	O
of	O
CYP3A4.	O
If	O
concomitant	O
use	O
of	O
a	O
CYP3A4	O
inhibitor	O
is	O
necessary	O
or	O
if	O
a	O
CYP3A4	O
inducer	O
is	O
discontinued,	O
consider	O
dosage	O
reduction	O
of	O
ASCOMP	O
with	O
CODEINE	O
until	O
stable	O
drug	O
effects	O
are	O
achieved.	O
Monitor	O
patients	O
for	O
respiratory	O
depression	O
and	O
sedation	O
at	O
frequent	O
intervals.	O
If	O
concomitant	O
use	O
of	O
a	O
CYP3A4	O
inducer	O
is	O
necessary	O
or	O
if	O
a	O
CYP3A4	O
inhibitor	O
is	O
discontinued,	O
consider	O
increasing	O
the	O
ASCOMP	O
with	O
CODEINE	O
dosage	O
until	O
stable	O
drug	O
effects	O
are	O
achieved.	O
Monitor	O
for	O
signs	O
of	O
opioid	O
withdrawal.	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Risk	B-D012306
s	O
of	O
Concomitant	O
Use	O
or	O
Discontinuation	O
of	O
Cytochrome	O
P450	O
2D6	O
Inhibitors	O
The	O
concomitant	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
with	O
all	O
cytochrome	O
P450	O
2D6	O
inhibitors	O
(e.g.,	O
amiodarone,	O
quinidine)	O
may	O
result	O
in	O
an	O
increase	O
in	O
codeine	O
plasma	O
concentrations	O
and	O
a	O
decrease	O
in	O
active	O
metabolite	O
morphine	O
plasma	O
concentration	O
which	O
could	O
result	O
in	O
an	O
analgesic	O
efficacy	O
reduction	O
or	O
symptoms	O
of	O
opioid	O
withdrawal.	O
Discontinuation	O
of	O
a	O
concomitantly	O
used	O
cytochrome	O
P450	O
2D6	O
inhibitor	O
may	O
result	O
in	O
a	O
decrease	O
in	O
codeine	O
plasma	O
concentration	O
and	O
an	O
increase	O
in	O
active	O
metabolite	O
morphine	O
plasma	O
concentration	O
which	O
could	O
increase	O
or	O
prolong	O
adverse	O
reactions	O
and	O
may	O
cause	O
potentially	O
fatal	O
respiratory	O
depression.	O
Follow	O
patients	O
receiving	O
ASCOMP	O
with	O
CODEINE	O
and	O
any	O
CYP2D6	O
inhibitor	O
for	O
signs	O
and	O
symptoms	O
that	O
may	O
reflect	O
opioid	O
toxicity	O
and	O
opioid	O
withdrawal	O
when	O
ASCOMP	O
with	O
CODEINE	O
are	O
used	O
in	O
conjunction	O
with	O
inhibitors	O
of	O
CYP2D6.	O
If	O
concomitant	O
use	O
with	O
a	O
CYP2D6	O
inhibitor	O
is	O
necessary,	O
follow	O
the	O
patient	O
for	O
signs	O
of	O
reduced	O
efficacy	O
or	O
opioid	O
withdrawal	O
and	O
consider	O
increasing	O
the	O
ASCOMP	O
with	O
CODEINE	O
dosage.	O
After	O
stopping	O
use	O
of	O
a	O
CYP2D6	O
inhibitor,	O
consider	O
reducing	O
the	O
ASCOMP	O
with	O
CODEINE	O
dosage	O
and	O
follow	O
the	O
patient	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
or	O
sedation.	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.8	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
or	O
in	O
Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
The	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
in	O
patients	O
with	O
acute	O
or	O
severe	O
bronchial	O
asthma	O
in	O
an	O
unmonitored	O
setting	O
or	O
in	O
the	O
absence	O
of	O
resuscitative	O
equipment	O
is	O
contraindicated.	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
:	O
ASCOMP	O
with	O
CODEINE-treated	O
patients	O
with	O
significant	O
chronic	O
obstructive	O
pulmonary	O
disease	O
or	O
cor	O
pulmonale,	O
and	O
those	O
with	O
a	O
substantially	O
decreased	O
respiratory	O
reserve,	O
hypoxia,	O
hypercapnia,	O
or	O
pre-existing	O
respiratory	O
depression	O
are	O
at	O
increased	O
risk	O
of	O
decreased	O
respiratory	O
drive	O
including	O
apnea,	O
even	O
at	O
recommended	O
dosages	O
of	O
ASCOMP	O
with	O
CODEINE	O
[see	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
:	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
is	O
more	O
likely	O
to	O
occur	O
in	O
elderly,	O
cachectic,	O
or	O
debilitated	O
patients	O
because	O
they	O
may	O
have	O
altered	O
pharmacokinetics	O
or	O
altered	O
clearance	O
compared	O
to	O
younger,	O
healthier	O
patients	O
[see	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Monitor	O
such	O
patients	O
closely,	O
particularly	O
when	O
initiating	O
and	O
titrating	O
ASCOMP	O
with	O
CODEINE	O
and	O
when	O
ASCOMP	O
with	O
CODEINE	O
is	O
given	O
concomitantly	O
with	O
other	O
drugs	O
that	O
depress	O
respiration	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
].	O
Alternatively,	O
consider	O
the	O
use	O
of	O
non-opioid	O
analgesics	O
in	O
these	O
patients.	O
5.9	O
Interaction	O
with	O
Monoamine	B-D008996
Oxidase	I-D008996
Inhibitors	I-D008996
Monoamine	O
oxidase	O
inhibitors	O
(MAOIs)	O
may	O
potentiate	O
the	O
effects	O
of	O
morphine,	O
codeine’s	O
active	O
metabolite,	O
including	O
respiratory	O
depression,	O
coma,	O
and	O
confusion.	O
ASCOMP	O
with	O
CODEINE	O
should	O
not	O
be	O
used	O
in	O
patients	O
taking	O
MAOIs	O
or	O
within	O
14	O
days	O
of	O
stopping	O
such	O
treatment.	O
5.10	O
Adrenal	B-D000309
Insufficiency	I-D000309
Cases	O
of	O
adrenal	O
insufficiency	O
have	O
been	O
reported	O
with	O
opioid	O
use,	O
more	O
often	O
following	O
greater	O
than	O
one	O
month	O
of	O
use.	O
Presentation	O
of	O
adrenal	O
insufficiency	O
may	O
include	O
non-specific	O
symptoms	O
and	O
signs	O
including	O
nausea,	O
vomiting,	O
anorexia,	O
fatigue,	O
weakness,	O
dizziness,	O
and	O
low	O
blood	O
pressure.	O
If	O
adrenal	O
insufficiency	O
is	O
suspected,	O
confirm	O
the	O
diagnosis	O
with	O
diagnostic	O
testing	O
as	O
soon	O
as	O
possible.	O
If	O
adrenal	O
insufficiency	O
is	O
diagnosed,	O
treat	O
with	O
physiologic	O
replacement	O
doses	O
of	O
corticosteroids.	O
Wean	O
the	O
patient	O
off	O
of	O
the	O
opioid	O
to	O
allow	O
adrenal	O
function	O
to	O
recover	O
and	O
continue	O
corticosteroid	O
treatment	O
until	O
adrenal	O
function	O
recovers.	O
Other	O
opioids	O
may	O
be	O
tried	O
as	O
some	O
cases	O
reported	O
use	O
of	O
a	O
different	O
opioid	O
without	O
recurrence	O
of	O
adrenal	O
insufficiency.	O
The	O
information	O
available	O
does	O
not	O
identify	O
any	O
particular	O
opioids	O
as	O
being	O
more	O
likely	O
to	O
be	O
associated	O
with	O
adrenal	O
insufficiency.	O
5.11	O
Severe	O
Hypotension	B-D007022
ASCOMP	O
with	O
CODEINE	O
may	O
cause	O
severe	O
hypotension	O
including	O
orthostatic	O
hypotension	O
and	O
syncope	O
in	O
ambulatory	O
patients.	O
There	O
is	O
increased	O
risk	O
in	O
patients	O
whose	O
ability	O
to	O
maintain	O
blood	O
pressure	O
has	O
already	O
been	O
compromised	O
by	O
a	O
reduced	O
blood	O
volume	O
or	O
concurrent	O
administration	O
of	O
certain	O
CNS	O
depressant	O
drugs	O
(e.g.,	O
phenothiazine	B-C031637
s	O
or	O
general	O
anesthetics)	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
hypotension	O
after	O
initiating	O
or	O
titrating	O
the	O
dosage	O
of	O
ASCOMP	O
with	O
CODEINE.	O
In	O
patients	O
with	O
circulatory	O
shock,	O
ASCOMP	O
with	O
CODEINE	O
may	O
cause	O
vasodilation	O
that	O
can	O
further	O
reduce	O
cardiac	O
output	O
and	O
blood	O
pressure.	O
Avoid	O
the	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
in	O
patients	O
with	O
circulatory	O
shock.	O
5.12	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Increased	O
Intracranial	B-D007427
Pressure	I-D007427
,	O
Brain	B-D001921
Tumors,	O
Head	B-D006257
Injury,	O
or	O
Impaired	O
Consciousness	B-D003243
In	O
patients	O
who	O
may	O
be	O
susceptible	O
to	O
the	O
intracranial	O
effects	O
of	O
CO2	O
retention	O
(e.g.,	O
those	O
with	O
evidence	O
of	O
increased	O
intracranial	O
pressure	O
or	O
brain	O
tumors),	O
ASCOMP	O
with	O
CODEINE	O
may	O
reduce	O
respiratory	O
drive,	O
and	O
the	O
resultant	O
CO2	O
retention	O
can	O
further	O
increase	O
intracranial	O
pressure.	O
Monitor	O
such	O
patients	O
for	O
signs	O
of	O
sedation	O
and	O
respiratory	O
depression,	O
particularly	O
when	O
initiating	O
therapy	O
with	O
ASCOMP	O
with	O
CODEINE.	O
Opioids	O
may	O
also	O
obscure	O
the	O
clinical	O
course	O
in	O
a	O
patient	O
with	O
a	O
head	O
injury.	O
Avoid	O
the	O
use	O
of	O
ASCOMP	O
with	O
CODEINE	O
in	O
patients	O
with	O
impaired	O
consciousness	O
or	O
coma.	O
5.13	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Gastrointestinal	O
Conditions	O
Including	O
Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
ASCOMP	O
with	O
CODEINE	O
is	O
contraindicated	O
in	O
patients	O
with	O
known	O
or	O
suspected	O
gastrointestinal	O
obstruction,	O
including	O
paralytic	O
ileus.	O
The	O
codeine	O
in	O
ASCOMP	O
with	O
CODEINE	O
may	O
cause	O
spasm	O
of	O
the	O
sphincter	O
of	O
Oddi.	O
Opioids	O
may	O
cause	O
increases	O
in	O
serum	O
amylase.	O
Monitor	O
patients	O
with	O
biliary	O
tract	O
disease,	O
including	O
acute	O
pancreatitis	O
for	O
worsening	O
symptoms.	O
Patients	B-D010361
with	O
a	O
history	O
of	O
active	O
peptic	O
ulcer	O
disease	O
should	O
avoid	O
using	O
aspirin,	O
which	O
can	O
cause	O
gastric	O
mucosal	O
irritation	O
and	O
bleeding.	O
The	O
aspirin	O
in	O
ASCOMP	O
with	O
CODEINE	O
can	O
cause	O
GI	O
side	O
effects	O
including	O
stomach	O
pain,	O
heartburn,	O
nausea,	O
vomiting,	O
and	O
gross	O
GI	O
bleeding.	O
Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
dyspepsia,	O
are	O
common	O
and	O
can	O
occur	O
anytime	O
during	O
therapy,	O
physicians	O
should	O
remain	O
alert	O
for	O
signs	O
of	O
ulceration	O
and	O
bleeding,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
GI	O
symptoms.	O
Physicians	B-D010820
should	O
inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
GI	O
side	O
effects	O
and	O
what	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
5.14	O
Increased	O
Risk	B-D012306
of	O
Seizures	B-D012640
in	O
Patients	B-D010361
with	O
Seizure	O
Disorders	O
The	O
codeine	O
in	O
ASCOMP	O
with	O
CODEINE	O
may	O
increase	O
the	O
frequency	O
of	O
seizures	O
in	O
patients	O
with	O
seizure	O
disorders	O
and	O
may	O
increase	O
the	O
risk	O
of	O
seizures	O
occurring	O
in	O
other	O
clinical	O
settings	O
associated	O
with	O
seizures.	O
Monitor	O
patients	O
with	O
a	O
history	O
of	O
seizure	O
disorders	O
for	O
worsened	O
seizure	O
control	O
during	O
ASCOMP	O
with	O
CODEINE	O
therapy.	O
5.15	O
Withdrawal	O
Do	O
not	O
abruptly	O
discontinue	O
ASCOMP	O
with	O
Codeine	B-D003061
in	O
a	O
patient	O
physically	O
dependent	O
on	O
opioids.	O
Rapid	O
tapering	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
in	O
a	O
patient	O
physically	O
dependent	O
on	O
opioids	O
may	O
lead	O
to	O
a	O
withdrawal	O
syndrome	O
and	O
return	O
of	O
pain	O
[see	O
Dosage	O
and	O
Administration	O
(2.3),	O
Drug	O
Abuse	O
and	O
Dependence	O
(9.3)].	O
Additionally,	O
avoid	O
the	O
use	O
of	O
mixed	O
agonist/antagonist	O
(e.g.,	O
pentazocine,	O
nalbuphine,	O
and	O
butorphan	B-C520649
ol)	O
or	O
partial	O
agonist	O
(e.g.,	O
buprenorphine)	O
analgesics	O
in	O
patients	O
who	O
are	O
receiving	O
a	O
full	O
opioid	O
agonist	O
analgesic,	O
including	O
ASCOMP	O
with	O
CODEINE.	O
In	O
these	O
patients,	O
mixed	O
agonist/antagonist	O
and	O
partial	O
agonist	O
analgesics	O
may	O
reduce	O
the	O
analgesic	O
effect	O
and/or	O
precipitate	O
withdrawal	O
symptoms.	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
When	O
discontinuing	O
ASCOMP	O
with	O
CODEINE	O
in	O
a	O
physically-dependent	O
patient,	O
gradually	O
taper	O
the	O
dosage	O
[see	O
Dosage	O
and	O
Administration	O
(2.3)	O
].	O
Abrupt	O
discontinuation	O
of	O
butalbital	B-C004470
can	O
cause	O
seizures	O
[see	O
Drug	O
Abuse	O
and	O
Dependence	O
(	O
9.3	O
)].	O
5.16	O
Risk	B-D012306
s	O
of	O
Driving	O
and	O
Operating	O
Machinery	O
ASCOMP	O
with	O
CODEINE	O
may	O
impair	O
the	O
mental	O
or	O
physical	O
abilities	O
needed	O
to	O
perform	O
potentially	O
hazardous	O
activities	O
such	O
as	O
driving	O
a	O
car	O
or	O
operating	O
machinery.	O
Warn	O
patients	O
not	O
to	O
drive	O
or	O
operate	O
dangerous	O
machinery	O
unless	O
they	O
are	O
tolerant	O
to	O
the	O
effects	O
of	O
ASCOMP	O
with	O
CODEINE	O
and	O
know	O
how	O
they	O
will	O
react	O
to	O
the	O
medication.	O
5.17	O
Coagulation	O
Abnormalities	O
and	O
Bleeding	O
Risk	B-D012306
s	O
Even	O
low	O
doses	O
of	O
aspirin	O
can	O
inhibit	O
platelet	O
function	O
leading	O
to	O
an	O
increase	O
in	O
bleeding	O
time.	O
This	O
can	O
adversely	O
affect	O
patients	O
with	O
inherited	O
(i.e.	O
hemophilia)	O
or	O
acquired	O
(i.e.	O
liver	O
disease	O
or	O
vitamin	O
K	O
deficiency)	O
bleeding	O
disorders.	O
Aspirin	B-D001241
is	O
contraindicated	O
in	O
patients	O
with	O
hemophilia.	O
Aspirin	B-D001241
administered	O
pre-operatively	O
may	O
prolong	O
the	O
bleeding	O
time.	O
Patients	B-D010361
who	O
consume	O
three	O
or	O
more	O
alcoholic	O
drinks	O
every	O
day	O
should	O
be	O
counseled	O
about	O
the	O
bleeding	O
risks	O
involved	O
with	O
chronic,	O
heavy	O
alcohol	O
use	O
while	O
taking	O
aspirin.	O
5.18	O
Reye’s	O
Syndrome	B-D013577
Aspirin	B-D001241
should	O
not	O
be	O
used	O
in	O
children	O
or	O
teenagers	O
for	O
viral	O
infections,	O
with	O
or	O
without	O
fever,	O
because	O
of	O
the	O
risk	O
of	O
Reye	O
syndrome	O
with	O
concomitant	O
use	O
of	O
aspirin	O
in	O
certain	O
viral	O
illnesses.	O
5.19	O
Allergy	O
Aspirin	B-D001241
is	O
contraindicated	O
in	O
patients	O
with	O
known	O
allergy	O
to	O
nonsteroidal	O
anti-inflammatory	O
drug	O
products	O
(NSAIDs)	O
and	O
in	O
patients	O
with	O
the	O
syndrome	O
of	O
asthma,	O
rhinitis,	O
and	O
nas	B-C015378
al	O
polyps.	O
Aspirin	B-D001241
may	O
cause	O
severe	O
urticaria,	O
angioedema,	O
or	O
bronchospasm	O
(asthma).	O
5.20	O
Drug/Laboratory	O
Test	O
Interactions	O
Aspirin	B-D001241
:	O
Aspirin	B-D001241
may	O
interfere	O
with	O
the	O
following	O
laboratory	O
determinations	O
in	O
blood:	O
serum	O
amylase,	O
fasting	O
blood	O
glucose,	O
cholesterol,	O
protein,	O
serum	O
glutamic-oxalacetic	O
transaminase	O
(SGOT),	O
uric	O
acid,	O
prothrombin	O
time	O
and	O
bleeding	O
time.	O
Aspirin	B-D001241
may	O
interfere	O
with	O
the	O
following	O
laboratory	O
determinations	O
in	O
urine:	O
glucose,	O
5-hydroxy-indoleacetic	O
acid,	O
Gerhardt	O
ketone,	O
vanillylmandelic	O
acid	O
(VMA),	O
uric	O
acid,	O
diacetic	O
acid,	O
and	O
spectrophotometric	O
detection	O
of	O
barbiturates.	O
Codeine	B-D003061
:	O
Codeine	B-D003061
may	O
increase	O
serum	O
amylase	O
levels.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described,	O
or	O
described	O
in	O
greater	O
detail,	O
in	O
other	O
sections:	O
•Addiction,	O
Abuse,	O
and	O
Misuse	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
•Life-Threatening	O
Respiratory	O
Depression	B-D003863
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
•Interactions	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
•Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
•Neonatal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
•Adrenal	O
Insufficiency	O
[see	O
Warnings	O
and	O
Precautions	O
(5.10)	O
]	O
•Severe	O
Hypotension	B-D007022
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
•Gastrointestinal	O
Adverse	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.13)	O
]	O
•Seizures	O
[see	O
Warnings	O
and	O
Precautions	O
(5.14)	O
]	O
•Withdrawal	O
[see	O
Warnings	O
and	O
Precautions	O
(5.15)	O
]	O
•Coagulation	O
Abnormalities	O
and	O
Bleeding	O
[see	O
Warnings	O
and	O
Precautions	O
(5.17)	O
]	O
•Reye’s	O
Syndrome	B-D013577
[see	O
Warnings	O
and	O
Precautions	O
(5.18)	O
]	O
•Allergy	O
[see	O
Warnings	O
and	O
Precautions	O
(5.19)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
1%)	O
are	O
nausea	O
and/or	O
abdominal	O
pain,	O
drowsiness,	O
and	O
dizziness.	O
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Nexgen	O
Pharma	O
at	O
1-888-710-0006	O
or	O
online	O
at	O
www.nexgenpharma.com	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Incidence	B-D015994
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
s:	O
The	O
following	O
table	O
summarizes	O
the	O
incidence	O
rates	O
of	O
the	O
adverse	O
events	O
reported	O
by	O
at	O
least	O
1%	O
of	O
the	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate,	O
USP	O
Capsules	B-D002214
treated	O
patients	O
in	O
controlled	O
clinical	O
trials	O
comparing	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate,	O
USP	O
Capsules	B-D002214
to	O
placebo,	O
and	O
provides	O
a	O
comparison	O
to	O
the	O
incidence	O
rates	O
reported	O
by	O
the	O
placebo-treated	O
patients.	O
The	O
prescriber	O
should	O
be	O
aware	O
that	O
these	O
figures	O
cannot	O
be	O
used	O
to	O
predict	O
the	O
incidence	O
of	O
side	O
effects	O
in	O
the	O
course	O
of	O
usual	O
medical	O
practice	O
where	O
patient	O
characteristics	O
and	O
other	O
factors	O
differ	O
from	O
those	O
that	O
prevailed	O
in	O
the	O
clinical	O
trials.	O
Similarly,	O
the	O
cited	O
frequencies	O
cannot	O
be	O
compared	O
with	O
figures	O
obtained	O
from	O
other	O
clinical	O
investigations	O
involving	O
different	O
treatments,	O
uses,	O
and	O
investigators.	O
Adverse	O
Events	O
Reported	O
by	O
at	O
Least	O
1%	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate,	O
USP	O
Capsules	B-D002214
Treated	O
Patients	B-D010361
During	O
Placebo	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
s	O
Incidence	B-D015994
Rate	O
of	O
Adverse	O
Events	O
Body	O
System/Adverse	O
Event	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate,	O
USP	O
Capsules	B-D002214
(N=382)	O
Placebo	O
(N	O
=377)	O
Central	O
Nervous	O
Drowsiness	O
2.4%	O
0.5%	O
Dizziness	B-D004244
/Lightheadedness	O
2.6%	O
0.5%	O
Intoxicated	O
Feeling	O
1.0%	O
0%	O
Gastrointestinal	O
Nausea	B-D009325
/Abdominal	O
Pain	B-D010146
3.7%	O
0.8%	O
Other	O
Adverse	O
Events	O
Reported	O
During	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
s	O
The	O
listing	O
that	O
follows	O
represents	O
the	O
proportion	O
of	O
the	O
382	O
patients	O
exposed	O
to	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate,	O
USP	O
Capsules	B-D002214
while	O
participating	O
in	O
the	O
controlled	O
clinical	O
trials	O
who	O
reported,	O
on	O
at	O
least	O
one	O
occasion,	O
an	O
adverse	O
event	O
of	O
the	O
type	O
cited.	O
All	O
reported	O
adverse	O
events,	O
except	O
those	O
already	O
presented	O
in	O
the	O
previous	O
table,	O
are	O
included.	O
It	O
is	O
important	O
to	O
emphasize	O
that,	O
although	O
the	O
adverse	O
events	O
reported	O
did	O
occur	O
while	O
the	O
patient	O
was	O
receiving	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate,	O
USP	O
Capsules	B-D002214
,	O
the	O
adverse	O
events	O
were	O
not	O
necessarily	O
caused	O
by	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate,	O
USP	O
Capsules	B-D002214
.	O
Adverse	O
events	O
are	O
classified	O
by	O
body	O
system	O
and	O
frequency.	O
“Frequent”	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
which	O
occurred	O
in	O
at	O
least	O
1/100	O
(1%)	O
of	O
the	O
patients;	O
all	O
adverse	O
events	O
listed	O
in	O
the	O
previous	O
table	O
are	O
frequent.	O
“Infrequent”	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
that	O
occurred	O
in	O
less	O
than	O
1/100	O
patients	O
but	O
at	O
least	O
1/1000	O
patients.	O
All	O
adverse	O
events	O
tabulated	O
below	O
are	O
classified	O
as	O
infrequent.	O
Central	O
Nervous:	O
headache,	O
shaky	O
feeling,	O
tingling,	O
agitation,	O
fainting,	O
fatigue,	O
heavy	O
eyelids,	O
high	O
energy,	O
hot	O
spells,	O
numbness,	O
and	O
sluggishness.	O
Autonomic	O
Nervous:	O
dry	O
mouth	O
and	O
hyperhidrosis.	O
Gastrointestinal:	O
vomiting,	O
difficulty	O
swallowing,	O
and	O
heartburn.	O
Cardiovascular:	O
tachycardia.	O
Musculoskeletal:	O
leg	O
pain	O
and	O
muscle	O
fatigue.	O
Genitourinary:	O
diuresis.	O
Miscellaneous:	O
pruritus,	O
fever,	O
earache,	O
nas	B-C015378
al	O
congestion,	O
and	O
tinnitus.	O
The	O
following	O
adverse	O
drug	O
reactions	O
have	O
been	O
reported	O
with	O
the	O
components	O
of	O
ASCOMP	O
with	O
CODEINE.	O
Potential	O
effects	O
of	O
high	O
dosage	O
are	O
listed	O
in	O
the	O
[see	O
Overdosage	O
(10)	O
]	O
section	O
of	O
this	O
insert.	O
Aspirin	B-D001241
:	O
occult	O
blood	O
loss,	O
hemolytic	O
anemia,	O
iron	O
deficiency	O
anemia,	O
gastric	O
distress,	O
heartburn,	O
nausea,	O
peptic	O
ulcer,	O
prolonged	O
bleeding	O
time,	O
acute	O
airway	O
obstruction,	O
renal	O
toxicity	O
when	O
taken	O
in	O
high	O
doses	O
for	O
prolonged	O
periods,	O
impaired	O
urate	O
excretion,	O
hepatitis.	O
Caffeine	B-D002110
:	O
cardiac	O
stimulation,	O
irritability,	O
tremor,	O
dependence,	O
nephrotoxicity,	O
hyperglycemia.	O
Codeine	B-D003061
:	O
nausea,	O
vomiting,	O
drowsiness,	O
lightheadedness,	O
constipation,	O
pruritus.	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate,	O
USP	O
Capsules	B-D002214
.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Central	O
Nervous:	O
abuse,	O
addiction,	O
anxiety,	O
depression,	O
disorientation,	O
hallucination,	O
hyperactivity,	O
insomnia,	O
libido	O
decrease,	O
nervousness,	O
neuropathy,	O
psychosis,	O
sedation,	O
sexual	O
activity	O
increase,	O
slurred	O
speech,	O
twitching,	O
unconsciousness,	O
vertigo.	O
Autonomic	O
Nervous:	O
epistaxis,	O
flushing,	O
miosis,	O
salivation.	O
Gastrointestinal:	O
anorexia,	O
appetite	O
increased,	O
constipation,	O
diarrhea,	O
esophagitis,	O
gastroenteritis,	O
gastrointestinal	O
spasm,	O
hiccup,	O
mouth	O
burning,	O
pyloric	O
ulcer.	O
Cardiovascular:	O
chest	O
pain,	O
hypotensive	O
reaction,	O
palpitations,	O
syncope.	O
Skin	B-D012867
:	O
erythema,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
hives,	O
rash,	O
toxic	O
epidermal	O
necrolysis.	O
Urinary:	O
kidney	O
impairment,	O
urinary	O
difficulty.	O
Miscellaneous:	O
allergic	O
reaction,	O
anaphylactic	O
shock,	O
cholangiocarcinoma,	O
drug	O
interaction	O
with	O
erythromycin	O
(stomach	O
upset),	O
edema.	O
Serotonin	B-D012701
syndrome:	O
Cases	O
of	O
serotonin	O
syndrome,	O
a	O
potentially	O
life-threatening	O
condition,	O
have	O
been	O
reported	O
during	O
concomitant	O
use	O
of	O
opioids	O
with	O
serotonergic	O
drugs.	O
Adrenal	O
insufficiency:	O
Cases	O
of	O
adrenal	O
insufficiency	O
have	O
been	O
reported	O
with	O
opioid	O
use,	O
more	O
often	O
following	O
greater	O
than	O
one	O
month	O
of	O
use.	O
Anaphylaxis	B-D000707
:	O
Anaphylaxis	B-D000707
has	O
been	O
reported	O
with	O
ingredients	O
contained	O
in	O
ASCOMP	O
with	O
CODEINE.	O
Androgen	O
deficiency:	O
Cases	O
of	O
androgen	O
deficiency	O
have	O
occurred	O
with	O
chronic	O
use	O
of	O
opioids	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS	O
].	O
Ibuprofen	B-D007052
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	O
and	O
WARNINGS	O
].	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
WARNINGS	O
].	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	O
tablets	O
is	O
gastrointestinal.	O
In	O
controlled	O
clinical	O
trials	O
the	O
percentage	O
of	O
patients	O
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%.	O
In	O
controlled	O
studies	O
when	O
ibuprofen	O
tablets	O
were	O
compared	O
to	O
aspirin	O
and	O
indomethacin	O
in	O
equally	O
effective	O
doses,	O
the	O
overall	O
incidence	O
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	O
or	O
indomethacin-treated	O
patients.	O
Adverse	O
reactions	O
observed	O
during	O
controlled	O
clinical	O
trials	O
at	O
an	O
incidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table.	O
Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	O
in	O
approximately	O
3,000	O
patients.	O
More	O
than	O
500	O
of	O
these	O
patients	O
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks.	O
Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	O
clinical	O
trials	O
and	O
from	O
marketing	O
experience.	O
These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	O
tablets	O
where	O
the	O
probability	O
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	O
tablets	O
has	O
not	O
been	O
established.	O
Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	O
trials	O
of	O
patients	O
with	O
rheumatoid	O
arthritis.	O
The	O
increases	O
in	O
incidence	O
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table.	O
Incidence	B-D015994
Greater	O
Than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
ibuprofen	O
tablets.	O
(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.)	O
**	O
Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related.	O
Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met.	O
GASTROINTESTINAL	O
Nausea	B-D009325
*,	O
epigastric	O
pain*,	O
heartburn*,	O
diarrhea,	O
abdominal	O
distress,	O
nausea	O
and	O
vomiting,	O
indigestion,	O
constipation,	O
abdominal	O
cramps	O
or	O
pain,	O
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	O
Gastric	O
or	O
duodenal	O
ulcer	O
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	O
hemorrhage,	O
melena,	O
gastritis,	O
hepatitis,	O
jaundice,	O
abnormal	O
liver	O
function	O
tests;	O
pancreatitis	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
Dizziness	B-D004244
*,	O
headache,	O
nervousness	O
Depression	B-D003863
,	O
insomnia,	O
confusion,	O
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	O
with	O
fever	O
and	O
coma	O
[see	O
PRECAUTIONS	O
]	O
Paresthesia	B-D010292
s,	O
hallucinations,	O
dream	O
abnormalities,	O
pseudotumor	O
cerebri	O
DERMATOLOGIC	O
Rash*	O
(including	O
maculopapular	O
type),	O
pruritus	O
Vesiculobullous	O
eruptions,	O
urticaria,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome,	O
alopecia	O
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	O
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D006309
loss,	O
amblyopia	O
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	O
and/or	O
changes	O
in	O
color	O
vision)	O
[see	O
PRECAUTIONS	O
]	O
Conjunctivitis	B-D003231
,	O
diplopia,	O
optic	O
neuritis,	O
cataracts	O
HEMATOLOGIC	O
Neutropenia	B-D009503
,	O
agranulocytosis,	O
aplastic	O
anemia,	O
hemolytic	O
anemia	O
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	O
with	O
or	O
without	O
purpura,	O
eosinophilia,	O
decreases	O
in	O
hemoglobin	O
and	O
hematocrit	O
[see	O
PRECAUTIONS	O
]	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	O
menorrhagia)	O
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	O
Gynecomastia	B-D006177
,	O
hypoglycemic	O
reaction,	O
acidosis	O
CARDIOVASCULAR	O
Edema	B-D004487
,	O
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS	O
)	O
Congestive	O
heart	O
failure	O
in	O
patients	O
with	O
marginal	O
cardiac	O
function,	O
elevated	O
blood	O
pressure,	O
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	O
sinus	O
bradycardia)	O
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	O
pain,	O
fever,	O
chills,	O
nausea	O
and	O
vomiting;	O
anaphylaxis;	O
bronchospasm	O
[see	O
CONTRAINDICATIONS	O
]	O
Serum	B-D044967
sickness,	O
lupus	O
erythematosus	O
syndrome.	O
Henoch-Schonlein	O
vasculitis,	O
angioedema	O
RENAL	O
Acute	O
renal	O
failure	O
[see	O
PRECAUTIONS	O
],	O
decreased	O
creatinine	O
clearance,	O
polyuria,	O
azotemia,	O
cystitis,	O
hematuria	O
Renal	O
papillary	O
necrosis	O
MISCELLANEOUS	O
Dry	O
eyes	O
and	O
mouth,	O
gingival	O
ulcer,	O
rhinitis	O
tests	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
Etodolac	B-D017308
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
capsules	O
and	O
tablets	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1,000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
or	O
Equal	O
to	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain*,	O
diarrhea*,	O
flatulence*,	O
nausea*,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise*,	O
dizziness*,	O
depression,	O
nervousness,	O
fatigue.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
Musculoskeletal	O
-	O
Arthralgia	B-D018771
.	O
*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
fatal	O
fulminant	O
hepatitis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
–	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis,leukocytoclastic	O
vasculitis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.	O
Musculoskeletal	O
-	O
Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
–	O
Sepsis	B-D018805
,	O
death.	O
Cardiovascular	O
system	O
–	O
Tachycardia	B-D013610
.	O
Digestive	O
system	O
–	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis.	O
Hemic	O
and	O
lymphatic	O
system	O
–	O
Lymphadenopathy	B-D000072281
.	O
Nervous	O
system	O
–	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo.	O
Respiratory	O
system	O
–	O
Respiratory	O
depression,	O
pneumonia.	O
Urogenital	O
system	O
–	O
Oliguria	B-D009846
/polyuria,	O
proteinuria.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure.	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment.	O
ADVERSE	O
REACTIONS	O
Transient	O
burning	O
and	O
stinging	O
upon	O
instillation	O
and	O
other	O
minor	O
symptoms	O
of	O
ocular	O
irritation	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
flurbiprofen	O
sodium	O
ophthalmic	O
solution	O
0.03%.	O
Other	O
adverse	O
reactions	O
reported	O
with	O
the	O
use	O
of	O
flurbiprofen	O
sodium	O
ophthalmic	O
solution	O
0.03%	O
include:	O
fibrosis,	O
miosis,	O
and	O
mydriasis.	O
Increased	O
bleeding	O
tendency	O
of	O
ocular	O
tissues	O
in	O
conjunction	O
with	O
ocular	O
surgery	O
has	O
also	O
been	O
reported.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(5.1)	O
FLECTOR	O
PATCH	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
FLECTOR	O
PATCH	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)•	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
FLECTOR	O
PATCH	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
FLECTOR	O
PATCH	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
FLECTOR	O
PATCH	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials	O
of	O
oral	O
diclofenac	O
containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
sodium	O
for	O
2-6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3-8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
FLECTOR	O
PATCH	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
FLECTOR	O
PATCH	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
FLECTOR	O
PATCH,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
FLECTOR	O
PATCH	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
FLECTOR	O
PATCH,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
FLECTOR	O
PATCH	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
pre-existing	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
FLECTOR	O
PATCH.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
FLECTOR	O
PATCH	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
FLECTOR	O
PATCH	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
FLECTOR	O
PATCH	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
FLECTOR	O
PATCH,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
FLECTOR	O
PATCH	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
FLECTOR	O
PATCH,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
FLECTOR	O
PATCH	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
].	O
5.14	O
Accidental	O
Exposure	O
in	O
Child	B-D002648
ren	O
Even	O
a	O
used	O
Flector	O
Patch	O
contains	O
a	O
large	O
amount	O
of	O
diclofenac	O
epolamine	B-C104862
(as	O
much	O
as	O
170	O
mg).	O
The	O
potential	O
therefore	O
exists	O
for	O
a	O
small	O
child	O
or	O
pet	O
to	O
suffer	O
serious	O
adverse	O
effects	O
from	O
chewing	O
or	O
ingesting	O
a	O
new	O
or	O
used	O
Flector	O
Patch.	O
It	O
is	O
important	O
for	O
patients	O
to	O
store	O
and	O
dispose	O
of	O
Flector	O
Patch	O
out	O
of	O
the	O
reach	O
of	O
children	O
and	O
pets.	O
5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Flector	O
Patch	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Do	O
not	O
use	O
combination	O
therapy	O
with	O
Flector	O
Patch	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
are	O
application	O
site	O
conditions,	O
occurring	O
in	O
11%	O
and	O
12%,	O
respectively,	O
of	O
FLECTOR	O
PATCH	O
and	O
Placebo	O
Patch-treated	O
patients	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
Inc.	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
controlled	O
trials	O
during	O
the	O
premarketing	O
development	O
of	O
FLECTOR	O
PATCH,	O
approximately	O
600	O
patients	O
with	O
minor	O
sprains,	O
strains,	O
and	O
contusions	O
were	O
treated	O
with	O
FLECTOR	O
PATCH	O
for	O
up	O
to	O
two	O
weeks.	O
Adverse	O
Events	O
Lead	B-D007854
ing	O
to	O
Discontinuation	O
of	O
Treatment	O
In	O
the	O
controlled	O
trials,	O
3%	O
of	O
patients	O
in	O
both	O
the	O
FLECTOR	O
PATCH	O
and	O
placebo	O
patch	O
groups	O
discontinued	O
treatment	O
due	O
to	O
an	O
adverse	O
event.	O
The	O
most	O
common	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
were	O
application	O
site	O
reactions,	O
occurring	O
in	O
2%	O
of	O
both	O
the	O
FLECTOR	O
PATCH	O
and	O
placebo	O
patch	O
groups.	O
Application	O
site	O
reactions	O
leading	O
to	O
dropout	O
included	O
pruritus,	O
dermatitis,	O
and	O
burning.	O
Common	O
Adverse	O
Events	O
Localized	O
Reactions	O
Overall	B-D016424
,	O
the	O
most	O
common	O
adverse	O
events	O
associated	O
with	O
FLECTOR	O
PATCH	O
treatment	O
were	O
skin	O
reactions	O
at	O
the	O
site	O
of	O
treatment.	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥	O
1%	O
of	O
patients	O
in	O
controlled	O
trials	O
of	O
FLECTOR	O
PATCH.	O
A	O
majority	O
of	O
patients	O
treated	O
with	O
FLECTOR	O
PATCH	O
had	O
adverse	O
events	O
with	O
a	O
maximum	O
intensity	O
of	O
"mild"	O
or	O
"moderate."	O
Table	O
1.	O
Common	O
Adverse	O
Events	O
(by	O
body	O
system	O
and	O
preferred	O
term)	O
in	O
≥	O
1%	O
of	O
Patients	B-D010361
treated	O
with	O
FLECTOR	O
PATCH	O
or	O
Placebo	O
Patch	O
The	O
table	O
lists	O
adverse	O
events	O
occurring	O
in	O
placebo-treated	O
patients	O
because	O
the	O
placebo-patch	O
was	O
comprised	O
of	O
the	O
same	O
ingredients	O
as	O
FLECTOR	O
PATCH	O
except	O
for	O
diclofenac.	O
Adverse	O
events	O
in	O
the	O
placebo	O
group	O
may	O
therefore	O
reflect	O
effects	O
of	O
the	O
non-active	O
ingredients.	O
Category	O
Diclofenac	B-D004008
N=572	O
Placebo	O
N=564	O
N	O
Percent	O
N	O
Percent	O
Application	O
Site	O
Conditions	O
64	O
11	O
70	O
12	O
Pruritus	B-D011537
31	O
5	O
44	O
8	O
Dermatitis	B-D003872
9	O
2	O
3	O
<1	O
Burning	O
2	O
<1	O
8	O
1	O
OtherIncludes:	O
application	O
site	O
dryness,	O
irritation,	O
erythema,	O
atrophy,	O
discoloration,	O
hyperhidriosis,	O
and	O
vesicles.	O
22	O
4	O
15	O
3	O
Gastrointestinal	O
Disorders	O
49	O
9	O
33	O
6	O
Nausea	B-D009325
17	O
3	O
11	O
2	O
Dysgeusia	B-D004408
10	O
2	O
3	O
<1	O
Dyspepsia	B-D004415
7	O
1	O
8	O
1	O
OtherIncludes:	O
gastritis,	O
vomiting,	O
diarrhea,	O
constipation,	O
upper	O
abdominal	O
pain,	O
and	O
dry	O
mouth.	O
15	O
3	O
11	O
2	O
Nervous	B-D009420
System	I-D009420
Disorders	O
13	O
2	O
18	O
3	O
Headache	B-D006261
7	O
1	O
10	O
2	O
Paresthesia	B-D010292
6	O
1	O
8	O
1	O
Somnolence	O
4	O
1	O
6	O
1	O
Other	O
Includes:	O
hypoesthesia,	O
dizziness,	O
and	O
hyperkinesias.	O
4	O
1	O
3	O
<1	O
Foreign	O
labeling	O
describes	O
that	O
dermal	O
allergic	O
reactions	O
may	O
occur	O
with	O
FLECTOR	O
PATCH	O
treatment.	O
Additionally,	O
the	O
treated	O
area	O
may	O
become	O
irritated	O
or	O
develop	O
itching,	O
erythema,	O
edema,	O
vesicles,	O
or	O
abnormal	O
sensation.	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Delayed	O
healing	O
(5.1)	O
Cross-sensitivity	O
or	O
hypersensitivity	O
(5.2)	O
Increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
thrombocyte	O
aggregation	O
(5.3)	O
Cornea	B-D003315
l	O
effects	O
including	O
keratitis	O
(5.4)	O
5.1	O
Delayed	O
Healing	O
Topical	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
slow	O
or	O
delay	O
healing.	O
Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing.	O
Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
steroids	O
may	O
increase	O
the	O
potential	O
for	O
healing	O
problems.	O
5.	O
2	O
Cross-Sensitivity	O
or	O
Hypersensitivity	B-D006967
There	O
is	O
the	O
potential	O
for	O
cross-sensitivity	O
to	O
acetylsalicylic	O
acid,	O
phenylacetic	B-C025136
acid	I-C025136
derivatives,	O
and	O
other	O
NSAIDs.	O
There	O
have	O
been	O
reports	O
of	O
bronchospasm	O
or	O
exacerbation	O
of	O
asthma	O
associated	O
with	O
the	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solution	O
in	O
patients	O
who	O
either	O
have	O
a	O
known	O
hypersensitivity	O
to	O
aspirin/non-steroidal	O
anti-inflammatory	O
drugs,	O
or	O
a	O
past	O
medical	O
history	O
of	O
asthma.	O
Therefore,	O
caution	O
should	O
be	O
used	O
when	O
treating	O
individuals	O
who	O
have	O
previously	O
exhibited	O
sensitivities	O
to	O
these	O
drugs.	O
5.	O
3	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
With	O
some	O
NSAIDs,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
thrombocyte	O
aggregation.	O
There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
tissues	O
(including	O
hyphemas)	O
in	O
conjunction	O
with	O
ocular	O
surgery.	O
It	O
is	O
recommended	O
that	O
ACUVAIL	O
ophthalmic	O
solution	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
known	O
bleeding	O
tendencies	O
or	O
who	O
are	O
receiving	O
other	O
medications,	O
which	O
may	O
prolong	O
bleeding	O
time.	O
5.	O
4	O
Cornea	B-D003315
l	O
E	O
ffects	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
keratitis.	O
In	O
some	O
susceptible	O
patients,	O
continued	O
use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
epithelial	O
breakdown,	O
corneal	O
thinning,	O
corneal	O
erosion,	O
corneal	O
ulceration,	O
or	O
corneal	O
perforation.	O
These	O
events	O
may	O
be	O
sight	O
threatening.	O
Patients	B-D010361
with	O
evidence	O
of	O
corneal	O
epithelial	O
breakdown	O
should	O
immediately	O
discontinue	O
use	O
of	O
topical	O
NSAIDs	O
and	O
should	O
be	O
closely	O
monitored	O
for	O
corneal	O
health.	O
Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
patients	O
with	O
complicated	O
ocular	O
surgeries,	O
corneal	O
denervation,	O
corneal	O
epithelial	O
defects,	O
diabetes	O
mellitus,	O
ocular	O
surface	O
diseases	O
(e.g.,	O
dry	O
eye	O
syndrome),	O
rheumatoid	O
arthritis,	O
or	O
repeat	O
ocular	O
surgeries	O
within	O
a	O
short	O
period	O
of	O
time	O
may	O
be	O
at	O
increased	O
risk	O
for	O
corneal	O
adverse	O
events	O
which	O
may	O
become	O
sight	O
threatening.	O
Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients.	O
Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
1	O
day	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
post-surgery	O
may	O
increase	O
patient	O
risk	O
for	O
the	O
occurrence	O
and	O
severity	O
of	O
corneal	O
adverse	O
events.	O
5.5	O
Contact	O
Lens	O
Wear	O
ACUVAIL	O
should	O
not	O
be	O
administered	O
while	O
wearing	O
contact	O
lenses.	O
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
the	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
1-6%	O
of	O
patients	O
were	O
increased	O
intraocular	O
pressure,	O
conjunctival	O
hemorrhage,	O
and	O
vision	O
blurred.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Allergan	O
at	O
1-800-678-1605	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
The	O
most	O
common	O
adverse	O
reactions	O
were	O
reported	O
in	O
1-6%	O
of	O
patients	O
and	O
included	O
increased	O
intraocular	O
pressure,	O
conjunctival	O
hyperemia	O
and/or	O
hemorrhage,	O
corneal	O
edema,	O
ocular	O
pain,	O
headache,	O
tearing	O
and	O
vision	O
blurred.	O
Some	O
of	O
these	O
reactions	O
may	O
be	O
the	O
consequence	O
of	O
the	O
cataract	O
surgical	O
procedure.	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postmarketing	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
in	O
clinical	O
practice.	O
Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size,	O
estimates	O
of	O
frequency	O
cannot	O
be	O
made.	O
The	O
reactions,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
bronchospasm,	O
exacerbation	O
of	O
asthma,	O
corneal	O
erosion,	O
corneal	O
perforation,	O
corneal	O
thinning	O
and	O
corneal	O
melt,	O
epithelial	O
breakdown	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
,	O
5.4	O
)]	O
and	O
ulcerative	O
keratitis.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(5.1)	O
Oxaprozin	B-D000077431
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
Oxaprozin	B-D000077431
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
oxaprozin	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
oxaprozin	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Oxaprozin	B-D000077431
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
oxaprozin	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
oxaprozin,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
oxaprozin	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
oxaprozin	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
oxaprozin,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients,	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy,	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-times	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
oxaprozin	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
alanine	O
aminotransferase	O
(ALT)	O
or	O
aspartate	O
aminotransferase	O
(AST)	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
oxaprozin.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
discontinue	O
oxaprozin	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
oxaprozin,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
oxaprozin	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
oxaprozin	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
oxaprozin	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
oxaprozin	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
oxaprozin	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
oxaprozin.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
oxaprozin	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
oxaprozin	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
oxaprozin	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Oxaprozin	B-D000077431
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
oxaprozin	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
oxaprozin	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
oxaprozin	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
oxaprozin,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
oxaprozin	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
oxaprozin	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Oxaprozin	B-D000077431
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
oxaprozin,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
oxaprozin	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
oxaprozin,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	O
SSRIs,	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
oxaprozin	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
complete	O
blood	O
count	O
(CBC)	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
].	O
5.14	O
Photosensitivity	O
Oxaprozin	B-D000077431
has	O
been	O
associated	O
with	O
rash	O
and/or	O
mild	O
photosensitivity	O
in	O
dermatologic	O
testing.	O
An	O
increased	O
incidence	O
of	O
rash	O
on	O
sun-exposed	O
skin	O
was	O
seen	O
in	O
some	O
patients	O
in	O
the	O
clinical	O
trials.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(>3	O
%)	O
are:	O
constipation,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
rash	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Greenstone	O
LLC	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Adverse	O
reaction	O
data	O
were	O
derived	O
from	O
patients	O
who	O
received	O
oxaprozin	O
in	O
multidose,	O
controlled,	O
and	O
open-label	O
clinical	O
trials.	O
Rates	O
for	O
events	O
from	O
clinical	O
trial	O
experience	O
are	O
based	O
on	O
2253	O
patients	O
who	O
took	O
1200	O
mg	O
to	O
1800	O
mg	O
oxaprozin	O
per	O
day	O
in	O
clinical	O
trials.	O
Of	O
these,	O
1721	O
patients	O
were	O
treated	O
for	O
at	O
least	O
1	O
month,	O
971	O
patients	O
for	O
at	O
least	O
3	O
months,	O
and	O
366	O
patients	O
for	O
more	O
than	O
1	O
year.	O
Incidence	B-D015994
Greater	O
than	O
1%:	O
In	O
clinical	O
trials	O
of	O
oxaprozin	O
or	O
in	O
patients	O
taking	O
other	O
NSAIDs,	O
the	O
following	O
adverse	O
reactions	O
occurred	O
at	O
an	O
incidence	O
greater	O
than	O
1%.	O
Cardiovascular	O
system:	O
edema.	O
Digestive	O
system:	O
abdominal	O
pain/distress,	O
anorexia,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gastrointestinal	O
ulcers	O
(gastric/duodenal),	O
gross	O
bleeding/perforation,	O
heartburn,	O
liver	O
enzyme	O
elevations,	O
nausea,	O
vomiting.	O
Hematologic	O
system:	O
anemia,	O
increased	O
bleeding	O
time.	O
Nervous	O
system:	O
CNS	O
inhibition	O
(depression,	O
sedation,	O
somnolence,	O
or	O
confusion),	O
disturbance	O
of	O
sleep,	O
dizziness,	O
headache.	O
Skin	B-D012867
and	O
appendages:	O
pruritus,	O
rash.	O
Special	O
senses:	O
tinnitus.	O
Urogenital	O
system:	O
abnormal	O
renal	O
function,	O
dysuria	O
or	O
frequency.	O
Incidence	B-D015994
Less	O
than	O
1%:	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
clinical	O
trials	O
or	O
in	O
patients	O
taking	O
other	O
NSAIDs.	O
Body	O
as	O
a	O
whole:	O
appetite	O
changes,	O
death,	O
drug	O
hypersensitivity	O
reactions	O
including	O
anaphylaxis,	O
fever,	O
infection,	O
sepsis.	O
Cardiovascular	O
system:	O
arrhythmia,	O
blood	O
pressure	O
changes,	O
congestive	O
heart	O
failure,	O
hypertension,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
tachycardia,	O
syncope,	O
vasculitis.	O
Digestive	O
system:	O
alteration	O
in	O
taste,	O
dry	O
mouth,	O
eructation,	O
esophagitis,	O
gastritis,	O
glossitis,	O
hematemesis,	O
jaundice,	O
liver	O
function	O
abnormalities	O
including	O
liver	O
failure,	O
stomatitis,	O
hemorrhoidal	O
or	O
rectal	O
bleeding.	O
Hematologic	O
system:	O
aplastic	O
anemia,	O
ecchymoses,	O
eosinophilia,	O
hemolytic	O
anemia,	O
lymphadenopathy,	O
melena,	O
purpura,	O
thrombocytopenia,	O
leukopenia.	O
Metabolic	O
system:	O
hyperglycemia,	O
weight	O
changes.	O
Nervous	O
system:	O
anxiety,	O
asthenia,	O
coma,	O
convulsions,	O
dream	O
abnormalities,	O
drowsiness,	O
hallucinations,	O
insomnia,	O
malaise,	O
meningitis,	O
nervousness,	O
paresthesia,	O
tremors,	O
vertigo,	O
weakness.	O
Respiratory	O
system:	O
asthma,	O
dyspnea,	O
pulmonary	O
infections,	O
pneumonia,	O
sinusitis,	O
symptoms	O
of	O
upper	O
respiratory	O
tract	O
infection,	O
respiratory	O
depression.	O
Skin	B-D012867
:	O
alopecia,	O
angioedema,	O
urticaria,	O
photosensitivity,	O
sweat.	O
Special	O
senses:	O
blurred	O
vision,	O
conjunctivitis,	O
hearing	O
decrease.	O
Urogenital:	O
cystitis,	O
hematuria,	O
increase	O
in	O
menstrual	O
flow,	O
oliguria/	O
polyuria,	O
proteinuria,	O
renal	O
insufficiency,	O
decreased	O
menstrual	O
flow.	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
oxaprozin.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
whole:	O
serum	O
sickness.	O
Digestive	O
system:	O
hepatitis,	O
pancreatitis.	O
Hematologic	O
system:	O
agranulocytosis,	O
pancytopenia.	O
Skin	B-D012867
:	O
pseudoporphyria,	O
exfoliative	O
dermatitis,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
(Lyell's	O
syndrome).	O
Urogenital:	O
acute	O
interstitial	O
nephritis,	O
nephrotic	O
syndrome,	O
acute	O
renal	O
failure.	O
CARDIOVASCULAR	O
RISK	O
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS.)	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
GASTROINTESTINAL	O
RISK	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%–10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/	O
perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages	O
:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-	O
Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses	O
:	O
conjunctivitis,	O
hearing	O
impairment	O
ADVERSE	O
REACTIONS	O
Transient	O
burning	O
and	O
stinging	O
upon	O
instillation	O
and	O
other	O
minor	O
symptoms	O
of	O
ocular	O
irritation	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
Flurbiprofen	B-D005480
Sodium	B-D012964
Ophthalmic	O
Solution.	O
Other	O
adverse	O
reactions	O
reported	O
with	O
the	O
use	O
of	O
Flurbiprofen	B-D005480
Sodium	B-D012964
Ophthalmic	O
Solution	O
include:	O
fibrosis,	O
hyphema,	O
miosis,	O
mydriasis,	O
and	O
ocular	O
hyperemia.	O
Increased	O
bleeding	O
tendency	O
of	O
ocular	O
tissues	O
in	O
conjunction	O
with	O
ocular	O
surgery	O
has	O
also	O
been	O
reported	O
(see	O
Warnings	O
).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Bausch	O
+	O
Lomb,	O
a	O
division	O
of	O
Valeant	O
Pharmaceuticals	O
North	B-D009656
America	I-D009656
LLC,	O
at	O
1-800-321-4576	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
Adverse	O
ReactionsREPREXAIN™	O
was	O
administered	O
to	O
approximately	O
300	O
pain	O
patients	O
in	O
a	O
safety	O
study	O
that	O
employed	O
dosages	O
and	O
a	O
duration	O
of	O
treatment	O
sufficient	O
to	O
encompass	O
the	O
recommended	O
usage	O
(see	O
DOSAGE	O
AND	O
ADMINISTRATION).	O
Adverse	O
event	O
rates	O
generally	O
increased	O
with	O
increasing	O
daily	O
dose.	O
The	O
event	O
rates	O
reported	O
below	O
are	O
from	O
approximately	O
150	O
patients	O
who	O
were	O
in	O
a	O
group	O
that	O
received	O
one	O
tablet	O
of	O
REPREXAIN™	O
an	O
average	O
of	O
three	O
to	O
four	O
times	O
daily.	O
The	O
overall	O
incidence	O
rates	O
of	O
adverse	O
experiences	O
in	O
the	O
trials	O
were	O
fairly	O
similar	O
for	O
this	O
patient	O
group	O
and	O
those	O
who	O
received	O
the	O
comparison	O
treatment,	O
acetaminophen	O
600	O
mg	O
with	O
codeine	O
60	O
mg.	O
The	O
following	O
lists	O
adverse	O
events	O
that	O
occurred	O
with	O
an	O
incidence	O
of	O
1%	O
or	O
greater	O
in	O
clinical	O
trials	O
of	O
REPREXAIN™,	O
without	O
regard	O
to	O
the	O
causal	O
relationship	O
of	O
the	O
events	O
to	O
the	O
drug.	O
To	O
distinguish	O
different	O
rates	O
of	O
occurrence	O
in	O
clinical	O
studies,	O
the	O
adverse	O
events	O
are	O
listed	O
as	O
follows:	O
name	O
of	O
adverse	O
event	O
=	O
less	O
than	O
3%	O
adverse	O
events	O
marked	O
with	O
an	O
asterisk	O
*	O
=	O
3%	O
to	O
9%	O
adverse	O
event	O
rates	O
over	O
9%	O
are	O
in	O
parentheses.	O
Body	O
as	O
a	O
Whole	O
:	O
Abdominal	O
pain*;	O
Asthenia	B-D001247
*;	O
Fever	B-D005334
;	O
Flu	O
syndrome;	O
Headache	B-D006261
(27%);	O
Infection*;	O
Pain	B-D010146
.	O
Cardiovascular	O
:	O
Palpitations;	O
Vasodilation	B-D014664
.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Anxiety	B-D001007
*;	O
Confusion	B-D003221
;	O
Dizziness	B-D004244
(14%);	O
Hypertonia;	O
Insomnia*;	O
Nervousness*;	O
Paresthesia	B-D010292
;	O
Somnolence	O
(22%);	O
Thinking	B-D013850
abnormalities.	O
Digestive:	O
Anorexia	B-D000855
;	O
Constipation	B-D003248
(22%);	O
Diarrhea	B-D003967
*;	O
Dry	O
mouth*;	O
Dyspepsia	B-D004415
(12%);	O
Flatulence	B-D005414
*;	O
Gastritis	B-D005756
;	O
Melena	B-D008551
;	O
Mouth	B-D009055
ulcers;	O
Nausea	B-D009325
(21%);	O
Thirst	B-D013894
;	O
Vomiting	B-D014839
*.	O
Metabolic	O
and	O
Nutritional	O
Disorders:	O
Edema	B-D004487
*.	O
Respiratory:	O
Dyspnea	B-D004417
;	O
Hiccup	B-D006606
s;	O
Pharyngitis	B-D010612
;	O
Rhinitis	B-D012220
.	O
Skin	B-D012867
and	O
Appendages:	O
Pruritus	B-D011537
*;	O
Sweating	B-D013546
*.	O
Special	O
Senses:	O
Tinnitus	B-D014012
.	O
Urogenital	O
:	O
Urinary	O
frequency.	O
Incidence	B-D015994
less	O
than	O
1%	O
Body	O
as	O
a	O
Whole:	O
Allergic	O
reaction.	O
Cardiovascular:	O
Arrhythmia;	O
Hypotension	B-D007022
;	O
Tachycardia	B-D013610
.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Agitation;	O
Abnormal	O
dreams;	O
Decreased	O
libido;	O
Depression	B-D003863
;	O
Euphoria	B-D005059
;	O
Mood	O
changes;	O
Neuralgia	B-D009437
;	O
Slurred	O
speech;	O
Tremor	B-D014202
,	O
Vertigo	B-D014717
.	O
Digestive:	O
Chalky	O
stool;	O
“Clenching	O
teeth”;	O
Dysphagia;	O
Esophageal	O
spasm;	O
Esophagitis	B-D004941
;	O
Gastroenteritis	B-D005759
;	O
Glossitis	B-D005928
;	O
Liver	B-D008099
enzyme	O
elevation.	O
Metabolic	O
and	O
Nutritional:	O
Weight	O
decrease.	O
Musculoskeletal:	O
Arthralgia	B-D018771
;	O
Myalgia	B-D063806
.	O
Respiratory:	O
Asthma	B-D001249
;	O
Bronchitis	B-D001991
;	O
Hoarseness	B-D006685
;	O
Increased	O
cough;	O
Pulmonary	O
congestion;	O
Pneumonia	B-D011014
;	O
Shallow	O
breathing;	O
Sinusitis	B-D012852
.	O
Skin	B-D012867
and	O
Appendages:	O
Rash;	O
Urticaria	B-D014581
.	O
Special	O
Senses:	O
Altered	O
vision;	O
Bad	O
taste;	O
Dry	O
eyes.	O
Urogenital:	O
Cystitis	B-D003556
;	O
Glycosuria	B-D006029
;	O
Impotence;	O
Urinary	O
incontinence;	O
Urinary	O
retention.	O
Drug	O
Abuse	O
and	O
Dependence	O
Misuse	O
Abuse	O
and	O
Diversion	O
of	O
Opioids	O
REPREXAIN™	O
contains	O
hydrocodone,	O
an	O
opioid	O
agonist,	O
and	O
is	O
a	O
Schedule	O
III	O
controlled	O
substance.	O
REPREXAIN™,	O
and	O
other	O
opioids	O
used	O
in	O
analgesia	O
can	O
be	O
abused	O
and	O
are	O
subject	O
to	O
criminal	O
diversion.	O
Addiction	O
is	O
a	O
primary,	O
chronic,	O
neurobiologic	O
disease,	O
with	O
genetic,	O
psychosocial,	O
and	O
environmental	O
factors	O
influencing	O
its	O
development	O
and	O
manifestations.	O
It	O
is	O
characterized	O
by	O
behaviors	O
that	O
include	O
one	O
or	O
more	O
of	O
the	O
following:	O
impaired	O
control	O
over	O
drug	O
use,	O
compulsive	O
use,	O
continued	O
use	O
despite	O
harm,	O
and	O
craving.	O
Drug	O
addiction	O
is	O
a	O
treatable	O
disease	O
utilizing	O
a	O
multidisciplinary	O
approach,	O
but	O
relapse	O
is	O
common.	O
“Drug	O
seeking”	O
behavior	O
is	O
very	O
common	O
in	O
addicts	O
and	O
drug	O
abusers.	O
Drug-seeking	O
tactics	O
include	O
emergency	O
calls	O
or	O
visits	O
near	O
the	O
end	O
of	O
office	O
hours,	O
refusal	O
to	O
undergo	O
appropriate	O
examination,	O
testing	O
or	O
referral,	O
repeated	O
“loss”	O
of	O
prescriptions,	O
tampering	O
with	O
prescriptions	O
and	O
reluctance	O
to	O
provide	O
prior	O
medical	O
records	O
or	O
contact	O
information	O
for	O
other	O
treating	O
physician(s).	O
“Doctor	O
shopping”	O
to	O
obtain	O
additional	O
prescriptions	O
is	O
common	O
among	O
drug	O
abusers	O
and	O
people	O
suffering	O
from	O
untreated	O
addiction.	O
Abuse	O
and	O
addiction	O
are	O
separate	O
and	O
distinct	O
from	O
physical	O
dependence	O
and	O
tolerance.	O
Physical	O
dependence	O
usually	O
assumes	O
clinically	O
significant	O
dimensions	O
only	O
after	O
several	O
weeks	O
of	O
continued	O
opioid	O
use,	O
although	O
a	O
mild	O
degree	O
of	O
physical	O
dependence	O
may	O
develop	O
after	O
a	O
few	O
days	O
of	O
opioid	O
therapy.	O
Tolerance,	O
in	O
which	O
increasingly	O
large	O
doses	O
are	O
required	O
in	O
order	O
to	O
produce	O
the	O
same	O
degree	O
of	O
analgesia,	O
is	O
manifested	O
initially	O
by	O
a	O
shortened	O
duration	O
of	O
analgesic	O
effect,	O
and	O
subsequently	O
by	O
decreases	O
in	O
the	O
intensity	O
of	O
analgesia.	O
The	O
rate	O
of	O
development	O
of	O
tolerance	O
varies	O
among	O
patients.	O
Physicians	B-D010820
should	O
be	O
aware	O
that	O
abuse	O
of	O
opioids	O
can	O
occur	O
in	O
the	O
absence	O
of	O
true	O
addiction	O
and	O
is	O
characterized	O
by	O
misuse	O
for	O
nonmedical	O
purposes,	O
often	O
in	O
combination	O
with	O
other	O
psychoactive	O
substances.	O
REPREXAIN™,	O
like	O
other	O
opioids,	O
may	O
be	O
diverted	O
for	O
non-medical	O
use.	O
Record-keeping	O
of	O
prescribing	O
information,	O
including	O
quantity,	O
frequency,	O
and	O
renewal	O
requests	O
is	O
strongly	O
advised.	O
Proper	O
assessment	O
of	O
the	O
patient,	O
proper	O
prescribing	O
practices,	O
periodic	O
re-evaluation	O
of	O
therapy,	O
and	O
proper	O
dispensing	O
and	O
storage	O
are	O
appropriate	O
measures	O
that	O
help	O
to	O
limit	O
abuse	O
of	O
opioid	O
drugs.	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
].	O
•	O
Etodolac	B-D017308
extended-release	O
tablets	O
arecontraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
and	O
Warnings	O
].	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
A	O
total	O
of	O
1552	O
patients	O
were	O
exposed	O
to	O
etodolac	O
extended-release	O
tablets	O
in	O
controlled	O
clinical	O
studies	O
of	O
at	O
least	O
4	O
weeks	O
in	O
length	O
and	O
using	O
daily	O
doses	O
in	O
the	O
range	O
of	O
400	O
to	O
1200	O
mg.	O
In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
incidence	O
of	O
events	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	O
extended-release	O
tablets.	O
As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
time	O
with	O
extended	O
therapy.	O
In	O
patients	O
taking	O
NSAIDs,	O
including	O
etodolac	O
extended-release	O
tablets,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including	O
abdominal	O
pain	O
constipation	O
Diarrhea	B-D003967
dyspepsia	O
flatulence	O
GI	O
ulcers	O
(gastric/duodenal)*	O
gross	O
bleeding/perforation*	O
nausea	O
Vomiting	B-D014839
Other	O
events	O
including:	O
abnormal	O
renal	O
functionAdverse	O
events	O
that	O
were	O
observed	O
in	O
<	O
1%	O
of	O
patients	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	O
extended-release	O
tablets	O
in	O
clinical	O
trials.	O
Anemia	B-D000740
asthenia	O
dizziness	O
edema	O
elevated	O
liver	O
enzymes	O
headaches	O
hypertension	O
increased	O
bleeding	O
time	O
infection	O
pharyngitis	O
pruritus	O
rashes	O
rhinitis	O
tinnitus	O
Additional	O
NSAID	O
Adverse	O
Experiences	O
Reported	O
Occasionally	O
with	O
NSAIDs	O
or	O
Etodolac	B-D017308
Extended-release	O
Tablets	B-D013607
Include	O
Body	O
as	O
a	O
whole	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock),	O
chills,	O
fever,	O
sepsis	O
Cardiovascular	O
system	O
Congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
tachycardia,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic)	O
Digestive	O
system	O
Anorexia	B-D000855
,	O
cholestatic	O
hepatitis,	O
cholestatic	O
jaundice,	O
dry	O
mouth,	O
duodenitis,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastric/peptic	O
ulcers,	O
glossitis,	O
hepatic	O
failure,	O
hepatitis,	O
hematemesis,	O
intestinal	O
ulceration,	O
jaundice,	O
liver	O
necrosis,	O
melena,	O
pancreatitis,	O
rectal	O
bleeding,	O
stomatitis	O
Hemic	O
and	O
lymphatic	O
system	O
Agranulocytosis	B-D000380
,	O
ecchymosis,	O
eosinophilia,	O
hemolytic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia,	O
purpura,	O
thrombocytopenia	O
Metabolic	O
and	O
nutritional	O
Hyperglycemia	B-D006943
in	O
previously	O
controlled	O
diabetic	O
patients	O
Nervous	O
system	O
Anxiety	B-D001007
,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
insomnia,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
Asthma	B-D001249
,	O
dyspnea,	O
pulmonary	O
infiltration	O
with	O
eosinophilia	O
Skin	B-D012867
and	O
appendages	O
Angioedema	B-D000799
,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
erythema	O
multiforme,	O
hyperpigmentation,	O
sweating,	O
urticaria,	O
vesiculobullous	O
rash	O
Special	O
senses	O
Blurred	O
vision,	O
photophobia,	O
transient	O
visual	O
disturbances	O
Urogenital	O
system	O
Dysuria	B-D053159
,	O
elevated	O
BUN,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis,	O
serum	O
creatinine	O
increase,	O
urinary	O
frequency	O
Other	O
NSAID	O
Adverse	O
Reactions,	O
Which	O
Occur	O
Rarely	O
Are	O
Body	O
as	O
a	O
whole	O
Anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	O
system	O
Arrhythmia,	O
cerebrovascular	O
accident,	O
hypotension,	O
myocardial	O
infarction	O
Digestive	O
system	O
Colitis	B-D003092
,	O
esophagitis	O
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
thirst,	O
ulcerative	O
stomatitis	O
Hemic	O
and	O
lymphatic	O
system	O
Aplastic	O
anemia,	O
lymphadenopathy	O
Metabolic	O
and	O
nutritional	O
Change	O
in	O
weight	O
Nervous	O
system	O
Coma	B-D003128
,	O
convulsions,	O
hallucinations,	O
meningitis	O
Respiratory	O
Bronchitis	B-D001991
,	O
pneumonia,	O
respiratory	O
depression,	O
sinusitis	O
Skin	B-D012867
and	O
appendages	O
Alopecia	B-D000505
,	O
exfoliative	O
dermatitis,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrosis	O
Special	O
senses	O
Conjunctivitis	B-D003231
,	O
deafness,	O
hearing	O
impairment,	O
taste	O
perversion	O
Urogenital	O
system	O
Cystitis	B-D003556
,	O
hematuria,	O
interstitial	O
nephritis,	O
leukorrhea,	O
renal	O
calculus,	O
uterine	O
bleeding	O
irregularities	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Flurbiprofen	B-D005480
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(	O
5.1	O
)	O
Flurbiprofen	B-D005480
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(	O
4	O
,	O
5.1	O
)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(	O
5.2	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
flurbiprofen	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
flurbiprofen	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Flurbiprofen	B-D005480
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
flurbiprofen	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation.	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
flurbiprofen,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(	O
4	O
)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
flurbiprofen	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
flurbiprofen	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
flurbiprofen,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients,	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy,	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-times	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
flurbiprofen	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
flurbiprofen.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
flurbiprofen	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
flurbiprofen,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(5.1,	O
7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
flurbiprofen	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
Avoid	O
the	O
use	O
of	O
flurbiprofen	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
flurbiprofen	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
In	O
clinical	O
studies,	O
the	O
elimination	O
half-life	O
of	O
flurbiprofen	O
was	O
unchanged	O
in	O
patients	O
with	O
renal	O
impairment.	O
Flurbiprofen	B-D005480
metabolites	O
are	O
eliminated	O
primarily	O
by	O
the	O
kidneys.	O
Elimination	O
of	O
4’hydroxy-flurbiprofen	O
was	O
reduced	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
renal	O
impairment.	O
Therefore,	O
treatment	O
with	O
flurbiprofen	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
flurbiprofen	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patients	O
renal	O
function	O
is	O
advisable	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12)].	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
flurbiprofen.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
flurbiprofen	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
flurbiprofen	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
flurbiprofen	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Flurbiprofen	B-D005480
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
flurbiprofen	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
flurbiprofen	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
flurbiprofen	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
flurbiprofen,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
flurbiprofen	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Flurbiprofen	B-D005480
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Flurbiprofen	B-D005480
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
flurbiprofen,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
flurbiprofen	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
flurbiprofen,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
of	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs),	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
flurbiprofen	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
5.14	O
Vision	O
changes	O
Blurred	O
and/or	O
diminished	O
vision	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
flurbiprofen	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs.	O
Patients	B-D010361
experiencing	O
eye	O
complaints	O
should	O
have	O
ophthalmologic	O
examinations.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
3%	O
from	O
clinical	O
trials)	O
are:	O
abdominal	O
pain,	O
dyspepsia,	O
nausea,	O
diarrhea,	O
constipation,	O
headache,	O
edema,	O
signs	O
and	O
symptoms	O
suggesting	O
urinary	O
tract	O
infection	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
TEVA	O
USA,	O
PHARMACOVIGILANCE	O
at	O
1-866-832-8537	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Incidence	B-D015994
of	O
1%	O
or	O
greater	O
Body	O
as	O
a	O
whole:	O
edema	O
Digestive	O
system:	O
GI	O
bleeding,	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia/heartburn,	O
flatulence,	O
nausea,	O
vomiting,	O
elevated	O
liver	O
enzymes	O
Metabolic	O
and	O
nutritional	O
system:	O
body	O
weight	O
changes	O
Nervous	O
system:	O
headache,	O
nervousness,	O
anxiety,	O
insomnia,	O
increased	O
reflexes,	O
tremor,	O
amnesia,	O
asthenia,	O
depression,	O
malaise,	O
somnolence	O
Respiratory	O
system:	O
rhinitis	O
Skin	B-D012867
and	O
appendages:	O
rash	O
Special	O
senses:	O
changes	O
in	O
vision,	O
dizziness,	O
tinnitus	O
Urogenital	O
system:	O
signs	O
and	O
symptoms	O
suggesting	O
urinary	O
tract	O
infection	O
Incidence	B-D015994
<	O
1%	O
Body	O
as	O
a	O
whole:	O
anaphylactic	O
reaction,	O
chills,	O
fever	O
Cardiovascular	O
system:	O
myocardial	O
infarction,	O
congestive	O
heart	O
failure,	O
hypertension,	O
vascular	O
diseases,	O
vasodilation	O
Digestive	O
system:	O
gastric/peptic	O
ulcer	O
disease,	O
hematemesis,	O
bloody	O
diarrhea,	O
hepatitis,	O
esophageal	O
disease,	O
gastritis,	O
stomatitis/glossitis,	O
dry	O
mouth	O
Hemic	O
and	O
lymphatic	O
system:	O
iron	O
deficiency	O
anemia,	O
decrease	O
in	O
hemoglobin	O
and	O
hematocrit,	O
purpura,	O
eosinophilia	O
Metabolic	O
and	O
nutritional	O
system:	O
hyperuricemia	O
Nervous	O
system:	O
cerebrovascular	O
ischemia,	O
convulsion,	O
ataxia,	O
confusion,	O
hypertonia,	O
paresthesia,	O
twitching,	O
emotional	O
lability	O
Respiratory	O
system:	O
asthma,	O
dyspnea,	O
epistaxis,	O
bronchitis,	O
laryngitis	O
Skin	B-D012867
and	O
appendages:	O
angioedema,	O
urticaria,	O
eczema,	O
pruritus,	O
herpes	O
simplex,	O
alopecia,	O
dry	O
skin	O
Special	O
senses:	O
vertigo,	O
corneal	O
opacity,	O
parosmia,	O
conjunctivitis	O
Urogenital	O
system:	O
renal	O
failure,	O
vaginal	O
hemorrhage,	O
hematuria	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
flurbiprofen.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Cardiovascular	O
system:	O
angina	O
pectoris,	O
arrhythmias	O
Digestive	O
system:	O
jaundice	O
(cholestatic	O
and	O
noncholestatic),	O
colitis,	O
small	O
intestine	O
inflammation	O
with	O
loss	O
of	O
blood	O
and	O
protein,	O
exacerbation	O
of	O
inflammatory	O
bowel	O
disease,	O
cholecystitis,	O
periodontal	O
abscess,	O
appetite	O
changes	O
Hemic	O
and	O
lymphatic	O
system:	O
aplastic	O
anemia	O
(including	O
agranulocytosis	O
or	O
pancytopenia),	O
hemolytic	O
anemia,	O
leukopenia,	O
thrombocytopenia,	O
ecchymosis,	O
lymphadenopathy	O
Metabolic	O
and	O
nutritional	O
system:	O
hyperkalemia	O
Nervous	O
system:	O
cerebrovascular	O
accident,	O
subarachnoid	O
hemorrhage,	O
meningitis,	O
myasthenia	O
Respiratory	O
system:	O
pulmonary	O
infarct,	O
pulmonary	O
embolism,	O
hyperventilation,	O
Skin	B-D012867
and	O
appendages:	O
toxic	O
epidermal	O
necrolysis,	O
exfoliative	O
dermatitis,	O
zoster,	O
photosensitivity,	O
nail	O
disorder,	O
sweating	O
Special	O
senses:	O
retinal	O
hemorrhage,	O
glaucoma,	O
retrobulbar	O
neuritis,	O
transient	O
hearing	O
loss,	O
changes	O
in	O
taste,	O
ear	O
disease	O
Urogenital	O
system:	O
interstitial	O
nephritis,	O
uterine	O
hemorrhage,	O
menstrual	O
disturbances,	O
prostate	O
disease,	O
vulvovaginitis	O
Cardiovascular	O
Thrombotic	O
Events	O
•Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS	O
].	O
•Ibuprofen	O
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	O
and	O
WARNINGS	O
].	O
Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
WARNINGS	O
].	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	O
tablets	O
is	O
gastrointestinal.	O
In	O
controlled	O
clinical	O
trials	O
the	O
percentage	O
of	O
patients	O
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%.	O
In	O
controlled	O
studies	O
when	O
ibuprofen	O
tablets	O
were	O
compared	O
to	O
aspirin	O
and	O
indomethacin	O
in	O
equally	O
effective	O
doses,	O
the	O
overall	O
incidence	O
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	O
or	O
indomethacin-treated	O
patients.	O
Adverse	O
reactions	O
observed	O
during	O
controlled	O
clinical	O
trials	O
at	O
an	O
incidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table.	O
Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	O
in	O
approximately	O
3,000	O
patients.	O
More	O
than	O
500	O
of	O
these	O
patients	O
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks.	O
Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	O
clinical	O
trials	O
and	O
from	O
marketing	O
experience.	O
These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	O
tablets	O
where	O
the	O
probability	O
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	O
tablets	O
has	O
not	O
been	O
established.	O
Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	O
trials	O
of	O
patients	O
with	O
rheumatoid	O
arthritis.	O
The	O
increases	O
in	O
incidence	O
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table.	O
Incidence	B-D015994
Greater	O
Than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
ibuprofen	O
tablets.	O
(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.)	O
**	O
Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related.	O
Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met.	O
GASTROINTESTINAL	O
Nausea	B-D009325
*,	O
epigastric	O
pain*,	O
heartburn*,	O
diarrhea,	O
abdominal	O
distress,	O
nausea	O
and	O
vomiting,	O
indigestion,	O
constipation,	O
abdominal	O
cramps	O
or	O
pain,	O
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	O
Gastric	O
or	O
duodenal	O
ulcer	O
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	O
hemorrhage,	O
melena,	O
gastritis,	O
hepatitis,	O
jaundice,	O
abnormal	O
liver	O
function	O
tests;	O
pancreatitis	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
Dizziness	B-D004244
*,	O
headache,	O
nervousness	O
Depression	B-D003863
,	O
insomnia,	O
confusion,	O
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	O
with	O
fever	O
and	O
coma	O
[see	O
PRECAUTIONS	O
]	O
Paresthesia	B-D010292
s,	O
hallucinations,	O
dream	O
abnormalities,	O
pseudotumor	O
cerebri	O
DERMATOLOGIC	O
Rash*	O
(including	O
maculopapular	O
type),	O
pruritus	O
Vesiculobullous	O
eruptions,	O
urticaria,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome,	O
alopecia	O
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	O
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D006309
loss,	O
amblyopia	O
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	O
and/or	O
changes	O
in	O
color	O
vision)	O
[see	O
PRECAUTIONS	O
]	O
Conjunctivitis	B-D003231
,	O
diplopia,	O
optic	O
neuritis,	O
cataracts	O
HEMATOLOGIC	O
Neutropenia	B-D009503
,	O
agranulocytosis,	O
aplastic	O
anemia,	O
hemolytic	O
anemia	O
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	O
with	O
or	O
without	O
purpura,	O
eosinophilia,	O
decreases	O
in	O
hemoglobin	O
and	O
hematocrit	O
[see	O
PRECAUTIONS	O
]	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	O
menorrhagia)	O
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	O
Gynecomastia	B-D006177
,	O
hypoglycemic	O
reaction,	O
acidosis	O
CARDIOVASCULAR	O
Edema	B-D004487
,	O
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS	O
)	O
Congestive	O
heart	O
failure	O
in	O
patients	O
with	O
marginal	O
cardiac	O
function,	O
elevated	O
blood	O
pressure,	O
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	O
sinus	O
bradycardia)	O
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	O
pain,	O
fever,	O
chills,	O
nausea	O
and	O
vomiting;	O
anaphylaxis;	O
bronchospasm	O
[see	O
CONTRAINDICATIONS	O
]	O
Serum	B-D044967
sickness,	O
lupus	O
erythematosus	O
syndrome.	O
Henoch-Schonlein	O
vasculitis,	O
angioedema	O
RENAL	O
Acute	O
renal	O
failure	O
[see	O
PRECAUTIONS	O
],	O
decreased	O
creatinine	O
clearance,	O
polyuria,	O
azotemia,	O
cystitis,	O
hematuria	O
Renal	O
papillary	O
necrosis	O
MISCELLANEOUS	O
Dry	O
eyes	O
and	O
mouth,	O
gingival	O
ulcer,	O
rhinitis	O
tests	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS	O
].	O
Ibuprofen	B-D007052
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	O
and	O
WARNINGS	O
].	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
WARNINGS	O
].	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	O
tablets	O
is	O
gastrointestinal.	O
In	O
controlled	O
clinical	O
trials	O
the	O
percentage	O
of	O
patients	O
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%.	O
In	O
controlled	O
studies	O
when	O
ibuprofen	O
tablets	O
were	O
compared	O
to	O
aspirin	O
and	O
indomethacin	O
in	O
equally	O
effective	O
doses,	O
the	O
overall	O
incidence	O
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	O
or	O
indomethacin-treated	O
patients.	O
Adverse	O
reactions	O
observed	O
during	O
controlled	O
clinical	O
trials	O
at	O
an	O
incidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table.	O
Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	O
in	O
approximately	O
3,000	O
patients.	O
More	O
than	O
500	O
of	O
these	O
patients	O
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks.	O
Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	O
clinical	O
trials	O
and	O
from	O
marketing	O
experience.	O
These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	O
tablets	O
where	O
the	O
probability	O
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	O
tablets	O
has	O
not	O
been	O
established.	O
Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	O
trials	O
of	O
patients	O
with	O
rheumatoid	O
arthritis.	O
The	O
increases	O
in	O
incidence	O
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table.	O
Incidence	B-D015994
Greater	O
Than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea	B-D009325
*,	O
epigastric	O
pain*,	O
heartburn*,	O
diarrhea,	O
abdominal	O
distress,	O
nausea	O
and	O
vomiting,	O
indigestion,	O
constipation,	O
abdominal	O
cramps	O
or	O
pain,	O
fullness	O
of	O
Gl	O
tract	O
(bloating	O
and	O
flatulence)	O
Gastric	O
or	O
duodenal	O
ulcer	O
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	O
hemorrhage,	O
melena,	O
gastritis,	O
hepatitis,	O
jaundice,	O
abnormal	O
liver	O
function	O
tests;	O
pancreatitis	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
Dizziness	B-D004244
*,	O
headache,	O
nervousness	O
Depression	B-D003863
,	O
insomnia,	O
confusion,	O
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	O
with	O
fever	O
and	O
coma	O
[see	O
PRECAUTIONS]	O
Paresthesia	B-D010292
s,	O
hallucinations,	O
dream	O
abnormalities,	O
pseudotumor	O
cerebri	O
DERMATOLOGIC	O
Rash*	O
(including	O
maculopapular	O
type),	O
pruritus	O
Vesiculobullous	O
eruptions,	O
urticaria,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome,	O
alopecia	O
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	O
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D006309
loss,	O
amblyopia	O
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	O
and/or	O
changes	O
in	O
color	O
vision)	O
[see	O
PRECAUTIONS]	O
Conjunctivitis	B-D003231
,	O
diplopia,	O
optic	O
neuritis,	O
cataracts	O
HEMATOLOGIC	O
Neutropenia	B-D009503
,	O
agranulocytosis,	O
aplastic	O
anemia,	O
hemolytic	O
anemia	O
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	O
with	O
or	O
without	O
purpura,	O
eosinophilia,	O
decreases	O
in	O
hemoglobin	O
and	O
hematocrit	O
[see	O
PRECAUTIONS]	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	O
menorrhagia)	O
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	O
Gynecomastia	B-D006177
,	O
hypoglycemic	O
reaction,	O
acidosis	O
CARDIOVASCULAR	O
Edema	B-D004487
,	O
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
[see	O
PRECAUTIONS]	O
Congestive	O
heart	O
failure	O
in	O
patients	O
with	O
marginal	O
cardiac	O
function,	O
elevated	O
blood	O
pressure,	O
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	O
sinus	O
bradycardia)	O
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	O
pain,	O
fever,	O
chills,	O
nausea	O
and	O
vomiting;	O
anaphylaxis;	O
bronchospasm	O
[see	O
CONTRAINDICATIONS]	O
Serum	B-D044967
sickness,	O
lupus	O
erythematosus	O
syndrome,	O
Henoch-Schonlein	O
vasculitis,	O
angioedema	O
RENAL	O
Acute	O
renal	O
failure	O
[see	O
PRECAUTIONS],	O
decreased	O
creatinine	O
clearance,	O
polyuria,	O
azotemia,	O
cystitis,	O
hematuria	O
Renal	O
papillary	O
necrosis	O
MISCELLANEOUS	O
Dry	O
eyes	O
and	O
mouth,	O
gingival	O
ulcer,	O
rhinitis	O
tests	O
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
ibuprofen	O
tablets.	O
(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.)	O
**	O
Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related.	O
Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met.	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Amneal	O
Pharmaceuticals	O
at	O
1-877-835-5472	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
Cardiovascular	O
Risk	B-D012306
NSAIDs1	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
potassium	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS).	O
1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug.	O
ADVERSE	O
REACTIONS	O
In	O
718	O
patients	O
treated	O
for	O
shorter	O
periods,	O
i.e.,	O
2	O
weeks	O
or	O
less,	O
with	O
diclofenac	O
potassium	O
tablets,	O
adverse	O
reactions	O
were	O
reported	O
one-half	O
to	O
one-tenth	O
as	O
frequently	O
as	O
by	O
patients	O
treated	O
for	O
longer	O
periods.	O
In	O
a	O
6	O
month,	O
double-blind	O
trial	O
comparing	O
diclofenac	O
potassium	O
tablets	O
(N	O
=	O
196)	O
versus	O
diclofenac	O
sodium	O
delayed-release	O
tablets	O
(N	O
=	O
197)	O
versus	O
ibuprofen	O
(N	O
=	O
197),	O
adverse	O
reactions	O
were	O
similar	O
in	O
nature	O
and	O
frequency.	O
In	O
patients	O
taking	O
diclofenac	O
potassium	O
tablets	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes,	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk..	O
(See	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
extended-release	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
inflammation,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(See	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
extended-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
As	O
A	O
Whole:fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
And	O
Lymphatic	B-D008208
System	I-D008208
:ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
And	O
Nutritional:weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:asthma,	O
dyspnea	O
Skin	B-D012867
And	O
Appendages:alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
As	O
A	O
Whole:anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
And	O
Lymphatic	B-D008208
System	I-D008208
:agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
And	O
Nutritional:hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
And	O
Appendages:angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN	O
and	O
ANAPROX	O
DS	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN	O
and	O
ANAPROX	O
DS	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop.	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure.	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN	O
and	O
ANAPROX	O
DS	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure.	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN	O
and	O
ANAPROX	O
DS	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function.	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN	O
and	O
ANAPROX	O
DS	O
are	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity).	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN	O
and	O
ANAPROX	O
DS	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity.	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation.	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia.	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
naproxen,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
and	O
ANAPROX	O
DS	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN	O
and	O
ANAPROX	O
DS	O
are	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
naproxen,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
or	O
ANAPROX	O
DS	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
naproxen.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
or	O
ANAPROX	O
DS	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
and	O
ANAPROX	O
DS,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
naproxen	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
or	O
ANAPROX	O
DS	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
or	O
ANAPROX	O
DS	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
Since	O
each	O
ANAPROX	O
DS	O
tablet	O
contains	O
50	O
mg	O
of	O
sodium	O
(about	O
2	O
mEq	O
per	O
each	O
500	O
mg	O
of	O
naproxen),	O
this	O
should	O
be	O
considered	O
in	O
patients	O
whose	O
overall	O
intake	O
of	O
sodium	O
must	O
be	O
severely	O
restricted.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
or	O
ANAPROX	O
DS	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
or	O
ANAPROX	O
DS	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
or	O
ANAPROX	O
DS.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
and	O
ANAPROX	O
DS	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
and	O
ANAPROX	O
DS	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
or	O
ANAPROX	O
DS	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Naproxen	B-D009288
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
naproxen	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)]	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
and	O
ANAPROX	O
DS	O
are	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
or	O
ANAPROX	O
DS	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
naproxen,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
or	O
ANAPROX	O
DS	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
and	O
ANAPROX	O
DS	O
are	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Naproxen	B-D009288
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
and	O
ANAPROX	O
DS,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
or	O
ANAPROX	O
DS	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
and	O
ANAPROX	O
DS,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin	O
and	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs),	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
NAPROSYN	O
Tablets	B-D013607
,	O
EC-NAPROSYN,	O
and	O
ANAPROX	O
DS	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Long-Term	O
Use	O
and	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
Patients	B-D010361
with	O
initial	O
hemoglobin	O
values	O
of	O
10g	O
or	O
less	O
who	O
are	O
to	O
receive	O
long-term	O
therapy	O
should	O
have	O
hemoglobin	O
values	O
determined	O
periodically.	O
Because	O
of	O
adverse	O
eye	O
findings	O
in	O
animal	O
studies	O
with	O
drugs	O
of	O
this	O
class,	O
it	O
is	O
recommended	O
that	O
ophthalmic	O
studies	O
be	O
carried	O
out	O
if	O
any	O
change	O
or	O
disturbance	O
in	O
vision	O
occurs.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
to	O
naproxen	O
were	O
dyspepsia,	O
abdominal	O
pain,	O
nausea,	O
headache,	O
rash,	O
ecchymosis,	O
and	O
edema.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Canton	O
Laboratories	B-D007753
LLC.at1-844-302-5227	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Adverse	O
reactions	O
reported	O
in	O
controlled	O
clinical	O
trials	O
in	O
960	O
patients	O
treated	O
for	O
rheumatoid	O
arthritis	O
or	O
osteoarthritis	O
are	O
listed	O
below.	O
In	O
general,	O
reactions	O
in	O
patients	O
treated	O
chronically	O
were	O
reported	O
2	O
to	O
10	O
times	O
more	O
frequently	O
than	O
they	O
were	O
in	O
short-term	O
studies	O
in	O
the	O
962	O
patients	O
treated	O
for	O
mild	O
to	O
moderate	O
pain	O
or	O
for	O
dysmenorrhea.	O
The	O
most	O
frequent	O
complaints	O
reported	O
related	O
to	O
the	O
gastrointestinal	O
tract.	O
A	O
clinical	O
study	O
found	O
gastrointestinal	O
reactions	O
to	O
be	O
more	O
frequent	O
and	O
more	O
severe	O
in	O
rheumatoid	O
arthritis	O
patients	O
taking	O
daily	O
doses	O
of	O
1500	O
mg	O
naproxen	O
compared	O
to	O
those	O
taking	O
750	O
mg	O
naproxen.	O
In	O
controlled	O
clinical	O
trials	O
with	O
about	O
80	O
pediatric	O
patients	O
and	O
in	O
well-monitored,	O
open-label	O
studies	O
with	O
about	O
400	O
pediatric	O
patients	O
with	O
polyarticular	O
juvenile	O
idiopathic	O
arthritis	O
treated	O
with	O
naproxen,	O
the	O
incidence	O
of	O
rash	O
and	O
prolonged	O
bleeding	O
times	O
were	O
greater,	O
the	O
incidence	O
of	O
gastrointestinal	O
and	O
central	O
nervous	O
system	O
reactions	O
were	O
about	O
the	O
same,	O
and	O
the	O
incidence	O
of	O
other	O
reactions	O
were	O
lower	O
in	O
pediatric	O
patients	O
than	O
in	O
adults.	O
In	O
patients	O
taking	O
naproxen	O
in	O
clinical	O
trials,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
were:	O
Gastrointestinal	O
(GI)	O
Experiences,	O
including:	O
heartburn*,	O
abdominal	O
pain*,	O
nausea*,	O
constipation*,	O
diarrhea,	O
dyspepsia,	O
stomatitis	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
headache*,	O
dizziness*,	O
drowsiness*,	O
lightheadedness,	O
vertigo	O
Dermatologic:	O
pruritus	O
(itching)*,	O
skin	O
eruptions*,	O
ecchymoses*,	O
sweating,	O
purpura	O
Special	O
Senses:	O
tinnitus*,	O
visual	O
disturbances,	O
hearing	O
disturbances	O
Cardiovascular:	O
edema*,	O
palpitations	O
General:	O
dyspnea*,	O
thirst	O
*Incidence	O
of	O
reported	O
reaction	O
between	O
3%	O
and	O
9%.	O
Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.	O
In	O
patients	O
taking	O
NSAIDs,	O
the	O
following	O
adverse	O
experiences	O
have	O
also	O
been	O
reported	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients.	O
Gastrointestinal	O
(GI)	O
Experiences,	O
including:	O
flatulence,	O
gross	O
bleeding/perforation,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting	O
General:	O
abnormal	O
renal	O
function,	O
anemia,	O
elevated	O
liver	O
enzymes,	O
increased	O
bleeding	O
time,	O
rashes	O
The	O
following	O
are	O
additional	O
adverse	O
experiences	O
reported	O
in	O
<1%	O
of	O
patients	O
taking	O
naproxen	O
during	O
clinical	O
trials.	O
Gastrointestinal:	O
pancreatitis,	O
vomiting	O
Hepatobiliary:	O
jaundice	O
Hemic	O
and	O
Lymph	B-D008196
atic:	O
melena,	O
thrombocytopenia,	O
agranulocytosis	O
Nervous	B-D009420
System	I-D009420
:	O
inability	O
to	O
concentrate	O
Dermatologic:	O
skin	O
rashes	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
naproxen.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
The	O
following	O
are	O
additional	O
adverse	O
experiences	O
reported	O
in	O
<1%	O
of	O
patients	O
taking	O
naproxen	O
during	O
clinical	O
trials	O
and	O
through	O
postmarketing	O
reports.	O
Those	O
adverse	O
reactions	O
observed	O
through	O
postmarketing	O
reports	O
are	O
italicized.	O
Body	O
as	O
a	O
Whole:	O
anaphylactoid	O
reactions,	O
angioneurotic	O
edema,	O
menstrual	O
disorders,	O
pyrexia	O
(chills	O
and	O
fever)	O
Cardiovascular:	O
congestive	O
heart	O
failure,	O
vasculitis,	O
hypertension,	O
pulmonary	O
edema	O
Gastrointestinal:	O
inflammation,	O
bleeding	O
(sometimes	O
fatal,	O
particularly	O
in	O
the	O
elderly),	O
ulceration,	O
perforation	O
and	O
obstruction	O
of	O
the	O
upper	O
or	O
lower	O
gastrointestinal	O
tract.	O
Esophagitis	B-D004941
,	O
stomatitis,	O
hematemesis,	O
colitis,	O
exacerbation	O
of	O
inflammatory	O
bowel	O
disease	O
(ulcerative	O
colitis,	O
Crohn’s	O
disease).	O
Hepatobiliary:	O
abnormal	O
liver	O
function	O
tests,	O
hepatitis	O
(some	O
cases	O
have	O
been	O
fatal)	O
Hemic	O
and	O
Lymph	B-D008196
atic:	O
eosinophilia,	O
leucopenia,	O
granulocytopenia,	O
hemolytic	O
anemia,	O
aplastic	O
anemia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia,	O
hypoglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
depression,	O
dream	O
abnormalities,	O
insomnia,	O
malaise,	O
myalgia,	O
muscle	O
weakness,	O
aseptic	O
meningitis,	O
cognitive	O
dysfunction,	O
convulsions	O
Respiratory:	O
eosinophilic	O
pneumonitis,	O
asthma	O
Dermatologic:	O
alopecia,	O
urticaria,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
erythema	O
nodosum,	O
fixed	O
drug	O
eruption,	O
lichen	O
planus,	O
pustular	O
reaction,	O
systemic	O
lupus	O
erythematoses,	O
bullous	O
reactions,	O
including	O
Stevens-Johnson	O
syndrome,	O
photosensitive	O
dermatitis,	O
photosensitivity	O
reactions,	O
including	O
rare	O
cases	O
resembling	O
porphyria	O
cutanea	O
tarda	O
(pseudoporphyria)	O
or	O
epidermolysis	O
bullosa.	O
If	O
skin	O
fragility,	O
blistering	O
or	O
other	O
symptoms	O
suggestive	O
of	O
pseudoporphyria	O
occur,	O
treatment	O
should	O
be	O
discontinued	O
and	O
the	O
patient	O
monitored.	O
Special	O
Senses:	O
hearing	O
impairment,	O
corneal	O
opacity,	O
papillitis,	O
retrobulbar	O
optic	O
neuritis,	O
papilledema	O
Urogenital:	O
glomerular	O
nephritis,	O
hematuria,	O
hyperkalemia,	O
interstitial	O
nephritis,	O
nephrotic	O
syndrome,	O
renal	O
disease,	O
renal	O
failure,	O
renal	O
papillary	O
necrosis,	O
raised	O
serum	O
creatinine	O
Reproduction	B-D012098
(female):	O
infertility	O
In	O
patients	O
taking	O
NSAIDs,	O
the	O
following	O
adverse	O
experiences	O
have	O
also	O
been	O
reported	O
in	O
<1%	O
of	O
patients.	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis,	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular:	O
hypertension,	O
tachycardia,	O
syncope,	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction	O
Gastrointestinal:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
glossitis,	O
eructation	O
Hepatobiliary:	O
hepatitis,	O
liver	O
failure	O
Hemic	O
and	O
Lymph	B-D008196
atic:	O
rectal	O
bleeding,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
convulsions,	O
coma,	O
hallucinations	O
Respiratory:	O
asthma,	O
respiratory	O
depression,	O
pneumonia	O
Dermatologic:	O
exfoliative	O
dermatitis	O
Special	O
Senses:	O
blurred	O
vision,	O
conjunctivitis	O
Urogenital:	O
cystitis,	O
dysuria,	O
oliguria/polyuria,	O
proteinuria	O
BOXED	O
WARNING	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS).Diclofenac	O
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(See	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
CONTRAINDICATIONS	O
AND	O
WARNINGS	O
ARTHROTEC®	O
CONTAINS	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL.	O
ADMINISTRATION	O
OF	O
MISOPROSTOL	O
TO	O
WOMEN	O
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
OR	O
BIRTH	O
DEFECTS.	O
UTERINE	O
RUPTURE	O
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	O
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	O
WOMEN	O
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O
BEYOND	O
THE	O
EIGHTH	O
WEEK	O
OF	O
PREGNANCY	O
(see	O
also	O
PRECAUTIONS	O
).	O
ARTHROTEC	O
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	O
WOMEN	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS	O
and	O
PRECAUTIONS	O
).	O
PATIENTS	O
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS.ARTHROTEC	O
should	O
not	O
be	O
used	O
in	O
women	O
of	O
childbearing	O
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	O
of	O
developing	O
gastric	O
or	O
duodenal	O
ulceration	O
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	O
ulcers	O
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID	O
(see	O
WARNINGS	O
).	O
In	O
such	O
patients,	O
ARTHROTEC	O
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
has	O
had	O
a	O
negative	O
serum	O
pregnancy	O
test	O
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy.	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures.	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	O
the	O
risk	O
of	O
possible	O
contraception	O
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	O
of	O
childbearing	O
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake.	O
will	O
begin	O
ARTHROTEC	O
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	O
period.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS	O
).	O
ARTHROTEC	O
is	O
contraindicated	O
for	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
Adverse	O
reactions	O
associated	O
with	O
ARTHROTEC	O
Adverse	O
reaction	O
information	O
for	O
ARTHROTEC	O
is	O
derived	O
from	O
Phase	O
III	O
multinational	O
controlled	O
clinical	O
trials	O
in	O
over	O
2,000	O
patients,	O
receiving	O
ARTHROTEC	O
50	O
or	O
ARTHROTEC	O
75,	O
as	O
well	O
as	O
from	O
blinded,	O
controlled	O
trials	O
of	O
Voltaren®	O
Delayed-Release	O
Tablets	B-D013607
(diclofenac)	O
and	O
Cytotec®	O
Tablets	B-D013607
(misoprostol).	O
Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
incidence	O
of	O
adverse	O
events	O
for	O
patients	O
receiving	O
ARTHROTEC.	O
These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
patients	O
on	O
ARTHROTEC	O
and	O
5%	O
of	O
patients	O
on	O
diclofenac.	O
For	O
GI	O
ulcer	O
rates,	O
see	O
CLINICAL	O
STUDIES—Upper	O
gastrointestinal	O
safety	O
.	O
GI	O
disorder	O
ARTHROTEC	O
Diclofenac	B-D004008
Abdominal	O
pain	O
21%	O
15%	O
Diarrhea	B-D003967
19%	O
11%	O
Dyspepsia	B-D004415
14%	O
11%	O
Nausea	B-D009325
11%	O
6%	O
Flatulence	B-D005414
9%	O
4%	O
ARTHROTEC	O
can	O
cause	O
more	O
abdominal	O
pain,	O
diarrhea	O
and	O
other	O
GI	O
symptoms	O
than	O
diclofenac	O
alone.	O
Diarrhea	B-D003967
and	O
abdominal	O
pain	O
developed	O
early	O
in	O
the	O
course	O
of	O
therapy,	O
and	O
were	O
usually	O
self-limited	O
(resolved	O
after	O
2	O
to	O
7	O
days).	O
Rare	O
instances	O
of	O
profound	O
diarrhea	O
leading	O
to	O
severe	O
dehydration	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
misoprostol.	O
Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
disease,	O
or	O
those	O
in	O
whom	O
dehydration,	O
were	O
it	O
to	O
occur,	O
would	O
be	O
dangerous,	O
should	O
be	O
monitored	O
carefully	O
if	O
ARTHROTEC	O
is	O
prescribed.	O
The	O
incidence	O
of	O
diarrhea	O
can	O
be	O
minimized	O
by	O
administering	O
ARTHROTEC	O
with	O
food	O
and	O
by	O
avoiding	O
coadministration	O
with	O
magnesium-containing	O
antacids.	O
Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
misoprostol	O
use	O
have	O
also	O
been	O
reported	O
for	O
women	O
receiving	O
ARTHROTEC	O
(see	O
below).	O
Postmenopausal	O
vaginal	O
bleeding	O
may	O
be	O
related	O
to	O
administration	O
of	O
ARTHROTEC.	O
If	O
it	O
occurs,	O
diagnostic	O
workup	O
should	O
be	O
undertaken	O
to	O
rule	O
out	O
gynecological	O
pathology	O
(see	O
boxed	O
CONTRAINDICATIONS	O
AND	O
WARNINGS	O
).	O
Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
safety	O
profile	O
of	O
ARTHROTEC	O
in	O
over	O
500	O
patients	O
65	O
years	O
of	O
age	O
or	O
older	O
compared	O
with	O
younger	O
patients.	O
Other	O
adverse	O
experiences	O
reported	O
occasionally	O
or	O
rarely	O
with	O
ARTHROTEC,	O
diclofenac	O
or	O
other	O
NSAIDs,	O
or	O
misoprostol	O
are:	O
Body	O
as	O
a	O
whole:	O
Asthenia	B-D001247
,	O
death,	O
fatigue,	O
fever,	O
infection,	O
malaise,	O
sepsis,	O
chills.	O
Cardiovascular	O
system:	O
Arrhythmia,	O
atrial	O
fibrillation,	O
congestive	O
heart	O
failure,	O
hypertension,	O
hypotension,	O
increased	O
CPK,	O
increased	O
LDH,	O
myocardial	O
infarction,	O
palpitations,	O
phlebitis,	O
premature	O
ventricular	O
contractions,	O
syncope,	O
tachycardia,	O
vasculitis.	O
Central	O
and	O
peripheral	O
nervous	O
system:	O
Coma	B-D003128
,	O
convulsions,	O
dizziness,	O
drowsiness,	O
headache,	O
hyperesthesia,	O
hypertonia,	O
hypoesthesia,	O
insomnia,	O
meningitis,	O
migraine,	O
neuralgia,	O
paresthesia,	O
somnolence,	O
tremor,	O
vertigo.	O
Digestive:	O
Anorexia	B-D000855
,	O
appetite	O
changes,	O
constipation,	O
dry	O
mouth,	O
dysphagia,	O
enteritis,	O
esophageal	O
ulceration,	O
esophagitis,	O
eructation,	O
gastritis,	O
gastroesophageal	O
reflux,	O
GI	O
bleeding,	O
GI	O
neoplasm	O
benign,	O
glossitis,	O
heartburn,	O
hematemesis,	O
hemorrhoids,	O
intestinal	O
perforation,	O
peptic	O
ulcer,	O
stomatitis	O
and	O
ulcerative	O
stomatitis,	O
tenesmus,	O
vomiting.	O
Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940
pain,	O
dysmenorrhea,	O
intermenstrual	O
bleeding,	O
leukorrhea,	O
menstrual	O
disorder,	O
menorrhagia,	O
vaginal	O
hemorrhage.	O
Hemic	O
and	O
lymphatic	O
system:	O
Agranulocytosis	B-D000380
,	O
anemia,	O
aplastic	O
anemia,	O
coagulation	O
time	O
increased,	O
ecchymosis,	O
eosinophilia,	O
epistaxis,	O
hemolytic	O
anemia,	O
leukocytosis,	O
leukopenia,	O
lymphadenopathy,	O
melena,	O
pancytopenia,	O
pulmonary	O
embolism,	O
purpura,	O
rectal	O
bleeding,	O
thrombocythemia,	O
thrombocytopenia.	O
Hypersensitivity	B-D006967
:	O
Angioedema	B-D000799
,	O
laryngeal/pharyngeal	O
edema,	O
urticaria.	O
Liver	B-D008099
and	O
biliary	O
system:	O
Abnormal	O
hepatic	O
function,	O
bilirubinemia,	O
hepatitis,	O
jaundice,	O
liver	O
failure,	O
pancreatitis.	O
Male	B-D008297
reproductive	O
disorders:	O
Impotence,	O
perineal	O
pain.	O
Metabolic	O
and	O
nutritional:	O
Alkaline	O
phosphatase	O
increased,	O
BUN	O
increased,	O
dehydration,	O
glycosuria,	O
gout,	O
hypercholesterolemia,	O
hyperglycemia,	O
hyperuricemia,	O
hypoglycemia,	O
hyponatremia,	O
periorbital	O
edema,	O
porphyria,	O
weight	O
changes.	O
Musculoskeletal	O
system:	O
Arthralgia	B-D018771
,	O
myalgia.	O
Psychiatric:	O
Anxiety	B-D001007
,	O
concentration	O
impaired,	O
confusion,	O
depression,	O
disorientation,	O
dream	O
abnormalities,	O
hallucinations,	O
irritability,	O
nervousness,	O
paranoia,	O
psychotic	O
reaction.	O
Respiratory	O
system:	O
Asthma	B-D001249
,	O
coughing,	O
dyspnea,	O
hyperventilation,	O
pneumonia,	O
respiratory	O
depression.	O
Skin	B-D012867
and	O
appendages:	O
Acne,	O
alopecia,	O
bruising,	O
eczema,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
pemphigoid	O
reaction,	O
photosensitivity,	O
pruritus,	O
pruritus	O
ani,	O
rash,	O
skin	O
ulceration,	O
Stevens-Johnson	O
syndrome,	O
sweating	O
increased,	O
toxic	O
epidermal	O
necrolysis.	O
Special	O
senses:	O
Hearing	B-D006309
impairment,	O
taste	O
loss,	O
taste	O
perversion,	O
tinnitus.	O
Urinary	O
system:	O
Cystitis	B-D003556
,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
micturition	O
frequency,	O
nocturia,	O
nephrotic	O
syndrome,	O
oliguria/polyuria,	O
papillary	O
necrosis,	O
proteinuria,	O
renal	O
failure,	O
urinary	O
tract	O
infection.	O
Vision:	O
Amblyopia	B-D000550
,	O
blurred	O
vision,	O
conjunctivitis,	O
diplopia,	O
glaucoma,	O
iritis,	O
lacrimation	O
abnormal,	O
night	O
blindness,	O
vision	O
abnormal.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop.	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure.	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure.	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function.	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity).	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
gel	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity.	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation.	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia.	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	O
sodium	O
topical	O
gel	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials,	O
of	O
oral	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
sodium	O
for	O
2	O
to	O
6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
topical	O
gel	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
topical	O
gel	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
topical	O
gel	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
diclofenac	O
sodium	O
topical	O
gel.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactoid	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
areas	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light	O
induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
with	O
eyes	O
and	O
mucosa,	O
although	O
not	O
studied,	O
should	O
be	O
avoided.	O
Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
eye	O
contact	O
occurs,	O
they	O
should	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
2%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
greater	O
than	O
placebo)	O
are	O
application	O
site	O
reactions,	O
including	O
dermatitis.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Amneal	O
Pharmaceuticals	O
at	O
1-877-835-5472	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
During	O
clinical	O
development,	O
913	O
patients	O
were	O
exposed	O
to	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
randomized,	O
double-blind,	O
multicenter,	O
vehicle-controlled,	O
parallel-group	O
studies	O
in	O
osteoarthritis	O
of	O
the	O
superficial	O
joints	O
of	O
the	O
extremities.	O
Of	O
these,	O
513	O
patients	O
received	O
diclofenac	O
sodium	O
topical	O
gel	O
for	O
osteoarthritis	O
of	O
the	O
knee	O
and	O
400	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
the	O
hand.	O
Additionally,	O
583	O
patients	O
were	O
exposed	O
to	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
an	O
uncontrolled,	O
open-label,	O
long-term	O
safety	O
trial	O
in	O
osteoarthritis	O
of	O
the	O
knee.	O
Of	O
these,	O
355	O
patients	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
1	O
knee	O
and	O
228	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
both	O
knees.	O
Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
safety	O
trial.	O
Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel:	O
Non-serious	O
adverse	O
reactions	O
that	O
were	O
reported	O
during	O
the	O
short-term	O
placebo-controlled	O
studies	O
comparing	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
placebo	O
(vehicle	O
gel)	O
over	O
study	O
periods	O
of	O
8	O
to	O
12	O
weeks	O
(16	O
g	O
per	O
day),	O
were	O
application	O
site	O
reactions.	O
These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
1%	O
of	O
treated	O
patients	O
with	O
a	O
greater	O
frequency	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
gel	O
group	O
(7%)	O
than	O
the	O
placebo	O
group	O
(2%).	O
Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported.	O
Application	O
site	O
dermatitis	O
was	O
the	O
most	O
frequent	O
type	O
of	O
application	O
site	O
reaction	O
and	O
was	O
reported	O
by	O
4%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
compared	O
to	O
1%	O
of	O
placebo	O
patients.	O
Table	O
1.	O
Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
Patients	B-D010361
)-Short-term	O
Controlled	O
Trials	O
Adverse	O
Reaction	O
†	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
N=913	O
Placebo	O
(vehicle)	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
dermatitis	O
32	O
(4)	O
6	O
(˂1)	O
Application	O
site	O
pruritus	O
7	O
(˂1)	O
1	O
(˂1)	O
Application	O
site	O
erythema	O
6	O
(˂1)	O
3	O
(˂1)	O
Application	O
site	O
paresthesia	O
5	O
(˂1)	O
3	O
(˂1)	O
Application	O
site	O
dryness	O
4	O
(˂1)	O
3	O
(˂1)	O
Application	O
site	O
vesicles	O
3	O
(˂1)	O
0	O
Application	O
site	O
irritation	O
2	O
(˂1)	O
0	O
Application	O
site	O
papules	O
1	O
(˂1)	O
0	O
†Preferred	O
Term	O
according	O
to	O
MedDRA	O
9.1.	O
In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
and	O
3%	O
for	O
patients	O
in	O
the	O
placebo	O
group.	O
Application	O
site	O
reactions,	O
including	O
application	O
site	O
dermatitis,	O
were	O
the	O
most	O
frequent	O
reason	O
for	O
treatment	O
discontinuation.	O
Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
safety	O
study,	O
distribution	O
of	O
adverse	O
reactions	O
was	O
similar	O
to	O
that	O
in	O
the	O
placebo-controlled	O
studies.	O
In	O
this	O
study,	O
where	O
patients	O
were	O
treated	O
for	O
up	O
to	O
1	O
year	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
up	O
to	O
32	O
g	O
per	O
day,	O
application	O
site	O
dermatitis	O
was	O
observed	O
in	O
11%	O
of	O
patients.	O
Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
patients.	O
The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
dermatitis,	O
which	O
was	O
experienced	O
by	O
6%	O
of	O
patients.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages	O
:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses	O
:	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
MOBIC	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(5.1)	O
MOBIC	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
MOBIC	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
MOBIC	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
MOBIC	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
MOBIC	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
meloxicam,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
MOBIC	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
MOBIC	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
meloxicam,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10‑fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
MOBIC	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
meloxicam.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
MOBIC	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.6)	O
and	O
Clinical	O
Pharmacology	B-D010600
(12.3)].	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
MOBIC,	O
can	O
lead	O
to	O
new	O
onset	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
meloxicam	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
MOBIC	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
MOBIC	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs,	O
including	O
MOBIC,	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis,	O
renal	O
insufficiency,	O
acute	O
renal	O
failure,	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
The	O
renal	O
effects	O
of	O
MOBIC	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Because	O
some	O
MOBIC	O
metabolites	O
are	O
excreted	O
by	O
the	O
kidney,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
MOBIC.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
MOBIC	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
MOBIC	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Avoid	O
the	O
use	O
of	O
MOBIC	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
MOBIC	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.3)].	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Meloxicam	B-D000077239
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
meloxicam	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
MOBIC	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
MOBIC	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
meloxicam,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
MOBIC	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
MOBIC	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Meloxicam	B-D000077239
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
MOBIC,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
MOBIC	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
MOBIC,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
MOBIC	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
(≥5%	O
and	O
greater	O
than	O
placebo)	O
adverse	O
events	O
in	O
adults	O
are	O
diarrhea,	O
upper	O
respiratory	O
tract	O
infections,	O
dyspepsia,	O
and	O
influenza-like	O
symptoms	O
(6.1)	O
Adverse	O
events	O
observed	O
in	O
pediatric	O
studies	O
were	O
similar	O
in	O
nature	O
to	O
the	O
adult	O
clinical	O
trial	O
experience	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Boehringer	O
Ingelheim	O
Pharmaceuticals,	O
Inc.	O
at	O
(800)	O
542-6257	O
or	O
(800)	O
459-9906	O
TTY	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Adult	B-D000328
s	O
Osteoarthritis	B-D010003
and	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
The	O
MOBIC	O
Phase	O
2/3	O
clinical	O
trial	O
database	O
includes	O
10,122	O
OA	O
patients	O
and	O
1012	O
RA	O
patients	O
treated	O
with	O
MOBIC	O
7.5	O
mg/day,	O
3505	O
OA	O
patients	O
and	O
1351	O
RA	O
patients	O
treated	O
with	O
MOBIC	O
15	O
mg/day.	O
MOBIC	O
at	O
these	O
doses	O
was	O
administered	O
to	O
661	O
patients	O
for	O
at	O
least	O
6	O
months	O
and	O
to	O
312	O
patients	O
for	O
at	O
least	O
one	O
year.	O
Approximately	O
10,500	O
of	O
these	O
patients	O
were	O
treated	O
in	O
ten	O
placebo-	O
and/or	O
active-controlled	O
osteoarthritis	O
trials	O
and	O
2363	O
of	O
these	O
patients	O
were	O
treated	O
in	O
ten	O
placebo-	O
and/or	O
active-controlled	O
rheumatoid	O
arthritis	O
trials.	O
Gastrointestinal	O
(GI)	O
adverse	O
events	O
were	O
the	O
most	O
frequently	O
reported	O
adverse	O
events	O
in	O
all	O
treatment	O
groups	O
across	O
MOBIC	O
trials.	O
A	O
12-week	O
multicenter,	O
double-blind,	O
randomized	O
trial	O
was	O
conducted	O
in	O
patients	O
with	O
osteoarthritis	O
of	O
the	O
knee	O
or	O
hip	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
MOBIC	O
with	O
placebo	O
and	O
with	O
an	O
active	O
control.	O
Two	O
12-week	O
multicenter,	O
double-blind,	O
randomized	O
trials	O
were	O
conducted	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
MOBIC	O
with	O
placebo.	O
Table	O
1a	O
depicts	O
adverse	O
events	O
that	O
occurred	O
in	O
≥2%	O
of	O
the	O
MOBIC	O
treatment	O
groups	O
in	O
a	O
12-week	O
placebo-	O
and	O
active-controlled	O
osteoarthritis	O
trial.	O
Table	O
1b	O
depicts	O
adverse	O
events	O
that	O
occurred	O
in	O
≥2%	O
of	O
the	O
MOBIC	O
treatment	O
groups	O
in	O
two	O
12-week	O
placebo-controlled	O
rheumatoid	O
arthritis	O
trials.	O
Table	O
1a	O
Adverse	O
Events	O
(%)	O
Occurring	O
in	O
≥2%	O
of	O
MOBIC	O
Patients	B-D010361
in	O
a	O
12-Week	O
Osteoarthritis	B-D010003
Placebo-	O
and	O
Active-Controlled	O
Trial	O
1	O
WHO	O
preferred	O
terms	O
edema,	O
edema	O
dependent,	O
edema	O
peripheral,	O
and	O
edema	O
legs	O
combined	O
2	O
WHO	O
preferred	O
terms	O
rash,	O
rash	O
erythematous,	O
and	O
rash	O
maculo-papular	O
combined	O
Placebo	O
MOBIC	O
7.5	O
mg	O
daily	O
MOBIC	O
15	O
mg	O
daily	O
Diclofenac	B-D004008
100	O
mg	O
daily	O
No.	O
of	O
Patients	B-D010361
157	O
154	O
156	O
153	O
Gastrointestinal	O
17.2	O
20.1	O
17.3	O
28.1	O
Abdominal	O
pain	O
2.5	O
1.9	O
2.6	O
1.3	O
Diarrhea	B-D003967
3.8	O
7.8	O
3.2	O
9.2	O
Dyspepsia	B-D004415
4.5	O
4.5	O
4.5	O
6.5	O
Flatulence	B-D005414
4.5	O
3.2	O
3.2	O
3.9	O
Nausea	B-D009325
3.2	O
3.9	O
3.8	O
7.2	O
Body	O
as	O
a	O
Whole	O
Accident	O
household	O
1.9	O
4.5	O
3.2	O
2.6	O
Edema	B-D004487
1	O
2.5	O
1.9	O
4.5	O
3.3	O
Fall	O
0.6	O
2.6	O
0.0	O
1.3	O
Influenza-like	O
symptoms	O
5.1	O
4.5	O
5.8	O
2.6	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
3.2	O
2.6	O
3.8	O
2.0	O
Headache	B-D006261
10.2	O
7.8	O
8.3	O
5.9	O
Respiratory	O
Pharyngitis	B-D010612
1.3	O
0.6	O
3.2	O
1.3	O
Upper	O
respiratory	O
tract	O
infection	O
1.9	O
3.2	O
1.9	O
3.3	O
Skin	B-D012867
Rash2	O
2.5	O
2.6	O
0.6	O
2.0	O
Table	O
1b	O
Adverse	O
Events	O
(%)	O
Occurring	O
in	O
≥2%	O
of	O
MOBIC	O
Patients	B-D010361
in	O
two	O
12-Week	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Placebo-Controlled	O
Trials	O
1	O
MedDRA	O
high	O
level	O
term	O
(preferred	O
terms):	O
dyspeptic	O
signs	O
and	O
symptoms	O
(dyspepsia,	O
dyspepsia	O
aggravated,	O
eructation,	O
gastrointestinal	O
irritation),	O
upper	O
respiratory	O
tract	O
infections-pathogen	O
unspecified	O
(laryngitis	O
NOS,	O
pharyngitis	O
NOS,	O
sinusitis	O
NOS),	O
joint	O
related	O
signs	O
and	O
symptoms	O
(arthralgia,	O
arthralgia	O
aggravated,	O
joint	O
crepitation,	O
joint	O
effusion,	O
joint	O
swelling)	O
2	O
MedDRA	O
preferred	O
term:	O
nausea,	O
abdominal	O
pain	O
NOS,	O
influenza-like	O
illness,	O
headaches	O
NOS,	O
and	O
rash	O
NOS	O
Placebo	O
MOBIC7.5	O
mg	O
daily	O
MOBIC15	O
mg	O
daily	O
No.	O
of	O
Patients	B-D010361
469	O
481	O
477	O
Gastrointestinal	O
Disorders	O
14.1	O
18.9	O
16.8	O
Abdominal	O
pain	O
NOS2	O
0.6	O
2.9	O
2.3	O
Dyspeptic	O
signs	O
and	O
symptoms1	O
3.8	O
5.8	O
4.0	O
Nausea	B-D009325
2	O
2.6	O
3.3	O
3.8	O
General	O
Disorders	O
and	O
Administration	O
Site	O
Conditions	O
Influenza-like	O
illness2	O
2.1	O
2.9	O
2.3	O
Infection	O
and	O
Infestations	O
Upper	O
respiratory	O
tract	O
infections-pathogen	O
class	O
unspecified1	O
4.1	O
7.0	O
6.5	O
Musculoskeletal	O
and	O
Connective	B-D003238
Tissue	I-D003238
Disorders	O
Joint	O
related	O
signs	O
and	O
symptoms1	O
1.9	O
1.5	O
2.3	O
Nervous	B-D009420
System	I-D009420
Disorders	O
Headache	B-D006261
s	O
NOS2	O
6.4	O
6.4	O
5.5	O
Skin	B-D012867
and	O
Subcutaneous	B-D040521
Tissue	I-D040521
Disorders	O
Rash	O
NOS2	O
1.7	O
1.0	O
2.1	O
The	O
adverse	O
events	O
that	O
occurred	O
with	O
MOBIC	O
in	O
≥2%	O
of	O
patients	O
treated	O
short-term	O
(4	O
to	O
6	O
weeks)	O
and	O
long-term	O
(6	O
months)	O
in	O
active-controlled	O
osteoarthritis	O
trials	O
are	O
presented	O
in	O
Table	O
2.	O
Table	O
2	O
Adverse	O
Events	O
(%)	O
Occurring	O
in	O
≥2%	O
of	O
MOBIC	O
Patients	B-D010361
in	O
4	O
to	O
6	O
Weeks	O
and	O
6	O
Month	O
Active-Controlled	O
Osteoarthritis	B-D010003
Trials	O
1	O
WHO	O
preferred	O
terms	O
edema,	O
edema	O
dependent,	O
edema	O
peripheral,	O
and	O
edema	O
legs	O
combined	O
2	O
WHO	O
preferred	O
terms	O
rash,	O
rash	O
erythematous,	O
and	O
rash	O
maculo-papular	O
combined	O
4	O
to	O
6	O
Weeks	O
Controlled	O
Trials	O
6	O
Month	O
Controlled	O
Trials	O
MOBIC7.5	O
mg	O
daily	O
MOBIC15	O
mg	O
daily	O
MOBIC7.5	O
mg	O
daily	O
MOBIC15	O
mg	O
daily	O
No.	O
of	O
Patients	B-D010361
8955	O
256	O
169	O
306	O
Gastrointestinal	O
11.8	O
18.0	O
26.6	O
24.2	O
Abdominal	O
pain	O
2.7	O
2.3	O
4.7	O
2.9	O
Constipation	B-D003248
0.8	O
1.2	O
1.8	O
2.6	O
Diarrhea	B-D003967
1.9	O
2.7	O
5.9	O
2.6	O
Dyspepsia	B-D004415
3.8	O
7.4	O
8.9	O
9.5	O
Flatulence	B-D005414
0.5	O
0.4	O
3.0	O
2.6	O
Nausea	B-D009325
2.4	O
4.7	O
4.7	O
7.2	O
Vomiting	B-D014839
0.6	O
0.8	O
1.8	O
2.6	O
Body	O
as	O
a	O
Whole	O
Accident	O
household	O
0.0	O
0.0	O
0.6	O
2.9	O
Edema	B-D004487
1	O
0.6	O
2.0	O
2.4	O
1.6	O
Pain	B-D010146
0.9	O
2.0	O
3.6	O
5.2	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
1.1	O
1.6	O
2.4	O
2.6	O
Headache	B-D006261
2.4	O
2.7	O
3.6	O
2.6	O
Hematologic	O
Anemia	B-D000740
0.1	O
0.0	O
4.1	O
2.9	O
Musculoskeletal	O
Arthralgia	B-D018771
0.5	O
0.0	O
5.3	O
1.3	O
Back	B-D001415
pain	O
0.5	O
0.4	O
3.0	O
0.7	O
Psychiatric	O
Insomnia	O
0.4	O
0.0	O
3.6	O
1.6	O
Respiratory	O
Cough	B-D003371
ing	O
0.2	O
0.8	O
2.4	O
1.0	O
Upper	O
respiratory	O
tract	O
infection	O
0.2	O
0.0	O
8.3	O
7.5	O
Skin	B-D012867
Pruritus	B-D011537
0.4	O
1.2	O
2.4	O
0.0	O
Rash2	O
0.3	O
1.2	O
3.0	O
1.3	O
Urinary	O
Micturition	O
frequency	O
0.1	O
0.4	O
2.4	O
1.3	O
Urinary	O
tract	O
infection	O
0.3	O
0.4	O
4.7	O
6.9	O
Higher	O
doses	O
of	O
MOBIC	O
(22.5	O
mg	O
and	O
greater)	O
have	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
GI	O
events;	O
therefore,	O
the	O
daily	O
dose	O
of	O
MOBIC	O
should	O
not	O
exceed	O
15	O
mg.	O
Pediatrics	B-D010372
Pauciarticular	O
and	O
Polyarticular	O
Course	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
(JRA)	O
Three	O
hundred	O
and	O
eighty-seven	O
patients	O
with	O
pauciarticular	O
and	O
polyarticular	O
course	O
JRA	O
were	O
exposed	O
to	O
MOBIC	O
with	O
doses	O
ranging	O
from	O
0.125	O
to	O
0.375	O
mg/kg	O
per	O
day	O
in	O
three	O
clinical	O
trials.	O
These	O
studies	O
consisted	O
of	O
two	O
12-week	O
multicenter,	O
double-blind,	O
randomized	O
trials	O
(one	O
with	O
a	O
12-week	O
open-label	O
extension	O
and	O
one	O
with	O
a	O
40-week	O
extension)	O
and	O
one	O
1-year	O
open-label	O
PK	O
study.	O
The	O
adverse	O
events	O
observed	O
in	O
these	O
pediatric	O
studies	O
with	O
MOBIC	O
were	O
similar	O
in	O
nature	O
to	O
the	O
adult	O
clinical	O
trial	O
experience,	O
although	O
there	O
were	O
differences	O
in	O
frequency.	O
In	O
particular,	O
the	O
following	O
most	O
common	O
adverse	O
events,	O
abdominal	O
pain,	O
vomiting,	O
diarrhea,	O
headache,	O
and	O
pyrexia,	O
were	O
more	O
common	O
in	O
the	O
pediatric	O
than	O
in	O
the	O
adult	O
trials.	O
Rash	O
was	O
reported	O
in	O
seven	O
(<2%)	O
patients	O
receiving	O
MOBIC.	O
No	O
unexpected	O
adverse	O
events	O
were	O
identified	O
during	O
the	O
course	O
of	O
the	O
trials.	O
The	O
adverse	O
events	O
did	O
not	O
demonstrate	O
an	O
age	O
or	O
gender-specific	O
subgroup	O
effect.	O
The	O
following	O
is	O
a	O
list	O
of	O
adverse	O
drug	O
reactions	O
occurring	O
in	O
<2%	O
of	O
patients	O
receiving	O
MOBIC	O
in	O
clinical	O
trials	O
involving	O
approximately	O
16,200	O
patients.	O
Body	O
as	O
a	O
Whole	O
allergic	O
reaction,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
malaise,	O
syncope,	O
weight	O
decrease,	O
weight	O
increase	O
Cardiovascular	O
angina	O
pectoris,	O
cardiac	O
failure,	O
hypertension,	O
hypotension,	O
myocardial	O
infarction,	O
vasculitis	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
convulsions,	O
paresthesia,	O
tremor,	O
vertigo	O
Gastrointestinal	O
colitis,	O
dry	O
mouth,	O
duodenal	O
ulcer,	O
eructation,	O
esophagitis,	O
gastric	O
ulcer,	O
gastritis,	O
gastroesophageal	O
reflux,	O
gastrointestinal	O
hemorrhage,	O
hematemesis,	O
hemorrhagic	O
duodenal	O
ulcer,	O
hemorrhagic	O
gastric	O
ulcer,	O
intestinal	O
perforation,	O
melena,	O
pancreatitis,	O
perforated	O
duodenal	O
ulcer,	O
perforated	O
gastric	O
ulcer,	O
stomatitis	O
ulcerative	O
Heart	B-D006339
Rate	I-D006339
and	O
Rhythm	O
arrhythmia,	O
palpitation,	O
tachycardia	O
Hematologic	O
leukopenia,	O
purpura,	O
thrombocytopenia	O
Liver	B-D008099
and	O
Biliary	O
System	O
ALT	O
increased,	O
AST	O
increased,	O
bilirubinemia,	O
GGT	O
increased,	O
hepatitis	O
Metabolic	O
and	O
Nutritional	O
dehydration	O
Psychiatric	O
abnormal	O
dreaming,	O
anxiety,	O
appetite	O
increased,	O
confusion,	O
depression,	O
nervousness,	O
somnolence	O
Respiratory	O
asthma,	O
bronchospasm,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
alopecia,	O
angioedema,	O
bullous	O
eruption,	O
photosensitivity	O
reaction,	O
pruritus,	O
sweating	O
increased,	O
urticaria	O
Special	O
Senses	O
abnormal	O
vision,	O
conjunctivitis,	O
taste	O
perversion,	O
tinnitus	O
Urinary	O
System	O
albuminuria,	O
BUN	O
increased,	O
creatinine	O
increased,	O
hematuria,	O
renal	O
failure	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
MOBIC.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Decisions	O
about	O
whether	O
to	O
include	O
an	O
adverse	O
event	O
from	O
spontaneous	O
reports	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
event,	O
(2)	O
number	O
of	O
reports,	O
or	O
(3)	O
strength	O
of	O
causal	O
relationship	O
to	O
the	O
drug.	O
Adverse	O
reactions	O
reported	O
in	O
worldwide	O
post	O
marketing	O
experience	O
or	O
the	O
literature	O
include:	O
acute	O
urinary	O
retention;	O
agranulocytosis;	O
alterations	O
in	O
mood	O
(such	O
as	O
mood	O
elevation);	O
anaphylactoid	O
reactions	O
including	O
shock;	O
erythema	O
multiforme;	O
exfoliative	O
dermatitis;	O
interstitial	O
nephritis;	O
jaundice;	O
liver	O
failure;	O
Stevens-Johnson	O
syndrome;	O
toxic	O
epidermal	O
necrolysis,	O
and	O
infertility	O
female.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)].	O
Indomethacin	B-D007213
Capsules	B-D002214
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)].	O
WARNING:	O
RISK	O
OF	O
SERIOUD	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(	O
5.1	O
)	O
Indomethacin	B-D007213
Capsules	B-D002214
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(	O
4	O
,	O
5.1	O
)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(	O
5.2	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity	O
:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(	O
5.3	O
)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(	O
5.4	O
,	O
7	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
indomethacin	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(	O
5.5	O
)	O
Renal	O
Toxicity	O
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
indomethacin	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(	O
5.6	O
)	O
Anaphylactic	O
Reactions	O
:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7	O
)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
:	O
Indomethacin	B-D007213
Capsules	B-D002214
are	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(	O
5.8	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
:	O
Discontinue	O
indomethacin	O
capsules	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(	O
5.9	O
)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(	O
5.10	O
,	O
8.1	O
)	O
Hematologic	O
Toxicity	O
:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(	O
5.11	O
,	O
7	O
)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
indomethacin,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
indomethacin	O
capsules	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
indomethacin	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
indomethacin,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients	O
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
indomethacin	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
indomethacin.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
indomethacin	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
indomethacin	O
capsules,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
indomethacin	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
Avoid	O
the	O
use	O
of	O
indomethacin	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
indomethacin	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
indomethacin	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
indomethacin	O
capsules	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
indomethacin	O
capsules.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
indomethacin	O
capsules	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
Avoid	O
the	O
use	O
of	O
indomethacin	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
indomethacin	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
It	O
has	O
been	O
reported	O
that	O
the	O
addition	O
of	O
the	O
potassium-sparing	O
diuretic,	O
triamterene,	O
to	O
a	O
maintenance	O
schedule	O
of	O
indomethacin	O
resulted	O
in	O
reversible	O
acute	O
renal	O
failure	O
in	O
two	O
of	O
four	O
healthy	O
volunteers.	O
Indomethacin	B-D007213
and	O
triamterene	O
should	O
not	O
be	O
administered	O
together.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
Both	O
indomethacin	O
and	O
potassium-sparing	O
diuretics	O
may	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	O
levels.	O
The	O
potential	O
effects	O
of	O
indomethacin	O
and	O
potassium-sparing	O
diuretics	O
on	O
potassium	O
levels	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently.	O
5.7	O
Anaphylactic	O
Reactions	O
Indomethacin	B-D007213
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
indomethacin	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
indomethacin	O
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)].	O
When	O
indomethacin	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
indomethacin,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
indomethacin	O
capsules	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Indomethacin	B-D007213
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Indomethacin	B-D007213
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
indomethacin	O
capsules,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(	O
8.1	O
)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
indomethacin	O
capsules	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
indomethacin	O
capsules,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
indomethacin	O
capsules	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
,	O
5.3	O
,	O
5.6	O
)].	O
5.14	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects:	O
Indomethacin	B-D007213
may	O
aggravate	O
depression	O
or	O
other	O
psychiatric	O
disturbances,	O
epilepsy,	O
and	O
parkinsonism,	O
and	O
should	O
be	O
used	O
with	O
considerable	O
caution	O
in	O
patients	O
with	O
these	O
conditions.	O
If	O
severe	O
CNS	O
adverse	O
reactions	O
develop,	O
indomethacin	O
should	O
be	O
discontinued.	O
Indomethacin	B-D007213
may	O
cause	O
drowsiness;	O
therefore,	O
patients	O
should	O
be	O
cautioned	O
about	O
engaging	O
in	O
activities	O
requiring	O
mental	O
alertness	O
and	O
motor	O
coordination,	O
such	O
as	O
driving	O
a	O
car.	O
Indomethacin	B-D007213
may	O
also	O
cause	O
headache.	O
Headache	B-D006261
which	O
persists	O
despite	O
dosage	O
reduction	O
requires	O
cessation	O
of	O
therapy	O
with	O
indomethacin.	O
5.15	O
Ocular	O
Effects:	O
Cornea	B-D003315
l	O
deposits	O
and	O
retinal	O
disturbances,	O
including	O
those	O
of	O
the	O
macula,	O
have	O
been	O
observed	O
in	O
some	O
patients	O
who	O
had	O
received	O
prolonged	O
therapy	O
with	O
indomethacin.	O
The	O
prescribing	O
physician	O
should	O
be	O
alert	O
to	O
the	O
possible	O
association	O
between	O
the	O
changes	O
noted	O
and	O
indomethacin.	O
It	O
is	O
advisable	O
to	O
discontinue	O
therapy	O
if	O
such	O
changes	O
are	O
observed.	O
Blurred	O
vision	O
may	O
be	O
a	O
significant	O
symptom	O
and	O
warrants	O
a	O
thorough	O
ophthalmological	O
examination.	O
Since	O
these	O
changes	O
may	O
be	O
asymptomatic,	O
ophthalmologic	O
examination	O
at	O
periodic	O
intervals	O
is	O
desirable	O
in	O
patients	O
where	O
therapy	O
is	O
prolonged.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11	O
)]	O
Most	O
common	O
adverse	O
(incidence	O
≥	O
3%)	O
are	O
headache,	O
dizziness,	O
dyspepsia	O
and	O
nausea.	O
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Heritage	O
Pharmaceuticals	O
Inc.	O
at	O
1.866.901.DRUG	O
(3784)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice.	O
In	O
a	O
gastroscopic	O
study	O
in	O
45	O
healthy	O
subjects,	O
the	O
number	O
of	O
gastric	O
mucosal	O
abnormalities	O
was	O
significantly	O
higher	O
in	O
the	O
group	O
receiving	O
indomethacin	O
capsules	O
than	O
in	O
the	O
group	O
taking	O
indomethacin	O
Suppositories	B-D013488
or	O
placebo.	O
In	O
a	O
double-blind	O
comparative	O
clinical	O
study	O
involving	O
175	O
patients	O
with	O
rheumatoid	O
arthritis,	O
however,	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
effects	O
with	O
indomethacin	O
Suppositories	B-D013488
or	O
Capsules	B-D002214
was	O
comparable.	O
The	O
incidence	O
of	O
lower	O
gastrointestinal	O
adverse	O
effects	O
was	O
greater	O
in	O
the	O
suppository	O
group.	O
The	O
adverse	O
reactions	O
for	O
indomethacin	O
capsules	O
listed	O
in	O
the	O
following	O
table	O
have	O
been	O
arranged	O
into	O
two	O
groups:	O
(1)	O
incidence	O
greater	O
than	O
1%;	O
and	O
(2)	O
incidence	O
less	O
than	O
1%.	O
The	O
incidence	O
for	O
group	O
(1)	O
was	O
obtained	O
from	O
33	O
double-blind	O
controlled	O
clinical	O
trials	O
reported	O
in	O
the	O
literature	O
(1,092	O
patients).	O
The	O
incidence	O
for	O
group	O
(2)	O
was	O
based	O
on	O
reports	O
in	O
clinical	O
trials,	O
in	O
the	O
literature,	O
and	O
on	O
voluntary	O
reports	O
since	O
marketing.	O
The	O
probability	O
of	O
a	O
causal	O
relationship	O
exists	O
between	O
indomethacin	O
and	O
these	O
adverse	O
reactions,	O
some	O
of	O
which	O
have	O
been	O
reported	O
only	O
rarely.	O
Table	O
1:	O
Summary	O
of	O
Adverse	O
reactions	O
for	O
Indomethacin	B-D007213
Capsules	B-D002214
Incidence	B-D015994
greater	O
than	O
1%	O
Incidence	B-D015994
less	O
than	O
1%	O
GASTROINTESTINAL	O
nausea*	O
with	O
or	O
without	O
vomiting	O
dyspepsia*	O
(including	O
indigestion,	O
heartburn	O
and	O
epigastric	O
pain)	O
diarrhea	O
abdominal	O
distress	O
or	O
pain	O
constipation	O
Anorexia	B-D000855
bloating	O
(includes	O
distension)	O
flatulence	O
peptic	O
ulcer	O
gastroenteritis	O
rectal	O
bleeding	O
proctitis	O
single	O
or	O
multiple	O
ulcerations,	O
including	O
perforation	O
and	O
hemorrhage	O
of	O
the	O
esophagus,	O
stomach,	O
duodenum	O
or	O
small	O
and	O
large	O
intestines	O
intestinal	O
ulceration	O
associated	O
with	O
stenosis	O
and	O
obstruction	O
gastrointestinal	O
bleeding	O
without	O
obvious	O
ulcer	O
formation	O
and	O
perforation	O
of	O
pre-existing	O
sigmoid	O
lesions	O
(diverticulum,	O
carcinoma,	O
etc.)	O
development	O
of	O
ulcerative	O
colitis	O
and	O
regional	O
ileitis	O
ulcerative	O
stomatitis	O
toxic	O
hepatitis	O
and	O
jaundice	O
(some	O
fatal	O
cases	O
have	O
been	O
reported)	O
intestinal	O
strictures	O
(diaphragms)	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
headache	O
(11.7%)	O
dizziness*	O
vertigo	O
somnolence	O
depression	O
and	O
fatigue	O
(including	O
malaise	O
and	O
listlessness)	O
anxiety	O
(includes	O
nervousness)	O
muscle	O
weakness	O
involuntary	O
muscle	O
movements	O
insomnia	O
muzziness	O
psychic	O
disturbances	O
including	O
psychotic	O
episodes	O
mental	O
confusion	O
drowsiness	O
light-headedness	O
syncope	O
paresthesia	O
aggravation	O
of	O
epilepsy	O
and	O
parkinsonism	O
depersonalization	O
coma	O
peripheral	O
neuropathy	O
convulsion	O
dysarthria	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
ocular	O
—	O
corneal	O
deposits	O
and	O
retinal	O
disturbances,	O
including	O
those	O
of	O
the	O
macula,	O
have	O
been	O
reported	O
in	O
some	O
patients	O
on	O
prolonged	O
therapy	O
with	O
indomethacin	O
blurred	O
vision	O
diplopia	O
hearing	O
disturbances,	O
deafness	O
CARDIOVASCULAR	O
None	O
Hypertension	B-D006973
hypotension	O
tachycardia	O
chest	O
pain	O
congestive	O
heart	O
failure	O
arrhythmia;	O
palpitations	O
METABOLIC	O
none	O
Edema	B-D004487
weight	O
gain	O
fluid	O
retention	O
flushing	O
or	O
sweating	O
Hyperglycemia	B-D006943
glycosuria	O
hyperkalemia	O
INTEGUMENTARY	O
None	O
Pruritus	B-D011537
rash;	O
urticaria	O
petechiae	O
or	O
ecchymosis	O
exfoliative	O
dermatitis	O
erythema	O
nodosum	O
loss	O
of	O
hair	O
Stevens-Johnson	O
syndrome	O
erythema	O
multiforme	O
toxic	O
epidermal	O
necrolysis	O
HEMATOLOGIC	O
None	O
Leucopenia	O
bone	O
marrow	O
depression	O
anemia	O
secondary	O
to	O
obvious	O
or	O
occult	O
gastrointestinal	O
bleeding	O
aplastic	O
anemia	O
hemolytic	O
anemia	O
agranulocytosis	O
thrombocytopenic	O
purpura	O
disseminated	O
intravascular	O
coagulation	O
HYPERSENSITIVITY	O
None	O
acute	O
anaphylaxis	O
acute	O
respiratory	O
distress	O
rapid	O
fall	O
in	O
blood	O
pressure	O
resembling	O
a	O
shock-like	O
state	O
angioedema	O
Dyspnea	B-D004417
asthma	O
purpura	O
angiitis	O
pulmonary	O
edema	O
fever	O
GENITOURINARY	O
None	O
Hematuria	B-D006417
vaginal	O
bleeding	O
proteinuria	O
nephrotic	O
syndrome	O
interstitial	O
nephritis	O
BUN	O
elevation	O
renal	O
insufficiency,	O
including	O
renal	O
failure	O
MISCELLANEOUS	O
None	O
Epistaxis	B-D004844
breast	O
changes,	O
including	O
enlargement	O
and	O
tenderness,	O
or	O
gynecomastia	O
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
indomethacin.	O
(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.)	O
Causal	O
relationship	O
unknown	O
:	O
Other	O
reactions	O
have	O
been	O
reported	O
but	O
occurred	O
under	O
circumstances	O
where	O
a	O
causal	O
relationship	O
could	O
not	O
be	O
established.	O
However,	O
in	O
these	O
rarely	O
reported	O
events,	O
the	O
possibility	O
cannot	O
be	O
excluded.	O
Therefore,	O
these	O
observations	O
are	O
being	O
listed	O
to	O
serve	O
as	O
alerting	O
information	O
to	O
physicians:	O
Cardiovascular	O
:	O
Thrombophlebitis	B-D013924
Hematologic	O
:	O
Although	O
there	O
have	O
been	O
several	O
reports	O
of	O
leukemia,	O
the	O
supporting	O
information	O
is	O
weak.	O
Genitourinary	O
:	O
Urinary	O
frequency.	O
A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
fasciitis,	O
particularly	O
in	O
association	O
with	O
Group	O
Aß	O
hemolytic	O
streptococcus,	O
has	O
been	O
described	O
in	O
persons	O
treated	O
with	O
nonsteroidal	O
anti-inflammatory	O
agents,	O
including	O
indomethacin,	O
sometimes	O
with	O
fatal	O
outcome.	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
].	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
and	O
Warnings	O
].	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
Diclofenac	B-D004008
Sodium	B-D012964
Delayed-Release	O
Tablets	B-D013607
,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Rising	O
Pharmaceuticals,	O
Inc.	O
at	O
1-866-562-4597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
RISK	O
EVALUATION	O
AND	O
MITIGATION	O
STRATEGY	O
(REMS);	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION;	O
ACCIDENTAL	O
INGESTION;	O
NEONATAL	O
OPIOID	O
WITHDRAWAL	O
SYNDROME;	O
CYTOCHROME	O
P450	O
3A4	O
INTERACTION;	O
RISKS	O
FROM	O
CONCOMITANT	O
USE	O
WITH	O
BENZODIAZEPINES	O
OR	O
OTHER	O
CNS	O
DEPRESSANTS;	O
and	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
Hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	O
exposes	O
patients	O
and	O
other	O
users	O
to	O
the	O
risks	O
of	O
opioid	O
addiction,	O
abuse,	O
and	O
misuse,	O
which	O
can	O
lead	O
to	O
overdose	O
and	O
death.	O
Assess	O
each	O
patient’s	O
risk	O
prior	O
to	O
prescribing	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen,	O
and	O
monitor	O
all	O
patients	O
regularly	O
for	O
the	O
development	O
of	O
these	O
behaviors	O
and	O
conditions	O
(see	O
WARNINGS:	O
Addiction,	O
Abuse,	O
and	O
Misuse).	O
Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
REMS	O
for	O
these	O
products	O
(see	O
WARNINGS).	O
Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
education	O
programs	O
available	O
to	O
healthcare	O
providers.	O
Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
complete	O
a	O
REMS-compliant	O
education	O
program.	O
counsel	O
patients	O
and/or	O
their	O
caregivers,	O
with	O
every	O
prescription,	O
on	O
safe	O
use,	O
serious	O
risks,	O
storage,	O
and	O
disposal	O
of	O
these	O
products.	O
emphasize	O
to	O
patients	O
and	O
their	O
caregivers	O
the	O
importance	O
of	O
reading	O
the	O
Medication	O
Guide	O
every	O
time	O
it	O
is	O
provided	O
by	O
their	O
pharmacist.	O
consider	O
other	O
tools	O
to	O
improve	O
patient,	O
household,	O
and	O
community	O
safety.	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
may	O
occur	O
with	O
use	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen.	O
Monitor	O
for	O
respiratory	O
depression,	O
especially	O
during	O
initiation	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
or	O
following	O
a	O
dose	O
increase	O
(see	O
WARNINGS:	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
).	O
Accidental	O
Ingestion	O
Accidental	O
ingestion	O
of	O
even	O
one	O
dose	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
a	O
fatal	O
overdose	O
of	O
hydrocodone	O
(see	O
WARNINGS:	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
).	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
during	O
pregnancy	O
can	O
result	O
in	O
neonatal	O
opioid	O
withdrawal	O
syndrome,	O
which	O
may	O
be	O
life-threatening	O
if	O
not	O
recognized	O
and	O
treated,	O
and	O
requires	O
management	O
according	O
to	O
protocols	O
developed	O
by	O
neonatology	O
experts.	O
If	O
opioid	O
use	O
is	O
required	O
for	O
a	O
prolonged	O
period	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available	O
(see	O
WARNINGS:	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
).	O
Cytochrome	O
P450	O
3A4	O
Interaction	O
The	O
concomitant	O
use	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
with	O
all	O
cytochrome	O
P450	O
3A4	O
inhibitors	O
may	O
result	O
in	O
an	O
increase	O
in	O
hydrocodone	O
plasma	O
concentrations,	O
which	O
may	O
cause	O
potentially	O
fatal	O
respiratory	O
depression.	O
In	O
addition,	O
discontinuation	O
of	O
a	O
concomitantly	O
used	O
cytochrome	O
P450	O
3A4	O
inducer	O
may	O
result	O
in	O
an	O
increase	O
in	O
hydrocodone	O
plasma	O
concentration.	O
Monitor	O
patients	O
taking	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
and	O
any	O
CYP3A4	O
inhibitor	O
or	O
upon	O
discontinuation	O
of	O
a	O
CYP3A4	O
inducer	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation	O
(see	O
WARNINGS:	O
Risk	B-D012306
s	O
of	O
Concomitant	O
Use	O
or	O
Discontinuation	O
of	O
Cytochrome	O
P450	O
3A4	O
Inhibitors	O
and	O
Inducers,	O
PRECAUTIONS:	O
Drug	B-D004347
Interactions	I-D004347
).	O
Risk	B-D012306
s	O
From	O
Concomitant	O
Use	O
With	O
Benzodiazepines	B-D001569
Or	O
Other	O
CNS	O
Depressants	O
Concomitant	O
use	O
of	O
opioids	O
with	O
benzodiazepines	O
or	O
other	O
central	O
nervous	O
system	O
(CNS)	O
depressants,	O
including	O
alcohol,	O
may	O
result	O
in	O
profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death	O
(see	O
WARNINGS:	O
Risk	B-D012306
s	O
from	O
Concomitant	O
Use	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants,	O
PRECAUTIONS:	O
Drug	B-D004347
Interactions	I-D004347
).	O
Reserve	O
concomitant	O
prescribing	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
and	O
benzodiazepines	O
or	O
other	O
CNS	O
depressants	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
treatment	O
options	O
are	O
inadequate.	O
Limit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required.	O
Follow	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS:	O
Cardiovascular	O
Thrombotic	O
Events).	O
Hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS:	O
Cardiovascular	O
Thrombotic	O
Events).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS:	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
described	O
below	O
and	O
elsewhere	O
in	O
the	O
labeling	O
including	O
the	O
WARNINGS	O
section.	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Interactions	O
with	O
Cytochrome	O
P450	O
3A4	O
Inhibitors	O
and	O
Inducers	O
Interactions	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
Adrenal	B-D000309
Insufficiency	I-D000309
Severe	O
Hypotension	B-D007022
Seizures	B-D012640
Withdrawal	O
Cardiovascular	O
Thrombotic	O
Events	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Hepatotoxicity	O
Hypertension	B-D006973
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Anaphylactic	O
Reactions	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
Serious	O
Skin	B-D012867
Reactions	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Hematologic	O
Toxicity	O
Aseptic	O
Meningitis	B-D008581
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	O
was	O
administered	O
to	O
approximately	O
300	O
pain	O
patients	O
in	O
a	O
safety	O
study	O
that	O
employed	O
dosages	O
and	O
a	O
duration	O
of	O
treatment	O
sufficient	O
to	O
encompass	O
the	O
recommended	O
usage	O
(see	O
DOSAGE	O
AND	O
ADMINISTRATION	O
).	O
Adverse	O
event	O
rates	O
generally	O
increased	O
with	O
increasing	O
daily	O
dose.	O
The	O
event	O
rates	O
reported	O
below	O
are	O
from	O
approximately	O
150	O
patients	O
who	O
were	O
in	O
a	O
group	O
that	O
received	O
one	O
tablet	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
an	O
average	O
of	O
three	O
to	O
four	O
times	O
daily.	O
The	O
overall	O
incidence	O
rates	O
of	O
adverse	O
experiences	O
in	O
the	O
trials	O
were	O
fairly	O
similar	O
for	O
this	O
patient	O
group	O
and	O
those	O
who	O
received	O
the	O
comparison	O
treatment,	O
acetaminophen	O
600	O
mg	O
with	O
codeine	O
60	O
mg.	O
The	O
following	O
lists	O
adverse	O
events	O
that	O
occurred	O
with	O
an	O
incidence	O
of	O
1%	O
or	O
greater	O
in	O
clinical	O
trials	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen,	O
without	O
regard	O
to	O
the	O
causal	O
relationship	O
of	O
the	O
events	O
to	O
the	O
drug.	O
To	O
distinguish	O
different	O
rates	O
of	O
occurrence	O
in	O
clinical	O
studies,	O
the	O
adverse	O
events	O
are	O
listed	O
as	O
follows:	O
name	O
of	O
adverse	O
event	O
=	O
less	O
than	O
3%	O
adverse	O
events	O
marked	O
with	O
an	O
asterisk	O
*	O
=	O
3%	O
to	O
9%	O
adverse	O
event	O
rates	O
over	O
9%	O
are	O
in	O
parentheses.	O
Body	O
as	O
a	O
Whole	O
Abdominal	O
pain*;	O
Asthenia	B-D001247
*;	O
Fever	B-D005334
;	O
Flu	O
syndrome;	O
Headache	B-D006261
(27%);	O
Infection*;	O
Pain	B-D010146
.	O
Cardiovascular	O
Palpitations;	O
Vasodilation	B-D014664
.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Anxiety	B-D001007
*;	O
Confusion	B-D003221
;	O
Dizziness	B-D004244
(14%);	O
Hypertonia;	O
Insomnia*;	O
Nervousness*;	O
Paresthesia	B-D010292
;	O
Somnolence	O
(22%);	O
Thinking	B-D013850
abnormalities.	O
Digestive	O
Anorexia	B-D000855
;	O
Constipation	B-D003248
(22%);	O
Diarrhea	B-D003967
*;	O
Dry	O
mouth*;	O
Dyspepsia	B-D004415
(12%);	O
Flatulence	B-D005414
*;	O
Gastritis	B-D005756
;	O
Melena	B-D008551
;	O
Mouth	B-D009055
ulcers;	O
Nausea	B-D009325
(21%);	O
Thirst	B-D013894
;	O
Vomiting	B-D014839
*.	O
Metabolic	O
and	O
Nutritional	O
Disorders	O
Edema	B-D004487
*.	O
Respiratory	O
Dyspnea	B-D004417
;	O
Hiccup	B-D006606
s;	O
Pharyngitis	B-D010612
;	O
Rhinitis	B-D012220
.	O
Skin	B-D012867
and	O
Appendages	O
Pruritus	B-D011537
*;	O
Sweating	B-D013546
*.	O
Special	O
Senses	O
Tinnitus	B-D014012
.	O
Urogenital	O
Urinary	O
frequency.	O
Incidence	B-D015994
less	O
than	O
1%	O
Body	O
as	O
a	O
Whole	O
Allergic	O
reaction.	O
Cardiovascular	O
Arrhythmia;	O
Hypotension	B-D007022
;	O
Tachycardia	B-D013610
.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Agitation;	O
Abnormal	O
dreams;	O
Decreased	O
libido;	O
Depression	B-D003863
;	O
Euphoria	B-D005059
;	O
Mood	O
changes;	O
Neuralgia	B-D009437
;	O
Slurred	O
speech;	O
Tremor	B-D014202
,	O
Vertigo	B-D014717
.	O
Digestive	O
Chalky	O
stool;	O
"Clenching	O
teeth";	O
Dysphagia;	O
Esophageal	O
spasm;	O
Esophagitis	B-D004941
;	O
Gastroenteritis	B-D005759
;	O
Glossitis	B-D005928
;	O
Liver	B-D008099
enzyme	O
elevation.	O
Metabolic	O
and	O
Nutritional	O
Weight	O
decrease.	O
Musculoskeletal	O
Arthralgia	B-D018771
;	O
Myalgia	B-D063806
.	O
Respiratory	O
Asthma	B-D001249
;	O
Bronchitis	B-D001991
;	O
Hoarseness	B-D006685
;	O
Increased	O
cough;	O
Pulmonary	O
congestion;	O
Pneumonia	B-D011014
;	O
Shallow	O
breathing;	O
Sinusitis	B-D012852
.	O
Skin	B-D012867
and	O
Appendages	O
Rash;	O
Urticaria	B-D014581
.	O
Special	O
Senses	O
Altered	O
vision;	O
Bad	O
taste;	O
Dry	O
eyes.	O
Urogenital	O
Cystitis	B-D003556
;	O
Glycosuria	B-D006029
;	O
Impotence;	O
Urinary	O
incontinence;	O
Urinary	O
retention.	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
hydrocodone.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Serotonin	B-D012701
syndrome:	O
Cases	O
of	O
serotonin	O
syndrome,	O
a	O
potentially	O
life-threatening	O
condition,	O
have	O
been	O
reported	O
during	O
concomitant	O
use	O
of	O
opioids	O
with	O
serotonergic	O
drugs.	O
Adrenal	O
insufficiency:	O
Cases	O
of	O
adrenal	O
insufficiency	O
have	O
been	O
reported	O
with	O
opioid	O
use,	O
more	O
often	O
following	O
greater	O
than	O
one	O
month	O
of	O
use.	O
Anaphylaxis	B-D000707
:	O
Anaphylaxis	B-D000707
has	O
been	O
reported	O
with	O
ingredients	O
contained	O
in	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen.	O
Androgen	O
deficiency:	O
Cases	O
of	O
androgen	O
deficiency	O
have	O
occurred	O
with	O
chronic	O
use	O
of	O
opioids	O
(see	O
CLINICAL	O
PHARMACOLOGY:	O
Pharmacodynamics	O
).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Amneal	O
Pharmaceuticals	O
at	O
1-877-835-5472	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
WARNING:	O
DIMINISHED	O
ANTIPLATELET	O
EFFECT	O
IN	O
PATIENTS	O
WITH	O
TWO	O
LOSS-OF-FUNCTION	O
ALLELES	O
OF	O
THE	O
CYP2C19	O
GENE	O
WARNING:	O
DIMINISHED	O
ANTIPLATELET	O
EFFECT	O
IN	O
PATIENTS	O
WITH	O
TWO	O
LOSS-OF-FUNCTION	O
ALLELES	O
OF	O
THE	O
CYP2C19	O
GENE	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
•	O
Effectiveness	O
of	O
clopidogrel	O
bisulfate	O
depends	O
on	O
conversion	O
to	O
an	O
active	O
metabolite	O
by	O
the	O
cytochrome	O
P450	O
(CYP)	O
system,	O
principally	O
CYP2C19.	O
(5.1,	O
12.3)	O
•	O
Tests	O
are	O
available	O
to	O
identify	O
patients	O
who	O
are	O
CYP2C19	O
poor	O
metabolizers.	O
(12.5)	O
•	O
Consider	O
use	O
of	O
another	O
platelet	O
P2Y12	O
inhibitor	O
in	O
patients	O
identified	O
as	O
CYP2C19	O
poor	O
metabolizers.	O
(5.1)	O
The	O
effectiveness	O
of	O
clopidogrel	O
bisulfate	O
results	O
from	O
its	O
antiplatelet	O
activity,	O
which	O
is	O
dependent	O
on	O
its	O
conversion	O
to	O
an	O
active	O
metabolite	O
by	O
the	O
cytochrome	O
P450	O
(CYP)	O
system,	O
principally	O
CYP2C19	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1),	O
Clinical	O
Pharmacology	B-D010600
(12.3)].	O
Clopidogrel	B-D000077144
bisulfate	O
at	O
recommended	O
doses	O
forms	O
less	O
of	O
the	O
active	O
metabolite	O
and	O
so	O
has	O
a	O
reduced	O
effect	O
on	O
platelet	O
activity	O
in	O
patients	O
who	O
are	O
homozygous	O
for	O
nonfunctional	O
alleles	O
of	O
the	O
CYP2C19	O
gene,	O
(termed	O
"CYP2C19	O
poor	O
metabolizers").	O
Tests	O
are	O
available	O
to	O
identify	O
patients	O
who	O
are	O
CYP2C19	O
poor	O
metabolizers	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.5)].	O
Consider	O
use	O
of	O
another	O
platelet	O
P2Y12	O
inhibitor	O
in	O
patients	O
identified	O
as	O
CYP2C19	O
poor	O
metabolizers.	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•CYP2C19	O
inhibitors:	O
Avoid	O
concomitant	O
use	O
of	O
omeprazole	O
or	O
esomeprazole.	O
(5.1)	O
•Bleeding:	O
Clopidogrel	B-D000077144
bisulfate	O
increases	O
risk	O
of	O
bleeding.	O
(5.2)	O
•Discontinuation:	O
Prema	B-C070504
ture	O
discontinuation	O
increases	O
risk	O
of	O
cardiovascular	O
events.	O
Discontinue	O
5	O
days	O
prior	O
to	O
elective	O
surgery	O
that	O
has	O
a	O
major	O
risk	O
of	O
bleeding.	O
(5.3)	O
•Thrombotic	O
thrombocytopenic	O
purpura	O
(TTP)	O
has	O
been	O
reported.	O
(5.4)	O
•Cross-reactivity	O
among	O
thienopyridine	B-C446540
s	O
has	O
been	O
reported.	O
(5.5)	O
5.1	O
Diminished	O
Antiplatelet	O
Activity	O
in	O
Patients	B-D010361
with	O
Impaired	O
CYP2C19	O
Function	O
Clopidogrel	B-D000077144
is	O
a	O
prodrug.	O
Inhibition	O
of	O
platelet	O
aggregation	O
by	O
clopidogrel	O
is	O
achieved	O
through	O
an	O
active	O
metabolite.	O
The	O
metabolism	O
of	O
clopidogrel	O
to	O
its	O
active	O
metabolite	O
can	O
be	O
impaired	O
by	O
genetic	O
variations	O
in	O
CYP2C19	O
[see	O
Boxed	O
Warning].	O
The	O
metabolism	O
of	O
clopidogrel	O
can	O
also	O
be	O
impaired	O
by	O
drugs	O
that	O
inhibit	O
CYP2C19,	O
such	O
as	O
omeprazole	O
or	O
esomeprazole.	O
Avoid	O
concomitant	O
use	O
of	O
clopidogrel	O
with	O
omeprazole	O
or	O
esomeprazole	O
because	O
both	O
significantly	O
reduce	O
the	O
antiplatelet	O
activity	O
of	O
clopidogrel	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)].	O
5.2	O
General	O
Risk	B-D012306
of	O
Bleeding	O
Thienopyridines	B-D058924
,	O
including	O
clopidogrel	O
bisulfate,	O
increase	O
the	O
risk	O
of	O
bleeding.	O
Thienopyridines	B-D058924
inhibit	O
platelet	O
aggregation	O
for	O
the	O
lifetime	O
of	O
the	O
platelet	O
(7	O
to	O
10	O
days).	O
Because	O
the	O
half-life	O
of	O
clopidogrel’s	O
active	O
metabolite	O
is	O
short,	O
it	O
may	O
be	O
possible	O
to	O
restore	O
hemostasis	O
by	O
administering	O
exogenous	O
platelets;	O
however,	O
platelet	O
transfusions	O
within	O
4	O
hours	O
of	O
the	O
loading	O
dose	O
or	O
2	O
hours	O
of	O
the	O
maintenance	O
dose	O
may	O
be	O
less	O
effective.	O
5.3	O
Discontinuation	O
of	O
Clopidogrel	B-D000077144
Bisulfate	O
Discontinuation	O
of	O
clopidogrel	O
bisulfate	O
increases	O
the	O
risk	O
of	O
cardiovascular	O
events.	O
If	O
clopidogrel	O
must	O
be	O
temporarily	O
discontinued	O
(e.g.,	O
to	O
treat	O
bleeding	O
or	O
for	O
surgery	O
with	O
a	O
major	O
risk	O
of	O
bleeding),	O
restart	O
it	O
as	O
soon	O
as	O
possible.	O
When	O
possible,	O
interrupt	O
therapy	O
with	O
clopidogrel	O
for	O
five	O
days	O
prior	O
to	O
such	O
surgery.	O
Resume	O
clopidogrel	O
as	O
soon	O
as	O
hemostasis	O
is	O
achieved.	O
5.4	O
Thrombotic	O
Thrombocytopenic	O
Purpura	B-D011693
(TTP)	O
TTP,	O
sometimes	O
fatal,	O
has	O
been	O
reported	O
following	O
use	O
of	O
clopidogrel	O
bisulfate,	O
sometimes	O
after	O
a	O
short	O
exposure	O
(<2	O
weeks).	O
TTP	O
is	O
a	O
serious	O
condition	O
that	O
requires	O
urgent	O
treatment	O
including	O
plasmapheresis	O
(plasma	O
exchange).	O
It	O
is	O
characterized	O
by	O
thrombocytopenia,	O
microangiopathic	O
hemolytic	O
anemia	O
(schistocytes	O
[fragmented	O
RBCs]	O
seen	O
on	O
peripheral	O
smear),	O
neurological	O
findings,	O
renal	O
dysfunction,	O
and	O
fever	O
[see	O
Adverse	O
Reactions	O
(6.2)].	O
5.5	O
Cross-Reactivity	O
among	O
Thienopyridines	B-D058924
Hypersensitivity	B-D006967
including	O
rash,	O
angioedema	O
or	O
hematologic	O
reaction	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
clopidogrel,	O
including	O
patients	O
with	O
a	O
history	O
of	O
hypersensitivity	O
or	O
hematologic	O
reaction	O
to	O
other	O
thienopyridine	B-C446540
s	O
[see	O
Contraindications	B-D000075202
(4.2)	O
and	O
Adverse	O
Reactions	O
(6.2)].	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
below	O
and	O
elsewhere	O
in	O
the	O
labeling:	O
•Bleeding	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
•Thrombotic	O
thrombocytopenic	O
purpura	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Bleeding,	O
including	O
life-threatening	O
and	O
fatal	O
bleeding,	O
is	O
the	O
most	O
commonly	O
reported	O
adverse	O
reaction.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Cambridge	O
Therapeutic	O
Technologies,	O
LLC	O
at	O
1-844-810-0004	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
and	O
durations	O
of	O
follow	O
up,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Clopidogrel	B-D000077144
bisulfate	O
has	O
been	O
evaluated	O
for	O
safety	O
in	O
more	O
than	O
54,000	O
patients,	O
including	O
over	O
21,000	O
patients	O
treated	O
for	O
one	O
year	O
or	O
more.	O
The	O
clinically	O
important	O
adverse	O
reactions	O
observed	O
in	O
trials	O
comparing	O
clopidogrel	O
plus	O
aspirin	O
to	O
placebo	O
plus	O
aspirin	O
and	O
trials	O
comparing	O
clopidogrel	O
bisulfate	O
alone	O
to	O
aspirin	O
alone	O
are	O
discussed	O
below.	O
Bleeding	O
CURE	O
In	O
CURE,	O
clopidogrel	O
bisulfate	O
use	O
with	O
aspirin	O
was	O
associated	O
with	O
an	O
increase	O
in	O
major	O
bleeding	O
(primarily	O
gastrointestinal	O
and	O
at	O
puncture	O
sites)	O
compared	O
to	O
placebo	O
with	O
aspirin	O
(see	O
Table	O
1).	O
The	O
incidence	O
of	O
intracranial	O
hemorrhage	O
(0.1%)	O
and	O
fatal	O
bleeding	O
(0.2%)	O
were	O
the	O
same	O
in	O
both	O
groups.	O
Other	O
bleeding	O
events	O
that	O
were	O
reported	O
more	O
frequently	O
in	O
the	O
clopidogrel	O
group	O
were	O
epistaxis,	O
hematuria,	O
and	O
bruise.	O
The	O
overall	O
incidence	O
of	O
bleeding	O
is	O
described	O
in	O
Table	O
1.	O
Table	O
1:	O
CURE	O
Incidence	B-D015994
of	O
Bleeding	O
Complications	O
(%	O
patients)	O
Event	O
Clopidogrel	B-D000077144
Bisulfate	O
(+aspirin)	O
(n=6259)	O
Placebo	O
(+	O
aspirin)	O
(n=6303)	O
Major	O
bleeding	O
†	O
3.7	O
2.7	O
Life	B-D019369
-threatening	O
bleeding	O
2.2	O
1.8	O
Fatal	O
0.2	O
0.2	O
5	O
g/dL	O
hemoglobin	O
drop	O
0.9	O
0.9	O
Requiring	O
surgical	O
intervention	O
0.7	O
0.7	O
Hemorrhagic	O
strokes	O
0.1	O
0.1	O
Requiring	O
inotropes	O
0.5	O
0.5	O
Requiring	O
transfusion	O
(>4	O
units)	O
1.2	O
1.0	O
Other	O
major	O
bleeding	O
1.6	O
1.0	O
Significantly	O
disabling	O
0.4	O
0.3	O
Intraocular	O
bleeding	O
with	O
significant	O
loss	O
of	O
vision	O
0.05	O
0.03	O
Requiring	O
2	O
to	O
3	O
units	O
of	O
blood	O
1.3	O
0.9	O
Minor	O
bleeding	O
¶	O
5.1	O
2.4	O
†	O
Life	B-D019369
-threatening	O
and	O
other	O
major	O
bleeding.	O
¶	O
Led	O
to	O
interruption	O
of	O
study	O
medication.	O
COMMIT	O
In	O
COMMIT,	O
similar	O
rates	O
of	O
major	O
bleeding	O
were	O
observed	O
in	O
the	O
clopidogrel	O
bisulfate	O
and	O
placebo	O
groups,	O
both	O
of	O
which	O
also	O
received	O
aspirin	O
(see	O
Table	O
2).	O
Table	O
2:	O
Incidence	B-D015994
of	O
Bleeding	O
Events	O
in	O
COMMIT	O
(%	O
patients)	O
Type	O
of	O
bleeding	O
Clopidogrel	B-D000077144
bisulfate	O
(+	O
aspirin)	O
(n=22961)	O
Placebo	O
(+	O
aspirin)	O
(n=22891)	O
p-value	O
Major*	O
noncerebral	O
or	O
cerebral	O
bleeding	O
0.6	O
0.5	O
0.59	O
Major	O
noncerebral	O
0.4	O
0.3	O
0.48	O
Fatal	O
0.2	O
0.2	O
0.90	O
Hemorrhagic	O
stroke	O
0.2	O
0.2	O
0.91	O
Fatal	O
0.2	O
0.2	O
0.81	O
Other	O
noncerebral	O
bleeding	O
(non-major)	O
3.6	O
3.1	O
0.005	O
Any	O
noncerebral	O
bleeding	O
3.9	O
3.4	O
0.004	O
*	O
Major	O
bleeds	O
were	O
cerebral	O
bleeds	O
or	O
non-cerebral	O
bleeds	O
thought	O
to	O
have	O
caused	O
death	O
or	O
that	O
required	O
transfusion.	O
CAPRIE	O
(Clopidogrel	O
bisulfate	O
vs.	O
Aspirin	B-D001241
)	O
In	O
CAPRIE,	O
gastrointestinal	O
hemorrhage	O
occurred	O
at	O
a	O
rate	O
of	O
2.0%	O
in	O
those	O
taking	O
clopidogrel	O
bisulfate	O
vs.	O
2.7%	O
in	O
those	O
taking	O
aspirin;	O
bleeding	O
requiring	O
hospitalization	O
occurred	O
in	O
0.7%	O
and	O
1.1%,	O
respectively.	O
The	O
incidence	O
of	O
intracranial	O
hemorrhage	O
was	O
0.4%	O
for	O
clopidogrel	O
bisulfate	O
compared	O
to	O
0.5%	O
for	O
aspirin.	O
Other	O
bleeding	O
events	O
that	O
were	O
reported	O
more	O
frequently	O
in	O
the	O
clopidogrel	O
bisulfate	O
group	O
were	O
epistaxis	O
and	O
hematoma.	O
Other	O
Adverse	O
Events	O
In	O
CURE	O
and	O
CHARISMA,	O
which	O
compared	O
clopidogrel	O
bisulfate	O
plus	O
aspirin	O
to	O
aspirin	O
alone,	O
there	O
was	O
no	O
difference	O
in	O
the	O
rate	O
of	O
adverse	O
events	O
(other	O
than	O
bleeding)	O
between	O
clopidogrel	O
bisulfate	O
and	O
placebo.	O
In	O
CAPRIE,	O
which	O
compared	O
clopidogrel	O
bisulfate	O
to	O
aspirin,	O
pruritus	O
was	O
more	O
frequently	O
reported	O
in	O
those	O
taking	O
clopidogrel	O
bisulfate.	O
No	O
other	O
difference	O
in	O
the	O
rate	O
of	O
adverse	O
events	O
(other	O
than	O
bleeding)	O
was	O
reported.	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
clopidogrel	O
bisulfate.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
an	O
unknown	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Hemorrhage	B-D006470
s,	O
including	O
those	O
with	O
fatal	O
outcome,	O
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
clopidogrel.	O
•	O
Blood	B-D001769
and	O
lymphatic	O
system	O
disorders:	O
Agranulocytosis	B-D000380
,	O
aplastic	O
anemia/pancytopenia,	O
thrombotic	O
thrombocytopenic	O
purpura	O
(TTP),	O
acquired	O
hemophilia	O
A	O
•	O
Gastrointestinal	O
disorders:	O
Colitis	B-D003092
(including	O
ulcerative	O
or	O
lymphocytic	O
colitis),	O
pancreatitis,	O
stomatitis,	O
gastric/duodenal	O
ulcer,	O
diarrhea	O
•	O
General	O
disorders	O
and	O
administration	O
site	O
condition:	O
Fever	B-D005334
•	O
Hepato-biliary	O
disorders:	O
Acute	O
liver	O
failure,	O
hepatitis	O
(non-infectious),	O
abnormal	O
liver	O
function	O
test	O
•	O
Immune	O
system	O
disorders:	O
Hypersensitivity	B-D006967
reactions,	O
anaphylactoid	O
reactions,	O
serum	O
sickness	O
•	O
Musculoskeletal,	O
connective	O
tissue	O
and	O
bone	O
disorders:	O
Myalgia	B-D063806
,	O
arthralgia,	O
arthritis	O
•	O
Nervous	O
system	O
disorders:	O
Taste	B-D013649
disorders,	O
headache	O
•	O
Psychiatric	O
disorders:	O
Confusion	B-D003221
,	O
hallucinations	O
•	O
Respiratory,	O
thoracic	O
and	O
mediastinal	O
disorders:	O
Bronchospasm,	O
interstitial	O
pneumonitis,	O
eosinophilic	O
pneumonia	O
•	O
Renal	O
and	O
urinary	O
disorders:	O
Increased	O
creatinine	O
levels	O
•	O
Skin	B-D012867
and	O
subcutaneous	O
tissue	O
disorders:	O
Maculopapular,	O
erythematous	O
or	O
exfoliative	O
rash,	O
urticaria,	O
bullous	O
dermatitis,	O
eczema,	O
toxic	O
epidermal	O
necrolysis,	O
Stevens-Johnson	O
syndrome,	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(AGEP),	O
angioedema,	O
drug-induced	O
hypersensitivity	O
syndrome,	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS),	O
erythema	O
multiforme,	O
lichen	O
planus,	O
generalized	O
pruritus	O
•	O
Vascular	O
disorders:	O
Vasculitis	B-D014657
,	O
hypotension	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
).	O
Diflunisal	B-D004061
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
).	O
1	O
1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug.	O
ADVERSE	O
REACTIONS	O
The	O
adverse	O
reactions	O
observed	O
in	O
controlled	O
clinical	O
trials	O
encompass	O
observations	O
in	O
2,427	O
patients.	O
Listed	O
below	O
are	O
the	O
adverse	O
reactions	O
reported	O
in	O
the	O
1,314	O
of	O
these	O
patients	O
who	O
received	O
treatment	O
in	O
studies	O
of	O
two	O
weeks	O
or	O
longer.	O
Five	O
hundred	O
thirteen	O
patients	O
were	O
treated	O
for	O
at	O
least	O
24	O
weeks,	O
255	O
patients	O
were	O
treated	O
for	O
at	O
least	O
48	O
weeks,	O
and	O
46	O
patients	O
were	O
treated	O
for	O
96	O
weeks.	O
In	O
general,	O
the	O
adverse	O
reactions	O
listed	O
below	O
were	O
2	O
to	O
14	O
times	O
less	O
frequent	O
in	O
the	O
1,113	O
patients	O
who	O
received	O
short‑term	O
treatment	O
for	O
mild	O
to	O
moderate	O
pain.	O
Incidence	B-D015994
Greater	O
Than	O
1%	O
GastrointestinalThe	O
most	O
frequent	O
types	O
of	O
adverse	O
reactions	O
occurring	O
with	O
diflunisal	O
are	O
gastrointestinal:	O
these	O
include	O
nausea*2,	O
vomiting,	O
dyspepsia*2,	O
gastrointestinal	O
pain*2,	O
diarrhea*2,	O
constipation,	O
and	O
flatulence.	O
PsychiatricSomnolence,	O
insomnia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Dizziness	B-D004244
.	O
Special	O
SensesTinnitus.	O
DermatologicRash*2.	O
MiscellaneousHeadache*2,	O
fatigue/tiredness.2	O
*	O
Incidence	B-D015994
between	O
3%	O
and	O
9%.	O
Those	O
reactions	O
occurring	O
in	O
1%	O
to	O
3%	O
are	O
not	O
marked	O
with	O
an	O
asterisk.	O
Incidence	B-D015994
Less	O
Than	O
1	O
in	O
100The	O
following	O
adverse	O
reactions,	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100,	O
were	O
reported	O
in	O
clinical	O
trials	O
or	O
since	O
the	O
drug	O
was	O
marketed.	O
The	O
probability	O
exists	O
of	O
a	O
causal	O
relationship	O
between	O
diflunisal	O
and	O
these	O
adverse	O
reactions.	O
DermatologicErythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis,	O
urticaria,	O
pruritus,	O
sweating,	O
dry	O
mucous	O
membranes,	O
stomatitis,	O
photosensitivity.	O
GastrointestinalPeptic	O
ulcer,	O
gastrointestinal	O
bleeding,	O
anorexia,	O
eructation,	O
gastrointestinal	O
perforation,	O
gastritis.	O
Liver	B-D008099
function	O
abnormalities;	O
jaundice,	O
sometimes	O
with	O
fever;	O
cholestasis;	O
hepatitis.	O
HematologicThrombocytopenia;	O
agranulocytosis;	O
hemolytic	O
anemia.	O
GenitourinaryDysuria;	O
renal	O
impairment,	O
including	O
renal	O
failure;	O
interstitial	O
nephritis;	O
hematuria;	O
proteinuria.	O
PsychiatricNervousness,	O
depression,	O
hallucinations,	O
confusion,	O
disorientation.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Vertigo	B-D014717
;	O
light‑headedness;	O
paresthesias.	O
Special	O
SensesTransient	O
visual	O
disturbances	O
including	O
blurred	O
vision.	O
Hypersensitivity	B-D006967
ReactionsAcute	O
anaphylactic	O
reaction	O
with	O
bronchospasm;	O
angioedema;	O
flushing.	O
Hypersensitivity	B-D006967
vasculitis.	O
Hypersensitivity	B-D006967
syndrome	O
(see	O
PRECAUTIONS).	O
MiscellaneousAsthenia,	O
edema.	O
Causal	O
Relationship	O
UnknownOther	O
reactions	O
have	O
been	O
reported	O
in	O
clinical	O
trials	O
or	O
since	O
the	O
drug	O
was	O
marketed,	O
but	O
occurred	O
under	O
circumstances	O
where	O
a	O
causal	O
relationship	O
could	O
not	O
be	O
established.	O
However,	O
in	O
these	O
rarely	O
reported	O
events,	O
that	O
possibility	O
cannot	O
be	O
excluded.	O
Therefore,	O
these	O
observations	O
are	O
listed	O
to	O
serve	O
as	O
alerting	O
information	O
to	O
physicians.	O
RespiratoryDyspnea.	O
CardiovascularPalpitation,	O
syncope.	O
MusculoskeletalMuscle	O
cramps.	O
GenitourinaryNephrotic	O
syndrome.	O
Special	O
SensesHearing	O
loss.	O
MiscellaneousChest	O
pain.	O
A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
fasciitis,	O
particularly	O
in	O
association	O
with	O
Group	O
A	O
β-hemolytic	O
streptococcus,	O
has	O
been	O
described	O
in	O
persons	O
treated	O
with	O
non-steroidal	O
anti-inflammatory	O
agents,	O
including	O
diflunisal,	O
sometimes	O
with	O
fatal	O
outcome	O
(see	O
also	O
PRECAUTIONS,	O
General).	O
Potential	O
Adverse	O
EffectsIn	O
addition,	O
a	O
variety	O
of	O
adverse	O
effects	O
not	O
observed	O
with	O
diflunisal	O
in	O
clinical	O
trials	O
or	O
in	O
marketing	O
experience,	O
but	O
reported	O
with	O
other	O
non-steroidal	O
analgesic/anti-inflammatory	O
agents	O
should	O
be	O
considered	O
potential	O
adverse	O
effects	O
of	O
diflunisal.	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
.	O
Voltaren®	O
Gel	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)]	O
.	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Warnings	O
and	O
Precautions(5.2)].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Elevations	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
diclofenac	O
sodium.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy.	O
Borderline	O
elevations	O
(i.e.	O
less	O
than	O
3	O
times	O
the	O
ULN	O
[ULN	O
=	O
the	O
upper	O
limit	O
of	O
normal	O
range])	O
or	O
greater	O
elevations	O
of	O
transaminases	O
occurred	O
in	O
about	O
15%	O
of	O
diclofenac-treated	O
patients.	O
Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	O
injury.	O
In	O
clinical	O
trials,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(GOT)	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment.	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
for	O
2-6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/orAST	O
occurred	O
in	O
about	O
4%	O
of	O
patients	O
and	O
included	O
marked	O
elevations	O
(i.e.,	O
more	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3-8	O
times	O
the	O
ULN),	O
and	O
marked	O
(>8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
should	O
be	O
discontinued	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
physicians	O
should	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
“flu-like”	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
patients	O
should	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Caution	O
should	O
be	O
exercised	O
in	O
prescribing	O
diclofenac	O
sodium	O
with	O
concomitant	O
drugs	O
that	O
are	O
know	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
antibiotics,	O
anti-epileptics).	O
(5.3)	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
should	O
be	O
discontinued	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
physicians	O
should	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
“flu-like”	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
patients	O
should	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Caution	O
should	O
be	O
exercised	O
in	O
prescribing	O
diclofenac	O
sodium	O
with	O
concomitant	O
drugs	O
that	O
are	O
know	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
antibiotics,	O
anti-epileptics).	O
(5.3)	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose	O
dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
(5.6)	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
Voltaren®	O
Gel.	O
Voltaren®	O
Gel	O
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
(5.7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
NSAIDs,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAIDs	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
NSAIDs	O
such	O
as	O
diclofenac,	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAIDs	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
possible	O
duration.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
diclofenac	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
5.3	O
Hepatic	O
Effects	O
Elevations	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
diclofenac	O
sodium.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy.	O
Borderline	O
elevations	O
(i.e.	O
less	O
than	O
3	O
times	O
the	O
ULN	O
[ULN	O
=	O
the	O
upper	O
limit	O
of	O
normal	O
range])	O
or	O
greater	O
elevations	O
of	O
transaminases	O
occurred	O
in	O
about	O
15%	O
of	O
diclofenac-treated	O
patients.	O
Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	O
injury.	O
In	O
clinical	O
trials,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(GOT)	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment.	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
for	O
2-6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/orAST	O
occurred	O
in	O
about	O
4%	O
of	O
patients	O
and	O
included	O
marked	O
elevations	O
(i.e.,	O
more	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3-8	O
times	O
the	O
ULN),	O
and	O
marked	O
(>8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
should	O
be	O
discontinued	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
physicians	O
should	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
“flu-like”	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
patients	O
should	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Caution	O
should	O
be	O
exercised	O
in	O
prescribing	O
diclofenac	O
sodium	O
with	O
concomitant	O
drugs	O
that	O
are	O
know	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Voltaren®	O
Gel,	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
cardiovascular	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
Voltaren®	O
Gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
Voltaren®	O
Gel	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs,	O
including	O
Voltaren®	O
Gel.	O
Voltaren®	O
Gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Voltaren®	O
Gel	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
Voltaren®	O
Gel	O
is	O
not	O
recommended	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
Voltaren®	O
Gel	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
Voltaren®	O
Gel.	O
Voltaren®	O
Gel	O
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Voltaren®	O
Gel,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations,	O
and	O
the	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity.	O
Voltaren®	O
Gel	O
should	O
not	O
be	O
applied	O
to	O
open	O
skin	O
wounds,	O
infections,	O
inflammations,	O
or	O
exfoliative	O
dermatitis,	O
as	O
it	O
may	O
affect	O
absorption	O
and	O
tolerability	O
of	O
the	O
drug.	O
Voltaren®	O
Gel	O
should	O
not	O
be	O
allowed	O
to	O
come	O
into	O
contact	O
with	O
the	O
eyes	O
or	O
with	O
mucous	O
membranes.	O
The	O
effect	O
of	O
Voltaren®	O
Gel	O
under	O
occlusive	O
dressings	O
has	O
not	O
been	O
evaluated,	O
and	O
should	O
be	O
avoided.	O
5.9	O
Pregnancy	B-D011247
As	O
with	O
other	O
NSAIDs,	O
Voltaren®	O
Gel	O
should	O
be	O
avoided	O
in	O
late	O
pregnancy,	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
5.10	O
Corticosteroid	O
treatment	O
Voltaren®	O
Gel	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.12	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoeisis.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
including	O
Voltaren®	O
Gel,	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration,	O
and	O
reversible.	O
Patients	B-D010361
treated	O
with	O
Voltaren®	O
Gel	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alteration	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants	O
should	O
be	O
carefully	O
monitored.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin	O
sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
Voltaren®	O
Gel	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
areas	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light	O
induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
Voltaren®	O
Gel	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
Voltaren®	O
Gel	O
with	O
eyes	O
and	O
mucosa,	O
although	O
not	O
studied,	O
should	O
be	O
avoided.	O
Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
eye	O
contact	O
occurs,	O
they	O
should	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
Voltaren®	O
Gel	O
should	O
be	O
discontinued.	O
6	O
ADVERSE	O
REACTIONS	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
During	O
clinical	O
development,	O
913	O
patients	O
were	O
exposed	O
to	O
Voltaren®	O
Gel	O
in	O
randomized,	O
double-blind,	O
multicenter,	O
vehicle-controlled,	O
parallel-group	O
studies	O
in	O
osteoarthritis	O
of	O
the	O
superficial	O
joints	O
of	O
the	O
extremities.	O
Of	O
these,	O
513	O
patients	O
received	O
Voltaren®	O
Gel	O
for	O
osteoarthritis	O
of	O
the	O
knee	O
and	O
400	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
the	O
hand.	O
Additionally,	O
583	O
patients	O
were	O
exposed	O
to	O
Voltaren®	O
Gel	O
in	O
an	O
uncontrolled,	O
open-label,	O
long-term	O
safety	O
trial	O
in	O
osteoarthritis	O
of	O
the	O
knee.	O
Of	O
these,	O
355	O
patients	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
1	O
knee	O
and	O
228	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
both	O
knees.	O
Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
safety	O
trial.	O
Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
patients	O
treated	O
with	O
Voltaren®	O
Gel:	O
Non-serious	O
adverse	O
reactions	O
that	O
were	O
reported	O
during	O
the	O
short-term	O
placebo-controlled	O
studies	O
comparing	O
Voltaren®	O
Gel	O
and	O
placebo	O
(vehicle	O
gel)	O
over	O
study	O
periods	O
of	O
8	O
to	O
12	O
weeks	O
(16	O
g	O
per	O
day),	O
were	O
application	O
site	O
reactions.	O
These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
1%	O
of	O
treated	O
patients	O
with	O
a	O
greater	O
frequency	O
in	O
the	O
Voltaren®	O
Gel	O
group	O
(7%)	O
than	O
the	O
placebo	O
group	O
(2%).	O
Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported.	O
Application	O
site	O
dermatitis	O
was	O
the	O
most	O
frequent	O
type	O
of	O
application	O
site	O
reaction	O
and	O
was	O
reported	O
by	O
4%	O
of	O
patients	O
treated	O
with	O
Voltaren®	O
Gel,	O
compared	O
to	O
1%	O
of	O
placebo	O
patients.	O
Table	O
1:	O
Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥	O
1%	O
Voltaren®	O
Gel	O
Patients	B-D010361
)	O
–	O
Short-term	O
Controlled	O
Trials	O
Adverse	O
Reaction	O
†	O
Voltaren	O
®	O
Gel	O
N	O
=	O
913	O
Placebo	O
(vehicle)	O
N	O
=	O
876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
dermatitis	O
32	O
(4)	O
6	O
(<1)	O
Application	O
site	O
pruritus	O
7	O
(<1)	O
1	O
(<1)	O
Application	O
site	O
erythema	O
6	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
paresthesia	O
5	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
dryness	O
4	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
vesicles	O
3	O
(<1)	O
0	O
Application	O
site	O
irritation	O
2	O
(<1)	O
0	O
Application	O
site	O
papules	O
1	O
(<1)	O
0	O
†	O
Preferred	O
Term	O
according	O
to	O
MedDRA	O
9.1.	O
In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
patients	O
treated	O
with	O
Voltaren®	O
Gel,	O
and	O
3%	O
for	O
patients	O
in	O
the	O
placebo	O
group.	O
Application	O
site	O
reactions,	O
including	O
application	O
site	O
dermatitis,	O
were	O
the	O
most	O
frequent	O
reason	O
for	O
treatment	O
discontinuation.	O
Long-term	O
Open-label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
safety	O
study,	O
distribution	O
of	O
adverse	O
reactions	O
was	O
similar	O
to	O
that	O
in	O
the	O
placebo-controlled	O
studies.	O
In	O
this	O
study,	O
where	O
patients	O
were	O
treated	O
for	O
up	O
to	O
1	O
year	O
with	O
Voltaren®	O
Gel	O
up	O
to	O
32	O
g	O
per	O
day,	O
application	O
site	O
dermatitis	O
was	O
observed	O
in	O
11%	O
of	O
patients.	O
Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
patients.	O
The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
dermatitis,	O
which	O
was	O
experienced	O
by	O
6%	O
of	O
patients.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
TREXIMET	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
TREXIMET	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
.	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Cardiovascular	O
Thrombotic	O
Events:	O
Perform	O
cardiac	O
evaluation	O
in	O
patients	O
with	O
cardiovascular	O
risk	O
factors.	O
(5.1)	O
Arrhythmias:	O
Discontinue	O
TREXIMET	O
if	O
occurs.	O
(5.3)	O
Chest,	O
Throat,	O
Neck	B-D009333
,	O
and/or	O
Jaw	B-D007568
Pain	B-D010146
/Tightness/Pressure:	O
Generally	O
not	O
associated	O
with	O
myocardial	O
ischemia;	O
evaluate	O
for	O
coronary	O
artery	O
disease	O
in	O
patients	O
at	O
high	O
risk.	O
(5.4)	O
Cerebrovascular	O
Events:	O
Discontinue	O
TREXIMET	O
if	O
occurs.	O
(5.5)	O
Other	O
Vasospasm	O
Reactions:	O
Discontinue	O
TREXIMET	O
if	O
non-coronary	O
vasospastic	O
reaction	O
occurs.	O
(5.6)	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop.	O
(5.7)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure.	O
(5.8)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
TREXIMET	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure.	O
(5.9)	O
Medication	O
Overuse	O
Headache	B-D006261
:	O
Detoxification	O
may	O
be	O
necessary.	O
(5.10)	O
Serotonin	B-D020230
Syndrome	I-D020230
:	O
Discontinue	O
TREXIMET	O
if	O
occurs.	O
(5.11)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
TREXIMET	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
(5.12)	O
Anaphylactic	O
Reactions:	O
TREXIMET	O
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
Seep	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.(5.13)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
TREXIMET	O
at	O
first	O
sign	O
of	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity.	O
(5.14)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia.	O
(5.16)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
TREXIMET	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity).	O
(5.17)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
The	O
use	O
of	O
TREXIMET	O
is	O
contraindicated	O
in	O
patients	O
with	O
ischemic	O
or	O
vasospastic	O
coronary	O
artery	O
disease	O
(CAD)	O
and	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
due	O
to	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
events	O
with	O
sumatriptan	O
and	O
NSAIDS	O
[see	O
Contraindications	B-D000075202
(4)].	O
Cardiovascular	O
Events	O
with	O
Sumatriptan	B-D018170
There	O
have	O
been	O
rare	O
reports	O
of	O
serious	O
cardiac	O
adverse	O
reactions,	O
including	O
acute	O
myocardial	O
infarction,	O
occurring	O
within	O
a	O
few	O
hours	O
following	O
administration	O
of	O
sumatriptan.	O
Some	O
of	O
these	O
reactions	O
occurred	O
in	O
patients	O
without	O
known	O
CAD.	O
TREXIMET	O
may	O
cause	O
coronary	O
artery	O
vasospasm	O
(Prinzmetal's	O
angina),	O
even	O
in	O
patients	O
without	O
a	O
history	O
of	O
CAD.	O
Cardiovascular	O
Thrombotic	O
Events	O
with	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
naproxen,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Perform	O
a	O
cardiovascular	O
evaluation	O
in	O
patients	O
who	O
have	O
multiple	O
cardiovascular	O
risk	O
factors	O
(e.g.,	O
increased	O
age,	O
diabetes,	O
hypertension,	O
smoking,	O
obesity,	O
strong	O
family	O
history	O
of	O
CAD)	O
prior	O
to	O
receiving	O
TREXIMET.	O
If	O
there	O
is	O
evidence	O
of	O
CAD	O
or	O
coronary	O
artery	O
vasospasm,	O
TREXIMET	O
is	O
contraindicated.	O
For	O
patients	O
with	O
multiple	O
cardiovascular	O
risk	O
factors	O
who	O
have	O
a	O
negative	O
cardiovascular	O
evaluation,	O
consider	O
administering	O
the	O
first	O
dose	O
of	O
TREXIMET	O
in	O
a	O
medically	O
supervised	O
setting	O
and	O
performing	O
an	O
electrocardiogram	O
(ECG)	O
immediately	O
following	O
administration	O
of	O
TREXIMET.	O
For	O
such	O
patients,	O
consider	O
periodic	O
cardiovascular	O
evaluation	O
in	O
intermittent	O
long-term	O
users	O
of	O
TREXIMET.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
cardiovascular	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
cardiovascular	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
cardiovascular	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
naproxen,	O
a	O
component	O
of	O
TREXIMET,	O
cause	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
1	O
in	O
5	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
gastrointestinal	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
gastrointestinal	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
appear	O
to	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
daily	O
for	O
3	O
to	O
6	O
months	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
1	O
year.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Among	O
3,302	O
adult	O
patients	O
with	O
migraine	O
who	O
received	O
TREXIMET	O
in	O
controlled	O
and	O
uncontrolled	O
clinical	O
trials,	O
1	O
patient	O
experienced	O
a	O
recurrence	O
of	O
gastric	O
ulcer	O
after	O
taking	O
8	O
doses	O
over	O
3	O
weeks,	O
and	O
1	O
patient	O
developed	O
a	O
gastric	O
ulcer	O
after	O
treating	O
an	O
average	O
of	O
8	O
attacks	O
per	O
month	O
over	O
7	O
months.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
gastrointestinal	O
bleeding	O
compared	O
with	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
for	O
gastrointestinal	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
gastrointestinal	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients,	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
high	O
risk	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
TREXIMET	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.3	O
Arrhythmias	O
Life	B-D019369
-threatening	O
disturbances	O
of	O
cardiac	O
rhythm,	O
including	O
ventricular	O
tachycardia	O
and	O
ventricular	O
fibrillation	O
leading	O
to	O
death,	O
have	O
been	O
reported	O
within	O
a	O
few	O
hours	O
following	O
the	O
administration	O
of	O
5-HT1	O
agonists.	O
Discontinue	O
TREXIMET	O
if	O
these	O
disturbances	O
occur.	O
TREXIMET	O
is	O
contraindicated	O
in	O
patients	O
with	O
Wolff-Parkinson-White	O
syndrome	O
or	O
arrhythmias	O
associated	O
with	O
other	O
cardiac	O
accessory	O
conduction	O
pathway	O
disorders.	O
5.4	O
Chest,	O
Throat,	O
Neck	B-D009333
,	O
and/or	O
Jaw	B-D007568
Pain	B-D010146
/Tightness/Pressure	O
Sensation	B-D012677
s	O
of	O
tightness,	O
pain,	O
pressure,	O
and	O
heaviness	O
in	O
the	O
precordium,	O
throat,	O
neck,	O
and	O
jaw	O
commonly	O
occur	O
after	O
treatment	O
with	O
sumatriptan	O
and	O
are	O
usually	O
non-cardiac	O
in	O
origin.	O
However,	O
perform	O
a	O
cardiac	O
evaluation	O
if	O
these	O
patients	O
are	O
at	O
high	O
cardiac	O
risk.	O
The	O
use	O
of	O
TREXIMET	O
is	O
contraindicated	O
in	O
patients	O
with	O
CAD	O
and	O
those	O
with	O
Prinzmetal's	B-C536421
variant	I-C536421
angina	I-C536421
.	O
5.5	O
Cerebrovascular	O
Events	O
Cerebral	O
hemorrhage,	O
subarachnoid	O
hemorrhage,	O
and	O
stroke	O
have	O
occurred	O
in	O
patients	O
treated	O
with	O
5-HT1	O
agonists,	O
and	O
some	O
have	O
resulted	O
in	O
fatalities.	O
In	O
a	O
number	O
of	O
cases,	O
it	O
appears	O
possible	O
that	O
the	O
cerebrovascular	O
events	O
were	O
primary,	O
the	O
5-HT1	O
agonist	O
having	O
been	O
administered	O
in	O
the	O
incorrect	O
belief	O
that	O
the	O
symptoms	O
experienced	O
were	O
a	O
consequence	O
of	O
migraine	O
when	O
they	O
were	O
not.	O
Also,	O
patients	O
with	O
migraine	O
may	O
be	O
at	O
increased	O
risk	O
of	O
certain	O
cerebrovascular	O
events	O
(e.g.,	O
stroke,	O
hemorrhage,	O
TIA).	O
Discontinue	O
TREXIMET	O
if	O
a	O
cerebrovascular	O
event	O
occurs.	O
Before	O
treating	O
headaches	O
in	O
patients	O
not	O
previously	O
diagnosed	O
as	O
migraineurs,	O
and	O
in	O
migraineurs	O
who	O
present	O
with	O
atypical	O
symptoms,	O
exclude	O
other	O
potentially	O
serious	O
neurological	O
conditions.	O
TREXIMET	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
history	O
of	O
stroke	O
or	O
TIA	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.6	O
Other	O
Vasospasm	O
Reactions	O
Sumatriptan	B-D018170
may	O
cause	O
non-coronary	O
vasospastic	O
reactions,	O
such	O
as	O
peripheral	O
vascular	O
ischemia,	O
gastrointestinal	O
vascular	O
ischemia	O
and	O
infarction	O
(presenting	O
with	O
abdominal	O
pain	O
and	O
bloody	O
diarrhea),	O
splenic	O
infarction,	O
and	O
Raynaud's	O
syndrome.	O
In	O
patients	O
who	O
experience	O
symptoms	O
or	O
signs	O
suggestive	O
of	O
non-coronary	O
vasospasm	O
reaction	O
following	O
the	O
use	O
of	O
any	O
5-HT1	O
agonist,	O
rule	O
out	O
a	O
vasospastic	O
reaction	O
before	O
receiving	O
additional	O
TREXIMET.	O
Reports	O
of	O
transient	O
and	O
permanent	O
blindness	O
and	O
significant	O
partial	O
vision	O
loss	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
5-HT1	O
agonists.	O
Since	O
visual	O
disorders	O
may	O
be	O
part	O
of	O
a	O
migraine	O
attack,	O
a	O
causal	O
relationship	O
between	O
these	O
events	O
and	O
the	O
use	O
of	O
5-HT1	O
agonists	O
have	O
not	O
been	O
clearly	O
established.	O
5.7	O
Hepatotoxicity	O
Borderline	O
elevations	O
of	O
1	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
who	O
take	O
NSAIDs	O
including	O
naproxen,	O
a	O
component	O
of	O
TREXIMET.	O
Hepatic	O
abnormalities	O
may	O
be	O
the	O
result	O
of	O
hypersensitivity	O
rather	O
than	O
direct	O
toxicity.	O
These	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
essentially	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy.	O
Notable	O
(3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
elevations	O
of	O
SGPT	O
(ALT)	O
or	O
SGOT	O
(AST)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported	O
with	O
NSAIDs.	O
TREXIMET	O
is	O
contraindicated	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.7),	O
Clinical	O
Pharmacology	B-D010600
(12.3)].	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
evaluated	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
TREXIMET.	O
TREXIMET	O
should	O
be	O
discontinued	O
if	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
or	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flulike"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
TREXIMET	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.8	O
Hypertension	B-D006973
Significant	O
elevation	O
in	O
blood	O
pressure,	O
including	O
hypertensive	O
crisis	O
with	O
acute	O
impairment	O
of	O
organ	O
systems,	O
has	O
been	O
reported	O
on	O
rare	O
occasions	O
in	O
patients	O
treated	O
with	O
5-HT1	O
agonists,	O
including	O
sumatriptan,	O
a	O
component	O
of	O
TREXIMET.	O
This	O
occurrence	O
has	O
included	O
patients	O
without	O
a	O
history	O
of	O
hypertension.	O
NSAIDs,	O
including	O
naproxen,	O
a	O
component	O
of	O
TREXIMET,	O
can	O
also	O
lead	O
to	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
cardiovascular	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
angiotensin	O
receptor	O
blockers	O
(ARBs),	O
beta-blockers,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Monitor	O
blood	O
pressure	O
in	O
patients	O
treated	O
with	O
TREXIMET.	O
TREXIMET	O
is	O
contraindicated	O
in	O
patients	O
with	O
uncontrolled	O
hypertension	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.9	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
naproxen	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
TREXIMET	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
TREXIMET	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
Since	O
each	O
TREXIMET	O
85/500	O
mg	O
tablet	O
contains	O
approximately	O
60	O
mg	O
of	O
sodium	O
and	O
each	O
TREXIMET	O
10/60	O
mg	O
tablet	O
contains	O
approximately	O
20	O
mg	O
of	O
sodium,	O
this	O
should	O
be	O
considered	O
in	O
patients	O
whose	O
overall	O
intake	O
of	O
sodium	O
must	O
be	O
severely	O
restricted.	O
5.10	O
Medication	O
Overuse	O
Headache	B-D006261
Overuse	O
of	O
acute	O
migraine	O
drugs	O
(e.g.,	O
ergotamine,	O
triptans,	O
opioids,	O
or	O
a	O
combination	O
of	O
these	O
drugs	O
for	O
10	O
or	O
more	O
days	O
per	O
month)	O
may	O
lead	O
to	O
exacerbation	O
of	O
headache	O
(medication	O
overuse	O
headache).	O
Medication	O
overuse	O
headache	O
may	O
present	O
as	O
migraine-like	O
daily	O
headaches,	O
or	O
as	O
a	O
marked	O
increase	O
in	O
frequency	O
of	O
migraine	O
attacks.	O
Detoxification	O
of	O
patients,	O
including	O
withdrawal	O
of	O
the	O
overused	O
drugs,	O
and	O
treatment	O
of	O
withdrawal	O
symptoms	O
(which	O
often	O
includes	O
a	O
transient	O
worsening	O
of	O
headache)	O
may	O
be	O
necessary.	O
5.11	O
Serotonin	B-D020230
Syndrome	I-D020230
Serotonin	B-D012701
syndrome	O
may	O
occur	O
with	O
TREXIMET,	O
particularly	O
during	O
coadministration	O
with	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs),	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs),	O
tricyclic	O
antidepressants	O
(TCAs),	O
and	O
MAO	O
inhibitors	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Drug	B-D004347
Interactions	I-D004347
(7.1)].	O
Serotonin	B-D012701
syndrome	O
symptoms	O
may	O
include	O
mental	O
status	O
changes	O
(e.g.,	O
agitation,	O
hallucinations,	O
coma),	O
autonomic	O
instability	O
(e.g.,	O
tachycardia,	O
labile	O
blood	O
pressure,	O
hyperthermia),	O
neuromuscular	O
aberrations	O
(e.g.,	O
hyperreflexia,	O
incoordination),	O
and/or	O
gastrointestinal	O
symptoms	O
(e.g.,	O
nausea,	O
vomiting,	O
diarrhea).	O
The	O
onset	O
of	O
symptoms	O
usually	O
occurs	O
within	O
minutes	O
to	O
hours	O
of	O
receiving	O
a	O
new	O
or	O
a	O
greater	O
dose	O
of	O
a	O
serotonergic	O
medication.	O
Discontinue	O
TREXIMET	O
if	O
serotonin	O
syndrome	O
is	O
suspected.	O
5.12	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
salt	O
depletion,	O
those	O
taking	O
diuretics	O
and	O
angiotensin-converting	O
enzyme	O
(ACE)	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
TREXIMET	O
should	O
be	O
discontinued	O
if	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
renal	O
disease	O
develop	O
or	O
if	O
systemic	O
manifestations	O
occur.	O
TREXIMET	O
is	O
not	O
recommended	O
for	O
use	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
(creatinine	O
clearance	O
[CrCl]	O
<30	O
mL/min)	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.6),	O
Clinical	O
Pharmacology	B-D010600
(12.3)].	O
If	O
TREXIMET	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
mild	O
(CrCl	O
=	O
60	O
to	O
89	O
mL/min)	O
or	O
moderate	O
(CrCl	O
=	O
30	O
to	O
59	O
mL/min)	O
renal	O
impairment,	O
preexisting	O
kidney	O
disease,	O
or	O
dehydration.	O
The	O
renal	O
effects	O
of	O
TREXIMET	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
pre-existing	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
TREXIMET.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
TREXIMET	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
TREXIMET	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
TREXIMET	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.13	O
Anaphylactic	O
Reactions	O
Anaphylactic	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
either	O
component	O
of	O
TREXIMET.	O
Such	O
reactions	O
can	O
be	O
life-threatening	O
or	O
fatal.	O
In	O
general,	O
anaphylactic	O
reactions	O
to	O
drugs	O
are	O
more	O
likely	O
to	O
occur	O
in	O
individuals	O
with	O
a	O
history	O
of	O
sensitivity	O
to	O
multiple	O
allergens	O
although	O
anaphylactic	O
reactions	O
with	O
naproxen	O
have	O
occurred	O
in	O
patient	O
without	O
known	O
hypersensitivity	O
to	O
naproxen	O
or	O
to	O
patients	O
with	O
aspirin	O
sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.17)].	O
TREXIMET	O
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
patients	O
with	O
asthma	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
TREXIMET	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
history	O
of	O
hypersensitivity	O
reaction	O
to	O
sumatriptan,	O
naproxen,	O
or	O
any	O
other	O
component	O
of	O
TREXIMET.	O
Naproxen	B-D009288
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
without	O
known	O
hypersensitivity	O
to	O
naproxen	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.17)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.14	O
Serious	O
Skin	B-D012867
Reactions	O
NSAID-containing	O
products	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
TREXIMET	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
TREXIMET	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.15	O
Prema	B-C070504
ture	O
Closure	O
of	O
the	O
Ductus	B-D004373
Arteriosus	I-D004373
TREXIMET	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
TREXIMET,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Contraindications	B-D000075202
(4),	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.16	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
gastrointestinal	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
TREXIMET	O
has	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
TREXIMET,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs),	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.17	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
TREXIMET	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
TREXIMET	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.18	O
Seizures	B-D012640
Seizures	B-D012640
have	O
been	O
reported	O
following	O
administration	O
of	O
sumatriptan.	O
Some	O
have	O
occurred	O
in	O
patients	O
with	O
either	O
a	O
history	O
of	O
seizures	O
or	O
concurrent	O
conditions	O
predisposing	O
to	O
seizures.	O
There	O
are	O
also	O
reports	O
in	O
patients	O
where	O
no	O
such	O
predisposing	O
factors	O
are	O
apparent.	O
TREXIMET	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
a	O
history	O
of	O
epilepsy	O
or	O
conditions	O
associated	O
with	O
a	O
lowered	O
seizure	O
threshold.	O
5.19	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
TREXIMET	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.20	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.7,	O
5.12)].	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
below	O
and	O
elsewhere	O
in	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Arrhythmias	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Chest,	O
Throat,	O
Neck	B-D009333
,	O
and/or	O
Jaw	B-D007568
Pain	B-D010146
/Tightness/Pressure	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Cerebrovascular	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Other	O
Vasospasm	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.8)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Medication	O
Overuse	O
Headache	B-D006261
[see	O
Warnings	O
and	O
Precautions	O
(5.10)]	O
Serotonin	B-D020230
Syndrome	I-D020230
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.12)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.13)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.14)]	O
Hematological	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.16)]	O
Exacerbation	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.17)]	O
Seizures	B-D012640
[see	O
Warnings	O
and	O
Precautions	O
(5.18)]	O
The	O
most	O
common	O
adverse	O
reactions	O
(incidence	O
≥2%)	O
were:	O
Adult	B-D000328
s:	O
Dizziness	B-D004244
,	O
somnolence,	O
nausea,	O
chest	O
discomfort/chest	O
pain,	O
neck/throat/jaw	O
pain/tightness/pressure,	O
paresthesia,	O
dyspepsia,	O
dry	O
mouth.	O
(6.1)	O
Pediatrics	B-D010372
:	O
Hot	O
flush	O
(i.e.,	O
hot	O
flash[es])	O
and	O
muscle	O
tightness.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pernix	O
Therapeutics	B-D013812
at	O
1-800-793-2145	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Adult	B-D000328
s	O
The	O
adverse	O
reactions	O
reported	O
below	O
are	O
specific	O
to	O
the	O
clinical	O
trials	O
with	O
TREXIMET	O
85/500	O
mg.	O
See	O
also	O
the	O
full	O
prescribing	O
information	O
for	O
naproxen	O
and	O
sumatriptan	O
products.	O
Table	O
1	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
2	O
placebo-controlled	O
clinical	O
trials	O
(Study	O
1	O
and	O
2)	O
in	O
adult	O
patients	O
who	O
received	O
1	O
dose	O
of	O
study	O
drug.	O
Only	O
adverse	O
reactions	O
that	O
occurred	O
at	O
a	O
frequency	O
of	O
2%	O
or	O
more	O
in	O
any	O
group	O
treated	O
with	O
TREXIMET	O
85/500	O
mg	O
and	O
that	O
occurred	O
at	O
a	O
frequency	O
greater	O
than	O
the	O
placebo	O
group	O
are	O
included	O
in	O
Table	O
1.	O
Table	O
1.	O
Adverse	O
Reactions	O
in	O
Pooled	O
Placebo-Controlled	O
Trials	O
in	O
Adult	B-D000328
Patients	B-D010361
with	O
Migraine	O
Adverse	O
Reactions	O
TREXIMET	O
85/500	O
mg%(n	O
=	O
737)	O
Placebo%(n	O
=	O
752)	O
Sumatriptan	B-D018170
85	O
mg%(n	O
=	O
735)	O
Naproxen	B-D009288
Sodium	B-D012964
500	O
mg%(n	O
=	O
732)	O
Nervous	O
system	O
disorders	O
Dizziness	B-D004244
4	O
2	O
2	O
2	O
Somnolence	O
3	O
2	O
2	O
2	O
Paresthesia	B-D010292
2	O
<1	O
2	O
<1	O
Gastrointestinal	O
disorders	O
Nausea	B-D009325
3	O
1	O
3	O
<1	O
Dyspepsia	B-D004415
2	O
1	O
2	O
1	O
Dry	O
mouth	O
2	O
1	O
2	O
<1	O
Pain	B-D010146
and	O
other	O
pressure	O
sensations	O
Chest	O
discomfort/chest	O
pain	O
3	O
<1	O
2	O
1	O
Neck	B-D009333
/throat/jaw	O
pain/tightness/pressure	O
3	O
1	O
3	O
1	O
The	O
incidence	O
of	O
adverse	O
reactions	O
in	O
controlled	O
clinical	O
trials	O
was	O
not	O
affected	O
by	O
gender	O
or	O
age	O
of	O
the	O
patients.	O
There	O
were	O
insufficient	O
data	O
to	O
assess	O
the	O
impact	O
of	O
race	O
on	O
the	O
incidence	O
of	O
adverse	O
reactions.	O
Pediatric	O
Patients	B-D010361
12	O
to	O
17	O
Years	O
of	O
Age	O
In	O
a	O
placebo-controlled	O
clinical	O
trial	O
that	O
evaluated	O
pediatric	O
patients	O
12	O
to	O
17	O
years	O
of	O
age	O
who	O
received	O
1	O
dose	O
of	O
TREXIMET	O
10/60	O
mg,	O
30/180	O
mg,	O
or	O
85/500	O
mg,	O
adverse	O
reactions	O
occurred	O
in	O
13%	O
of	O
patients	O
who	O
received	O
10/60	O
mg,	O
9%	O
of	O
patients	O
who	O
received	O
30/180	O
mg,	O
13%	O
who	O
received	O
85/500	O
mg,	O
and	O
8%	O
who	O
received	O
placebo.	O
No	O
patients	O
who	O
received	O
TREXIMET	O
experienced	O
adverse	O
reactions	O
leading	O
to	O
withdrawal	O
from	O
the	O
trial.	O
The	O
incidence	O
of	O
adverse	O
reactions	O
in	O
pediatric	O
patients	O
12	O
to	O
17	O
years	O
of	O
age	O
was	O
comparable	O
across	O
all	O
3	O
doses	O
compared	O
with	O
placebo.	O
Table	O
2	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
a	O
placebo-controlled	O
trial	O
in	O
pediatric	O
patients	O
12	O
to	O
17	O
years	O
of	O
age	O
at	O
a	O
frequency	O
of	O
2%	O
or	O
more	O
with	O
TREXIMET	O
and	O
were	O
more	O
frequent	O
than	O
the	O
placebo	O
group.	O
Table	O
2.	O
Adverse	O
Reactions	O
in	O
a	O
Placebo-Controlled	O
Trial	O
in	O
Pediatric	O
Patients	B-D010361
12	O
to	O
17	O
Years	O
of	O
Age	O
with	O
Migraine	O
Adverse	O
Reactions	O
TREXIMET	O
10/60	O
mg%	O
TREXIMET	O
30/180	O
mg%	O
TREXIMET	O
85/500	O
mg%	O
Placebo%	O
(n	O
=	O
96)	O
(n	O
=	O
97)	O
(n	O
=	O
152)	O
(n	O
=	O
145)	O
Vascular	O
Hot	O
flush	O
(i.e.,	O
hot	O
flash[es])	O
0	O
2	O
<1	O
0	O
Musculoskeletal	O
Muscle	O
tightness	O
0	O
0	O
2	O
0	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS	O
).	O
Etodolac	B-D017308
capsules	O
USP,	O
200	O
mg	O
and	O
300	O
mg,	O
and	O
Etodolac	B-D017308
tablets	O
USP,	O
400	O
mg	O
and	O
500	O
mg	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(See	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
capsules	O
and	O
tablets,	O
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
capsules	O
and	O
tablets	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
RelatedBody	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain1,	O
diarrhea1,	O
flatulence1,	O
nausea1,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise1,	O
dizziness1,	O
depression,	O
nervousness,	O
fatigue.Skin	O
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.Musculoskeletal—Arthralgia.	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
1Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.Skin	O
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
leukocytoclastic	O
vasculitis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.Skin	O
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.Musculoskeletal—Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDsBody	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
deathCardiovascular	O
system	O
-	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesisHemic	O
and	O
lymphatic	O
system	O
-	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigoRespiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumoniaUrogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(	O
5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(	O
4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(	O
5.4)	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(	O
5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(	O
4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(	O
5.4)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(	O
5.1,	O
14.6,	O
17.2).	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
(	O
5.4,	O
8.5,	O
14.6,	O
17.3).	O
Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
celecoxib	O
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen	O
(	O
5.5,	O
17.4).	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
celecoxib	O
(	O
5.2,	O
7.4,	O
17.2).	O
Fluid	O
retention	O
and	O
edema.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure	O
(	O
5.3,	O
17.6).	O
Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
celecoxib	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists	O
(	O
5.6,	O
7.4,	O
8.7,	O
17.6).	O
Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
celecoxib	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(	O
5.7,	O
10,	O
17.7).	O
Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions	O
(	O
5.8,	O
17.5).	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
celecoxib,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
celecoxib	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
].	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
celecoxib	O
[	O
see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
the	O
CLASS	O
study	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
celecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
active	O
GI	O
bleeding.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[	O
see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
celecoxib	O
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
celecoxib	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
celecoxib.	O
In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
celecoxib.	O
Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
celecoxib	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(	O
6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General	O
:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional	O
:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia,	O
Psychiatric	O
:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders	O
:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary	O
:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular	O
:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal	O
:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic	O
:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous	O
:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS,	O
or	O
hypersensitivity	O
syndrome)	O
General	O
:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events	O
:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[	O
see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials	O
,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders	O
:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth	O
:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders	O
:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders	O
:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(See	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(	O
5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(	O
4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(	O
5.4)	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(	O
5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(	O
4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(	O
5.4)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(	O
5.1,	O
14.6,	O
17.2).	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
(	O
5.4,	O
8.5,	O
14.6,	O
17.3).	O
Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
celecoxib	O
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen	O
(	O
5.5,	O
17.4).	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
celecoxib	O
(	O
5.2,	O
7.4,	O
17.2).	O
Fluid	O
retention	O
and	O
edema.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure	O
(	O
5.3,	O
17.6).	O
Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
celecoxib	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists	O
(	O
5.6,	O
7.4,	O
8.7,	O
17.6).	O
Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
celecoxib	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(	O
5.7,	O
10,	O
17.7).	O
Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions	O
(	O
5.8,	O
17.5).	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
celecoxib,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
celecoxib	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
].	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
celecoxib	O
[	O
see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
the	O
CLASS	O
study	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
celecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
active	O
GI	O
bleeding.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[	O
see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
celecoxib	O
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
celecoxib	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
celecoxib.	O
In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
celecoxib.	O
Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
celecoxib	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(	O
6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Lupin	O
Pharmaceuticals,	O
Inc	O
.	O
at	O
1-800-399-2561	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General	O
:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional	O
:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia,	O
Psychiatric	O
:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders	O
:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary	O
:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular	O
:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal	O
:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic	O
:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous	O
:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS,	O
or	O
hypersensitivity	O
syndrome)	O
General	O
:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events	O
:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[	O
see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials	O
,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders	O
:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth	O
:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders	O
:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders	O
:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
ADVERSE	O
REACTIONS	O
Ocular	O
Transient	O
burning	O
and	O
stinging	O
were	O
reported	O
in	O
approximately	O
15%	O
of	O
patients	O
across	O
studies	O
with	O
the	O
use	O
of	O
Diclofenac	B-D004008
sodium	O
ophthalmic	O
solution,	O
0.1%.	O
In	O
cataract	O
surgery	O
studies,	O
keratitis	O
was	O
reported	O
in	O
up	O
to	O
28%	O
of	O
patients	O
using	O
Diclofenac	B-D004008
sodium	O
ophthalmic	O
solution,	O
0.1%,	O
although	O
in	O
many	O
of	O
these	O
cases	O
keratitis	O
was	O
initially	O
noted	O
prior	O
to	O
the	O
initiation	O
of	O
treatment.	O
Elevated	O
intraocular	O
pressure	O
following	O
cataract	O
surgery	O
was	O
reported	O
in	O
approximately	O
15%	O
of	O
patients	O
undergoing	O
cataract	O
surgery.	O
Lacrimation	O
complaints	O
were	O
reported	O
in	O
approximately	O
30%	O
of	O
case	O
studies	O
undergoing	O
incisional	O
refractive	O
surgery.	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
approximately	O
10%	O
or	O
less	O
of	O
the	O
patients:	O
abnormal	O
vision,	O
acute	O
elevated	O
IOP,	O
blurred	O
vision,	O
conjunctivitis,	O
corneal	O
deposits,	O
corneal	O
edema,	O
corneal	O
opacity,	O
corneal	O
lesions,	O
discharge,	O
eyelid	O
swelling,	O
eye	O
pain,	O
injection	O
(redness),	O
iritis,	O
irritation,	O
itching,	O
lacrimation	O
disorder,	O
and	O
ocular	O
allergy.	O
Systemic	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
3%	O
or	O
less	O
of	O
the	O
patients:	O
abdominal	O
pain,	O
asthenia,	O
chills,	O
dizziness,	O
facial	O
edema,	O
fever,	O
headache,	O
insomnia,	O
nausea,	O
pain,	O
rhinitis,	O
viral	O
infection	O
and	O
vomiting.	O
Clinical	O
Practice	O
The	O
following	O
reactions	O
have	O
been	O
identified	O
during	O
postmarketing	O
use	O
of	O
topical	O
diclofenac	O
sodium	O
ophthalmic	O
solution,	O
0.1%	O
in	O
clinical	O
practice.	O
Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size,	O
estimates	O
of	O
frequency	O
cannot	O
be	O
made.	O
The	O
reactions,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
diclofenac	O
sodium	O
ophthalmic	O
solution,	O
0.1%,	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
corneal	O
erosion,	O
corneal	O
infiltrates,	O
corneal	O
perforation,	O
corneal	O
thinning,	O
corneal	O
ulceration	O
and	O
epithelilal	O
breakdown	O
(see	O
PRECAUTIONS,	O
General).	O
TO	O
REPORT	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Altaire	O
Pharmaceuticals,	O
Inc.,	O
at	O
1-800-258-2471	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
Cardiovascular	O
Thrombotic	O
Events	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
].	O
Etodolac	B-D017308
extended-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
and	O
Warnings	O
and	O
Precautions	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions].	O
ADVERSE	O
REACTIONS	O
A	O
total	O
of	O
1552	O
patients	O
were	O
exposed	O
to	O
etodolac	O
extended-release	O
tablets	O
in	O
controlled	O
clinical	O
studies	O
of	O
at	O
least	O
4	O
weeks	O
in	O
length	O
and	O
using	O
daily	O
doses	O
in	O
the	O
range	O
of	O
400	O
to	O
1200	O
mg.	O
In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
incidence	O
of	O
events	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	O
extended-release	O
tablets.	O
As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
time	O
with	O
extended	O
therapy.	O
In	O
patients	O
taking	O
NSAIDs,	O
including	O
etodolac	O
extended-release	O
tablets,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including	O
abdominal	O
pain	O
constipation	O
Diarrhea	B-D003967
dyspepsia	O
flatulence	O
GI	O
ulcers	O
(gastric/duodenal)*	O
gross	O
bleeding/perforation*	O
nausea	O
Vomiting	B-D014839
Other	O
events	O
including:	O
abnormal	O
renal	O
functionAdverse	O
events	O
that	O
were	O
observed	O
in	O
<	O
1%	O
of	O
patients	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	O
extended-release	O
tablets	O
in	O
clinical	O
trials.	O
Anemia	B-D000740
asthenia	O
dizziness	O
edema	O
elevated	O
liver	O
enzymes	O
headaches	O
hypertension	O
increased	O
bleeding	O
time	O
infection	O
pharyngitis	O
pruritus	O
rashes	O
rhinitis	O
tinnitus	O
Additional	O
NSAID	O
Adverse	O
Experiences	O
Reported	O
Occasionally	O
with	O
NSAIDs	O
or	O
Etodolac	B-D017308
Extended-release	O
Tablets	B-D013607
Include	O
Body	O
as	O
a	O
whole	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock),	O
chills,	O
fever,	O
sepsis	O
Cardiovascular	O
system	O
Congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
tachycardia,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic)	O
Digestive	O
system	O
Anorexia	B-D000855
,	O
cholestatic	O
hepatitis,	O
cholestatic	O
jaundice,	O
dry	O
mouth,	O
duodenitis,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastric/peptic	O
ulcers,	O
glossitis,	O
hepatic	O
failure,	O
hepatitis,	O
hematemesis,	O
intestinal	O
ulceration,	O
jaundice,	O
liver	O
necrosis,	O
melena,	O
pancreatitis,	O
rectal	O
bleeding,	O
stomatitis	O
Hemic	O
and	O
lymphatic	O
system	O
Agranulocytosis	B-D000380
,	O
ecchymosis,	O
eosinophilia,	O
hemolytic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia,	O
purpura,	O
thrombocytopenia	O
Metabolic	O
and	O
nutritional	O
Hyperglycemia	B-D006943
in	O
previously	O
controlled	O
diabetic	O
patients	O
Nervous	O
system	O
Anxiety	B-D001007
,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
insomnia,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
Asthma	B-D001249
,	O
dyspnea,	O
pulmonary	O
infiltration	O
with	O
eosinophilia	O
Skin	B-D012867
and	O
appendages	O
Angioedema	B-D000799
,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
erythema	O
multiforme,	O
hyperpigmentation,	O
sweating,	O
urticaria,	O
vesiculobullous	O
rash	O
Special	O
senses	O
Blurred	O
vision,	O
photophobia,	O
transient	O
visual	O
disturbances	O
Urogenital	O
system	O
Dysuria	B-D053159
,	O
elevated	O
BUN,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis,	O
serum	O
creatinine	O
increase,	O
urinary	O
frequency	O
Other	O
NSAID	O
Adverse	O
Reactions,	O
Which	O
Occur	O
Rarely	O
Are	O
Body	O
as	O
a	O
whole	O
Anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	O
system	O
Arrhythmia,	O
cerebrovascular	O
accident,	O
hypotension,	O
myocardial	O
infarction	O
Digestive	O
system	O
Colitis	B-D003092
,	O
esophagitis	O
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
thirst,	O
ulcerative	O
stomatitis	O
Hemic	O
and	O
lymphatic	O
system	O
Aplastic	O
anemia,	O
lymphadenopathy	O
Metabolic	O
and	O
nutritional	O
Change	O
in	O
weight	O
Nervous	O
system	O
Coma	B-D003128
,	O
convulsions,	O
hallucinations,	O
meningitis	O
Respiratory	O
Bronchitis	B-D001991
,	O
pneumonia,	O
respiratory	O
depression,	O
sinusitis	O
Skin	B-D012867
and	O
appendages	O
Alopecia	B-D000505
,	O
exfoliative	O
dermatitis,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrosis	O
Special	O
senses	O
Conjunctivitis	B-D003231
,	O
deafness,	O
hearing	O
impairment,	O
taste	O
perversion	O
Urogenital	O
system	O
Cystitis	B-D003556
,	O
hematuria,	O
interstitial	O
nephritis,	O
leukorrhea,	O
renal	O
calculus,	O
uterine	O
bleeding	O
irregularities	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
adverse	O
reactions	O
are	O
drowsiness	O
and	O
dizziness.	O
Less	O
frequent	O
adverse	O
reactions	O
are	O
lightheadedness	O
and	O
gastrointestinal	O
disturbances	O
including	O
nausea,	O
vomiting,	O
and	O
flatulence.	O
A	O
single	O
incidence	O
of	O
bone	O
marrow	O
suppression	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
and	O
caffeine.	O
Several	O
cases	O
of	O
dermatological	O
reactions	O
including	O
toxic	O
epidermal	O
necrolysis	O
and	O
erythema	O
multiforme	O
have	O
been	O
reported.	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Vensun	O
Pharmaceuticals,	O
Inc.	O
at	O
1-800-385-1540	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(	O
s	O
ee	O
WARNINGS	O
).	O
•	O
Diclofenac	B-D004008
sodium	O
e	O
xtended-release	O
tablets	O
,	O
USP	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
,	O
WARNINGS	O
).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(	O
s	O
ee	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS	O
)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
Hypertension	B-D006973
(see	O
WARNINGS	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
extended-release	O
tablets,	O
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses	O
:	O
blurred	O
vision	O
Urogen	O
i	O
tal	O
System	O
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure.	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages	O
:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses	O
:	O
conjunctivitis,	O
hearing	O
impairment.	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
EVENTS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
http://www.fda.gov/	O
for	O
voluntary	O
reporting	O
of	O
adverse	O
reactions.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS	O
.)	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/	O
polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(see	O
WARNINGS.)	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(see	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%–10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
atulence,	O
gross	O
bleeding/	O
perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
•	O
Solaraze	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
423	O
patients	O
evaluable	O
for	O
safety	O
in	O
adequate	O
and	O
well-controlled	O
trials,	O
211	O
were	O
treated	O
with	O
Solaraze®	O
drug	O
product	O
and	O
212	O
were	O
treated	O
with	O
a	O
vehicle	O
gel.	O
Eighty-seven	O
percent	O
(87%)	O
of	O
the	O
Solaraze®-treated	O
patients	O
(183	O
patients)	O
and	O
84%	O
of	O
the	O
vehicle-treated	O
patients	O
(178	O
patients)	O
experienced	O
one	O
or	O
more	O
adverse	O
events	O
(AEs)	O
during	O
the	O
studies.	O
The	O
majority	O
of	O
these	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
upon	O
discontinuation	O
of	O
therapy.	O
Of	O
the	O
211	O
patients	O
treated	O
with	O
Solaraze®,	O
172	O
(82%)	O
experienced	O
AEs	O
involving	O
skin	O
and	O
the	O
application	O
site	O
compared	O
to	O
160	O
(75%)	O
vehicle-treated	O
patients.	O
Application	O
site	O
reactions	O
(ASRs)	O
were	O
the	O
most	O
frequent	O
AEs	O
in	O
both	O
Solaraze®-and	O
vehicle-treated	O
groups.	O
Of	O
note,	O
four	O
reactions,	O
contact	O
dermatitis,	O
rash,	O
dry	O
skin	O
and	O
exfoliation	O
(scaling)	O
were	O
significantly	O
more	O
prevalent	O
in	O
the	O
Solaraze®	O
group	O
than	O
in	O
the	O
vehicle-treated	O
patients.	O
Eighteen	O
percent	O
of	O
Solaraze®-treated	O
patients	O
and	O
4%	O
of	O
vehicle-treated	O
patients	O
discontinued	O
from	O
the	O
clinical	O
trials	O
due	O
to	O
adverse	O
events	O
(whether	O
considered	O
related	O
to	O
treatment	O
or	O
not).	O
These	O
discontinuations	O
were	O
mainly	O
due	O
to	O
skin	O
irritation	O
or	O
related	O
cutaneous	O
adverse	O
reactions.	O
Table	O
1	O
below	O
presents	O
the	O
AEs	O
reported	O
at	O
an	O
incidence	O
of	O
>1%	O
for	O
patients	O
treated	O
with	O
either	O
Solaraze®	O
Gel	O
or	O
vehicle	O
(60-	O
and	O
90-day	O
treatment	O
groups)	O
during	O
the	O
phase	O
3	O
studies.	O
Table	O
1.	O
Adverse	O
Events	O
Reported	O
(>1%	O
in	O
Any	O
Treatment	O
Group)	O
During	O
Solaraze®	O
Phase	O
3	O
Clinical	B-D016430
Trial	I-D016430
s	O
Incidence	B-D015994
s	O
for	O
60-Day	O
and	O
90-Day	O
Treatments	O
60-day	O
Treatment	O
90-day	O
Treatment	O
Solaraze®	O
(%)	O
Gel	O
Vehicle	O
(%)	O
Solaraze®	O
(%)	O
Gel	O
Vehicle	O
(%)	O
N=48	O
N=49	O
N=114	O
N=114	O
BODY	O
AS	O
A	O
WHOLE	O
21	O
20	O
20	O
18	O
Abdominal	B-D015746
Pain	I-D015746
2	O
0	O
1	O
0	O
Accidental	O
Injury	O
0	O
0	O
4	O
2	O
Allergic	O
Reaction	O
0	O
0	O
1	O
3	O
Asthenia	B-D001247
0	O
0	O
2	O
0	O
Back	B-D001416
Pain	I-D001416
4	O
0	O
2	O
2	O
Chest	B-D002637
Pain	I-D002637
2	O
0	O
1	O
0	O
Chills	B-D023341
0	O
2	O
0	O
0	O
Flu	O
Syndrome	B-D013577
10	O
6	O
1	O
4	O
Headache	B-D006261
0	O
6	O
7	O
6	O
Infection	O
4	O
6	O
4	O
5	O
Neck	B-D019547
Pain	I-D019547
0	O
0	O
2	O
0	O
Pain	B-D010146
2	O
0	O
2	O
2	O
CARDIOVASCULAR	O
SYSTEM	O
2	O
4	O
3	O
1	O
Hypertension	B-D006973
2	O
0	O
1	O
0	O
Migraine	O
0	O
2	O
1	O
0	O
Phlebitis	B-D010689
0	O
2	O
0	O
0	O
DIGESTIVE	O
SYSTEM	O
4	O
0	O
6	O
8	O
Constipation	B-D003248
0	O
0	O
0	O
2	O
Diarrhea	B-D003967
2	O
0	O
2	O
3	O
Dyspepsia	B-D004415
2	O
0	O
3	O
4	O
METABOLIC	O
AND	O
NUTRITIONAL	O
DISORDERS	O
2	O
8	O
7	O
2	O
Creatine	B-D003401
Phosphokinase	O
Increased	O
0	O
0	O
4	O
1	O
Creatinine	B-D003404
Increased	O
2	O
2	O
0	O
1	O
Edema	B-D004487
0	O
2	O
0	O
0	O
Hypercholesteremia	O
0	O
2	O
1	O
0	O
Hyperglycemia	B-D006943
0	O
2	O
1	O
0	O
SGOT	O
Increased	O
0	O
0	O
3	O
0	O
SGPT	O
Increased	O
0	O
0	O
2	O
0	O
MUSCULOSKELETAL	O
SYSTEM	O
4	O
0	O
3	O
4	O
Arthralgia	B-D018771
2	O
0	O
0	O
2	O
Art	B-D001154
hrosis	O
2	O
0	O
0	O
0	O
Myalgia	B-D063806
2	O
0	O
3	O
1	O
NERVOUS	O
SYSTEM	O
2	O
2	O
2	O
5	O
Anxiety	B-D001007
0	O
2	O
0	O
1	O
Dizziness	B-D004244
0	O
0	O
0	O
4	O
Hypokinesia	B-D018476
2	O
0	O
0	O
0	O
RESPIRATORY	O
SYSTEM	O
8	O
8	O
7	O
6	O
Asthma	B-D001249
2	O
0	O
0	O
0	O
Dyspnea	B-D004417
2	O
0	O
2	O
0	O
Pharyngitis	B-D010612
2	O
8	O
2	O
4	O
Pneumonia	B-D011014
2	O
0	O
0	O
1	O
Rhinitis	B-D012220
2	O
2	O
2	O
2	O
Sinusitis	B-D012852
0	O
0	O
2	O
0	O
SKIN	O
AND	O
APPENDAGES	O
75	O
86	O
86	O
71	O
Acne	O
0	O
2	O
0	O
1	O
Application	O
Site	O
Reaction	O
75	O
71	O
84	O
70	O
Acne	O
0	O
4	O
1	O
0	O
Alopecia	B-D000505
2	O
0	O
1	O
1	O
Contact	O
Dermatitis	B-D003872
19	O
4	O
33	O
4	O
Dry	O
Skin	B-D012867
27	O
12	O
25	O
17	O
Edema	B-D004487
4	O
0	O
3	O
0	O
Exfoliation	O
6	O
4	O
24	O
13	O
Hyperesthesia	B-D006941
0	O
0	O
3	O
1	O
Pain	B-D010146
15	O
22	O
26	O
30	O
Paresthesia	B-D010292
8	O
4	O
20	O
20	O
Photosensitivity	O
Reaction	O
0	O
2	O
3	O
0	O
Pruritus	B-D011537
31	O
59	O
52	O
45	O
Rash	O
35	O
20	O
46	O
17	O
Vesiculobullous	O
Rash	O
0	O
0	O
4	O
1	O
Contact	O
Dermatitis	B-D003872
2	O
0	O
0	O
0	O
Dry	O
Skin	B-D012867
0	O
4	O
3	O
0	O
Herpes	B-D006561
Simplex	I-D006561
0	O
2	O
0	O
0	O
Maculopapular	O
Rash	O
0	O
2	O
0	O
0	O
Pain	B-D010146
2	O
2	O
1	O
0	O
Pruritus	B-D011537
4	O
6	O
4	O
1	O
Rash	O
2	O
10	O
4	O
0	O
Skin	B-D012867
Carcinoma	B-D002277
0	O
6	O
2	O
2	O
Skin	B-D012867
Nodule	O
0	O
2	O
0	O
0	O
Skin	B-D012883
Ulcer	I-D012883
2	O
0	O
1	O
0	O
SPECIAL	O
SENSES	O
2	O
0	O
4	O
2	O
Conjunctivitis	B-D003231
2	O
0	O
4	O
1	O
Eye	B-D058447
Pain	I-D058447
0	O
2	O
2	O
0	O
UROGENITAL	O
SYSTEM	O
0	O
0	O
4	O
5	O
Hematuria	B-D006417
0	O
0	O
2	O
1	O
OTHER	O
0	O
0	O
0	O
3	O
Procedure	O
0	O
0	O
0	O
3	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Events	O
Reported	O
for	O
Solaraze	O
®	O
at	O
Less	O
Than	O
1%	O
Incidence	B-D015994
in	O
the	O
Phase	O
3	O
Studies:	O
skin	O
hypertrophy,	O
paresthesia,	O
seborrhea,	O
urticaria,	O
application	O
site	O
reactions	O
(skin	O
carcinoma,	O
hypertonia,	O
skin	O
hypertrophy	O
lacrimation	O
disorder,	O
maculopapular	O
rash,	O
purpuric	O
rash,	O
vasodilation).	O
Adverse	O
Reactions	O
Reported	O
for	O
Oral	O
Diclofenac	B-D004008
Dosage	O
Form	B-D020478
(not	O
topical	O
Solaraze	O
®	O
Gel):	O
*Incidence	O
Greater	O
than	O
1%	O
marked	O
with	O
asterisk.	O
Body	O
as	O
a	O
Whole:	O
abdominal	O
pain	O
or	O
cramps*,	O
headache*,	O
fluid	O
retention*,	O
abdominal	O
distention*,	O
malaise,	O
swelling	O
of	O
lips	O
and	O
tongue,	O
photosensitivity,	O
anaphylaxis,	O
anaphylactoid	O
reactions,	O
chest	O
pain.	O
Cardiovascular:	O
hypertension,	O
congestive	O
heart	O
failure,	O
palpitations,	O
flushing,	O
tachycardia,	O
premature	O
ventricular	O
contractions,	O
myocardial	O
infarction,	O
hypotension.	O
Digestive:	O
diarrhea*,	O
indigestion*,	O
nausea*,	O
constipation*,	O
flatulence*,	O
liver	O
test	O
abnormalities*,	O
PUB*,	O
i.e.,	O
peptic	O
ulcer,	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
or	O
bleeding	O
without	O
ulcer,	O
vomiting,	O
jaundice,	O
melena,	O
esophageal	O
lesions,	O
aphthous	O
stomatitis,	O
dry	O
mouth	O
and	O
mucous	O
membranes,	O
bloody	O
diarrhea,	O
hepatitis,	O
hepatic	O
necrosis,	O
cirrhosis,	O
hepatorenal	O
syndrome,	O
appetite	O
change,	O
pancreatitis	O
with	O
or	O
without	O
concomitant	O
hepatitis,	O
colitis,	O
intestinal	O
perforation.	O
Hemic	O
and	O
Lymph	B-D008196
atic:	O
hemoglobin	O
decrease,	O
leukopenia,	O
thrombocytopenia,	O
eosinophilia,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
agranulocytosis,	O
purpura,	O
allergic	O
purpura,	O
bruising.	O
Metabolic	O
and	O
Nutritional	O
Disorders:	O
azotemia,	O
hypoglycemia,	O
weight	O
loss.	O
Nervous	B-D009420
System	I-D009420
:	O
dizziness*,	O
insomnia,	O
drowsiness,	O
depression,	O
diplopia,	O
anxiety,	O
irritability,	O
aseptic	O
meningitis,	O
convulsions,	O
paresthesia,	O
memory	O
disturbance,	O
nightmares,	O
tremor,	O
tic,	O
abnormal	O
coordination,	O
disorientation,	O
psychotic	O
reaction.	O
Respiratory:	O
epistaxis,	O
asthma,	O
laryngeal	O
edema,	O
dyspnea,	O
hyperventilation,	O
edema	O
of	O
pharynx.	O
Skin	B-D012867
and	O
Appendages:	O
rash*,	O
pruritus*,	O
alopecia,	O
urticaria,	O
eczema,	O
dermatitis,	O
bullous	O
eruption,	O
erythema	O
multiforme	O
major,	O
angioedema,	O
Stevens-Johnson	O
syndrome,	O
excess	O
perspiration,	O
exfoliative	O
dermatitis.	O
Special	O
Senses:	O
tinnitus*,	O
blurred	O
vision,	O
taste	O
disorder,	O
reversible	O
and	O
irreversible	O
hearing	O
loss,	O
scotoma,	O
vitreous	O
floaters,	O
night	O
blindness,	O
amblyopia.	O
Urogenital:	O
nephrotic	O
syndrome,	O
proteinuria,	O
oliguria,	O
interstitial	O
nephritis,	O
papillary	O
necrosis,	O
acute	O
renal	O
failure,	O
urinary	O
frequency,	O
nocturia,	O
hematuria,	O
impotence,	O
vaginal	O
bleeding.	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(	O
5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(	O
4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(	O
5.4)	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(	O
5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(	O
4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(	O
5.4)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(	O
5.1,	O
14.6,	O
17.2).	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
(	O
5.4,	O
8.5,	O
14.6,	O
17.3).	O
Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
celecoxib	O
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen	O
(	O
5.5,	O
17.4).	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
celecoxib	O
(	O
5.2,	O
7.4,	O
17.2).	O
Fluid	O
retention	O
and	O
edema.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure	O
(	O
5.3,	O
17.6).	O
Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
celecoxib	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists	O
(	O
5.6,	O
7.4,	O
8.7,	O
17.6).	O
Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
celecoxib	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(	O
5.7,	O
10,	O
17.7).	O
Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions	O
(	O
5.8,	O
17.5).	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
celecoxib,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
celecoxib	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
].	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
celecoxib	O
[	O
see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
the	O
CLASS	O
study	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
celecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
active	O
GI	O
bleeding.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[	O
see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
celecoxib	O
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
celecoxib	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
celecoxib.	O
In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
celecoxib.	O
Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
celecoxib	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(	O
6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Lupin	O
Pharmaceuticals,	O
Inc	O
.	O
at	O
1-800-399-2561	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General	O
:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional	O
:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia,	O
Psychiatric	O
:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders	O
:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary	O
:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular	O
:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal	O
:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic	O
:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous	O
:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS,	O
or	O
hypersensitivity	O
syndrome)	O
General	O
:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events	O
:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[	O
see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials	O
,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders	O
:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth	O
:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders	O
:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders	O
:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(see	O
WARNINGS.)	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(see	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%–10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
atulence,	O
gross	O
bleeding/	O
perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(see	O
WARNINGS.)	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(see	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%–10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
atulence,	O
gross	O
bleeding/	O
perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
Etodolac	B-D017308
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
capsules	O
and	O
tablets	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1,000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
or	O
Equal	O
to	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain*,	O
diarrhea*,	O
flatulence*,	O
nausea*,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise*,	O
dizziness*,	O
depression,	O
nervousness,	O
fatigue.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
Musculoskeletal	O
-	O
Arthralgia	B-D018771
.	O
*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
fatal	O
fulminant	O
hepatitis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
–	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis,leukocytoclastic	O
vasculitis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.	O
Musculoskeletal	O
-	O
Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
–	O
Sepsis	B-D018805
,	O
death.	O
Cardiovascular	O
system	O
–	O
Tachycardia	B-D013610
.	O
Digestive	O
system	O
–	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis.	O
Hemic	O
and	O
lymphatic	O
system	O
–	O
Lymphadenopathy	B-D000072281
.	O
Nervous	O
system	O
–	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo.	O
Respiratory	O
system	O
–	O
Respiratory	O
depression,	O
pneumonia.	O
Urogenital	O
system	O
–	O
Oliguria	B-D009846
/polyuria,	O
proteinuria.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs1	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS).	O
Etodolac	B-D017308
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS).	O
1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug.	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
capsules	O
and	O
tablets	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1,000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
or	O
Equal	O
to	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain*,	O
diarrhea*,	O
flatulence*,	O
nausea*,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise*,	O
dizziness*,	O
depression,	O
nervousness,	O
fatigue.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
Musculoskeletal	O
-	O
Arthralgia	B-D018771
.	O
*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
fatal	O
fulminant	O
hepatitis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
–	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis,	O
leukocytoclastic	O
vasculitis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.	O
Musculoskeletal	O
-	O
Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
–	O
Sepsis	B-D018805
,	O
death.	O
Cardiovascular	O
system	O
–	O
Tachycardia	B-D013610
.	O
Digestive	O
system	O
–	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis.	O
Hemic	O
and	O
lymphatic	O
system	O
–	O
Lymphadenopathy	B-D000072281
.	O
Nervous	O
system	O
–	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo.	O
Respiratory	O
system	O
–	O
Respiratory	O
depression,	O
pneumonia.	O
Urogenital	O
system	O
–	O
Oliguria	B-D009846
/polyuria,	O
proteinuria.	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
in	O
the	O
perioperative	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)].	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDS)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1)	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.2)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
Use	O
the	O
lowest	O
effective	O
dose	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
(5.1)	O
NSAIDs	O
can	O
cause	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation.	O
Prescribe	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
(5.2)	O
Elevation	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
NSAIDs.	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen.	O
(5.3)	O
Hypertension	B-D006973
can	O
occur	O
with	O
NSAID	O
treatment.	O
Monitor	O
blood	O
pressure	O
closely	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
treatment.	O
(5.4)	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
(5.5)	O
Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
at	O
greatest	O
risk	O
of	O
this	O
reaction,	O
including	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors.	O
(5.6)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
or	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution.	O
(5.7)	O
NSAIDs	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
(5.8)	O
Not	O
for	O
use	O
during	O
pregnancy.	O
(5.9)	O
Do	O
not	O
administer	O
to	O
patients	O
with	O
aspirin	O
sensitive	O
asthma	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
(5.10)	O
Avoid	O
exposure	O
of	O
treated	O
knee(s)	O
to	O
natural	O
or	O
artificial	O
sunlight.	O
(5.11)	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
(5.12)	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs.	O
(5.13)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
oral	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
COX-2	O
selective	O
and	O
nonselective	O
orally	O
administered	O
NSAIDs,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Inform	O
patients	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
an	O
orally	O
administered	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
NSAIDS,	O
such	O
as	O
diclofenac,	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Prescribe	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore,	O
use	O
special	O
care	O
when	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
diclofencac	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs.	O
5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
[ULN]	O
range)	O
or	O
greater	O
elevations	O
of	O
transaminases	O
occurred	O
in	O
about	O
15%	O
of	O
oral	O
diclofenac-treated	O
patients	O
in	O
clinical	O
trials	O
of	O
indications	O
other	O
than	O
acute	O
pain.	O
Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	O
injury.	O
In	O
clinical	O
trials	O
of	O
an	O
oral	O
diclofenac	O
–	O
misoprostol	O
combination	O
product,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
for	O
2	O
to	O
6	O
months,	O
patients	O
with	O
oral	O
diclofenac	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(>8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
this	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(>8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
test	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
oral	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
sever	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
oral	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Measure	O
transaminases	O
(ALT	O
and	O
AST)	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
monitor	O
transaminases	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flulike"	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
to	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver-related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
certain	O
antibiotics,	O
antiepileptics).	O
Caution	O
patients	O
to	O
avoid	O
taking	O
unprescribed	O
acetaminophen	O
while	O
using	O
diclofenac	O
sodium	O
topical	O
solution.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac,	O
can	O
lead	O
to	O
new	O
onset	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Use	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Monitor	O
blood	O
pressure	O
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
Patients	B-D010361
taking	O
ACE-inhibitors,	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution.	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
considerable	O
dehydration.	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
is	O
not	O
recommended	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
diclofenac	O
sodium	O
topical	O
solution	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution.	O
Do	O
not	O
prescribe	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.10)].	O
Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Do	O
not	O
apply	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
open	O
skin	O
wounds,	O
infections,	O
inflammations,	O
or	O
exfoliative	O
dermatitis,	O
as	O
it	O
may	O
affect	O
absorption	O
and	O
tolerability	O
of	O
the	O
drug.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations,	O
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
should	O
not	O
be	O
used	O
by	O
pregnant	O
or	O
nursing	O
women	O
or	O
those	O
intending	O
to	O
become	O
pregnant.	O
5.10	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross-reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
do	O
not	O
administer	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.11	O
Sun	O
Exposure	O
Instruct	O
patients	O
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
knee(s)	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light-induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.13	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	O
and	O
conduct	O
periodic	O
laboratory	O
evaluations.	O
5.14	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-response	O
illness.	O
For	O
patients	O
on	O
prolonged	O
corticosteroid	O
therapy,	O
taper	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Hematological	O
Effects	O
The	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	O
subjects	O
administered	O
80	O
drops	O
four	O
times	O
a	O
day	O
for	O
7	O
days.	O
There	O
was	O
no	O
significant	O
change	O
in	O
platelet	O
aggregation	O
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)].	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
Check	O
hemoglobin	O
or	O
hematocrit	O
of	O
patients	O
on	O
diclofenac	O
sodium	O
topical	O
solution	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration	O
and	O
reversible.	O
Carefully	O
monitor	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alteration	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants.	O
5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms	O
in	O
patients	O
taking	O
NSAIDs,	O
monitor	O
patients	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Check	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
in	O
patients	O
on	O
long-term	O
treatment	O
with	O
NSAIDs.	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
if	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen.	O
6.	O
ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
are	O
application	O
site	O
reactions.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
IGI	O
Laboratories	B-D007753
,	O
Inc.	O
at	O
1-856-697-1441,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trial	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution	O
of	O
911	O
patients	O
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	O
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	O
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	O
treated	O
for	O
at	O
least	O
12	O
months.	O
The	O
population	O
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	O
were	O
Caucasians,	O
64%	O
were	O
females,	O
and	O
all	O
patients	O
had	O
primary	O
osteoarthritis.	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies.	O
Application	O
site	O
reactions:	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment	O
related	O
adverse	O
events	O
in	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
Application	O
site	O
reactions	O
were	O
characterized	O
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	O
induration,	O
vesicles,	O
paresthesia,	O
pruritus,	O
vasodilation,	O
acne,	O
and	O
urticaria.	O
The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	O
(32%),	O
contact	O
dermatitis	O
characterized	O
by	O
skin	O
erythema	O
and	O
induration	O
(9%),	O
contact	O
dermatitis	O
with	O
vescicles	O
(2%)	O
and	O
pruritus	O
(4%).	O
In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	O
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac.	O
In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	O
study,	O
contact	O
dermatitis	O
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	O
with	O
vesicles	O
in	O
10%	O
of	O
patients,	O
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	O
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%.	O
Adverse	O
events	O
common	O
to	O
the	O
NSAID	O
class:	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
flatulence,	O
abdominal	O
pain,	O
edema;	O
see	O
Table	O
1).	O
The	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac,	O
compared	O
to	O
oral	O
diclofenac	O
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	O
(3%	O
vs.	O
less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	O
(12%	O
vs.	O
7%),	O
urea	O
(20%	O
vs.	O
12%),	O
and	O
hemoglobin	O
(13%	O
vs.	O
9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	O
transaminases.	O
Table	O
1:	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
osteoarthritis.	O
Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	O
trials.	O
Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
SolutionN=911	O
Topical	O
PlaceboN=332	O
Adverse	O
ReactionPreferred	O
Term	O
according	O
to	O
COSTART	O
N(%)	O
N(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non	O
–	O
U.S.	O
postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
Whole:	O
abdominal	O
pain,	O
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	O
back	O
pain,	O
body	O
odor,	O
chest	O
pain,	O
edema,	O
face	O
edema,	O
halitosis,	O
headache,	O
lack	O
of	O
drug	O
effect,	O
neck	O
rigidity,	O
pain	O
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	O
dry	O
mouth,	O
dyspepsia,	O
gastroenteritis,	O
decreased	O
appetite,	O
mouth	O
ulceration,	O
nausea,	O
rectal	O
hemorrhage,	O
ulcerative	O
stomatitis	O
Metabolic	O
and	O
Nutritional:	O
creatinine	O
increased	O
Musculoskeletal:	O
leg	O
cramps,	O
myalgia	O
Nervous:	O
depression,	O
dizziness,	O
drowsiness,	O
lethargy,	O
paresthesia,	O
paresthesia	O
at	O
application	O
site	O
Respiratory:	O
asthma,	O
dyspnea,	O
laryngismus,	O
laryngitis,	O
pharyngitis	O
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	O
contact	O
dermatitis	O
with	O
vesicles,	O
dry	O
skin,	O
pruritus,	O
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	O
rash,	O
pruritus,	O
skin	O
discoloration,	O
urticaria	O
Special	O
senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	O
ear	O
pain,	O
eye	O
disorder,	O
eye	O
pain,	O
taste	O
perversion	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
].	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
and	O
Warnings	O
].	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
Diclofenac	B-D004008
Sodium	B-D012964
Delayed-release	O
Tablets	B-D013607
,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Unique	O
Pharmaceutical	O
Laboratories	B-D007753
toll-free	O
at	O
(800)	O
521-5340	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS	O
.)	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
Diclofenac	B-D004008
Sodium	B-D012964
Delayed-release	O
Tablets	B-D013607
,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Unique	O
Pharmaceutical	O
Laboratories	B-D007753
toll-free	O
at	O
(800)	O
521-5340	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
Rx	O
only	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS	O
).	O
Etodolac	B-D017308
capsules	O
USP,	O
200	O
mg	O
and	O
300	O
mg,	O
and	O
Etodolac	B-D017308
tablets	O
USP,	O
400	O
mg	O
and	O
500	O
mg	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(See	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
capsules	O
and	O
tablets,	O
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
capsules	O
and	O
tablets	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
RelatedBody	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain1,	O
diarrhea1,	O
flatulence1,	O
nausea1,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise1,	O
dizziness1,	O
depression,	O
nervousness,	O
fatigue.Skin	O
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.Musculoskeletal—Arthralgia.	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
1Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.Skin	O
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
leukocytoclastic	O
vasculitis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.Skin	O
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.Musculoskeletal—Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDsBody	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
deathCardiovascular	O
system	O
-	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesisHemic	O
and	O
lymphatic	O
system	O
-	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigoRespiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumoniaUrogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS).	O
Naproxen	B-D009288
as	O
NAPRELAN	O
®	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(SeeWARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
people	O
are	O
at	O
greater	O
risk	O
for	O
serous	O
gastrointestinal	O
events.	O
(SeeWARNINGS).	O
ADVERSE	O
REACTIONS	O
As	O
with	O
all	O
drugs	O
in	O
this	O
class,	O
the	O
frequency	O
and	O
severity	O
of	O
adverse	O
events	O
depends	O
on	O
several	O
factors:	O
the	O
dose	O
of	O
the	O
drug	O
and	O
duration	O
of	O
treatment;	O
the	O
age,	O
the	O
sex,	O
physical	O
condition	O
of	O
the	O
patient;	O
any	O
concurrent	O
medical	O
diagnoses	O
or	O
individual	O
risk	O
factors.	O
The	O
following	O
adverse	O
reactions	O
are	O
divided	O
into	O
three	O
parts	O
based	O
on	O
frequency	O
and	O
whether	O
or	O
not	O
the	O
possibility	O
exists	O
of	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
these	O
adverse	O
events.	O
In	O
those	O
reactions	O
listed	O
as	O
“Probable	O
Causal	O
Relationship”	O
there	O
is	O
at	O
least	O
one	O
case	O
for	O
each	O
adverse	O
reaction	O
where	O
there	O
is	O
evidence	O
to	O
suggest	O
that	O
there	O
is	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
the	O
reported	O
event.	O
The	O
adverse	O
reactions	O
reported	O
were	O
based	O
on	O
the	O
results	O
from	O
two	O
double-blind	O
controlled	O
clinical	O
trials	O
of	O
three	O
months	O
duration	O
with	O
an	O
additional	O
nine	O
month	O
open-label	O
extension.	O
A	O
total	O
of	O
542	O
patients	O
received	O
NAPRELAN®	O
Tablets	B-D013607
either	O
in	O
the	O
double-blind	O
period	O
or	O
in	O
the	O
nine	O
month	O
open-label	O
extension.	O
Of	O
these	O
542	O
patients,	O
232	O
received	O
NAPRELAN®	O
Tablets	B-D013607
,	O
167	O
were	O
initially	O
treated	O
with	O
Naprosyn®	O
***	O
and	O
143	O
were	O
initially	O
treated	O
with	O
placebo.	O
Adverse	O
reactions	O
reported	O
by	O
patients	O
who	O
received	O
NAPRELAN®	O
Tablets	B-D013607
are	O
shown	O
by	O
body	O
system.	O
Those	O
adverse	O
reactions	O
observed	O
with	O
naproxen	O
but	O
not	O
reported	O
in	O
controlled	O
trials	O
with	O
NAPRELAN®	O
Tablets	B-D013607
are	O
italicized.	O
The	O
most	O
frequent	O
adverse	O
events	O
from	O
the	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
were	O
headache	O
(15%),	O
followed	O
by	O
dyspepsia	O
(14%),	O
and	O
flu	O
syndrome	O
(10%).	O
The	O
incidence	O
of	O
other	O
adverse	O
events	O
occurring	O
in	O
3%	O
-	O
9%	O
of	O
the	O
patients	O
are	O
marked	O
with	O
an	O
asterisk.	O
Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.	O
INCIDENCE	O
GREATER	O
THAN	O
1%	O
(PROBABLE	O
CAUSAL	O
RELATIONSHIP)	O
Body	O
as	O
a	O
Whole—Pain	O
(back)*,	O
pain*,	O
infection*,	O
fever,	O
injury	O
(accident),	O
asthenia,	O
pain	O
chest,	O
headache	O
(15%),	O
flu	O
syndrome	O
(10%).	O
Gastrointestinal—Nausea*,	O
diarrhea*,	O
constipation*,	O
abdominal	O
pain*,	O
flatulence,	O
gastritis,	O
vomiting,	O
dysphagia,	O
dyspepsia	O
(14%),	O
heartburn*,	O
stomatitis.	O
Hematologic—Anemia,	O
ecchymosis.	O
Respiratory—Pharyngitis*,	O
rhinitis*,	O
sinusitis*,	O
bronchitis,	O
cough	O
increased.	O
Renal—Urinary	O
tract	O
infection*,	O
cystitis.	O
Dermatologic—Skin	O
rash*,	O
skin	O
eruptions*,	O
ecchymoses*,	O
purpura.	O
Metabolic	O
and	O
Nutrition—Peripheral	O
edema,	O
hyperglycemia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Dizziness,	O
paresthesia,	O
insomnia,	O
drowsiness*,	O
lightheadedness.	O
Cardiovascular—Hypertension,	O
edema*,	O
dyspnea*,	O
palpitations.	O
Musculoskeletal—Cramps	O
(leg),	O
myalgia,	O
arthralgia,	O
joint	O
disorder,	O
tendon	O
disorder.	O
Special	O
Senses—Tinnitus*,	O
hearing	O
disturbances,	O
visual	O
disturbances.	O
General—Thirst.	O
INCIDENCE	O
LESS	O
THAN	O
1%	O
(PROBABLE	O
CAUSAL	O
RELATIONSHIP)	O
Body	O
as	O
a	O
Whole—Abscess,	O
monilia,	O
neck	O
rigid,	O
pain	O
neck,	O
abdomen	O
enlarged,	O
carcinoma,	O
cellulitis,	O
edema	O
general,	O
LE	O
syndrome,	O
malaise,	O
mucous	O
membrane	O
disorder,	O
allergic	O
reaction,	O
pain	O
pelvic.	O
Gastrointestinal—Anorexia,	O
cholecystitis,	O
cholelithiasis,	O
eructation,	O
GI	O
hemorrhage,	O
rectal	O
hemorrhage,	O
stomatitis	O
aphthous,	O
stomatitis	O
ulcer,	O
ulcer	O
mouth,	O
ulcer	O
stomach,	O
periodontal	O
abscess,	O
cardiospasm,	O
colitis,	O
esophagitis,	O
gastroenteritis,	O
GI	O
disorder,	O
rectal	O
disorder,	O
tooth	O
disorder,	O
hepatosplenomegaly,	O
liver	O
function	O
abnormality,	O
melena,	O
ulcer	O
esophagus,	O
hematemesis,	O
jaundice,	O
pancreatitis,	O
necrosis.	O
Renal—Dysmenorrhea,	O
dysuria,	O
kidney	O
function	O
abnormality,	O
nocturia,	O
prostate	O
disorder,	O
pyelonephritis,	O
carcinoma	O
breast,	O
urinary	O
incontinence,	O
kidney	O
calculus,	O
kidney	O
failure,	O
menorrhagia,	O
metrorrhagia,	O
neoplasm	O
breast,	O
nephrosclerosis,	O
hematuria,	O
pain	O
kidney,	O
pyuria,	O
urine	O
abnormal,	O
urinary	O
frequency,	O
urinary	O
retention,	O
uterine	O
spasm,	O
vaginitis,	O
glomerular	O
nephritis,	O
hyperkalemia,	O
interstitial	O
nephritis,	O
nephrotic	O
syndrome,	O
renal	O
disease,	O
renal	O
failure,	O
renal	O
papillary	O
necrosis.	O
Hematologic—Leukopenia,	O
bleeding	O
time	O
increased,	O
eosinophilia,	O
abnormal	O
RBC,	O
abnormal	O
WBC,	O
thrombocytopenia,	O
agranulocytosis,	O
granulocytopenia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Depression,	O
anxiety,	O
hypertonia,	O
nervousness,	O
neuralgia,	O
neuritis,	O
vertigo,	O
amnesia,	O
confusion,	O
co-ordination,	O
abnormal	O
diplopia,	O
emotional	O
lability,	O
hematoma	O
subdural,	O
paralysis,	O
dream	O
abnormalities,	O
inability	O
to	O
concentrate,	O
muscle	O
weakness.	O
Dermatologic:	O
Angiodermatitis,	O
herpes	O
simplex,	O
dry	O
skin,	O
sweating,	O
ulcer	O
skin,	O
acne,	O
alopecia,	O
dermatitis	O
contact,	O
eczema,	O
herpes	O
zoster,	O
nail	O
disorder,	O
skin	O
necrosis,	O
subcutaneous	O
nodule,	O
pruritus,	O
urticaria,	O
neoplasm	O
skin,	O
photosensitive	O
dermatitis,	O
photosensitivity	O
reactions	O
resembling	O
porphyria	O
cutaneous	O
tarda,	O
epidermolysis	O
bullosa.	O
Special	O
Senses—Amblyopia,	O
scleritis,	O
cataract,	O
conjunctivitis,	O
deaf,	O
ear	O
disorder,	O
keratoconjunctivitis,	O
lacrimation	O
disorder,	O
otitis	O
media,	O
pain	O
eye.	O
Cardiovascular—Angina	O
pectoris,	O
coronary	O
artery	O
disease,	O
myocardial	O
infarction,	O
deep	O
thrombophlebitis,	O
vasodilation,	O
vascular	O
anomaly,	O
arrhythmia,	O
bundle	O
branch	O
block,	O
abnormal	O
ECG,	O
heart	O
failure	O
right,	O
hemorrhage,	O
migraine,	O
aortic	O
stenosis,	O
syncope,	O
tachycardia,	O
congestive	O
heart	O
failure.	O
Respiratory—Asthma,	O
dyspnea,	O
lung	O
edema,	O
laryngitis,	O
lung	O
disorder,	O
epistaxis,	O
pneumonia,	O
respiratory	O
distress,	O
respiratory	O
disorder,	O
eosinophilic	O
pneumonitis.	O
Musculoskeletal—Myasthenia,	O
bone	O
disorder,	O
spontaneous	O
bone	O
fracture,	O
fibrotendinitis,	O
bone	O
pain,	O
ptosis,	O
spasm	O
general,	O
bursitis.	O
Metabolic	O
and	O
Nutrition—Creatinine	O
increase,	O
glucosuria,	O
hypercholesteremia,	O
albuminuria,	O
alkalosis,	O
BUN	O
increased,	O
dehydration,	O
edema,	O
glucose	O
tolerance	O
decrease,	O
hyperuricemia,	O
hypokalemia,	O
SGOT	O
increase,	O
SGPT	O
increase,	O
weight	O
decrease.	O
General—Anaphylactoid	O
reactions,	O
angioneurotic	O
edema,	O
menstrual	O
disorders,	O
hypoglycemia,	O
pyrexia	O
(chills	O
and	O
fevers).	O
INCIDENCE	O
LESS	O
THAN	O
1%	O
(CAUSAL	O
RELATIONSHIP	O
UNKNOWN)	O
Other	O
adverse	O
reactions	O
listed	O
in	O
the	O
naproxen	O
package	O
label,	O
but	O
not	O
reported	O
by	O
those	O
who	O
received	O
NAPRELAN®	O
Tablets	B-D013607
are	O
shown	O
in	O
italics.	O
These	O
observations	O
are	O
being	O
listed	O
as	O
alerting	O
information	O
to	O
the	O
physician.	O
Hematologic—Aplastic	O
anemia,	O
hemolytic	O
anemia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Aseptic	O
meningitis,	O
cognitive	O
dysfunction.	O
Dermatologic—Epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome.	O
Gastrointestinal—Non-peptic	O
GI	O
ulceration,	O
ulcerative	O
stomatitis.	O
Cardiovascular—Vasculitis.	O
ADVERSE	O
REACTIONS	O
Clinical	O
Practice:	O
The	O
following	O
events	O
have	O
been	O
identified	O
during	O
postmarketing	O
use	O
of	O
topical	O
Diclofenac	B-D004008
Sodium	B-D012964
Ophthalmic	O
Solution,	O
0.1%	O
in	O
clinical	O
practice.	O
Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size,	O
estimates	O
of	O
frequency	O
cannot	O
be	O
made.	O
The	O
events,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
Diclofenac	B-D004008
Sodium	B-D012964
Ophthalmic	O
Solution,	O
0.1%,	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
corneal	O
erosion,	O
corneal	O
infiltrates,	O
corneal	O
perforation,	O
corneal	O
thinning,	O
corneal	O
ulceration,	O
epithelial	O
breakdown,	O
and	O
superficial	O
punctate	O
keratitis,	O
(see	O
PRECAUTIONS,	O
General).	O
Ocular:	O
Transient	O
burning	O
and	O
stinging	O
were	O
reported	O
in	O
approximately	O
15%	O
of	O
patients	O
across	O
studies	O
with	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Ophthalmic.	O
In	O
cataract	O
surgery	O
studies,	O
keratitis	O
was	O
reported	O
in	O
up	O
to	O
28%	O
of	O
patients	O
receiving	O
Diclofenac	B-D004008
Sodium	B-D012964
Ophthalmic,	O
although	O
in	O
many	O
of	O
these	O
cases	O
keratitis	O
was	O
initially	O
noted	O
prior	O
to	O
the	O
initiation	O
of	O
treatment.	O
Elevated	O
intraocular	O
pressure	O
following	O
cataract	O
surgery	O
was	O
reported	O
in	O
approximately	O
15%	O
of	O
patients	O
undergoing	O
cataract	O
surgery.	O
Lacrimation	O
complaints	O
were	O
reported	O
in	O
approximately	O
30%	O
of	O
case	O
studies	O
undergoing	O
incisional	O
refractive	O
surgery.	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
approximately	O
5%	O
or	O
less	O
of	O
the	O
patients:	O
abnormal	O
vision,	O
acute	O
elevated	O
IOP,	O
blurred	O
vision,	O
conjunctivitis,	O
corneal	O
deposits,	O
corneal	O
edema,	O
corneal	O
opacity,	O
corneal	O
lesions,	O
discharge,	O
eyelid	O
swelling,	O
injection,	O
iritis,	O
irritation,	O
itching,	O
lacrimation	O
disorder	O
and	O
ocular	O
allergy.	O
Systemic:	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
3%	O
or	O
less	O
of	O
the	O
patients:	O
abdominal	O
pain,	O
asthenia,	O
chills,	O
dizziness,	O
facial	O
edema,	O
fever,	O
headache,	O
insomnia,	O
nausea,	O
pain,	O
rhinitis,	O
viral	O
infection,	O
and	O
vomiting.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
).	O
•	O
Diclofenac	B-D004008
Sodium	B-D012964
Extended-release	O
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
WARNINGS)	O
•	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
•	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
•	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
•	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
•	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
•	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
•	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
•	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
Diclofenac	B-D004008
Sodium	B-D012964
Extended-release	O
Tablets	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Oceanside	O
Pharmaceuticals	O
at	O
1-800-321-4576	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
Cardiovascular	O
Thrombotic	O
Events	O
•Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs1)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(See	O
WARNINGS	O
).	O
•Etodolac	O
capsules	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(See	O
CONTRAINDICATIONS	O
and	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(See	O
WARNINGS	O
).	O
1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
nonsteroidal	O
anti-inflammatory	O
drug.	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
capsules	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
or	O
Equal	O
to	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain*,	O
diarrhea*,	O
flatulence*,	O
nausea*,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise*,	O
dizziness*,	O
depression,	O
nervousness,	O
fatigue.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
Musculoskeletal	O
-	O
Arthralgia	B-D018771
.	O
*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
leukocytoclastic	O
vasculitis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.	O
Musculoskeletal	O
-	O
Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death.	O
Cardiovascular	O
system	O
-	O
Tachycardia	B-D013610
.	O
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Lymphadenopathy	B-D000072281
.	O
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo.	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia.	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria.	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
adverse	O
reactions	O
are	O
drowsiness	O
and	O
dizziness.	O
Less	O
frequent	O
adverse	O
reactions	O
are	O
lightheadedness	O
and	O
gastrointestinal	O
disturbances	O
including	O
nausea,	O
vomiting,	O
and	O
flatulence.	O
A	O
single	O
incidence	O
of	O
bone	O
marrow	O
suppression	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
and	O
caffeine	O
capsules.	O
Several	O
cases	O
of	O
dermatological	O
reactions	O
including	O
toxic	O
epidermal	O
necrolysis	O
and	O
erythema	O
multiforme	O
have	O
been	O
reported.	O
CONTRAINDICATIONS	O
AND	O
WARNINGS	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
CONTAINS	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL.	O
ADMINISTRATION	O
OF	O
MISOPROSTOL	O
TO	O
WOMEN	O
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
OR	O
BIRTH	O
DEFECTS.	O
UTERINE	O
RUPTURE	O
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	O
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	O
WOMEN	O
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O
BEYOND	O
THE	O
EIGHTH	O
WEEK	O
OF	O
PREGNANCY	O
(see	O
also	O
PRECAUTIONS	O
).	O
DICLOFENAC	O
SODIUM/MISOPROSTOL	O
TABLETS	O
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	O
WOMEN	O
(see	O
CONTRAINDICATIONS	O
,	O
WARNINGS	O
and	O
PRECAUTIONS	O
).	O
PATIENTS	O
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS.	O
DICLOFENAC	O
SODIUM/MISOPROSTOL	O
TABLETS	O
should	O
not	O
be	O
used	O
in	O
women	O
of	O
childbearing	O
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-­inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	O
of	O
developing	O
gastric	O
or	O
duodenal	O
ulceration	O
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	O
ulcers	O
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID	O
(see	O
WARNINGS	O
)	O
.	O
In	O
such	O
patients,	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
has	O
had	O
a	O
negative	O
serum	O
pregnancy	O
test	O
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy.	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures.	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	O
the	O
risk	O
of	O
possible	O
contraception	O
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	O
of	O
childbearing	O
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake.	O
will	O
begin	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	O
period.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS	O
).	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
Adverse	O
reactions	O
associated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
and	O
Misoprostol	B-D016595
Delayed-Release	O
Tablets	B-D013607
Adverse	O
reaction	O
information	O
for	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
is	O
derived	O
from	O
Phase	O
III	O
multinational	O
controlled	O
clinical	O
trials	O
in	O
over	O
2,000	O
patients	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets,	O
as	O
well	O
as	O
from	O
blinded,	O
controlled	O
trials	O
of	O
Voltaren	O
®	O
Delayed-Release	O
tablets	O
(diclofenac)	O
and	O
Cytotec	O
®	O
tablets	O
(misoprostol).	O
Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
incidence	O
of	O
adverse	O
events	O
for	O
patients	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets.	O
These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
patients	O
on	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
and	O
5%	O
of	O
patients	O
on	O
diclofenac.	O
For	O
GI	O
ulcer	O
rates,	O
see	O
CLINICAL	O
STUDIES	O
—	O
Upper	O
gastrointestinal	O
safety	O
.	O
GI	O
disorder	O
Diclofenac	B-D004008
Sodium	B-D012964
and	O
Misoprostol	B-D016595
Delayed-Release	O
Tablets	B-D013607
Diclofenac	B-D004008
Abdominal	O
pain	O
21%	O
15%	O
Diarrhea	B-D003967
19%	O
11%	O
Dyspepsia	B-D004415
14%	O
11%	O
Nausea	B-D009325
11%	O
6%	O
Flatulence	B-D005414
9%	O
4%	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
can	O
cause	O
more	O
abdominal	O
pain,	O
diarrhea,	O
and	O
other	O
GI	O
symptoms	O
than	O
diclofenac	O
alone.	O
Diarrhea	B-D003967
and	O
abdominal	O
pain	O
developed	O
early	O
in	O
the	O
course	O
of	O
therapy,	O
and	O
were	O
usually	O
self-limited	O
(resolved	O
after	O
2	O
to	O
7	O
days).	O
Rare	O
instances	O
of	O
profound	O
diarrhea	O
leading	O
to	O
severe	O
dehydration	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
misoprostol.	O
Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
disease,	O
or	O
those	O
in	O
whom	O
dehydration,	O
were	O
it	O
to	O
occur,	O
would	O
be	O
dangerous,	O
should	O
be	O
monitored	O
carefully	O
if	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
is	O
prescribed.	O
The	O
incidence	O
of	O
diarrhea	O
can	O
be	O
minimized	O
by	O
administering	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
with	O
food	O
and	O
by	O
avoiding	O
coadministration	O
with	O
magnesium-containing	O
antacids.	O
Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
misoprostol	O
use	O
have	O
also	O
been	O
reported	O
for	O
women	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
(see	O
below).	O
Postmenopausal	O
vaginal	O
bleeding	O
may	O
be	O
related	O
to	O
administration	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets.	O
If	O
it	O
occurs,	O
diagnostic	O
workup	O
should	O
be	O
undertaken	O
to	O
rule	O
out	O
gynecological	O
pathology	O
(see	O
boxed	O
CONTRAINDICATIONS	O
AND	O
WARNINGS	O
).	O
Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
safety	O
profile	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
in	O
over	O
500	O
patients	O
65	O
years	O
of	O
age	O
or	O
older	O
compared	O
with	O
younger	O
patients.	O
Other	O
adverse	O
experiences	O
reported	O
occasionally	O
or	O
rarely	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets,	O
diclofenac	O
or	O
other	O
NSAIDs,	O
or	O
misoprostol	O
are:	O
Body	O
as	O
a	O
whole:	O
Asthenia	B-D001247
,	O
death,	O
fatigue,	O
fever,	O
infection,	O
malaise,	O
sepsis,	O
chills,	O
edema.	O
Cardiovascular	O
system:	O
Arrhythmia,	O
atrial	O
fibrillation,	O
congestive	O
heart	O
failure,	O
hypertension,	O
hypotension,	O
increased	O
CPK,	O
increased	O
LDH,	O
myocardial	O
infarction,	O
palpitations,	O
phlebitis,	O
premature	O
ventricular	O
contractions,	O
syncope,	O
tachycardia,	O
vasculitis.	O
Central	O
and	O
peripheral	O
nervous	O
system:	O
Coma	B-D003128
,	O
convulsions,	O
dizziness,	O
drowsiness,	O
headache,	O
hyperesthesia,	O
hypertonia,	O
hypoesthesia,	O
insomnia,	O
meningitis,	O
migraine,	O
neuralgia,	O
paresthesia,	O
somnolence,	O
stroke,	O
tremor,	O
vertigo.	O
Congenital,	O
familial	O
and	O
genetic	O
disorders:	O
birth	O
defects	O
Digestive:	O
Anorexia	B-D000855
,	O
appetite	O
changes,	O
constipation,	O
dry	O
mouth,	O
dysphagia,	O
enteritis,	O
esophageal	O
ulceration,	O
esophagitis,	O
eructation,	O
gastritis,	O
gastroesophageal	O
reflux,	O
GI	O
bleeding,	O
GI	O
neoplasm	O
benign,	O
glossitis,	O
heartburn,	O
hematemesis,	O
hemorrhoids,	O
intestinal	O
perforation,	O
peptic	O
ulcer,	O
stomatitis	O
and	O
ulcerative	O
stomatitis,	O
tenesmus,	O
vomiting.	O
Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940
pain,	O
dysmenorrhea,	O
intermenstrual	O
bleeding,	O
leukorrhea,	O
menstrual	O
disorder,	O
menorrhagia,	O
vaginal	O
hemorrhage,	O
vaginitis,	O
uterine	O
cramping,	O
uterine	O
hemorrhage.	O
Hemic	O
and	O
lymphatic	O
system:	O
Agranulocytosis	B-D000380
,	O
anemia,	O
aplastic	O
anemia,	O
coagulation	O
time	O
increased,	O
ecchymosis,	O
eosinophilia,	O
epistaxis,	O
hemolytic	O
anemia,	O
leukocytosis,	O
leukopenia,	O
lymphadenopathy,	O
melena,	O
pancytopenia,	O
pulmonary	O
embolism,	O
purpura,	O
rectal	O
bleeding,	O
thrombocythemia,	O
thrombocytopenia,	O
decreased	O
hematocrit.	O
Hypersensitivity	B-D006967
:	O
Angioedema	B-D000799
,	O
laryngeal/pharyngeal	O
edema,	O
urticaria.	O
Liver	B-D008099
and	O
biliary	O
system:	O
Abnormal	O
hepatic	O
function,	O
bilirubinemia,	O
hepatitis,	O
jaundice,	O
liver	O
failure,	O
pancreatitis.	O
Male	B-D008297
reproductive	O
disorders:	O
Impotence,	O
perineal	O
pain.	O
Metabolic	O
and	O
nutritional:	O
Alanine	B-D000409
aminotransferase	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
aspartate	O
aminotransferase	O
increased,	O
BUN	O
increased,	O
dehydration,	O
glycosuria,	O
gout,	O
hypercholesterolemia,	O
hyperglycemia,	O
hyperuricemia,	O
hypoglycemia,	O
hyponatremia,	O
periorbital	O
edema,	O
porphyria,	O
weight	O
changes,	O
fluid	O
retention.	O
Musculoskeletal	O
system:	O
Arthralgia	B-D018771
,	O
myalgia.	O
Pregnancy	B-D011247
,	O
puerperium	O
and	O
perinatal	O
conditions	O
:	O
abnormal	O
uterine	O
contractions,	O
uterine	O
rupture/perforation,	O
retained	O
placenta,	O
amniotic	O
fluid	O
embolism,	O
incomplete	O
abortion,	O
premature	O
birth,	O
fetal	O
death.	O
Psychiatric:	O
Anxiety	B-D001007
,	O
concentration	O
impaired,	O
confusion,	O
depression,	O
disorientation,	O
dream	O
abnormalities,	O
hallucinations,	O
irritability,	O
nervousness,	O
paranoia,	O
psychotic	O
reaction.	O
Respiratory	O
system:	O
Asthma	B-D001249
,	O
coughing,	O
dyspnea,	O
hyperventilation,	O
pneumonia,	O
respiratory	O
depression.	O
Skin	B-D012867
and	O
appendages:	O
Acne,	O
alopecia,	O
bruising,	O
eczema,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
pemphigoid	O
reaction,	O
photosensitivity,	O
pruritus,	O
pruritus	O
ani,	O
rash,	O
skin	O
ulceration,	O
Stevens-Johnson	O
syndrome,	O
sweating	O
increased,	O
toxic	O
epidermal	O
necrolysis,	O
cutaneous	O
reactions	O
(bullous	O
eruption).	O
Special	O
senses:	O
Hearing	B-D006309
impairment,	O
taste	O
loss,	O
taste	O
perversion,	O
tinnitus.	O
Urinary	O
system:	O
Cystitis	B-D003556
,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
micturition	O
frequency,	O
nocturia,	O
nephrotic	O
syndrome,	O
oliguria/polyuria,	O
papillary	O
necrosis,	O
proteinuria,	O
renal	O
failure,	O
urinary	O
tract	O
infection,	O
glomerulonephritis	O
membranous,	O
glomerulonephritis	O
minimal	O
lesion.	O
Vision:	O
Amblyopia	B-D000550
,	O
blurred	O
vision,	O
conjunctivitis,	O
diplopia,	O
glaucoma,	O
iritis,	O
lacrimation	O
abnormal,	O
night	O
blindness,	O
vision	O
abnormal.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS	O
).	O
Diclofenac	B-D004008
Sodium	B-D012964
Extended-release	O
Tablets	B-D013607
,	O
USP	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
extended-release	O
tablets,	O
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure.	O
Other	O
adverse	O
reactions	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs1	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS.)	O
Etodolac	B-D017308
extended-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(See	O
WARNINGS.)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS.)	O
1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug.	O
ADVERSE	O
REACTIONS	O
A	O
total	O
of	O
1552	O
patients	O
were	O
exposed	O
to	O
etodolac	O
extended-release	O
tablets	O
in	O
controlled	O
clinical	O
studies	O
of	O
at	O
least	O
4	O
weeks	O
in	O
length	O
and	O
using	O
daily	O
doses	O
in	O
the	O
range	O
of	O
400	O
to	O
1200	O
mg.	O
In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
incidence	O
of	O
events	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	O
extended-release	O
tablets.	O
As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
time	O
with	O
extended	O
therapy.	O
In	O
patients	O
taking	O
NSAIDs,	O
including	O
etodolac	O
extended-release	O
tablets,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain	O
constipation	O
diarrhea	O
dyspepsia	O
flatulence	O
GI	O
ulcers	O
(gastric/duodenal)*	O
gross	O
bleeding/perforation*	O
nausea	O
vomiting	O
other	O
events	O
including:	O
abnormal	O
renal	O
function*	O
anemia*	O
asthenia	O
dizziness	O
edema*	O
elevated	O
liver	O
enzymes*	O
headaches	O
hypertension	O
increased	O
bleeding	O
time*	O
infection	O
pharyngitis	O
pruritus	O
rashes	O
rhinitis	O
tinnitus*	O
*	O
Adverse	O
events	O
that	O
were	O
observed	O
in	O
<	O
1%	O
of	O
patients	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	O
extended-release	O
tablets	O
in	O
clinical	O
trials.	O
Additional	O
NSAID	O
Adverse	O
Experiences	O
Reported	O
Occasionally	O
with	O
NSAIDs	O
or	O
Etodolac	B-D017308
Extended-Release	O
Tablets	B-D013607
Include	O
Body	O
as	O
a	O
whole	O
-	O
allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock),	O
chills,	O
fever,	O
sepsis	O
Cardiovascular	O
system	O
-	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
tachycardia,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic)	O
Digestive	O
system	O
-	O
anorexia,	O
cholestatic	O
hepatitis,	O
cholestatic	O
jaundice,	O
dry	O
mouth,	O
duodenitis,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastric/peptic	O
ulcers,	O
glossitis,	O
hepatic	O
failure,	O
hepatitis,	O
hematemesis,	O
intestinal	O
ulceration,	O
jaundice,	O
liver	O
necrosis,	O
melena,	O
pancreatitis,	O
rectal	O
bleeding,	O
stomatitis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
agranulocytosis,	O
ecchymosis,	O
eosinophilia,	O
hemolytic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia,	O
purpura,	O
thrombocytopenia	O
Metabolic	O
and	O
nutritional	O
-	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients	O
Nervous	O
system	O
-	O
anxiety,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
insomnia,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
asthma,	O
dyspnea,	O
pulmonary	O
infiltration	O
with	O
eosinophilia	O
Skin	B-D012867
and	O
appendages	O
-	O
angioedema,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
erythema	O
multiforme,	O
hyperpigmentation,	O
sweating,	O
urticaria,	O
vesiculobullous	O
rash	O
Special	O
senses	O
-	O
blurred	O
vision,	O
photophobia,	O
transient	O
visual	O
disturbances	O
Urogenital	O
system	O
-	O
dysuria,	O
elevated	O
BUN,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis,	O
serum	O
creatinine	O
increase,	O
urinary	O
frequency	O
Other	O
NSAID	O
Adverse	O
Reactions,	O
Which	O
Occur	O
Rarely	O
Are	O
Body	O
as	O
a	O
whole	O
-	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	O
system	O
-	O
arrhythmia,	O
cerebrovascular	O
accident,	O
hypotension,	O
myocardial	O
infarction	O
Digestive	O
system	O
-	O
colitis,	O
esophagitis	O
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
thirst,	O
ulcerative	O
stomatitis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
aplastic	O
anemia,	O
lymphadenopathy	O
Metabolic	O
and	O
nutritional	O
-	O
change	O
in	O
weight	O
Nervous	O
system	O
-	O
coma,	O
convulsions,	O
hallucinations,	O
meningitis	O
Respiratory	O
-	O
bronchitis,	O
pneumonia,	O
respiratory	O
depression,	O
sinusitis	O
Skin	B-D012867
and	O
appendages	O
-	O
alopecia,	O
exfoliative	O
dermatitis,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrosis	O
Special	O
senses	O
-	O
conjunctivitis,	O
deafness,	O
hearing	O
impairment,	O
taste	O
perversion	O
Urogenital	O
system	O
-	O
cystitis,	O
hematuria,	O
interstitial	O
nephritis,	O
leukorrhea,	O
renal	O
calculus,	O
uterine	O
bleeding	O
irregularities	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
1.Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(See	O
WARNINGS	O
and	O
PRECAUTIONS).	O
2.IBU	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(See	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
1.NSAIDS	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinaladverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforationof	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
eventscan	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinalevents.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
withIbuprofen	O
tablets	O
is	O
gastrointestinal.	O
In	O
controlled	O
clinical	O
trials	O
thepercentage	O
of	O
patients	O
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaintsranged	O
from	O
4%	O
to	O
16%.	O
In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	O
were	O
compared	O
toaspirin	O
and	O
indomethacin	O
in	O
equally	O
effective	O
doses,	O
the	O
overall	O
incidenceof	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
eitherthe	O
aspirin-	O
or	O
indomethacin-treated	O
patients.	O
Adverse	O
reactions	O
observed	O
during	O
controlled	O
clinical	O
trials	O
at	O
anincidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table.	O
Those	O
reactions	O
listedin	O
Column	O
one	O
encompass	O
observations	O
in	O
approximately	O
3,000patients.	O
More	O
than	O
500	O
of	O
these	O
patients	O
were	O
treated	O
for	O
periods	O
ofat	O
least	O
54	O
weeks.	O
Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
werereported	O
in	O
controlled	O
clinical	O
trials	O
and	O
from	O
marketing	O
experience.These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
twoof	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	O
wherethe	O
probability	O
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
inColumn	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	O
has	O
notbeen	O
established.	O
Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
thanat	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	O
trials	O
of	O
patients	O
withrheumatoid	O
arthritis.	O
The	O
increases	O
in	O
incidence	O
were	O
slight	O
and	O
stillwithin	O
the	O
ranges	O
reported	O
in	O
the	O
table.	O
table	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Diclofenac	B-D004008
sodium	O
gel,	O
3%	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
423	O
patients	O
evaluable	O
for	O
safety	O
in	O
adequate	O
and	O
well-controlled	O
trials,	O
211	O
were	O
treated	O
with	O
diclofenac	O
sodium	O
gel,	O
3%	O
drug	O
product	O
and	O
212	O
were	O
treated	O
with	O
a	O
vehicle	O
gel.	O
Eighty-seven	O
percent	O
(87%)	O
of	O
the	O
diclofenac	O
sodium	O
gel,	O
3%-treated	O
patients	O
(183	O
patients)	O
and	O
84%	O
of	O
the	O
vehicle-treated	O
patients	O
(178	O
patients)	O
experienced	O
one	O
or	O
more	O
adverse	O
events	O
(AEs)	O
during	O
the	O
studies.	O
The	O
majority	O
of	O
these	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
upon	O
discontinuation	O
of	O
therapy.	O
Of	O
the	O
211	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
gel,	O
3%,	O
172	O
(82%)	O
experienced	O
AEs	O
involving	O
skin	O
and	O
the	O
application	O
site	O
compared	O
to	O
160	O
(75%)	O
vehicle-treated	O
patients.	O
Application	O
site	O
reactions	O
(ASRs)	O
were	O
the	O
most	O
frequent	O
AEs	O
in	O
both	O
diclofenac	O
sodium	O
gel,	O
3%-and	O
vehicle-treated	O
groups.	O
Of	O
note,	O
four	O
reactions,	O
contact	O
dermatitis,	O
rash,	O
dry	O
skin	O
and	O
exfoliation	O
(scaling)	O
were	O
significantly	O
more	O
prevalent	O
in	O
the	O
diclofenac	O
sodium	O
gel,	O
3%	O
group	O
than	O
in	O
the	O
vehicle-treated	O
patients.	O
Eighteen	O
percent	O
of	O
diclofenac	O
sodium	O
gel,	O
3%-treated	O
patients	O
and	O
4%	O
of	O
vehicle-treated	O
patients	O
discontinued	O
from	O
the	O
clinical	O
trials	O
due	O
to	O
adverse	O
events	O
(whether	O
considered	O
related	O
to	O
treatment	O
or	O
not).	O
These	O
discontinuations	O
were	O
mainly	O
due	O
to	O
skin	O
irritation	O
or	O
related	O
cutaneous	O
adverse	O
reactions.	O
Table	O
1	O
below	O
presents	O
the	O
AEs	O
reported	O
at	O
an	O
incidence	O
of	O
greater	O
than	O
1%	O
for	O
patients	O
treated	O
with	O
either	O
diclofenac	O
sodium	O
gel,	O
3%	O
or	O
vehicle	O
(60-	O
and	O
90-day	O
treatment	O
groups)	O
during	O
the	O
phase	O
3	O
studies.	O
Table	O
1.	O
Adverse	O
Events	O
Reported	O
(Greater	O
Than	O
1%	O
in	O
Any	O
Treatment	O
Group)	O
During	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
Phase	O
3	O
Clinical	B-D016430
Trial	I-D016430
s	O
Incidence	B-D015994
s	O
for	O
60-Day	O
and	O
90-Day	O
Treatments	O
60-day	O
Treatment	O
90-day	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
(%)	O
Gel	O
Vehicle	O
(%)	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
(%)	O
Gel	O
Vehicle	O
(%)	O
N=48	O
N=49	O
N=114	O
N=114	O
BODY	O
AS	O
A	O
WHOLE	O
21	O
20	O
20	O
18	O
Abdominal	B-D015746
Pain	I-D015746
2	O
0	O
1	O
0	O
Accidental	O
Injury	O
0	O
0	O
4	O
2	O
Allergic	O
Reaction	O
0	O
0	O
1	O
3	O
Asthenia	B-D001247
0	O
0	O
2	O
0	O
Back	B-D001416
Pain	I-D001416
4	O
0	O
2	O
2	O
Chest	B-D002637
Pain	I-D002637
2	O
0	O
1	O
0	O
Chills	B-D023341
0	O
2	O
0	O
0	O
Flu	O
Syndrome	B-D013577
10	O
6	O
1	O
4	O
Headache	B-D006261
0	O
6	O
7	O
6	O
Infection	O
4	O
6	O
4	O
5	O
Neck	B-D019547
Pain	I-D019547
0	O
0	O
2	O
0	O
Pain	B-D010146
2	O
0	O
2	O
2	O
CARDIOVASCULAR	O
SYSTEM	O
2	O
4	O
3	O
1	O
Hypertension	B-D006973
2	O
0	O
1	O
0	O
Migraine	O
0	O
2	O
1	O
0	O
Phlebitis	B-D010689
0	O
2	O
0	O
0	O
DIGESTIVE	O
SYSTEM	O
4	O
0	O
6	O
8	O
Constipation	B-D003248
0	O
0	O
0	O
2	O
Diarrhea	B-D003967
2	O
0	O
2	O
3	O
Dyspepsia	B-D004415
2	O
0	O
3	O
4	O
METABOLICS	O
AND	O
NUTRITIONAL	O
DISORDERS	O
2	O
8	O
7	O
2	O
Creatine	B-D003401
Phosphokinase	O
Increased	O
0	O
0	O
4	O
1	O
Creatinine	B-D003404
Increased	O
2	O
2	O
0	O
1	O
Edema	B-D004487
0	O
2	O
0	O
0	O
Hypercholesteremia	O
0	O
2	O
1	O
0	O
Hyperglycemia	B-D006943
0	O
2	O
1	O
0	O
SGOT	O
Increased	O
0	O
0	O
3	O
0	O
SGPT	O
Increased	O
0	O
0	O
2	O
0	O
MUSCULOSKELETAL	O
SYSTEM	O
4	O
0	O
3	O
4	O
Arthralgia	B-D018771
2	O
0	O
0	O
2	O
Art	B-D001154
hrosis	O
2	O
0	O
0	O
0	O
Myalgia	B-D063806
2	O
0	O
3	O
1	O
NERVOUS	O
SYSTEM	O
2	O
2	O
2	O
5	O
Anxiety	B-D001007
0	O
2	O
0	O
1	O
Dizziness	B-D004244
0	O
0	O
0	O
4	O
Hypokinesia	B-D018476
2	O
0	O
0	O
0	O
RESPIRATORY	O
SYSTEM	O
8	O
8	O
7	O
6	O
Asthma	B-D001249
2	O
0	O
0	O
0	O
Dyspnea	B-D004417
2	O
0	O
2	O
0	O
Pharyngitis	B-D010612
2	O
8	O
2	O
4	O
Pneumonia	B-D011014
2	O
0	O
0	O
1	O
Rhinitis	B-D012220
2	O
2	O
2	O
2	O
Sinusitis	B-D012852
0	O
0	O
2	O
0	O
SKIN	O
AND	O
APPENDAGES	O
75	O
86	O
86	O
71	O
Acne	O
0	O
2	O
0	O
1	O
Application	O
Site	O
Reaction	O
75	O
71	O
84	O
70	O
Acne	O
0	O
4	O
1	O
0	O
Alopecia	B-D000505
2	O
0	O
1	O
1	O
Contact	O
Dermatitis	B-D003872
19	O
4	O
33	O
4	O
Dry	O
Skin	B-D012867
27	O
12	O
25	O
17	O
Edema	B-D004487
4	O
0	O
3	O
0	O
Exfoliation	O
6	O
4	O
24	O
13	O
Hyperesthesia	B-D006941
0	O
0	O
3	O
1	O
Pain	B-D010146
15	O
22	O
26	O
30	O
Paresthesia	B-D010292
8	O
4	O
20	O
20	O
Photosensitivity	O
Reaction	O
0	O
2	O
3	O
0	O
Pruritus	B-D011537
31	O
59	O
52	O
45	O
Rash	O
35	O
20	O
46	O
17	O
Vesiculobullous	O
Rash	O
0	O
0	O
4	O
1	O
Contact	O
Dermatitis	B-D003872
2	O
0	O
0	O
0	O
Dry	O
Skin	B-D012867
0	O
4	O
3	O
0	O
Herpes	B-D006561
Simplex	I-D006561
0	O
2	O
0	O
0	O
Maculopapular	O
Rash	O
0	O
2	O
0	O
0	O
Pain	B-D010146
2	O
2	O
1	O
0	O
Pruritus	B-D011537
4	O
6	O
4	O
1	O
Rash	O
2	O
10	O
4	O
0	O
Skin	B-D012867
Carcinoma	B-D002277
0	O
6	O
2	O
2	O
Skin	B-D012867
Nodule	O
0	O
2	O
0	O
0	O
Skin	B-D012883
Ulcer	I-D012883
2	O
0	O
1	O
0	O
SPECIAL	O
SENSES	O
2	O
0	O
4	O
2	O
Conjunctivitis	B-D003231
2	O
0	O
4	O
1	O
Eye	B-D058447
Pain	I-D058447
0	O
2	O
2	O
0	O
UROGENITAL	O
SYSTEM	O
0	O
0	O
4	O
5	O
Hematuria	B-D006417
0	O
0	O
2	O
1	O
OTHER	O
0	O
0	O
0	O
3	O
Procedure	O
0	O
0	O
0	O
3	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Events	O
Reported	O
for	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
at	O
Less	O
Than	O
1%	O
Incidence	B-D015994
in	O
the	O
Phase	O
3	O
Studies:	O
skin	O
hypertrophy,	O
paresthesia,	O
seborrhea,	O
urticaria,	O
application	O
site	O
reactions	O
(skin	O
carcinoma,	O
hypertonia,	O
skin	O
hypertrophy	O
lacrimation	O
disorder,	O
maculopapular	O
rash,	O
purpuric	O
rash,	O
vasodilation).	O
Adverse	O
Reactions	O
Reported	O
for	O
Oral	O
Diclofenac	B-D004008
Dosage	O
Form	B-D020478
(not	O
topical	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%):	O
*Incidence	O
greater	O
than	O
1%	O
marked	O
with	O
asterisk.	O
Body	O
as	O
a	O
Whole:	O
abdominal	O
pain	O
or	O
cramps*,	O
headache*,	O
fluid	O
retention*,	O
abdominal	O
distention*,	O
malaise,	O
swelling	O
of	O
lips	O
and	O
tongue,	O
photosensitivity,	O
anaphylaxis,	O
anaphylactoid	O
reactions,	O
chest	O
pain.	O
Cardiovascular:	O
hypertension,	O
congestive	O
heart	O
failure,	O
palpitations,	O
flushing,	O
tachycardia,	O
premature	O
ventricular	O
contractions,	O
myocardial	O
infarction,	O
hypotension.	O
Digestive:	O
diarrhea*,	O
indigestion*,	O
nausea*,	O
constipation*,	O
flatulence*,	O
liver	O
test	O
abnormalities*,	O
PUB*,	O
i.e.,	O
peptic	O
ulcer,	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
or	O
bleeding	O
without	O
ulcer,	O
vomiting,	O
jaundice,	O
melena,	O
esophageal	O
lesions,	O
aphthous	O
stomatitis,	O
dry	O
mouth	O
and	O
mucous	O
membranes,	O
bloody	O
diarrhea,	O
hepatitis,	O
hepatic	O
necrosis,	O
cirrhosis,	O
hepatorenal	O
syndrome,	O
appetite	O
change,	O
pancreatitis	O
with	O
or	O
without	O
concomitant	O
hepatitis,	O
colitis,	O
intestinal	O
perforation.	O
Hemic	O
and	O
Lymph	B-D008196
atic:	O
hemoglobin	O
decrease,	O
leukopenia,	O
thrombocytopenia,	O
eosinophilia,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
agranulocytosis,	O
purpura,	O
allergic	O
purpura,	O
bruising.	O
Metabolic	O
and	O
Nutritional	O
Disorders:	O
azotemia,	O
hypoglycemia,	O
weight	O
loss.	O
Nervous	B-D009420
System	I-D009420
:	O
dizziness*,	O
insomnia,	O
drowsiness,	O
depression,	O
diplopia,	O
anxiety,	O
irritability,	O
aseptic	O
meningitis,	O
convulsions,	O
paresthesia,	O
memory	O
disturbance,	O
nightmares,	O
tremor,	O
tic,	O
abnormal	O
coordination,	O
disorientation,	O
psychotic	O
reaction.	O
Respiratory:	O
epistaxis,	O
asthma,	O
laryngeal	O
edema,	O
dyspnea,	O
hyperventilation,	O
edema	O
of	O
pharynx.	O
Skin	B-D012867
and	O
Appendages:	O
rash*,	O
pruritus*,	O
alopecia,	O
urticaria,	O
eczema,	O
dermatitis,	O
bullous	O
eruption,	O
erythema	O
multiforme	O
major,	O
angioedema,	O
Stevens-Johnson	O
syndrome,	O
excess	O
perspiration,	O
exfoliative	O
dermatitis.	O
Special	O
Senses:	O
tinnitus*,	O
blurred	O
vision,	O
taste	O
disorder,	O
reversible	O
and	O
irreversible	O
hearing	O
loss,	O
scotoma,	O
vitreous	O
floaters,	O
night	O
blindness,	O
amblyopia.	O
Urogenital:	O
nephrotic	O
syndrome,	O
proteinuria,	O
oliguria,	O
interstitial	O
nephritis,	O
papillary	O
necrosis,	O
acute	O
renal	O
failure,	O
urinary	O
frequency,	O
nocturia,	O
hematuria,	O
impotence,	O
vaginal	O
bleeding.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS).	O
•Diclofenac	O
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS	O
)	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
•Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
•Hypertension	O
(see	O
WARNINGS	O
)	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
•Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
•Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
•Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
NAPROSYN	O
Suspension	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1	O
Cardiovascular	O
Thrombotic	O
Events)].	O
NAPROSYN	O
Suspension	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.1	O
Cardiovascular	O
Thrombotic	O
Events)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop.	O
(5.3	O
Hepatotoxicity)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure.	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
NAPROSYN	O
Suspension	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure.	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
NAPROSYN	O
Suspension	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function.	O
(5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
NAPROSYN	O
Suspension	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity).	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
NAPROSYN	O
Suspension	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity.	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation.	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia.	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
naproxen,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
NAPROSYN	O
Suspension	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
NAPROSYN	O
Suspension	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
naproxen,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDS.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
NAPROSYN	O
Suspension	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
naproxen.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flulike"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
NAPROSYN	O
Suspension	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
NAPROSYN	O
Suspension,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
naproxen	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
NAPROSYN	O
Suspension	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
NAPROSYN	O
Suspension	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
Each	O
5	O
mL	O
of	O
NAPROSYN	O
Suspension	O
contains	O
39	O
mg	O
of	O
sodium.	O
This	O
should	O
be	O
considered	O
in	O
patients	O
whose	O
overall	O
intake	O
of	O
sodium	O
must	O
be	O
severely	O
restricted.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
NAPROSYN	O
Suspension	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
NAPROSYN	O
Suspension	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
NAPROSYN	O
Suspension.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
NAPROSYN	O
Suspension	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
NAPROSYN	O
Suspension	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
NAPROSYN	O
Suspension	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Naproxen	B-D009288
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
naproxen	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)]	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
NAPROSYN	O
Suspension	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].When	O
NAPROSYN	O
Suspension	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
naproxen	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
NAPROSYN	O
Suspension	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
NAPROSYN	O
Suspension	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Naproxen	B-D009288
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
NAPROSYN	O
Suspension,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
NAPROSYN	O
Suspension	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
NAPROSYN	O
Suspension,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Concomitant	O
use	O
of	O
warfarin	O
and	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs),	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
NAPROSYN	O
Suspension	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Long-Term	O
Use	O
and	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3	O
Hepatotoxicity,	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
)].	O
Patients	B-D010361
with	O
initial	O
hemoglobin	O
values	O
of	O
10	O
g	O
or	O
less	O
who	O
are	O
to	O
receive	O
long-term	O
therapy	O
should	O
have	O
hemoglobin	O
values	O
determined	O
periodically.	O
Because	O
of	O
adverse	O
eye	O
findings	O
in	O
animal	O
studies	O
with	O
drugs	O
of	O
this	O
class,	O
it	O
is	O
recommended	O
that	O
ophthalmic	O
studies	O
be	O
carried	O
out	O
if	O
any	O
change	O
or	O
disturbance	O
in	O
vision	O
occurs.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1	O
Cardiovascular	O
Thrombotic	O
Events)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3	O
Hepatotoxicity)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4	O
Hypertension	B-D006973
)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
to	O
naproxen	O
were	O
dyspepsia,	O
abdominal	O
pain,	O
nausea,	O
headache,	O
rash,	O
ecchymosis,	O
and	O
edema.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Athena	O
Bioscience	O
LLC	O
at	O
1-833-284-3622or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Adverse	O
reactions	O
reported	O
in	O
controlled	O
clinical	O
trials	O
in	O
960	O
patients	O
treated	O
for	O
rheumatoid	O
arthritis	O
or	O
osteoarthritis	O
are	O
listed	O
below.	O
In	O
general,	O
reactions	O
in	O
patients	O
treated	O
chronically	O
were	O
reported	O
2	O
to	O
10	O
times	O
more	O
frequently	O
than	O
they	O
were	O
in	O
short-term	O
studies	O
in	O
the	O
962	O
patients	O
treated	O
for	O
mild	O
to	O
moderate	O
pain	O
or	O
for	O
dysmenorrhea.	O
The	O
most	O
frequent	O
complaints	O
reported	O
related	O
to	O
the	O
gastrointestinal	O
tract.	O
A	O
clinical	O
study	O
found	O
gastrointestinal	O
reactions	O
to	O
be	O
more	O
frequent	O
and	O
more	O
severe	O
in	O
rheumatoid	O
arthritis	O
patients	O
taking	O
daily	O
doses	O
of	O
1500	O
mg	O
naproxen	O
compared	O
to	O
those	O
taking	O
750	O
mg	O
naproxen.	O
In	O
controlled	O
clinical	O
trials	O
with	O
about	O
80	O
pediatric	O
patients	O
and	O
in	O
well-monitored,	O
open-label	O
studies	O
with	O
about	O
400	O
pediatric	O
patients	O
with	O
polyarticular	O
juvenile	O
idiopathic	O
arthritis	O
treated	O
with	O
naproxen,	O
the	O
incidence	O
of	O
rash	O
and	O
prolonged	O
bleeding	O
times	O
were	O
greater,	O
the	O
incidence	O
of	O
gastrointestinal	O
and	O
central	O
nervous	O
system	O
reactions	O
were	O
about	O
the	O
same,	O
and	O
the	O
incidence	O
of	O
other	O
reactions	O
were	O
lower	O
in	O
pediatric	O
patients	O
than	O
in	O
adults.	O
In	O
patients	O
taking	O
naproxen	O
in	O
clinical	O
trials,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
(GI)	O
Experiences,	O
including:	O
heartburn*,	O
abdominal	O
pain*,	O
nausea*,	O
constipation*,	O
diarrhea,	O
dyspepsia,	O
stomatitis	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
headache*,	O
dizziness*,	O
drowsiness*,	O
lightheadedness,	O
vertigo	O
Dermatologic:	O
pruritus	O
(itching)*,	O
skin	O
eruptions*,	O
ecchymoses*,	O
sweating,	O
purpura	O
Special	O
Senses:	O
tinnitus*,	O
visual	O
disturbances,	O
hearing	O
disturbances	O
Cardiovascular:	O
edema*,	O
palpitations	O
General:	O
dyspnea*,	O
thirst	O
*Incidence	O
of	O
reported	O
reaction	O
between	O
3%	O
and	O
9%.	O
Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.	O
In	O
patients	O
taking	O
NSAIDs,	O
the	O
following	O
adverse	O
experiences	O
have	O
also	O
been	O
reported	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients.	O
Gastrointestinal	O
(GI)	O
Experiences,	O
including:	O
flatulence,	O
gross	O
bleeding/perforation,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting	O
General:	O
abnormal	O
renal	O
function,	O
anemia,	O
elevated	O
liver	O
enzymes,	O
increased	O
bleeding	O
time,	O
rashes	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
naproxen.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
The	O
following	O
are	O
additional	O
adverse	O
experiences	O
reported	O
in	O
<1%	O
of	O
patients	O
taking	O
naproxen	O
during	O
clinical	O
trials	O
and	O
through	O
postmarketing	O
reports.	O
Those	O
adverse	O
reactions	O
observed	O
through	O
postmarketing	O
reports	O
are	O
italicized.	O
Body	O
as	O
a	O
Whole:	O
anaphylactoid	O
reactions,	O
angioneurotic	O
edema,	O
menstrual	O
disorders,	O
pyrexia	O
(chills	O
and	O
fever)	O
Cardiovascular:	O
congestive	O
heart	O
failure,	O
vasculitis,	O
hypertension,	O
pulmonary	O
edema	O
Gastrointestinal:	O
inflammation,	O
bleeding	O
(sometimes	O
fatal,	O
particularly	O
in	O
the	O
elderly),	O
ulceration,	O
perforation	O
and	O
obstruction	O
of	O
the	O
upper	O
or	O
lower	O
gastrointestinal	O
tract.	O
Esophagitis	B-D004941
,	O
stomatitis,	O
hematemesis,	O
pancreatitis,	O
vomiting,	O
colitis,	O
exacerbation	O
of	O
inflammatory	O
bowel	O
disease	O
(ulcerative	O
colitis,	O
Crohn’s	O
disease).	O
Hepatobiliary:	O
jaundice,	O
abnormal	O
liver	O
function	O
tests,	O
hepatitis	O
(some	O
cases	O
have	O
been	O
fatal)	O
Hemic	O
and	O
Lymph	B-D008196
atic:	O
eosinophilia,	O
leucopenia,	O
melena,	O
thrombocytopenia,	O
agranulocytosis,	O
granulocytopenia,	O
hemolytic	O
anemia,	O
aplastic	O
anemia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia,	O
hypoglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
inability	O
to	O
concentrate,	O
depression,	O
dream	O
abnormalities,	O
insomnia,	O
malaise,	O
myalgia,	O
muscle	O
weakness,	O
aseptic	O
meningitis,	O
cognitive	O
dysfunction,	O
convulsions	O
Respiratory:	O
eosinophilic	O
pneumonitis,	O
asthma	O
Dermatologic:	O
alopecia,	O
urticaria,	O
skin	O
rashes,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
erythema	O
nodosum,	O
fixed	O
drug	O
eruption,	O
lichen	O
planus,	O
pustular	O
reaction,	O
systemic	O
lupus	O
erythematoses,	O
bullous	O
reactions,	O
including	O
Stevens-Johnson	O
syndrome,	O
photosensitive	O
dermatitis,	O
photosensitivity	O
reactions,	O
including	O
rare	O
cases	O
resembling	O
porphyria	O
cutanea	O
tarda	O
(pseudoporphyria)	O
or	O
epidermolysis	O
bullosa.	O
If	O
skin	O
fragility,	O
blistering	O
or	O
other	O
symptoms	O
suggestive	O
of	O
pseudoporphyria	O
occur,	O
treatment	O
should	O
be	O
discontinued	O
and	O
the	O
patient	O
monitored.	O
Special	O
Senses:	O
hearing	O
impairment,	O
corneal	O
opacity,	O
papillitis,	O
retrobulbar	O
optic	O
neuritis,	O
papilledema	O
Urogenital:	O
glomerular	O
nephritis,	O
hematuria,	O
hyperkalemia,	O
interstitial	O
nephritis,	O
nephrotic	O
syndrome,	O
renal	O
disease,	O
renal	O
failure,	O
renal	O
papillary	O
necrosis,	O
raised	O
serum	O
creatinine	O
Reproduction	B-D012098
(female):	O
infertility	O
In	O
patients	O
taking	O
NSAIDs,	O
the	O
following	O
adverse	O
experiences	O
have	O
also	O
been	O
reported	O
in	O
<1%	O
of	O
patients.	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis,	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular:	O
hypertension,	O
tachycardia,	O
syncope,	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction	O
Gastrointestinal:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
glossitis,	O
eructation	O
Hepatobiliary:	O
hepatitis,	O
liver	O
failure	O
Hemic	O
and	O
Lymph	B-D008196
atic:	O
rectal	O
bleeding,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
convulsions,	O
coma,	O
hallucinations	O
Respiratory:	O
asthma,	O
respiratory	O
depression,	O
pneumonia	O
Dermatologic:	O
exfoliative	O
dermatitis	O
Special	O
Senses:	O
blurred	O
vision,	O
conjunctivitis	O
Urogenital:	O
cystitis,	O
dysuria,	O
oliguria/polyuria,	O
proteinuria	O
Adverse	O
Reactions	O
The	O
most	O
commonly	O
reported	O
adverse	O
experiences	O
reported	O
following	O
use	O
of	O
bromfenac	B-C053083
ophthalmic	O
solution	O
after	O
cataract	O
surgery	O
include:	O
abnormal	O
sensation	O
in	O
eye,	O
conjunctival	O
hyperemia,	O
eye	O
irritation	O
(including	O
burning/stinging),	O
eye	O
pain,	O
eye	O
pruritus,	O
eye	O
redness,	O
headache,	O
and	O
iritis.	O
These	O
events	O
were	O
reported	O
in	O
2-7%	O
of	O
patients.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.(5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity	O
:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity	O
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions	O
:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
:	O
Celecoxib	B-D000068579
capsules	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions	O
:	O
Discontinue	O
celecoxib	O
capsules	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity	O
:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	O
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
for	O
the	O
celecoxib	O
capsules	O
400	O
mg	O
twice	O
daily	O
and	O
celecoxib	O
capsules	O
200	O
mg	O
twice	O
daily	O
treatment	O
arms	O
compared	O
to	O
placebo.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.7	O
)].	O
A	O
randomized	O
controlled	O
trial	O
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs.	O
Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	O
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	O
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	O
and	O
ibuprofen.	O
Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	O
375	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	O
600	O
to	O
800	O
mg	O
three	O
times	O
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists'	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	O
(including	O
hemorrhagic	O
death),	O
non-fatal	O
myocardial	O
infarction,	O
and	O
non-fatal	O
stroke	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
celecoxib	O
capsules.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	O
anticoagulants;	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.7)].	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	O
capsules	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib	O
capsules,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
capsules	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
capsules	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
discontinue	O
celecoxib	O
capsules	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	O
capsules	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
blood	O
pressure	O
data	O
for	O
celecoxib	O
capsules.	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
celecoxib	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
capsules	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE	O
inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
celecoxib	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
celecoxib	O
capsules.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
celecoxib	O
capsules	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
celecoxib	O
and	O
in	O
patients	O
with	O
aspirin	O
sensitive	O
asthma.	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	O
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	O
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib	O
capsules,	O
including	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(AGEP).	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	O
capsules	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Celecoxib	B-D000068579
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
celecoxib	O
capsules	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
capsules	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
capsules	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	O
SSRIs	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
capsules	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation	O
with	O
use	O
of	O
celecoxib	O
capsules	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	O
and	O
their	O
caregivers	O
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible.	O
6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
NorthStar	O
Rx	O
LLC	O
at	O
1-800-206-7821	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labelling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
capsules	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
capsules	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
capsules	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
$	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Celecoxib	B-D000068579
=	O
Celecoxib	B-D000068579
capsules	O
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Celecoxib	B-D000068579
(N=4146)	O
Placebo	O
(N=1864)	O
NAP	O
(N=1366)	O
DCF	O
(N=387)	O
IBU	O
(N=345)	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
capsules	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
capsules	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
Capsules	B-D002214
(100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular	O
:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
Allergy	O
General	O
:	O
Hypersensitivity	B-D006967
,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
blood	O
urea	O
nitrogen	O
(BUN)	O
increased,	O
creatine	O
phosphokinase	O
(CPK)	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis	O
ileus	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
,	O
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia	B-D001259
,	O
suicide	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)	O
]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Clinical	O
Studies	O
(14.7)]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
capsules	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
capsules	O
was	O
maintained	O
with	O
or	O
without	O
aspirin	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)].	O
Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
twice	O
daily.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
$	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
*Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
capsules	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
capsules	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
capsules	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
capsules	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.7)].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
capsules	O
pre-marketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
capsules	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
Capsules	B-D002214
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib	O
capsules,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
celecoxib	O
capsules.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis	B-D014657
,	O
deep	O
venous	O
thrombosis	O
General:	O
Anaphylactoid	O
reaction,	O
angioedema	O
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	O
hepatitis,	O
jaundice,	O
hepatic	O
failure	O
Hemic	O
and	O
lymphatic	O
Agranulocytosis	B-D000380
,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
Renal	O
Interstitial	O
nephritis	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)].	O
Indomethacin	B-D007213
Capsules	B-D002214
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)].	O
WARNING:	O
RISK	O
OF	O
SERIOUD	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(	O
5.1	O
)	O
Indomethacin	B-D007213
Capsules	B-D002214
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(	O
4	O
,	O
5.1	O
)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(	O
5.2	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity	O
:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(	O
5.3	O
)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(	O
5.4	O
,	O
7	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
indomethacin	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(	O
5.5	O
)	O
Renal	O
Toxicity	O
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
indomethacin	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(	O
5.6	O
)	O
Anaphylactic	O
Reactions	O
:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7	O
)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
:	O
Indomethacin	B-D007213
Capsules	B-D002214
are	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(	O
5.8	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
:	O
Discontinue	O
indomethacin	O
capsules	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(	O
5.9	O
)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(	O
5.10	O
,	O
8.1	O
)	O
Hematologic	O
Toxicity	O
:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(	O
5.11	O
,	O
7	O
)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
indomethacin,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
indomethacin	O
capsules	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
indomethacin	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
indomethacin,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients	O
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
indomethacin	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
indomethacin.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
indomethacin	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
indomethacin	O
capsules,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
indomethacin	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
Avoid	O
the	O
use	O
of	O
indomethacin	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
indomethacin	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
indomethacin	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
indomethacin	O
capsules	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
indomethacin	O
capsules.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
indomethacin	O
capsules	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
Avoid	O
the	O
use	O
of	O
indomethacin	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
indomethacin	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
It	O
has	O
been	O
reported	O
that	O
the	O
addition	O
of	O
the	O
potassium-sparing	O
diuretic,	O
triamterene,	O
to	O
a	O
maintenance	O
schedule	O
of	O
indomethacin	O
resulted	O
in	O
reversible	O
acute	O
renal	O
failure	O
in	O
two	O
of	O
four	O
healthy	O
volunteers.	O
Indomethacin	B-D007213
and	O
triamterene	O
should	O
not	O
be	O
administered	O
together.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
Both	O
indomethacin	O
and	O
potassium-sparing	O
diuretics	O
may	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	O
levels.	O
The	O
potential	O
effects	O
of	O
indomethacin	O
and	O
potassium-sparing	O
diuretics	O
on	O
potassium	O
levels	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently.	O
5.7	O
Anaphylactic	O
Reactions	O
Indomethacin	B-D007213
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
indomethacin	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
indomethacin	O
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)].	O
When	O
indomethacin	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
indomethacin,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
indomethacin	O
capsules	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Indomethacin	B-D007213
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Indomethacin	B-D007213
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
indomethacin	O
capsules,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(	O
8.1	O
)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
indomethacin	O
capsules	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
indomethacin	O
capsules,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
indomethacin	O
capsules	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
,	O
5.3	O
,	O
5.6	O
)].	O
5.14	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects:	O
Indomethacin	B-D007213
may	O
aggravate	O
depression	O
or	O
other	O
psychiatric	O
disturbances,	O
epilepsy,	O
and	O
parkinsonism,	O
and	O
should	O
be	O
used	O
with	O
considerable	O
caution	O
in	O
patients	O
with	O
these	O
conditions.	O
If	O
severe	O
CNS	O
adverse	O
reactions	O
develop,	O
indomethacin	O
should	O
be	O
discontinued.	O
Indomethacin	B-D007213
may	O
cause	O
drowsiness;	O
therefore,	O
patients	O
should	O
be	O
cautioned	O
about	O
engaging	O
in	O
activities	O
requiring	O
mental	O
alertness	O
and	O
motor	O
coordination,	O
such	O
as	O
driving	O
a	O
car.	O
Indomethacin	B-D007213
may	O
also	O
cause	O
headache.	O
Headache	B-D006261
which	O
persists	O
despite	O
dosage	O
reduction	O
requires	O
cessation	O
of	O
therapy	O
with	O
indomethacin.	O
5.15	O
Ocular	O
Effects:	O
Cornea	B-D003315
l	O
deposits	O
and	O
retinal	O
disturbances,	O
including	O
those	O
of	O
the	O
macula,	O
have	O
been	O
observed	O
in	O
some	O
patients	O
who	O
had	O
received	O
prolonged	O
therapy	O
with	O
indomethacin.	O
The	O
prescribing	O
physician	O
should	O
be	O
alert	O
to	O
the	O
possible	O
association	O
between	O
the	O
changes	O
noted	O
and	O
indomethacin.	O
It	O
is	O
advisable	O
to	O
discontinue	O
therapy	O
if	O
such	O
changes	O
are	O
observed.	O
Blurred	O
vision	O
may	O
be	O
a	O
significant	O
symptom	O
and	O
warrants	O
a	O
thorough	O
ophthalmological	O
examination.	O
Since	O
these	O
changes	O
may	O
be	O
asymptomatic,	O
ophthalmologic	O
examination	O
at	O
periodic	O
intervals	O
is	O
desirable	O
in	O
patients	O
where	O
therapy	O
is	O
prolonged.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11	O
)]	O
Most	O
common	O
adverse	O
(incidence	O
≥	O
3%)	O
are	O
headache,	O
dizziness,	O
dyspepsia	O
and	O
nausea.	O
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Heritage	O
Pharmaceuticals	O
Inc.	O
at	O
1.866.901.DRUG	O
(3784)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice.	O
In	O
a	O
gastroscopic	O
study	O
in	O
45	O
healthy	O
subjects,	O
the	O
number	O
of	O
gastric	O
mucosal	O
abnormalities	O
was	O
significantly	O
higher	O
in	O
the	O
group	O
receiving	O
indomethacin	O
capsules	O
than	O
in	O
the	O
group	O
taking	O
indomethacin	O
Suppositories	B-D013488
or	O
placebo.	O
In	O
a	O
double-blind	O
comparative	O
clinical	O
study	O
involving	O
175	O
patients	O
with	O
rheumatoid	O
arthritis,	O
however,	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
effects	O
with	O
indomethacin	O
Suppositories	B-D013488
or	O
Capsules	B-D002214
was	O
comparable.	O
The	O
incidence	O
of	O
lower	O
gastrointestinal	O
adverse	O
effects	O
was	O
greater	O
in	O
the	O
suppository	O
group.	O
The	O
adverse	O
reactions	O
for	O
indomethacin	O
capsules	O
listed	O
in	O
the	O
following	O
table	O
have	O
been	O
arranged	O
into	O
two	O
groups:	O
(1)	O
incidence	O
greater	O
than	O
1%;	O
and	O
(2)	O
incidence	O
less	O
than	O
1%.	O
The	O
incidence	O
for	O
group	O
(1)	O
was	O
obtained	O
from	O
33	O
double-blind	O
controlled	O
clinical	O
trials	O
reported	O
in	O
the	O
literature	O
(1,092	O
patients).	O
The	O
incidence	O
for	O
group	O
(2)	O
was	O
based	O
on	O
reports	O
in	O
clinical	O
trials,	O
in	O
the	O
literature,	O
and	O
on	O
voluntary	O
reports	O
since	O
marketing.	O
The	O
probability	O
of	O
a	O
causal	O
relationship	O
exists	O
between	O
indomethacin	O
and	O
these	O
adverse	O
reactions,	O
some	O
of	O
which	O
have	O
been	O
reported	O
only	O
rarely.	O
Table	O
1:	O
Summary	O
of	O
Adverse	O
reactions	O
for	O
Indomethacin	B-D007213
Capsules	B-D002214
Incidence	B-D015994
greater	O
than	O
1%	O
Incidence	B-D015994
less	O
than	O
1%	O
GASTROINTESTINAL	O
nausea*	O
with	O
or	O
without	O
vomiting	O
dyspepsia*	O
(including	O
indigestion,	O
heartburn	O
and	O
epigastric	O
pain)	O
diarrhea	O
abdominal	O
distress	O
or	O
pain	O
constipation	O
Anorexia	B-D000855
bloating	O
(includes	O
distension)	O
flatulence	O
peptic	O
ulcer	O
gastroenteritis	O
rectal	O
bleeding	O
proctitis	O
single	O
or	O
multiple	O
ulcerations,	O
including	O
perforation	O
and	O
hemorrhage	O
of	O
the	O
esophagus,	O
stomach,	O
duodenum	O
or	O
small	O
and	O
large	O
intestines	O
intestinal	O
ulceration	O
associated	O
with	O
stenosis	O
and	O
obstruction	O
gastrointestinal	O
bleeding	O
without	O
obvious	O
ulcer	O
formation	O
and	O
perforation	O
of	O
pre-existing	O
sigmoid	O
lesions	O
(diverticulum,	O
carcinoma,	O
etc.)	O
development	O
of	O
ulcerative	O
colitis	O
and	O
regional	O
ileitis	O
ulcerative	O
stomatitis	O
toxic	O
hepatitis	O
and	O
jaundice	O
(some	O
fatal	O
cases	O
have	O
been	O
reported)	O
intestinal	O
strictures	O
(diaphragms)	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
headache	O
(11.7%)	O
dizziness*	O
vertigo	O
somnolence	O
depression	O
and	O
fatigue	O
(including	O
malaise	O
and	O
listlessness)	O
anxiety	O
(includes	O
nervousness)	O
muscle	O
weakness	O
involuntary	O
muscle	O
movements	O
insomnia	O
muzziness	O
psychic	O
disturbances	O
including	O
psychotic	O
episodes	O
mental	O
confusion	O
drowsiness	O
light-headedness	O
syncope	O
paresthesia	O
aggravation	O
of	O
epilepsy	O
and	O
parkinsonism	O
depersonalization	O
coma	O
peripheral	O
neuropathy	O
convulsion	O
dysarthria	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
ocular	O
—	O
corneal	O
deposits	O
and	O
retinal	O
disturbances,	O
including	O
those	O
of	O
the	O
macula,	O
have	O
been	O
reported	O
in	O
some	O
patients	O
on	O
prolonged	O
therapy	O
with	O
indomethacin	O
blurred	O
vision	O
diplopia	O
hearing	O
disturbances,	O
deafness	O
CARDIOVASCULAR	O
None	O
Hypertension	B-D006973
hypotension	O
tachycardia	O
chest	O
pain	O
congestive	O
heart	O
failure	O
arrhythmia;	O
palpitations	O
METABOLIC	O
none	O
Edema	B-D004487
weight	O
gain	O
fluid	O
retention	O
flushing	O
or	O
sweating	O
Hyperglycemia	B-D006943
glycosuria	O
hyperkalemia	O
INTEGUMENTARY	O
None	O
Pruritus	B-D011537
rash;	O
urticaria	O
petechiae	O
or	O
ecchymosis	O
exfoliative	O
dermatitis	O
erythema	O
nodosum	O
loss	O
of	O
hair	O
Stevens-Johnson	O
syndrome	O
erythema	O
multiforme	O
toxic	O
epidermal	O
necrolysis	O
HEMATOLOGIC	O
None	O
Leucopenia	O
bone	O
marrow	O
depression	O
anemia	O
secondary	O
to	O
obvious	O
or	O
occult	O
gastrointestinal	O
bleeding	O
aplastic	O
anemia	O
hemolytic	O
anemia	O
agranulocytosis	O
thrombocytopenic	O
purpura	O
disseminated	O
intravascular	O
coagulation	O
HYPERSENSITIVITY	O
None	O
acute	O
anaphylaxis	O
acute	O
respiratory	O
distress	O
rapid	O
fall	O
in	O
blood	O
pressure	O
resembling	O
a	O
shock-like	O
state	O
angioedema	O
Dyspnea	B-D004417
asthma	O
purpura	O
angiitis	O
pulmonary	O
edema	O
fever	O
GENITOURINARY	O
None	O
Hematuria	B-D006417
vaginal	O
bleeding	O
proteinuria	O
nephrotic	O
syndrome	O
interstitial	O
nephritis	O
BUN	O
elevation	O
renal	O
insufficiency,	O
including	O
renal	O
failure	O
MISCELLANEOUS	O
None	O
Epistaxis	B-D004844
breast	O
changes,	O
including	O
enlargement	O
and	O
tenderness,	O
or	O
gynecomastia	O
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
indomethacin.	O
(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.)	O
Causal	O
relationship	O
unknown	O
:	O
Other	O
reactions	O
have	O
been	O
reported	O
but	O
occurred	O
under	O
circumstances	O
where	O
a	O
causal	O
relationship	O
could	O
not	O
be	O
established.	O
However,	O
in	O
these	O
rarely	O
reported	O
events,	O
the	O
possibility	O
cannot	O
be	O
excluded.	O
Therefore,	O
these	O
observations	O
are	O
being	O
listed	O
to	O
serve	O
as	O
alerting	O
information	O
to	O
physicians:	O
Cardiovascular	O
:	O
Thrombophlebitis	B-D013924
Hematologic	O
:	O
Although	O
there	O
have	O
been	O
several	O
reports	O
of	O
leukemia,	O
the	O
supporting	O
information	O
is	O
weak.	O
Genitourinary	O
:	O
Urinary	O
frequency.	O
A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
fasciitis,	O
particularly	O
in	O
association	O
with	O
Group	O
Aß	O
hemolytic	O
streptococcus,	O
has	O
been	O
described	O
in	O
persons	O
treated	O
with	O
nonsteroidal	O
anti-inflammatory	O
agents,	O
including	O
indomethacin,	O
sometimes	O
with	O
fatal	O
outcome.	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
in	O
the	O
perioperative	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)].	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDS)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1)	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.2)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
Use	O
the	O
lowest	O
effective	O
dose	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
(5.1)	O
NSAIDs	O
can	O
cause	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation.	O
Prescribe	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
(5.2)	O
Elevation	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
NSAIDs.	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen.	O
(5.3)	O
Hypertension	B-D006973
can	O
occur	O
with	O
NSAID	O
treatment.	O
Monitor	O
blood	O
pressure	O
closely	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
treatment.	O
(5.4)	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
(5.5)	O
Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
at	O
greatest	O
risk	O
of	O
this	O
reaction,	O
including	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors.	O
(5.6)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
or	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution.	O
(5.7)	O
NSAIDs	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
(5.8)	O
Not	O
for	O
use	O
during	O
pregnancy.	O
(5.9)	O
Do	O
not	O
administer	O
to	O
patients	O
with	O
aspirin	O
sensitive	O
asthma	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
(5.10)	O
Avoid	O
exposure	O
of	O
treated	O
knee(s)	O
to	O
natural	O
or	O
artificial	O
sunlight.	O
(5.11)	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
(5.12)	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs.	O
(5.13)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
oral	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
COX-2	O
selective	O
and	O
nonselective	O
orally	O
administered	O
NSAIDs,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Inform	O
patients	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
an	O
orally	O
administered	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
NSAIDS,	O
such	O
as	O
diclofenac,	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Prescribe	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore,	O
use	O
special	O
care	O
when	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
diclofencac	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs.	O
5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
[ULN]	O
range)	O
or	O
greater	O
elevations	O
of	O
transaminases	O
occurred	O
in	O
about	O
15%	O
of	O
oral	O
diclofenac-treated	O
patients	O
in	O
clinical	O
trials	O
of	O
indications	O
other	O
than	O
acute	O
pain.	O
Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	O
injury.	O
In	O
clinical	O
trials	O
of	O
an	O
oral	O
diclofenac	O
–	O
misoprostol	O
combination	O
product,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
for	O
2	O
to	O
6	O
months,	O
patients	O
with	O
oral	O
diclofenac	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(>8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
this	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(>8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
test	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
oral	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
sever	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
oral	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Measure	O
transaminases	O
(ALT	O
and	O
AST)	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
monitor	O
transaminases	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flulike"	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
to	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver-related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
certain	O
antibiotics,	O
antiepileptics).	O
Caution	O
patients	O
to	O
avoid	O
taking	O
unprescribed	O
acetaminophen	O
while	O
using	O
diclofenac	O
sodium	O
topical	O
solution.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac,	O
can	O
lead	O
to	O
new	O
onset	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Use	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Monitor	O
blood	O
pressure	O
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
Patients	B-D010361
taking	O
ACE-inhibitors,	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution.	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
considerable	O
dehydration.	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
is	O
not	O
recommended	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
diclofenac	O
sodium	O
topical	O
solution	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution.	O
Do	O
not	O
prescribe	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.10)].	O
Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Do	O
not	O
apply	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
open	O
skin	O
wounds,	O
infections,	O
inflammations,	O
or	O
exfoliative	O
dermatitis,	O
as	O
it	O
may	O
affect	O
absorption	O
and	O
tolerability	O
of	O
the	O
drug.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations,	O
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
should	O
not	O
be	O
used	O
by	O
pregnant	O
or	O
nursing	O
women	O
or	O
those	O
intending	O
to	O
become	O
pregnant.	O
5.10	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross-reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
do	O
not	O
administer	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.11	O
Sun	O
Exposure	O
Instruct	O
patients	O
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
knee(s)	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light-induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.13	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	O
and	O
conduct	O
periodic	O
laboratory	O
evaluations.	O
5.14	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-response	O
illness.	O
For	O
patients	O
on	O
prolonged	O
corticosteroid	O
therapy,	O
taper	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Hematological	O
Effects	O
The	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	O
subjects	O
administered	O
80	O
drops	O
four	O
times	O
a	O
day	O
for	O
7	O
days.	O
There	O
was	O
no	O
significant	O
change	O
in	O
platelet	O
aggregation	O
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)].	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
Check	O
hemoglobin	O
or	O
hematocrit	O
of	O
patients	O
on	O
diclofenac	O
sodium	O
topical	O
solution	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration	O
and	O
reversible.	O
Carefully	O
monitor	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alteration	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants.	O
5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms	O
in	O
patients	O
taking	O
NSAIDs,	O
monitor	O
patients	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Check	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
in	O
patients	O
on	O
long-term	O
treatment	O
with	O
NSAIDs.	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
if	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen.	O
6.	O
ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
are	O
application	O
site	O
reactions.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
IGI	O
Laboratories	B-D007753
,	O
Inc.	O
at	O
1-856-697-1441,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trial	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution	O
of	O
911	O
patients	O
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	O
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	O
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	O
treated	O
for	O
at	O
least	O
12	O
months.	O
The	O
population	O
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	O
were	O
Caucasians,	O
64%	O
were	O
females,	O
and	O
all	O
patients	O
had	O
primary	O
osteoarthritis.	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies.	O
Application	O
site	O
reactions:	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment	O
related	O
adverse	O
events	O
in	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
Application	O
site	O
reactions	O
were	O
characterized	O
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	O
induration,	O
vesicles,	O
paresthesia,	O
pruritus,	O
vasodilation,	O
acne,	O
and	O
urticaria.	O
The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	O
(32%),	O
contact	O
dermatitis	O
characterized	O
by	O
skin	O
erythema	O
and	O
induration	O
(9%),	O
contact	O
dermatitis	O
with	O
vescicles	O
(2%)	O
and	O
pruritus	O
(4%).	O
In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	O
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac.	O
In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	O
study,	O
contact	O
dermatitis	O
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	O
with	O
vesicles	O
in	O
10%	O
of	O
patients,	O
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	O
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%.	O
Adverse	O
events	O
common	O
to	O
the	O
NSAID	O
class:	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
flatulence,	O
abdominal	O
pain,	O
edema;	O
see	O
Table	O
1).	O
The	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac,	O
compared	O
to	O
oral	O
diclofenac	O
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	O
(3%	O
vs.	O
less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	O
(12%	O
vs.	O
7%),	O
urea	O
(20%	O
vs.	O
12%),	O
and	O
hemoglobin	O
(13%	O
vs.	O
9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	O
transaminases.	O
Table	O
1:	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
osteoarthritis.	O
Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	O
trials.	O
Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
SolutionN=911	O
Topical	O
PlaceboN=332	O
Adverse	O
ReactionPreferred	O
Term	O
according	O
to	O
COSTART	O
N(%)	O
N(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non	O
–	O
U.S.	O
postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
Whole:	O
abdominal	O
pain,	O
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	O
back	O
pain,	O
body	O
odor,	O
chest	O
pain,	O
edema,	O
face	O
edema,	O
halitosis,	O
headache,	O
lack	O
of	O
drug	O
effect,	O
neck	O
rigidity,	O
pain	O
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	O
dry	O
mouth,	O
dyspepsia,	O
gastroenteritis,	O
decreased	O
appetite,	O
mouth	O
ulceration,	O
nausea,	O
rectal	O
hemorrhage,	O
ulcerative	O
stomatitis	O
Metabolic	O
and	O
Nutritional:	O
creatinine	O
increased	O
Musculoskeletal:	O
leg	O
cramps,	O
myalgia	O
Nervous:	O
depression,	O
dizziness,	O
drowsiness,	O
lethargy,	O
paresthesia,	O
paresthesia	O
at	O
application	O
site	O
Respiratory:	O
asthma,	O
dyspnea,	O
laryngismus,	O
laryngitis,	O
pharyngitis	O
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	O
contact	O
dermatitis	O
with	O
vesicles,	O
dry	O
skin,	O
pruritus,	O
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	O
rash,	O
pruritus,	O
skin	O
discoloration,	O
urticaria	O
Special	O
senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	O
ear	O
pain,	O
eye	O
disorder,	O
eye	O
pain,	O
taste	O
perversion	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS).	O
Naproxen	B-D009288
as	O
NAPRELAN	O
®	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(SeeWARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
people	O
are	O
at	O
greater	O
risk	O
for	O
serous	O
gastrointestinal	O
events.	O
(SeeWARNINGS).	O
ADVERSE	O
REACTIONS	O
As	O
with	O
all	O
drugs	O
in	O
this	O
class,	O
the	O
frequency	O
and	O
severity	O
of	O
adverse	O
events	O
depends	O
on	O
several	O
factors:	O
the	O
dose	O
of	O
the	O
drug	O
and	O
duration	O
of	O
treatment;	O
the	O
age,	O
the	O
sex,	O
physical	O
condition	O
of	O
the	O
patient;	O
any	O
concurrent	O
medical	O
diagnoses	O
or	O
individual	O
risk	O
factors.	O
The	O
following	O
adverse	O
reactions	O
are	O
divided	O
into	O
three	O
parts	O
based	O
on	O
frequency	O
and	O
whether	O
or	O
not	O
the	O
possibility	O
exists	O
of	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
these	O
adverse	O
events.	O
In	O
those	O
reactions	O
listed	O
as	O
“Probable	O
Causal	O
Relationship”	O
there	O
is	O
at	O
least	O
one	O
case	O
for	O
each	O
adverse	O
reaction	O
where	O
there	O
is	O
evidence	O
to	O
suggest	O
that	O
there	O
is	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
the	O
reported	O
event.	O
The	O
adverse	O
reactions	O
reported	O
were	O
based	O
on	O
the	O
results	O
from	O
two	O
double-blind	O
controlled	O
clinical	O
trials	O
of	O
three	O
months	O
duration	O
with	O
an	O
additional	O
nine	O
month	O
open-label	O
extension.	O
A	O
total	O
of	O
542	O
patients	O
received	O
NAPRELAN®	O
Tablets	B-D013607
either	O
in	O
the	O
double-blind	O
period	O
or	O
in	O
the	O
nine	O
month	O
open-label	O
extension.	O
Of	O
these	O
542	O
patients,	O
232	O
received	O
NAPRELAN®	O
Tablets	B-D013607
,	O
167	O
were	O
initially	O
treated	O
with	O
Naprosyn®	O
***	O
and	O
143	O
were	O
initially	O
treated	O
with	O
placebo.	O
Adverse	O
reactions	O
reported	O
by	O
patients	O
who	O
received	O
NAPRELAN®	O
Tablets	B-D013607
are	O
shown	O
by	O
body	O
system.	O
Those	O
adverse	O
reactions	O
observed	O
with	O
naproxen	O
but	O
not	O
reported	O
in	O
controlled	O
trials	O
with	O
NAPRELAN®	O
Tablets	B-D013607
are	O
italicized.	O
The	O
most	O
frequent	O
adverse	O
events	O
from	O
the	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
were	O
headache	O
(15%),	O
followed	O
by	O
dyspepsia	O
(14%),	O
and	O
flu	O
syndrome	O
(10%).	O
The	O
incidence	O
of	O
other	O
adverse	O
events	O
occurring	O
in	O
3%	O
-	O
9%	O
of	O
the	O
patients	O
are	O
marked	O
with	O
an	O
asterisk.	O
Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.	O
INCIDENCE	O
GREATER	O
THAN	O
1%	O
(PROBABLE	O
CAUSAL	O
RELATIONSHIP)	O
Body	O
as	O
a	O
Whole—Pain	O
(back)*,	O
pain*,	O
infection*,	O
fever,	O
injury	O
(accident),	O
asthenia,	O
pain	O
chest,	O
headache	O
(15%),	O
flu	O
syndrome	O
(10%).	O
Gastrointestinal—Nausea*,	O
diarrhea*,	O
constipation*,	O
abdominal	O
pain*,	O
flatulence,	O
gastritis,	O
vomiting,	O
dysphagia,	O
dyspepsia	O
(14%),	O
heartburn*,	O
stomatitis.	O
Hematologic—Anemia,	O
ecchymosis.	O
Respiratory—Pharyngitis*,	O
rhinitis*,	O
sinusitis*,	O
bronchitis,	O
cough	O
increased.	O
Renal—Urinary	O
tract	O
infection*,	O
cystitis.	O
Dermatologic—Skin	O
rash*,	O
skin	O
eruptions*,	O
ecchymoses*,	O
purpura.	O
Metabolic	O
and	O
Nutrition—Peripheral	O
edema,	O
hyperglycemia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Dizziness,	O
paresthesia,	O
insomnia,	O
drowsiness*,	O
lightheadedness.	O
Cardiovascular—Hypertension,	O
edema*,	O
dyspnea*,	O
palpitations.	O
Musculoskeletal—Cramps	O
(leg),	O
myalgia,	O
arthralgia,	O
joint	O
disorder,	O
tendon	O
disorder.	O
Special	O
Senses—Tinnitus*,	O
hearing	O
disturbances,	O
visual	O
disturbances.	O
General—Thirst.	O
INCIDENCE	O
LESS	O
THAN	O
1%	O
(PROBABLE	O
CAUSAL	O
RELATIONSHIP)	O
Body	O
as	O
a	O
Whole—Abscess,	O
monilia,	O
neck	O
rigid,	O
pain	O
neck,	O
abdomen	O
enlarged,	O
carcinoma,	O
cellulitis,	O
edema	O
general,	O
LE	O
syndrome,	O
malaise,	O
mucous	O
membrane	O
disorder,	O
allergic	O
reaction,	O
pain	O
pelvic.	O
Gastrointestinal—Anorexia,	O
cholecystitis,	O
cholelithiasis,	O
eructation,	O
GI	O
hemorrhage,	O
rectal	O
hemorrhage,	O
stomatitis	O
aphthous,	O
stomatitis	O
ulcer,	O
ulcer	O
mouth,	O
ulcer	O
stomach,	O
periodontal	O
abscess,	O
cardiospasm,	O
colitis,	O
esophagitis,	O
gastroenteritis,	O
GI	O
disorder,	O
rectal	O
disorder,	O
tooth	O
disorder,	O
hepatosplenomegaly,	O
liver	O
function	O
abnormality,	O
melena,	O
ulcer	O
esophagus,	O
hematemesis,	O
jaundice,	O
pancreatitis,	O
necrosis.	O
Renal—Dysmenorrhea,	O
dysuria,	O
kidney	O
function	O
abnormality,	O
nocturia,	O
prostate	O
disorder,	O
pyelonephritis,	O
carcinoma	O
breast,	O
urinary	O
incontinence,	O
kidney	O
calculus,	O
kidney	O
failure,	O
menorrhagia,	O
metrorrhagia,	O
neoplasm	O
breast,	O
nephrosclerosis,	O
hematuria,	O
pain	O
kidney,	O
pyuria,	O
urine	O
abnormal,	O
urinary	O
frequency,	O
urinary	O
retention,	O
uterine	O
spasm,	O
vaginitis,	O
glomerular	O
nephritis,	O
hyperkalemia,	O
interstitial	O
nephritis,	O
nephrotic	O
syndrome,	O
renal	O
disease,	O
renal	O
failure,	O
renal	O
papillary	O
necrosis.	O
Hematologic—Leukopenia,	O
bleeding	O
time	O
increased,	O
eosinophilia,	O
abnormal	O
RBC,	O
abnormal	O
WBC,	O
thrombocytopenia,	O
agranulocytosis,	O
granulocytopenia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Depression,	O
anxiety,	O
hypertonia,	O
nervousness,	O
neuralgia,	O
neuritis,	O
vertigo,	O
amnesia,	O
confusion,	O
co-ordination,	O
abnormal	O
diplopia,	O
emotional	O
lability,	O
hematoma	O
subdural,	O
paralysis,	O
dream	O
abnormalities,	O
inability	O
to	O
concentrate,	O
muscle	O
weakness.	O
Dermatologic:	O
Angiodermatitis,	O
herpes	O
simplex,	O
dry	O
skin,	O
sweating,	O
ulcer	O
skin,	O
acne,	O
alopecia,	O
dermatitis	O
contact,	O
eczema,	O
herpes	O
zoster,	O
nail	O
disorder,	O
skin	O
necrosis,	O
subcutaneous	O
nodule,	O
pruritus,	O
urticaria,	O
neoplasm	O
skin,	O
photosensitive	O
dermatitis,	O
photosensitivity	O
reactions	O
resembling	O
porphyria	O
cutaneous	O
tarda,	O
epidermolysis	O
bullosa.	O
Special	O
Senses—Amblyopia,	O
scleritis,	O
cataract,	O
conjunctivitis,	O
deaf,	O
ear	O
disorder,	O
keratoconjunctivitis,	O
lacrimation	O
disorder,	O
otitis	O
media,	O
pain	O
eye.	O
Cardiovascular—Angina	O
pectoris,	O
coronary	O
artery	O
disease,	O
myocardial	O
infarction,	O
deep	O
thrombophlebitis,	O
vasodilation,	O
vascular	O
anomaly,	O
arrhythmia,	O
bundle	O
branch	O
block,	O
abnormal	O
ECG,	O
heart	O
failure	O
right,	O
hemorrhage,	O
migraine,	O
aortic	O
stenosis,	O
syncope,	O
tachycardia,	O
congestive	O
heart	O
failure.	O
Respiratory—Asthma,	O
dyspnea,	O
lung	O
edema,	O
laryngitis,	O
lung	O
disorder,	O
epistaxis,	O
pneumonia,	O
respiratory	O
distress,	O
respiratory	O
disorder,	O
eosinophilic	O
pneumonitis.	O
Musculoskeletal—Myasthenia,	O
bone	O
disorder,	O
spontaneous	O
bone	O
fracture,	O
fibrotendinitis,	O
bone	O
pain,	O
ptosis,	O
spasm	O
general,	O
bursitis.	O
Metabolic	O
and	O
Nutrition—Creatinine	O
increase,	O
glucosuria,	O
hypercholesteremia,	O
albuminuria,	O
alkalosis,	O
BUN	O
increased,	O
dehydration,	O
edema,	O
glucose	O
tolerance	O
decrease,	O
hyperuricemia,	O
hypokalemia,	O
SGOT	O
increase,	O
SGPT	O
increase,	O
weight	O
decrease.	O
General—Anaphylactoid	O
reactions,	O
angioneurotic	O
edema,	O
menstrual	O
disorders,	O
hypoglycemia,	O
pyrexia	O
(chills	O
and	O
fevers).	O
INCIDENCE	O
LESS	O
THAN	O
1%	O
(CAUSAL	O
RELATIONSHIP	O
UNKNOWN)	O
Other	O
adverse	O
reactions	O
listed	O
in	O
the	O
naproxen	O
package	O
label,	O
but	O
not	O
reported	O
by	O
those	O
who	O
received	O
NAPRELAN®	O
Tablets	B-D013607
are	O
shown	O
in	O
italics.	O
These	O
observations	O
are	O
being	O
listed	O
as	O
alerting	O
information	O
to	O
the	O
physician.	O
Hematologic—Aplastic	O
anemia,	O
hemolytic	O
anemia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Aseptic	O
meningitis,	O
cognitive	O
dysfunction.	O
Dermatologic—Epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome.	O
Gastrointestinal—Non-peptic	O
GI	O
ulceration,	O
ulcerative	O
stomatitis.	O
Cardiovascular—Vasculitis.	O
BOXED	O
WARNING	O
Cardiovascular	O
Risk	B-D012306
1.NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascularthrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
ofuse.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
forcardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(See	O
WARNINGS	O
).	O
2.IBU	O
tablets	O
are	O
contraindicated	O
for	O
treatment	O
of	O
peri-operativepain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)surgery	O
(See	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
1.NSAIDS	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinaladverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforationof	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
eventscan	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinalevents.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
withIbuprofen	O
tablets	O
is	O
gastrointestinal.	O
In	O
controlled	O
clinical	O
trials	O
thepercentage	O
of	O
patients	O
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaintsranged	O
from	O
4%	O
to	O
16%.	O
In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	O
were	O
compared	O
toaspirin	O
and	O
indomethacin	O
in	O
equally	O
effective	O
doses,	O
the	O
overall	O
incidenceof	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
eitherthe	O
aspirin-	O
or	O
indomethacin-treated	O
patients.	O
Adverse	O
reactions	O
observed	O
during	O
controlled	O
clinical	O
trials	O
at	O
anincidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table.	O
Those	O
reactions	O
listedin	O
Column	O
one	O
encompass	O
observations	O
in	O
approximately	O
3,000patients.	O
More	O
than	O
500	O
of	O
these	O
patients	O
were	O
treated	O
for	O
periods	O
ofat	O
least	O
54	O
weeks.	O
Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
werereported	O
in	O
controlled	O
clinical	O
trials	O
and	O
from	O
marketing	O
experience.These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
twoof	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	O
wherethe	O
probability	O
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
inColumn	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	O
has	O
notbeen	O
established.	O
Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
thanat	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	O
trials	O
of	O
patients	O
withrheumatoid	O
arthritis.	O
The	O
increases	O
in	O
incidence	O
were	O
slight	O
and	O
stillwithin	O
the	O
ranges	O
reported	O
in	O
the	O
table.	O
table	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS	O
).	O
Etodolac	B-D017308
capsules	O
USP,	O
200	O
mg	O
and	O
300	O
mg,	O
and	O
Etodolac	B-D017308
tablets	O
USP,	O
400	O
mg	O
and	O
500	O
mg	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(See	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
capsules	O
and	O
tablets,	O
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
capsules	O
and	O
tablets	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
painDrug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.,	O
diarrhea,	O
flatulence,	O
nausea,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise,	O
dizziness,	O
depression,	O
nervousness,	O
fatigue.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
Musculoskeletal—Arthralgia.	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
leukocytoclastic	O
vasculitis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.	O
Musculoskeletal—Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death	O
Cardiovascular	O
system	O
-	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS	O
.)	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/	O
polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE::RISK	O
EVALUATION	O
AND	O
MITIGATION	O
STRATEGY	O
(REMS);	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION;	O
ACCIDENTAL	O
INGESTION;	O
NEONATAL	O
OPIOID	O
WITHDRAWAL	O
SYNDROME;	O
CYTOCHROME	O
P4503A4	O
INTERACTION;	O
RISKS	O
FROM	O
CONCOMITANT	O
USE	O
WITH	O
BENZODIAZEPINES	O
OR	O
OTHER	O
CNS	O
DEPRESSANTS;	O
and	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
Hydrocodone	B-D006853
Bitartrate	O
and	O
Ibuprofen	B-D007052
Tablets	B-D013607
exposes	O
patients	O
and	O
other	O
users	O
to	O
the	O
risks	O
of	O
opioid	O
addiction,	O
abuse,	O
and	O
misuse,	O
which	O
can	O
lead	O
to	O
overdose	O
and	O
death.	O
Assess	O
each	O
patient’s	O
risk	O
prior	O
to	O
prescribing	O
Hydrocodone	B-D006853
Bitartrate	O
and	O
Ibuprofen	B-D007052
Tablets	B-D013607
,	O
and	O
monitor	O
all	O
patients	O
regularly	O
for	O
the	O
development	O
of	O
these	O
behaviors	O
and	O
conditions	O
(see	O
WARNINGS:	O
Addiction,	O
Abuse,	O
and	O
Misuse).	O
Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS):	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
REMS	O
for	O
these	O
products	O
[see	O
Warnings].	O
Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
education	O
programs	O
available	O
to	O
healthcare	O
providers.	O
Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
•	O
complete	O
a	O
REMS-compliant	O
education	O
program,	O
•	O
counsel	O
patients	O
and/or	O
their	O
caregivers,	O
with	O
every	O
prescription,	O
on	O
safe	O
use,	O
serious	O
risks,	O
storage,	O
and	O
disposal	O
of	O
these	O
products,	O
•	O
emphasize	O
to	O
patients	O
and	O
their	O
caregivers	O
the	O
importance	O
of	O
reading	O
the	O
Medication	O
Guide	O
every	O
time	O
it	O
is	O
provided	O
by	O
their	O
pharmacist,	O
and	O
•	O
Consider	O
other	O
tools	O
to	O
improve	O
patient,	O
household,	O
and	O
community	O
safety.	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
may	O
occur	O
with	O
use	O
of	O
Hydrocodone	B-D006853
Bitartrate	O
and	O
Ibuprofen	B-D007052
Tablets	B-D013607
.	O
Monitor	O
for	O
respiratory	O
depression,	O
especially	O
during	O
initiation	O
of	O
Hydrocodone	B-D006853
Bitartrate	O
and	O
Ibuprofen	B-D007052
Tablets	B-D013607
or	O
following	O
a	O
dose	O
increase	O
(see	O
WARNINGS:	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
).	O
Accidental	O
Ingestion	O
Accidental	O
ingestion	O
of	O
even	O
one	O
dose	O
of	O
Hydrocodone	B-D006853
Bitartrate	O
and	O
Ibuprofen	B-D007052
Tablets	B-D013607
,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
a	O
fatal	O
overdose	O
of	O
hydrocodone	O
(see	O
WARNINGS:	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
)	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
Hydrocodone	B-D006853
Bitartrate	O
and	O
Ibuprofen	B-D007052
Tablets	B-D013607
during	O
pregnancy	O
can	O
result	O
in	O
neonatal	O
opioid	O
withdrawal	O
syndrome,	O
which	O
may	O
be	O
life	O
threatening	O
if	O
not	O
recognized	O
and	O
treated,	O
and	O
requires	O
management	O
according	O
to	O
protocols	O
developed	O
by	O
neonatology	O
experts.	O
If	O
opioid	O
use	O
is	O
required	O
for	O
a	O
prolonged	O
period	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available	O
(see	O
WARNINGS:	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
).	O
Cytochrome	O
P450	O
3A4	O
Interaction	O
The	O
concomitant	O
use	O
of	O
Hydrocodone	B-D006853
Bitartrate	O
and	O
Ibuprofen	B-D007052
Tablets	B-D013607
with	O
all	O
cytochrome	O
P450	O
3A4	O
inhibitors	O
may	O
result	O
in	O
an	O
increase	O
in	O
hydrocodone	O
plasma	O
concentrations,	O
which	O
may	O
cause	O
potentially	O
fatal	O
respiratory	O
depression.	O
In	O
addition,	O
discontinuation	O
of	O
a	O
concomitantly	O
used	O
cytochrome	O
P450	O
3A4	O
inducer	O
may	O
result	O
in	O
an	O
increase	O
in	O
hydrocodone	O
plasma	O
concentration.	O
Monitor	O
patients	O
taking	O
Hydrocodone	B-D006853
Bitartrate	O
and	O
Ibuprofen	B-D007052
Tablets	B-D013607
and	O
any	O
CYP3A4	O
inhibitor	O
or	O
upon	O
discontinuation	O
of	O
a	O
CYP3A4	O
inducer	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation	O
(see	O
WARNINGS:	O
Risk	B-D012306
s	O
of	O
Concomitant	O
Use	O
or	O
Discontinuation	O
of	O
Cytochrome	O
P450	O
3A4	O
Inhibitors	O
and	O
Inducers,	O
PRECAUTIONS:	O
Drug	B-D004347
Interactions	I-D004347
).	O
Risk	B-D012306
s	O
from	O
Concomitant	O
Use	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
Concomitant	O
use	O
of	O
opioids	O
with	O
benzodiazepines	O
or	O
other	O
central	O
nervous	O
system	O
(CNS)	O
depressants,	O
including	O
alcohol,	O
may	O
result	O
in	O
profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death	O
(see	O
WARNINGS:	O
Risk	B-D012306
s	O
from	O
Concomitant	O
Use	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants,	O
PRECAUTIONS:	O
Drug	B-D004347
Interactions	I-D004347
).	O
Reserve	O
concomitant	O
prescribing	O
of	O
Hydrocodone	B-D006853
Bitartrate	O
and	O
Ibuprofen	B-D007052
Tablets	B-D013607
and	O
benzodiazepines	O
or	O
other	O
CNS	O
depressants	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
treatment	O
options	O
are	O
inadequate.	O
•	O
Limit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required.	O
•	O
Follow	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS:	O
Cardiovascular	O
Thrombotic	O
Events).	O
Hydrocodone	B-D006853
Bitartrate	O
and	O
Ibuprofen	B-D007052
Tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS:	O
Cardiovascular	O
Thrombotic	O
Events).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS:	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
described	O
below	O
and	O
elsewhere	O
in	O
the	O
labeling	O
including	O
the	O
WARNINGS	O
section.	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Interactions	O
with	O
Cytochrome	O
P450	O
3A4	O
Inhibitors	O
and	O
Inducers	O
Interactions	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
Adrenal	B-D000309
Insufficiency	I-D000309
Severe	O
Hypotension	B-D007022
Seizures	B-D012640
Withdrawal	O
Cardiovascular	O
Thrombotic	O
Events	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Hepatotoxicity	O
Hypertension	B-D006973
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Anaphylactic	O
Reactions	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
Serious	O
Skin	B-D012867
Reactions	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Hematologic	O
Toxicity	O
Aseptic	O
Meningitis	B-D008581
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	O
tablets	O
were	O
administered	O
to	O
approximately	O
300	O
pain	O
patients	O
in	O
a	O
safety	O
study	O
that	O
employed	O
dosages	O
and	O
a	O
duration	O
of	O
treatment	O
sufficient	O
to	O
encompass	O
the	O
recommended	O
usage	O
(see	O
DOSAGE	O
AND	O
ADMINISTRATION	O
).	O
Adverse	O
event	O
rates	O
generally	O
increased	O
with	O
increasing	O
daily	O
dose.	O
The	O
event	O
rates	O
reported	O
below	O
are	O
from	O
approximately	O
150	O
patients	O
who	O
were	O
in	O
a	O
group	O
that	O
received	O
one	O
tablet	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
tablets	O
an	O
average	O
of	O
three	O
to	O
four	O
times	O
daily.	O
The	O
overall	O
incidence	O
rates	O
of	O
adverse	O
experiences	O
in	O
the	O
trials	O
were	O
fairly	O
similar	O
for	O
this	O
patient	O
group	O
and	O
those	O
who	O
received	O
the	O
comparison	O
treatment,	O
acetaminophen	O
600	O
mg	O
with	O
codeine	O
60	O
mg.	O
The	O
following	O
lists	O
adverse	O
events	O
that	O
occurred	O
with	O
an	O
incidence	O
of	O
1%	O
or	O
greater	O
in	O
clinical	O
trials	O
of	O
Hydrocodone	B-D006853
Bitartrate	O
and	O
Ibuprofen	B-D007052
Tablets	B-D013607
,	O
without	O
regard	O
to	O
the	O
causal	O
relationship	O
of	O
the	O
events	O
to	O
the	O
drug.	O
To	O
distinguish	O
different	O
rates	O
of	O
occurrence	O
in	O
clinical	O
studies,	O
the	O
adverse	O
events	O
are	O
listed	O
as	O
follows:	O
name	O
of	O
adverse	O
event	O
=	O
less	O
than	O
3%	O
adverse	O
events	O
marked	O
with	O
an	O
asterisk	O
*	O
=	O
3%	O
to	O
9%	O
adverse	O
event	O
rates	O
over	O
9%	O
are	O
in	O
parentheses.	O
Body	O
as	O
a	O
Whole	O
Abdominal	O
pain*;	O
Asthenia	B-D001247
*;	O
Fever	B-D005334
;	O
Flu	O
syndrome;	O
Headache	B-D006261
(27%);	O
Infection*;	O
Pain	B-D010146
.	O
Cardiovascular	O
Palpitations;	O
Vasodilation	B-D014664
.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Anxiety	B-D001007
*;	O
Confusion	B-D003221
;	O
Dizziness	B-D004244
(14%);	O
Hypertonia;	O
Insomnia*;	O
Nervousness*;	O
Paresthesia	B-D010292
;	O
Somnolence	O
(22%);	O
Thinking	B-D013850
abnormalities.	O
Digestive	O
Anorexia	B-D000855
;	O
Constipation	B-D003248
(22%);	O
Diarrhea	B-D003967
*;	O
Dry	O
mouth*;	O
Dyspepsia	B-D004415
(12%);	O
Flatulence	B-D005414
*;	O
Gastritis	B-D005756
;	O
Melena	B-D008551
;	O
Mouth	B-D009055
ulcers;	O
Nausea	B-D009325
(21%);	O
Thirst	B-D013894
;	O
Vomiting	B-D014839
*.	O
Metabolic	O
and	O
Nutritional	O
Disorders	O
Edema	B-D004487
*.	O
Respiratory	O
Dyspnea	B-D004417
;	O
Hiccup	B-D006606
s;	O
Pharyngitis	B-D010612
;	O
Rhinitis	B-D012220
.	O
Skin	B-D012867
and	O
Appendages	O
Pruritus	B-D011537
*;	O
Sweating	B-D013546
*.	O
Special	O
Senses	O
Tinnitus	B-D014012
.	O
Urogenital	O
Urinary	O
frequency.	O
Incidence	B-D015994
less	O
than	O
1%	O
Body	O
as	O
a	O
Whole	O
Allergic	O
reaction.	O
Cardiovascular	O
Arrhythmia;	O
Hypotension	B-D007022
;	O
Tachycardia	B-D013610
.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Agitation;	O
Abnormal	O
dreams;	O
Decreased	O
libido;	O
Depression	B-D003863
;	O
Euphoria	B-D005059
;	O
Mood	O
changes;	O
Neuralgia	B-D009437
;	O
Slurred	O
speech;	O
Tremor	B-D014202
,	O
Vertigo	B-D014717
.	O
Digestive	O
Chalky	O
stool;	O
"Clenching	O
teeth";	O
Dysphagia;	O
Esophageal	O
spasm;	O
Esophagitis	B-D004941
;	O
Gastroenteritis	B-D005759
;	O
Glossitis	B-D005928
;	O
Liver	B-D008099
enzyme	O
elevation.	O
Metabolic	O
and	O
Nutritional	O
Weight	O
decrease.	O
Musculoskeletal	O
Arthralgia	B-D018771
;	O
Myalgia	B-D063806
.	O
Respiratory	O
Asthma	B-D001249
;	O
Bronchitis	B-D001991
;	O
Hoarseness	B-D006685
;	O
Increased	O
cough;	O
Pulmonary	O
congestion;	O
Pneumonia	B-D011014
;	O
Shallow	O
breathing;	O
Sinusitis	B-D012852
.	O
Skin	B-D012867
and	O
Appendages	O
Rash;	O
Urticaria	B-D014581
.	O
Special	O
Senses	O
Altered	O
vision;	O
Bad	O
taste;	O
Dry	O
eyes.	O
Urogenital	O
Cystitis	B-D003556
;	O
Glycosuria	B-D006029
;	O
Impotence;	O
Urinary	O
incontinence;	O
Urinary	O
retention.	O
Post	O
marketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
hydrocodone.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Serotonin	B-D012701
syndrome:	O
Cases	O
of	O
serotonin	O
syndrome,	O
a	O
potentially	O
life-threatening	O
condition,	O
have	O
been	O
reported	O
during	O
concomitant	O
use	O
of	O
opioids	O
with	O
serotonergic	O
drugs.	O
Adrenal	O
insufficiency:	O
Cases	O
of	O
adrenal	O
insufficiency	O
have	O
been	O
reported	O
with	O
opioid	O
use,	O
more	O
often	O
following	O
greater	O
than	O
one	O
month	O
of	O
use.	O
Anaphylaxis	B-D000707
:	O
Anaphylaxis	B-D000707
has	O
been	O
reported	O
with	O
ingredients	O
contained	O
in	O
Hydrocodone	B-D006853
Bitartrate	O
and	O
Ibuprofen	B-D007052
Tablets	B-D013607
.	O
Androgen	O
deficiency:	O
Cases	O
of	O
androgen	O
deficiency	O
have	O
occurred	O
with	O
chronic	O
use	O
of	O
opioids	O
(see	O
CLINICAL	O
PHARMACOLOGY:	O
Pharmacodynamics	O
).	O
ADVERSE	O
REACTIONS	O
Clinical	O
Practice	O
The	O
following	O
reactions	O
have	O
been	O
identified	O
during	O
postmarketing	O
use	O
of	O
topical	O
diclofenac	O
sodium	O
ophthalmic	O
solution,	O
0.1%	O
in	O
clinical	O
practice.	O
Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size,	O
estimates	O
of	O
frequency	O
cannot	O
be	O
made.	O
The	O
reactions,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
diclofenac	O
sodium	O
ophthalmic	O
solution,	O
0.1%,	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
corneal	O
erosion,	O
corneal	O
infiltrates,	O
corneal	O
perforation,	O
corneal	O
thinning,	O
corneal	O
ulceration	O
and	O
epithelilal	O
breakdown	O
(see	O
PRECAUTIONS,	O
General).	O
Ocular	O
Transient	O
burning	O
and	O
stinging	O
were	O
reported	O
in	O
approximately	O
15%	O
of	O
patients	O
across	O
studies	O
with	O
the	O
use	O
of	O
diclofenac	O
sodium	O
ophthalmic	O
solution,	O
0.1%	O
in	O
clinical	O
practice.	O
In	O
cataract	O
surgery	O
studies,	O
keratitis	O
was	O
reported	O
in	O
up	O
to	O
28%	O
of	O
patients	O
receiving	O
diclofenac	O
sodium	O
ophthalmic	O
solution	O
although	O
in	O
many	O
of	O
these	O
cases	O
keratitis	O
was	O
initially	O
noted	O
prior	O
to	O
the	O
initiation	O
of	O
treatment.	O
Elevated	O
intraocular	O
pressure	O
following	O
cataract	O
surgery	O
was	O
reported	O
in	O
approximately	O
15%	O
of	O
patients	O
undergoing	O
cataract	O
surgery.	O
Lacrimation	O
complaints	O
were	O
reported	O
in	O
approximately	O
30%	O
of	O
case	O
studies	O
undergoing	O
incisional	O
refractive	O
surgery.	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
approximately	O
5%	O
or	O
less	O
of	O
the	O
patients:	O
abnormal	O
vision,	O
acute	O
elevated	O
IOP,	O
blurred	O
vision,	O
conjunctivitis,	O
corneal	O
deposits,	O
corneal	O
edema,	O
corneal	O
opacity,	O
corneal	O
lesions,	O
discharge,	O
eyelid	O
swelling,	O
eye	O
pain,	O
injection,	O
iritis,	O
irritation,	O
itching,	O
lacrimation	O
disorder,	O
and	O
ocular	O
allergy.	O
Systemic	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
3%	O
or	O
less	O
of	O
the	O
patients:	O
abdominal	O
pain,	O
asthenia,	O
chills,	O
dizziness,	O
facial	O
edema,	O
fever,	O
headache,	O
insomnia,	O
nausea,	O
pain,	O
rhinitis,	O
viral	O
infection	O
and	O
vomiting.	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Rising	O
Pharmaceuticals,	O
Inc.,	O
at	O
1-866-562-4597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[See	O
Warnings	O
and	O
Precautions	O
and	O
(5.1)].	O
Flector	O
Patch	O
is	O
contraindicated	O
in	O
the	O
peri-operative	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[See	O
Contraindications	B-D000075202
(4)].	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[See	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1)	O
Flector	O
Patch	O
is	O
contraindicated	O
in	O
the	O
peri-operative	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
diclofenac,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Cardiovascular	O
Thrombotic	O
Events:	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
Use	O
the	O
lowest	O
effective	O
dose	O
of	O
Flector	O
Patch	O
in	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
(5.1)	O
Gastrointestinal	O
(GI)	O
Effects:	O
NSAIDs	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation.	O
Prescribe	O
Flector	O
Patch	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
(5.2)	O
Hepatic	O
Effects:	O
Elevation	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
Flector	O
Patch.	O
Discontinue	O
Flector	O
Patch	O
immediately	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen.	O
(5.3)	O
Hypertension	B-D006973
can	O
occur	O
with	O
NSAID	O
treatment.	O
Monitor	O
blood	O
pressure	O
closely	O
with	O
Flector	O
Patch	O
treatment.	O
(5.4)	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Use	O
Flector	O
Patch	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
(5.5)	O
Renal	O
effects:	O
Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Use	O
Flector	O
Patch	O
with	O
caution	O
in	O
patients	O
at	O
greatest	O
risk	O
of	O
this	O
reaction,	O
including	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors.	O
(5.6)	O
Anaphylactic	O
reactions	O
may	O
occur	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
and	O
in	O
patients	O
with	O
or	O
without	O
known	O
sensitivity	O
to	O
NSAIDs	O
or	O
prior	O
exposure	O
to	O
Flector	O
Patch.	O
Anaphylaxis	B-D000707
type	O
reactions	O
have	O
been	O
reported	O
with	O
NSAID	O
products,	O
including	O
diclofenac	O
products	O
such	O
as	O
Flector	O
Patch.	O
(5.7)	O
Skin	B-D012867
Reactions:	O
NSAIDs	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
(5.8)	O
Pregnancy	B-D011247
:	O
Avoid	O
the	O
use	O
of	O
Flector	O
Patch	O
at	O
or	O
beyond	O
30	O
weeks	O
gestation.	O
(5.9)	O
Preexisting	O
Asthma	B-D001249
:	O
Do	O
not	O
administer	O
to	O
patients	O
with	O
aspirin	O
sensitive	O
asthma	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
(5.13)	O
New	O
or	O
used	O
Flector	O
Patch	O
contains	O
sufficient	O
diclofenac	O
to	O
result	O
in	O
serious	O
harm	O
following	O
accidental	O
exposure	O
by	O
a	O
child	O
or	O
pet.	O
(5.14)	O
Eye	B-D005123
s:	O
Avoid	O
contact	O
of	O
Flector	O
Patch	O
with	O
eyes	O
and	O
mucosa.	O
(5.15)	O
Oral	O
NSAIDs:	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs.	O
(5.16)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Inform	O
patients	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
NSAIDs,	O
such	O
as	O
diclofenac,	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients,	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy,	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Prescribe	O
NSAIDs,	O
including	O
Flector	O
Patch,	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
for	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore,	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
diclofenac	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high	O
risk	O
patients,	O
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs.	O
5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
[ULN]	O
range)	O
or	O
greater	O
elevations	O
of	O
transaminases	O
occurred	O
in	O
about	O
15%	O
of	O
oral	O
diclofenac-treated	O
patients	O
in	O
clinical	O
trials	O
of	O
indications	O
other	O
than	O
acute	O
pain.	O
Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	O
injury.	O
In	O
clinical	O
trials	O
of	O
an	O
oral	O
diclofenac	O
–	O
misoprostol	O
combination	O
product,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
for	O
2-6	O
months,	O
patients	O
with	O
oral	O
diclofenac	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(>8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
this	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3-8	O
times	O
the	O
ULN),	O
and	O
marked	O
(>8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
oral	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
Measure	O
transaminases	O
(ALT	O
and	O
AST)	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
monitor	O
transaminases	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
discontinue	O
Flector	O
Patch	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
patients	O
should	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
Flector	O
Patch,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
Flector	O
Patch	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
certain	O
antibiotics,	O
anti-epileptics).	O
Caution	O
patients	O
to	O
avoid	O
taking	O
unprescribed	O
acetaminophen	O
while	O
using	O
Flector	O
Patch.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Flector	O
Patch,	O
can	O
lead	O
to	O
new	O
onset	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Use	O
Flector	O
Patch,	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Monitor	O
blood	O
pressure	O
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
Patients	B-D010361
taking	O
ACE	O
inhibitors,	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
Flector	O
Patch.	O
Use	O
Flector	O
Patch	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
Flector	O
Patch	O
in	O
patients	O
with	O
considerable	O
dehydration.	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Flector	O
Patch	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
Flector	O
Patch	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
Flector	O
Patch	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactic	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactic	O
reactions	O
may	O
occur	O
both	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
and	O
in	O
patients	O
without	O
known	O
sensitivity	O
to	O
NSAIDs	O
or	O
prior	O
exposure	O
to	O
Flector	O
Patch.	O
Do	O
not	O
prescribe	O
Flector	O
Patch	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs.	O
Anaphylaxis	B-D000707
type	O
reactions	O
have	O
been	O
reported	O
with	O
NSAID	O
products,	O
including	O
diclofenac	O
products,	O
such	O
as	O
Flector	O
Patch	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.13)].	O
Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Flector	O
Patch,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations,	O
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
Starting	O
at	O
30	O
weeks	O
gestation,	O
Flector	O
Patch,	O
and	O
other	O
NSAIDs,	O
should	O
be	O
avoided	O
by	O
pregnant	O
women	O
as	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
in	O
the	O
fetus	O
may	O
occur	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.10	O
Corticosteroid	O
Monitoring	O
Flector	O
Patch	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
disease	O
exacerbation.	O
Slowly	O
taper	O
patients	O
on	O
prolonged	O
corticosteroid	O
therapy	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Flector	O
Patch	O
in	O
reducing	O
inflammation	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.12	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
including	O
Flector	O
Patch,	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia.	O
NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration,	O
and	O
reversible.	O
Carefully	O
monitor	O
patients	O
receiving	O
Flector	O
Patch	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alterations	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
do	O
not	O
administer	O
Flector	O
Patch	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Accidental	O
Exposure	O
in	O
Child	B-D002648
ren	O
Even	O
a	O
used	O
Flector	O
Patch	O
contains	O
a	O
large	O
amount	O
of	O
diclofenac	O
epolamine	B-C104862
(as	O
much	O
as	O
170	O
mg).	O
The	O
potential	O
therefore	O
exists	O
for	O
a	O
small	O
child	O
or	O
pet	O
to	O
suffer	O
serious	O
adverse	O
effects	O
from	O
chewing	O
or	O
ingesting	O
a	O
new	O
or	O
used	O
Flector	O
Patch.	O
It	O
is	O
important	O
for	O
patients	O
to	O
store	O
and	O
dispose	O
of	O
Flector	O
Patch	O
out	O
of	O
the	O
reach	O
of	O
children	O
and	O
pets.	O
5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Flector	O
Patch	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Do	O
not	O
use	O
combination	O
therapy	O
with	O
Flector	O
Patch	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk.	O
5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Check	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
in	O
patients	O
on	O
long-term	O
treatment	O
with	O
NSAIDs.	O
Discontinue	O
Flector	O
Patch	O
if	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
adverse	O
events	O
with	O
Flector	O
Patch	O
are	O
application	O
site	O
reactions.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
King	O
Pharmaceuticals,	O
Inc.	O
at	O
1-800-546-4905	O
or	O
DSP@kingpharm.com	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
controlled	O
trials	O
during	O
the	O
premarketing	O
development	O
of	O
Flector	O
Patch,	O
approximately	O
600	O
patients	O
with	O
minor	O
sprains,	O
strains,	O
and	O
contusions	O
have	O
been	O
treated	O
with	O
Flector	O
Patch	O
for	O
up	O
to	O
two	O
weeks.	O
Adverse	O
Events	O
Lead	B-D007854
ing	O
to	O
Discontinuation	O
of	O
Treatment	O
In	O
the	O
controlled	O
trials,	O
3%	O
of	O
patients	O
in	O
both	O
the	O
Flector	O
Patch	O
and	O
placebo	O
patch	O
groups	O
discontinued	O
treatment	O
due	O
to	O
an	O
adverse	O
event.	O
The	O
most	O
common	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
were	O
application	O
site	O
reactions,	O
occurring	O
in	O
2%	O
of	O
both	O
the	O
Flector	O
Patch	O
and	O
placebo	O
patch	O
groups.	O
Application	O
site	O
reactions	O
leading	O
to	O
dropout	O
included	O
pruritus,	O
dermatitis,	O
and	O
burning.	O
Common	O
Adverse	O
Events	O
Localized	O
Reactions	O
Overall	B-D016424
,	O
the	O
most	O
common	O
adverse	O
events	O
associated	O
with	O
Flector	O
Patch	O
treatment	O
were	O
skin	O
reactions	O
at	O
the	O
site	O
of	O
treatment.	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥	O
1%	O
of	O
patients	O
in	O
controlled	O
trials	O
of	O
Flector	O
Patch.	O
A	O
majority	O
of	O
patients	O
treated	O
with	O
Flector	O
Patch	O
had	O
adverse	O
events	O
with	O
a	O
maximum	O
intensity	O
of	O
"mild"	O
or	O
"moderate."	O
Table	O
1.	O
Common	O
Adverse	O
Events	O
(by	O
body	O
system	O
and	O
preferred	O
term)	O
in	O
≥1%	O
of	O
Patients	B-D010361
treated	O
with	O
Flector	O
Patch	O
or	O
Placebo	O
Patch	O
The	O
table	O
lists	O
adverse	O
events	O
occurring	O
in	O
placebo-treated	O
patients	O
because	O
the	O
placebo-patch	O
was	O
comprised	O
of	O
the	O
same	O
ingredients	O
as	O
Flector	O
Patch	O
except	O
for	O
diclofenac.	O
Adverse	O
events	O
in	O
the	O
placebo	O
group	O
may	O
therefore	O
reflect	O
effects	O
of	O
the	O
non-active	O
ingredients.	O
Diclofenac	B-D004008
N=572	O
Placebo	O
N=564	O
N	O
Percent	O
N	O
Percent	O
Application	O
Site	O
Conditions	O
64	O
11	O
70	O
12	O
Pruritus	B-D011537
31	O
5	O
44	O
8	O
Dermatitis	B-D003872
9	O
2	O
3	O
<1	O
Burning	O
2	O
<1	O
8	O
1	O
OtherIncludes:	O
application	O
site	O
dryness,	O
irritation,	O
erythema,	O
atrophy,	O
discoloration,	O
hyperhidriosis,	O
and	O
vesicles.	O
22	O
4	O
15	O
3	O
Gastrointestinal	O
Disorders	O
49	O
9	O
33	O
6	O
Nausea	B-D009325
17	O
3	O
11	O
2	O
Dysgeusia	B-D004408
10	O
2	O
3	O
<1	O
Dyspepsia	B-D004415
7	O
1	O
8	O
1	O
OtherIncludes:	O
gastritis,	O
vomiting,	O
diarrhea,	O
constipation,	O
upper	O
abdominal	O
pain,	O
and	O
dry	O
mouth.	O
15	O
3	O
11	O
2	O
Nervous	B-D009420
System	I-D009420
Disorders	O
13	O
2	O
18	O
3	O
Headache	B-D006261
7	O
1	O
10	O
2	O
Paresthesia	B-D010292
6	O
1	O
8	O
1	O
Somnolence	O
4	O
1	O
6	O
1	O
Other	O
Includes:	O
hypoaesthesia,	O
dizziness,	O
and	O
hyperkinesias.	O
4	O
1	O
3	O
<1	O
Foreign	O
labeling	O
describes	O
that	O
dermal	O
allergic	O
reactions	O
may	O
occur	O
with	O
Flector	O
Patch	O
treatment.	O
Additionally,	O
the	O
treated	O
area	O
may	O
become	O
irritated	O
or	O
develop	O
itching,	O
erythema,	O
edema,	O
vesicles,	O
or	O
abnormal	O
sensation.	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(	O
5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(	O
4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(	O
5.4)	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(	O
5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(	O
4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(	O
5.4)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(	O
5.1,	O
14.6,	O
17.2).	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
(	O
5.4,	O
8.5,	O
14.6,	O
17.3).	O
Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
celecoxib	O
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen	O
(	O
5.5,	O
17.4).	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
celecoxib	O
(	O
5.2,	O
7.4,	O
17.2).	O
Fluid	O
retention	O
and	O
edema.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure	O
(	O
5.3,	O
17.6).	O
Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
celecoxib	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists	O
(	O
5.6,	O
7.4,	O
8.7,	O
17.6).	O
Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
celecoxib	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(	O
5.7,	O
10,	O
17.7).	O
Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions	O
(	O
5.8,	O
17.5).	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
celecoxib,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
celecoxib	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
].	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
celecoxib	O
[	O
see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
the	O
CLASS	O
study	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
celecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
active	O
GI	O
bleeding.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[	O
see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
celecoxib	O
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
celecoxib	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
celecoxib.	O
In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
celecoxib.	O
Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
celecoxib	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(	O
6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Greenstone	O
LLC	O
Professional	O
Information	B-D007255
Services	I-D007255
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General	O
:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional	O
:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia,	O
Psychiatric	O
:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders	O
:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary	O
:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular	O
:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal	O
:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic	O
:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous	O
:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS,	O
or	O
hypersensitivity	O
syndrome)	O
General	O
:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events	O
:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[	O
see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials	O
,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders	O
:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth	O
:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders	O
:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders	O
:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)].	O
•	O
VOLTAREN®	O
GEL	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1).	O
•	O
VOLTAREN®	O
GEL	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
•	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
•	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
VOLTAREN®	O
GEL	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
•	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
VOLTAREN®	O
GEL	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
•	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
•	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
VOLTAREN®	O
GEL	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
•	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
VOLTAREN®	O
GEL	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
•	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation.	O
(5.10,	O
8.1)	O
•	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
VOLTAREN®	O
GEL	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
VOLTAREN®	O
GEL	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
•Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
•Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
•Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
•Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
•If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
VOLTAREN®	O
GEL	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
•In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials,	O
of	O
oral	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
sodium	O
for	O
2-6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3-8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),VOLTAREN®	O
GEL	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
VOLTAREN®	O
GEL	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
VOLTAREN®	O
GEL,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
VOLTAREN®	O
GEL	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
VOLTAREN®	O
GEL,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	O
interactions	O
(	O
7)].	O
Avoid	O
the	O
use	O
of	O
VOLTAREN®	O
GEL	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
VOLTAREN®	O
GEL	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
VOLTAREN®	O
GEL	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
VOLTAREN®	O
GEL	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
VOLTAREN®	O
GEL.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
VOLTAREN®	O
GEL	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)].	O
Avoid	O
the	O
use	O
of	O
VOLTAREN®	O
GEL	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
VOLTAREN®	O
GEL	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactoid	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
VOLTAREN®	O
GEL	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
VOLTAREN®	O
GEL	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
VOLTAREN®	O
GEL	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
VOLTAREN®	O
GEL	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(	O
4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
VOLTAREN®	O
GEL,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(	O
8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
VOLTAREN®	O
GEL	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
VOLTAREN®	O
GEL,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
VOLTAREN®	O
GEL	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2,	O
5.3,	O
5.6)].	O
5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
areas	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light	O
induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
VOLTAREN®	O
GEL	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
VOLTAREN®	O
GEL	O
with	O
eyes	O
and	O
mucosa,	O
although	O
not	O
studied,	O
should	O
be	O
avoided.	O
Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
eye	O
contact	O
occurs,	O
they	O
should	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Do	O
not	O
use	O
combination	O
therapy	O
with	O
VOLTAREN®	O
GEL	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
•Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
•Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
•Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
•Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
•Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
patients	O
treated	O
with	O
VOLTAREN®	O
GEL	O
and	O
greater	O
than	O
placebo)	O
are	O
application	O
site	O
reactions,	O
including	O
dermatitis.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sand	B-D000080463
oz	O
Inc.	O
at	O
1-800-525-8747	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
During	O
clinical	O
development,	O
913	O
patients	O
were	O
exposed	O
to	O
VOLTAREN®	O
GEL	O
in	O
randomized,	O
double-blind,	O
multicenter,	O
vehicle-controlled,	O
parallel-group	O
studies	O
in	O
osteoarthritis	O
of	O
the	O
superficial	O
joints	O
of	O
the	O
extremities.	O
Of	O
these,	O
513	O
patients	O
received	O
VOLTAREN®	O
GEL	O
for	O
osteoarthritis	O
of	O
the	O
knee	O
and	O
400	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
the	O
hand.	O
Additionally,	O
583	O
patients	O
were	O
exposed	O
to	O
VOLTAREN®	O
GEL	O
in	O
an	O
uncontrolled,	O
open-label,	O
long-term	O
safety	O
trial	O
in	O
osteoarthritis	O
of	O
the	O
knee.	O
Of	O
these,	O
355	O
patients	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
1	O
knee	O
and	O
228	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
both	O
knees.	O
Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
safety	O
trial.	O
Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
patients	O
treated	O
with	O
VOLTAREN®	O
GEL:	O
Non-serious	O
adverse	O
reactions	O
that	O
were	O
reported	O
during	O
the	O
short-term	O
placebo-controlled	O
studies	O
comparing	O
VOLTAREN®	O
GEL	O
and	O
placebo	O
(vehicle	O
gel)	O
over	O
study	O
periods	O
of	O
8	O
to	O
12	O
weeks	O
(16	O
g	O
per	O
day),	O
were	O
application	O
site	O
reactions.	O
These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>1%	O
of	O
treated	O
patients	O
with	O
a	O
greater	O
frequency	O
in	O
the	O
VOLTAREN®	O
GEL	O
group	O
(7%)	O
than	O
the	O
placebo	O
group	O
(2%).	O
Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported.	O
Application	O
site	O
dermatitis	O
was	O
the	O
most	O
frequent	O
type	O
of	O
application	O
site	O
reaction	O
and	O
was	O
reported	O
by	O
4%	O
of	O
patients	O
treated	O
with	O
VOLTAREN®	O
GEL,	O
compared	O
to	O
1%	O
of	O
placebo	O
patients.	O
Table	O
1:	O
Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
VOLTAREN®	O
GEL	O
Patients	B-D010361
)	O
–	O
Short-term	O
Controlled	O
Trials	O
Adverse	O
Reaction†	O
VOLTAREN®	O
GEL	O
N=913	O
Placebo	O
(vehicle)	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
dermatitis	O
32	O
(4)	O
6	O
(<1)	O
Application	O
site	O
pruritus	O
7	O
(<1)	O
1	O
(<1)	O
Application	O
site	O
erythema	O
6	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
paresthesia	O
5	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
dryness	O
4	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
vesicles	O
3	O
(<1)	O
0	O
Application	O
site	O
irritation	O
2	O
(<1)	O
0	O
Application	O
site	O
papules	O
1	O
(<1)	O
0	O
†	O
Preferred	O
Term	O
according	O
to	O
MedDRA	O
9.1.	O
In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
patients	O
treated	O
with	O
VOLTAREN®	O
GEL,	O
and	O
3%	O
for	O
patients	O
in	O
the	O
placebo	O
group.	O
Application	O
site	O
reactions,	O
including	O
application	O
site	O
dermatitis,	O
were	O
the	O
most	O
frequent	O
reason	O
for	O
treatment	O
discontinuation.	O
Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
safety	O
study,	O
distribution	O
of	O
adverse	O
reactions	O
was	O
similar	O
to	O
that	O
in	O
the	O
placebo-controlled	O
studies.	O
In	O
this	O
study,	O
where	O
patients	O
were	O
treated	O
for	O
up	O
to	O
1	O
year	O
with	O
VOLTAREN®	O
GEL	O
up	O
to	O
32	O
g	O
per	O
day,	O
application	O
site	O
dermatitis	O
was	O
observed	O
in	O
11%	O
of	O
patients.	O
Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
patients.	O
The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
dermatitis,	O
which	O
was	O
experienced	O
by	O
6%	O
of	O
patients.	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
Etodolac	B-D017308
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
a	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1,000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain*,	O
diarrhea*,	O
flatulence*,	O
nausea*,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise*,	O
dizziness*,	O
depression,	O
nervousness.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death	O
Cardiovascular	O
system	O
-	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Indomethacin	B-D007213
may	O
mask	O
the	O
usual	O
signs	O
of	O
infection.	O
(5.1)	O
Monitor	O
for	O
signs	O
of	O
hepatic	O
reactions.	O
Indomethacin	B-D007213
for	O
Injection	O
may	O
need	O
to	O
be	O
discontinued.	O
(5.2)	O
Indomethacin	B-D007213
for	O
Injection	O
may	O
inhibit	O
platelet	O
aggregation.	O
(5.3)	O
Gastrointestinal	O
Effects:	O
Monitor	O
neonates	O
for	O
blood	O
in	O
stool.	O
(5.4)	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects:	O
Monitor	O
neonates	O
for	O
intraventricular	O
hemorrhage.	O
(5.5)	O
Renal	O
Effects:	O
Monitor	O
renal	O
function	O
and	O
serum	O
electrolytes.	O
(5.6)	O
5.1	O
Infection	O
Indomethacin	B-D007213
may	O
mask	O
the	O
usual	O
signs	O
and	O
symptoms	O
of	O
infection.	O
Therefore,	O
the	O
physician	O
must	O
be	O
continually	O
on	O
the	O
alert	O
for	O
this	O
and	O
should	O
use	O
the	O
drug	O
with	O
extra	O
care	O
in	O
the	O
presence	O
of	O
existing	O
controlled	O
infection.	O
5.2	O
Hepatic	O
Reactions	O
Severe	O
hepatic	O
reactions	O
have	O
been	O
reported	O
in	O
adults	O
treated	O
chronically	O
with	O
oral	O
indomethacin	O
for	O
arthritic	O
disorders.	O
[For	O
further	O
information,	O
see	O
package	O
insert	O
for	O
oral	O
indomethacin].	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop	O
in	O
the	O
neonate,	O
or	O
if	O
systemic	O
manifestations	O
occur,	O
discontinue	O
Indomethacin	B-D007213
for	O
Injection.	O
5.3	O
Platelet	B-D010974
Aggregation	I-D010974
Indomethacin	B-D007213
for	O
Injection	O
may	O
inhibit	O
platelet	O
aggregation.	O
In	O
one	O
small	O
study,	O
platelet	O
aggregation	O
was	O
grossly	O
abnormal	O
after	O
indomethacin	O
therapy	O
(given	O
orally	O
to	O
premature	O
infants	O
to	O
close	O
the	O
ductus	O
arteriosus).	O
Platelet	O
aggregation	O
returned	O
to	O
normal	O
by	O
the	O
tenth	O
day.	O
Observe	O
premature	O
infants	O
for	O
signs	O
of	O
bleeding.	O
5.4	O
Gastrointestinal	O
Effects	O
In	O
the	O
collaborative	O
study,	O
major	O
gastrointestinal	O
bleeding	O
was	O
no	O
more	O
common	O
in	O
neonates	O
receiving	O
indomethacin	O
than	O
in	O
neonates	O
on	O
placebo.	O
However,	O
minor	O
gastrointestinal	O
bleeding	O
(i.e.,	O
chemical	O
detection	O
of	O
blood	O
in	O
the	O
stool)	O
was	O
more	O
commonly	O
noted	O
in	O
neonates	O
treated	O
with	O
indomethacin.	O
Severe	O
gastrointestinal	O
effects	O
have	O
been	O
reported	O
in	O
adults	O
with	O
various	O
arthritic	O
disorders	O
treated	O
chronically	O
with	O
oral	O
indomethacin.	O
[For	O
further	O
information,	O
see	O
package	O
insert	O
for	O
oral	O
indomethacin].	O
5.5	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Prema	B-C070504
turity	O
per	O
se	O
is	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
spontaneous	O
intraventricular	O
hemorrhage.	O
Because	O
indomethacin	O
may	O
inhibit	O
platelet	O
aggregation,	O
the	O
potential	O
for	O
intraventricular	O
bleeding	O
may	O
be	O
increased.	O
However,	O
in	O
the	O
large	O
multicenter	O
study	O
of	O
Indomethacin	B-D007213
for	O
Injection,	O
the	O
incidence	O
of	O
intraventricular	O
hemorrhage	O
in	O
neonates	O
treated	O
with	O
Indomethacin	B-D007213
for	O
Injection	O
was	O
not	O
significantly	O
higher	O
than	O
in	O
the	O
control	O
neonates.	O
5.6	O
Renal	O
Effects	O
Indomethacin	B-D007213
for	O
Injection	O
may	O
cause	O
significant	O
reduction	O
in	O
urine	O
output	O
(50	O
percent	O
or	O
more)	O
with	O
concomitant	O
elevations	O
of	O
blood	O
urea	O
nitrogen	O
and	O
creatinine,	O
and	O
reductions	O
in	O
glomerular	O
filtration	O
rate	O
and	O
creatinine	O
clearance.	O
These	O
effects	O
in	O
most	O
neonates	O
are	O
transient,	O
disappearing	O
with	O
cessation	O
of	O
therapy	O
with	O
Indomethacin	B-D007213
for	O
Injection.	O
However,	O
because	O
adequate	O
renal	O
function	O
can	O
depend	O
upon	O
renal	O
prostaglandin	O
synthesis,	O
Indomethacin	B-D007213
for	O
Injection	O
may	O
precipitate	O
renal	O
insufficiency,	O
including	O
acute	O
renal	O
failure,	O
especially	O
in	O
neonates	O
with	O
other	O
conditions	O
that	O
may	O
adversely	O
affect	O
renal	O
function	O
(e.g.,	O
extracellular	O
volume	O
depletion	O
from	O
any	O
cause,	O
congestive	O
heart	O
failure,	O
sepsis,	O
concomitant	O
use	O
of	O
any	O
nephrotoxic	O
drug,	O
hepatic	O
dysfunction).	O
When	O
significant	O
suppression	O
of	O
urine	O
volume	O
occurs	O
after	O
a	O
dose	O
of	O
Indomethacin	B-D007213
for	O
Injection,	O
do	O
not	O
give	O
additional	O
doses	O
until	O
urine	O
output	O
returns	O
to	O
normal	O
levels.	O
Indomethacin	B-D007213
for	O
Injection	O
in	O
pre-term	O
infants	O
may	O
suppress	O
water	O
excretion	O
to	O
a	O
greater	O
extent	O
than	O
sodium	O
excretion.	O
When	O
this	O
occurs,	O
a	O
significant	O
reduction	O
in	O
serum	O
sodium	O
values	O
(i.e.,	O
hyponatremia)	O
may	O
result.	O
Monitor	O
renal	O
function	O
and	O
serum	O
electrolyte	O
levels	O
during	O
therapy	O
with	O
Indomethacin	B-D007213
for	O
Injection	O
[see	O
Dosage	O
and	O
Administration	O
(2)]	O
.	O
5.7	O
Administration	O
Administer	O
Indomethacin	B-D007213
for	O
Injection	O
carefully	O
to	O
avoid	O
extravascular	O
injection	O
or	O
leakage	O
as	O
the	O
solution	O
may	O
be	O
irritating	O
to	O
tissue.	O
6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
are	O
bleeding	O
problems,	O
higher	O
incidence	O
of	O
transient	O
oliguria	O
and	O
elevations	O
of	O
serum	O
creatinine.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Fresenius	O
Kabi	O
USA,	O
LLC	O
at	O
1-800-551-7176	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
In	O
a	O
double-blind,	O
placebo-controlled	O
trial	O
of	O
405	O
premature	O
infants	O
weighing	O
less	O
than	O
or	O
equal	O
to	O
1,750	O
g	O
with	O
evidence	O
of	O
large	O
ductal	O
shunting,	O
in	O
those	O
neonates	O
treated	O
with	O
indomethacin	O
(n=206),	O
there	O
was	O
a	O
statistically	O
significantly	O
greater	O
incidence	O
of	O
bleeding	O
problems,	O
including	O
gross	O
or	O
microscopic	O
bleeding	O
into	O
the	O
gastrointestinal	O
tract,	O
oozing	O
from	O
the	O
skin	O
after	O
needle	O
stick,	O
pulmonary	O
hemorrhage,	O
and	O
disseminated	O
intravascular	O
coagulopathy.	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
treatment	O
groups	O
in	O
intracranial	O
hemorrhage.	O
The	O
neonates	O
treated	O
with	O
Indomethacin	B-D007213
for	O
Injection	O
had	O
a	O
significantly	O
higher	O
incidence	O
of	O
transient	O
oliguria	O
and	O
elevations	O
of	O
serum	O
creatinine	O
(greater	O
than	O
or	O
equal	O
to	O
1.8	O
mg/dL)	O
than	O
did	O
the	O
neonates	O
treated	O
with	O
placebo.	O
The	O
incidences	O
of	O
retrolental	O
fibroplasia	O
(grades	O
III	O
and	O
IV)	O
and	O
pneumothorax	O
in	O
neonates	O
treated	O
with	O
Indomethacin	B-D007213
for	O
Injection	O
were	O
no	O
greater	O
than	O
in	O
placebo	O
controls	O
and	O
were	O
statistically	O
significantly	O
lower	O
than	O
in	O
surgically-treated	O
neonates.	O
The	O
following	O
additional	O
adverse	O
reactions	O
in	O
neonates	O
have	O
been	O
reported	O
from	O
the	O
collaborative	O
study,	O
anecdotal	O
case	O
reports,	O
from	O
other	O
studies	O
using	O
rectal,	O
oral,	O
or	O
intravenous	O
indomethacin	O
for	O
treatment	O
of	O
patent	O
ductus	O
arteriosus	O
or	O
in	O
marketed	O
use.	O
The	O
rates	O
are	O
calculated	O
from	O
a	O
database	O
that	O
contains	O
experience	O
of	O
849	O
indomethacin-treated	O
neonates	O
reported	O
in	O
the	O
medical	O
literature,	O
regardless	O
of	O
the	O
route	O
of	O
administration.	O
One	O
year	O
follow-up	O
is	O
available	O
on	O
175	O
neonates	O
and	O
shows	O
no	O
long-term	O
sequelae	O
that	O
could	O
be	O
attributed	O
to	O
indomethacin.	O
In	O
controlled	O
clinical	O
studies,	O
only	O
electrolyte	O
imbalance	O
and	O
renal	O
dysfunction	O
(of	O
the	O
reactions	O
listed	O
below)	O
occurred	O
statistically	O
significantly	O
more	O
frequently	O
after	O
Indomethacin	B-D007213
for	O
Injection	O
than	O
after	O
placebo.	O
Reactions	O
marked	O
with	O
a	O
single	O
asterisk	O
(*)	O
occurred	O
in	O
3	O
to	O
9	O
percent	O
of	O
indomethacin-treated	O
neonates;	O
those	O
marked	O
with	O
a	O
double	O
asterisk	O
(**)	O
occurred	O
in	O
3	O
to	O
9	O
percent	O
of	O
both	O
indomethacin-	O
and	O
placebo-treated	O
neonates.	O
Unmarked	O
reactions	O
occurred	O
in	O
less	O
than	O
3	O
percent	O
of	O
neonates.	O
Renal:	O
renal	O
failure,	O
renal	O
dysfunction	O
in	O
41	O
percent	O
of	O
neonates,	O
including	O
one	O
or	O
more	O
of	O
the	O
following:	O
reduced	O
urinary	O
output;	O
reduced	O
urine	O
sodium,	O
chloride,	O
or	O
potassium,	O
urine	O
osmolality,	O
free	O
water	O
clearance,	O
or	O
glomerular	O
filtration	O
rate;	O
elevated	O
serum	O
creatinine	O
or	O
BUN;	O
uremia.	O
Cardiovascular:	O
intracranial	O
bleeding**,	O
pulmonary	O
hypertension.	O
Gastrointestinal:	O
gastrointestinal	O
bleeding*,	O
vomiting,	O
abdominal	O
distention,	O
transient	O
ileus,	O
gastric	O
perforation,	O
localized	O
perforation(s)	O
of	O
the	O
small	O
and/or	O
large	O
intestine,	O
necrotizing	O
enterocolitis.	O
Metabolic:	O
hyponatremia*,	O
elevated	O
serum	O
potassium*,	O
reduction	O
in	O
blood	O
sugar,	O
including	O
hypoglycemia,	O
increased	O
weight	O
gain	O
(fluid	O
retention).	O
Coagulation:	O
decreased	O
platelet	O
aggregation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
.	O
The	O
following	O
adverse	O
reactions	O
have	O
also	O
been	O
reported	O
in	O
neonates	O
treated	O
with	O
indomethacin,	O
however,	O
a	O
causal	O
relationship	O
to	O
therapy	O
with	O
Indomethacin	B-D007213
for	O
Injection	O
has	O
not	O
been	O
established:	O
Cardiovascular:	O
bradycardia.	O
Respiratory:	O
apnea,	O
exacerbation	O
of	O
pre-existing	O
pulmonary	O
infection.	O
Metabolic:	O
acidosis/alkalosis.	O
Hematologic:	O
disseminated	O
intravascular	O
coagulation,	O
thrombocytopenia.	O
Ophthalmic:	O
retrolental	O
fibroplasia.**	O
A	O
variety	O
of	O
additional	O
adverse	O
experiences	O
have	O
been	O
reported	O
in	O
adults	O
treated	O
with	O
oral	O
indomethacin	O
for	O
moderate	O
to	O
severe	O
rheumatoid	O
arthritis,	O
osteoarthritis,	O
ankylosing	O
spondylitis,	O
acute	O
painful	O
shoulder	O
and	O
acute	O
gouty	O
arthritis	O
(see	O
package	O
insert	O
for	O
oral	O
indomethacin	O
for	O
additional	O
information	O
concerning	O
adverse	O
reactions	O
and	O
other	O
cautionary	O
statements).	O
Their	O
relevance	O
to	O
the	O
pre-term	O
infant	O
receiving	O
indomethacin	O
for	O
patent	O
ductus	O
arteriosus	O
is	O
unknown,	O
however,	O
the	O
possibility	O
exists	O
that	O
these	O
experiences	O
may	O
be	O
associated	O
with	O
the	O
use	O
of	O
Indomethacin	B-D007213
for	O
Injection	O
in	O
pre-term	O
infants.	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(5.4)	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.4)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(5.1,	O
14.6,	O
17.2).	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
(5.4,	O
8.5,	O
14.6,	O
17.3).	O
Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
celecoxib	O
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen	O
(5.5,	O
17.4).	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
celecoxib	O
(5.2,	O
7.4,	O
17.2).	O
Fluid	O
retention	O
and	O
edema.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure	O
(5.3,	O
17.6).	O
Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
celecoxib	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6).	O
Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
celecoxib	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(5.7,	O
10,	O
17.7).	O
Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions	O
(5.8,	O
17.5).	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
celecoxib,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
celecoxib	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
celecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
active	O
GI	O
bleeding.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
celecoxib	O
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
celecoxib	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
celecoxib.	O
In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
celecoxib.	O
Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
celecoxib	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General	O
:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional	O
:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia,	O
Psychiatric	O
:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders	O
:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary	O
:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular	O
:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal	O
:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic	O
:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous	O
:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS,	O
or	O
hypersensitivity	O
syndrome)	O
General	O
:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events	O
:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kgN=77	O
Celecoxib	B-D000068579
6	O
mg/kgN=82	O
Naproxen	B-D009288
7.5	O
mg/kgN=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
InvestigationsAbnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials	O
,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)N	O
=	O
2285	O
PlaceboN=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders	O
:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth	O
:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders	O
:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders	O
:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
in	O
the	O
perioperative	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)]	O
.	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
strong>Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
in	O
the	O
perioperative	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)]	O
.	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
Use	O
the	O
lowest	O
effective	O
dose	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
(	O
5.1)	O
NSAIDs	O
can	O
cause	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation.	O
Prescribe	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
(	O
5.2)	O
Elevation	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
NSAIDs.	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen.	O
(	O
5.3)	O
Hypertension	B-D006973
can	O
occur	O
with	O
NSAID	O
treatment.	O
Monitor	O
blood	O
pressure	O
closely	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
treatment.	O
(	O
5.4)	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
(	O
5.5)	O
Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
at	O
greatest	O
risk	O
of	O
this	O
reaction,	O
including	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors.	O
(	O
5.6)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
or	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution.	O
(	O
5.7)	O
NSAIDs	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
(	O
5.8)	O
Not	O
for	O
use	O
during	O
pregnancy.	O
(	O
5.9)	O
Do	O
not	O
administer	O
to	O
patients	O
with	O
aspirin	O
sensitive	O
asthma	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
(	O
5.10)	O
Avoid	O
exposure	O
of	O
treated	O
knee(s)	O
to	O
natural	O
or	O
artificial	O
sunlight.	O
(	O
5.11)	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
(	O
5.12)	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs.	O
(	O
5.13)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
oral	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
COX-2	O
selective	O
and	O
nonselective	O
orally	O
administered	O
NSAIDs,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Inform	O
patients	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
an	O
orally	O
administered	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
NSAIDS,	O
such	O
as	O
diclofenac,	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Prescribe	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore,	O
use	O
special	O
care	O
when	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
diclofencac	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs.	O
5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
[ULN]	O
range)	O
or	O
greater	O
elevations	O
of	O
transaminases	O
occurred	O
in	O
about	O
15%	O
of	O
oral	O
diclofenac-treated	O
patients	O
in	O
clinical	O
trials	O
of	O
indications	O
other	O
than	O
acute	O
pain.	O
Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	O
injury.	O
In	O
clinical	O
trials	O
of	O
an	O
oral	O
diclofenac	O
–	O
misoprostol	O
combination	O
product,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
for	O
2	O
to	O
6	O
months,	O
patients	O
with	O
oral	O
diclofenac	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(>8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
this	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(>8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
test	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
oral	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
sever	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
oral	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Measure	O
transaminases	O
(ALT	O
and	O
AST)	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
monitor	O
transaminases	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flulike"	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
to	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver-related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
certain	O
antibiotics,	O
antiepileptics).	O
Caution	O
patients	O
to	O
avoid	O
taking	O
unprescribed	O
acetaminophen	O
while	O
using	O
diclofenac	O
sodium	O
topical	O
solution.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac,	O
can	O
lead	O
to	O
new	O
onset	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Use	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Monitor	O
blood	O
pressure	O
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
Patients	B-D010361
taking	O
ACE-inhibitors,	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution.	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
considerable	O
dehydration.	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
is	O
not	O
recommended	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
diclofenac	O
sodium	O
topical	O
solution	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution.	O
Do	O
not	O
prescribe	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.10)].	O
Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Do	O
not	O
apply	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
open	O
skin	O
wounds,	O
infections,	O
inflammations,	O
or	O
exfoliative	O
dermatitis,	O
as	O
it	O
may	O
affect	O
absorption	O
and	O
tolerability	O
of	O
the	O
drug.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations,	O
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
should	O
not	O
be	O
used	O
by	O
pregnant	O
or	O
nursing	O
women	O
or	O
those	O
intending	O
to	O
become	O
pregnant.	O
5.10	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross-reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
do	O
not	O
administer	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.11	O
Sun	O
Exposure	O
Instruct	O
patients	O
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
knee(s)	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light-induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.13	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	O
and	O
conduct	O
periodic	O
laboratory	O
evaluations.	O
5.14	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-response	O
illness.	O
For	O
patients	O
on	O
prolonged	O
corticosteroid	O
therapy,	O
taper	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Hematological	O
Effects	O
The	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	O
subjects	O
administered	O
80	O
drops	O
four	O
times	O
a	O
day	O
for	O
7	O
days.	O
There	O
was	O
no	O
significant	O
change	O
in	O
platelet	O
aggregation	O
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)].	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
Check	O
hemoglobin	O
or	O
hematocrit	O
of	O
patients	O
on	O
diclofenac	O
sodium	O
topical	O
solution	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration	O
and	O
reversible.	O
Carefully	O
monitor	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alteration	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants.	O
5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms	O
in	O
patients	O
taking	O
NSAIDs,	O
monitor	O
patients	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Check	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
in	O
patients	O
on	O
long-term	O
treatment	O
with	O
NSAIDs.	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
if	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen.	O
6.	O
ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
are	O
application	O
site	O
reactions.	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp.	O
at	O
1-800-667-4708	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trial	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution	O
of	O
911	O
patients	O
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	O
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	O
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	O
treated	O
for	O
at	O
least	O
12	O
months.	O
The	O
population	O
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	O
were	O
Caucasians,	O
64%	O
were	O
females,	O
and	O
all	O
patients	O
had	O
primary	O
osteoarthritis.	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies.	O
Application	O
site	O
reactions:	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment	O
related	O
adverse	O
events	O
in	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
Application	O
site	O
reactions	O
were	O
characterized	O
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	O
induration,	O
vesicles,	O
paresthesia,	O
pruritus,	O
vasodilation,	O
acne,	O
and	O
urticaria.	O
The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	O
(32%),	O
contact	O
dermatitis	O
characterized	O
by	O
skin	O
erythema	O
and	O
induration	O
(9%),	O
contact	O
dermatitis	O
with	O
vescicles	O
(2%)	O
and	O
pruritus	O
(4%).	O
In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	O
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac.	O
In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	O
study,	O
contact	O
dermatitis	O
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	O
with	O
vesicles	O
in	O
10%	O
of	O
patients,	O
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	O
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%.	O
Adverse	O
events	O
common	O
to	O
the	O
NSAID	O
class:	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
flatulence,	O
abdominal	O
pain,	O
edema;	O
see	O
Table	O
1).	O
The	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac,	O
compared	O
to	O
oral	O
diclofenac	O
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	O
(3%	O
vs.	O
less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	O
(12%	O
vs.	O
7%),	O
urea	O
(20%	O
vs.	O
12%),	O
and	O
hemoglobin	O
(13%	O
vs.	O
9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	O
transaminases.	O
Table	O
1:	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
osteoarthritis.	O
Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	O
trials.	O
Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
N=911	O
Topical	O
Placebo	O
N=332	O
Adverse	O
Reaction	O
Preferred	O
Term	O
according	O
to	O
COSTART	O
N(%)	O
N(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non	O
–	O
U.S.	O
postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
Whole:	O
abdominal	O
pain,	O
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	O
back	O
pain,	O
body	O
odor,	O
chest	O
pain,	O
edema,	O
face	O
edema,	O
halitosis,	O
headache,	O
lack	O
of	O
drug	O
effect,	O
neck	O
rigidity,	O
pain	O
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	O
dry	O
mouth,	O
dyspepsia,	O
gastroenteritis,	O
decreased	O
appetite,	O
mouth	O
ulceration,	O
nausea,	O
rectal	O
hemorrhage,	O
ulcerative	O
stomatitis	O
Metabolic	O
and	O
Nutritional:	O
creatinine	O
increased	O
Musculoskeletal:	O
leg	O
cramps,	O
myalgia	O
Nervous:	O
depression,	O
dizziness,	O
drowsiness,	O
lethargy,	O
paresthesia,	O
paresthesia	O
at	O
application	O
site	O
Respiratory:	O
asthma,	O
dyspnea,	O
laryngismus,	O
laryngitis,	O
pharyngitis	O
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	O
contact	O
dermatitis	O
with	O
vesicles,	O
dry	O
skin,	O
pruritus,	O
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	O
rash,	O
pruritus,	O
skin	O
discoloration,	O
urticaria	O
Special	O
senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	O
ear	O
pain,	O
eye	O
disorder,	O
eye	O
pain,	O
taste	O
perversion	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Delayed	O
healing	O
(5.1)	O
Cross-sensitivity	O
or	O
hypersensitivity	O
(5.2)	O
Increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
thrombocyte	O
aggregation	O
(5.3)	O
Cornea	B-D003315
l	O
effects	O
including	O
keratitis	O
(5.4)	O
5.1	O
Delayed	O
Healing	O
Topical	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
slow	O
or	O
delay	O
healing.	O
Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing.	O
Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
steroids	O
may	O
increase	O
the	O
potential	O
for	O
healing	O
problems.	O
5.2	O
Cross-Sensitivity	O
or	O
Hypersensitivity	B-D006967
There	O
is	O
the	O
potential	O
for	O
cross-sensitivity	O
to	O
acetylsalicylic	O
acid,	O
phenylacetic	B-C025136
acid	I-C025136
derivatives,	O
and	O
other	O
NSAIDs.	O
There	O
have	O
been	O
reports	O
of	O
bronchospasm	O
or	O
exacerbation	O
of	O
asthma	O
associated	O
with	O
the	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solution	O
in	O
patients	O
who	O
have	O
either	O
a	O
known	O
hypersensitivity	O
to	O
aspirin/non-steroidal	O
anti-inflammatory	O
drugs	O
or	O
a	O
past	O
medical	O
history	O
of	O
asthma.	O
Therefore,	O
caution	O
should	O
be	O
used	O
when	O
treating	O
individuals	O
who	O
have	O
previously	O
exhibited	O
sensitivities	O
to	O
these	O
drugs.	O
5.3	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
With	O
some	O
NSAIDs,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
thrombocyte	O
aggregation.	O
There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
tissues	O
(including	O
hyphemas)	O
in	O
conjunction	O
with	O
ocular	O
surgery.	O
It	O
is	O
recommended	O
that	O
ACULAR	O
®	O
ophthalmic	O
solution	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
known	O
bleeding	O
tendencies	O
or	O
who	O
are	O
receiving	O
other	O
medications,	O
which	O
may	O
prolong	O
bleeding	O
time.	O
5.4	O
Cornea	B-D003315
l	O
Effects	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
keratitis.	O
In	O
some	O
susceptible	O
patients,	O
continued	O
use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
epithelial	O
breakdown,	O
corneal	O
thinning,	O
corneal	O
erosion,	O
corneal	O
ulceration,	O
or	O
corneal	O
perforation.	O
These	O
events	O
may	O
be	O
sight	O
threatening.	O
Patients	B-D010361
with	O
evidence	O
of	O
corneal	O
epithelial	O
breakdown	O
should	O
immediately	O
discontinue	O
use	O
of	O
topical	O
NSAIDs	O
and	O
should	O
be	O
closely	O
monitored	O
for	O
corneal	O
health.	O
Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
patients	O
with	O
complicated	O
ocular	O
surgeries,	O
corneal	O
denervation,	O
corneal	O
epithelial	O
defects,	O
diabetes	O
mellitus,	O
ocular	O
surface	O
diseases	O
(e.g.,	O
dry	O
eye	O
syndrome),	O
rheumatoid	O
arthritis,	O
or	O
repeat	O
ocular	O
surgeries	O
within	O
a	O
short	O
period	O
of	O
time	O
may	O
be	O
at	O
increased	O
risk	O
for	O
corneal	O
adverse	O
events	O
which	O
may	O
become	O
sight	O
threatening.	O
Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients.	O
Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
1	O
day	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
post-surgery	O
may	O
increase	O
patient	O
risk	O
for	O
the	O
occurrence	O
and	O
severity	O
of	O
corneal	O
adverse	O
events.	O
5.5	O
Contact	O
Lens	O
Wear	O
ACULAR	O
®	O
should	O
not	O
be	O
administered	O
while	O
wearing	O
contact	O
lenses.	O
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
the	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
most	O
frequent	O
adverse	O
reactions	O
reported	O
by	O
up	O
to	O
40%	O
of	O
patients	O
participating	O
in	O
clinical	O
trials	O
have	O
been	O
transient	O
stinging	O
and	O
burning	O
on	O
instillation.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Allergan	O
at	O
1-800-433-8871	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
The	O
most	O
frequent	O
adverse	O
reactions	O
reported	O
with	O
the	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
have	O
been	O
transient	O
stinging	O
and	O
burning	O
on	O
instillation.	O
These	O
reactions	O
were	O
reported	O
by	O
up	O
to	O
40%	O
of	O
patients	O
participating	O
in	O
clinical	O
trials.	O
Other	O
adverse	O
reactions	O
occurring	O
approximately	O
1	O
to	O
10%	O
of	O
the	O
time	O
during	O
treatment	O
with	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
included	O
allergic	O
reactions,	O
corneal	O
edema,	O
iritis,	O
ocular	O
inflammation,	O
ocular	O
irritation,	O
superficial	O
keratitis,	O
and	O
superficial	O
ocular	O
infections.	O
Other	O
adverse	O
reactions	O
reported	O
rarely	O
with	O
the	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
included:	O
corneal	O
infiltrates,	O
corneal	O
ulcer,	O
eye	O
dryness,	O
headaches,	O
and	O
visual	O
disturbance	O
(blurry	O
vision).	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-marketing	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solution	O
0.5%	O
in	O
clinical	O
practice.	O
Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size,	O
estimates	O
of	O
frequency	O
cannot	O
be	O
made.	O
The	O
reactions,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
ketorolac	O
tromethamine	O
ophthalmic	O
solution	O
0.5%	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
bronchospasm	O
or	O
exacerbation	O
of	O
asthma,	O
corneal	O
erosion,	O
corneal	O
perforation,	O
corneal	O
thinning,	O
and	O
epithelial	O
breakdown	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.4)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS).	O
•	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS	O
)	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
•Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
•Hypertension	O
(see	O
WARNINGS	O
)	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
•Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
•Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
•Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDS)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(see	O
Warnings	O
and	O
Precautions	O
)	O
(	O
5.1	O
)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
Contraindications	B-D000075202
,	O
Warnings	O
and	O
Precautions	O
).	O
(	O
4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(	O
5.4)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDS)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
).	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
Contraindications	B-D000075202
,	O
Warnings	O
and	O
Precautions	O
(	O
4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(	O
5.4)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(	O
5.1,	O
14.6,	O
17.2).	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
(	O
5.4,	O
8.5,	O
14.6,	O
17.3).	O
Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
celecoxib	O
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen	O
(	O
5.5,	O
17.4).	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
celecoxib	O
(	O
5.2,	O
7.4,	O
17.2).	O
Fluid	O
retention	O
and	O
edema.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure	O
(	O
5.3,	O
17.6).	O
Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
celecoxib	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists	O
(	O
5.6,	O
7.4,	O
8.7,	O
17.6).	O
Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
celecoxib	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(	O
5.7,	O
10,	O
17.7).	O
Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions	O
(	O
5.8,	O
17.5).	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDS	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(	O
4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post	O
MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
NSAIDs.	O
Use	O
of	O
[active	O
moiety]	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
[e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
clockers	O
(ARBs)]	O
(see	O
Drug	B-D004347
Interactions	I-D004347
).	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
celecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[	O
see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
celecoxib	O
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
celecoxib	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
celecoxib.	O
In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
celecoxib.	O
Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
celecoxib	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(	O
6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp.	O
at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CXB	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CXB	O
=	O
celecoxib	O
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General	O
:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional	O
:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia	O
Psychiatric	O
:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders	O
:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary	O
:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular	O
:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal	O
:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic	O
:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous	O
:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
General	O
:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events	O
:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[	O
see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials	O
,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders	O
:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth	O
:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders	O
:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders	O
:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(	O
5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(	O
4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(	O
5.4)	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(	O
5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(	O
4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(	O
5.4)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(	O
5.1,	O
14.6,	O
17.2).	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
(	O
5.4,	O
8.5,	O
14.6,	O
17.3).	O
Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
celecoxib	O
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen	O
(	O
5.5,	O
17.4).	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
celecoxib	O
(	O
5.2,	O
7.4,	O
17.2).	O
Fluid	O
retention	O
and	O
edema.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure	O
(	O
5.3,	O
17.6).	O
Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
celecoxib	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists	O
(	O
5.6,	O
7.4,	O
8.7,	O
17.6).	O
Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
celecoxib	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(	O
5.7,	O
10,	O
17.7).	O
Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions	O
(	O
5.8,	O
17.5).	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
celecoxib,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
celecoxib	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
].	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
celecoxib	O
[	O
see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
the	O
CLASS	O
study	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
celecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[	O
see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
celecoxib	O
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
celecoxib	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
celecoxib.	O
In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
celecoxib.	O
Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
celecoxib	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(	O
6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp.	O
at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CXB	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CXB	O
=	O
celecoxib	O
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General	O
:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional	O
:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia	O
Psychiatric	O
:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders	O
:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary	O
:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular	O
:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal	O
:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic	O
:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous	O
:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
General	O
:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events	O
:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[	O
see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials	O
,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders	O
:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth	O
:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders	O
:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders	O
:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
CARDIOVASCULAR	O
RISK	O
NSAIDs1	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
potassium	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
GASTROINTESTINAL	O
RISK	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS).	O
1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug.	O
ADVERSE	O
REACTIONS	O
In	O
718	O
patients	O
treated	O
for	O
shorter	O
periods,	O
i.e.,	O
2	O
weeks	O
or	O
less,	O
with	O
diclofenac	O
potassium	O
tablets,	O
adverse	O
reactions	O
were	O
reported	O
one-half	O
to	O
one-tenth	O
as	O
frequently	O
as	O
by	O
patients	O
treated	O
for	O
longer	O
periods.	O
In	O
a	O
6	O
month,	O
double-blind	O
trial	O
comparing	O
diclofenac	O
potassium	O
tablets	O
(N	O
=	O
196)	O
versus	O
diclofenac	O
sodium	O
delayed-release	O
tablets	O
(N	O
=	O
197)	O
versus	O
ibuprofen	O
(N	O
=	O
197),	O
adverse	O
reactions	O
were	O
similar	O
in	O
nature	O
and	O
frequency.	O
In	O
patients	O
taking	O
diclofenac	O
potassium	O
tablets	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(	O
5.1	O
)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(	O
4	O
,	O
5.1	O
)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(	O
5.2	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	O
capsules	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	O
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
for	O
the	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
treatment	O
arms	O
compared	O
to	O
placebo.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.7)	O
].	O
A	O
randomized	O
controlled	O
trial	O
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs.	O
Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	O
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	O
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	O
and	O
ibuprofen.	O
Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	O
375	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	O
600	O
to	O
800	O
mg	O
three	O
times	O
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists’	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	O
(including	O
hemorrhagic	O
death),	O
non-fatal	O
myocardial	O
infarction,	O
and	O
non-fatal	O
stroke	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
celecoxib.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	O
anticoagulants;	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.7)	O
].	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
discontinue	O
celecoxib	O
capsules	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
See	O
Clinical	O
Studies	O
(	O
14.	O
6	O
,	O
14.7)	O
for	O
additional	O
blood	O
pressure	O
data	O
for	O
celecoxib.	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
celecoxib	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
capsules	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE	O
inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
celecoxib	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
celecoxib.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
celecoxib	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
celecoxib	O
and	O
in	O
patients	O
with	O
aspirin	O
sensitive	O
asthma.	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	O
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	O
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib,	O
including	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(AGEP).	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	O
capsules	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
celecoxib	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs,	O
including	O
celecoxib,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	O
SSRIs	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
,	O
5.3	O
,	O
5.6	O
)].	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation	O
with	O
use	O
of	O
celecoxib	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	O
and	O
their	O
caregivers	O
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(greater	O
than	O
2%	O
and	O
greater	O
than	O
placebo)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Of	O
the	O
celecoxib	O
-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
greater	O
than	O
or	O
equal	O
to	O
2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
Greater	O
Than	O
or	O
Equal	O
to	O
2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
Placebo	O
NAP	O
DCF	O
IBU	O
N=4146	O
N=1864	O
N=1366	O
N=387	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1%	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General:	O
Hypersensitivity	B-D006967
,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
blood	O
urea	O
nitrogen	O
(BUN)	O
increased,	O
creatine	O
phosphokinase	O
(CPK)	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia,	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
less	O
than	O
0.1%	O
of	O
patients:	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia	B-D001259
,	O
suicide	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Clinical	O
Studies	O
(14.7)]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(greater	O
than	O
2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
aspirin	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
twice	O
daily.	O
The	O
most	O
commonly	O
occurring	O
(greater	O
than	O
or	O
equal	O
to	O
5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(greater	O
than	O
or	O
equal	O
to	O
5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
Greater	O
Than	O
or	O
Equal	O
to	O
5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
Celecoxib	B-D000068579
Celecoxib	B-D000068579
Naproxen	B-D009288
System	O
Organ	O
Class	O
3	O
mg/kg	O
6	O
mg/kg	O
7.5	O
mg/kg	O
Preferred	O
Term	O
N=77	O
N=82	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.7)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
Placebo	O
N	O
=	O
2285	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
greater	O
than	O
or	O
equal	O
to	O
0.1%	O
and	O
less	O
than	O
1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning,	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
celecoxib.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis	B-D014657
,	O
deep	O
venous	O
thrombosis	O
General:	O
Anaphylactoid	O
reaction,	O
angioedema	O
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	O
hepatitis,	O
jaundice,	O
hepatic	O
failure	O
Hemic	O
and	O
lymphatic:	O
Agranulocytosis	B-D000380
,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
Renal:	O
Interstitial	O
nephritis	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
nonsteroidal	O
antiinflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.4)	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(5.4)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(5.1,	O
14.6,	O
17.2).	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
(5.4,	O
8.5,	O
14.6,	O
17.3).	O
Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
celecoxib	O
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen	O
(5.5,	O
17.4).	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
celecoxib	O
(5.2,	O
7.4,	O
17.2).	O
Fluid	O
retention	O
and	O
edema.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure	O
(5.3,	O
17.6).	O
Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
celecoxib	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6).	O
Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
celecoxib	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(5.7,	O
10,	O
17.7).	O
Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions	O
(5.8,	O
17.5).	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovasculardeath,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
to	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
to	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
celecoxib,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
celecoxib	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
onlow-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
sometime	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
duringcelecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)].	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib.	O
If	O
clinical	O
signs	O
and	O
symptomsconsistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
celecoxib	O
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
ofan	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
celecoxib	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
celecoxib.	O
In	O
postmarketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
celecoxib.	O
Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),Warnings	O
and	O
Precautions	O
(5.7)].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibitany	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
withaspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
antiinflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
cautionin	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
celecoxib	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sydon	O
Labs,	O
LLC	O
at	O
1	O
866-487-4695	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
>2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4,	O
146	O
Placebo	O
N=1,	O
864	O
NAP	O
N=1,	O
366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%5.6%8.8%2.2%3.5%	O
2.8%3.8%6.2%1%4.2%	O
7.7%5.3%12.2%3.6%6%	O
9%9.3%10.9%4.1%3.4%	O
9%5.8%12.8%3.5%6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%2.1%2.9%	O
3.6%1.1%2.3%	O
2.2%2.1%3%	O
2.6%1%2.6%	O
0.9%3.5%3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
Headache	B-D006261
2%15.8%	O
1.7%20.2%	O
2.6%14.5%	O
1.3%15.5%	O
2.3%15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
Rhinitis	B-D012220
Sinusitis	B-D012852
Upper	O
Respiratory	O
Infection	O
2.3%2%5%8.1%	O
1.1%1.3%4.3%6.7%	O
1.7%2.4%4%9.9%	O
1.6%2.3%5.4%9.8%	O
2.6%0.6%5.8%9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatmentgroups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophagealreflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hotflushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,aplastic	O
anemia,pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-	O
Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
Thelower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
tobe	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
withnaproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
doubleblind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similarto	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
>5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
Abdominal	O
pain	O
upper	O
Vomiting	B-D014839
NOS	O
Diarrhea	B-D003967
NOS	O
Nausea	B-D009325
4	O
8	O
3	O
5	O
7	O
7	O
6	O
6	O
4	O
4	O
7	O
10	O
11	O
8	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
Dizziness	B-D004244
(excl	O
vertigo)	O
13	O
1	O
10	O
1	O
16	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
thosereported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
postdental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
premarketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
premarketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
inpatients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2,285	O
Placebo	O
N=1,303	O
Diarrhea	B-D003967
10.5%	O
7%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
>0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
withgreater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery,atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Sulfite	O
Allergic	O
Reactions	O
(5.1)	O
Slow	O
or	O
Delayed	O
Healing	O
(5.2)	O
Potential	O
for	O
cross-sensitivity	O
(5.3)	O
Increase	O
bleeding	O
of	O
ocular	O
tissues	O
(5.4)	O
Cornea	B-D003315
l	O
effects	O
including	O
keratitis	O
(5.5)	O
Contact	O
Lens	O
Wear	O
(5.6)	O
5.1	O
Sulfite	O
Allergic	O
Reactions	O
Contains	O
sodium	B-C025026
sulfite	I-C025026
,	O
a	O
sulfite	O
that	O
may	O
cause	O
allergic-type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people.	O
The	O
overall	O
prevalence	O
of	O
sulfite	O
sensitivity	O
in	O
the	O
general	O
population	O
is	O
unknown	O
and	O
probably	O
low.	O
Sulfite	O
sensitivity	O
is	O
seen	O
more	O
frequently	O
in	O
asthmatic	O
than	O
in	O
non-asthmatic	O
people.	O
5.2	O
Slow	O
or	O
Delayed	O
Healing	O
All	O
topical	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
slow	O
or	O
delay	O
healing.	O
Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing.	O
Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
steroids	O
may	O
increase	O
the	O
potential	O
for	O
healing	O
problems	O
5.3	O
Potential	O
for	O
Cross-Sensitivity	O
There	O
is	O
the	O
potential	O
for	O
cross-sensitivity	O
to	O
acetylsalicylic	O
acid,	O
phenylacetic	B-C025136
acid	I-C025136
derivatives,	O
and	O
other	O
NSAIDs.	O
Therefore,	O
caution	O
should	O
be	O
used	O
when	O
treating	O
individuals	O
who	O
have	O
previously	O
exhibited	O
sensitivities	O
to	O
these	O
drugs.	O
5.4	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
With	O
some	O
NSAIDs,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
platelet	O
aggregation.	O
There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
NSAIDs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
tissues	O
(including	O
hyphemas)	O
in	O
conjunction	O
with	O
ocular	O
surgery.	O
It	O
is	O
recommended	O
that	O
Bromday	O
ophthalmic	O
solution	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
known	O
bleeding	O
tendencies	O
or	O
who	O
are	O
receiving	O
other	O
medications	O
which	O
may	O
prolong	O
bleeding	O
time.	O
5.5	O
Keratitis	B-D007634
and	O
Cornea	B-D003315
l	O
Reactions	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
keratitis.	O
In	O
some	O
susceptible	O
patients,	O
continued	O
use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
epithelial	O
breakdown,	O
corneal	O
thinning,	O
corneal	O
erosion,	O
corneal	O
ulceration	O
or	O
corneal	O
perforation.	O
These	O
events	O
may	O
be	O
sight	O
threatening.	O
Patients	B-D010361
with	O
evidence	O
of	O
corneal	O
epithelial	O
breakdown	O
should	O
immediately	O
discontinue	O
use	O
of	O
topical	O
NSAIDs	O
and	O
should	O
be	O
closely	O
monitored	O
for	O
corneal	O
health.	O
Post-marketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
patients	O
with	O
complicated	O
ocular	O
surgeries,	O
corneal	O
denervation,	O
corneal	O
epithelial	O
defects,	O
diabetes	O
mellitus,	O
ocular	O
surface	O
diseases	O
(e.g.,	O
dry	O
eye	O
syndrome),	O
rheumatoid	O
arthritis,	O
or	O
repeat	O
ocular	O
surgeries	O
within	O
a	O
short	O
period	O
of	O
time	O
may	O
be	O
at	O
increased	O
risk	O
for	O
corneal	O
adverse	O
events	O
which	O
may	O
become	O
sight	O
threatening.	O
Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients.	O
Post-marketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
24	O
hours	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
post	O
surgery	O
may	O
increase	O
patient	O
risk	O
for	O
the	O
occurrence	O
and	O
severity	O
of	O
corneal	O
adverse	O
events.	O
5.6	O
Contact	O
Lens	O
Wear	O
Bromday	O
should	O
not	O
be	O
administered	O
while	O
wearing	O
contact	O
lenses.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
in	O
2-7%	O
of	O
patients	O
were	O
abnormal	O
sensation	O
in	O
eye,	O
conjunctival	O
hyperemia	O
and	O
eye	O
irritation	O
(including	O
burning/stinging)	O
.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
ISTA	O
Pharmaceuticals,	O
Inc.	O
at	O
1-877-788-2020,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
Experience	O
The	O
most	O
commonly	O
reported	O
adverse	O
experiences	O
reported	O
following	O
use	O
of	O
bromfenac	B-C053083
after	O
cataract	O
surgery	O
include:	O
abnormal	O
sensation	O
in	O
eye,	O
conjunctival	O
hyperemia,	O
eye	O
irritation	O
(including	O
burning/stinging),	O
eye	O
pain,	O
eye	O
pruritus,	O
eye	O
redness,	O
headache,	O
and	O
iritis.	O
These	O
events	O
were	O
reported	O
in	O
2-7%	O
of	O
patients.	O
6.2	O
Post-Marketing	O
Experience	O
The	O
following	O
events	O
have	O
been	O
identified	O
during	O
post-marketing	O
use	O
of	O
bromfenac	B-C053083
ophthalmic	O
solution	O
0.09%	O
in	O
clinical	O
practice.	O
Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size,	O
estimates	O
of	O
frequency	O
cannot	O
be	O
made.	O
The	O
events,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
bromfenac	B-C053083
ophthalmic	O
solution	O
0.09%	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
corneal	O
erosion,	O
corneal	O
perforation,	O
corneal	O
thinning,	O
and	O
epithelial	O
breakdown.	O
[	O
]	O
see	O
Warnings	O
and	O
Precautions	O
(5)	O
CONTRAINDICATIONS	O
AND	O
WARNINGS	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
CONTAIN	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL.	O
ADMINISTRATION	O
OF	O
MISOPROSTOL	O
TO	O
WOMEN	O
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
OR	O
BIRTH	O
DEFECTS.	O
UTERINE	O
RUPTURE	O
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	O
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	O
WOMEN	O
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O
BEYOND	O
THE	O
EIGHTH	O
WEEK	O
OF	O
PREGNANCY	O
(see	O
also	O
PRECAUTIONS	O
).	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	O
WOMEN	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS	O
and	O
PRECAUTIONS	O
).	O
PATIENTS	O
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS.	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
should	O
not	O
be	O
used	O
in	O
women	O
of	O
childbearing	O
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	O
of	O
developing	O
gastric	O
or	O
duodenal	O
ulceration	O
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	O
ulcers	O
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID	O
(see	O
WARNINGS	O
).	O
In	O
such	O
patients,	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
has	O
had	O
a	O
negative	O
serum	O
pregnancy	O
test	O
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy.	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures.	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	O
the	O
risk	O
of	O
possible	O
contraception	O
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	O
of	O
childbearing	O
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake.	O
will	O
begin	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	O
period.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS	O
).	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
Adverse	O
reactions	O
associated	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
Adverse	O
reaction	O
information	O
for	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
are	O
derived	O
from	O
Phase	O
III	O
multinational	O
controlled	O
clinical	O
trials	O
in	O
over	O
2,000	O
patients,	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets,	O
50/0.2	O
mg	O
or	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
75/0.2	O
mg	O
,	O
as	O
well	O
as	O
from	O
blinded,	O
controlled	O
trials	O
of	O
Voltaren®	O
Delayed-Release	O
Tablets	B-D013607
(diclofenac)	O
and	O
Cytotec®	O
Tablets	B-D013607
(misoprostol).	O
Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
incidence	O
of	O
adverse	O
events	O
for	O
patients	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets.	O
These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
patients	O
on	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
and	O
5%	O
of	O
patients	O
on	O
diclofenac.	O
For	O
GI	O
ulcer	O
rates,	O
see	O
CLINICAL	O
STUDIES—Upper	O
gastrointestinal	O
safety	O
.	O
GI	O
disorder	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
Diclofenac	B-D004008
Abdominal	O
pain	O
21%	O
15%	O
Diarrhea	B-D003967
19%	O
11%	O
Dyspepsia	B-D004415
14%	O
11%	O
Nausea	B-D009325
11%	O
6%	O
Flatulence	B-D005414
9%	O
4%	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
can	O
cause	O
more	O
abdominal	O
pain,	O
diarrhea	O
and	O
other	O
GI	O
symptoms	O
than	O
diclofenac	O
alone.	O
Diarrhea	B-D003967
and	O
abdominal	O
pain	O
developed	O
early	O
in	O
the	O
course	O
of	O
therapy,	O
and	O
were	O
usually	O
self-limited	O
(resolved	O
after	O
2	O
to	O
7	O
days).	O
Rare	O
instances	O
of	O
profound	O
diarrhea	O
leading	O
to	O
severe	O
dehydration	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
misoprostol.	O
Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
disease,	O
or	O
those	O
in	O
whom	O
dehydration,	O
were	O
it	O
to	O
occur,	O
would	O
be	O
dangerous,	O
should	O
be	O
monitored	O
carefully	O
if	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
is	O
prescribed.	O
The	O
incidence	O
of	O
diarrhea	O
can	O
be	O
minimized	O
by	O
administering	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
with	O
food	O
and	O
by	O
avoiding	O
coadministration	O
with	O
magnesium-containing	O
antacids.	O
Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
misoprostol	O
use	O
have	O
also	O
been	O
reported	O
for	O
women	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
(see	O
below).	O
Postmenopausal	O
vaginal	O
bleeding	O
may	O
be	O
related	O
to	O
administration	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets.	O
If	O
it	O
occurs,	O
diagnostic	O
workup	O
should	O
be	O
undertaken	O
to	O
rule	O
out	O
gynecological	O
pathology	O
(see	O
boxed	O
CONTRAINDICATIONS	O
AND	O
WARNINGS	O
).	O
Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
safety	O
profile	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
in	O
over	O
500	O
patients	O
65	O
years	O
of	O
age	O
or	O
older	O
compared	O
with	O
younger	O
patients.	O
Other	O
adverse	O
experiences	O
reported	O
occasionally	O
or	O
rarely	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets,	O
diclofenac	O
or	O
other	O
NSAIDs,	O
or	O
misoprostol	O
are:	O
Body	O
as	O
a	O
whole:	O
Asthenia	B-D001247
,	O
death,	O
fatigue,	O
fever,	O
infection,	O
malaise,	O
sepsis,	O
chills.	O
Cardiovascular	O
system:	O
Arrhythmia,	O
atrial	O
fibrillation,	O
congestive	O
heart	O
failure,	O
hypertension,	O
hypotension,	O
increased	O
CPK,	O
increased	O
LDH,	O
myocardial	O
infarction,	O
palpitations,	O
phlebitis,	O
premature	O
ventricular	O
contractions,	O
syncope,	O
tachycardia,	O
vasculitis.	O
Central	O
and	O
peripheral	O
nervous	O
system:	O
Coma	B-D003128
,	O
convulsions,	O
dizziness,	O
drowsiness,	O
headache,	O
hyperesthesia,	O
hypertonia,	O
hypoesthesia,	O
insomnia,	O
meningitis,	O
migraine,	O
neuralgia,	O
paresthesia,	O
somnolence,	O
stroke,	O
tremor,	O
vertigo.	O
Digestive:	O
Anorexia	B-D000855
,	O
appetite	O
changes,	O
constipation,	O
dry	O
mouth,	O
dysphagia,	O
enteritis,	O
esophageal	O
ulceration,	O
esophagitis,	O
eructation,	O
gastritis,	O
gastroesophageal	O
reflux,	O
GI	O
bleeding,	O
GI	O
neoplasm	O
benign,	O
glossitis,	O
heartburn,	O
hematemesis,	O
hemorrhoids,	O
intestinal	O
perforation,	O
peptic	O
ulcer,	O
stomatitis	O
and	O
ulcerative	O
stomatitis,	O
tenesmus,	O
vomiting.	O
Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940
pain,	O
dysmenorrhea,	O
intermenstrual	O
bleeding,	O
leukorrhea,	O
menstrual	O
disorder,	O
menorrhagia,	O
vaginal	O
hemorrhage.	O
Hemic	O
and	O
lymphatic	O
system:	O
Agranulocytosis	B-D000380
,	O
anemia,	O
aplastic	O
anemia,	O
coagulation	O
time	O
increased,	O
ecchymosis,	O
eosinophilia,	O
epistaxis,	O
hemolytic	O
anemia,	O
leukocytosis,	O
leukopenia,	O
lymphadenopathy,	O
melena,	O
pancytopenia,	O
pulmonary	O
embolism,	O
purpura,	O
rectal	O
bleeding,	O
thrombocythemia,	O
thrombocytopenia.	O
Hypersensitivity	B-D006967
:	O
Angioedema	B-D000799
,	O
laryngeal/pharyngeal	O
edema,	O
urticaria.	O
Liver	B-D008099
and	O
biliary	O
system:	O
Abnormal	O
hepatic	O
function,	O
bilirubinemia,	O
hepatitis,	O
jaundice,	O
liver	O
failure,	O
pancreatitis.	O
Male	B-D008297
reproductive	O
disorders:	O
Impotence,	O
perineal	O
pain.	O
Metabolic	O
and	O
nutritional:	O
Alanine	B-D000409
aminotransferase	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
aspartate	O
aminotransferase	O
increased,	O
BUN	O
increased,	O
dehydration,	O
glycosuria,	O
gout,	O
hypercholesterolemia,	O
hyperglycemia,	O
hyperuricemia,	O
hypoglycemia,	O
hyponatremia,	O
periorbital	O
edema,	O
porphyria,	O
weight	O
changes.	O
Musculoskeletal	O
system:	O
Arthralgia	B-D018771
,	O
myalgia.	O
Psychiatric:	O
Anxiety	B-D001007
,	O
concentration	O
impaired,	O
confusion,	O
depression,	O
disorientation,	O
dream	O
abnormalities,	O
hallucinations,	O
irritability,	O
nervousness,	O
paranoia,	O
psychotic	O
reaction.	O
Respiratory	O
system:	O
Asthma	B-D001249
,	O
coughing,	O
dyspnea,	O
hyperventilation,	O
pneumonia,	O
respiratory	O
depression	O
Skin	B-D012867
and	O
appendages:	O
Acne,	O
alopecia,	O
bruising,	O
eczema,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
pemphigoid	O
reaction,	O
photosensitivity,	O
pruritus,	O
pruritus	O
ani,	O
rash,	O
skin	O
ulceration,	O
Stevens-Johnson	O
syndrome,	O
sweating	O
increased,	O
toxic	O
epidermal	O
necrolysis.	O
Special	O
senses:	O
Hearing	B-D006309
impairment,	O
taste	O
loss,	O
taste	O
perversion,	O
tinnitus.	O
Urinary	O
system:	O
Cystitis	B-D003556
,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
micturition	O
frequency,	O
nocturia,	O
nephrotic	O
syndrome,	O
oliguria/polyuria,	O
papillary	O
necrosis,	O
proteinuria,	O
renal	O
failure,	O
urinary	O
tract	O
infection.	O
Vision:	O
Amblyopia	B-D000550
,	O
blurred	O
vision,	O
conjunctivitis,	O
diplopia,	O
glaucoma,	O
iritis,	O
lacrimation	O
abnormal,	O
night	O
blindness,	O
vision	O
abnormal.	O
WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
RISK	O
EVALUATION	O
AND	O
MITIGATION	O
STRATEGY	O
(REMS);	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION;	O
ACCIDENTAL	O
INGESTION;	O
RISKS	O
FROM	O
CONCOMITANT	O
USE	O
WITH	O
BENZODIAZEPINES	O
OR	O
OTHER	O
CNS	O
DEPRESSANTS;	O
ULTRA-RAPID	O
METABOLISM	O
OF	O
CODEINE	O
AND	O
OTHER	O
RISK	O
FACTORS	O
FOR	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION	O
IN	O
CHILDREN;	O
NEONATAL	O
OPIOID	O
WITHDRAWAL	O
SYNDROME;	O
and	O
INTERACTIONS	O
WITH	O
DRUGS	O
AFFECTING	O
CYTOCHROME	O
P450	O
ISOENZYMES	O
WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
RISK	O
EVALUATION	O
AND	O
MITIGATION	O
STRATEGY	O
(REMS);	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION;	O
ACCIDENTAL	O
INGESTION;	O
RISKS	O
FROM	O
CONCOMITANT	O
USE	O
WITH	O
BENZODIAZEPINES	O
OR	O
OTHER	O
CNS	O
DEPRESSANTS;	O
ULTRA-RAPID	O
METABOLISM	O
OF	O
CODEINE	O
AND	O
OTHER	O
RISK	O
FACTORS	O
FOR	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION	O
IN	O
CHILDREN;	O
NEONATAL	O
OPIOID	O
WITHDRAWAL	O
SYNDROME;	O
and	O
INTERACTIONS	O
WITH	O
DRUGS	O
AFFECTING	O
CYTOCHROME	O
P450	O
ISOENZYMES	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Butalbital,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
expose	O
users	O
to	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse,	O
which	O
can	O
lead	O
to	O
overdose	O
and	O
death.	O
Assess	O
patient's	O
risk	O
before	O
prescribing	O
and	O
monitor	O
regularly	O
for	O
these	O
behaviors	O
and	O
conditions.	O
(5.1)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
for	O
these	O
products	O
(5.2)	O
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
may	O
occur.	O
Monitor	O
closely,	O
especially	O
upon	O
initiation	O
or	O
following	O
a	O
dose	O
increase.	O
(5.3)	O
Accidental	O
ingestion	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
fatal	O
overdose.	O
(5.3)	O
Concomitant	O
use	O
of	O
opioids	O
or	O
a	O
barbiturate	O
with	O
benzodiazepines	O
or	O
other	O
central	O
nervous	O
system	O
(CNS)	O
depressants,	O
including	O
alcohol,	O
may	O
result	O
in	O
profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death.	O
Reserve	O
concomitant	O
prescribing	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
treatment	O
options	O
are	O
inadequate;	O
limit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required;	O
and	O
follow	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
(5.4,5.8)	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
and	O
death	O
have	O
occurred	O
in	O
children	O
who	O
received	O
codeine;	O
most	O
cases	O
followed	O
tonsillectomy	O
and	O
/or	O
adenoidectomy,	O
and	O
many	O
of	O
the	O
children	O
had	O
evidence	O
of	O
being	O
an	O
ultra-rapid	O
metabolizer	O
of	O
codeine	O
due	O
to	O
a	O
CYP2D6	O
polymorphism.	O
(5.5)	O
Butalbital,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
are	O
contraindicated	O
in	O
children	O
younger	O
than	O
12	O
years	O
of	O
age	O
and	O
in	O
children	O
younger	O
than	O
18	O
years	O
of	O
age	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy	O
(4).	O
Avoid	O
the	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
in	O
adolescents	O
12	O
to	O
18	O
years	O
of	O
age	O
who	O
have	O
other	O
risk	O
factors	O
that	O
may	O
increase	O
their	O
sensitivity	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine.	O
Prolonged	O
use	O
during	O
pregnancy	O
can	O
result	O
in	O
neonatal	O
opioid	O
withdrawal	O
syndrome,	O
which	O
may	O
be	O
life-threatening	O
if	O
not	O
recognized	O
and	O
treated.	O
If	O
prolonged	O
opioid	O
use	O
is	O
required	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available.	O
(5.6)	O
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
codeine	O
are	O
complex.	O
Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
require	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
codeine,	O
and	O
the	O
active	O
metabolite,	O
morphine.	O
(	O
5.7,	O
5.8	O
)	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
Butalbital,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
expose	O
patients	O
and	O
other	O
users	O
to	O
the	O
risks	O
of	O
opioid	O
addiction,	O
abuse,	O
and	O
misuse,	O
which	O
can	O
lead	O
to	O
overdose	O
and	O
death.	O
Assess	O
each	O
patient's	O
risk	O
prior	O
to	O
prescribing	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules,	O
and	O
monitor	O
all	O
patients	O
regularly	O
for	O
the	O
development	O
of	O
these	O
behaviors	O
and	O
conditions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
REMS	O
for	O
these	O
products	O
(see	O
Warnings	O
and	O
Precautions	O
(5.2).	O
Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
education	O
programs	O
available	O
to	O
healthcare	O
providers.	O
Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
complete	O
a	O
REMS-compliant	O
education	O
program,	O
counsel	O
patients	O
and/or	O
their	O
caregivers,	O
with	O
every	O
prescription,	O
on	O
safe	O
use,	O
serious	O
risks,	O
storage,	O
and	O
disposal	O
of	O
these	O
products,	O
emphasize	O
to	O
patients	O
and	O
their	O
caregivers	O
the	O
importance	O
of	O
reading	O
the	O
Medication	O
Guide	O
every	O
time	O
it	O
is	O
provided	O
by	O
their	O
pharmacist,	O
and	O
consider	O
other	O
tools	O
to	O
improve	O
patient,	O
household,	O
and	O
community	O
safety	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
may	O
occur	O
with	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules.	O
Monitor	O
for	O
respiratory	O
depression,	O
especially	O
during	O
initiation	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
or	O
following	O
a	O
dose	O
increase	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)].	O
Accidental	O
Ingestion	O
Accidental	O
ingestion	O
of	O
even	O
one	O
dose	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
a	O
fatal	O
overdose	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)].	O
Risk	B-D012306
s	O
From	O
Concomitant	O
Use	O
With	O
Benzodiazepines	B-D001569
Or	O
Other	O
CNS	O
Depressants	O
Concomitant	O
use	O
of	O
opioids	O
with	O
benzodiazepines	O
or	O
other	O
central	O
nervous	O
system	O
(CNS)	O
depressants,	O
including	O
alcohol,	O
may	O
result	O
in	O
profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4),	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Reserve	O
concomitant	O
prescribing	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
and	O
benzodiazepines	O
or	O
other	O
CNS	O
depressants	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
treatment	O
options	O
are	O
inadequate.	O
Limit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required.	O
Follow	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
and	O
death	O
have	O
occurred	O
in	O
children	O
who	O
received	O
codeine.	O
Most	O
of	O
the	O
reported	O
cases	O
occurred	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy,	O
and	O
many	O
of	O
the	O
children	O
had	O
evidence	O
of	O
being	O
an	O
ultra-rapid	O
metabolizer	O
of	O
codeine	O
due	O
to	O
a	O
CYP2D6	O
polymorphism.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.5)].	O
Butalbital,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
is	O
contraindicated	O
in	O
children	O
younger	O
than	O
12	O
years	O
of	O
age	O
and	O
in	O
children	O
younger	O
than	O
18	O
years	O
of	O
age	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy	O
[see	O
Contraindications	B-D000075202
(4)].	O
Avoid	O
the	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
in	O
adolescents	O
12	O
to	O
18	O
years	O
of	O
age	O
who	O
have	O
other	O
risk	O
factors	O
that	O
may	O
increase	O
their	O
sensitivity	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine.	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
during	O
pregnancy	O
can	O
result	O
in	O
neonatal	O
opioid	O
withdrawal	O
syndrome,	O
which	O
may	O
be	O
life-threatening	O
if	O
not	O
recognized	O
and	O
treated,	O
and	O
requires	O
management	O
according	O
to	O
protocols	O
developed	O
by	O
neonatology	O
experts.	O
If	O
opioid	O
use	O
is	O
required	O
for	O
a	O
prolonged	O
period	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available	O
[see	O
Warnings	O
and	O
Precautions	O
(5.6)].	O
Interactions	O
with	O
Drugs	O
Affect	B-D000339
ing	O
Cytochrome	O
P450	O
Isoenzymes	B-D007527
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
codeine	O
are	O
complex.	O
Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
require	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
codeine,	O
and	O
the	O
active	O
metabolite,	O
morphine	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7),	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
or	O
in	O
Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
:	O
Monitor	O
closely,	O
particularly	O
during	O
initiation	O
and	O
titration.	O
(5.8)	O
Adrenal	B-D000309
Insufficiency	I-D000309
:	O
If	O
diagnosed,	O
treat	O
with	O
physiologic	O
replacement	O
of	O
corticosteroids,	O
and	O
wean	O
patient	O
off	O
the	O
opioid.	O
(5.10)	O
Severe	O
Hypotension	B-D007022
:	O
Monitor	O
during	O
dose	O
initiation	O
and	O
titration.	O
Avoid	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
in	O
patients	O
with	O
circulatory	O
shock.	O
(5.11)	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Increased	O
Intracranial	B-D007427
Pressure	I-D007427
,	O
Brain	B-D001921
Tumors,	O
Head	B-D006257
Injury,	O
or	O
Impaired	O
Consciousness	B-D003243
:	O
Monitor	O
for	O
sedation	O
and	O
respiratory	O
depression.	O
Avoid	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
in	O
patients	O
with	O
impaired	O
consciousness	O
or	O
coma.	O
(5.12)	O
5.1	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
Butalbital,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
contain	O
codeine.	O
Codeine	B-D003061
in	O
combination	O
with	O
butalbital	B-C004470
,	O
aspirin,	O
and	O
caffeine	O
is	O
a	O
Schedule	O
III	O
controlled	O
substance.	O
As	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
contain	O
butalbital	B-C004470
and	O
codeine,	O
it	O
exposes	O
users	O
to	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse	O
[see	O
Drug	O
Abuse	O
and	O
Dependence	O
(9)].	O
Although	O
the	O
risk	O
of	O
addiction	O
in	O
any	O
individual	O
is	O
unknown,	O
it	O
can	O
occur	O
in	O
patients	O
appropriately	O
prescribed	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules.	O
Addiction	O
can	O
occur	O
at	O
recommended	O
dosages	O
and	O
if	O
the	O
drug	O
is	O
misused	O
or	O
abused.	O
Assess	O
each	O
patient's	O
risk	O
for	O
addiction,	O
abuse,	O
or	O
misuse	O
prior	O
to	O
prescribing	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules,	O
and	O
monitor	O
all	O
patients	O
receiving	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
for	O
the	O
development	O
of	O
these	O
behaviors	O
and	O
conditions.	O
Risk	B-D012306
s	O
are	O
increased	O
in	O
patients	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
substance	O
abuse	O
(including	O
drug	O
or	O
alcohol	O
abuse	O
or	O
addiction)	O
or	O
mental	O
illness	O
(e.g.,	O
major	O
depression).	O
The	O
potential	O
for	O
these	O
risks	O
should	O
not,	O
however,	O
prevent	O
the	O
proper	O
management	O
of	O
pain	O
in	O
any	O
given	O
patient.	O
Patients	B-D010361
at	O
increased	O
risk	O
may	O
be	O
prescribed	O
opioids	O
such	O
as	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules,	O
but	O
use	O
in	O
such	O
patients	O
necessitates	O
intensive	O
counseling	O
about	O
the	O
risks	O
and	O
proper	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
along	O
with	O
intensive	O
monitoring	O
for	O
signs	O
of	O
addiction,	O
abuse,	O
and	O
misuse.	O
Opioids	O
and	O
barbiturates	O
are	O
sought	O
by	O
drug	O
abusers	O
and	O
people	O
with	O
addiction	O
disorders	O
and	O
are	O
subject	O
to	O
criminal	O
diversion.	O
Consider	O
these	O
risks	O
when	O
prescribing	O
or	O
dispensing	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules.	O
Strategies	O
to	O
reduce	O
these	O
risks	O
include	O
prescribing	O
the	O
drug	O
in	O
the	O
smallest	O
appropriate	O
quantity	O
and	O
advising	O
the	O
patient	O
on	O
the	O
proper	O
disposal	O
of	O
unused	O
drug	O
[see	O
Patient	O
Counseling	B-D003376
Information	O
(17)].	O
Contact	O
local	O
state	O
professional	O
licensing	O
board	O
or	O
state	O
controlled	O
substances	O
authority	O
for	O
information	O
on	O
how	O
to	O
prevent	O
and	O
detect	O
abuse	O
or	O
diversion	O
of	O
this	O
product.	O
5.2	O
Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
for	O
these	O
products.	O
Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
education	O
programs	O
available	O
to	O
healthcare	O
providers.	O
Health	B-D006262
care	O
Providers	O
are	O
strongly	O
encouraged	O
to	O
do	O
all	O
of	O
the	O
following:	O
Complete	O
a	O
REMS-compliant	O
education	O
program	O
offered	O
by	O
an	O
accredited	O
provider	O
of	O
continuing	O
education	O
(CE)	O
or	O
another	O
education	O
program	O
that	O
includes	O
all	O
the	O
elements	O
of	O
the	O
FDA	O
Education	B-D004493
Blueprint	O
for	O
Health	B-D006262
Care	O
Providers	O
Involved	O
in	O
the	O
Management	O
or	O
Support	O
of	O
Patients	B-D010361
with	O
Pain	B-D010146
.	O
Discuss	O
the	O
safe	O
use,	O
serious	O
risks,	O
and	O
proper	O
storage	O
and	O
disposal	O
of	O
opioid	O
analgesics	O
with	O
patients	O
and/or	O
their	O
caregivers	O
every	O
time	O
these	O
medicines	O
are	O
prescribed.	O
The	O
Patient	O
Counseling	B-D003376
Guide	O
(PCG)	O
can	O
be	O
obtained	O
at	O
this	O
link:	O
www.fda.gov/OpioidAnalgesicREMSPCG.	O
Emphasize	O
to	O
patients	O
and	O
their	O
caregivers	O
the	O
importance	O
of	O
reading	O
the	O
Medication	O
Guide	O
that	O
they	O
will	O
receive	O
from	O
their	O
pharmacist	O
every	O
time	O
an	O
opioid	O
analgesic	O
is	O
dispensed	O
to	O
them.	O
Consider	O
using	O
other	O
tools	O
to	O
improve	O
patient,	O
household,	O
and	O
community	O
safety,	O
such	O
as	O
patient	O
prescriber	O
agreements	O
that	O
reinforce	O
patient-prescriber	O
responsibilities.	O
To	O
obtain	O
further	O
information	O
on	O
the	O
opioid	O
analgesic	O
REMS	O
and	O
for	O
a	O
list	O
of	O
accredited	O
REMS	O
CME/CE,	O
call	O
1-800-503-0784,	O
or	O
log	O
on	O
to	O
www.opioidanalgesicrems.com.	O
The	O
FDA	O
Blueprint	O
can	O
be	O
found	O
at	O
www.fda.gov/OpioidAnalgesicREMSBlueprint.	O
5.3	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
opioids,	O
even	O
when	O
used	O
as	O
recommended.	O
Respiratory	O
depression,	O
if	O
not	O
immediately	O
recognized	O
and	O
treated,	O
may	O
lead	O
to	O
respiratory	O
arrest	O
and	O
death.	O
Management	O
of	O
respiratory	O
depression	O
may	O
include	O
close	O
observation,	O
supportive	O
measures,	O
and	O
use	O
of	O
opioid	O
antagonists,	O
depending	O
on	O
the	O
patient's	O
clinical	O
status	O
[see	O
Overdosage	O
(10)].	O
Carbon	B-D002244
dioxide	O
(CO2)	O
retention	O
from	O
opioid-induced	O
respiratory	O
depression	O
can	O
exacerbate	O
the	O
sedatin	B-C493049
g	O
effects	O
of	O
opioids.	O
While	O
serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
can	O
occur	O
at	O
any	O
time	O
during	O
the	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules,	O
the	O
risk	O
is	O
greatest	O
during	O
the	O
initiation	O
of	O
therapy	O
or	O
following	O
a	O
dosage	O
increase.	O
Monitor	O
patients	O
closely	O
for	O
respiratory	O
depression,	O
especially	O
within	O
the	O
first	O
24-72	O
hours	O
of	O
initiating	O
therapy	O
with	O
and	O
following	O
dosage	O
increases	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules.	O
To	O
reduce	O
the	O
risk	O
of	O
respiratory	O
depression,	O
proper	O
dosing	O
and	O
titration	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
are	O
essential	O
[see	O
Dosage	O
and	O
Administration	O
(2.1)].	O
Overestimating	O
the	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
dosage	O
when	O
converting	O
patients	O
from	O
another	O
opioid	O
product	O
can	O
result	O
in	O
a	O
fatal	O
overdose	O
with	O
the	O
first	O
dose.	O
Accidental	O
ingestion	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
respiratory	O
depression	O
and	O
death	O
due	O
to	O
an	O
overdose	O
of	O
codeine	O
and	O
butalbital	B-C004470
.	O
5.4	O
Risk	B-D012306
s	O
from	O
Concomitant	O
Use	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
Profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death	O
may	O
result	O
from	O
the	O
concomitant	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
with	O
benzodiazepines	O
or	O
other	O
CNS	O
depressants	O
(e.g.,	O
non-benzodiazepine	O
sedatives/hypnotics,	O
anxiolytics,	O
tranquilizers,	O
muscle	O
relaxants,	O
general	O
anesthetics,	O
antipsychotics,	O
other	O
opioids,	O
alcohol).	O
Because	O
of	O
these	O
risks,	O
reserve	O
concomitant	O
prescribing	O
of	O
these	O
drugs	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
treatment	O
options	O
are	O
inadequate.	O
Observation	B-D019370
al	O
studies	O
have	O
demonstrated	O
that	O
concomitant	O
use	O
of	O
opioid	O
analgesics	O
and	O
benzodiazepines	O
increases	O
the	O
risk	O
of	O
drug-related	O
mortality	O
compared	O
to	O
use	O
of	O
opioid	O
analgesics	O
alone.	O
Because	O
of	O
similar	O
pharmacological	O
properties,	O
it	O
is	O
reasonable	O
to	O
expect	O
similar	O
risk	O
with	O
the	O
concomitant	O
use	O
of	O
other	O
CNS	O
depressant	O
drugs	O
with	O
opioid	O
analgesics	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
If	O
the	O
decision	O
is	O
made	O
to	O
prescribe	O
a	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant	O
concomitantly	O
with	O
an	O
opioid	O
analgesic,	O
prescribe	O
the	O
lowest	O
effective	O
dosages	O
and	O
minimum	O
durations	O
of	O
concomitant	O
use.	O
In	O
patients	O
already	O
receiving	O
an	O
opioid	O
analgesic,	O
prescribe	O
a	O
lower	O
initial	O
dose	O
of	O
the	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant	O
than	O
indicated	O
in	O
the	O
absence	O
of	O
an	O
opioid,	O
and	O
titrate	O
based	O
on	O
clinical	O
response.	O
If	O
an	O
opioid	O
analgesic	O
is	O
initiated	O
in	O
a	O
patient	O
already	O
taking	O
a	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant,	O
prescribe	O
a	O
lower	O
initial	O
dose	O
of	O
the	O
opioid	O
analgesic,	O
and	O
titrate	O
based	O
on	O
clinical	O
response.	O
Follow	O
patients	O
closely	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
Advise	O
both	O
patients	O
and	O
caregivers	O
about	O
the	O
risks	O
of	O
respiratory	O
depression	O
and	O
sedation	O
when	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
is	O
used	O
with	O
benzodiazepines	O
or	O
other	O
CNS	O
depressants	O
(including	O
alcohol	O
and	O
illicit	O
drugs).	O
Advise	O
patients	O
not	O
to	O
drive	O
or	O
operate	O
heavy	O
machinery	O
until	O
the	O
effects	O
of	O
concomitant	O
use	O
of	O
the	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant	O
have	O
been	O
determined.	O
Screen	O
patients	O
for	O
risk	O
of	O
substance	O
use	O
disorders,	O
including	O
opioid	O
abuse	O
and	O
misuse,	O
and	O
warn	O
them	O
of	O
the	O
risk	O
for	O
overdose	O
and	O
death	O
associated	O
with	O
the	O
use	O
of	O
additional	O
CNS	O
depressants	O
including	O
alcohol	O
and	O
illicit	O
drugs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
and	O
Patient	O
Counseling	B-D003376
Information	O
(17)	O
].	O
5.5	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
and	O
death	O
have	O
occurred	O
in	O
children	O
who	O
received	O
codeine.	O
Codeine	B-D003061
is	O
subject	O
to	O
variability	O
in	O
metabolism	O
based	O
upon	O
CYP2D6	O
genotype	O
(described	O
below),	O
which	O
can	O
lead	O
to	O
an	O
increased	O
exposure	O
to	O
the	O
active	O
metabolite	O
morphine.	O
Based	O
upon	O
postmarketing	O
reports,	O
children	O
younger	O
than	O
12	O
years	O
old	O
appear	O
to	O
be	O
more	O
susceptible	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine,	O
particularly	O
if	O
there	O
are	O
risk	O
factors	O
for	O
respiratory	O
depression.	O
For	O
example,	O
many	O
reported	O
cases	O
of	O
death	O
occurred	O
in	O
the	O
post-	O
operative	O
period	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy,	O
and	O
many	O
of	O
the	O
children	O
had	O
evidence	O
of	O
being	O
ultra-rapid	O
metabolizers	O
of	O
codeine.	O
Furthermore,	O
children	O
with	O
obstructive	O
sleep	O
apnea	O
who	O
are	O
treated	O
with	O
codeine	O
for	O
post-tonsillectomy	O
and/or	O
adenoidectomy	O
pain	O
may	O
be	O
particularly	O
sensitive	O
to	O
its	O
respiratory	O
depressant	O
effect.	O
Because	O
of	O
the	O
risk	O
of	O
life-threatening	O
respiratory	O
depression	O
and	O
death:	O
Butalbital,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
are	O
contraindicated	O
for	O
all	O
children	O
younger	O
than	O
12	O
years	O
of	O
age	O
[see	O
Contraindications	B-D000075202
(4)].	O
Butalbital,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
are	O
contraindicated	O
for	O
post-operative	O
management	O
in	O
pediatric	O
patients	O
younger	O
than	O
18	O
years	O
of	O
age	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy	O
[see	O
Contraindications	B-D000075202
(4)].	O
Avoid	O
the	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
in	O
adolescents	O
12	O
to	O
18	O
years	O
of	O
age	O
who	O
have	O
other	O
risk	O
factors	O
that	O
may	O
increase	O
their	O
sensitivity	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine	O
unless	O
the	O
benefits	O
outweigh	O
the	O
risks.	O
Risk	B-D012306
factors	O
include	O
conditions	O
associated	O
with	O
hypoventilation,	O
such	O
as	O
postoperative	O
status,	O
obstructive	O
sleep	O
apnea,	O
obesity,	O
severe	O
pulmonary	O
disease,	O
neuromuscular	O
disease,	O
and	O
concomitant	O
use	O
of	O
other	O
medications	O
that	O
cause	O
respiratory	O
depression.	O
As	O
with	O
adults,	O
when	O
prescribing	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
for	O
adolescents,	O
healthcare	O
providers	O
should	O
choose	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
period	O
of	O
time	O
and	O
inform	O
patients	O
and	O
caregivers	O
about	O
these	O
risks	O
and	O
the	O
signs	O
of	O
morphine	O
overdose	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.4),	O
Overdosage	O
(10)].	O
Nursing	B-D009729
Mothers	B-D009035
At	O
least	O
one	O
death	O
was	O
reported	O
in	O
a	O
nursing	O
infant	O
who	O
was	O
exposed	O
to	O
high	O
levels	O
of	O
morphine	O
in	O
breast	O
milk	O
because	O
the	O
mother	O
was	O
an	O
ultra-rapid	O
metabolizer	O
of	O
codeine.	O
Breast	B-D001940
feeding	O
is	O
not	O
recommended	O
during	O
treatment	O
with	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.2)].	O
CYP2D6	O
Genetic	O
Variability:	O
Ultra-rapid	O
metabolizer	O
Some	O
individuals	O
may	O
be	O
ultra-rapid	O
metabolizers	O
because	O
of	O
a	O
specific	O
CYP2D6	O
genotype	O
(gene	O
duplications	O
denoted	O
as	O
*1/*1×N	O
or	O
*1/*2×N).	O
The	O
prevalence	O
of	O
this	O
CYP2D6	O
phenotype	O
varies	O
widely	O
and	O
has	O
been	O
estimated	O
at	O
1	O
to	O
10%	O
for	O
Whites	O
(European,	O
North	B-D009656
America	I-D009656
n),	O
3	O
to	O
4%	O
for	O
Blacks	O
(African	O
Americans),	O
1	O
to	O
2%	O
for	O
East	O
Asia	B-D001208
ns	O
(Chinese,	O
Japan	B-D007564
ese,	O
Korea	B-D007723
n),	O
and	O
may	O
be	O
greater	O
than	O
10%	O
in	O
certain	O
racial/ethnic	O
groups	O
(i.e.,	O
Oceania	B-D044349
n,	O
Northern	O
Africa	B-D000349
n,	O
Middle	B-D008877
East	I-D008877
ern,	O
Ashkenazi	O
Jews	B-D007585
,	O
Puerto	O
Rican).	O
These	O
individuals	O
convert	O
codeine	O
into	O
its	O
active	O
metabolite,	O
morphine,	O
more	O
rapidly	O
and	O
completely	O
than	O
other	O
people.	O
This	O
rapid	O
conversion	O
results	O
in	O
higher	O
than	O
expected	O
serum	O
morphine	O
levels.	O
Even	O
at	O
labeled	O
dosage	O
regimens,	O
individuals	O
who	O
are	O
ultra-rapid	O
metabolizers	O
may	O
have	O
life-threatening	O
or	O
fatal	O
respiratory	O
depression	O
or	O
experience	O
signs	O
of	O
overdose	O
(such	O
as	O
extreme	O
sleepiness,	O
confusion,	O
or	O
shallow	O
breathing).	O
[see	O
Overdosage	O
(10)].	O
Therefore,	O
individuals	O
who	O
are	O
ultra-rapid	O
metabolizers	O
should	O
not	O
use	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules.	O
5.6	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
during	O
pregnancy	O
can	O
result	O
in	O
withdrawal	O
in	O
the	O
neonate.	O
Neon	B-D009356
atal	O
opioid	O
withdrawal	O
syndrome,	O
unlike	O
opioid	O
withdrawal	O
syndrome	O
in	O
adults,	O
may	O
be	O
life-threatening	O
if	O
not	O
recognized	O
and	O
treated,	O
and	O
requires	O
management	O
according	O
to	O
protocols	O
developed	O
by	O
neonatology	O
experts.	O
Observe	O
newborns	O
for	O
signs	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
manage	O
accordingly.	O
Advise	O
pregnant	O
women	O
using	O
opioids	O
for	O
a	O
prolonged	O
period	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1,	O
8.2),	O
Patient	O
Counseling	B-D003376
Information].	O
5.7	O
Risk	B-D012306
s	O
of	O
Interactions	O
with	O
Drugs	O
Affect	B-D000339
ing	O
Cytochrome	O
P450	O
Isoenzymes	B-D007527
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
codeine	O
are	O
complex.	O
Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
require	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
codeine	O
and	O
the	O
active	O
metabolite,	O
morphine.	O
•	O
Cytochrome	O
P450	O
3A4	O
Interaction	O
The	O
concomitant	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
with	O
all	O
cytochrome	O
P450	O
3A4	O
inhibitors,	O
such	O
as	O
macrolide	O
antibiotics	O
(e.g.,	O
erythromycin),	O
azole-antifungal	O
agents	O
(e.g.,	O
ketoconazole),	O
and	O
protease	O
inhibitors	O
(e.g.,	O
ritonavir)	O
or	O
discontinuation	O
of	O
a	O
cytochrome	O
P450	O
3A4	O
inducer	O
such	O
as	O
rifampin,	O
carbamazepine,	O
and	O
phenytoin,	O
may	O
result	O
in	O
an	O
increase	O
in	O
codeine	O
plasma	O
concentrations	O
with	O
subsequently	O
greater	O
metabolism	O
by	O
cytochrome	O
P450	O
2D6,	O
resulting	O
in	O
greater	O
morphine	O
levels,	O
which	O
could	O
increase	O
or	O
prolong	O
adverse	O
reactions	O
and	O
may	O
cause	O
potentially	O
fatal	O
respiratory	O
depression.	O
The	O
concomitant	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
with	O
all	O
cytochrome	O
P450	O
3A4	O
inducers	O
or	O
discontinuation	O
of	O
a	O
cytochrome	O
P450	O
3A4	O
inhibitor	O
may	O
result	O
in	O
lower	O
codeine	O
levels,	O
greater	O
norcodeine	B-C010414
levels,	O
and	O
less	O
metabolism	O
via	O
2D6	O
with	O
resultant	O
lower	O
morphine	O
levels.	O
This	O
may	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
efficacy,	O
and	O
in	O
some	O
patients,	O
may	O
result	O
in	O
signs	O
and	O
symptoms	O
of	O
opioid	O
withdrawal.	O
Follow	O
patients	O
receiving	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
and	O
any	O
CYP3A4	O
inhibitor	O
or	O
inducer	O
for	O
signs	O
and	O
symptoms	O
that	O
may	O
reflect	O
opioid	O
toxicity	O
and	O
opioid	O
withdrawal	O
when	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
is	O
used	O
in	O
conjunction	O
with	O
inhibitors	O
and	O
inducers	O
of	O
CYP3A4.	O
If	O
concomitant	O
use	O
of	O
a	O
CYP3A4	O
inhibitor	O
is	O
necessary	O
or	O
if	O
a	O
CYP3A4	O
inducer	O
is	O
discontinued,	O
consider	O
dosage	O
reduction	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
until	O
stable	O
drug	O
effects	O
are	O
achieved.	O
Monitor	O
patients	O
for	O
respiratory	O
depression	O
and	O
sedation	O
at	O
frequent	O
intervals.	O
If	O
concomitant	O
use	O
of	O
a	O
CYP3A4	O
inducer	O
is	O
necessary	O
or	O
if	O
a	O
CYP3A4	O
inhibitor	O
is	O
discontinued,	O
consider	O
increasing	O
the	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
dosage	O
until	O
stable	O
drug	O
effects	O
are	O
achieved.	O
Monitor	O
for	O
signs	O
of	O
opioid	O
withdrawal	O
[	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
•	O
Risk	B-D012306
s	O
of	O
Concomitant	O
Use	O
or	O
Discontinuation	O
of	O
Cytochrome	O
P450	O
2D6	O
Inhibitors	O
The	O
concomitant	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
with	O
all	O
cytochrome	O
P450	O
2D6	O
inhibitors	O
(e.g.,	O
amiodarone,	O
quinidine)	O
may	O
result	O
in	O
an	O
increase	O
in	O
codeine	O
plasma	O
concentrations	O
and	O
a	O
decrease	O
in	O
active	O
metabolite	O
morphine	O
plasma	O
concentration	O
which	O
could	O
result	O
in	O
an	O
analgesic	O
efficacy	O
reduction	O
or	O
symptoms	O
of	O
opioid	O
withdrawal.	O
Discontinuation	O
of	O
a	O
concomitantly	O
used	O
cytochrome	O
P450	O
2D6	O
inhibitor	O
may	O
result	O
in	O
a	O
decrease	O
in	O
codeine	O
plasma	O
concentration	O
and	O
an	O
increase	O
in	O
active	O
metabolite	O
morphine	O
plasma	O
concentration	O
which	O
could	O
increase	O
or	O
prolong	O
adverse	O
reactions	O
and	O
may	O
cause	O
potentially	O
fatal	O
respiratory	O
depression.	O
Follow	O
patients	O
receiving	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
and	O
any	O
CYP2D6	O
inhibitor	O
for	O
signs	O
and	O
symptoms	O
that	O
may	O
reflect	O
opioid	O
toxicity	O
and	O
opioid	O
withdrawal	O
when	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
are	O
used	O
in	O
conjunction	O
with	O
inhibitors	O
of	O
CYP2D6.	O
If	O
concomitant	O
use	O
with	O
a	O
CYP2D6	O
inhibitor	O
is	O
necessary,	O
follow	O
the	O
patient	O
for	O
signs	O
of	O
reduced	O
efficacy	O
or	O
opioid	O
withdrawal	O
and	O
consider	O
increasing	O
the	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
dosage.	O
After	O
stopping	O
use	O
of	O
a	O
CYP2D6	O
inhibitor,	O
consider	O
reducing	O
the	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
dosage	O
and	O
follow	O
the	O
patient	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
or	O
sedation	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.8	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
or	O
in	O
Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
The	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
in	O
patients	O
with	O
acute	O
or	O
severe	O
bronchial	O
asthma	O
in	O
an	O
unmonitored	O
setting	O
or	O
in	O
the	O
absence	O
of	O
resuscitative	O
equipment	O
is	O
contraindicated.	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
:	O
Butalbital,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules-treated	O
patients	O
with	O
significant	O
chronic	O
obstructive	O
pulmonary	O
disease	O
or	O
cor	O
pulmonale,	O
and	O
those	O
with	O
a	O
substantially	O
decreased	O
respiratory	O
reserve,	O
hypoxia,	O
hypercapnia,	O
or	O
pre-existing	O
respiratory	O
depression	O
are	O
at	O
increased	O
risk	O
of	O
decreased	O
respiratory	O
drive	O
including	O
apnea,	O
even	O
at	O
recommended	O
dosages	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
[see	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
:	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
is	O
more	O
likely	O
to	O
occur	O
in	O
elderly,	O
cachectic,	O
or	O
debilitated	O
patients	O
because	O
they	O
may	O
have	O
altered	O
pharmacokinetics	O
or	O
altered	O
clearance	O
compared	O
to	O
younger,	O
healthier	O
patients	O
[see	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Monitor	O
such	O
patients	O
closely,	O
particularly	O
when	O
initiating	O
and	O
titrating	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
and	O
when	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
is	O
given	O
concomitantly	O
with	O
other	O
drugs	O
that	O
depress	O
respiration	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)].	O
Alternatively,	O
consider	O
the	O
use	O
of	O
non-opioid	O
analgesics	O
in	O
these	O
patients.	O
5.9	O
Interaction	O
with	O
Monoamine	B-D008996
Oxidase	I-D008996
Inhibitors	I-D008996
Monoamine	O
oxidase	O
inhibitors	O
(MAOIs)	O
may	O
potentiate	O
the	O
effects	O
of	O
morphine,	O
codeine's	O
active	O
metabolite,	O
including	O
respiratory	O
depression,	O
coma,	O
and	O
confusion.	O
Butalbital,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
should	O
not	O
be	O
used	O
in	O
patients	O
taking	O
MAOIs	O
or	O
within	O
14	O
days	O
of	O
stopping	O
such	O
treatment.	O
5.10	O
Adrenal	B-D000309
Insufficiency	I-D000309
Cases	O
of	O
adrenal	O
insufficiency	O
have	O
been	O
reported	O
with	O
opioid	O
use,	O
more	O
often	O
following	O
greater	O
than	O
one	O
month	O
of	O
use.	O
Presentation	O
of	O
adrenal	O
insufficiency	O
may	O
include	O
non-specific	O
symptoms	O
and	O
signs	O
including	O
nausea,	O
vomiting,	O
anorexia,	O
fatigue,	O
weakness,	O
dizziness,	O
and	O
low	O
blood	O
pressure.	O
If	O
adrenal	O
insufficiency	O
is	O
suspected,	O
confirm	O
the	O
diagnosis	O
with	O
diagnostic	O
testing	O
as	O
soon	O
as	O
possible.	O
If	O
adrenal	O
insufficiency	O
is	O
diagnosed,	O
treat	O
with	O
physiologic	O
replacement	O
doses	O
of	O
corticosteroids.	O
Wean	O
the	O
patient	O
off	O
of	O
the	O
opioid	O
to	O
allow	O
adrenal	O
function	O
to	O
recover	O
and	O
continue	O
corticosteroid	O
treatment	O
until	O
adrenal	O
function	O
recovers.	O
Other	O
opioids	O
may	O
be	O
tried	O
as	O
some	O
cases	O
reported	O
use	O
of	O
a	O
different	O
opioid	O
without	O
recurrence	O
of	O
adrenal	O
insufficiency.	O
The	O
information	O
available	O
does	O
not	O
identify	O
any	O
particular	O
opioids	O
as	O
being	O
more	O
likely	O
to	O
be	O
associated	O
with	O
adrenal	O
insufficiency.	O
5.11	O
Severe	O
Hypotension	B-D007022
Butalbital,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
may	O
cause	O
severe	O
hypotension	O
including	O
orthostatic	O
hypotension	O
and	O
syncope	O
in	O
ambulatory	O
patients.	O
There	O
is	O
increased	O
risk	O
in	O
patients	O
whose	O
ability	O
to	O
maintain	O
blood	O
pressure	O
has	O
already	O
been	O
compromised	O
by	O
a	O
reduced	O
blood	O
volume	O
or	O
concurrent	O
administration	O
of	O
certain	O
CNS	O
depressant	O
drugs	O
(e.g.,	O
phenothiazine	B-C031637
s	O
or	O
general	O
anesthetics)	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
hypotension	O
after	O
initiating	O
or	O
titrating	O
the	O
dosage	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules.	O
In	O
patients	O
with	O
circulatory	O
shock,	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
may	O
cause	O
vasodilation	O
that	O
can	O
further	O
reduce	O
cardiac	O
output	O
and	O
blood	O
pressure.	O
Avoid	O
the	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
in	O
patients	O
with	O
circulatory	O
shock.	O
5.12	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Increased	O
Intracranial	B-D007427
Pressure	I-D007427
,	O
Brain	B-D001921
Tumors,	O
Head	B-D006257
Injury,	O
or	O
Impaired	O
Consciousness	B-D003243
In	O
patients	O
who	O
may	O
be	O
susceptible	O
to	O
the	O
intracranial	O
effects	O
of	O
CO2	O
retention	O
(e.g.,	O
those	O
with	O
evidence	O
of	O
increased	O
intracranial	O
pressure	O
or	O
brain	O
tumors),	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
may	O
reduce	O
respiratory	O
drive,	O
and	O
the	O
resultant	O
CO2	O
retention	O
can	O
further	O
increase	O
intracranial	O
pressure.	O
Monitor	O
such	O
patients	O
for	O
signs	O
of	O
sedation	O
and	O
respiratory	O
depression,	O
particularly	O
when	O
initiating	O
therapy	O
with	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules.	O
Opioids	O
may	O
also	O
obscure	O
the	O
clinical	O
course	O
in	O
a	O
patient	O
with	O
a	O
head	O
injury.	O
Avoid	O
the	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
in	O
patients	O
with	O
impaired	O
consciousness	O
or	O
coma.	O
5.13	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Gastrointestinal	O
Conditions	O
Including	O
Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
Butalbital,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
is	O
contraindicated	O
in	O
patients	O
with	O
known	O
or	O
suspected	O
gastrointestinal	O
obstruction,	O
including	O
paralytic	O
ileus.	O
The	O
codeine	O
in	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
may	O
cause	O
spasm	O
of	O
the	O
sphincter	O
of	O
Oddi.	O
Opioids	O
may	O
cause	O
increases	O
in	O
serum	O
amylase.	O
Monitor	O
patients	O
with	O
biliary	O
tract	O
disease,	O
including	O
acute	O
pancreatitis	O
for	O
worsening	O
symptoms.	O
Patients	B-D010361
with	O
a	O
history	O
of	O
active	O
peptic	O
ulcer	O
disease	O
should	O
avoid	O
using	O
aspirin,	O
which	O
can	O
cause	O
gastric	O
mucosal	O
irritation	O
and	O
bleeding.	O
The	O
aspirin	O
in	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
can	O
cause	O
GI	O
side	O
effects	O
including	O
stomach	O
pain,	O
heartburn,	O
nausea,	O
vomiting,	O
and	O
gross	O
GI	O
bleeding.	O
Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
dyspepsia,	O
are	O
common	O
and	O
can	O
occur	O
anytime	O
during	O
therapy,	O
physicians	O
should	O
remain	O
alert	O
for	O
signs	O
of	O
ulceration	O
and	O
bleeding,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
GI	O
symptoms.	O
Physicians	B-D010820
should	O
inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
GI	O
side	O
effects	O
and	O
what	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
5.14	O
Increased	O
Risk	B-D012306
of	O
Seizures	B-D012640
in	O
Patients	B-D010361
with	O
Seizure	O
Disorders	O
The	O
codeine	O
in	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
may	O
increase	O
the	O
frequency	O
of	O
seizures	O
in	O
patients	O
with	O
seizure	O
disorders,	O
and	O
may	O
increase	O
the	O
risk	O
of	O
seizures	O
occurring	O
in	O
other	O
clinical	O
settings	O
associated	O
with	O
seizures.	O
Monitor	O
patients	O
with	O
a	O
history	O
of	O
seizure	O
disorders	O
for	O
worsened	O
seizure	O
control	O
during	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
therapy.	O
5.15	O
Withdrawal	O
Avoid	O
the	O
use	O
of	O
mixed	O
agonist/antagonist	O
(e.g.,	O
pentazocine,	O
nalbuphine,	O
and	O
butorphan	B-C520649
ol)	O
or	O
partial	O
agonist	O
(e.g.,	O
buprenorphine)	O
analgesics	O
in	O
patients	O
who	O
are	O
receiving	O
a	O
full	O
opioid	O
agonist	O
analgesic,	O
including	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules.	O
In	O
these	O
patients,	O
mixed	O
agonist/antagonist	O
and	O
partial	O
agonist	O
analgesics	O
may	O
reduce	O
the	O
analgesic	O
effect	O
and/or	O
precipitate	O
withdrawal	O
symptoms.	O
When	O
discontinuing	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
in	O
a	O
physically-dependent	O
patient,	O
gradually	O
taper	O
the	O
dosage	O
[see	O
Dosage	O
and	O
Administration	O
(2.3)].	O
Do	O
not	O
abruptly	O
discontinue	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
in	O
these	O
patients	O
[see	O
Drug	O
Abuse	O
and	O
Dependence	O
(9.2,	O
9.3)].	O
5.16	O
Risk	B-D012306
s	O
of	O
Driving	O
and	O
Operating	O
Machinery	O
Butalbital,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
may	O
impair	O
the	O
mental	O
or	O
physical	O
abilities	O
needed	O
to	O
perform	O
potentially	O
hazardous	O
activities	O
such	O
as	O
driving	O
a	O
car	O
or	O
operating	O
machinery.	O
Warn	O
patients	O
not	O
to	O
drive	O
or	O
operate	O
dangerous	O
machinery	O
unless	O
they	O
are	O
tolerant	O
to	O
the	O
effects	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
and	O
know	O
how	O
they	O
will	O
react	O
to	O
the	O
medication.	O
5.17	O
Coagulation	O
Abnormalities	O
and	O
Bleeding	O
Risk	B-D012306
s	O
Even	O
low	O
doses	O
of	O
aspirin	O
can	O
inhibit	O
platelet	O
function	O
leading	O
to	O
an	O
increase	O
in	O
bleeding	O
time.	O
This	O
can	O
adversely	O
affect	O
patients	O
with	O
inherited	O
(i.e.	O
hemophilia)	O
or	O
acquired	O
(i.e.	O
liver	O
disease	O
or	O
vitamin	O
K	O
deficiency)	O
bleeding	O
disorders.	O
Aspirin	B-D001241
is	O
contraindicated	O
in	O
patients	O
with	O
hemophilia.	O
Aspirin	B-D001241
administered	O
pre-operatively	O
may	O
prolong	O
the	O
bleeding	O
time.	O
Patients	B-D010361
who	O
consume	O
three	O
or	O
more	O
alcoholic	O
drinks	O
every	O
day	O
should	O
be	O
counseled	O
about	O
the	O
bleeding	O
risks	O
involved	O
with	O
chronic,	O
heavy	O
alcohol	O
use	O
while	O
taking	O
aspirin.	O
5.18	O
Reye's	O
Syndrome	B-D013577
Aspirin	B-D001241
should	O
not	O
be	O
used	O
in	O
children	O
or	O
teenagers	O
for	O
viral	O
infections,	O
with	O
or	O
without	O
fever,	O
because	O
of	O
the	O
risk	O
of	O
Reye	O
syndrome	O
with	O
concomitant	O
use	O
of	O
aspirin	O
in	O
certain	O
viral	O
illnesses.	O
5.19	O
Allergy	O
Aspirin	B-D001241
is	O
contraindicated	O
in	O
patients	O
with	O
known	O
allergy	O
to	O
nonsteroidal	O
anti-inflammatory	O
drug	O
products	O
(NSAIDs)	O
and	O
in	O
patients	O
with	O
the	O
syndrome	O
of	O
asthma,	O
rhinitis,	O
and	O
nas	B-C015378
al	O
polyps.	O
Aspirin	B-D001241
may	O
cause	O
severe	O
urticaria,	O
angioedema,	O
or	O
bronchospasm	O
(asthma).	O
5.20	O
Drug/Laboratory	O
Test	O
Interactions	O
Aspirin	B-D001241
:	O
Aspirin	B-D001241
may	O
interfere	O
with	O
the	O
following	O
laboratory	O
determinations	O
in	O
blood:	O
serum	O
amylase,	O
fasting	O
blood	O
glucose,	O
cholesterol,	O
protein,	O
serum	O
glutamic-oxalacetic	O
transaminase	O
(SGOT),	O
uric	O
acid,	O
prothrombin	O
time	O
and	O
bleeding	O
time.	O
Aspirin	B-D001241
may	O
interfere	O
with	O
the	O
following	O
laboratory	O
determinations	O
in	O
urine:	O
glucose,	O
5-hydroxy-indoleacetic	O
acid,	O
Gerhardt	O
ketone,	O
vanillylmandelic	O
acid	O
(VMA),	O
uric	O
acid,	O
diacetic	O
acid,	O
and	O
spectrophotometric	O
detection	O
of	O
barbiturates.	O
Codeine	B-D003061
:	O
Codeine	B-D003061
may	O
increase	O
serum	O
amylase	O
levels.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described,	O
or	O
described	O
in	O
greater	O
detail,	O
in	O
other	O
sections:	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Interactions	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Adrenal	B-D000309
Insufficiency	I-D000309
[see	O
Warnings	O
and	O
Precautions	O
(5.10)]	O
Severe	O
Hypotension	B-D007022
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Gastrointestinal	O
Adverse	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.13)]	O
Seizures	B-D012640
[see	O
Warnings	O
and	O
Precautions	O
(5.14)]	O
Withdrawal	O
[see	O
Warnings	O
and	O
Precautions	O
(5.15)]	O
Coagulation	O
Abnormalities	O
and	O
Bleeding	O
[see	O
Warnings	O
and	O
Precautions	O
(5.17)]	O
Reye's	O
Syndrome	B-D013577
[see	O
Warnings	O
and	O
Precautions	O
(5.18)]	O
Allergy	O
[see	O
Warnings	O
and	O
Precautions	O
(5.19)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
1%)	O
are	O
nausea	O
and/or	O
abdominal	O
pain,	O
drowsiness,	O
and	O
dizziness.	O
(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Mayne	O
Pharma	O
at	O
1-844-825-8500	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Incidence	B-D015994
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
s	O
The	O
following	O
table	O
summarizes	O
the	O
incidence	O
rates	O
of	O
the	O
adverse	O
events	O
reported	O
by	O
at	O
least	O
1%	O
of	O
the	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
treated	O
patients	O
in	O
controlled	O
clinical	O
trials	O
comparing	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
to	O
placebo,	O
and	O
provides	O
a	O
comparison	O
to	O
the	O
incidence	O
rates	O
reported	O
by	O
the	O
placebo-treated	O
patients.	O
The	O
prescriber	O
should	O
be	O
aware	O
that	O
these	O
figures	O
cannot	O
be	O
used	O
to	O
predict	O
the	O
incidence	O
of	O
side	O
effects	O
in	O
the	O
course	O
of	O
usual	O
medical	O
practice	O
where	O
patient	O
characteristics	O
and	O
other	O
factors	O
differ	O
from	O
those	O
that	O
prevailed	O
in	O
the	O
clinical	O
trials.	O
Similarly,	O
the	O
cited	O
frequencies	O
cannot	O
be	O
compared	O
with	O
figures	O
obtained	O
from	O
other	O
clinical	O
investigations	O
involving	O
different	O
treatments,	O
uses,	O
and	O
investigators.	O
Adverse	O
Events	O
Reported	O
by	O
at	O
Least	O
1%	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
Treated	O
Patients	B-D010361
During	O
Placebo	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
s	O
Incidence	B-D015994
Rate	O
of	O
Adverse	O
Events	O
Body	O
System/Adverse	O
Event	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
(N=382)	O
Placebo(N=377)	O
Central	O
Nervous	O
Drowsiness	O
2.4%	O
0.5%	O
Dizziness	B-D004244
/Lightheadedness	O
2.6%	O
0.5%	O
Intoxicated	O
Feeling	O
1.0%	O
0%	O
Gastrointestinal	O
Nausea	B-D009325
/Abdominal	O
Pain	B-D010146
3.7%	O
0.8%	O
Other	O
Adverse	O
Events	O
Reported	O
During	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
s	O
The	O
listing	O
that	O
follows	O
represents	O
the	O
proportion	O
of	O
the	O
382	O
patients	O
exposed	O
to	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
while	O
participating	O
in	O
the	O
controlled	O
clinical	O
trials	O
who	O
reported,	O
on	O
at	O
least	O
one	O
occasion,	O
an	O
adverse	O
event	O
of	O
the	O
type	O
cited.	O
All	O
reported	O
adverse	O
events,	O
except	O
those	O
already	O
presented	O
in	O
the	O
previous	O
table,	O
are	O
included.	O
It	O
is	O
important	O
to	O
emphasize	O
that,	O
although	O
the	O
adverse	O
events	O
reported	O
did	O
occur	O
while	O
the	O
patient	O
was	O
receiving	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules,	O
the	O
adverse	O
events	O
were	O
not	O
necessarily	O
caused	O
by	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules.	O
Adverse	O
events	O
are	O
classified	O
by	O
body	O
system	O
and	O
frequency.	O
"Frequent"	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
which	O
occurred	O
in	O
at	O
least	O
1/100	O
(1%)	O
of	O
the	O
patients;	O
all	O
adverse	O
events	O
listed	O
in	O
the	O
previous	O
table	O
are	O
frequent.	O
"Infrequent"	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
that	O
occurred	O
in	O
less	O
than	O
1/100	O
patients	O
but	O
at	O
least	O
1/1000	O
patients.	O
All	O
adverse	O
events	O
tabulated	O
below	O
are	O
classified	O
as	O
infrequent.	O
Central	O
Nervous:	O
headache,	O
shaky	O
feeling,	O
tingling,	O
agitation,	O
fainting,	O
fatigue,	O
heavy	O
eyelids,	O
high	O
energy,	O
hot	O
spells,	O
numbness,	O
and	O
sluggishness.	O
Autonomic	O
Nervous:	O
dry	O
mouth	O
and	O
hyperhidrosis.	O
Gastrointestinal:	O
vomiting,	O
difficulty	O
swallowing,	O
and	O
heartburn.	O
Cardiovascular:	O
tachycardia.	O
Musculoskeletal:	O
leg	O
pain	O
and	O
muscle	O
fatigue.	O
Genitourinary:	O
diuresis.	O
Miscellaneous:	O
pruritus,	O
fever,	O
earache,	O
nas	B-C015378
al	O
congestion,	O
and	O
tinnitus.	O
The	O
following	O
adverse	O
drug	O
reactions	O
have	O
been	O
reported	O
with	O
the	O
components	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules.	O
Potential	O
effects	O
of	O
high	O
dosage	O
are	O
listed	O
in	O
the	O
[see	O
Overdosage	O
(10)]	O
section	O
of	O
this	O
insert.	O
Aspirin	B-D001241
:	O
occult	O
blood	O
loss,	O
hemolytic	O
anemia,	O
iron	O
deficiency	O
anemia,	O
gastric	O
distress,	O
heartburn,	O
nausea,	O
peptic	O
ulcer,	O
prolonged	O
bleeding	O
time,	O
acute	O
airway	O
obstruction,	O
renal	O
toxicity	O
when	O
taken	O
in	O
high	O
doses	O
for	O
prolonged	O
periods,	O
impaired	O
urate	O
excretion,	O
hepatitis.	O
Caffeine	B-D002110
:	O
cardiac	O
stimulation,	O
irritability,	O
tremor,	O
dependence,	O
nephrotoxicity,	O
hyperglycemia.	O
Codeine	B-D003061
:	O
nausea,	O
vomiting,	O
drowsiness,	O
lightheadedness,	O
constipation,	O
pruritus.	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Central	O
Nervous:	O
abuse,	O
addiction,	O
anxiety,	O
depression,	O
disorientation,	O
hallucination,	O
hyperactivity,	O
insomnia,	O
libido	O
decrease,	O
nervousness,	O
neuropathy,	O
psychosis,	O
sedation,	O
sexual	O
activity	O
increase,	O
slurred	O
speech,	O
twitching,	O
unconsciousness,	O
vertigo.	O
Autonomic	O
Nervous:	O
epistaxis,	O
flushing,	O
miosis,	O
salivation.	O
Gastrointestinal:	O
anorexia,	O
appetite	O
increased,	O
constipation,	O
diarrhea,	O
esophagitis,	O
gastroenteritis,	O
gastrointestinal	O
spasm,	O
hiccup,	O
mouth	O
burning,	O
pyloric	O
ulcer.	O
Cardiovascular:	O
chest	O
pain,	O
hypotensive	O
reaction,	O
palpitations,	O
syncope.	O
Skin	B-D012867
:	O
erythema,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
hives,	O
rash,	O
toxic	O
epidermal	O
necrolysis.	O
Urinary:	O
kidney	O
impairment,	O
urinary	O
difficulty.	O
Miscellaneous:	O
allergic	O
reaction,	O
anaphylactic	O
shock,	O
cholangiocarcinoma,	O
drug	O
interaction	O
with	O
erythromycin	O
(stomach	O
upset),	O
edema.	O
Serotonin	B-D012701
syndrome:	O
Cases	O
of	O
serotonin	O
syndrome,	O
a	O
potentially	O
life-threatening	O
condition,	O
have	O
been	O
reported	O
during	O
concomitant	O
use	O
of	O
opioids	O
with	O
serotonergic	O
drugs.	O
Adrenal	O
insufficiency:	O
Cases	O
of	O
adrenal	O
insufficiency	O
have	O
been	O
reported	O
with	O
opioid	O
use,	O
more	O
often	O
following	O
greater	O
than	O
one	O
month	O
of	O
use.	O
Anaphylaxis	B-D000707
:	O
Anaphylaxis	B-D000707
has	O
been	O
reported	O
with	O
ingredients	O
contained	O
in	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules.	O
Androgen	O
deficiency:	O
Cases	O
of	O
androgen	O
deficiency	O
have	O
occurred	O
with	O
chronic	O
use	O
of	O
opioids	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
NAPRELAN	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(5.1)	O
NAPRELAN®	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
NAPRELAN	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
NAPRELAN	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
NAPRELAN	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
NAPRELAN	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
naproxen,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
NAPRELAN	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
NAPRELAN	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
naproxen,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
NAPRELAN	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
naproxen.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
NAPRELAN	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
NAPRELAN,	O
can	O
lead	O
to	O
new	O
onset	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
naproxen	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
NAPRELAN	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
NAPRELAN	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
NAPRELAN	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
NAPRELAN	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
NAPRELAN.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
NAPRELAN	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
NAPRELAN	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
NAPRELAN	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Naproxen	B-D009288
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
naproxen	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
NAPRELAN	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
NAPRELAN	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
naproxen	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
NAPRELAN	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
NAPRELAN	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Naproxen	B-D009288
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
NAPRELAN,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
NAPRELAN	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
NAPRELAN,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
NAPRELAN	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
The	O
most	O
frequent	O
adverse	O
events	O
were	O
headache	O
(15%),	O
followed	O
by	O
dyspepsia	O
(14%),	O
and	O
flu	O
syndrome	O
(10%).	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Almatica	O
Pharma,	O
Inc.	O
at	O
1-877-447-7979	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
As	O
with	O
all	O
drugs	O
in	O
this	O
class,	O
the	O
frequency	O
and	O
severity	O
of	O
adverse	O
events	O
depends	O
on	O
several	O
factors:	O
the	O
dose	O
of	O
the	O
drug	O
and	O
duration	O
of	O
treatment;	O
the	O
age,	O
the	O
sex,	O
physical	O
condition	O
of	O
the	O
patient;	O
any	O
concurrent	O
medical	O
diagnoses	O
or	O
individual	O
risk	O
factors.	O
The	O
following	O
adverse	O
reactions	O
are	O
divided	O
into	O
three	O
parts	O
based	O
on	O
frequency	O
and	O
whether	O
or	O
not	O
the	O
possibility	O
exists	O
of	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
these	O
adverse	O
events.	O
In	O
those	O
reactions	O
listed	O
as	O
“Probable	O
Causal	O
Relationship”	O
there	O
is	O
at	O
least	O
one	O
case	O
for	O
each	O
adverse	O
reaction	O
where	O
there	O
is	O
evidence	O
to	O
suggest	O
that	O
there	O
is	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
the	O
reported	O
event.	O
The	O
adverse	O
reactions	O
reported	O
were	O
based	O
on	O
the	O
results	O
from	O
two	O
double-blind	O
controlled	O
clinical	O
trials	O
of	O
three	O
months	O
duration	O
with	O
an	O
additional	O
nine	O
month	O
open-label	O
extension.	O
A	O
total	O
of	O
542	O
patients	O
received	O
NAPRELAN	O
Tablets	B-D013607
either	O
in	O
the	O
double-blind	O
period	O
or	O
in	O
the	O
nine	O
month	O
open-label	O
extension.	O
Of	O
these	O
542	O
patients,	O
232	O
received	O
NAPRELAN	O
Tablets	B-D013607
,	O
167	O
were	O
initially	O
treated	O
with	O
Naprosyn®	O
and	O
143	O
were	O
initially	O
treated	O
with	O
placebo.	O
Adverse	O
reactions	O
reported	O
by	O
patients	O
who	O
received	O
NAPRELAN	O
Tablets	B-D013607
are	O
shown	O
by	O
body	O
system.	O
Those	O
adverse	O
reactions	O
observed	O
with	O
naproxen	O
but	O
not	O
reported	O
in	O
controlled	O
trials	O
with	O
NAPRELAN	O
Tablets	B-D013607
are	O
italicized.	O
The	O
most	O
frequent	O
adverse	O
events	O
from	O
the	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
were	O
headache	O
(15%),	O
followed	O
by	O
dyspepsia	O
(14%),	O
and	O
flu	O
syndrome	O
(10%).	O
The	O
incidence	O
of	O
other	O
adverse	O
events	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
the	O
patients	O
are	O
marked	O
with	O
an	O
asterisk.	O
Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.	O
Incidence	B-D015994
greater	O
than	O
1%	O
(probable	O
causal	O
relationship)	O
Body	O
as	O
a	O
Whole—Pain	O
(back)*,	O
pain*,	O
infection*,	O
fever,	O
injury	O
(accident),	O
asthenia,	O
pain	O
chest,	O
headache	O
(15%),	O
flu	O
syndrome	O
(10%).	O
Gastrointestinal—Nausea*,	O
diarrhea*,	O
constipation*,	O
abdominal	O
pain*,	O
flatulence,	O
gastritis,	O
vomiting,	O
dysphagia,	O
dyspepsia	O
(14%),	O
heartburn*,	O
stomatitis.	O
Hematologic—Anemia,	O
ecchymosis.	O
Respiratory—Pharyngitis*,	O
rhinitis*,	O
sinusitis*,	O
bronchitis,	O
cough	O
increased.	O
Renal—Urinary	O
tract	O
infection*,	O
cystitis.	O
Dermatologic—Skin	O
rash*,	O
skin	O
eruptions*,	O
ecchymoses*,	O
purpura.	O
Metabolic	O
and	O
Nutrition—Peripheral	O
edema,	O
hyperglycemia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Dizziness,	O
paresthesia,	O
insomnia,	O
drowsiness*,	O
lightheadedness.	O
Cardiovascular—Hypertension,	O
edema*,	O
dyspnea*,	O
palpitations.	O
Musculoskeletal—Cramps	O
(leg),	O
myalgia,	O
arthralgia,	O
joint	O
disorder,	O
tendon	O
disorder.	O
Special	O
Senses—Tinnitus*,	O
hearing	O
disturbances,	O
visual	O
disturbances.	O
General—Thirst.	O
Incidence	B-D015994
less	O
than	O
1%	O
(probable	O
causal	O
relationship)	O
Body	O
as	O
a	O
Whole—Abscess,	O
monilia,	O
neck	O
rigid,	O
pain	O
neck,	O
abdomen	O
enlarged,	O
carcinoma,	O
cellulitis,	O
edema	O
general,	O
LE	O
syndrome,	O
malaise,	O
mucous	O
membrane	O
disorder,	O
allergic	O
reaction,	O
pain	O
pelvic.	O
Gastrointestinal—Anorexia,	O
cholecystitis,	O
cholelithiasis,	O
eructation,	O
GI	O
hemorrhage,	O
rectal	O
hemorrhage,	O
stomatitis	O
aphthous,	O
stomatitis	O
ulcer,	O
ulcer	O
mouth,	O
ulcer	O
stomach,	O
periodontal	O
abscess,	O
cardiospasm,	O
colitis,	O
esophagitis,	O
gastroenteritis,	O
GI	O
disorder,	O
rectal	O
disorder,	O
tooth	O
disorder,	O
hepatosplenomegaly,	O
liver	O
function	O
abnormality,	O
melena,	O
ulcer	O
esophagus,	O
hematemesis,	O
jaundice,	O
pancreatitis,	O
necrosis.	O
Renal—Dysmenorrhea,	O
dysuria,	O
kidney	O
function	O
abnormality,	O
nocturia,	O
prostate	O
disorder,	O
pyelonephritis,	O
carcinoma	O
breast,	O
urinary	O
incontinence,	O
kidney	O
calculus,	O
kidney	O
failure,	O
menorrhagia,	O
metrorrhagia,	O
neoplasm	O
breast,	O
nephrosclerosis,	O
hematuria,	O
pain	O
kidney,	O
pyuria,	O
urine	O
abnormal,	O
urinary	O
frequency,	O
urinary	O
retention,	O
uterine	O
spasm,	O
vaginitis,	O
glomerular	O
nephritis,	O
hyperkalemia,	O
interstitial	O
nephritis,	O
nephrotic	O
syndrome,	O
renal	O
disease,	O
renal	O
failure,	O
renal	O
papillary	O
necrosis.	O
Hematologic—Leukopenia,	O
bleeding	O
time	O
increased,	O
eosinophilia,	O
abnormal	O
RBC,	O
abnormal	O
WBC,	O
thrombocytopenia,	O
agranulocytosis,	O
granulocytopenia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Depression,	O
anxiety,	O
hypertonia,	O
nervousness,	O
neuralgia,	O
neuritis,	O
vertigo,	O
amnesia,	O
confusion,	O
co-ordination,	O
abnormal	O
diplopia,	O
emotional	O
lability,	O
hematoma	O
subdural,	O
paralysis,	O
dream	O
abnormalities,	O
inability	O
to	O
concentrate,	O
muscle	O
weakness.	O
Dermatologic:	O
Angiodermatitis,	O
herpes	O
simplex,	O
dry	O
skin,	O
sweating,	O
ulcer	O
skin,	O
acne,	O
alopecia,	O
dermatitis	O
contact,	O
eczema,	O
herpes	O
zoster,	O
nail	O
disorder,	O
skin	O
necrosis,	O
subcutaneous	O
nodule,	O
pruritus,	O
urticaria,	O
neoplasm	O
skin,	O
photosensitive	O
dermatitis,	O
photosensitivity	O
reactions	O
resembling	O
porphyria	O
cutaneous	O
tarda,	O
epidermolysis	O
bullosa.	O
Special	O
Senses—Amblyopia,	O
scleritis,	O
cataract,	O
conjunctivitis,	O
deaf,	O
ear	O
disorder,	O
keratoconjunctivitis,	O
lacrimation	O
disorder,	O
otitis	O
media,	O
pain	O
eye.	O
Cardiovascular—Angina	O
pectoris,	O
coronary	O
artery	O
disease,	O
myocardial	O
infarction,	O
deep	O
thrombophlebitis,	O
vasodilation,	O
vascular	O
anomaly,	O
arrhythmia,	O
bundle	O
branch	O
block,	O
abnormal	O
ECG,	O
heart	O
failure	O
right,	O
hemorrhage,	O
migraine,	O
aortic	O
stenosis,	O
syncope,	O
tachycardia,	O
congestive	O
heart	O
failure.	O
Respiratory—Asthma,	O
dyspnea,	O
lung	O
edema,	O
laryngitis,	O
lung	O
disorder,	O
epistaxis,	O
pneumonia,	O
respiratory	O
distress,	O
respiratory	O
disorder,	O
eosinophilic	O
pneumonitis.	O
Musculoskeletal—Myasthenia,	O
bone	O
disorder,	O
spontaneous	O
bone	O
fracture,	O
fibrotendinitis,	O
bone	O
pain,	O
ptosis,	O
spasm	O
general,	O
bursitis.	O
Metabolic	O
and	O
Nutrition—Creatinine	O
increase,	O
glucosuria,	O
hypercholesteremia,	O
albuminuria,	O
alkalosis,	O
BUN	O
increased,	O
dehydration,	O
edema,	O
glucose	O
tolerance	O
decrease,	O
hyperuricemia,	O
hypokalemia,	O
SGOT	O
increase,	O
SGPT	O
increase,	O
weight	O
decrease.	O
General—Anaphylactoid	O
reactions,	O
angioneurotic	O
edema,	O
menstrual	O
disorders,	O
hypoglycemia,	O
pyrexia	O
(chills	O
and	O
fevers).	O
Incidence	B-D015994
less	O
than	O
1%	O
(causal	O
relationship	O
unknown)	O
Other	O
adverse	O
reactions	O
listed	O
in	O
the	O
naproxen	O
package	O
label,	O
but	O
not	O
reported	O
by	O
those	O
who	O
received	O
NAPRELAN	O
Tablets	B-D013607
are	O
shown	O
in	O
italics.	O
These	O
observations	O
are	O
being	O
listed	O
as	O
alerting	O
information	O
to	O
the	O
physician.	O
Hematologic—Aplastic	O
anemia,	O
hemolytic	O
anemia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Aseptic	O
meningitis,	O
cognitive	O
dysfunction.	O
Dermatologic—Epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome.	O
Gastrointestinal—Non-peptic	O
GI	O
ulceration,	O
ulcerative	O
stomatitis.	O
Cardiovascular—Vasculitis.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
Celecoxib	B-D000068579
capsules	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)]	O
Celecoxib	B-D000068579
capsules	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
[see	O
CONTRAINDICATIONS	O
(4)	O
and	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity	O
:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity	O
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions	O
:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
:	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions	O
:	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,8.1)	O
Hematologic	O
Toxicity	O
:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	O
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
for	O
the	O
celecoxib	O
capsules	O
400	O
mg	O
twice	O
daily	O
and	O
celecoxib	O
capsules	O
200	O
mg	O
twice	O
daily	O
treatment	O
arms	O
compared	O
to	O
placebo.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
CLINICAL	O
STUDIES	O
(14.7)].	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
CONTRAINDICATIONS	O
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
celecoxib	O
capsules	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
celecoxib	O
capsules.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	O
anticoagulants;	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
CLINICAL	O
STUDIES	O
(14.7)].	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	O
capsules	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib	O
capsules,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
capsules	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
capsules	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
discontinue	O
celecoxib	O
capsules	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
See	O
CLINICAL	O
STUDIES	O
(14.6,	O
14.7)	O
for	O
additional	O
blood	O
pressure	O
data	O
for	O
celecoxib	O
capsules.	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
celecoxib	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
In	O
the	O
CLASS	O
study	O
[see	O
CLINICAL	O
STUDIES	O
(14.7)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
capsules	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
celecoxib	O
capsules	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE	O
inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
celecoxib	O
capsules	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
celecoxib	O
capsules.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
celecoxib	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoadosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
celecoxib	O
and	O
in	O
patients	O
with	O
aspirin	O
sensitive	O
asthma.	O
Celecoxib	B-D000068579
capsules	O
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	O
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
CONTRAINDICATIONS	O
(4)	O
and	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
CONTRAINDICATIONS	O
(4)].	O
When	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	O
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib,	O
including	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(AGEP).	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
CONTRAINDICATIONS	O
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
USE	O
IN	O
SPECIFIC	O
POPULATIONS	O
(8.1)].	O
5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
celecoxib	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
capsules	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs,	O
including	O
celecoxib,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	O
SSRIs	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2,	O
5.3,	O
5.6)].	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
capsules	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation	O
with	O
use	O
of	O
celecoxib	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	O
and	O
their	O
caregivers	O
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible.	O
6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Lupin	O
Pharmaceuticals,	O
Inc	O
at	O
1-800-399-2561	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)]	O
Hepatotoxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.3)]	O
Hypertension	B-D006973
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.11)]	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
capsules	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
capsules	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥	O
2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥	O
2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
CBX	O
Placebo	O
NAP	O
DCF	O
IBU	O
N=4146	O
N=1864	O
N=1366	O
N=387	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
capsules	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1%	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General:	O
Hypersensitivity	B-D006967
,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
Blood	B-D001769
urea	O
nitrogen	O
(BUN)	O
increased,	O
creatine	O
phosphokinase	O
(CPK)	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia	B-D001259
,	O
suicide	O
[see	O
DRUG	O
INTERACTIONS	O
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
CLINICAL	O
STUDIES	O
(14.7)]	O
Hematological	O
Events	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
capsules	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
aspirin	O
use	O
[see	O
CLINICAL	O
PHARMACOLOGY	O
(12.2)].	O
Withdrawals/Serious	O
Adverse	O
Events	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
twice	O
daily.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
capsules	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years.	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.7)].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
Capsules	B-D002214
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib	O
capsules,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders	O
:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning,	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
celecoxib.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular	O
Vasculitis	B-D014657
,	O
deep	O
venous	O
thrombosis	O
General	O
Anaphylactoid	O
reaction,	O
angioedema	O
Liver	B-D008099
and	O
biliary	O
Liver	B-D008099
necrosis,	O
hepatitis,	O
jaundice,	O
hepatic	O
failure	O
Hemic	O
and	O
lymphatic	O
Agranulocytosis	B-D000380
,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous	O
Aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
Renal	O
Interstitial	O
nephritis	O
Cardiovascular	O
Thrombotic	O
Events	O
1.Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
2.Etodolac	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
1.NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
a	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1,000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain*,	O
diarrhea*,	O
flatulence*,	O
nausea*,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise*,	O
dizziness*,	O
depression,	O
nervousness.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death	O
Cardiovascular	O
system	O
-	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(	O
s	O
ee	O
WARNINGS	O
).	O
•	O
Diclofenac	B-D004008
sodium	O
e	O
xtended-release	O
tablets	O
,	O
USP	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
,	O
WARNINGS	O
).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(	O
s	O
ee	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS	O
)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
Hypertension	B-D006973
(see	O
WARNINGS	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
extended-release	O
tablets,	O
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses	O
:	O
blurred	O
vision	O
Urogen	O
i	O
tal	O
System	O
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure.	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages	O
:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses	O
:	O
conjunctivitis,	O
hearing	O
impairment.	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
EVENTS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
http://www.fda.gov/	O
for	O
voluntary	O
reporting	O
of	O
adverse	O
reactions.	O
Cardiovascular	O
Risk	B-D012306
•NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS	O
.)	O
•Diclofenac	O
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/	O
polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
].	O
Etodolac	B-D017308
capsules,	O
200	O
mg	O
and	O
300	O
mg,	O
and	O
Etodolac	B-D017308
tablets,	O
400	O
mg	O
and	O
500	O
mg	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
and	O
Warnings	O
].	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
capsules	O
and	O
tablets	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
capsules	O
and	O
tablets	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
painDrug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.,	O
diarrhea,	O
flatulence,	O
nausea,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise,	O
dizziness,	O
depression,	O
nervousness,	O
fatigue.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
Musculoskeletal—Arthralgia.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
leukocytoclastic	O
vasculitis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.	O
Musculoskeletal—Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death	O
Cardiovascular	O
system	O
-	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
BOXED	O
WARNINGS	O
Cardiovascular	O
Risk	B-D012306
•	O
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
a	O
greater	O
risk.	O
(See	O
WARNINGS	O
.)	O
•	O
Indomethacin	B-D007213
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS	O
.)	O
ADVERSE	O
REACTIONS	O
The	O
adverse	O
reactions	O
for	O
indomethacin	O
capsules	O
listed	O
in	O
the	O
following	O
table	O
have	O
been	O
arranged	O
into	O
two	O
groups:	O
(1)	O
incidence	O
greater	O
than	O
1%;	O
and	O
(2)	O
incidence	O
less	O
than	O
1%.	O
The	O
incidence	O
for	O
group	O
(1)	O
was	O
obtained	O
from	O
33	O
double-blind	O
controlled	O
clinical	O
trials	O
reported	O
in	O
the	O
literature	O
(1,092	O
patients).	O
The	O
incidence	O
for	O
group	O
(2)	O
was	O
based	O
on	O
reports	O
in	O
clinical	O
trials,	O
in	O
the	O
literature,	O
and	O
on	O
voluntary	O
reports	O
since	O
marketing.	O
The	O
probability	O
of	O
a	O
causal	O
relationship	O
exists	O
between	O
indomethacin	O
and	O
these	O
adverse	O
reactions,	O
some	O
of	O
which	O
have	O
been	O
reported	O
only	O
rarely.	O
Incidence	B-D015994
greater	O
than	O
1%	O
Incidence	B-D015994
less	O
than	O
1%	O
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
indomethacin.	O
(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.)	O
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
indomethacin.	O
(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.)	O
GASTROINTESTINAL	O
nausea*	O
with	O
or	O
without	O
vomitingdyspepsia*	O
(including	O
indigestion,	O
heartburn	O
and	O
epigastric	O
pain)diarrheaabdominal	O
distress	O
or	O
painconstipation	O
Anorexia	B-D000855
bloating	O
(includes	O
distension)flatulencepeptic	O
ulcergastroenteritisrectal	O
bleedingproctitissingle	O
or	O
multiple	O
ulcerations,	O
including	O
perforation	O
and	O
hemorrhage	O
of	O
the	O
esophagus,	O
stomach,	O
duodenum	O
or	O
small	O
and	O
large	O
intestinesintestinal	O
ulceration	O
associated	O
with	O
stenosis	O
and	O
obstruction	O
gastrointestinal	O
bleeding	O
without	O
obvious	O
ulcer	O
formation	O
and	O
perforation	O
of	O
pre-existing	O
sigmoid	O
lesions	O
(diverticulum,	O
carcinoma,	O
etc.)	O
development	O
of	O
ulcerative	O
colitis	O
and	O
regional	O
ileitisulcerative	O
stomatitistoxic	O
hepatitis	O
and	O
jaundice	O
(some	O
fatal	O
cases	O
have	O
been	O
reported)intestinal	O
strictures	O
(diaphragms)	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
headache	O
(11.7%)dizziness*	O
vertigosomnolencedepression	O
and	O
fatigue	O
(including	O
malaise	O
and	O
listlessness)	O
anxiety	O
(includes	O
nervousness)muscle	O
weaknessinvoluntary	O
muscle	O
movementsinsomniamuzzinesspsychic	O
disturbances	O
including	O
psychotic	O
episodesmental	O
confusiondrowsiness	O
light-headednesssyncopeparesthesiaaggravation	O
of	O
epilepsy	O
and	O
parkinsonismdepersonalizationcomaperipheral	O
neuropathyconvulsiondysarthria	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
ocular	O
—	O
corneal	O
deposits	O
and	O
retinal	O
disturbances,	O
including	O
those	O
of	O
the	O
macula,	O
have	O
been	O
reported	O
in	O
some	O
patients	O
on	O
prolonged	O
therapy	O
with	O
Indomethacin	B-D007213
blurred	O
visiondiplopiahearing	O
disturbances,	O
deafness	O
CARDIOVASCULAR	O
None	O
Hypertension	B-D006973
hypotensiontachycardiachest	O
pain	O
congestive	O
heart	O
failurearrhythmia;	O
palpitations	O
METABOLIC	O
none	O
Edema	B-D004487
weight	O
gainfluid	O
retentionflushing	O
or	O
sweating	O
Hyperglycemia	B-D006943
glycosuriahyperkalemia	O
INTEGUMENTARY	O
None	O
Pruritus	B-D011537
rash;	O
urticariapetechiae	O
or	O
ecchymosis	O
exfoliative	O
dermatitiserythema	O
nodosumloss	O
of	O
hairStevens-Johnson	O
syndromeerythema	O
multiformetoxic	O
epidermal	O
necrolysis	O
HEMATOLOGIC	O
None	O
Leucopeniabone	O
marrow	O
depressionanemia	O
secondary	O
to	O
obvious	O
or	O
occult	O
gastrointestinal	O
bleeding	O
aplastic	O
anemiahemolytic	O
anemiaagranulocytosisthrombocytopenic	O
purpuradisseminated	O
intravascular	O
coagulation	O
HYPERSENSITIVITY	O
None	O
acute	O
anaphylaxisacute	O
respiratory	O
distressrapid	O
fall	O
in	O
blood	O
pressure	O
resembling	O
a	O
shock-like	O
stateangioedema	O
Dyspnea	B-D004417
asthmapurpuraangiitispulmonary	O
edemafever	O
GENITOURINARY	O
None	O
Hematuria	B-D006417
vaginal	O
bleedingproteinurianephrotic	O
syndromeinterstitial	O
nephritis	O
BUN	O
elevationrenal	O
insufficiency,	O
including	O
renal	O
failure	O
MISCELLANEOUS	O
None	O
Epistaxis	B-D004844
breast	O
changes,	O
including	O
enlargement	O
and	O
tenderness,	O
or	O
gynecomastia	O
Causal	O
relationship	O
unknown:	O
Other	O
reactions	O
have	O
been	O
reported	O
but	O
occurred	O
under	O
circumstances	O
where	O
a	O
causal	O
relationship	O
could	O
not	O
be	O
established.	O
However,	O
in	O
these	O
rarely	O
reported	O
events,	O
the	O
possibility	O
cannot	O
be	O
excluded.	O
Therefore,	O
these	O
observations	O
are	O
being	O
listed	O
to	O
serve	O
as	O
alerting	O
information	O
to	O
physicians:	O
Cardiovascular:	O
Thrombophlebitis	B-D013924
Hematologic:	O
Although	O
there	O
have	O
been	O
several	O
reports	O
of	O
leukemia,	O
the	O
supporting	O
information	O
is	O
weak.	O
Genitourinary:	O
Urinary	O
frequency.	O
A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
fasciitis,	O
particularly	O
in	O
association	O
with	O
Group	O
Aβ	O
hemolytic	O
streptococcus,	O
has	O
been	O
described	O
in	O
persons	O
treated	O
with	O
non-steroidal	O
anti-inflammatory	O
agents,	O
including	O
indomethacin,	O
sometimes	O
with	O
fatal	O
outcome	O
(see	O
also	O
PRECAUTIONS,	O
General).	O
ADVERSE	O
REACTIONS	O
Ocular	O
Transient	O
burning	O
and	O
stinging	O
were	O
reported	O
in	O
approximately	O
15%	O
of	O
patients	O
across	O
studies	O
with	O
the	O
use	O
of	O
diclofenac	O
sodium	O
ophthalmic	O
solution.	O
In	O
cataract	O
surgery	O
studies,	O
keratitis	O
was	O
reported	O
in	O
up	O
to	O
28%	O
of	O
patients	O
receiving	O
diclofenac	O
sodium	O
ophthalmic	O
solution,	O
although	O
in	O
many	O
of	O
these	O
cases	O
keratitis	O
was	O
initially	O
noted	O
prior	O
to	O
the	O
initiation	O
of	O
treatment.	O
Elevated	O
intraocular	O
pressure	O
following	O
cataract	O
surgery	O
was	O
reported	O
in	O
approximately	O
15%	O
of	O
patients	O
undergoing	O
cataract	O
surgery.	O
Lacrimation	O
complaints	O
were	O
reported	O
in	O
approximately	O
30%	O
of	O
case	O
studies	O
undergoing	O
incisional	O
refractive	O
surgery.	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
approximately	O
10%	O
or	O
less	O
of	O
patients:	O
abnormal	O
vision,	O
acute	O
elevated	O
IOP,	O
blurred	O
vision,	O
conjunctivitis,	O
corneal	O
deposits,	O
corneal	O
edema,	O
corneal	O
opacity,	O
corneal	O
lesions,	O
discharge,	O
eyelid	O
swelling,	O
eye	O
pain,	O
injection	O
(redness),	O
iritis,	O
irritation,	O
itching,	O
lacrimation	O
disorder,	O
and	O
ocular	O
allergy.	O
Systemic	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
3%	O
or	O
less	O
of	O
patients:	O
abdominal	O
pain,	O
asthenia,	O
chills,	O
dizziness,	O
facial	O
edema,	O
fever,	O
headache,	O
insomnia,	O
nausea,	O
pain,	O
rhinitis,	O
viral	O
infection,	O
and	O
vomiting.	O
Clinical	O
Practice	O
The	O
following	O
reactions	O
have	O
been	O
identified	O
during	O
postmarketing	O
use	O
of	O
topical	O
diclofenac	O
sodium	O
ophthalmic	O
solution,	O
0.1%	O
in	O
clinical	O
practice.	O
Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size,	O
estimates	O
of	O
frequency	O
cannot	O
be	O
made.	O
The	O
reactions,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
diclofenac	O
sodium	O
ophthalmic	O
solution,	O
0.1%,	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
corneal	O
erosion,	O
corneal	O
infiltrates,	O
corneal	O
perforation,	O
corneal	O
thinning,	O
corneal	O
ulceration,	O
and	O
epithelial	O
breakdown	O
[see	O
PRECAUTIONS,	O
General].	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sand	B-D000080463
oz	O
Inc.,	O
at	O
1-800-525-8747	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
·	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
·	O
Ibuprofen	B-D007052
Tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	O
tablets	O
is	O
gastrointestinal.	O
In	O
controlled	O
clinical	O
trials	O
the	O
percentage	O
of	O
patients	O
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%.	O
In	O
controlled	O
studies	O
when	O
ibuprofen	O
tablets	O
were	O
compared	O
to	O
aspirin	O
and	O
indomethacin	O
in	O
equally	O
effective	O
doses,	O
the	O
overall	O
incidence	O
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin	O
or	O
indomethacin-treated	O
patients.	O
Adverse	O
reactions	O
observed	O
during	O
controlled	O
clinical	O
trials	O
at	O
an	O
incidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table.	O
Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	O
in	O
approximately	O
3,000	O
patients.	O
More	O
than	O
500	O
of	O
these	O
patients	O
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks.	O
Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	O
clinical	O
trials	O
and	O
from	O
marketing	O
experience.	O
These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	O
tablets	O
where	O
the	O
probability	O
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	O
tablets	O
has	O
not	O
been	O
established.	O
Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	O
trials	O
of	O
patients	O
with	O
rheumatoid	O
arthritis.	O
The	O
increases	O
in	O
incidence	O
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table.	O
Incidence	B-D015994
Greater	O
than	O
1%(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea	B-D009325
*,	O
epigastric	O
pain*,	O
heartburn*,	O
diarrhea,	O
abdominal	O
distress,	O
nausea	O
and	O
vomiting,	O
indigestion,	O
constipation,	O
abdominal	O
cramps	O
or	O
pain,	O
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	O
Gastric	O
or	O
duodenal	O
ulcer	O
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	O
hemorrhage,	O
melena,	O
gastritis,	O
hepatitis,	O
jaundice,	O
abnormal	O
liver	O
function	O
tests;	O
pancreatitis	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
Dizziness	B-D004244
*,	O
headache,	O
nervousness	O
Depression	B-D003863
,	O
insomnia,	O
confusion,	O
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	O
with	O
fever	O
and	O
coma	O
(see	O
PRECAUTIONS)	O
Paresthesia	B-D010292
s,	O
hallucinations,	O
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	O
DERMATOLOGIC	O
Rash*,	O
(including	O
maculopapular	O
type),	O
pruritus	O
Vesiculobullous	O
eruptions,	O
urticaria,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome,	O
alopecia	O
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	O
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D006309
loss,	O
amblyopia	O
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	O
and	O
/or	O
changes	O
in	O
color	O
vision)	O
(see	O
PRECAUTIONS)	O
Conjunctivitis	B-D003231
,	O
diplopia,	O
optic	O
neuritis,	O
cataracts	O
HEMATOLOGIC	O
Neutropenia	B-D009503
,	O
agranulocytosis,	O
aplastic	O
anemia,	O
hemolytic	O
anemia	O
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	O
with	O
or	O
without	O
purpura,	O
eosinophilia,	O
decreases	O
in	O
hemoglobin	O
and	O
hematocrit	O
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	O
menorrhagia)	O
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	O
Gynecomastia	B-D006177
,	O
hypoglycemic	O
reaction,	O
acidosis	O
CARDIOVASCULAR	O
Edema	B-D004487
,	O
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	O
failure	O
in	O
patients	O
with	O
marginal	O
cardiac	O
function,	O
elevate	O
blood	O
pressure,	O
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	O
sinus	O
bradycardia)	O
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	O
pain,	O
fever,	O
chills,	O
nausea	O
and	O
vomiting;	O
anaphylaxis;	O
bronchospasm	O
(see	O
CONTRAINDICATIONS)	O
Serum	B-D044967
sickness,	O
lupus	O
erythematosus	O
syndrome.	O
Henoch-Schonlein	O
vasculitis,	O
angioedema	O
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	O
clearance,	O
poliuria,	O
azotemia,	O
cystitis,	O
hematuria	O
Renal	O
papillary	O
necrosis	O
MISCELLANEOUS	O
Dry	O
eyes	O
and	O
mouth,	O
gingival	O
ulcer,	O
rhinitis	O
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
ibuprofen.	O
(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked).	O
**Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related.	O
Reactions	O
are	O
classified	O
under	O
“CausalRelationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
The	O
risk	O
of	O
GI	O
bleeding	O
is	O
increased,	O
especially	O
in	O
patients	O
who	O
are	O
heavy	O
alcohol	O
users,	O
have	O
a	O
history	O
of	O
peptic	O
ulcer,	O
or	O
have	O
coagulation	O
abnormalities	O
due	O
to	O
liver	O
disease	O
or	O
vitamin	O
K	O
deficiency	O
(5.1)	O
As	O
with	O
other	O
antiplatelets,	O
there	O
is	O
a	O
risk	O
of	O
intracranial	O
hemorrhage	O
(5.1)	O
Avoid	O
use	O
in	O
patients	O
with	O
severe	O
hepatic	O
or	O
renal	O
insufficiency	O
(5.2,	O
5.3)	O
Can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman,	O
especially	O
in	O
the	O
third	O
trimester	O
(5.4)	O
5.1	O
Risk	B-D012306
of	O
Bleeding	O
Intracranial	O
Hemorrhage	B-D006470
In	O
ESPS2	O
the	O
incidence	O
of	O
intracranial	O
hemorrhage	O
was	O
0.6%	O
in	O
the	O
AGGRENOX	O
group,	O
0.5%	O
in	O
the	O
extended-release	O
dipyridamole	O
(ER-DP)	O
group,	O
0.4%	O
in	O
the	O
aspirin	O
(ASA)	O
group	O
and	O
0.4%	O
in	O
the	O
placebo	O
groups.	O
Coagulation	O
Abnormalities	O
Even	O
low	O
doses	O
of	O
aspirin	O
can	O
inhibit	O
platelet	O
function	O
leading	O
to	O
an	O
increase	O
in	O
bleeding	O
time.	O
This	O
can	O
adversely	O
affect	O
patients	O
with	O
inherited	O
or	O
acquired	O
(liver	O
disease	O
or	O
vitamin	O
K	O
deficiency)	O
bleeding	O
disorders	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7.4)	O
].	O
Gastrointestinal	O
(GI)	O
Side	O
Effects	O
GI	O
side	O
effects	O
include	O
stomach	O
pain,	O
heartburn,	O
nausea,	O
vomiting,	O
and	O
gross	O
GI	O
bleeding.	O
Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
dyspepsia,	O
are	O
common	O
and	O
can	O
occur	O
anytime	O
during	O
therapy,	O
physicians	O
should	O
remain	O
alert	O
for	O
signs	O
of	O
ulceration	O
and	O
bleeding,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
GI	O
symptoms.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
GI	O
side	O
effects	O
and	O
what	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
In	O
ESPS2	O
the	O
incidence	O
of	O
gastrointestinal	O
bleeding	O
was	O
4.1%	O
in	O
the	O
AGGRENOX	O
group,	O
2.2%	O
in	O
the	O
extended-release	O
dipyridamole	O
group,	O
3.2%	O
in	O
the	O
aspirin	O
group,	O
and	O
2.1%	O
in	O
the	O
placebo	O
groups.	O
Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
Avoid	O
using	O
aspirin	O
in	O
patients	O
with	O
a	O
history	O
of	O
active	O
peptic	O
ulcer	O
disease,	O
which	O
can	O
cause	O
gastric	O
mucosal	O
irritation	O
and	O
bleeding.	O
Alcohol	O
Warning	O
Because	O
AGGRENOX	O
contains	O
aspirin,	O
counsel	O
patients	O
who	O
consume	O
three	O
or	O
more	O
alcoholic	O
drinks	O
every	O
day	O
about	O
the	O
bleeding	O
risks	O
involved	O
with	O
chronic,	O
heavy	O
alcohol	O
use	O
while	O
taking	O
aspirin.	O
5.2	O
Renal	O
Failure	O
Avoid	O
aspirin	O
in	O
patients	O
with	O
severe	O
renal	O
failure	O
(glomerular	O
filtration	O
rate	O
less	O
than	O
10	O
mL/minute)	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.6)	O
and	O
Clinical	O
Pharmacology	B-D010600
(12.3)	O
].	O
5.3	O
Hepatic	B-D048550
Insufficiency	I-D048550
Elevations	O
of	O
hepatic	O
enzymes	O
and	O
hepatic	O
failure	O
have	O
been	O
reported	O
in	O
association	O
with	O
dipyridamole	O
administration	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.6)	O
and	O
Clinical	O
Pharmacology	B-D010600
(12.3)	O
].	O
5.4	O
Pregnancy	B-D011247
Because	O
AGGRENOX	O
contains	O
aspirin,	O
AGGRENOX	O
can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman.	O
Maternal	O
aspirin	O
use	O
during	O
later	O
stages	O
of	O
pregnancy	O
may	O
cause	O
low	O
birth	O
weight,	O
increased	O
incidence	O
for	O
intracranial	O
hemorrhage	O
in	O
premature	O
infants,	O
stillbirths	O
and	O
neonatal	O
death.	O
Because	O
of	O
the	O
above	O
and	O
because	O
of	O
the	O
known	O
effects	O
of	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
on	O
the	O
fetal	O
cardiovascular	O
system	O
(closure	O
of	O
the	O
ductus	O
arteriosus),	O
avoid	O
AGGRENOX	O
in	O
the	O
third	O
trimester	O
of	O
pregnancy	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
Aspirin	B-D001241
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
rats	O
(spina	O
bifida,	O
exencephaly,	O
microphthalmia	O
and	O
coelosomia)	O
and	O
rabbits	O
(congested	O
fetuses,	O
agenesis	O
of	O
skull	O
and	O
upper	O
jaw,	O
generalized	O
edema	O
with	O
malformation	O
of	O
the	O
head,	O
and	O
diaphanous	O
skin)	O
at	O
oral	O
doses	O
of	O
330	O
mg/kg/day	O
and	O
110	O
mg/kg/day,	O
respectively.	O
These	O
doses,	O
which	O
also	O
resulted	O
in	O
a	O
high	O
resorption	O
rate	O
in	O
rats	O
(63%	O
of	O
implantations	O
versus	O
5%	O
in	O
controls),	O
are,	O
on	O
a	O
mg/m2	O
basis,	O
about	O
66	O
and	O
44	O
times,	O
respectively,	O
the	O
dose	O
of	O
aspirin	O
contained	O
in	O
the	O
maximum	O
recommended	O
daily	O
human	O
dose	O
of	O
AGGRENOX.	O
Reproduction	B-D012098
studies	O
with	O
dipyridamole	O
have	O
been	O
performed	O
in	O
mice,	O
rabbits	O
and	O
rats	O
at	O
oral	O
doses	O
of	O
up	O
to	O
125	O
mg/kg,	O
40	O
mg/kg	O
and	O
1000	O
mg/kg,	O
respectively	O
(about	O
1½,	O
2	O
and	O
25	O
times	O
the	O
maximum	O
recommended	O
daily	O
human	O
oral	O
dose,	O
respectively,	O
on	O
a	O
mg/m2	O
basis)	O
and	O
have	O
revealed	O
no	O
evidence	O
of	O
harm	O
to	O
the	O
fetus	O
due	O
to	O
dipyridamole.	O
When	O
330	O
mg	O
aspirin/kg/day	O
was	O
combined	O
with	O
75	O
mg	O
dipyridamole/kg/day	O
in	O
the	O
rat,	O
the	O
resorption	O
rate	O
approached	O
100%,	O
indicating	O
potentiation	O
of	O
aspirin-related	O
fetal	O
toxicity.	O
There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
of	O
the	O
use	O
of	O
AGGRENOX	O
in	O
pregnant	O
women.	O
If	O
AGGRENOX	O
is	O
used	O
during	O
pregnancy,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
AGGRENOX,	O
inform	O
the	O
patient	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus.	O
5.5	O
Coronary	B-D003324
Artery	I-D003324
Disease	I-D003324
Dipyridamole	B-D004176
has	O
a	O
vasodilatory	O
effect.	O
Chest	O
pain	O
may	O
be	O
precipitated	O
or	O
aggravated	O
in	O
patients	O
with	O
underlying	O
coronary	O
artery	O
disease	O
who	O
are	O
receiving	O
dipyridamole.	O
For	O
stroke	O
or	O
TIA	O
patients	O
for	O
whom	O
aspirin	O
is	O
indicated	O
to	O
prevent	O
recurrent	O
myocardial	O
infarction	O
(MI)	O
or	O
angina	O
pectoris,	O
the	O
aspirin	O
in	O
this	O
product	O
may	O
not	O
provide	O
adequate	O
treatment	O
for	O
the	O
cardiac	O
indications.	O
5.6	O
Hypotension	B-D007022
Dipyridamole	B-D004176
produces	O
peripheral	O
vasodilation,	O
which	O
can	O
exacerbate	O
pre-existing	O
hypotension.	O
5.7	O
General	O
AGGRENOX	O
capsules	O
are	O
not	O
interchangeable	O
with	O
the	O
individual	O
components	O
of	O
aspirin	O
and	O
dipyridamole	O
tablets.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Hypersensitivity	B-D006967
[	O
see	O
Contraindications	B-D000075202
(4.1)	O
].	O
Allergy	O
[	O
see	O
Contraindications	B-D000075202
(4.2)	O
].	O
Risk	B-D012306
of	O
Bleeding	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(>10%	O
and	O
greater	O
than	O
placebo)	O
were	O
headache,	O
dyspepsia,	O
abdominal	O
pain,	O
nausea,	O
and	O
diarrhea	O
(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Boehringer	O
Ingelheim	O
Pharmaceuticals,	O
Inc.	O
at	O
(800)	O
542-6257	O
or	O
(800)	O
459-9906	O
TTY	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
efficacy	O
and	O
safety	O
of	O
AGGRENOX	O
was	O
established	O
in	O
the	O
Europe	B-D005060
an	O
Stroke	B-D020521
Prevention	O
Study-2	O
(ESPS2).	O
ESPS2	O
was	O
a	O
double-blind,	O
placebo	O
controlled	O
study	O
that	O
evaluated	O
6602	O
patients	O
over	O
the	O
age	O
of	O
18	O
years	O
who	O
had	O
a	O
previous	O
ischemic	O
stroke	O
or	O
transient	O
ischemic	O
attack	O
within	O
ninety	O
days	O
prior	O
to	O
entry.	O
Patients	B-D010361
were	O
randomized	O
to	O
either	O
AGGRENOX,	O
aspirin,	O
ER-DP,	O
or	O
placebo	O
[	O
see	O
Clinical	O
Studies	O
(14)	O
];	O
primary	O
endpoints	O
included	O
stroke	O
(fatal	O
or	O
nonfatal)	O
and	O
death	O
from	O
all	O
causes.	O
This	O
24-month,	O
multicenter,	O
double-blind,	O
randomized	O
study	O
(ESPS2)	O
was	O
conducted	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
AGGRENOX	O
with	O
placebo,	O
extended-release	O
dipyridamole	O
alone	O
and	O
aspirin	O
alone.	O
The	O
study	O
was	O
conducted	O
in	O
a	O
total	O
of	O
6602	O
male	O
and	O
female	O
patients	O
who	O
had	O
experienced	O
a	O
previous	O
ischemic	O
stroke	O
or	O
transient	O
ischemia	O
of	O
the	O
brain	O
within	O
three	O
months	O
prior	O
to	O
randomization.	O
Table	O
1	O
presents	O
the	O
incidence	O
of	O
adverse	O
events	O
that	O
occurred	O
in	O
1%	O
or	O
more	O
of	O
patients	O
treated	O
with	O
AGGRENOX	O
where	O
the	O
incidence	O
was	O
also	O
greater	O
than	O
in	O
those	O
patients	O
treated	O
with	O
placebo.	O
There	O
is	O
no	O
clear	O
benefit	O
of	O
the	O
dipyridamole/aspirin	O
combination	O
over	O
aspirin	O
with	O
respect	O
to	O
safety.	O
Table	O
1	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
in	O
ESPS2*	O
Individual	O
Treatment	O
Group	O
Body	O
System/Preferred	O
Term	O
AGGRENOX	O
ER-DP	O
Alone	O
ASA	O
Alone	O
Placebo	O
*	O
Reported	O
by	O
≥1%	O
of	O
patients	O
during	O
AGGRENOX	O
treatment	O
where	O
the	O
incidence	O
was	O
greater	O
than	O
in	O
those	O
treated	O
with	O
placebo.	O
Note:	O
ER-DP	O
=	O
extended-release	O
dipyridamole	O
200	O
mg;	O
ASA	O
=	O
aspirin	O
25	O
mg.	O
The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O
NOS	O
=	O
not	O
otherwise	O
specified.	O
Total	O
Number	O
of	O
Patients	B-D010361
1650	O
1654	O
1649	O
1649	O
Total	O
Number	O
(%)	O
of	O
Patients	B-D010361
With	O
at	O
Least	O
One	O
On-Treatment	O
Adverse	O
Event	O
1319	O
(80%)	O
1305	O
(79%)	O
1323	O
(80%)	O
1304	O
(79%)	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Disorders	O
Headache	B-D006261
647	O
(39%)	O
634	O
(38%)	O
558	O
(34%)	O
543	O
(33%)	O
Convulsions	O
28	O
(2%)	O
15	O
(1%)	O
28	O
(2%)	O
26	O
(2%)	O
Gastrointestinal	O
System	O
Disorders	O
Dyspepsia	B-D004415
303	O
(18%)	O
288	O
(17%)	O
299	O
(18%)	O
275	O
(17%)	O
Abdominal	B-D015746
Pain	I-D015746
289	O
(18%)	O
255	O
(15%)	O
262	O
(16%)	O
239	O
(14%)	O
Nausea	B-D009325
264	O
(16%)	O
254	O
(15%)	O
210	O
(13%)	O
232	O
(14%)	O
Diarrhea	B-D003967
210	O
(13%)	O
257	O
(16%)	O
112	O
(7%)	O
161	O
(10%)	O
Vomiting	B-D014839
138	O
(8%)	O
129	O
(8%)	O
101	O
(6%)	O
118	O
(7%)	O
Hemorrhage	B-D006470
Rectum	B-D012007
26	O
(2%)	O
22	O
(1%)	O
16	O
(1%)	O
13	O
(1%)	O
Melena	B-D008551
31	O
(2%)	O
10	O
(1%)	O
20	O
(1%)	O
13	O
(1%)	O
Hemorrhoids	B-D006484
16	O
(1%)	O
13	O
(1%)	O
10	O
(1%)	O
10	O
(1%)	O
GI	O
Hemorrhage	B-D006470
20	O
(1%)	O
5	O
(0%)	O
15	O
(1%)	O
7	O
(0%)	O
Body	O
as	O
a	O
Whole	O
-	O
General	O
Disorders	O
Pain	B-D010146
105	O
(6%)	O
88	O
(5%)	O
103	O
(6%)	O
99	O
(6%)	O
Fatigue	B-D005221
95	O
(6%)	O
93	O
(6%)	O
97	O
(6%)	O
90	O
(5%)	O
Back	B-D001416
Pain	I-D001416
76	O
(5%)	O
77	O
(5%)	O
74	O
(4%)	O
65	O
(4%)	O
Accidental	O
Injury	O
42	O
(3%)	O
24	O
(1%)	O
51	O
(3%)	O
37	O
(2%)	O
Malaise	O
27	O
(2%)	O
23	O
(1%)	O
26	O
(2%)	O
22	O
(1%)	O
Asthenia	B-D001247
29	O
(2%)	O
19	O
(1%)	O
17	O
(1%)	O
18	O
(1%)	O
Syncope	B-D013575
17	O
(1%)	O
13	O
(1%)	O
16	O
(1%)	O
8	O
(0%)	O
Psychiatric	O
Disorders	O
Amnesia	B-D000647
39	O
(2%)	O
40	O
(2%)	O
57	O
(3%)	O
34	O
(2%)	O
Confusion	B-D003221
18	O
(1%)	O
9	O
(1%)	O
22	O
(1%)	O
15	O
(1%)	O
Anorexia	B-D000855
19	O
(1%)	O
17	O
(1%)	O
10	O
(1%)	O
15	O
(1%)	O
Somnolence	O
20	O
(1%)	O
13	O
(1%)	O
18	O
(1%)	O
9	O
(1%)	O
Musculoskeletal	B-D009141
System	I-D009141
Disorders	O
Arthralgia	B-D018771
91	O
(6%)	O
75	O
(5%)	O
91	O
(6%)	O
76	O
(5%)	O
Arthritis	B-D001168
34	O
(2%)	O
25	O
(2%)	O
17	O
(1%)	O
19	O
(1%)	O
Art	B-D001154
hrosis	O
18	O
(1%)	O
22	O
(1%)	O
13	O
(1%)	O
14	O
(1%)	O
Myalgia	B-D063806
20	O
(1%)	O
16	O
(1%)	O
11	O
(1%)	O
11	O
(1%)	O
Respiratory	B-D012137
System	I-D012137
Disorders	O
Cough	B-D003371
ing	O
25	O
(2%)	O
18	O
(1%)	O
32	O
(2%)	O
21	O
(1%)	O
Upper	O
Respiratory	O
Tract	O
Infection	O
16	O
(1%)	O
9	O
(1%)	O
16	O
(1%)	O
14	O
(1%)	O
Cardiovascular	O
Disorders,	O
General	O
Cardia	B-D002299
c	O
Failure	O
26	O
(2%)	O
17	O
(1%)	O
30	O
(2%)	O
25	O
(2%)	O
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders	O
Hemorrhage	B-D006470
NOS	O
52	O
(3%)	O
24	O
(1%)	O
46	O
(3%)	O
24	O
(1%)	O
Epistaxis	B-D004844
39	O
(2%)	O
16	O
(1%)	O
45	O
(3%)	O
25	O
(2%)	O
Purpura	B-D011693
23	O
(1%)	O
8	O
(0%)	O
9	O
(1%)	O
7	O
(0%)	O
Neoplasm	O
Neoplasm	O
NOS	O
28	O
(2%)	O
16	O
(1%)	O
23	O
(1%)	O
20	O
(1%)	O
Red	O
Blood	B-D001769
Cell	O
Disorders	O
Anemia	B-D000740
27	O
(2%)	O
16	O
(1%)	O
19	O
(1%)	O
9	O
(1%)	O
Discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
ESPS2	O
was	O
25%	O
for	O
AGGRENOX,	O
25%	O
for	O
extended-release	O
dipyridamole,	O
19%	O
for	O
aspirin,	O
and	O
21%	O
for	O
placebo	O
(refer	O
to	O
Table	O
2)	O
Table	O
2	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
that	O
Led	O
to	O
the	O
Discontinuation	O
of	O
Treatment:	O
Adverse	O
Events	O
with	O
an	O
Incidence	B-D015994
of	O
≥1%	O
in	O
the	O
AGGRENOX	O
Group	O
Treatment	O
Groups	O
AGGRENOX	O
ER-DP	O
ASA	O
Placebo	O
Note:	O
ER-DP	O
=	O
extended-release	O
dipyridamole	O
200	O
mg;	O
ASA	O
=	O
aspirin	O
25	O
mg.	O
The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O
Total	O
Number	O
of	O
Patients	B-D010361
1650	O
1654	O
1649	O
1649	O
Patients	B-D010361
with	O
at	O
least	O
one	O
Adverse	O
Eventthat	O
led	O
to	O
treatment	O
discontinuation	O
417	O
(25%)	O
419	O
(25%)	O
318	O
(19%)	O
352	O
(21%)	O
Headache	B-D006261
165	O
(10%)	O
166	O
(10%)	O
57	O
(3%)	O
69	O
(4%)	O
Dizziness	B-D004244
85	O
(5%)	O
97	O
(6%)	O
69	O
(4%)	O
68	O
(4%)	O
Nausea	B-D009325
91	O
(6%)	O
95	O
(6%)	O
51	O
(3%)	O
53	O
(3%)	O
Abdominal	B-D015746
Pain	I-D015746
74	O
(4%)	O
64	O
(4%)	O
56	O
(3%)	O
52	O
(3%)	O
Dyspepsia	B-D004415
59	O
(4%)	O
61	O
(4%)	O
49	O
(3%)	O
46	O
(3%)	O
Vomiting	B-D014839
53	O
(3%)	O
52	O
(3%)	O
28	O
(2%)	O
24	O
(1%)	O
Diarrhea	B-D003967
35	O
(2%)	O
41	O
(2%)	O
9	O
(<1%)	O
16	O
(<1%)	O
Stroke	B-D020521
39	O
(2%)	O
48	O
(3%)	O
57	O
(3%)	O
73	O
(4%)	O
Transient	O
Ischemic	O
Attack	O
35	O
(2%)	O
40	O
(2%)	O
26	O
(2%)	O
48	O
(3%)	O
Angina	B-D000787
Pectoris	I-D000787
23	O
(1%)	O
20	O
(1%)	O
16	O
(<1%)	O
26	O
(2%)	O
Headache	B-D006261
was	O
most	O
notable	O
in	O
the	O
first	O
month	O
of	O
treatment.	O
Other	O
Adverse	O
Events	O
Adverse	O
reactions	O
that	O
occurred	O
in	O
less	O
than	O
1%	O
of	O
patients	O
treated	O
with	O
AGGRENOX	O
in	O
the	O
ESPS2	O
study	O
and	O
that	O
were	O
medically	O
judged	O
to	O
be	O
possibly	O
related	O
to	O
either	O
dipyridamole	O
or	O
aspirin	O
are	O
listed	O
below.	O
Body	O
as	O
a	O
Whole	O
:	O
Allergic	O
reaction,	O
fever	O
Cardiovascular	O
:	O
Hypotension	B-D007022
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Coma	B-D003128
,	O
dizziness,	O
paresthesia,	O
cerebral	O
hemorrhage,	O
intracranial	O
hemorrhage,	O
subarachnoid	O
hemorrhage	O
Gastrointestinal	O
:	O
Gastritis	B-D005756
,	O
ulceration	O
and	O
perforation	O
Hearing	B-D006309
and	O
Vestibular	O
Disorders	O
:	O
Tinnitus	B-D014012
,	O
and	O
deafness.	O
Patients	B-D010361
with	O
high	O
frequency	O
hearing	O
loss	O
may	O
have	O
difficulty	O
perceiving	O
tinnitus.	O
In	O
these	O
patients,	O
tinnitus	O
cannot	O
be	O
used	O
as	O
a	O
clinical	O
indicator	O
of	O
salicylism	O
Heart	B-D006339
Rate	I-D006339
and	O
Rhythm	O
Disorders	O
:	O
Tachycardia	B-D013610
,	O
palpitation,	O
arrhythmia,	O
supraventricular	O
tachycardia	O
Liver	B-D008099
and	O
Biliary	O
System	O
Disorders	O
:	O
Cholelithiasis	B-D002769
,	O
jaundice,	O
hepatic	O
function	O
abnormal	O
Metabolic	O
and	O
Nutritional	O
Disorders	O
:	O
Hyperglycemia	B-D006943
,	O
thirst	O
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders	O
:	O
Hematoma	B-D006406
,	O
gingival	O
bleeding	O
Psychiatric	O
Disorders	O
:	O
Agitation	O
Reproductive	O
:	O
Uterine	O
hemorrhage	O
Respiratory	O
:	O
Hyperpnea,	O
asthma,	O
bronchospasm,	O
hemoptysis,	O
pulmonary	O
edema	O
Special	O
Senses	O
Other	O
Disorders	O
:	O
Taste	B-D013649
loss	O
Skin	B-D012867
and	O
Appendages	O
Disorders	O
:	O
Pruritus	B-D011537
,	O
urticaria	O
Urogenital	O
:	O
Renal	O
insufficiency	O
and	O
failure,	O
hematuria	O
Vascular	O
(Extracardiac)	O
Disorders	O
:	O
Flushing	B-D005483
Laboratory	O
Changes	O
Over	O
the	O
course	O
of	O
the	O
24-month	O
study	O
(ESPS2),	O
patients	O
treated	O
with	O
AGGRENOX	O
showed	O
a	O
decline	O
(mean	O
change	O
from	O
baseline)	O
in	O
hemoglobin	O
of	O
0.25	O
g/dL,	O
hematocrit	O
of	O
0.75%,	O
and	O
erythrocyte	O
count	O
of	O
0.13x106/mm3.	O
6.2	O
Post-Marketing	O
Experience	O
The	O
following	O
is	O
a	O
list	O
of	O
additional	O
adverse	O
reactions	O
that	O
have	O
been	O
reported	O
either	O
in	O
the	O
literature	O
or	O
are	O
from	O
post-marketing	O
spontaneous	O
reports	O
for	O
either	O
dipyridamole	O
or	O
aspirin.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
estimate	O
reliably	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Decisions	O
to	O
include	O
these	O
reactions	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
reaction,	O
(2)	O
frequency	O
of	O
reporting,	O
or	O
(3)	O
strength	O
of	O
causal	O
connection	O
to	O
AGGRENOX.	O
Body	O
as	O
a	O
Whole	O
:	O
Hypothermia	B-D007035
,	O
chest	O
pain	O
Cardiovascular	O
:	O
Angina	O
pectoris	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Cerebral	O
edema	O
Fluid	O
and	O
Electrolyte	O
:	O
Hyperkalemia	B-D006947
,	O
metabolic	O
acidosis,	O
respiratory	O
alkalosis,	O
hypokalemia	O
Gastrointestinal	O
:	O
Pancreatitis	B-D010195
,	O
Reye	O
syndrome,	O
hematemesis	O
Hearing	B-D006309
and	O
Vestibular	O
Disorders	O
:	O
Hearing	B-D006309
loss	O
Immune	B-D007107
System	I-D007107
Disorders	O
:	O
Hypersensitivity	B-D006967
,	O
acute	O
anaphylaxis,	O
laryngeal	O
edema	O
Liver	B-D008099
and	O
Biliary	O
System	O
Disorders	O
:	O
Hepatitis	B-D006505
,	O
hepatic	O
failure	O
Musculoskeletal	O
:	O
Rhabdomyolysis	B-D012206
Metabolic	O
and	O
Nutritional	O
Disorders	O
:	O
Hypoglycemia	B-D007003
,	O
dehydration	O
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders	O
:	O
Prolongation	O
of	O
the	O
prothrombin	O
time,	O
disseminated	O
intravascular	O
coagulation,	O
coagulopathy,	O
thrombocytopenia	O
Reproductive	O
:	O
Prolonged	O
pregnancy	O
and	O
labor,	O
stillbirths,	O
lower	O
birth	O
weight	O
infants,	O
antepartum	O
and	O
postpartum	O
bleeding	O
Respiratory	O
:	O
Tachypnea	B-D059246
,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
Disorders	O
:	O
Rash,	O
alopecia,	O
angioedema,	O
Stevens-Johnson	O
syndrome,	O
skin	O
hemorrhages	O
such	O
as	O
bruising,	O
ecchymosis,	O
and	O
hematoma	O
Urogenital	O
:	O
Interstitial	O
nephritis,	O
papillary	O
necrosis,	O
proteinuria	O
Vascular	O
(Extracardiac	O
Disorders)	O
:	O
Allergic	O
vasculitis	O
Other	O
adverse	O
events	O
:	O
anorexia,	O
aplastic	O
anemia,	O
migraine,	O
pancytopenia,	O
thrombocytosis.	O
WARNING:	O
RISK	O
OF	O
UTERINE	O
RUPTURE,	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
BIRTH	O
DEFECTS;	O
AND	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
CONTAIN	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL.	O
ADMINISTRATION	O
OF	O
MISOPROSTOL	O
TO	O
WOMEN	O
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
OR	O
BIRTH	O
DEFECTS.	O
UTERINE	O
RUPTURE	O
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	O
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	O
WOMEN	O
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O
BEYOND	O
THE	O
EIGHTH	O
WEEK	O
OF	O
PREGNANCY.	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	O
WOMEN	O
[see	O
Contraindications	B-D000075202
(4)	O
,	O
Warnings	O
and	O
Precautions	O
(5.10)	O
,	O
and	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
PATIENTS	O
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS.	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
should	O
not	O
be	O
used	O
in	O
women	O
of	O
childbearing	O
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	O
of	O
developing	O
gastric	O
or	O
duodenal	O
ulceration	O
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	O
ulcers	O
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID.	O
In	O
such	O
patients,	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
●	O
has	O
had	O
a	O
negative	O
serum	O
pregnancy	O
test	O
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy.	O
●	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures.	O
●	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	O
the	O
risk	O
of	O
possible	O
contraception	O
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	O
of	O
childbearing	O
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake.	O
●	O
will	O
begin	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	O
period	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.3)	O
].	O
Cardiovascular	O
Thrombotic	O
Events	O
●	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
●	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
,	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
●	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
WARNING:	O
RISK	O
OF	O
UTERINE	O
RUPTURE,	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
BIRTH	O
DEFECTS;	O
AND	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
CONTAINS	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL.	O
ADMINISTRATION	O
OF	O
MISOPROSTOL	O
TO	O
WOMEN	O
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
OR	O
BIRTH	O
DEFECTS.	O
UTERINE	O
RUPTURE	O
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	O
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	O
WOMEN	O
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O
BEYOND	O
THE	O
EIGHTH	O
WEEK	O
OF	O
PREGNANCY.	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	O
WOMEN	O
(4,	O
5.10,	O
8.1).	O
PATIENTS	O
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS.	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
should	O
not	O
be	O
used	O
in	O
women	O
of	O
childbearing	O
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	O
of	O
developing	O
gastric	O
or	O
duodenal	O
ulceration	O
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	O
ulcers	O
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID.	O
In	O
such	O
patients,	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
•	O
has	O
had	O
a	O
negative	O
serum	O
pregnancy	O
test	O
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy	O
(8.3).	O
•	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures.	O
•	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	O
the	O
risk	O
of	O
possible	O
contraception	O
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	O
of	O
childbearing	O
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake.	O
•	O
will	O
begin	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	O
period.	O
Cardiovascular	O
Thrombotic	O
Events	O
Risk	B-D012306
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(5.1).	O
•	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(4,	O
5.1).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(5.2).	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
•	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
•	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
•	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
•	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
•	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
•	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
•	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnancy.	O
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
(5.10,	O
8.1)	O
•	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
.	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O
.	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
diclofenac	O
sodium	O
and	O
misoprostol	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
●	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
●	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
●	O
Avoid	O
use	O
in	O
patients	O
at	O
high	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
●	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
●	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	O
sodium	O
and	O
misoprostol	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
●	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O
.	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
meaningful	O
elevation	O
of	O
ALT	O
(SGPT,	O
more	O
than	O
3	O
times	O
the	O
ULN	O
[ULN	O
=	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range])	O
occurred	O
in	O
1.6%	O
of	O
2,184	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
and	O
in	O
1.4%	O
of	O
1,691	O
patients	O
treated	O
with	O
diclofenac	O
sodium.	O
These	O
increases	O
were	O
generally	O
transient,	O
and	O
enzyme	O
levels	O
returned	O
to	O
within	O
the	O
normal	O
range	O
upon	O
discontinuation	O
of	O
therapy	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets.	O
The	O
misoprostol	O
component	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
does	O
not	O
appear	O
to	O
exacerbate	O
the	O
hepatic	O
effects	O
caused	O
by	O
the	O
diclofenac	O
sodium	O
component.	O
In	O
clinical	O
trials	O
of	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
sodium	O
for	O
2	O
to	O
6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
patients	O
and	O
included	O
marked	O
elevations	O
(i.e.,	O
greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O
.	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O
.	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
are	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
pre-existing	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
diclofenac	O
sodium	O
and	O
misoprostol.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O
.	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
/misoprostol	O
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac/misoprostol	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
]	O
.	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
diclofenac	O
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O
.	O
When	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
are	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O
.	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
pregnant	O
women.	O
Advise	O
pregnant	O
women	O
of	O
the	O
potential	O
risk	O
to	O
a	O
fetus.	O
Verify	O
the	O
pregnancy	O
status	O
of	O
females	O
of	O
reproductive	O
potential	O
prior	O
to	O
initiation	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol.	O
Advise	O
females	O
of	O
reproductive	O
potential	O
to	O
use	O
effective	O
contraception	O
during	O
treatment	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1,	O
8.3	O
)]	O
.	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin	O
and	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
and	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O
.	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
,	O
5.6	O
)]	O
.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
•Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
•Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
•Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
•Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
•Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
greater	O
than	O
2%	O
from	O
clinical	O
trials)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
flatulence,	O
gastritis,	O
vomiting,	O
constipation,	O
headache,	O
dizziness,	O
alanine	O
aminotransferase	O
increased,	O
hematocrit	O
decreased	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Adverse	O
reaction	O
information	O
for	O
diclofenac	O
sodium	O
and	O
misoprostol	O
is	O
derived	O
from	O
Phase	O
III	O
multinational	O
controlled	O
clinical	O
trials	O
in	O
over	O
2,000	O
patients	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets,	O
50	O
mg/0.2	O
mg	O
or	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets,	O
75	O
mg/0.2	O
mg,	O
as	O
well	O
as	O
from	O
blinded,	O
controlled	O
trials	O
of	O
diclofenac	O
delayed-release	O
tablets	O
and	O
misoprostol	O
tablets.	O
Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
incidence	O
of	O
adverse	O
events	O
for	O
patients	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol.	O
These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
patients	O
on	O
diclofenac	O
sodium	O
and	O
misoprostol	O
and	O
5%	O
of	O
patients	O
on	O
diclofenac.	O
For	O
GI	O
ulcer	O
rates,	O
[see	O
Clinical	O
Studies	O
(14)].	O
GI	O
disorder	O
Diclofenac	B-D004008
Sodium	B-D012964
and	O
Misoprostol	B-D016595
Diclofenac	B-D004008
Abdominal	O
pain	O
21%	O
15%	O
Diarrhea	B-D003967
19%	O
11%	O
Dyspepsia	B-D004415
14%	O
11%	O
Nausea	B-D009325
11%	O
6%	O
Flatulence	B-D005414
9%	O
4%	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
can	O
cause	O
more	O
abdominal	O
pain,	O
diarrhea,	O
and	O
other	O
GI	O
symptoms	O
than	O
diclofenac	O
alone.	O
Diarrhea	B-D003967
and	O
abdominal	O
pain	O
developed	O
early	O
in	O
the	O
course	O
of	O
therapy,	O
and	O
were	O
usually	O
self-limited	O
(resolved	O
after	O
2	O
to	O
7	O
days).	O
Rare	O
instances	O
of	O
profound	O
diarrhea	O
leading	O
to	O
severe	O
dehydration	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
misoprostol.	O
Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
disease,	O
or	O
those	O
in	O
whom	O
dehydration,	O
were	O
it	O
to	O
occur,	O
would	O
be	O
dangerous,	O
should	O
be	O
monitored	O
carefully	O
if	O
diclofenac	O
sodium	O
and	O
misoprostol	O
is	O
prescribed.	O
The	O
incidence	O
of	O
diarrhea	O
can	O
be	O
minimized	O
by	O
administering	O
diclofenac	O
sodium	O
and	O
misoprostol	O
with	O
food	O
and	O
by	O
avoiding	O
coadministration	O
with	O
magnesium-containing	O
antacids.	O
Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
misoprostol	O
use	O
have	O
also	O
been	O
reported	O
for	O
women	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol	O
(see	O
below).	O
Postmenopausal	O
vaginal	O
bleeding	O
may	O
be	O
related	O
to	O
administration	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol.	O
If	O
it	O
occurs,	O
diagnostic	O
workup	O
should	O
be	O
undertaken	O
to	O
rule	O
out	O
gynecological	O
pathology	O
[see	O
Boxed	O
Warnings,	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5)].	O
Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
safety	O
profile	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
over	O
500	O
patients	O
65	O
years	O
of	O
age	O
or	O
older	O
compared	O
with	O
younger	O
patients.	O
Other	O
adverse	O
experiences	O
reported	O
occasionally	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
diclofenac	O
or	O
other	O
NSAIDs,	O
or	O
misoprostol	O
are:	O
Body	O
as	O
a	O
whole:	O
asthenia,	O
fatigue,	O
malaise.	O
Central	O
and	O
peripheral	O
nervous	O
system:	O
dizziness,	O
drowsiness,	O
headache,	O
insomnia,	O
paresthesia,	O
vertigo.	O
Digestive:	O
anorexia,	O
appetite	O
changes,	O
constipation,	O
dry	O
mouth,	O
dysphagia,	O
esophageal	O
ulceration,	O
oesophagitis,	O
eructation,	O
gastritis,	O
gastroesophageal	O
reflux,	O
GI	O
neoplasm	O
benign,	O
peptic	O
ulcer,	O
tenesmus,	O
vomiting.	O
Female	B-D005260
reproductive	O
disorders:	O
breast	O
pain,	O
dysmenorrhea,	O
menstrual	O
disorder,	O
menorrhagia,	O
vaginal	O
hemorrhage.	O
Hemic	O
and	O
lymphatic	O
system:	O
epistaxis,	O
leukopenia,	O
melena,	O
purpura,	O
decreased	O
hematocrit.	O
Metabolic	O
and	O
nutritional:	O
alanine	O
aminotransferase	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
aspartate	O
aminotransferase	O
increased,	O
dehydration,	O
hyponatremia.	O
Musculoskeletal	O
system:	O
arthralgia,	O
myalgia.	O
Psychiatric:	O
anxiety,	O
concentration	O
impaired,	O
depression,	O
irritability.	O
Respiratory	O
system:	O
asthma,	O
coughing,	O
hyperventilation.	O
Skin	B-D012867
and	O
appendages:	O
alopecia,	O
eczema,	O
pemphigoid	O
reaction,	O
photosensitivity,	O
sweating	O
increased,	O
pruritus.	O
Special	O
senses:	O
taste	O
perversion,	O
tinnitus.	O
Renal	O
and	O
urinary	O
disorders:	O
dysuria,	O
nocturia,	O
polyuria,	O
proteinuria,	O
urinary	O
tract	O
infection.	O
Vision:	O
diplopia.	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
diclofenac	O
or	O
misoprostol.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliable	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
whole:	O
death,	O
fever,	O
infection,	O
sepsis,	O
chills,	O
edema.	O
Cardiovascular	O
system:	O
arrhythmia,	O
atrial	O
fibrillation,	O
congestive	O
heart	O
failure,	O
hypertension,	O
hypotension,	O
increased	O
CPK,	O
increased	O
LDH,	O
myocardial	O
infarction,	O
palpitations,	O
phlebitis,	O
premature	O
ventricular	O
contractions,	O
syncope,	O
tachycardia,	O
vasculitis.	O
Central	O
and	O
peripheral	O
nervous	O
system:	O
coma,	O
convulsions,	O
hyperesthesia,	O
hypertonia,	O
hypoesthesia,	O
meningitis,	O
migraine,	O
neuralgia,	O
somnolence,	O
stroke,	O
tremor.	O
Congenital,	O
familial	O
and	O
genetic	O
disorders:	O
birth	O
defects.	O
Digestive:	O
enteritis,	O
GI	O
bleeding,	O
glossitis,	O
heartburn,	O
hematemesis,	O
hemorrhoids,	O
intestinal	O
perforation,	O
stomatitis	O
and	O
ulcerative	O
stomatitis.	O
Female	B-D005260
reproductive	O
disorders:	O
intermenstrual	O
bleeding,	O
leukorrhea,	O
vaginitis,	O
uterine	O
cramping,	O
uterine	O
hemorrhage.	O
Hemic	O
and	O
lymphatic	O
system:	O
agranulocytosis,	O
anemia,	O
aplastic	O
anemia,	O
coagulation	O
time	O
increased,	O
ecchymosis,	O
eosinophilia,	O
hemolytic	O
anemia,	O
leukocytosis,	O
lymphadenopathy,	O
pancytopenia,	O
pulmonary	O
embolism,	O
rectal	O
bleeding,	O
thrombocythemia,	O
thrombocytopenia.	O
Hypersensitivity	B-D006967
:	O
angioedema,	O
laryngeal/pharyngeal	O
edema,	O
urticaria.	O
Liver	B-D008099
and	O
biliary	O
system:	O
abnormal	O
hepatic	O
function,	O
bilirubinemia,	O
liver	O
failure,	O
pancreatitis,	O
hepatitis,	O
jaundice.	O
Male	B-D008297
reproductive	O
disorders:	O
impotence,	O
perineal	O
pain.	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
glycosuria,	O
gout,	O
hypercholesterolemia,	O
hyperglycemia,	O
hyperuricemia,	O
hypoglycemia,	O
periorbital	O
edema,	O
porphyria,	O
weight	O
changes,	O
fluid	O
retention.	O
Pregnancy	B-D011247
,	O
puerperium	O
and	O
perinatal	O
conditions:	O
abnormal	O
uterine	O
contractions,	O
uterine	O
rupture/perforation,	O
retained	O
placenta,	O
amniotic	O
fluid	O
embolism,	O
incomplete	O
abortion,	O
premature	O
birth,	O
fetal	O
death.	O
Psychiatric:	O
confusion,	O
disorientation,	O
dream	O
abnormalities,	O
hallucinations,	O
nervousness,	O
paranoia,	O
psychotic	O
reaction.	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
female	O
fertility	O
decreased.	O
Respiratory	O
system:	O
dyspnea,	O
pneumonia,	O
respiratory	O
depression.	O
Skin	B-D012867
and	O
appendages:	O
acne,	O
bruising,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
pruritus	O
ani,	O
rash,	O
skin	O
ulceration,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis,	O
cutaneous	O
reactions	O
(bullous	O
eruption).	O
Special	O
senses:	O
hearing	O
impairment,	O
taste	O
loss.	O
Renal	O
and	O
urinary	O
disorders:	O
cystitis,	O
hematuria,	O
interstitial	O
nephritis,	O
micturition	O
frequency,	O
nephrotic	O
syndrome,	O
oliguria,	O
papillary	O
necrosis,	O
renal	O
failure,	O
glomerulonephritis	O
membranous,	O
glomerulonephritis	O
minimal	O
lesion,	O
glomerulohephritis.	O
Vision:	O
amblyopia,	O
blurred	O
vision,	O
conjunctivitis,	O
glaucoma,	O
iritis,	O
lacrimation	O
abnormal,	O
night	O
blindness,	O
vision	O
abnormal.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
potassium	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
718	O
patients	O
treated	O
for	O
shorter	O
periods,	O
i.e.,	O
2	O
weeks	O
or	O
less,	O
with	O
diclofenac	O
tablets,	O
adverse	O
reactions	O
were	O
reported	O
one-half	O
to	O
one-tenth	O
as	O
frequently	O
as	O
by	O
patients	O
treated	O
for	O
longer	O
periods.	O
In	O
a	O
6	O
month,	O
double-blind	O
trial	O
comparing	O
diclofenac	O
potassium	O
tablets	O
(N	O
=	O
196)	O
versus	O
diclofenac	O
sodium	O
delayed-release	O
tablets	O
(N	O
=	O
197)	O
versus	O
ibuprofen	O
(N	O
=	O
197),	O
adverse	O
reactions	O
were	O
similar	O
in	O
nature	O
and	O
frequency.	O
In	O
patients	O
taking	O
diclofenac	O
potassium	O
tablets	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDS)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1)	O
•	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4	O
)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.2)	O
Cardiovascular	O
Risk	B-D012306
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
•	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
in	O
the	O
perioperative	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)].	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
Use	O
the	O
lowest	O
effective	O
dose	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
(5.1)	O
•NSAIDs	O
can	O
cause	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation.	O
Prescribe	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
(5.2)	O
•Elevation	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
NSAIDs.	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen.	O
(5.3)	O
•Hypertension	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
Monitor	O
blood	O
pressure	O
closely	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
treatment.	O
(5.4)	O
•Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
(5.5)	O
•Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
at	O
greatest	O
risk	O
of	O
this	O
reaction,	O
including	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors.	O
(5.6)	O
•Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
or	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution.	O
(5.7)	O
•NSAIDs	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
(5.8)	O
•Not	O
for	O
use	O
during	O
pregnancy.	O
(5.9)	O
•Do	O
not	O
administer	O
to	O
patients	O
with	O
aspirin	O
sensitive	O
asthma	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
(5.10)	O
•Avoid	O
exposure	O
of	O
treated	O
knee(s)	O
to	O
natural	O
or	O
artificial	O
sunlight.	O
(5.11)	O
•Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
(5.12)	O
•Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs.	O
(5.13)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
oral	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
COX-2	O
selective	O
and	O
nonselective	O
orally	O
administered	O
NSAIDs,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Inform	O
patients	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
an	O
orally	O
administered	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
NSAIDS,	O
such	O
as	O
diclofenac,	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Prescribe	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore,	O
use	O
special	O
care	O
when	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
diclofenac	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAID's.	O
5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
[ULN]	O
range)	O
or	O
greater	O
elevations	O
of	O
transaminases	O
occurred	O
in	O
about	O
15%	O
of	O
oral	O
diclofenac-treated	O
patients	O
in	O
clinical	O
trials	O
of	O
indications	O
other	O
than	O
acute	O
pain.	O
Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	O
injury.	O
In	O
clinical	O
trials	O
of	O
an	O
oral	O
diclofenac	O
–	O
misoprostol	O
combination	O
product,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
for	O
2	O
to	O
6	O
months,	O
patients	O
with	O
oral	O
diclofenac	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(>8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
this	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(>8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
test	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
oral	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
post	O
marketing	O
reports,	O
cases	O
of	O
drug-	O
induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy.	O
Post	O
marketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
sever	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
oral	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Measure	O
transaminases	O
(ALT	O
and	O
AST)	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
monitor	O
transaminases	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flulike"	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
to	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver-related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
certain	O
antibiotics,	O
antiepileptics).	O
Caution	O
patients	O
to	O
avoid	O
taking	O
unprescribed	O
acetaminophen	O
while	O
using	O
diclofenac	O
sodium	O
topical	O
solution.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac,	O
can	O
lead	O
to	O
new	O
onset	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Use	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Monitor	O
blood	O
pressure	O
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
Patients	B-D010361
taking	O
ACE-inhibitors,	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution.	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
considerable	O
dehydration.	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-	O
dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
is	O
not	O
recommended	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
diclofenac	O
sodium	O
topical	O
solution	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution.	O
Do	O
not	O
prescribe	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.10)].	O
Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Do	O
not	O
apply	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
open	O
skin	O
wounds,	O
infections,	O
inflammations,	O
or	O
exfoliative	O
dermatitis,	O
as	O
it	O
may	O
affect	O
absorption	O
and	O
tolerability	O
of	O
the	O
drug.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations,	O
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
should	O
not	O
be	O
used	O
by	O
pregnant	O
or	O
nursing	O
women	O
or	O
those	O
intending	O
to	O
become	O
pregnant.	O
5.10	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-	O
sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross-	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
do	O
not	O
administer	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.11	O
Sun	O
Exposure	O
Instruct	O
patients	O
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
knee(s)	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light-induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.13	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	O
and	O
conduct	O
periodic	O
laboratory	O
evaluations.	O
5.14	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-response	O
illness.	O
For	O
patients	O
on	O
prolonged	O
corticosteroid	O
therapy,	O
taper	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Hematological	O
Effects	O
The	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	O
subjects	O
administered	O
80	O
drops	O
four	O
times	O
a	O
day	O
for	O
7	O
days.	O
There	O
was	O
no	O
significant	O
change	O
in	O
platelet	O
aggregation	O
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)].	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
Check	O
hemoglobin	O
or	O
hematocrit	O
of	O
patients	O
on	O
diclofenac	O
sodium	O
topical	O
solution	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration	O
and	O
reversible.	O
Carefully	O
monitor	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alteration	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants.	O
5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms	O
in	O
patients	O
taking	O
NSAIDs,	O
monitor	O
patients	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Check	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
in	O
patients	O
on	O
long-term	O
treatment	O
with	O
NSAIDs.	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
if	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen.	O
6.	O
ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
are	O
application	O
site	O
reactions.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sircle	O
Laboratories	B-D007753
,	O
Inc.	O
at	O
1-888-452-9975,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trial	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution	O
of	O
911	O
patients	O
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	O
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	O
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	O
treated	O
for	O
at	O
least	O
12	O
months.	O
The	O
population	O
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	O
were	O
Caucasians,	O
64%	O
were	O
females,	O
and	O
all	O
patients	O
had	O
primary	O
osteoarthritis.	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies.	O
Application	O
site	O
reactions:	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment	O
related	O
adverse	O
events	O
in	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
Application	O
site	O
reactions	O
were	O
characterized	O
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	O
induration,	O
vesicles,	O
paresthesia,	O
pruritus,	O
vasodilation,	O
acne,	O
and	O
urticaria.	O
The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	O
(32%),	O
contact	O
dermatitis	O
characterized	O
by	O
skin	O
erythema	O
and	O
induration	O
(9%),	O
contact	O
dermatitis	O
with	O
vesicles	O
(2%)	O
and	O
pruritus	O
(4%).	O
In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	O
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac.	O
In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	O
study,	O
contact	O
dermatitis	O
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	O
with	O
vesicles	O
in	O
10%	O
of	O
patients,	O
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	O
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%.	O
Adverse	O
events	O
common	O
to	O
the	O
NSAID	O
class:	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
flatulence,	O
abdominal	O
pain,	O
edema;	O
see	O
Table	O
1).	O
The	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac,	O
compared	O
to	O
oral	O
diclofenac	O
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	O
(3%	O
vs.	O
less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	O
(12%	O
vs.	O
7%),	O
urea	O
(20%	O
vs.	O
12%),	O
and	O
hemoglobin	O
(13%	O
vs.	O
9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	O
transaminases.	O
Table	O
1:	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
osteoarthritis.	O
Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	O
trials.	O
Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
N=911	O
Topical	O
Placebo	O
N=332	O
Adverse	O
Reaction	O
Preferred	O
Term	O
according	O
to	O
COSTART	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non	O
–	O
U.S.	O
postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
there	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
Whole:	O
abdominal	O
pain,	O
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	O
back	O
pain,	O
body	O
odor,	O
chest	O
pain,	O
edema,	O
face	O
edema,	O
halitosis,	O
headache,	O
lack	O
of	O
drug	O
effect,	O
neck	O
rigidity,	O
pain	O
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	O
dry	O
mouth,	O
dyspepsia,	O
gastroenteritis,	O
decreased	O
appetite,	O
mouth	O
ulceration,	O
nausea,	O
rectal	O
hemorrhage,	O
and	O
ulcerative	O
stomatitis	O
Metabolic	O
and	O
Nutritional:	O
creatinine	O
increased	O
Musculoskeletal:	O
leg	O
cramps,	O
myalgia	O
Nervous:	O
depression,	O
dizziness,	O
drowsiness,	O
lethargy,	O
paresthesia,	O
and	O
paresthesia	O
at	O
application	O
site	O
Respiratory:	O
asthma,	O
dyspnea,	O
laryngismus,	O
laryngitis,	O
pharyngitis	O
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	O
contact	O
dermatitis	O
with	O
vesicles,	O
dry	O
skin,	O
pruritus,	O
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	O
rash,	O
pruritus,	O
skin	O
discoloration,	O
urticaria	O
Special	O
senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	O
ear	O
pain,	O
eye	O
disorder,	O
and	O
eye	O
pain,	O
taste	O
perversion	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Risk	B-D012306
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
increase	O
the	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
].	O
CAMBIA	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
increase	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
increase	O
the	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use.	O
(	O
5.1	O
)	O
CAMBIA	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(	O
4	O
,	O
5.1	O
)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
increase	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
Events	O
can	O
occur	O
at	O
any	O
time	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk.	O
(	O
5.2	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
CV	O
thrombotic	O
events:	O
Use	O
lowest	O
effective	O
dose	O
of	O
CAMBIA	O
for	O
shortest	O
possible	O
duration	O
(5.1)	O
Serious	O
and	O
potentially	O
fatal	O
GI	O
reactions:	O
Use	O
lowest	O
effective	O
dose	O
of	O
CAMBIA	O
for	O
shortest	O
possible	O
duration;	O
use	O
with	O
caution	O
in	O
patients	O
with	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding	O
(5.2)	O
Hepatic	O
effects:	O
Range	O
from	O
transaminase	O
elevations	O
to	O
liver	O
failure;	O
discontinue	O
CAMBIA	O
immediately	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
(5.3,	O
5.13)	O
Hypertension	B-D006973
:	O
Can	O
occur	O
with	O
NSAID	O
treatment.	O
Monitor	O
blood	O
pressure	O
closely	O
during	O
treatment	O
with	O
CAMBIA	O
(5.4)	O
Congestive	O
heart	O
failure	O
and	O
edema:	O
Fluid	O
retention	O
and	O
edema	O
can	O
occur	O
with	O
NSAID	O
treatment;	O
use	O
CAMBIA	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure	O
(5.5)	O
Renal	O
effects:	O
Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury;	O
use	O
CAMBIA	O
with	O
caution	O
in	O
patients	O
at	O
risk	O
(e.g.,	O
the	O
elderly,	O
those	O
with	O
renal	O
impairment,	O
heart	O
failure,	O
liver	O
impairment,	O
and	O
those	O
taking	O
diuretics	O
or	O
ACE	O
inhibitors)	O
(5.6)	O
Anaphylactoid	O
reactions:	O
May	O
occur	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
or	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
CAMBIA;	O
discontinue	O
CAMBIA	O
immediately	O
if	O
an	O
anaphylactoid	O
reaction	O
occurs	O
(5.7)	O
Serious	O
skin	O
reactions:	O
Include	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
and	O
toxic	O
epidermal	O
necrolysis,	O
which	O
can	O
be	O
fatal;	O
discontinue	O
CAMBIA	O
if	O
rash	O
or	O
other	O
signs	O
of	O
local	O
skin	O
reaction	O
occur	O
(5.8)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years’	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID	O
increases	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(	O
4	O
)	O
].	O
5.2	O
Gastrointestinal	O
Effects	O
-	O
Risk	B-D012306
of	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
CAMBIA,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
such	O
as	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
thus	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Prescribe	O
NSAIDs,	O
including	O
CAMBIA,	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
than	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
for	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients,	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration.	O
Patients	B-D010361
and	O
physicians	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
CAMBIA	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
This	O
should	O
include	O
discontinuation	O
of	O
the	O
CAMBIA	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
For	O
high	O
risk	O
patients,	O
alternative	O
therapies	O
that	O
do	O
not	O
include	O
NSAIDs	O
should	O
be	O
considered.	O
5.3	O
Hepatic	O
Effects	O
Elevations	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
CAMBIA.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
persist,	O
or	O
may	O
only	O
be	O
transient	O
with	O
continued	O
therapy.	O
Borderline	O
elevations	O
(less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
[ULN]	O
range)	O
or	O
greater	O
elevations	O
of	O
transaminases	O
occurred	O
in	O
about	O
15%	O
of	O
diclofenac-treated	O
patients.	O
Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	O
injury.	O
In	O
clinical	O
trials,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
for	O
2–6	O
months,	O
patients	O
were	O
monitored	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(>8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
this	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3–8	O
times	O
the	O
ULN),	O
and	O
marked	O
(>8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs..	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
Measure	O
transaminases	O
(ALT	O
and	O
AST)	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
discontinue	O
CAMBIA	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
patients	O
should	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver-related	O
event	O
in	O
patients	O
treated	O
with	O
CAMBIA,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
CAMBIA	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
certain	O
antibiotics,	O
antiepileptics).	O
Caution	O
patients	O
to	O
avoid	O
taking	O
nonprescription	O
acetaminophen-containing	O
products	O
while	O
using	O
CAMBIA.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
CAMBIA,	O
can	O
lead	O
to	O
new	O
onset	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Use	O
NSAIDs,	O
including	O
CAMBIA,	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Monitor	O
blood	O
pressure	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
Patients	B-D010361
taking	O
ACE	O
inhibitors,	O
thiazides,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs.	O
Use	O
CAMBIA	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.	O
6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
CAMBIA	O
in	O
patients	O
with	O
considerable	O
dehydration.	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
or	O
ACE	O
inhibitors,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CAMBIA	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
CAMBIA	O
is	O
not	O
recommended	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
CAMBIA	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.	O
7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
CAMBIA.	O
CAMBIA	O
is	O
contraindicated	O
in	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs.	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)	O
].	O
5.	O
8	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
CAMBIA,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
to	O
discontinue	O
CAMBIA	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
CAMBIA	O
can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman.	O
Starting	O
at	O
30	O
weeks	O
gestation,	O
CAMBIA	O
and	O
other	O
NSAIDs	O
should	O
be	O
avoided	O
by	O
pregnant	O
women	O
as	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
in	O
the	O
fetus	O
may	O
occur.	O
If	O
this	O
drug	O
is	O
used	O
during	O
this	O
time	O
period	O
in	O
pregnancy,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
a	O
fetus	O
[s	O
ee	O
Use	O
in	O
Special	O
Population	B-D011153
s	O
(	O
8.1	O
)].	O
5.1	O
0	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
NSAIDs	O
in	O
reducing	O
inflammation	O
and	O
possibly	O
fever	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.	O
1	O
1	O
Hematologic	O
Effects	O
Anemia	B-D000740
may	O
occur	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
In	O
patients	O
on	O
long-term	O
therapy	O
with	O
NSAIDs,	O
including	O
CAMBIA,	O
check	O
hemoglobin	O
or	O
hematocrit	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
the	O
NSAID	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration,	O
and	O
reversible.	O
Carefully	O
monitor	O
patients	O
treated	O
with	O
CAMBIA	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alterations	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants.	O
5.	O
1	O
2	O
Use	O
in	O
Patients	B-D010361
With	O
Pre-existing	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm	O
which	O
can	O
be	O
fatal.	O
Since	O
cross-reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
CAMBIA	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
all	O
patients	O
with	O
pre-existing	O
asthma.	O
5.	O
1	O
3	O
Monitoring	O
Because	O
serious	O
GI	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
For	O
patients	O
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
including	O
CAMBIA,	O
periodically	O
perform	O
a	O
CBC	O
and	O
chemistry	O
profile.	O
Discontinue	O
CAMBIA	O
if	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen.	O
5.1	O
4	O
Phenylketonurics	O
CAMBIA	O
contains	O
aspartame	O
equivalent	O
to	O
phenylalanine	O
25	O
mg	O
per	O
packet.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Cardiovascular	O
thrombotic	O
events	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
Gastrointestinal	O
effects	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O
Hepatic	O
effects	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)]	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)]	O
Renal	O
Effects	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)]	O
Anaphylactoid	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)]	O
The	O
most	O
common	O
adverse	O
reactions	O
reported	O
with	O
CAMBIA	O
are	O
nausea	O
and	O
dizziness.	O
The	O
most	O
common	O
adverse	O
events	O
resulting	O
in	O
discontinuation	O
of	O
patients	O
following	O
CAMBIA	O
dosing	O
in	O
controlled	O
clinical	O
trials	O
were	O
urticaria	O
(0.2%)	O
and	O
flushing	O
(0.2%).	O
Most	O
common	O
adverse	O
reactions	O
(≥1%	O
and	O
>placebo)	O
were	O
nausea	O
and	O
dizziness	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
contact	O
Nautilus	B-D049850
Neurosciences	B-D009488
,	O
Inc.	O
at	O
877-874-2440	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
With	O
CAMBIA	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
safety	O
of	O
a	O
single	O
dose	O
of	O
CAMBIA	O
was	O
evaluated	O
in	O
2	O
placebo-controlled	O
trials	O
with	O
a	O
total	O
of	O
634	O
migraine	O
patients	O
treated	O
with	O
CAMBIA	O
for	O
a	O
single	O
migraine	O
headache.	O
Following	O
treatment	O
with	O
diclofenac	O
potassium	O
(either	O
CAMBIA	O
or	O
diclofenac	O
potassium	O
immediate-release	O
tablets	O
[as	O
a	O
control]),	O
5	O
subjects	O
(0.8%)	O
withdrew	O
from	O
the	O
studies;	O
following	O
placebo	O
exposure,	O
1	O
subject	O
(0.2%)	O
withdrew.	O
No	O
withdrawals	O
were	O
due	O
to	O
a	O
serious	O
reaction.	O
The	O
most	O
common	O
adverse	O
reactions	O
(i.e.,	O
that	O
occurred	O
in	O
1%	O
or	O
more	O
of	O
CAMBIA-treated	O
patients)	O
and	O
more	O
frequent	O
with	O
CAMBIA	O
than	O
with	O
placebo	O
were	O
nausea	O
and	O
dizziness	O
(see	O
Table	O
1).	O
Table	O
1:	O
Treatment-Related	O
Adverse	O
Reactions	O
With	O
Incidence	B-D015994
>1%	O
and	O
Greater	O
Than	O
Placebo	O
in	O
Studies	O
1	O
and	O
2	O
Combined	O
Disorder	O
Event	O
CAMBIA	O
N=634	O
Placebo	O
N=646	O
Gastrointestinal	O
Nausea	B-D009325
3%	O
2%	O
Nervous	B-D009420
System	I-D009420
Dizziness	B-D004244
1%	O
0.5%	O
6.2	O
Adverse	O
Reactions	O
Reported	O
With	O
Diclofenac	B-D004008
and	O
Other	O
NSAIDs	O
In	O
patients	O
taking	O
diclofenac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
GI	O
reactions	O
(including	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
[gastric/duodenal],	O
and	O
vomiting),	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes,	O
and	O
tinnitus.	O
Additional	O
adverse	O
reactions	O
reported	O
in	O
patients	O
taking	O
NSAIDs	O
include	O
occasionally:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334
,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
Congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
Dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
Ecchymosis	B-D004438
,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
Weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
Anxiety	B-D001007
,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
Asthma	B-D001249
,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
Alopecia	B-D000505
,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
Blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
Cystitis	B-D003556
,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions	O
in	O
patients	O
taking	O
NSAIDs,	O
which	O
occur	O
rarely	O
,	O
are:	O
Body	O
as	O
a	O
Whole:	O
Anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
Arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
Colitis	B-D003092
,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
Agranulocytosis	B-D000380
,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
Hyperglycemia	B-D006943
Nervous	B-D009420
System	I-D009420
:	O
Convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
Respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
Angioedema	B-D000799
,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
Conjunctivitis	B-D003231
,	O
hearing	O
impairment	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Slow	O
or	O
Delayed	O
Healing	O
(5.1)	O
Potential	O
for	O
Cross-Sensitivity	O
(5.2)	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
of	O
Ocular	O
Tissue	O
(5.3)	O
Keratitis	B-D007634
and	O
Cornea	B-D003315
l	O
Effects	O
(5.4)	O
Contact	O
Lens	O
Wear	O
(5.5)	O
5.1	O
Slow	O
or	O
Delayed	O
Healing	O
All	O
topical	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs),	O
including	O
BromSite	O
(bromfenac	O
ophthalmic	O
solution)	O
0.075%,	O
may	O
slow	O
or	O
delay	O
healing.	O
Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing.	O
Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
steroids	O
may	O
increase	O
the	O
potential	O
for	O
healing	O
problems.	O
5.2	O
Potential	O
for	O
Cross-Sensitivity	O
There	O
is	O
the	O
potential	O
for	O
cross-sensitivity	O
to	O
acetylsalicylic	O
acid,	O
phenylacetic	B-C025136
acid	I-C025136
derivatives,	O
and	O
other	O
NSAIDs,	O
including	O
BromSite	O
(bromfenac	O
ophthalmic	O
solution)	O
0.075%.	O
Therefore,	O
caution	O
should	O
be	O
used	O
when	O
treating	O
individuals	O
who	O
have	O
previously	O
exhibited	O
sensitivities	O
to	O
these	O
drugs.	O
5.3	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
of	O
Ocular	O
Tissue	O
With	O
some	O
NSAIDs,	O
including	O
BromSite	O
(bromfenac	O
ophthalmic	O
solution)	O
0.075%,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
platelet	O
aggregation.	O
There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
NSAIDs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
tissues	O
(including	O
hyphemas)	O
in	O
conjunction	O
with	O
ocular	O
surgery.	O
It	O
is	O
recommended	O
that	O
BromSite	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
known	O
bleeding	O
tendencies	O
or	O
who	O
are	O
receiving	O
other	O
medications	O
which	O
may	O
prolong	O
bleeding	O
time.	O
5.4	O
Keratitis	B-D007634
and	O
Cornea	B-D003315
l	O
Reactions	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
keratitis.	O
In	O
some	O
susceptible	O
patients,	O
continued	O
use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
epithelial	O
breakdown,	O
corneal	O
thinning,	O
corneal	O
erosion,	O
corneal	O
ulceration	O
or	O
corneal	O
perforation.	O
These	O
events	O
may	O
be	O
sight	O
threatening.	O
Patients	B-D010361
with	O
evidence	O
of	O
corneal	O
epithelial	O
breakdown	O
should	O
immediately	O
discontinue	O
use	O
of	O
topical	O
NSAIDs,	O
including	O
BromSite	O
(bromfenac	O
ophthalmic	O
solution)	O
0.075%,	O
and	O
should	O
be	O
closely	O
monitored	O
for	O
corneal	O
health.	O
Post-marketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
patients	O
with	O
complicated	O
ocular	O
surgeries,	O
corneal	O
denervation,	O
corneal	O
epithelial	O
defects,	O
diabetes	O
mellitus,	O
ocular	O
surface	O
diseases	O
(e.g.,	O
dry	O
eye	O
syndrome),	O
rheumatoid	O
arthritis,	O
or	O
repeat	O
ocular	O
surgeries	O
within	O
a	O
short	O
period	O
of	O
time	O
may	O
be	O
at	O
increased	O
risk	O
for	O
corneal	O
adverse	O
events	O
which	O
may	O
become	O
sight	O
threatening.	O
Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients.	O
Post-marketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
24	O
hours	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
postsurgery	O
may	O
increase	O
patient	O
risk	O
for	O
the	O
occurrence	O
and	O
severity	O
of	O
corneal	O
adverse	O
events.	O
5.5	O
Contact	O
Lens	O
Wear	O
BromSite	O
should	O
not	O
be	O
administered	O
while	O
wearing	O
contact	O
lenses.	O
The	O
preservative	O
in	O
BromSite,	O
benzalkonium	O
chloride,	O
may	O
be	O
absorbed	O
by	O
soft	O
contact	O
lenses.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
elsewhere	O
in	O
the	O
labeling:	O
Slow	O
or	O
Delayed	O
Healing	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Potential	O
for	O
Cross-Sensitivity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
of	O
Ocular	O
Tissue	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Keratitis	B-D007634
and	O
Cornea	B-D003315
l	O
Reactions[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Contact	O
Lens	O
Wear	O
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
in	O
1-8%	O
of	O
patients	O
were:	O
anterior	O
chamber	O
inflammation,	O
headache,	O
vitreous	O
floaters,	O
iritis,	O
eye	O
pain	O
and	O
ocular	O
hypertension.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sun	O
Pharmaceutical	O
Industries,	O
Inc.	O
at	O
1-800-406-7984	O
(toll	O
free),	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice.	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
in	O
1-8%	O
of	O
patients	O
were:	O
anterior	O
chamber	O
inflammation,	O
headache,	O
vitreous	O
floaters,	O
iritis,	O
eye	O
pain	O
and	O
ocular	O
hypertension.	O
BOXED	O
WARNING	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascularthrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
ofuse.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
forcardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(See	O
WARNINGS).	O
IBU	O
tablets	O
are	O
contraindicated	O
for	O
treatment	O
of	O
peri-operativepain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)surgery	O
(See	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDS	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinaladverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforationof	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
eventscan	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinalevents.	O
(See	O
WARNINGS).	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
withIbuprofen	O
tablets	O
is	O
gastrointestinal.	O
In	O
controlled	O
clinical	O
trials	O
thepercentage	O
of	O
patients	O
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaintsranged	O
from	O
4%	O
to	O
16%.	O
In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	O
were	O
compared	O
toaspirin	O
and	O
indomethacin	O
in	O
equally	O
effective	O
doses,	O
the	O
overall	O
incidenceof	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
eitherthe	O
aspirin-	O
or	O
indomethacin-treated	O
patients.	O
Adverse	O
reactions	O
observed	O
during	O
controlled	O
clinical	O
trials	O
at	O
anincidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table.	O
Those	O
reactions	O
listedin	O
Column	O
one	O
encompass	O
observations	O
in	O
approximately	O
3,000patients.	O
More	O
than	O
500	O
of	O
these	O
patients	O
were	O
treated	O
for	O
periods	O
ofat	O
least	O
54	O
weeks.	O
Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
werereported	O
in	O
controlled	O
clinical	O
trials	O
and	O
from	O
marketing	O
experience.These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
twoof	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	O
wherethe	O
probability	O
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
inColumn	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	O
has	O
notbeen	O
established.	O
Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
thanat	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	O
trials	O
of	O
patients	O
withrheumatoid	O
arthritis.	O
The	O
increases	O
in	O
incidence	O
were	O
slight	O
and	O
stillwithin	O
the	O
ranges	O
reported	O
in	O
the	O
table.	O
table	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Celecoxib	B-D000068579
capsules	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
Celecoxib	B-D000068579
capsules	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	O
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
for	O
the	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
treatment	O
arms	O
compared	O
to	O
placebo.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.7)].	O
A	O
randomized	O
controlled	O
trial	O
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs.	O
Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	O
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	O
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	O
and	O
ibuprofen.	O
Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	O
375	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	O
600	O
to	O
800	O
mg	O
three	O
times	O
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists’	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	O
(including	O
hemorrhagic	O
death),	O
non-fatal	O
myocardial	O
infarction,	O
and	O
non-fatal	O
stroke	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
celecoxib.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	O
anticoagulants;	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.7)].	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
discontinue	O
celecoxib	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
blood	O
pressure	O
data	O
for	O
celecoxib.	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two­-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
celecoxib	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE	O
inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
celecoxib	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
celecoxib.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
celecoxib	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
celecoxib	O
and	O
in	O
patients	O
with	O
aspirin	O
sensitive	O
asthma.	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	O
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	O
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib,	O
including	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(AGEP).	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
celecoxib	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs,	O
including	O
celecoxib,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	O
SSRIs	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation	O
with	O
use	O
of	O
celecoxib	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	O
and	O
their	O
caregivers	O
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible.	O
6.	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Jubilant	O
Cadista	O
Pharmaceuticals	O
Inc.	O
at	O
1-800-313-4623	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%	O
5.6%	O
8.8%	O
2.2%	O
3.5%	O
2.8%	O
3.8%	O
6.2%	O
1.0%	O
4.2%	O
7.7%	O
5.3%	O
12.2%	O
3.6%	O
6.0%	O
9.0%	O
9.3%	O
10.9%	O
4.1%	O
3.4%	O
9.0%	O
5.8%	O
12.8%	O
3.5%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%	O
2.1%	O
2.9%	O
3.6%	O
1.1%	O
2.3%	O
2.2%	O
2.1%	O
3.0%	O
2.6%	O
1.0%	O
2.6%	O
0.9%	O
3.5%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
Headache	B-D006261
2.0%	O
15.8%	O
1.7%	O
20.2%	O
2.6%	O
14.5%	O
1.3%	O
15.5%	O
2.3%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
Rhinitis	B-D012220
Sinusitis	B-D012852
Upper	O
Respiratory	O
Infection	O
2.3%	O
2.0%	O
5.0%	O
8.1%	O
1.1%	O
1.3%	O
4.3%	O
6.7%	O
1.7%	O
2.4%	O
4.0%	O
9.9%	O
1.6%	O
2.3%	O
5.4%	O
9.8%	O
2.6%	O
0.6%	O
5.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1%	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General	O
:	O
Hypersensitivity	B-D006967
,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
blood	O
urea	O
nitrogen	O
(BUN)	O
increased,	O
creatine	O
phosphokinase	O
(CPK)	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia	O
Psychiatric	O
:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders	O
:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary	O
:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	O
Cardiovascular	O
:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis	O
Gastrointestinal	O
:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death	O
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic	O
:	O
Thrombocytopenia	B-D013921
Nervous	O
:	O
Ataxia	B-D001259
,	O
suicide	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Clinical	O
Studies	O
(14.7)]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
aspirin	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
twice	O
daily.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.7)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N	O
=	O
1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning,	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
celecoxib.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis	B-D014657
,	O
deep	O
venous	O
thrombosis	O
General:	O
Anaphylactoid	O
reaction,	O
angioedema	O
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	O
hepatitis,	O
jaundice,	O
hepatic	O
failure	O
Hemic	O
and	O
lymphatic:	O
Agranulocytosis	B-D000380
,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
Renal:	O
Interstitial	O
nephritis	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
Etodolac	B-D017308
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
a	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1,000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain*,	O
diarrhea*,	O
flatulence*,	O
nausea*,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise*,	O
dizziness*,	O
depression,	O
nervousness.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death	O
Cardiovascular	O
system	O
-	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
Cardiovascular	O
Risk	B-D012306
Gastrointestinal	O
Risk	B-D012306
1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug.	O
ADVERSE	O
REACTIONS	O
In	O
controlled	O
trials	O
during	O
the	O
premarketing	O
development	O
of	O
Flector®	O
Patch,	O
approximately	O
600	O
patients	O
with	O
minor	O
sprains,	O
strains,	O
and	O
contusions	O
have	O
been	O
treated	O
with	O
Flector®	O
Patch	O
for	O
up	O
to	O
two	O
weeks.	O
Adverse	O
Events	O
Lead	B-D007854
ing	O
to	O
Discontinuation	O
of	O
Treatment	O
In	O
the	O
controlled	O
trials,	O
3%	O
of	O
patients	O
in	O
both	O
the	O
Flector®	O
Patch	O
and	O
placebo	O
patch	O
groups	O
discontinued	O
treatment	O
due	O
to	O
an	O
adverse	O
event.	O
The	O
most	O
common	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
were	O
application	O
site	O
reactions,	O
occurring	O
in	O
2%	O
of	O
both	O
the	O
Flector®	O
Patch	O
and	O
placebo	O
patch	O
groups.	O
Application	O
site	O
reactions	O
leading	O
to	O
dropout	O
included	O
pruritus,	O
dermatitis,	O
and	O
burning.	O
Common	O
Adverse	O
Events	O
Localized	O
Reactions	O
Overall	B-D016424
,	O
the	O
most	O
common	O
adverse	O
events	O
associated	O
with	O
Flector®	O
Patch	O
treatment	O
were	O
skin	O
reactions	O
at	O
the	O
site	O
of	O
treatment.	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥	O
1%	O
of	O
patients	O
in	O
controlled	O
trials	O
of	O
Flector®	O
Patch.	O
A	O
majority	O
of	O
patients	O
treated	O
with	O
Flector®	O
Patch	O
had	O
adverse	O
events	O
with	O
a	O
maximum	O
intensity	O
of	O
“mild”	O
or	O
“moderate.”	O
Table	O
1.	O
Common	O
Adverse	O
Events	O
(by	O
body	O
system	O
and	O
preferred	O
term)	O
in	O
≥1%	O
of	O
Patients	B-D010361
treated	O
with	O
Flector®	O
Patch	O
or	O
Placebo	O
Patch1	O
Diclofenac	B-D004008
N=572	O
Placebo	O
N=564	O
N	O
Percent	O
N	O
Percent	O
1	O
The	O
table	O
lists	O
adverse	O
events	O
occurring	O
in	O
placebo-treated	O
patients	O
because	O
the	O
placebo-patch	O
was	O
comprised	O
of	O
the	O
same	O
ingredients	O
as	O
Flector®	O
Patch	O
except	O
for	O
diclofenac.	O
Adverse	O
events	O
in	O
the	O
placebo	O
group	O
may	O
therefore	O
reflect	O
effects	O
of	O
the	O
non-active	O
ingredients.	O
2	O
Includes:	O
application	O
site	O
dryness,	O
irritation,	O
erythema,	O
atrophy,	O
discoloration,	O
hyperhidriosis,	O
and	O
vesicles.	O
3	O
Includes:	O
gastritis,	O
vomiting,	O
diarrhea,	O
constipation,	O
upper	O
abdominal	O
pain,	O
and	O
dry	O
mouth.	O
4	O
Includes:	O
hypoaesthesia,	O
dizziness,	O
and	O
hyperkinesias.	O
Application	O
Site	O
Conditions	O
64	O
11	O
70	O
12	O
Pruritus	B-D011537
31	O
5	O
44	O
8	O
Dermatitis	B-D003872
9	O
2	O
3	O
<	O
1	O
Burning	O
2	O
<1	O
8	O
1	O
Other2	O
22	O
4	O
15	O
3	O
Gastrointestinal	O
Disorders	O
49	O
9	O
33	O
6	O
Nausea	B-D009325
17	O
3	O
11	O
2	O
Dysgeusia	B-D004408
10	O
2	O
3	O
<	O
1	O
Dyspepsia	B-D004415
7	O
1	O
8	O
1	O
Other3	O
15	O
3	O
11	O
2	O
Nervous	B-D009420
System	I-D009420
Disorders	O
13	O
2	O
18	O
3	O
Headache	B-D006261
7	O
1	O
10	O
2	O
Paresthesia	B-D010292
6	O
1	O
8	O
1	O
Somnolence	O
4	O
1	O
6	O
1	O
Other4	O
4	O
1	O
3	O
<	O
1	O
Foreign	O
labeling	O
describes	O
that	O
dermal	O
allergic	O
reactions	O
may	O
occur	O
with	O
Flector®	O
Patch	O
treatment.	O
Additionally,	O
the	O
treated	O
area	O
may	O
become	O
irritated	O
or	O
develop	O
itching,	O
erythema,	O
edema,	O
vesicles,	O
or	O
abnormal	O
sensation.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs1	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS	O
and	O
CLINICAL	O
TRIALS	O
).	O
Flector®	O
Patch	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS	O
).	O
1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug.	O
ADVERSE	O
REACTIONS	O
In	O
controlled	O
trials	O
during	O
the	O
premarketing	O
development	O
of	O
Flector®	O
Patch,	O
approximately	O
600	O
patients	O
with	O
minor	O
sprains,	O
strains,	O
and	O
contusions	O
have	O
been	O
treated	O
with	O
Flector®	O
Patch	O
for	O
up	O
to	O
two	O
weeks.	O
Adverse	O
Events	O
Lead	B-D007854
ing	O
to	O
Discontinuation	O
of	O
TreatmentIn	O
the	O
controlled	O
trials,	O
3%	O
of	O
patients	O
in	O
both	O
the	O
Flector®	O
Patch	O
and	O
placebo	O
patch	O
groups	O
discontinued	O
treatment	O
due	O
to	O
an	O
adverse	O
event.	O
The	O
most	O
common	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
were	O
application	O
site	O
reactions,	O
occurring	O
in	O
2%	O
of	O
both	O
the	O
Flector®	O
Patch	O
and	O
placebo	O
patch	O
groups.	O
Application	O
site	O
reactions	O
leading	O
to	O
dropout	O
included	O
pruritus,	O
dermatitis,	O
and	O
burning.	O
Common	O
Adverse	O
Events	O
Localized	O
Reactions	O
Overall	B-D016424
,	O
the	O
most	O
common	O
adverse	O
events	O
associated	O
with	O
Flector®	O
Patch	O
treatment	O
were	O
skin	O
reactions	O
at	O
the	O
site	O
of	O
treatment.	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥	O
1%	O
of	O
patients	O
in	O
controlled	O
trials	O
of	O
Flector®	O
Patch.	O
A	O
majority	O
of	O
patients	O
treated	O
with	O
Flector®	O
Patch	O
had	O
adverse	O
events	O
with	O
a	O
maximum	O
intensity	O
of	O
“mild”	O
or	O
“moderate.”	O
Table	O
1.	O
Common	O
Adverse	O
Events	O
(by	O
body	O
system	O
and	O
preferred	O
term)	O
in	O
≥1%	O
of	O
Patients	B-D010361
treated	O
with	O
Flector®	O
Patch	O
or	O
Placebo	O
Patch1	O
Diclofenac	B-D004008
N=572	O
Placebo	O
N=564	O
N	O
Percent	O
N	O
Percent	O
Application	O
Site	O
Conditions	O
64	O
11	O
70	O
12	O
Pruritus	B-D011537
31	O
5	O
44	O
8	O
Dermatitis	B-D003872
9	O
2	O
3	O
less	O
than	O
1	O
Burning	O
2	O
less	O
than	O
1	O
8	O
1	O
Other2	O
22	O
4	O
15	O
3	O
Gastrointestinal	O
Disorders	O
49	O
9	O
33	O
6	O
Nausea	B-D009325
17	O
3	O
11	O
2	O
Dysgeusia	B-D004408
10	O
2	O
3	O
less	O
than	O
1	O
Dyspepsia	B-D004415
7	O
1	O
8	O
1	O
Other3	O
15	O
3	O
11	O
2	O
Nerous	O
System	O
Disorders	O
13	O
2	O
18	O
3	O
Headache	B-D006261
7	O
1	O
10	O
2	O
Paresthesia	B-D010292
6	O
1	O
8	O
1	O
Somnolence	O
4	O
1	O
6	O
1	O
Other4	O
4	O
1	O
3	O
less	O
than	O
1	O
1	O
The	O
table	O
lists	O
adverse	O
events	O
occurring	O
in	O
placebo-treated	O
patients	O
because	O
the	O
placebo-patch	O
was	O
comprised	O
of	O
the	O
same	O
ingredients	O
as	O
Flector®	O
Patch	O
except	O
for	O
diclofenac.	O
Adverse	O
events	O
in	O
the	O
placebo	O
group	O
may	O
therefore	O
reflect	O
effects	O
of	O
the	O
non-active	O
ingredients.	O
2	O
Includes:	O
application	O
site	O
dryness,	O
irritation,	O
erythema,	O
atrophy,	O
discoloration,	O
hyperhidriosis,	O
and	O
vesicles.	O
3	O
Includes:	O
gastritis,	O
vomiting,	O
diarrhea,	O
constipation,	O
upper	O
abdominal	O
pain,	O
and	O
dry	O
mouth.	O
4	O
Includes:	O
hypoaesthesia,	O
dizziness,	O
and	O
hyperkinesias.	O
Foreign	O
labeling	O
describes	O
that	O
dermal	O
allergic	O
reactions	O
may	O
occur	O
with	O
Flector®	O
Patch	O
treatment.	O
Additionally,	O
the	O
treated	O
area	O
may	O
become	O
irritated	O
or	O
develop	O
itching,	O
erythema,	O
edema,	O
vesicles,	O
or	O
abnormal	O
sensation.	O
WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
RISK	O
EVALUATION	O
AND	O
MITIGATION	O
STRATEGY	O
(REMS);	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION;	O
ACCIDENTAL	O
INGESTION;	O
RISKS	O
FROM	O
CONCOMITANT	O
USE	O
WITH	O
BENZODIAZEPINES	O
OR	O
OTHER	O
CNS	O
DEPRESSANTS;	O
ULTRA-RAPID	O
METABOLISM	O
OF	O
CODEINE	O
AND	O
OTHER	O
RISK	O
FACTORS	O
FOR	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION	O
IN	O
CHILDREN;	O
NEONATAL	O
OPIOID	O
WITHDRAWAL	O
SYNDROME;	O
and	O
INTERACTIONS	O
WITH	O
DRUGS	O
AFFECTING	O
CYTOCHROME	O
P450	O
ISOENZYMES	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
FIORINAL	O
®	O
with	O
CODEINE	O
exposes	O
patients	O
and	O
other	O
users	O
to	O
the	O
risks	O
of	O
opioid	O
addiction,	O
abuse,	O
and	O
misuse,	O
which	O
can	O
lead	O
to	O
overdose	O
and	O
death.	O
Assess	O
each	O
patient’s	O
risk	O
prior	O
to	O
prescribing	O
FIORINAL	O
with	O
CODEINE,	O
and	O
monitor	O
all	O
patients	O
regularly	O
for	O
the	O
development	O
of	O
these	O
behaviors	O
and	O
conditions	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)].	O
Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
REMS	O
for	O
these	O
products	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O
.	O
Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
education	O
programs	O
available	O
to	O
healthcare	O
providers.	O
Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
•	O
complete	O
a	O
REMS-compliant	O
education	O
program,	O
•	O
counsel	O
patients	O
and/or	O
their	O
caregivers,	O
with	O
every	O
prescription,	O
on	O
safe	O
use,	O
serious	O
risks,	O
storage,	O
and	O
disposal	O
of	O
these	O
products,	O
•	O
emphasize	O
to	O
patients	O
and	O
their	O
caregivers	O
the	O
importance	O
of	O
reading	O
the	O
Medication	O
Guide	O
every	O
time	O
it	O
is	O
provided	O
by	O
their	O
pharmacist,	O
and	O
•	O
consider	O
other	O
tools	O
to	O
improve	O
patient,	O
household,	O
and	O
community	O
safety.	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
may	O
occur	O
with	O
use	O
of	O
FIORINAL	O
with	O
CODEINE.	O
Monitor	O
for	O
respiratory	O
depression,	O
especially	O
during	O
initiation	O
of	O
FIORINAL	O
with	O
CODEINE	O
or	O
following	O
a	O
dose	O
increase	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)].	O
Accidental	O
Ingestion	O
Accidental	O
ingestion	O
of	O
even	O
one	O
dose	O
of	O
FIORINAL	O
with	O
CODEINE,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
a	O
fatal	O
overdose	O
of	O
FIORINAL	O
with	O
CODEINE	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)].	O
Risk	B-D012306
s	O
From	O
Concomitant	O
Use	O
With	O
Benzodiazepines	B-D001569
Or	O
Other	O
CNS	O
Depressants	O
Concomitant	O
use	O
of	O
opioids	O
with	O
benzodiazepines	O
or	O
other	O
central	O
nervous	O
system	O
(CNS)	O
depressants,	O
including	O
alcohol,	O
may	O
result	O
in	O
profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
,	O
5.8	O
),	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
•	O
Reserve	O
concomitant	O
prescribing	O
of	O
FIORINAL	O
with	O
CODEINE	O
and	O
benzodiazepines	O
or	O
other	O
CNS	O
depressants	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
treatment	O
options	O
are	O
inadequate.	O
•	O
Limit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required.	O
•	O
Follow	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
and	O
death	O
have	O
occurred	O
in	O
children	O
who	O
received	O
codeine.	O
Most	O
of	O
the	O
reported	O
cases	O
occurred	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy,	O
and	O
many	O
of	O
the	O
children	O
had	O
evidence	O
of	O
being	O
an	O
ultra-rapid	O
metabolizer	O
of	O
codeine	O
due	O
to	O
a	O
CYP2D6	O
polymorphism	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)].	O
FIORINAL	O
with	O
CODEINE	O
is	O
contraindicated	O
in	O
children	O
younger	O
than	O
12	O
years	O
of	O
age	O
and	O
in	O
children	O
younger	O
than	O
18	O
years	O
of	O
age	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy	O
[see	O
Contraindications	B-D000075202
(	O
4	O
)].	O
Avoid	O
the	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
in	O
adolescents	O
12	O
to	O
18	O
years	O
of	O
age	O
who	O
have	O
other	O
risk	O
factors	O
that	O
may	O
increase	O
their	O
sensitivity	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine.	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
during	O
pregnancy	O
can	O
result	O
in	O
neonatal	O
opioid	O
withdrawal	O
syndrome,	O
which	O
may	O
be	O
life-threatening	O
if	O
not	O
recognized	O
and	O
treated,	O
and	O
requires	O
management	O
according	O
to	O
protocols	O
developed	O
by	O
neonatology	O
experts.	O
If	O
opioid	O
use	O
is	O
required	O
for	O
a	O
prolonged	O
period	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)].	O
Interactions	O
with	O
Drugs	O
Affect	B-D000339
ing	O
Cytochrome	O
P450	O
Isoenzymes	B-D007527
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
codeine	O
are	O
complex.	O
Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
FIORINAL	O
with	O
CODEINE	O
requires	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
codeine,	O
and	O
the	O
active	O
metabolite,	O
morphine	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
,	O
5.8	O
)	O
,	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
RISK	O
EVALUATION	O
AND	O
MITIGATION	O
STRATEGY	O
(REMS);	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION;	O
ACCIDENTAL	O
INGESTION;	O
RISKS	O
FROM	O
CONCOMITANT	O
USE	O
WITH	O
BENZODIAZEPINES	O
OR	O
OTHER	O
CNS	O
DEPRESSANTS;	O
ULTRA-RAPID	O
METABOLISM	O
OF	O
CODEINE	O
AND	O
OTHER	O
RISK	O
FACTORS	O
FOR	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION	O
IN	O
CHILDREN	O
;	O
NEONATAL	O
OPIOID	O
WITHDRAWAL	O
SYNDROME;	O
and	O
INTERACTIONS	O
WITH	O
DRUGS	O
AFFECTING	O
CYTOCHROME	O
P450	O
ISOENZYMES	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
FIORINAL	O
®	O
with	O
CODEINE	O
exposes	O
users	O
to	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse,	O
which	O
can	O
lead	O
to	O
overdose	O
and	O
death.	O
Assess	O
patient’s	O
risk	O
before	O
prescribing	O
and	O
monitor	O
regularly	O
for	O
these	O
behaviors	O
and	O
conditions.	O
(	O
5.1	O
)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opio	O
i	O
d	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
for	O
these	O
products	O
.	O
(	O
5.2	O
)	O
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
may	O
occur.	O
Monitor	O
closely,	O
especially	O
upon	O
initiation	O
or	O
following	O
a	O
dose	O
increase.	O
(	O
5.3	O
)	O
Accidental	O
ingestion	O
of	O
FIORINAL	O
with	O
CODEINE,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
fatal	O
overdose.	O
(	O
5.3	O
)	O
Concomitant	O
use	O
of	O
opioids	O
or	O
a	O
barbiturate	O
with	O
benzodiazepines	O
or	O
other	O
central	O
nervous	O
system	O
(CNS)	O
depressants,	O
including	O
alcohol,	O
may	O
result	O
in	O
profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death.	O
Reserve	O
concomitant	O
prescribing	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
treatment	O
options	O
are	O
inadequate;	O
limit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required;	O
and	O
follow	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
(	O
5.4	O
,	O
5.8	O
,	O
7	O
)	O
Life	B-D019369
-threatening	O
r	O
espiratory	O
depression	O
and	O
death	O
have	O
occurred	O
in	O
children	O
who	O
received	O
codeine	O
;	O
most	O
cases	O
follow	O
ed	O
tonsillectomy	O
and/or	O
adenoidectomy	O
,	O
and	O
many	O
of	O
the	O
children	O
had	O
evidence	O
of	O
being	O
an	O
ultra-rapid	O
metabolizer	O
of	O
codeine	O
due	O
to	O
a	O
CYP2D6	O
polymorphism	O
.	O
(	O
5.5	O
)	O
FIORINAL	O
with	O
CODEINE	O
is	O
contraindicated	O
in	O
ch	O
ildren	O
younger	O
than	O
12	O
years	O
of	O
age	O
and	O
in	O
children	O
younger	O
than	O
18	O
years	O
of	O
age	O
foll	O
owing	O
tonsillectomy	O
and/or	O
adenoidectomy	O
.	O
(	O
4	O
)	O
Avoid	O
the	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
in	O
adolescents	O
12	O
to	O
18	O
years	O
of	O
age	O
who	O
have	O
other	O
risk	O
factors	O
that	O
may	O
increase	O
their	O
sensitivity	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine.	O
Prolonged	O
use	O
during	O
pregnancy	O
can	O
result	O
in	O
neonatal	O
opioid	O
withdrawal	O
syndrome,	O
which	O
may	O
be	O
life-threatening	O
if	O
not	O
recognized	O
and	O
treated.	O
If	O
prolonged	O
opioid	O
use	O
is	O
required	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available.	O
(	O
5.6	O
)	O
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
codeine	O
are	O
complex.	O
Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
FIORINAL	O
with	O
CODEINE	O
requires	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
codeine,	O
and	O
the	O
active	O
metabolite,	O
morphine	O
.	O
(	O
5.7	O
,	O
5.8	O
,	O
7	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
or	O
in	O
Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
:	O
Monitor	O
closely,	O
particularly	O
during	O
initiation	O
and	O
titration.	O
(5.8)	O
Adrenal	B-D000309
Insufficiency	I-D000309
:	O
If	O
diagnosed,	O
treat	O
with	O
physiologic	O
replacement	O
of	O
corticosteroids,	O
and	O
wean	O
patient	O
off	O
the	O
opioid.	O
(5.10)	O
Severe	O
Hypotensi	O
on:	O
Monitor	O
during	O
dose	O
initiation	O
and	O
titration.	O
Avoid	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
in	O
patients	O
with	O
circulatory	O
shock.	O
(5.11)	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Increased	O
Intracranial	B-D007427
Pressure	I-D007427
,	O
Brain	B-D001921
Tumors,	O
Head	B-D006257
Injury,	O
or	O
Impaired	O
Consciousness	B-D003243
:	O
Monitor	O
for	O
sedation	O
and	O
respiratory	O
depression.	O
Avoid	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
in	O
patients	O
with	O
impaired	O
consciousness	O
or	O
coma.	O
(5.12)	O
5.	O
1	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
FIORINAL	O
with	O
CODEINE	O
contains	O
codeine.	O
Codeine	B-D003061
in	O
combination	O
with	O
butalbital	B-C004470
,	O
aspirin,	O
and	O
caffeine	O
is	O
a	O
Schedule	O
III	O
controlled	O
substance.	O
As	O
FIORINAL	O
with	O
CODEINE	O
contains	O
butalbital	B-C004470
and	O
codeine,	O
it	O
exposes	O
users	O
to	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse	O
[see	O
Drug	O
Abuse	O
and	O
Dependence	O
(	O
9	O
)].	O
Although	O
the	O
risk	O
of	O
addiction	O
in	O
any	O
individual	O
is	O
unknown,	O
it	O
can	O
occur	O
in	O
patients	O
appropriately	O
prescribed	O
FIORINAL	O
with	O
CODEINE.	O
Addiction	O
can	O
occur	O
at	O
recommended	O
dosages	O
and	O
if	O
the	O
drug	O
is	O
misused	O
or	O
abused.	O
Assess	O
each	O
patient’s	O
risk	O
for	O
addiction,	O
abuse,	O
or	O
misuse	O
prior	O
to	O
prescribing	O
FIORINAL	O
with	O
CODEINE,	O
and	O
monitor	O
all	O
patients	O
receiving	O
FIORINAL	O
with	O
CODEINE	O
for	O
the	O
development	O
of	O
these	O
behaviors	O
and	O
conditions.	O
Risk	B-D012306
s	O
are	O
increased	O
in	O
patients	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
substance	O
abuse	O
(including	O
drug	O
or	O
alcohol	O
abuse	O
or	O
addiction)	O
or	O
mental	O
illness	O
(e.g.,	O
major	O
depression).	O
The	O
potential	O
for	O
these	O
risks	O
should	O
not,	O
however,	O
prevent	O
the	O
proper	O
management	O
of	O
pain	O
in	O
any	O
given	O
patient.	O
Patients	B-D010361
at	O
increased	O
risk	O
may	O
be	O
prescribed	O
opioids	O
such	O
as	O
FIORINAL	O
with	O
CODEINE,	O
but	O
use	O
in	O
such	O
patients	O
necessitates	O
intensive	O
counseling	O
about	O
the	O
risks	O
and	O
proper	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
along	O
with	O
intensive	O
monitoring	O
for	O
signs	O
of	O
addiction,	O
abuse,	O
and	O
misuse.	O
Opioids	O
and	O
barbiturates	O
are	O
sought	O
by	O
drug	O
abusers	O
and	O
people	O
with	O
addiction	O
disorders	O
and	O
are	O
subject	O
to	O
criminal	O
diversion.	O
Consider	O
these	O
risks	O
when	O
prescribing	O
or	O
dispensing	O
FIORINAL	O
with	O
CODEINE.	O
Strategies	O
to	O
reduce	O
these	O
risks	O
include	O
prescribing	O
the	O
drug	O
in	O
the	O
smallest	O
appropriate	O
quantity	O
and	O
advising	O
the	O
patient	O
on	O
the	O
proper	O
disposal	O
of	O
unused	O
drug	O
[see	O
Patient	O
Counseling	B-D003376
Information	O
(	O
17	O
)].	O
Contact	O
local	O
state	O
professional	O
licensing	O
board	O
or	O
state	O
controlled	O
substances	O
authority	O
for	O
information	O
on	O
how	O
to	O
prevent	O
and	O
detect	O
abuse	O
or	O
diversion	O
of	O
this	O
product.	O
5.2	O
Opio	O
i	O
d	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
for	O
these	O
products.	O
Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
education	O
programs	O
available	O
to	O
healthcare	O
providers.	O
Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
do	O
all	O
of	O
the	O
following:	O
Complete	O
a	O
REMS-compliant	O
education	O
program	O
offered	O
by	O
an	O
accredited	O
provider	O
of	O
continuing	O
education	O
(CE)	O
or	O
another	O
education	O
program	O
that	O
includes	O
all	O
the	O
elements	O
of	O
the	O
FDA	O
Education	B-D004493
Blueprint	O
for	O
Health	B-D006262
care	O
Providers	O
Involved	O
in	O
the	O
Management	O
or	O
Support	O
of	O
Patients	B-D010361
with	O
Pain	B-D010146
.	O
Discuss	O
the	O
safe	O
use,	O
serious	O
risks,	O
and	O
proper	O
storage	O
and	O
disposal	O
of	O
opioid	O
analgesics	O
with	O
patients	O
and/or	O
their	O
caregivers	O
every	O
time	O
these	O
medicines	O
are	O
prescribed.	O
The	O
Patient	O
Counseling	B-D003376
Guide	O
(PCG)	O
can	O
be	O
obtained	O
at	O
this	O
link:	O
www.fda.gov/OpioidAnalgesicREMSPCG.	O
Emphasize	O
to	O
patients	O
and	O
their	O
caregivers	O
the	O
importance	O
of	O
reading	O
the	O
Medication	O
Guide	O
that	O
they	O
will	O
receive	O
from	O
their	O
pharmacist	O
every	O
time	O
an	O
opioid	O
analgesic	O
is	O
dispensed	O
to	O
them.	O
Consider	O
using	O
other	O
tools	O
to	O
improve	O
patient,	O
household,	O
and	O
community	O
safety,	O
such	O
as	O
patient-prescriber	O
agreements	O
that	O
reinforce	O
patient-prescriber	O
responsibilities.	O
To	O
obtain	O
further	O
information	O
on	O
the	O
opioid	O
analgesic	O
REMS	O
and	O
for	O
a	O
list	O
of	O
accredited	O
REMS	O
CME/CE,	O
call	O
1-800-503-0784,	O
or	O
log	O
on	O
to	O
www.opioidanalgesicrems.com.	O
The	O
FDA	O
Blueprint	O
can	O
be	O
found	O
at	O
www.fda.gov/OpioidAnalgesicREMSBlueprint.	O
5.	O
3	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
opioids,	O
even	O
when	O
used	O
as	O
recommended.	O
Respiratory	O
depression,	O
if	O
not	O
immediately	O
recognized	O
and	O
treated,	O
may	O
lead	O
to	O
respiratory	O
arrest	O
and	O
death.	O
Management	O
of	O
respiratory	O
depression	O
may	O
include	O
close	O
observation,	O
supportive	O
measures,	O
and	O
use	O
of	O
opioid	O
antagonists,	O
depending	O
on	O
the	O
patient’s	O
clinical	O
status	O
[see	O
Overdosage	O
(	O
10	O
)].	O
Carbon	B-D002244
dioxide	O
(CO2)	O
retention	O
from	O
opioid-induced	O
respiratory	O
depression	O
can	O
exacerbate	O
the	O
sedatin	B-C493049
g	O
effects	O
of	O
opioids.	O
While	O
serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
can	O
occur	O
at	O
any	O
time	O
during	O
the	O
use	O
of	O
FIORINAL	O
with	O
CODEINE,	O
the	O
risk	O
is	O
greatest	O
during	O
the	O
initiation	O
of	O
therapy	O
or	O
following	O
a	O
dosage	O
increase.	O
Monitor	O
patients	O
closely	O
for	O
respiratory	O
depression,	O
especially	O
within	O
the	O
first	O
24-72	O
hours	O
of	O
initiating	O
therapy	O
with	O
and	O
following	O
dosage	O
increases	O
of	O
FIORINAL	O
with	O
CODEINE.	O
To	O
reduce	O
the	O
risk	O
of	O
respiratory	O
depression,	O
proper	O
dosing	O
and	O
titration	O
of	O
FIORINAL	O
with	O
CODEINE	O
are	O
essential	O
[see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)].	O
Overestimating	O
the	O
FIORINAL	O
with	O
CODEINE	O
dosage	O
when	O
converting	O
patients	O
from	O
another	O
opioid	O
product	O
can	O
result	O
in	O
a	O
fatal	O
overdose	O
with	O
the	O
first	O
dose.	O
Accidental	O
ingestion	O
of	O
FIORINAL	O
with	O
CODEINE,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
respiratory	O
depression	O
and	O
death	O
due	O
to	O
an	O
overdose	O
of	O
codeine	O
and	O
butalbital	B-C004470
.	O
Opioids	O
can	O
cause	O
sleep-related	O
breathing	O
disorders	O
including	O
central	O
sleep	O
apnea	O
(CSA)	O
and	O
sleep-related	O
hypoxemia.	O
Opioid	O
use	O
increases	O
the	O
risk	O
of	O
CSA	O
in	O
a	O
dose-dependent	O
fashion.	O
In	O
patients	O
who	O
present	O
with	O
CSA,	O
consider	O
decreasing	O
the	O
opioid	O
dosage	O
using	O
best	O
practices	O
for	O
opioid	O
taper	O
[see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)].	O
5.	O
4	O
Risk	B-D012306
s	O
from	O
Concomitant	O
Use	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
Profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death	O
may	O
result	O
from	O
the	O
concomitant	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
with	O
benzodiazepines	O
or	O
other	O
CNS	O
depressants	O
(e.g.,	O
non-benzodiazepine	O
sedatives/hypnotics,	O
anxiolytics,	O
tranquilizers,	O
muscle	O
relaxants,	O
general	O
anesthetics,	O
antipsychotics,	O
other	O
opioids,	O
alcohol).	O
Because	O
of	O
these	O
risks,	O
reserve	O
concomitant	O
prescribing	O
of	O
these	O
drugs	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
treatment	O
options	O
are	O
inadequate.	O
Observation	B-D019370
al	O
studies	O
have	O
demonstrated	O
that	O
concomitant	O
use	O
of	O
opioid	O
analgesics	O
and	O
benzodiazepines	O
increases	O
the	O
risk	O
of	O
drug-related	O
mortality	O
compared	O
to	O
use	O
of	O
opioid	O
analgesics	O
alone.	O
Because	O
of	O
similar	O
pharmacological	O
properties,	O
it	O
is	O
reasonable	O
to	O
expect	O
similar	O
risk	O
with	O
the	O
concomitant	O
use	O
of	O
other	O
CNS	O
depressant	O
drugs	O
with	O
opioid	O
analgesics	O
[	O
s	O
e	O
e	O
Drug	O
I	O
nt	O
e	O
ra	O
c	O
tions	O
(	O
7	O
)].	O
If	O
the	O
decision	O
is	O
made	O
to	O
prescribe	O
a	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant	O
concomitantly	O
with	O
an	O
opioid	O
analgesic,	O
prescribe	O
the	O
lowest	O
effective	O
dosages	O
and	O
minimum	O
durations	O
of	O
concomitant	O
use.	O
In	O
patients	O
already	O
receiving	O
an	O
opioid	O
analgesic,	O
prescribe	O
a	O
lower	O
initial	O
dose	O
of	O
the	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant	O
than	O
indicated	O
in	O
the	O
absence	O
of	O
an	O
opioid,	O
and	O
titrate	O
based	O
on	O
clinical	O
response.	O
If	O
an	O
opioid	O
analgesic	O
is	O
initiated	O
in	O
a	O
patient	O
already	O
taking	O
a	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant,	O
prescribe	O
a	O
lower	O
initial	O
dose	O
of	O
the	O
opioid	O
analgesic,	O
and	O
titrate	O
based	O
on	O
clinical	O
response.	O
Follow	O
patients	O
closely	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
Advise	O
both	O
patients	O
and	O
caregivers	O
about	O
the	O
risks	O
of	O
respiratory	O
depression	O
and	O
sedation	O
when	O
FIORINAL	O
with	O
CODEINE	O
is	O
used	O
with	O
benzodiazepines	O
or	O
other	O
CNS	O
depressants	O
(including	O
alcohol	O
and	O
illicit	O
drugs).	O
Advise	O
patients	O
not	O
to	O
drive	O
or	O
operate	O
heavy	O
machinery	O
until	O
the	O
effects	O
of	O
concomitant	O
use	O
of	O
the	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant	O
have	O
been	O
determined.	O
Screen	O
patients	O
for	O
risk	O
of	O
substance	O
use	O
disorders,	O
including	O
opioid	O
abuse	O
and	O
misuse,	O
and	O
warn	O
them	O
of	O
the	O
risk	O
for	O
overdose	O
and	O
death	O
associated	O
with	O
the	O
use	O
of	O
additional	O
CNS	O
depressants	O
including	O
alcohol	O
and	O
illicit	O
drugs	O
[	O
s	O
e	O
e	O
Drug	O
I	O
nt	O
e	O
r	O
a	O
c	O
tions	O
(	O
7	O
)	O
and	O
Pati	O
e	O
nt	O
C	O
ouns	O
e	O
ling	O
I	O
nformation	O
(	O
17	O
)	O
].	O
5.	O
5	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
and	O
death	O
have	O
occurred	O
in	O
children	O
who	O
received	O
codeine.	O
Codeine	B-D003061
is	O
subject	O
to	O
variability	O
in	O
metabolism	O
based	O
upon	O
CYP2D6	O
genotype	O
(described	O
below),	O
which	O
can	O
lead	O
to	O
an	O
increased	O
exposure	O
to	O
the	O
active	O
metabolite	O
morphine.	O
Based	O
upon	O
postmarketing	O
reports,	O
children	O
younger	O
than	O
12	O
years	O
old	O
appear	O
to	O
be	O
more	O
susceptible	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine,	O
particularly	O
if	O
there	O
are	O
risk	O
factors	O
for	O
respiratory	O
depression.	O
For	O
example,	O
many	O
reported	O
cases	O
of	O
death	O
occurred	O
in	O
the	O
post-	O
operative	O
period	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy,	O
and	O
many	O
of	O
the	O
children	O
had	O
evidence	O
of	O
being	O
ultra-rapid	O
metabolizers	O
of	O
codeine.	O
Furthermore,	O
children	O
with	O
obstructive	O
sleep	O
apnea	O
who	O
are	O
treated	O
with	O
codeine	O
for	O
post-tonsillectomy	O
and/or	O
adenoidectomy	O
pain	O
may	O
be	O
particularly	O
sensitive	O
to	O
its	O
respiratory	O
depressant	O
effect.	O
Because	O
of	O
the	O
risk	O
of	O
life-threatening	O
respiratory	O
depression	O
and	O
death:	O
FIORINAL	O
with	O
CODEINE	O
is	O
contraindicated	O
for	O
all	O
children	O
younger	O
than	O
12	O
years	O
of	O
age	O
[s	O
e	O
e	O
C	O
ontraindi	O
c	O
ations	O
(	O
4	O
)]	O
.	O
FIORINAL	O
with	O
CODEINE	O
is	O
contraindicated	O
for	O
post-operative	O
management	O
in	O
pediatric	O
patients	O
younger	O
than	O
18	O
years	O
of	O
age	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy	O
[see	O
Contraindications	B-D000075202
(	O
4	O
)].	O
Avoid	O
the	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
in	O
adolescents	O
12	O
to	O
18	O
years	O
of	O
age	O
who	O
have	O
other	O
risk	O
factors	O
that	O
may	O
increase	O
their	O
sensitivity	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine	O
unless	O
the	O
benefits	O
outweigh	O
the	O
risks.	O
Risk	B-D012306
factors	O
include	O
conditions	O
associated	O
with	O
hypoventilation,	O
such	O
as	O
postoperative	O
status,	O
obstructive	O
sleep	O
apnea,	O
obesity,	O
severe	O
pulmonary	O
disease,	O
neuromuscular	O
disease,	O
and	O
concomitant	O
use	O
of	O
other	O
medications	O
that	O
cause	O
respiratory	O
depression.	O
As	O
with	O
adults,	O
when	O
prescribing	O
FIORINAL	O
with	O
CODEINE	O
for	O
adolescents,	O
healthcare	O
providers	O
should	O
choose	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
period	O
of	O
time	O
and	O
inform	O
patients	O
and	O
caregivers	O
about	O
these	O
risks	O
and	O
the	O
signs	O
of	O
morphine	O
overdose	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(	O
8.4	O
),	O
Overdosage	O
(	O
10	O
)].	O
N	O
ursing	O
M	O
oth	O
e	O
rs	O
At	O
least	O
one	O
death	O
was	O
reported	O
in	O
a	O
nursing	O
infant	O
who	O
was	O
exposed	O
to	O
high	O
levels	O
of	O
morphine	O
in	O
breast	O
milk	O
because	O
the	O
mother	O
was	O
an	O
ultra-rapid	O
metabolizer	O
of	O
codeine.	O
Breast	B-D001940
feeding	O
is	O
not	O
recommended	O
during	O
treatment	O
with	O
FIORINAL	O
with	O
CODEINE	O
[s	O
e	O
e	O
Use	O
in	O
S	O
p	O
ec	O
ific	O
Population	B-D011153
s	O
(	O
8.2	O
)].	O
C	O
Y	O
P2D6	O
G	O
e	O
n	O
e	O
tic	O
Variabilit	O
y	O
:	O
Ultra	O
-	O
rapid	O
m	O
e	O
taboliz	O
e	O
r	O
Some	O
individuals	O
may	O
be	O
ultra-rapid	O
metabolizers	O
because	O
of	O
a	O
specific	O
CYP2D6	O
genotype	O
(gene	O
duplications	O
denoted	O
as	O
*1/*1xN	O
or	O
*1/*2xN).	O
The	O
prevalence	O
of	O
this	O
CYP2D6	O
phenotype	O
varies	O
widely	O
and	O
has	O
been	O
estimated	O
at	O
1	O
to	O
10%	O
for	O
Whites	O
(European,	O
North	B-D009656
America	I-D009656
n),	O
3	O
to	O
4%	O
for	O
Blacks	O
(African	O
Americans),	O
1	O
to	O
2%	O
for	O
East	O
Asia	B-D001208
ns	O
(Chinese,	O
Japan	B-D007564
ese,	O
Korea	B-D007723
n),	O
and	O
may	O
be	O
greater	O
than	O
10%	O
in	O
certain	O
racial/ethnic	O
groups	O
(i.e.,	O
Oceania	B-D044349
n,	O
Northern	O
Africa	B-D000349
n,	O
Middle	B-D008877
East	I-D008877
ern,	O
Ashkenazi	O
Jews	B-D007585
,	O
Puerto	O
Rican).	O
These	O
individuals	O
convert	O
codeine	O
into	O
its	O
active	O
metabolite,	O
morphine,	O
more	O
rapidly	O
and	O
completely	O
than	O
other	O
people.	O
This	O
rapid	O
conversion	O
results	O
in	O
higher	O
than	O
expected	O
serum	O
morphine	O
levels.	O
Even	O
at	O
labeled	O
dosage	O
regimens,	O
individuals	O
who	O
are	O
ultra-rapid	O
metabolizers	O
may	O
have	O
life-threatening	O
or	O
fatal	O
respiratory	O
depression	O
or	O
experience	O
signs	O
of	O
overdose	O
(such	O
as	O
extreme	O
sleepiness,	O
confusion,	O
or	O
shallow	O
breathing)	O
[see	O
Overdosage	O
(	O
10	O
)].	O
Therefore,	O
individuals	O
who	O
are	O
ultra-rapid	O
metabolizers	O
should	O
not	O
use	O
FIORINAL	O
with	O
CODEINE.	O
5.	O
6	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
during	O
pregnancy	O
can	O
result	O
in	O
withdrawal	O
in	O
the	O
neonate.	O
Neon	B-D009356
atal	O
opioid	O
withdrawal	O
syndrome,	O
unlike	O
opioid	O
withdrawal	O
syndrome	O
in	O
adults,	O
may	O
be	O
life-threatening	O
if	O
not	O
recognized	O
and	O
treated,	O
and	O
requires	O
management	O
according	O
to	O
protocols	O
developed	O
by	O
neonatology	O
experts.	O
Observe	O
newborns	O
for	O
signs	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
manage	O
accordingly.	O
Advise	O
pregnant	O
women	O
using	O
opioids	O
for	O
a	O
prolonged	O
period	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available	O
[s	O
e	O
e	O
Use	O
in	O
Sp	O
e	O
c	O
ific	O
Po	O
p	O
ulations	O
(	O
8.1	O
,	O
8.2	O
)	O
,	O
Pati	O
e	O
nt	O
C	O
ouns	O
e	O
ling	O
I	O
nformatio	O
n	O
(	O
17	O
)	O
].	O
5.	O
7	O
Risk	B-D012306
s	O
of	O
Interactions	O
with	O
Drugs	O
Affect	B-D000339
ing	O
Cytochrome	O
P450	O
Isoenzymes	B-D007527
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
codeine	O
are	O
complex.	O
Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
FIORINAL	O
with	O
CODEINE	O
requires	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
codeine	O
and	O
the	O
active	O
metabolite,	O
morphine.	O
Cytochrome	O
P450	O
3A4	O
Interaction	O
The	O
concomitant	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
with	O
all	O
cytochrome	O
P450	O
3A4	O
inhibitors,	O
such	O
as	O
macrolide	O
antibiotics	O
(e.g.,	O
erythromycin),	O
azole-antifungal	O
agents	O
(e.g.,	O
ketoconazole),	O
and	O
protease	O
inhibitors	O
(e.g.,	O
ritonavir)	O
or	O
discontinuation	O
of	O
a	O
cytochrome	O
P450	O
3A4	O
inducer	O
such	O
as	O
rifampin,	O
carbamazepine,	O
and	O
phenytoin,	O
may	O
result	O
in	O
an	O
increase	O
in	O
codeine	O
plasma	O
concentrations	O
with	O
subsequently	O
greater	O
metabolism	O
by	O
cytochrome	O
P450	O
2D6,	O
resulting	O
in	O
greater	O
morphine	O
levels,	O
which	O
could	O
increase	O
or	O
prolong	O
adverse	O
reactions	O
and	O
may	O
cause	O
potentially	O
fatal	O
respiratory	O
depression.	O
The	O
concomitant	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
with	O
all	O
cytochrome	O
P450	O
3A4	O
inducers	O
or	O
discontinuation	O
of	O
a	O
cytochrome	O
P450	O
3A4	O
inhibitor	O
may	O
result	O
in	O
lower	O
codeine	O
levels,	O
greater	O
norcodeine	B-C010414
levels,	O
and	O
less	O
metabolism	O
via	O
2D6	O
with	O
resultant	O
lower	O
morphine	O
levels.	O
This	O
may	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
efficacy,	O
and	O
in	O
some	O
patients,	O
may	O
result	O
in	O
signs	O
and	O
symptoms	O
of	O
opioid	O
withdrawal.	O
Follow	O
patients	O
receiving	O
FIORINAL	O
with	O
CODEINE	O
and	O
any	O
CYP3A4	O
inhibitor	O
or	O
inducer	O
for	O
signs	O
and	O
symptoms	O
that	O
may	O
reflect	O
opioid	O
toxicity	O
and	O
opioid	O
withdrawal	O
when	O
FIORINAL	O
with	O
CODEINE	O
is	O
used	O
in	O
conjunction	O
with	O
inhibitors	O
and	O
inducers	O
of	O
CYP3A4.	O
If	O
concomitant	O
use	O
of	O
a	O
CYP3A4	O
inhibitor	O
is	O
necessary	O
or	O
if	O
a	O
CYP3A4	O
inducer	O
is	O
discontinued,	O
consider	O
dosage	O
reduction	O
of	O
FIORINAL	O
with	O
CODEINE	O
until	O
stable	O
drug	O
effects	O
are	O
achieved.	O
Monitor	O
patients	O
for	O
respiratory	O
depression	O
and	O
sedation	O
at	O
frequent	O
intervals.	O
If	O
concomitant	O
use	O
of	O
a	O
CYP3A4	O
inducer	O
is	O
necessary	O
or	O
if	O
a	O
CYP3A4	O
inhibitor	O
is	O
discontinued,	O
consider	O
increasing	O
the	O
FIORINAL	O
with	O
CODEINE	O
dosage	O
until	O
stable	O
drug	O
effects	O
are	O
achieved.	O
Monitor	O
for	O
signs	O
of	O
opioid	O
withdrawal	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
Risk	B-D012306
s	O
of	O
Concomitant	O
Use	O
or	O
Discontinuation	O
of	O
Cytochrome	O
P450	O
2D6	O
Inhibitors	O
The	O
concomitant	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
with	O
all	O
cytochrome	O
P450	O
2D6	O
inhibitors	O
(e.g.,	O
amiodarone,	O
quinidine)	O
may	O
result	O
in	O
an	O
increase	O
in	O
codeine	O
plasma	O
concentrations	O
and	O
a	O
decrease	O
in	O
active	O
metabolite	O
morphine	O
plasma	O
concentration	O
which	O
could	O
result	O
in	O
an	O
analgesic	O
efficacy	O
reduction	O
or	O
symptoms	O
of	O
opioid	O
withdrawal.	O
Discontinuation	O
of	O
a	O
concomitantly	O
used	O
cytochrome	O
P450	O
2D6	O
inhibitor	O
may	O
result	O
in	O
a	O
decrease	O
in	O
codeine	O
plasma	O
concentration	O
and	O
an	O
increase	O
in	O
active	O
metabolite	O
morphine	O
plasma	O
concentration	O
which	O
could	O
increase	O
or	O
prolong	O
adverse	O
reactions	O
and	O
may	O
cause	O
potentially	O
fatal	O
respiratory	O
depression.	O
Follow	O
patients	O
receiving	O
FIORINAL	O
with	O
CODEINE	O
and	O
any	O
CYP2D6	O
inhibitor	O
for	O
signs	O
and	O
symptoms	O
that	O
may	O
reflect	O
opioid	O
toxicity	O
and	O
opioid	O
withdrawal	O
when	O
FIORINAL	O
with	O
CODEINE	O
are	O
used	O
in	O
conjunction	O
with	O
inhibitors	O
of	O
CYP2D6.	O
If	O
concomitant	O
use	O
with	O
a	O
CYP2D6	O
inhibitor	O
is	O
necessary,	O
follow	O
the	O
patient	O
for	O
signs	O
of	O
reduced	O
efficacy	O
or	O
opioid	O
withdrawal	O
and	O
consider	O
increasing	O
the	O
FIORINAL	O
with	O
CODEINE	O
dosage.	O
After	O
stopping	O
use	O
of	O
a	O
CYP2D6	O
inhibitor,	O
consider	O
reducing	O
the	O
FIORINAL	O
with	O
CODEINE	O
dosage	O
and	O
follow	O
the	O
patient	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
or	O
sedation	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
5.	O
8	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
or	O
in	O
Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
The	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
in	O
patients	O
with	O
acute	O
or	O
severe	O
bronchial	O
asthma	O
in	O
an	O
unmonitored	O
setting	O
or	O
in	O
the	O
absence	O
of	O
resuscitative	O
equipment	O
is	O
contraindicated.	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
:	O
FIORINAL	O
with	O
CODEINE-treated	O
patients	O
with	O
significant	O
chronic	O
obstructive	O
pulmonary	O
disease	O
or	O
cor	O
pulmonale,	O
and	O
those	O
with	O
a	O
substantially	O
decreased	O
respiratory	O
reserve,	O
hypoxia,	O
hypercapnia,	O
or	O
pre-existing	O
respiratory	O
depression	O
are	O
at	O
increased	O
risk	O
of	O
decreased	O
respiratory	O
drive	O
including	O
apnea,	O
even	O
at	O
recommended	O
dosages	O
of	O
FIORINAL	O
with	O
CODEINE	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)].	O
Elderly,	O
Cachectic	O
,	O
or	O
Debilitated	O
Patients	B-D010361
:	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
is	O
more	O
likely	O
to	O
occur	O
in	O
elderly,	O
cachectic,	O
or	O
debilitated	O
patients	O
because	O
they	O
may	O
have	O
altered	O
pharmacokinetics	O
or	O
altered	O
clearance	O
compared	O
to	O
younger,	O
healthier	O
patients	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)].	O
Monitor	O
such	O
patients	O
closely,	O
particularly	O
when	O
initiating	O
and	O
titrating	O
FIORINAL	O
with	O
CODEINE	O
and	O
when	O
FIORINAL	O
with	O
CODEINE	O
is	O
given	O
concomitantly	O
with	O
other	O
drugs	O
that	O
depress	O
respiration	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)].	O
Alternatively,	O
consider	O
the	O
use	O
of	O
non-opioid	O
analgesics	O
in	O
these	O
patients.	O
5.	O
9	O
Interaction	O
with	O
Monoamine	B-D008996
Oxidase	I-D008996
Inhibitors	I-D008996
Monoamine	O
oxidase	O
inhibitors	O
(MAOIs)	O
may	O
potentiate	O
the	O
effects	O
of	O
morphine,	O
codeine’s	O
active	O
metabolite,	O
including	O
respiratory	O
depression,	O
coma,	O
and	O
confusion.	O
FIORINAL	O
with	O
CODEINE	O
should	O
not	O
be	O
used	O
in	O
patients	O
taking	O
MAOIs	O
or	O
within	O
14	O
days	O
of	O
stopping	O
such	O
treatment.	O
5.	O
10	O
Adrenal	B-D000309
Insufficiency	I-D000309
Cases	O
of	O
adrenal	O
insufficiency	O
have	O
been	O
reported	O
with	O
opioid	O
use,	O
more	O
often	O
following	O
greater	O
than	O
one	O
month	O
of	O
use.	O
Presentation	O
of	O
adrenal	O
insufficiency	O
may	O
include	O
non-specific	O
symptoms	O
and	O
signs	O
including	O
nausea,	O
vomiting,	O
anorexia,	O
fatigue,	O
weakness,	O
dizziness,	O
and	O
low	O
blood	O
pressure.	O
If	O
adrenal	O
insufficiency	O
is	O
suspected,	O
confirm	O
the	O
diagnosis	O
with	O
diagnostic	O
testing	O
as	O
soon	O
as	O
possible.	O
If	O
adrenal	O
insufficiency	O
is	O
diagnosed,	O
treat	O
with	O
physiologic	O
replacement	O
doses	O
of	O
corticosteroids.	O
Wean	O
the	O
patient	O
off	O
of	O
the	O
opioid	O
to	O
allow	O
adrenal	O
function	O
to	O
recover	O
and	O
continue	O
corticosteroid	O
treatment	O
until	O
adrenal	O
function	O
recovers.	O
Other	O
opioids	O
may	O
be	O
tried	O
as	O
some	O
cases	O
reported	O
use	O
of	O
a	O
different	O
opioid	O
without	O
recurrence	O
of	O
adrenal	O
insufficiency.	O
The	O
information	O
available	O
does	O
not	O
identify	O
any	O
particular	O
opioids	O
as	O
being	O
more	O
likely	O
to	O
be	O
associated	O
with	O
adrenal	O
insufficiency.	O
5.	O
1	O
1	O
Severe	O
Hypotension	B-D007022
FIORINAL	O
with	O
CODEINE	O
may	O
cause	O
severe	O
hypotension	O
including	O
orthostatic	O
hypotension	O
and	O
syncope	O
in	O
ambulatory	O
patients.	O
There	O
is	O
increased	O
risk	O
in	O
patients	O
whose	O
ability	O
to	O
maintain	O
blood	O
pressure	O
has	O
already	O
been	O
compromised	O
by	O
a	O
reduced	O
blood	O
volume	O
or	O
concurrent	O
administration	O
of	O
certain	O
CNS	O
depressant	O
drugs	O
(e.g.,	O
phenothiazine	B-C031637
s	O
or	O
general	O
anesthetics)	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
hypotension	O
after	O
initiating	O
or	O
titrating	O
the	O
dosage	O
of	O
FIORINAL	O
with	O
CODEINE.	O
In	O
patients	O
with	O
circulatory	O
shock,	O
FIORINAL	O
with	O
CODEINE	O
may	O
cause	O
vasodilation	O
that	O
can	O
further	O
reduce	O
cardiac	O
output	O
and	O
blood	O
pressure.	O
Avoid	O
the	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
in	O
patients	O
with	O
circulatory	O
shock.	O
5.	O
1	O
2	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Increased	O
Intracranial	B-D007427
Pressure	I-D007427
,	O
Brain	B-D001921
Tumors,	O
Head	B-D006257
Injury,	O
or	O
Impaired	O
Consciousness	B-D003243
In	O
patients	O
who	O
may	O
be	O
susceptible	O
to	O
the	O
intracranial	O
effects	O
of	O
CO2	O
retention	O
(e.g.,	O
those	O
with	O
evidence	O
of	O
increased	O
intracranial	O
pressure	O
or	O
brain	O
tumors),	O
FIORINAL	O
with	O
CODEINE	O
may	O
reduce	O
respiratory	O
drive,	O
and	O
the	O
resultant	O
CO2	O
retention	O
can	O
further	O
increase	O
intracranial	O
pressure.	O
Monitor	O
such	O
patients	O
for	O
signs	O
of	O
sedation	O
and	O
respiratory	O
depression,	O
particularly	O
when	O
initiating	O
therapy	O
with	O
FIORINAL	O
with	O
CODEINE.	O
Opioids	O
may	O
also	O
obscure	O
the	O
clinical	O
course	O
in	O
a	O
patient	O
with	O
a	O
head	O
injury.	O
Avoid	O
the	O
use	O
of	O
FIORINAL	O
with	O
CODEINE	O
in	O
patients	O
with	O
impaired	O
consciousness	O
or	O
coma.	O
5.	O
1	O
3	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Gastrointestinal	O
Conditions	O
Including	O
Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
FIORINAL	O
with	O
CODEINE	O
is	O
contraindicated	O
in	O
patients	O
with	O
known	O
or	O
suspected	O
gastrointestinal	O
obstruction,	O
including	O
paralytic	O
ileus.	O
The	O
codeine	O
in	O
FIORINAL	O
with	O
CODEINE	O
may	O
cause	O
spasm	O
of	O
the	O
sphincter	O
of	O
Oddi.	O
Opioids	O
may	O
cause	O
increases	O
in	O
serum	O
amylase.	O
Monitor	O
patients	O
with	O
biliary	O
tract	O
disease,	O
including	O
acute	O
pancreatitis	O
for	O
worsening	O
symptoms.	O
Patients	B-D010361
with	O
a	O
history	O
of	O
active	O
peptic	O
ulcer	O
disease	O
should	O
avoid	O
using	O
aspirin,	O
which	O
can	O
cause	O
gastric	O
mucosal	O
irritation	O
and	O
bleeding.	O
The	O
aspirin	O
in	O
FIORINAL	O
with	O
CODEINE	O
can	O
cause	O
GI	O
side	O
effects	O
including	O
stomach	O
pain,	O
heartburn,	O
nausea,	O
vomiting,	O
and	O
gross	O
GI	O
bleeding.	O
Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
dyspepsia,	O
are	O
common	O
and	O
can	O
occur	O
anytime	O
during	O
therapy,	O
physicians	O
should	O
remain	O
alert	O
for	O
signs	O
of	O
ulceration	O
and	O
bleeding,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
GI	O
symptoms.	O
Physicians	B-D010820
should	O
inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
GI	O
side	O
effects	O
and	O
what	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
5.	O
1	O
4	O
Increased	O
Risk	B-D012306
of	O
Seizures	B-D012640
in	O
Patients	B-D010361
with	O
Seizure	O
Disorders	O
The	O
codeine	O
in	O
FIORINAL	O
with	O
CODEINE	O
may	O
increase	O
the	O
frequency	O
of	O
seizures	O
in	O
patients	O
with	O
seizure	O
disorders,	O
and	O
may	O
increase	O
the	O
risk	O
of	O
seizures	O
occurring	O
in	O
other	O
clinical	O
settings	O
associated	O
with	O
seizures.	O
Monitor	O
patients	O
with	O
a	O
history	O
of	O
seizure	O
disorders	O
for	O
worsened	O
seizure	O
control	O
during	O
FIORINAL	O
with	O
CODEINE	O
therapy.	O
5.	O
1	O
5	O
Withdrawal	O
Do	O
not	O
abruptly	O
discontinue	O
FIORINAL	O
with	O
CODEINE	O
in	O
a	O
patient	O
physically	O
dependent	O
on	O
opioids.	O
Rapid	O
tapering	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
in	O
a	O
patient	O
physically	O
dependent	O
on	O
opioids	O
may	O
lead	O
to	O
a	O
withdrawal	O
syndrome	O
and	O
return	O
of	O
pain	O
[see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
),	O
Drug	O
Abuse	O
and	O
Dependence	O
(	O
9.3	O
)].	O
Additionally,	O
avoid	O
the	O
use	O
of	O
mixed	O
agonist/antagonist	O
(e.g.,	O
pentazocine,	O
nalbuphine,	O
and	O
butorphan	B-C520649
ol)	O
or	O
partial	O
agonist	O
(e.g.,	O
buprenorphine)	O
analgesics	O
in	O
patients	O
who	O
are	O
receiving	O
a	O
full	O
opioid	O
agonist	O
analgesic,	O
including	O
FIORINAL	O
with	O
CODEINE.	O
In	O
these	O
patients,	O
mixed	O
agonist/antagonist	O
and	O
partial	O
agonist	O
analgesics	O
may	O
reduce	O
the	O
analgesic	O
effect	O
and/or	O
precipitate	O
withdrawal	O
symptoms	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
When	O
discontinuing	O
FIORINAL	O
with	O
CODEINE	O
in	O
a	O
physically	O
dependent	O
patient,	O
gradually	O
taper	O
the	O
dosage	O
[see	O
Dosage	O
and	O
Administration	O
(2.3)].	O
Abrupt	O
discontinuation	O
of	O
butalbital	B-C004470
can	O
cause	O
seizures	O
[see	O
Drug	O
Abuse	O
and	O
Dependence	O
(9.3)].	O
5.	O
1	O
6	O
Risk	B-D012306
s	O
of	O
Driving	O
and	O
Operating	O
Machinery	O
FIORINAL	O
with	O
CODEINE	O
may	O
impair	O
the	O
mental	O
or	O
physical	O
abilities	O
needed	O
to	O
perform	O
potentially	O
hazardous	O
activities	O
such	O
as	O
driving	O
a	O
car	O
or	O
operating	O
machinery.	O
Warn	O
patients	O
not	O
to	O
drive	O
or	O
operate	O
dangerous	O
machinery	O
unless	O
they	O
are	O
tolerant	O
to	O
the	O
effects	O
of	O
FIORINAL	O
with	O
CODEINE	O
and	O
know	O
how	O
they	O
will	O
react	O
to	O
the	O
medication.	O
5.1	O
7	O
Coagulation	O
Abnormalities	O
and	O
Bleeding	O
Risk	B-D012306
s	O
Even	O
low	O
doses	O
of	O
aspirin	O
can	O
inhibit	O
platelet	O
function	O
leading	O
to	O
an	O
increase	O
in	O
bleeding	O
time.	O
This	O
can	O
adversely	O
affect	O
patients	O
with	O
inherited	O
(i.e.	O
hemophilia)	O
or	O
acquired	O
(i.e.	O
liver	O
disease	O
or	O
vitamin	O
K	O
deficiency)	O
bleeding	O
disorders.	O
Aspirin	B-D001241
is	O
contraindicated	O
in	O
patients	O
with	O
hemophilia.	O
Aspirin	B-D001241
administered	O
pre-operatively	O
may	O
prolong	O
the	O
bleeding	O
time.	O
Patients	B-D010361
who	O
consume	O
three	O
or	O
more	O
alcoholic	O
drinks	O
every	O
day	O
should	O
be	O
counseled	O
about	O
the	O
bleeding	O
risks	O
involved	O
with	O
chronic,	O
heavy	O
alcohol	O
use	O
while	O
taking	O
aspirin.	O
5.1	O
8	O
Reye’s	O
Syndrome	B-D013577
Aspirin	B-D001241
should	O
not	O
be	O
used	O
in	O
children	O
or	O
teenagers	O
for	O
viral	O
infections,	O
with	O
or	O
without	O
fever,	O
because	O
of	O
the	O
risk	O
of	O
Reye’s	O
syndrome	O
with	O
concomitant	O
use	O
of	O
aspirin	O
in	O
certain	O
viral	O
illnesses.	O
5.1	O
9	O
Allergy	O
Aspirin	B-D001241
is	O
contraindicated	O
in	O
patients	O
with	O
known	O
allergy	O
to	O
nonsteroidal	O
anti-inflammatory	O
drug	O
products	O
(NSAIDs)	O
and	O
in	O
patients	O
with	O
the	O
syndrome	O
of	O
asthma,	O
rhinitis,	O
and	O
nas	B-C015378
al	O
polyps.	O
Aspirin	B-D001241
may	O
cause	O
severe	O
urticaria,	O
angioedema,	O
or	O
bronchospasm	O
(asthma).	O
5.	O
20	O
Drug/Laboratory	O
Test	O
Interactions	O
Aspirin	B-D001241
:	O
Aspirin	B-D001241
may	O
interfere	O
with	O
the	O
following	O
laboratory	O
determinations	O
in	O
blood:	O
serum	O
amylase,	O
fasting	O
blood	O
glucose,	O
cholesterol,	O
protein,	O
serum	O
glutamic-oxalacetic	O
transaminase	O
(SGOT),	O
uric	O
acid,	O
prothrombin	O
time	O
and	O
bleeding	O
time.	O
Aspirin	B-D001241
may	O
interfere	O
with	O
the	O
following	O
laboratory	O
determinations	O
in	O
urine:	O
glucose,	O
5-hydroxy-indoleacetic	O
acid,	O
Gerhardt	O
ketone,	O
vanillylmandelic	O
acid	O
(VMA),	O
uric	O
acid,	O
diacetic	O
acid,	O
and	O
spectrophotometric	O
detection	O
of	O
barbiturates.	O
Codeine	B-D003061
:	O
Codeine	B-D003061
may	O
increase	O
serum	O
amylase	O
levels.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described,	O
or	O
described	O
in	O
greater	O
detail,	O
in	O
other	O
sections:	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
Interactions	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
[s	O
e	O
e	O
W	O
arni	O
n	O
gs	O
and	O
Pr	O
ec	O
autions	O
(	O
5.4	O
)]	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)]	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)]	O
Adrenal	B-D000309
Insufficiency	I-D000309
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.10	O
)]	O
Severe	O
Hypotension	B-D007022
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.11	O
)]	O
Gastrointestinal	O
Adverse	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.13	O
)]	O
Seizures	B-D012640
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.14	O
)]	O
Withdrawal	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.15	O
)]	O
Coagulation	O
Abnormalities	O
and	O
Bleeding	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.17	O
)]	O
Reye’s	O
Syndrome	B-D013577
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.18	O
)]	O
Allergy	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.19	O
)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
1%)	O
are	O
nausea	O
and/or	O
abdominal	O
pain,	O
drowsiness,	O
and	O
dizziness.	O
(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Allergan	O
at	O
1-800-678-1605	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Incidence	B-D015994
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
s	O
The	O
following	O
table	O
summarizes	O
the	O
incidence	O
rates	O
of	O
the	O
adverse	O
events	O
reported	O
by	O
at	O
least	O
1%	O
of	O
the	O
FIORINAL	O
with	O
CODEINE	O
treated	O
patients	O
in	O
controlled	O
clinical	O
trials	O
comparing	O
FIORINAL	O
with	O
CODEINE	O
to	O
placebo,	O
and	O
provides	O
a	O
comparison	O
to	O
the	O
incidence	O
rates	O
reported	O
by	O
the	O
placebo-treated	O
patients.	O
The	O
prescriber	O
should	O
be	O
aware	O
that	O
these	O
figures	O
cannot	O
be	O
used	O
to	O
predict	O
the	O
incidence	O
of	O
side	O
effects	O
in	O
the	O
course	O
of	O
usual	O
medical	O
practice	O
where	O
patient	O
characteristics	O
and	O
other	O
factors	O
differ	O
from	O
those	O
that	O
prevailed	O
in	O
the	O
clinical	O
trials.	O
Similarly,	O
the	O
cited	O
frequencies	O
cannot	O
be	O
compared	O
with	O
figures	O
obtained	O
from	O
other	O
clinical	O
investigations	O
involving	O
different	O
treatments,	O
uses,	O
and	O
investigators.	O
Adverse	O
Events	O
Reported	O
by	O
at	O
Least	O
1%	O
of	O
FIORINAL	O
with	O
CODEINE	O
Treated	O
Patients	B-D010361
During	O
Placebo	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
s	O
Incidence	B-D015994
Rate	O
of	O
Adverse	O
Events	O
Body	O
System/Adverse	O
Event	O
FIORINAL	O
with	O
CODEINE	O
(N=382)	O
Placebo	O
(N=377)	O
Central	O
Nervous	O
Drowsiness	O
2.4%	O
0.5%	O
Dizziness	B-D004244
/Lightheadedness	O
2.6%	O
0.5%	O
Intoxicated	O
Feeling	O
1.0%	O
0%	O
Gastrointestinal	O
Nausea	B-D009325
/Abdominal	O
Pain	B-D010146
3.7%	O
0.8%	O
Othe	O
r	O
Advers	O
e	O
Event	O
s	O
Reporte	O
d	O
Durin	O
g	O
Controlle	O
d	O
Clinica	O
l	O
Trials	O
The	O
listing	O
that	O
follows	O
represents	O
the	O
proportion	O
of	O
the	O
382	O
patients	O
exposed	O
to	O
FIORINAL	O
with	O
CODEINE	O
while	O
participating	O
in	O
the	O
controlled	O
clinical	O
trials	O
who	O
reported,	O
on	O
at	O
least	O
one	O
occasion,	O
an	O
adverse	O
event	O
of	O
the	O
type	O
cited.	O
All	O
reported	O
adverse	O
events,	O
except	O
those	O
already	O
presented	O
in	O
the	O
previous	O
table,	O
are	O
included.	O
It	O
is	O
important	O
to	O
emphasize	O
that,	O
although	O
the	O
adverse	O
events	O
reported	O
did	O
occur	O
while	O
the	O
patient	O
was	O
receiving	O
FIORINAL	O
with	O
CODEINE,	O
the	O
adverse	O
events	O
were	O
not	O
necessarily	O
caused	O
by	O
FIORINAL	O
with	O
CODEINE.	O
Adverse	O
events	O
are	O
classified	O
by	O
body	O
system	O
and	O
frequency.	O
“Frequent”	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
which	O
occurred	O
in	O
at	O
least	O
1/100	O
(1%)	O
of	O
the	O
patients;	O
all	O
adverse	O
events	O
listed	O
in	O
the	O
previous	O
table	O
are	O
frequent.	O
“Infrequent”	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
that	O
occurred	O
in	O
less	O
than	O
1/100	O
patients	O
but	O
at	O
least	O
1/1000	O
patients.	O
All	O
adverse	O
events	O
tabulated	O
below	O
are	O
classified	O
as	O
infrequent.	O
Centra	O
l	O
Nervous:	O
headache,	O
shaky	O
feeling,	O
tingling,	O
agitation,	O
fainting,	O
fatigue,	O
heavy	O
eyelids,	O
high	O
energy,	O
hot	O
spells,	O
numbness,	O
and	O
sluggishness.	O
Autonomic	O
Nervous:	O
dry	O
mouth	O
and	O
hyperhidrosis.	O
Gastrointestinal:	O
vomiting,	O
difficulty	O
swallowing,	O
and	O
heartburn.	O
Cardiovascular:	O
tachycardia.	O
Musculoskeletal:	O
leg	O
pain	O
and	O
muscle	O
fatigue.	O
Genitourinary:	O
diuresis.	O
Miscellaneous:	O
pruritus,	O
fever,	O
earache,	O
nas	B-C015378
al	O
congestion,	O
and	O
tinnitus.	O
The	O
following	O
adverse	O
drug	O
reactions	O
have	O
been	O
reported	O
with	O
the	O
components	O
of	O
FIORINAL	O
with	O
CODEINE.	O
Potential	O
effects	O
of	O
high	O
dosage	O
are	O
listed	O
in	O
the	O
[	O
Overdosage	O
(	O
10	O
)]	O
section	O
of	O
this	O
insert.	O
Aspirin	B-D001241
:	O
occult	O
blood	O
loss,	O
hemolytic	O
anemia,	O
iron	O
deficiency	O
anemia,	O
gastric	O
distress,	O
heartburn,	O
nausea,	O
peptic	O
ulcer,	O
prolonged	O
bleeding	O
time,	O
acute	O
airway	O
obstruction,	O
renal	O
toxicity	O
when	O
taken	O
in	O
high	O
doses	O
for	O
prolonged	O
periods,	O
impaired	O
urate	O
excretion,	O
hepatitis.	O
Caffeine	B-D002110
:	O
cardiac	O
stimulation,	O
irritability,	O
tremor,	O
dependence,	O
nephrotoxicity,	O
hyperglycemia.	O
Codeine	B-D003061
:	O
nausea,	O
vomiting,	O
drowsiness,	O
lightheadedness,	O
constipation,	O
pruritus.	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
FIORINAL	O
with	O
CODEINE.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Centra	O
l	O
Nervous:	O
abuse,	O
addiction,	O
anxiety,	O
depression,	O
disorientation,	O
hallucination,	O
hyperactivity,	O
insomnia,	O
libido	O
decrease,	O
nervousness,	O
neuropathy,	O
psychosis,	O
sedation,	O
sexual	O
activity	O
increase,	O
slurred	O
speech,	O
twitching,	O
unconsciousness,	O
vertigo.	O
Autonomic	O
Nervous:	O
epistaxis,	O
flushing,	O
miosis,	O
salivation.	O
Gastrointestinal:	O
anorexia,	O
appetite	O
increased,	O
constipation,	O
diarrhea,	O
esophagitis,	O
gastroenteritis,	O
gastrointestinal	O
spasm,	O
hiccup,	O
mouth	O
burning,	O
pyloric	O
ulcer.	O
Cardiovascular:	O
chest	O
pain,	O
hypotensive	O
reaction,	O
palpitations,	O
syncope.	O
Skin	B-D012867
:	O
erythema,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
hives,	O
rash,	O
toxic	O
epidermal	O
necrolysis.	O
Urinary:	O
kidney	O
impairment,	O
urinary	O
difficulty.	O
Miscellaneous:	O
allergic	O
reaction,	O
anaphylactic	O
shock,	O
cholangiocarcinoma,	O
drug	O
interaction	O
with	O
erythromycin	O
(stomach	O
upset),	O
edema.	O
Serotonin	B-D012701
syndrome:	O
Cases	O
of	O
serotonin	O
syndrome,	O
a	O
potentially	O
life-threatening	O
condition,	O
have	O
been	O
reported	O
during	O
concomitant	O
use	O
of	O
opioids	O
with	O
serotonergic	O
drugs.	O
Adrenal	O
insufficiency:	O
Cases	O
of	O
adrenal	O
insufficiency	O
have	O
been	O
reported	O
with	O
opioid	O
use,	O
more	O
often	O
following	O
greater	O
than	O
one	O
month	O
of	O
use.	O
Anaphylaxis	B-D000707
:	O
Anaphylaxis	B-D000707
has	O
been	O
reported	O
with	O
ingredients	O
contained	O
in	O
FIORINAL	O
with	O
CODEINE.	O
Androgen	O
deficiency:	O
Cases	O
of	O
androgen	O
deficiency	O
have	O
occurred	O
with	O
chronic	O
use	O
of	O
opioids	O
[see	O
Clinical	O
Pharmacology	B-D010600
(	O
12.2	O
)].	O
BOXED	O
WARNING	O
SECTION	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.4)	O
WARNINGS	O
AND	O
PRECAUTIONS	O
SECTION	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
celecoxib,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
celecoxib	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
celecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
active	O
GI	O
bleeding.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)].	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
celecoxib	O
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
celecoxib	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
celecoxib.	O
In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
celecoxib.	O
Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
celecoxib	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
ADVERSE	O
REACTIONS	O
SECTION	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia,	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS,	O
or	O
hypersensitivity	O
syndrome)	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
*Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations	O
*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
BOXED	O
WARNING	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(see	O
WARNINGS.)	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(see	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%–10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
atulence,	O
gross	O
bleeding/	O
perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
ADVERSE	O
REACTIONS	O
Hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	O
tablets	O
were	O
administered	O
to	O
approximately	O
300	O
pain	O
patients	O
in	O
a	O
safety	O
study	O
that	O
employed	O
dosages	O
and	O
a	O
duration	O
of	O
treatment	O
sufficient	O
to	O
encompass	O
the	O
recommended	O
usage	O
(see	O
DOSAGE	O
AND	O
ADMINISTRATION).	O
Adverse	O
event	O
rates	O
generally	O
increased	O
with	O
increasing	O
daily	O
dose.	O
The	O
event	O
rates	O
reported	O
below	O
are	O
from	O
approximately	O
150	O
patients	O
who	O
were	O
in	O
a	O
group	O
that	O
received	O
one	O
tablet	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
an	O
average	O
of	O
three	O
to	O
four	O
times	O
daily.	O
The	O
overall	O
incidence	O
rates	O
of	O
adverse	O
experiences	O
in	O
the	O
trials	O
were	O
fairly	O
similar	O
for	O
this	O
patient	O
group	O
and	O
those	O
who	O
received	O
the	O
comparison	O
treatment,	O
acetaminophen	O
600	O
mg	O
with	O
codeine	O
60	O
mg.	O
The	O
following	O
lists	O
adverse	O
events	O
that	O
occurred	O
with	O
an	O
incidence	O
of	O
1%	O
or	O
greater	O
in	O
clinical	O
trials	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
tablets,	O
without	O
regard	O
to	O
the	O
causal	O
relationship	O
of	O
the	O
events	O
to	O
the	O
drug.	O
To	O
distinguish	O
different	O
rates	O
of	O
occurrence	O
in	O
clinical	O
studies,	O
the	O
adverse	O
events	O
are	O
listed	O
as	O
follows:	O
name	O
of	O
adverse	O
event	O
=	O
less	O
than	O
3%	O
adverse	O
events	O
marked	O
with	O
an	O
asterisk	O
*	O
=	O
3%	O
to	O
9%	O
adverse	O
event	O
rates	O
over	O
9%	O
are	O
in	O
parentheses.	O
Body	O
as	O
a	O
Whole:	O
Abdominal	O
pain*;	O
Asthenia	B-D001247
*;	O
Fever	B-D005334
;	O
Flu	O
syndrome;	O
Headache	B-D006261
(27%);	O
Infection*;	O
Pain	B-D010146
.	O
Cardiovascular:	O
Palpitations;	O
Vasodilation	B-D014664
.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Anxiety	B-D001007
*;	O
Confusion	B-D003221
;	O
Dizziness	B-D004244
(14%);	O
Hypertonia;	O
Insomnia*;	O
Nervousness*;	O
Paresthesia	B-D010292
;	O
Somnolence	O
(22%);	O
Thinking	B-D013850
abnormalities.	O
Digestive:	O
Anorexia	B-D000855
;	O
Constipation	B-D003248
(22%);	O
Diarrhea	B-D003967
*;	O
Dry	O
mouth*;	O
Dyspepsia	B-D004415
(12%);	O
Flatulence	B-D005414
*;	O
Gastritis	B-D005756
;	O
Melena	B-D008551
;	O
Mouth	B-D009055
ulcers;	O
Nausea	B-D009325
(21%);	O
Thirst	B-D013894
;	O
Vomiting	B-D014839
*.	O
Metabolic	O
and	O
Nutritional	O
Disorders:	O
Edema	B-D004487
*.	O
Respiratory:	O
Dyspnea	B-D004417
;	O
Hiccup	B-D006606
s;	O
Pharyngitis	B-D010612
;	O
Rhinitis	B-D012220
.	O
Skin	B-D012867
and	O
Appendages:	O
Pruritus	B-D011537
*;	O
Sweating	B-D013546
*.	O
Special	O
Senses:	O
Tinnitus	B-D014012
.	O
Urogenital:	O
Urinary	O
frequency.	O
Incidence	B-D015994
less	O
than	O
1%	O
Body	O
as	O
a	O
Whole:	O
Allergic	O
reaction.	O
Cardiovascular:	O
Arrhythmia;	O
Hypotension	B-D007022
;	O
Tachycardia	B-D013610
.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Agitation;	O
Abnormal	O
dreams;	O
Decreased	O
libido;	O
Depression	B-D003863
;	O
Euphoria	B-D005059
;	O
Mood	O
changes;	O
Neuralgia	B-D009437
;	O
Slurred	O
speech;	O
Tremor	B-D014202
,	O
Vertigo	B-D014717
.	O
Digestive:	O
Chalky	O
stool;	O
"Clenching	O
teeth";	O
Dysphagia;	O
Esophageal	O
spasm;	O
Esophagitis	B-D004941
;	O
Gastroenteritis	B-D005759
;	O
Glossitis	B-D005928
;	O
Liver	B-D008099
enzyme	O
elevation.	O
Metabolic	O
and	O
Nutritional:	O
Weight	O
decrease.	O
Musculoskeletal:	O
Arthralgia	B-D018771
;	O
Myalgia	B-D063806
.	O
Respiratory:	O
Asthma	B-D001249
;	O
Bronchitis	B-D001991
;	O
Hoarseness	B-D006685
;	O
Increased	O
cough;	O
Pulmonary	O
congestion;	O
Pneumonia	B-D011014
;	O
Shallow	O
breathing;	O
Sinusitis	B-D012852
.	O
Skin	B-D012867
and	O
Appendages:	O
Rash;	O
Urticaria	B-D014581
.	O
Special	O
Senses:	O
Altered	O
vision;	O
Bad	O
taste;	O
Dry	O
eyes.	O
Urogenital:	O
Cystitis	B-D003556
;	O
Glycosuria	B-D006029
;	O
Impotence;	O
Urinary	O
incontinence;	O
Urinary	O
retention.	O
BOXED	O
WARNING	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS	O
).	O
Ibuprofen	B-D007052
tablets	O
are	O
contraindicated	O
for	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	O
tablets	O
is	O
gastrointestinal.	O
In	O
controlled	O
clinical	O
trials	O
the	O
percentage	O
of	O
patients	O
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%.	O
In	O
controlled	O
studies	O
when	O
ibuprofen	O
tablets	O
were	O
compared	O
to	O
aspirin	O
and	O
indomethacin	O
in	O
equally	O
effective	O
doses,	O
the	O
overall	O
incidence	O
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin	O
or	O
indomethacin-treated	O
patients.	O
Adverse	O
reactions	O
observed	O
during	O
controlled	O
clinical	O
trials	O
at	O
an	O
incidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table.	O
Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	O
in	O
approximately	O
3,000	O
patients.	O
More	O
than	O
500	O
of	O
these	O
patients	O
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks.	O
Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	O
clinical	O
trials	O
and	O
from	O
marketing	O
experience.	O
These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	O
tablets	O
where	O
the	O
probability	O
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	O
tablets	O
has	O
not	O
been	O
established.	O
Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	O
trials	O
of	O
patients	O
with	O
rheumatoid	O
arthritis.	O
The	O
increases	O
in	O
incidence	O
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table.	O
Incidence	B-D015994
Greater	O
than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship­	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea	B-D009325
*,	O
epigastric	O
pain*,	O
heartburn*,	O
diarrhea,	O
abdominal	O
distress,	O
nausea	O
and	O
vomiting,	O
indigestion,	O
constipation,	O
abdominal	O
cramps	O
or	O
pain,	O
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	O
Gastric	O
or	O
duodenal	O
ulcer	O
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	O
hemorrhage,	O
melena,	O
gastritis,	O
hepatitis,	O
jaundice,	O
abnormal	O
liver	O
function	O
tests;	O
pancreatitis	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
Dizziness	B-D004244
*,	O
headache,	O
nervousness	O
Depression	B-D003863
,	O
insomnia,	O
confusion,	O
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	O
with	O
fever	O
and	O
coma	O
(see	O
PRECAUTIONS	O
)	O
Paresthesia	B-D010292
s,	O
hallucinations,	O
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	O
DERMATOLOGIC	O
Rash*,	O
(including	O
maculopapular	O
type),	O
pruritus	O
Vesiculobullous	O
eruptions,	O
urticaria,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome,	O
alopecia	O
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	O
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D006309
loss,	O
amblyopia	O
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	O
and	O
/or	O
changes	O
in	O
color	O
vision)	O
(see	O
PRECAUTIONS	O
)	O
Conjunctivitis	B-D003231
,	O
diplopia,	O
optic	O
neuritis,	O
cataracts	O
HEMATOLOGIC	O
Neutropenia	B-D009503
,	O
agranulocytosis,	O
aplastic	O
anemia,	O
hemolytic	O
anemia	O
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	O
with	O
or	O
without	O
purpura,	O
eosinophilia,	O
decreases	O
in	O
hemoglobin	O
and	O
hematocrit	O
(see	O
PRECAUTIONS	O
)	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	O
menorrhagia)	O
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	O
Gynecomastia	B-D006177
,	O
hypoglycemic	O
reaction,	O
acidosis	O
CARDIOVASCULAR	O
Edema	B-D004487
,	O
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS	O
)	O
Congestive	O
heart	O
failure	O
in	O
patients	O
with	O
marginal	O
cardiac	O
function,	O
elevate	O
blood	O
pressure,	O
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	O
sinus	O
bradycardia)	O
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	O
pain,	O
fever,	O
chills,	O
nausea	O
and	O
vomiting;	O
anaphylaxis;	O
bronchospasm	O
(see	O
CONTRAINDICATIONS	O
)	O
Serum	B-D044967
sickness,	O
lupus	O
erythematosus	O
syndrome.	O
Henoch-Schonlein	O
vasculitis,	O
angioedema	O
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS	O
),	O
decreased	O
creatinine	O
clearance,	O
poliuria,	O
azotemia,	O
cystitis,	O
hematuria	O
Renal	O
papillary	O
necrosis	O
MISCELLANEOUS	O
Dry	O
eyes	O
and	O
mouth,	O
gingival	O
ulcer,	O
rhinitis	O
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
ibuprofen.	O
(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked).**Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related.	O
Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
celecoxib	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	O
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
for	O
the	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
treatment	O
arms	O
compared	O
to	O
placebo.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.7)	O
].	O
A	O
randomized	O
controlled	O
trial	O
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs.	O
Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	O
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	O
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	O
and	O
ibuprofen.	O
Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	O
375	O
mg	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	O
600	O
mg	O
to	O
800	O
mg	O
three	O
times	O
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists'	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	O
(including	O
hemorrhagic	O
death),	O
non-fatal	O
myocardial	O
infarction,	O
and	O
non-fatal	O
stroke	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
celecoxib.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	O
anticoagulants;	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.7)	O
].	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
discontinue	O
celecoxib	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
blood	O
pressure	O
data	O
for	O
Celecoxib	B-D000068579
.	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
celecoxib	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
celecoxib	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
celecoxib.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
celecoxib	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
celecoxib	O
and	O
in	O
patients	O
with	O
aspirin	O
sensitive	O
asthma.	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	O
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	O
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib,	O
including	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(AGEP).	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
celecoxib	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs,	O
including	O
celecoxib,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	O
SSRIs	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
].	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation	O
with	O
use	O
of	O
celecoxib	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	O
and	O
their	O
caregivers	O
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible.	O
6.	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Greenstone	O
LLC	O
Professional	O
Information	B-D007255
Services	I-D007255
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1%	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular	O
:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General:	O
Hypersensitivity	B-D006967
,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
Blood	B-D001769
urea	O
nitrogen	O
(BUN)	O
increased,	O
creatine	O
phosphokinase	O
(CPK)	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia	B-D001259
,	O
suicide	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Clinical	O
Studies	O
(14.7)	O
]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
aspirin	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
twice	O
daily.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kgN=77	O
Celecoxib	B-D000068579
6	O
mg/kgN=82	O
Naproxen	B-D009288
7.5	O
mg/kgN=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
InvestigationsAbnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.7)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials	O
,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N=2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning,	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
celecoxib.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis	B-D014657
,	O
deep	O
venous	O
thrombosis	O
General:	O
Anaphylactoid	O
reaction,	O
angioedema	O
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	O
hepatitis,	O
jaundice,	O
hepatic	O
failure	O
Hemic	O
and	O
lymphatic	O
:	O
Agranulocytosis	B-D000380
,	O
aplasticanemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
Renal:	O
Interstitial	O
nephritis	O
BOXED	O
WARNING	O
SECTION	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[See	O
Warnings	O
and	O
Precautions	O
and	O
(5.1)].	O
Flector	O
Patch	O
is	O
contraindicated	O
in	O
the	O
peri-operative	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[See	O
Contraindications	B-D000075202
(4)].	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[See	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNINGS	O
AND	O
PRECAUTIONS	O
SECTION	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Inform	O
patients	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
NSAIDs,	O
such	O
as	O
diclofenac,	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients,	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy,	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Prescribe	O
NSAIDs,	O
including	O
Flector	O
Patch,	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
for	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore,	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
diclofenac	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high	O
risk	O
patients,	O
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs.	O
5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
[ULN]	O
range)	O
or	O
greater	O
elevations	O
of	O
transaminases	O
occurred	O
in	O
about	O
15%	O
of	O
oral	O
diclofenac-treated	O
patients	O
in	O
clinical	O
trials	O
of	O
indications	O
other	O
than	O
acute	O
pain.	O
Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	O
injury.	O
In	O
clinical	O
trials	O
of	O
an	O
oral	O
diclofenac	O
–	O
misoprostol	O
combination	O
product,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
for	O
2-6	O
months,	O
patients	O
with	O
oral	O
diclofenac	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(>8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
this	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3-8	O
times	O
the	O
ULN),	O
and	O
marked	O
(>8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
oral	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
Measure	O
transaminases	O
(ALT	O
and	O
AST)	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
monitor	O
transaminases	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
discontinue	O
Flector	O
Patch	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
patients	O
should	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
Flector	O
Patch,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
Flector	O
Patch	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
certain	O
antibiotics,	O
anti-epileptics).	O
Caution	O
patients	O
to	O
avoid	O
taking	O
unprescribed	O
acetaminophen	O
while	O
using	O
Flector	O
Patch.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Flector	O
Patch,	O
can	O
lead	O
to	O
new	O
onset	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Use	O
Flector	O
Patch,	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Monitor	O
blood	O
pressure	O
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
Patients	B-D010361
taking	O
ACE	O
inhibitors,	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
Flector	O
Patch.	O
Use	O
Flector	O
Patch	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
Flector	O
Patch	O
in	O
patients	O
with	O
considerable	O
dehydration.	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Flector	O
Patch	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
Flector	O
Patch	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
Flector	O
Patch	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactic	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactic	O
reactions	O
may	O
occur	O
both	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
and	O
in	O
patients	O
without	O
known	O
sensitivity	O
to	O
NSAIDs	O
or	O
prior	O
exposure	O
to	O
Flector	O
Patch.	O
Do	O
not	O
prescribe	O
Flector	O
Patch	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs.	O
Anaphylaxis	B-D000707
type	O
reactions	O
have	O
been	O
reported	O
with	O
NSAID	O
products,	O
including	O
diclofenac	O
products,	O
such	O
as	O
Flector	O
Patch	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.13)].	O
Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Flector	O
Patch,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations,	O
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
Starting	O
at	O
30	O
weeks	O
gestation,	O
Flector	O
Patch,	O
and	O
other	O
NSAIDs,	O
should	O
be	O
avoided	O
by	O
pregnant	O
women	O
as	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
in	O
the	O
fetus	O
may	O
occur	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.10	O
Corticosteroid	O
Monitoring	O
Flector	O
Patch	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
disease	O
exacerbation.	O
Slowly	O
taper	O
patients	O
on	O
prolonged	O
corticosteroid	O
therapy	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Flector	O
Patch	O
in	O
reducing	O
inflammation	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.12	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
including	O
Flector	O
Patch,	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia.	O
NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration,	O
and	O
reversible.	O
Carefully	O
monitor	O
patients	O
receiving	O
Flector	O
Patch	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alterations	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
do	O
not	O
administer	O
Flector	O
Patch	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Accidental	O
Exposure	O
in	O
Child	B-D002648
ren	O
Even	O
a	O
used	O
Flector	O
Patch	O
contains	O
a	O
large	O
amount	O
of	O
diclofenac	O
epolamine	B-C104862
(as	O
much	O
as	O
170	O
mg).	O
The	O
potential	O
therefore	O
exists	O
for	O
a	O
small	O
child	O
or	O
pet	O
to	O
suffer	O
serious	O
adverse	O
effects	O
from	O
chewing	O
or	O
ingesting	O
a	O
new	O
or	O
used	O
Flector	O
Patch.	O
It	O
is	O
important	O
for	O
patients	O
to	O
store	O
and	O
dispose	O
of	O
Flector	O
Patch	O
out	O
of	O
the	O
reach	O
of	O
children	O
and	O
pets.	O
5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Flector	O
Patch	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Do	O
not	O
use	O
combination	O
therapy	O
with	O
Flector	O
Patch	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk.	O
5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Check	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
in	O
patients	O
on	O
long-term	O
treatment	O
with	O
NSAIDs.	O
Discontinue	O
Flector	O
Patch	O
if	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen.	O
ADVERSE	O
REACTIONS	O
SECTION	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
controlled	O
trials	O
during	O
the	O
premarketing	O
development	O
of	O
Flector	O
Patch,	O
approximately	O
600	O
patients	O
with	O
minor	O
sprains,	O
strains,	O
and	O
contusions	O
have	O
been	O
treated	O
with	O
Flector	O
Patch	O
for	O
up	O
to	O
two	O
weeks.	O
Adverse	O
Events	O
Lead	B-D007854
ing	O
to	O
Discontinuation	O
of	O
Treatment	O
In	O
the	O
controlled	O
trials,	O
3%	O
of	O
patients	O
in	O
both	O
the	O
Flector	O
Patch	O
and	O
placebo	O
patch	O
groups	O
discontinued	O
treatment	O
due	O
to	O
an	O
adverse	O
event.	O
The	O
most	O
common	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
were	O
application	O
site	O
reactions,	O
occurring	O
in	O
2%	O
of	O
both	O
the	O
Flector	O
Patch	O
and	O
placebo	O
patch	O
groups.	O
Application	O
site	O
reactions	O
leading	O
to	O
dropout	O
included	O
pruritus,	O
dermatitis,	O
and	O
burning.	O
Common	O
Adverse	O
Events	O
Localized	O
Reactions	O
Overall	B-D016424
,	O
the	O
most	O
common	O
adverse	O
events	O
associated	O
with	O
Flector	O
Patch	O
treatment	O
were	O
skin	O
reactions	O
at	O
the	O
site	O
of	O
treatment.	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥	O
1%	O
of	O
patients	O
in	O
controlled	O
trials	O
of	O
Flector	O
Patch.	O
A	O
majority	O
of	O
patients	O
treated	O
with	O
Flector	O
Patch	O
had	O
adverse	O
events	O
with	O
a	O
maximum	O
intensity	O
of	O
"mild"	O
or	O
"moderate."	O
Table	O
1.	O
Common	O
Adverse	O
Events	O
(by	O
body	O
system	O
and	O
preferred	O
term)	O
in	O
≥1%	O
of	O
Patients	B-D010361
treated	O
with	O
Flector	O
Patch	O
or	O
Placebo	O
Patch	O
*	O
Diclofenac	B-D004008
N=572	O
Placebo	O
N=564	O
N	O
Percent	O
N	O
Percent	O
*The	O
table	O
lists	O
adverse	O
events	O
occurring	O
in	O
placebo-treated	O
patients	O
because	O
the	O
placebo-patch	O
was	O
comprised	O
of	O
the	O
same	O
ingredients	O
as	O
Flector	O
Patch	O
except	O
for	O
diclofenac.	O
Adverse	O
events	O
in	O
the	O
placebo	O
group	O
may	O
therefore	O
reflect	O
effects	O
of	O
the	O
non-active	O
ingredients.	O
†Includes:	O
application	O
site	O
dryness,	O
irritation,	O
erythema,	O
atrophy,	O
discoloration,	O
hyperhidriosis,	O
and	O
vesicles.	O
‡Includes:	O
gastritis,	O
vomiting,	O
diarrhea,	O
constipation,	O
upper	O
abdominal	O
pain,	O
and	O
dry	O
mouth.	O
§Includes:	O
hypoaesthesia,	O
dizziness,	O
and	O
hyperkinesias.	O
Application	O
Site	O
Conditions	O
64	O
11	O
70	O
12	O
Pruritus	B-D011537
31	O
5	O
44	O
8	O
Dermatitis	B-D003872
9	O
2	O
3	O
<1	O
Burning	O
2	O
<1	O
8	O
1	O
Other	O
†	O
22	O
4	O
15	O
3	O
Gastrointestinal	O
Disorders	O
49	O
9	O
33	O
6	O
Nausea	B-D009325
17	O
3	O
11	O
2	O
Dysgeusia	B-D004408
10	O
2	O
3	O
<1	O
Dyspepsia	B-D004415
7	O
1	O
8	O
1	O
Other	O
‡	O
15	O
3	O
11	O
2	O
Nervous	B-D009420
System	I-D009420
Disorders	O
13	O
2	O
18	O
3	O
Headache	B-D006261
7	O
1	O
10	O
2	O
Paresthesia	B-D010292
6	O
1	O
8	O
1	O
Somnolence	O
4	O
1	O
6	O
1	O
Other	O
§	O
4	O
1	O
3	O
<1	O
Foreign	O
labeling	O
describes	O
that	O
dermal	O
allergic	O
reactions	O
may	O
occur	O
with	O
Flector	O
Patch	O
treatment.	O
Additionally,	O
the	O
treated	O
area	O
may	O
become	O
irritated	O
or	O
develop	O
itching,	O
erythema,	O
edema,	O
vesicles,	O
or	O
abnormal	O
sensation.	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
Cardiovascular	O
Risk	B-D012306
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
.	O
•	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)]	O
.	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
.	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Cardiovascular	O
Risk	B-D012306
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
(5.1)	O
•	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
Gastrointestinal	O
Risk	B-D012306
(4,	O
5.1)	O
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs),	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
The	O
lowest	O
possible	O
dose	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
should	O
be	O
used	O
in	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
(5.1)	O
•NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
be	O
prescribed	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
(5.2)	O
•Elevation	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
diclofenac.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
be	O
discontinued	O
immediately	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen.	O
(5.3)	O
•Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
at	O
greatest	O
risk	O
of	O
this	O
reaction,	O
including	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors.	O
(5.6)	O
•Hypertension	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
gel.	O
(5.4)	O
•Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
(5.5)	O
•Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
or	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
should	O
be	O
discontinued	O
immediately	O
if	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
(5.7)	O
•NSAIDs	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
be	O
discontinued	O
if	O
rash	O
or	O
other	O
signs	O
of	O
local	O
skin	O
reaction	O
occur.	O
(5.8)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
NSAIDs,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAIDs	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
NSAIDs	O
such	O
as	O
diclofenac,	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
.Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)]	O
.	O
5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAIDs	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
possible	O
duration.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
diclofenac	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
5.3	O
Hepatic	O
Effects	O
Elevations	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
diclofenac	O
sodium.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy.	O
Borderline	O
elevations	O
(i.e.	O
less	O
than	O
3	O
times	O
the	O
ULN	O
[ULN	O
=	O
the	O
upper	O
limit	O
of	O
normal	O
range])	O
or	O
greater	O
elevations	O
of	O
transaminases	O
occurred	O
in	O
about	O
15%	O
of	O
diclofenac-treated	O
patients.	O
Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	O
injury.In	O
clinical	O
trials,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(GOT)	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment.	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
for	O
2-6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
patients	O
and	O
included	O
marked	O
elevations	O
(i.e.,	O
more	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3-8	O
times	O
the	O
ULN),	O
and	O
marked	O
(>8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.Physicians	O
should	O
measure	O
transaminases	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
should	O
be	O
discontinued	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
physicians	O
should	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
“flu-like”	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
patients	O
should	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Caution	O
should	O
be	O
exercised	O
in	O
prescribing	O
diclofenac	O
sodium	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
cardiovascular	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
not	O
recommended	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
diclofenac	O
sodium	O
topical	O
gel	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
gel.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)]..	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations,	O
and	O
the	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
not	O
be	O
applied	O
to	O
open	O
skin	O
wounds,	O
infections,	O
inflammations,	O
or	O
exfoliative	O
dermatitis,	O
as	O
it	O
may	O
affect	O
absorption	O
and	O
tolerability	O
of	O
the	O
drug.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
not	O
be	O
allowed	O
to	O
come	O
into	O
contact	O
with	O
the	O
eyes	O
or	O
with	O
mucous	O
membranes.The	O
effect	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
under	O
occlusive	O
dressings	O
has	O
not	O
been	O
evaluated,	O
and	O
should	O
be	O
avoided.	O
5.9	O
Pregnancy	B-D011247
As	O
with	O
other	O
NSAIDs,	O
diclofenac	O
sodium	O
topical	O
gel	O
should	O
be	O
avoided	O
in	O
late	O
pregnancy,	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
5.10	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.12	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoeisis.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration,	O
and	O
reversible.	O
Patients	B-D010361
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alteration	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants	O
should	O
be	O
carefully	O
monitored.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
non-steroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
diclofenac	O
sodium	O
topical	O
gel	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
areas	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light	O
induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
with	O
eyes	O
and	O
mucosa,	O
although	O
not	O
studied,	O
should	O
be	O
avoided.	O
Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
eye	O
contact	O
occurs,	O
they	O
should	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
diclofenac	O
sodium	O
topical	O
gel	O
should	O
be	O
discontinued.	O
6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
greater	O
than	O
placebo)	O
are	O
application	O
site	O
reactions,	O
including	O
dermatitis.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sand	B-D000080463
oz	O
Inc.	O
at	O
1-800-398-5876	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.During	O
clinical	O
development,	O
913	O
patients	O
were	O
exposed	O
to	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
randomized,	O
double-blind,	O
multicenter,	O
vehicle-controlled,	O
parallel-group	O
studies	O
in	O
osteoarthritis	O
of	O
the	O
superficial	O
joints	O
of	O
the	O
extremities.	O
Of	O
these,	O
513	O
patients	O
received	O
diclofenac	O
sodium	O
topical	O
gel	O
for	O
osteoarthritis	O
of	O
the	O
knee	O
and	O
400	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
the	O
hand.	O
Additionally,	O
583	O
patients	O
were	O
exposed	O
to	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
an	O
uncontrolled,	O
open-label,	O
long-term	O
safety	O
trial	O
in	O
osteoarthritis	O
of	O
the	O
knee.	O
Of	O
these,	O
355	O
patients	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
1	O
knee	O
and	O
228	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
both	O
knees.	O
Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
safety	O
trial.	O
Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel:	O
Non-serious	O
adverse	O
reactions	O
that	O
were	O
reported	O
during	O
the	O
short-term	O
placebo-controlled	O
studies	O
comparing	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
placebo	O
(vehicle	O
gel)	O
over	O
study	O
periods	O
of	O
8	O
to	O
12	O
weeks	O
(16	O
g	O
per	O
day),	O
were	O
application	O
site	O
reactions.	O
These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>1%	O
of	O
treated	O
patients	O
with	O
a	O
greater	O
frequency	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
gel	O
group	O
(7%)	O
than	O
the	O
placebo	O
group	O
(2%).	O
Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported.	O
Application	O
site	O
dermatitis	O
was	O
the	O
most	O
frequent	O
type	O
of	O
application	O
site	O
reaction	O
and	O
was	O
reported	O
by	O
4%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
compared	O
to	O
1%	O
of	O
placebo	O
patients.	O
Table	O
1:	O
Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
Patients	B-D010361
)	O
–	O
Short-term	O
Controlled	O
Trials	O
Adverse	O
Reaction†	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
N=913	O
Placebo	O
(vehicle)	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
dermatitis	O
32	O
(4)	O
6	O
(<1)	O
Application	O
site	O
pruritus	O
7	O
(<1)	O
1	O
(<1)	O
Application	O
site	O
erythema	O
6	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
paresthesia	O
5	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
dryness	O
4	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
vesicles	O
3	O
(<1)	O
0	O
Application	O
site	O
irritation	O
2	O
(<1)	O
0	O
Application	O
site	O
papules	O
1	O
(<1)	O
0	O
†	O
Preferred	O
Term	O
according	O
to	O
MedDRA	O
9.1.	O
In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
and	O
3%	O
for	O
patients	O
in	O
the	O
placebo	O
group.	O
Application	O
site	O
reactions,	O
including	O
application	O
site	O
dermatitis,	O
were	O
the	O
most	O
frequent	O
reason	O
for	O
treatment	O
discontinuation.	O
Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
safety	O
study,	O
distribution	O
of	O
adverse	O
reactions	O
was	O
similar	O
to	O
that	O
in	O
the	O
placebo-controlled	O
studies.	O
In	O
this	O
study,	O
where	O
patients	O
were	O
treated	O
for	O
up	O
to	O
1	O
year	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
up	O
to	O
32	O
g	O
per	O
day,	O
application	O
site	O
dermatitis	O
was	O
observed	O
in	O
11%	O
of	O
patients.	O
Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
patients.	O
The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
dermatitis,	O
which	O
was	O
experienced	O
by	O
6%	O
of	O
patients.	O
Cardiovascular	O
Thrombotic	O
Events	O
•Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
•Etodolac	O
extended-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
A	O
total	O
of	O
1552	O
patients	O
were	O
exposed	O
to	O
etodolac	O
extended-release	O
tablets	O
in	O
controlled	O
clinical	O
studies	O
of	O
at	O
least	O
4	O
weeks	O
in	O
length	O
and	O
using	O
daily	O
doses	O
in	O
the	O
range	O
of	O
400	O
to	O
1200	O
mg.	O
In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
incidence	O
of	O
events	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	O
extended-release	O
tablets.	O
As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
time	O
with	O
extended	O
therapy.	O
In	O
patients	O
taking	O
NSAIDs,	O
including	O
etodolac	O
extended-release	O
tablets,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain	O
constipation	O
diarrhea	O
dyspepsia	O
flatulence	O
GI	O
ulcers	O
(gastric/duodenal)*	O
gross	O
bleeding/perforation*	O
nausea	O
vomiting	O
other	O
events	O
including:	O
abnormal	O
renal	O
function*	O
anemia*	O
asthenia	O
dizziness	O
edema*	O
elevated	O
liver	O
enzymes*	O
headaches	O
hypertension	O
increased	O
bleeding	O
time*	O
infection	O
pharyngitis	O
pruritus	O
rashes	O
rhinitis	O
tinnitus*	O
*	O
Adverse	O
events	O
that	O
were	O
observed	O
in	O
<	O
1%	O
of	O
patients	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	O
extended-release	O
tablets	O
in	O
clinical	O
trials.	O
Additional	O
NSAID	O
Adverse	O
Experiences	O
Reported	O
Occasionally	O
with	O
NSAIDs	O
or	O
Etodolac	B-D017308
Extended-Release	O
Tablets	B-D013607
Include	O
Body	O
as	O
a	O
whole	O
-	O
allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock),	O
chills,	O
fever,	O
sepsis	O
Cardiovascular	O
system	O
-	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
tachycardia,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic)	O
Digestive	O
system	O
-	O
anorexia,	O
cholestatic	O
hepatitis,	O
cholestatic	O
jaundice,	O
dry	O
mouth,	O
duodenitis,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastric/peptic	O
ulcers,	O
glossitis,	O
hepatic	O
failure,	O
hepatitis,	O
hematemesis,	O
intestinal	O
ulceration,	O
jaundice,	O
liver	O
necrosis,	O
melena,	O
pancreatitis,	O
rectal	O
bleeding,	O
stomatitis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
agranulocytosis,	O
ecchymosis,	O
eosinophilia,	O
hemolytic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia,	O
purpura,	O
thrombocytopenia	O
Metabolic	O
and	O
nutritional	O
-	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients	O
Nervous	O
system	O
-	O
anxiety,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
insomnia,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
asthma,	O
dyspnea,	O
pulmonary	O
infiltration	O
with	O
eosinophilia	O
Skin	B-D012867
and	O
appendages	O
-	O
angioedema,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
erythema	O
multiforme,	O
hyperpigmentation,	O
sweating,	O
urticaria,	O
vesiculobullous	O
rash	O
Special	O
senses	O
-	O
blurred	O
vision,	O
photophobia,	O
transient	O
visual	O
disturbances	O
Urogenital	O
system	O
-	O
dysuria,	O
elevated	O
BUN,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis,	O
serum	O
creatinine	O
increase,	O
urinary	O
frequency	O
Other	O
NSAID	O
Adverse	O
Reactions,	O
Which	O
Occur	O
Rarely	O
Are	O
Body	O
as	O
a	O
whole	O
-	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	O
system	O
-	O
arrhythmia,	O
cerebrovascular	O
accident,	O
hypotension,	O
myocardial	O
infarction	O
Digestive	O
system	O
-	O
colitis,	O
esophagitis	O
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
thirst,	O
ulcerative	O
stomatitis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
aplastic	O
anemia,	O
lymphadenopathy	O
Metabolic	O
and	O
nutritional	O
-	O
change	O
in	O
weight	O
Nervous	O
system	O
-	O
coma,	O
convulsions,	O
hallucinations,	O
meningitis	O
Respiratory	O
-	O
bronchitis,	O
pneumonia,	O
respiratory	O
depression,	O
sinusitis	O
Skin	B-D012867
and	O
appendages	O
-	O
alopecia,	O
exfoliative	O
dermatitis,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrosis	O
Special	O
senses	O
-	O
conjunctivitis,	O
deafness,	O
hearing	O
impairment,	O
taste	O
perversion	O
Urogenital	O
system	O
-	O
cystitis,	O
hematuria,	O
interstitial	O
nephritis,	O
leukorrhea,	O
renal	O
calculus,	O
uterine	O
bleeding	O
irregularities	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(5.4)	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.4)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(5.1,	O
14.6,	O
17.2).	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
(5.4,	O
8.5,	O
14.6,	O
17.3).	O
Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
celecoxib	O
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen	O
(5.5,	O
17.4).	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
celecoxib	O
(5.2,	O
7.4,	O
17.2).	O
Fluid	O
retention	O
and	O
edema.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure	O
(5.3,	O
17.6).	O
Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
celecoxib	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6).	O
Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
celecoxib	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(5.7,	O
10,	O
17.7).	O
Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions	O
(5.8,	O
17.5).	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
celecoxib,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
celecoxib	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
celecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
active	O
GI	O
bleeding.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
celecoxib	O
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
celecoxib	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
celecoxib.	O
In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
celecoxib.	O
Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
celecoxib	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Greenstone	O
LLC	O
Professional	O
Information	B-D007255
Services	I-D007255
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General	O
:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional	O
:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia,	O
Psychiatric	O
:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders	O
:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary	O
:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular	O
:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal	O
:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic	O
:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous	O
:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS,	O
or	O
hypersensitivity	O
syndrome)	O
General	O
:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events	O
:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kgN=77	O
Celecoxib	B-D000068579
6	O
mg/kgN=82	O
Naproxen	B-D009288
7.5	O
mg/kgN=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
InvestigationsAbnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials	O
,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)N	O
=	O
2285	O
PlaceboN=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders	O
:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth	O
:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders	O
:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders	O
:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)].	O
•	O
VOLTAREN®	O
GEL	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1).	O
•	O
VOLTAREN®	O
GEL	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
•	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
•	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
VOLTAREN®	O
GEL	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
•	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
VOLTAREN®	O
GEL	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
•	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
•	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
VOLTAREN®	O
GEL	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
•	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
VOLTAREN®	O
GEL	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
•	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation.	O
(5.10,	O
8.1)	O
•	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
VOLTAREN®	O
GEL	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
VOLTAREN®	O
GEL	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
•Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
•Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
•Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
•Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
•If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
VOLTAREN®	O
GEL	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
•In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials,	O
of	O
oral	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
sodium	O
for	O
2-6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3-8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),VOLTAREN®	O
GEL	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
VOLTAREN®	O
GEL	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
VOLTAREN®	O
GEL,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
VOLTAREN®	O
GEL	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
VOLTAREN®	O
GEL,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	O
interactions	O
(	O
7)].	O
Avoid	O
the	O
use	O
of	O
VOLTAREN®	O
GEL	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
VOLTAREN®	O
GEL	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
VOLTAREN®	O
GEL	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
VOLTAREN®	O
GEL	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
VOLTAREN®	O
GEL.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
VOLTAREN®	O
GEL	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)].	O
Avoid	O
the	O
use	O
of	O
VOLTAREN®	O
GEL	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
VOLTAREN®	O
GEL	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactoid	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
VOLTAREN®	O
GEL	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
VOLTAREN®	O
GEL	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
VOLTAREN®	O
GEL	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
VOLTAREN®	O
GEL	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(	O
4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
VOLTAREN®	O
GEL,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(	O
8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
VOLTAREN®	O
GEL	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
VOLTAREN®	O
GEL,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
VOLTAREN®	O
GEL	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2,	O
5.3,	O
5.6)].	O
5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
areas	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light	O
induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
VOLTAREN®	O
GEL	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
VOLTAREN®	O
GEL	O
with	O
eyes	O
and	O
mucosa,	O
although	O
not	O
studied,	O
should	O
be	O
avoided.	O
Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
eye	O
contact	O
occurs,	O
they	O
should	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Do	O
not	O
use	O
combination	O
therapy	O
with	O
VOLTAREN®	O
GEL	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
•Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
•Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
•Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
•Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
•Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
patients	O
treated	O
with	O
VOLTAREN®	O
GEL	O
and	O
greater	O
than	O
placebo)	O
are	O
application	O
site	O
reactions,	O
including	O
dermatitis.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sand	B-D000080463
oz	O
Inc.	O
at	O
1-800-525-8747	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
During	O
clinical	O
development,	O
913	O
patients	O
were	O
exposed	O
to	O
VOLTAREN®	O
GEL	O
in	O
randomized,	O
double-blind,	O
multicenter,	O
vehicle-controlled,	O
parallel-group	O
studies	O
in	O
osteoarthritis	O
of	O
the	O
superficial	O
joints	O
of	O
the	O
extremities.	O
Of	O
these,	O
513	O
patients	O
received	O
VOLTAREN®	O
GEL	O
for	O
osteoarthritis	O
of	O
the	O
knee	O
and	O
400	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
the	O
hand.	O
Additionally,	O
583	O
patients	O
were	O
exposed	O
to	O
VOLTAREN®	O
GEL	O
in	O
an	O
uncontrolled,	O
open-label,	O
long-term	O
safety	O
trial	O
in	O
osteoarthritis	O
of	O
the	O
knee.	O
Of	O
these,	O
355	O
patients	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
1	O
knee	O
and	O
228	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
both	O
knees.	O
Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
safety	O
trial.	O
Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
patients	O
treated	O
with	O
VOLTAREN®	O
GEL:	O
Non-serious	O
adverse	O
reactions	O
that	O
were	O
reported	O
during	O
the	O
short-term	O
placebo-controlled	O
studies	O
comparing	O
VOLTAREN®	O
GEL	O
and	O
placebo	O
(vehicle	O
gel)	O
over	O
study	O
periods	O
of	O
8	O
to	O
12	O
weeks	O
(16	O
g	O
per	O
day),	O
were	O
application	O
site	O
reactions.	O
These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>1%	O
of	O
treated	O
patients	O
with	O
a	O
greater	O
frequency	O
in	O
the	O
VOLTAREN®	O
GEL	O
group	O
(7%)	O
than	O
the	O
placebo	O
group	O
(2%).	O
Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported.	O
Application	O
site	O
dermatitis	O
was	O
the	O
most	O
frequent	O
type	O
of	O
application	O
site	O
reaction	O
and	O
was	O
reported	O
by	O
4%	O
of	O
patients	O
treated	O
with	O
VOLTAREN®	O
GEL,	O
compared	O
to	O
1%	O
of	O
placebo	O
patients.	O
Table	O
1:	O
Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
VOLTAREN®	O
GEL	O
Patients	B-D010361
)	O
–	O
Short-term	O
Controlled	O
Trials	O
Adverse	O
Reaction†	O
VOLTAREN®	O
GEL	O
N=913	O
Placebo	O
(vehicle)	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
dermatitis	O
32	O
(4)	O
6	O
(<1)	O
Application	O
site	O
pruritus	O
7	O
(<1)	O
1	O
(<1)	O
Application	O
site	O
erythema	O
6	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
paresthesia	O
5	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
dryness	O
4	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
vesicles	O
3	O
(<1)	O
0	O
Application	O
site	O
irritation	O
2	O
(<1)	O
0	O
Application	O
site	O
papules	O
1	O
(<1)	O
0	O
†	O
Preferred	O
Term	O
according	O
to	O
MedDRA	O
9.1.	O
In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
patients	O
treated	O
with	O
VOLTAREN®	O
GEL,	O
and	O
3%	O
for	O
patients	O
in	O
the	O
placebo	O
group.	O
Application	O
site	O
reactions,	O
including	O
application	O
site	O
dermatitis,	O
were	O
the	O
most	O
frequent	O
reason	O
for	O
treatment	O
discontinuation.	O
Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
safety	O
study,	O
distribution	O
of	O
adverse	O
reactions	O
was	O
similar	O
to	O
that	O
in	O
the	O
placebo-controlled	O
studies.	O
In	O
this	O
study,	O
where	O
patients	O
were	O
treated	O
for	O
up	O
to	O
1	O
year	O
with	O
VOLTAREN®	O
GEL	O
up	O
to	O
32	O
g	O
per	O
day,	O
application	O
site	O
dermatitis	O
was	O
observed	O
in	O
11%	O
of	O
patients.	O
Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
patients.	O
The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
dermatitis,	O
which	O
was	O
experienced	O
by	O
6%	O
of	O
patients.	O
CARDIOVASCULAR	O
RISK	O
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS.)	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
GASTROINTESTINAL	O
RISK	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%–10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/	O
perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-	O
Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
thrombocyte	O
aggregation	O
(5.1)	O
Delayed	O
healing	O
(5.2)	O
Cornea	B-D003315
l	O
effects	O
including	O
keratitis	O
(5.3)	O
5.1	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
With	O
some	O
NSAIDS	O
including	O
ILEVRO*	O
0.3%,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
thrombocyte	O
aggregation.	O
There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
tissues	O
(including	O
hyphema)	O
in	O
conjunction	O
with	O
ocular	O
surgery.	O
It	O
is	O
recommended	O
that	O
ILEVRO*	O
0.3%	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
known	O
bleeding	O
tendencies	O
or	O
who	O
are	O
receiving	O
other	O
medications	O
which	O
may	O
prolong	O
bleeding	O
time.	O
5.2	O
Delayed	O
Healing	O
Topical	O
NSAIDs	O
including	O
ILEVRO*	O
0.3%,	O
may	O
slow	O
or	O
delay	O
healing.	O
Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing.	O
Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
steroids	O
may	O
increase	O
the	O
potential	O
for	O
healing	O
problems.	O
5.3	O
Cornea	B-D003315
l	O
Effects	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
keratitis.	O
In	O
some	O
susceptible	O
patients,	O
continued	O
use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
epithelial	O
breakdown,	O
corneal	O
thinning,	O
corneal	O
erosion,	O
corneal	O
ulceration,	O
or	O
corneal	O
perforation.	O
These	O
events	O
may	O
be	O
sight	O
threatening.	O
Patients	B-D010361
with	O
evidence	O
of	O
corneal	O
epithelial	O
breakdown	O
should	O
immediately	O
discontinue	O
use	O
of	O
topical	O
NSAIDs	O
including	O
ILEVRO*	O
0.3%	O
and	O
should	O
be	O
closely	O
monitored	O
for	O
corneal	O
health.	O
Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
patients	O
with	O
complicated	O
ocular	O
surgeries,	O
corneal	O
denervation,	O
corneal	O
epithelial	O
defects,	O
diabetes	O
mellitus,	O
ocular	O
surface	O
diseases	O
(e.g.,	O
dry	O
eye	O
syndrome),	O
rheumatoid	O
arthritis,	O
or	O
repeat	O
ocular	O
surgeries	O
within	O
a	O
short	O
period	O
of	O
time	O
may	O
be	O
at	O
increased	O
risk	O
for	O
corneal	O
adverse	O
events,	O
which	O
may	O
become	O
sight	O
threatening.	O
Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients.	O
Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
1	O
day	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
post-surgery	O
may	O
increase	O
patient	O
risk	O
and	O
severity	O
of	O
corneal	O
adverse	O
events.	O
5.4	O
Contact	O
Lens	O
Wear	O
ILEVRO*	O
0.3%	O
should	O
not	O
be	O
administered	O
while	O
using	O
contact	O
lenses.	O
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
the	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Most	O
common	O
adverse	O
reactions	O
(5%	O
to	O
10%)	O
are	O
capsular	O
opacity,	O
decreased	O
visual	O
acuity,	O
foreign	O
body	O
sensation,	O
increased	O
intraocular	O
pressure,	O
and	O
sticky	O
sensation.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Alcon	O
Laboratories	B-D007753
,	O
Inc.	O
at	O
1-800-757-9195	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Serious	O
and	O
Otherwise	O
Important	O
Adverse	O
Reactions	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
labeling.	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Delayed	O
Healing	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Cornea	B-D003315
l	O
Effects	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
6.2	O
Ocular	O
Adverse	O
Reactions	O
The	O
most	O
frequently	O
reported	O
ocular	O
adverse	O
reactions	O
following	O
cataract	O
surgery	O
were	O
capsular	O
opacity,	O
decreased	O
visual	O
acuity,	O
foreign	O
body	O
sensation,	O
increased	O
intraocular	O
pressure	O
(IOP),	O
and	O
sticky	O
sensation.	O
These	O
reactions	O
occurred	O
in	O
approximately	O
5%	O
to	O
10%	O
of	O
patients.	O
Other	O
ocular	O
adverse	O
reactions	O
occurring	O
at	O
an	O
incidence	O
of	O
approximately	O
1%	O
to	O
5%	O
included	O
conjunctival	O
edema,	O
corneal	O
edema,	O
dry	O
eye,	O
lid	O
margin	O
crusting,	O
ocular	O
discomfort,	O
ocular	O
hyperemia,	O
ocular	O
pain,	O
ocular	O
pruritus,	O
photophobia,	O
tearing,	O
and	O
vitreous	O
detachment.	O
Some	O
of	O
these	O
reactions	O
may	O
be	O
the	O
consequence	O
of	O
the	O
cataract	O
surgical	O
procedure.	O
6.3	O
Non-Ocular	O
Adverse	O
Reactions	O
Non-ocular	O
adverse	O
reactions	O
reported	O
at	O
an	O
incidence	O
of	O
1%	O
to	O
4%	O
included	O
headache,	O
hypertension,	O
nausea/vomiting,	O
and	O
sinusitis.	O
BOXED	O
WARNING	O
image	O
description	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
extended-release	O
tablets,	O
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure.	O
Other	O
adverse	O
reactions	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment.	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
·	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
·	O
Ibuprofen	B-D007052
Tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	O
tablets	O
is	O
gastrointestinal.	O
In	O
controlled	O
clinical	O
trials	O
the	O
percentage	O
of	O
patients	O
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%.	O
In	O
controlled	O
studies	O
when	O
ibuprofen	O
tablets	O
were	O
compared	O
to	O
aspirin	O
and	O
indomethacin	O
in	O
equally	O
effective	O
doses,	O
the	O
overall	O
incidence	O
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin	O
or	O
indomethacin-treated	O
patients.	O
Adverse	O
reactions	O
observed	O
during	O
controlled	O
clinical	O
trials	O
at	O
an	O
incidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table.	O
Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	O
in	O
approximately	O
3,000	O
patients.	O
More	O
than	O
500	O
of	O
these	O
patients	O
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks.	O
Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	O
clinical	O
trials	O
and	O
from	O
marketing	O
experience.	O
These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	O
tablets	O
where	O
the	O
probability	O
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	O
tablets	O
has	O
not	O
been	O
established.	O
Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	O
trials	O
of	O
patients	O
with	O
rheumatoid	O
arthritis.	O
The	O
increases	O
in	O
incidence	O
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table.	O
Incidence	B-D015994
Greater	O
than	O
1%(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea	B-D009325
*,	O
epigastric	O
pain*,	O
heartburn*,	O
diarrhea,	O
abdominal	O
distress,	O
nausea	O
and	O
vomiting,	O
indigestion,	O
constipation,	O
abdominal	O
cramps	O
or	O
pain,	O
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	O
Gastric	O
or	O
duodenal	O
ulcer	O
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	O
hemorrhage,	O
melena,	O
gastritis,	O
hepatitis,	O
jaundice,	O
abnormal	O
liver	O
function	O
tests;	O
pancreatitis	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
Dizziness	B-D004244
*,	O
headache,	O
nervousness	O
Depression	B-D003863
,	O
insomnia,	O
confusion,	O
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	O
with	O
fever	O
and	O
coma	O
(see	O
PRECAUTIONS)	O
Paresthesia	B-D010292
s,	O
hallucinations,	O
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	O
DERMATOLOGIC	O
Rash*,	O
(including	O
maculopapular	O
type),	O
pruritus	O
Vesiculobullous	O
eruptions,	O
urticaria,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome,	O
alopecia	O
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	O
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D006309
loss,	O
amblyopia	O
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	O
and	O
/or	O
changes	O
in	O
color	O
vision)	O
(see	O
PRECAUTIONS)	O
Conjunctivitis	B-D003231
,	O
diplopia,	O
optic	O
neuritis,	O
cataracts	O
HEMATOLOGIC	O
Neutropenia	B-D009503
,	O
agranulocytosis,	O
aplastic	O
anemia,	O
hemolytic	O
anemia	O
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	O
with	O
or	O
without	O
purpura,	O
eosinophilia,	O
decreases	O
in	O
hemoglobin	O
and	O
hematocrit	O
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	O
menorrhagia)	O
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	O
Gynecomastia	B-D006177
,	O
hypoglycemic	O
reaction,	O
acidosis	O
CARDIOVASCULAR	O
Edema	B-D004487
,	O
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	O
failure	O
in	O
patients	O
with	O
marginal	O
cardiac	O
function,	O
elevate	O
blood	O
pressure,	O
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	O
sinus	O
bradycardia)	O
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	O
pain,	O
fever,	O
chills,	O
nausea	O
and	O
vomiting;	O
anaphylaxis;	O
bronchospasm	O
(see	O
CONTRAINDICATIONS)	O
Serum	B-D044967
sickness,	O
lupus	O
erythematosus	O
syndrome.	O
Henoch-Schonlein	O
vasculitis,	O
angioedema	O
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	O
clearance,	O
poliuria,	O
azotemia,	O
cystitis,	O
hematuria	O
Renal	O
papillary	O
necrosis	O
MISCELLANEOUS	O
Dry	O
eyes	O
and	O
mouth,	O
gingival	O
ulcer,	O
rhinitis	O
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
ibuprofen.	O
(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked).	O
**Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related.	O
Reactions	O
are	O
classified	O
under	O
“CausalRelationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
adverse	O
reactions	O
are	O
drowsiness	O
and	O
dizziness.	O
Less	O
frequent	O
adverse	O
reactions	O
are	O
lightheadedness	O
and	O
gastrointestinal	O
disturbances	O
including	O
nausea,	O
vomiting,	O
and	O
flatulence.	O
A	O
single	O
incidence	O
of	O
bone	O
marrow	O
suppression	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
and	O
caffeine.	O
Several	O
cases	O
of	O
dermatological	O
reactions	O
including	O
toxic	O
epidermal	O
necrolysis	O
and	O
erythema	O
multiforme	O
have	O
been	O
reported.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages	O
:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses	O
:	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
FULL	O
PRESCRIBING	O
INFORMATION	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
•	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4	O
)and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
WARNING:	O
RISK	O
OF	O
SERIOUSCARDIOVASCULAR	O
AND	O
GASTROINTESTINALEVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(5.1)	O
•	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
•Hypertension:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
•Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
•Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
•Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
•Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
gel	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
•Premature	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation.	O
(5.10,	O
8.1)	O
•Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
•Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
•Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
•Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
•Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
•If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	O
sodium	O
topical	O
gel	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
•In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials,	O
of	O
oral	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
sodium	O
for	O
2	O
to	O
6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
topical	O
gel	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
topical	O
gel	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
topical	O
gel	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edem	O
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	O
interactions	O
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
diclofenac	O
sodium	O
topical	O
gel.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactoid	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[seeContraindications	O
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
areas	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light	O
induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
with	O
eyes	O
and	O
mucosa,	O
although	O
not	O
studied,	O
should	O
be	O
avoided.	O
Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
eye	O
contact	O
occurs,	O
they	O
should	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
•Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
•Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
•Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
•Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
•Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
greater	O
than	O
placebo)	O
are	O
application	O
site	O
reactions,	O
including	O
dermatitis.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Amneal	O
Pharmaceuticals	O
at	O
1-877-835-5472	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
During	O
clinical	O
development,	O
913	O
patients	O
were	O
exposed	O
to	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
randomized,	O
double-blind,	O
multicenter,	O
vehicle-controlled,	O
parallel-group	O
studies	O
in	O
osteoarthritis	O
of	O
the	O
superficial	O
joints	O
of	O
the	O
extremities.	O
Of	O
these,	O
513	O
patients	O
received	O
diclofenac	O
sodium	O
topical	O
gel	O
for	O
osteoarthritis	O
of	O
the	O
knee	O
and	O
400	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
the	O
hand.	O
Additionally,	O
583	O
patients	O
were	O
exposed	O
to	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
an	O
uncontrolled,	O
open-label,	O
long-term	O
safety	O
trial	O
in	O
osteoarthritis	O
of	O
the	O
knee.	O
Of	O
these,	O
355	O
patients	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
1	O
knee	O
and	O
228	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
both	O
knees.	O
Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
safety	O
trial.	O
Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel:	O
Non-serious	O
adverse	O
reactions	O
that	O
were	O
reported	O
during	O
the	O
short-term	O
placebo-controlled	O
studies	O
comparing	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
placebo	O
(vehicle	O
gel)	O
over	O
study	O
periods	O
of	O
8	O
to	O
12	O
weeks	O
(16	O
g	O
per	O
day),	O
were	O
application	O
site	O
reactions.	O
These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
1%	O
of	O
treated	O
patients	O
with	O
a	O
greater	O
frequency	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
gel	O
group	O
(7%)	O
than	O
the	O
placebo	O
group	O
(2%).	O
Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported.	O
Application	O
site	O
dermatitis	O
was	O
the	O
most	O
frequent	O
type	O
of	O
application	O
site	O
reaction	O
and	O
was	O
reported	O
by	O
4%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
compared	O
to	O
1%	O
of	O
placebo	O
patients.	O
Adverse	O
Reaction	O
†	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
N=913	O
Placebo	O
(vehicle)	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
dermatitis	O
32	O
(4)	O
6	O
(˂1)	O
Application	O
site	O
pruritus	O
7	O
(˂1)	O
1	O
(˂1)	O
Application	O
site	O
erythema	O
6	O
(˂1)	O
3	O
(˂1)	O
Application	O
site	O
paresthesia	O
5	O
(˂1)	O
3	O
(˂1)	O
Application	O
site	O
dryness	O
4	O
(˂1)	O
3	O
(˂1)	O
Application	O
site	O
vesicles	O
3	O
(˂1)	O
0	O
Application	O
site	O
irritation	O
2	O
(˂1)	O
0	O
Application	O
site	O
papules	O
1	O
(˂1)	O
0	O
†Preferred	O
Term	O
according	O
to	O
MedDRA	O
9.1	O
In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
and	O
3%	O
for	O
patients	O
in	O
the	O
placebo	O
group.	O
Application	O
site	O
reactions,	O
including	O
application	O
site	O
dermatitis,	O
were	O
the	O
most	O
frequent	O
reason	O
for	O
treatment	O
discontinuation.	O
Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
safety	O
study,	O
distribution	O
of	O
adverse	O
reactions	O
was	O
similar	O
to	O
that	O
in	O
the	O
placebo-controlled	O
studies.	O
In	O
this	O
study,	O
where	O
patients	O
were	O
treated	O
for	O
up	O
to	O
1	O
year	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
up	O
to	O
32	O
g	O
per	O
day,	O
application	O
site	O
dermatitis	O
was	O
observed	O
in	O
11%	O
of	O
patients.	O
Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
patients.	O
The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
dermatitis,	O
which	O
was	O
experienced	O
by	O
6%	O
of	O
patients.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
D	O
iclofenac	O
sodium	O
topical	O
solution	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
Exposure	O
to	O
light:	O
Avoid	O
exposure	O
of	O
treated	O
knee(s)	O
to	O
natural	O
or	O
artificial	O
sunlight.	O
(5.14)	O
Eye	B-D005123
Contact:	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
(5.15)	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs:	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs.	O
(5.16)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
diclofenac	O
sodium	O
topical	O
solution	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2	O
%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials,	O
of	O
oral	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
for	O
2	O
to	O
6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
topical	O
solution	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver-related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
antibiotics,	O
antiepileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension,	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
diclofenac	O
sodium	O
topical	O
solution	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
diclofenac	O
sodium	O
topical	O
solution.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
diclofenac	O
sodium	O
topical	O
solution	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
diclofenac	O
sodium	O
topical	O
solution	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
diclofenac	O
sodium	O
topical	O
solution	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
Do	O
not	O
apply	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
open	O
skin	O
wounds,	O
infections,	O
inflammations,	O
or	O
exfoliative	O
dermatitis,	O
as	O
it	O
may	O
affect	O
absorption	O
and	O
tolerability	O
of	O
the	O
drug.	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
The	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	O
subjects	O
administered	O
80	O
drops	O
four	O
times	O
a	O
day	O
for	O
7	O
days.	O
There	O
was	O
no	O
significant	O
change	O
in	O
platelet	O
aggregation	O
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
5.14	O
Sun	O
Exposure	O
Instruct	O
patients	O
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
knee(s)	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light-induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	O
and	O
conduct	O
periodic	O
laboratory	O
evaluations.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
are	O
application	O
site	O
reactions.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Amneal	O
Pharmaceuticals	O
at	O
1-877-835-5472	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution	O
of	O
911	O
patients	O
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	O
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	O
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	O
treated	O
for	O
at	O
least	O
12	O
months.	O
The	O
population	O
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	O
were	O
Caucasians,	O
64%	O
were	O
females,	O
and	O
all	O
patients	O
had	O
primary	O
osteoarthritis.	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies.	O
Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
Application	O
site	O
reactions	O
were	O
characterized	O
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	O
induration,	O
vesicles,	O
paresthesia,	O
pruritus,	O
vasodilation,	O
acne,	O
and	O
urticaria.	O
The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	O
(32%),	O
contact	O
dermatitis	O
characterized	O
by	O
skin	O
erythema	O
and	O
induration	O
(9%),	O
contact	O
dermatitis	O
with	O
vesicles	O
(2%)	O
and	O
pruritus	O
(4%).	O
In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	O
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac.	O
In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	O
study,	O
contact	O
dermatitis	O
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	O
with	O
vesicles	O
in	O
10%	O
of	O
patients,	O
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	O
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%.	O
Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
flatulence,	O
abdominal	O
pain,	O
edema;	O
see	O
Table	O
1).	O
The	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac,	O
compared	O
to	O
oral	O
diclofenac	O
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	O
(3%	O
vs.	O
less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	O
(12%	O
vs.	O
7%),	O
urea	O
(20%	O
vs.	O
12%),	O
and	O
hemoglobin	O
(13%	O
vs.	O
9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	O
transaminases.	O
Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
osteoarthritis.	O
Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	O
trials.	O
Treatment	O
Group:	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
N=911	O
Topical	O
Placebo	O
N=332	O
Adverse	O
Reaction†	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
†Preferred	O
Term	O
according	O
to	O
COSTART	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-U.S.	O
postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
Whole:	O
abdominal	O
pain,	O
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	O
back	O
pain,	O
body	O
odor,	O
chest	O
pain,	O
edema,	O
face	O
edema,	O
halitosis,	O
headache,	O
lack	O
of	O
drug	O
effect,	O
neck	O
rigidity,	O
pain	O
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	O
dry	O
mouth,	O
dyspepsia,	O
gastroenteritis,	O
decreased	O
appetite,	O
mouth	O
ulceration,	O
nausea,	O
rectal	O
hemorrhage,	O
ulcerative	O
stomatitis	O
Metabolic	O
and	O
Nutritional:	O
creatinine	O
increased	O
Musculoskeletal:	O
leg	O
cramps,	O
myalgia	O
Nervous:	O
depression,	O
dizziness,	O
drowsiness,	O
lethargy,	O
paresthesia,	O
paresthesia	O
at	O
application	O
site	O
Respiratory:	O
asthma,	O
dyspnea,	O
laryngismus,	O
laryngitis,	O
pharyngitis	O
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
Adverse	O
Reactions:	O
contact	O
dermatitis,	O
contact	O
dermatitis	O
with	O
vesicles,	O
dry	O
skin,	O
pruritus,	O
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
eczema,	O
rash,	O
pruritus,	O
skin	O
discoloration,	O
urticaria	O
Special	O
Senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	O
ear	O
pain,	O
eye	O
disorder,	O
eye	O
pain,	O
taste	O
perversion	O
Cardiovascular	O
Thrombotic	O
Events	O
1.Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
•Etodolac	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
capsules	O
and	O
tablets	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1,000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
or	O
Equal	O
to	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain*,	O
diarrhea*,	O
flatulence*,	O
nausea*,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise*,	O
dizziness*,	O
depression,	O
nervousness,	O
fatigue.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
Musculoskeletal	O
-	O
Arthralgia	B-D018771
.	O
*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
fatal	O
fulminant	O
hepatitis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
–	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis,leukocytoclastic	O
vasculitis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.	O
Musculoskeletal	O
-	O
Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
–	O
Sepsis	B-D018805
,	O
death.	O
Cardiovascular	O
system	O
–	O
Tachycardia	B-D013610
.	O
Digestive	O
system	O
–	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis.	O
Hemic	O
and	O
lymphatic	O
system	O
–	O
Lymphadenopathy	B-D000072281
.	O
Nervous	O
system	O
–	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo.	O
Respiratory	O
system	O
–	O
Respiratory	O
depression,	O
pneumonia.	O
Urogenital	O
system	O
–	O
Oliguria	B-D009846
/polyuria,	O
proteinuria.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS	O
.)	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/	O
polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
Diflunisal	B-D004061
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
adverse	O
reactions	O
observed	O
in	O
controlled	O
clinical	O
trials	O
encompass	O
observations	O
in	O
2,427	O
patients.	O
Listed	O
below	O
are	O
the	O
adverse	O
reactions	O
reported	O
in	O
the	O
1,314	O
of	O
these	O
patients	O
who	O
received	O
treatment	O
in	O
studies	O
of	O
two	O
weeks	O
or	O
longer.	O
Five	O
hundred	O
thirteen	O
patients	O
were	O
treated	O
for	O
at	O
least	O
24	O
weeks,	O
255	O
patients	O
were	O
treated	O
for	O
at	O
least	O
48	O
weeks,	O
and	O
46	O
patients	O
were	O
treated	O
for	O
96	O
weeks.	O
In	O
general,	O
the	O
adverse	O
reactions	O
listed	O
below	O
were	O
2	O
to	O
14	O
times	O
less	O
frequent	O
in	O
the	O
1,113	O
patients	O
who	O
received	O
short-term	O
treatment	O
for	O
mild	O
to	O
moderate	O
pain.	O
Incidence	B-D015994
Greater	O
Than	O
1%	O
Gastrointestinal	O
The	O
most	O
frequent	O
types	O
of	O
adverse	O
reactions	O
occurring	O
with	O
diflunisal	O
are	O
gastrointestinal:	O
these	O
include	O
nausea*,	O
vomiting,	O
dyspepsia*,	O
gastrointestinal	O
pain*,	O
diarrhea*,	O
constipation,	O
and	O
flatulence.	O
Psychiatric	O
Somnolence,	O
insomnia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Dizziness	B-D004244
.	O
Special	O
Senses	O
Tinnitus	B-D014012
.	O
Dermatologic	O
Rash*.	O
Miscellaneous	O
Headache	B-D006261
*,	O
fatigue/tiredness.	O
*	O
Incidence	B-D015994
between	O
3%	O
and	O
9%.	O
Those	O
reactions	O
occurring	O
in	O
1%	O
to	O
3%	O
are	O
not	O
marked	O
with	O
an	O
asterisk.	O
Incidence	B-D015994
Less	O
Than	O
1	O
in	O
100	O
The	O
following	O
adverse	O
reactions,	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100,	O
were	O
reported	O
in	O
clinical	O
trials	O
or	O
since	O
the	O
drug	O
was	O
marketed.	O
The	O
probability	O
exists	O
of	O
a	O
causal	O
relationship	O
between	O
diflunisal	O
and	O
these	O
adverse	O
reactions.	O
Dermatologic	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis,	O
urticaria,	O
pruritus,	O
sweating,	O
dry	O
mucous	O
membranes,	O
stomatitis,	O
photosensitivity.	O
Gastrointestinal	O
Peptic	O
ulcer,	O
gastrointestinal	O
bleeding,	O
anorexia,	O
eructation,	O
gastrointestinal	O
perforation,	O
gastritis.	O
Liver	B-D008099
function	O
abnormalities;	O
jaundice,	O
sometimes	O
with	O
fever;	O
cholestasis;	O
hepatitis.	O
Hematologic	O
Thrombocytopenia	B-D013921
;	O
agranulocytosis;	O
hemolytic	O
anemia.	O
Genitourinary	O
Dysuria	B-D053159
;	O
renal	O
impairment,	O
including	O
renal	O
failure;	O
interstitial	O
nephritis;	O
hematuria;	O
proteinuria.	O
Psychiatric	O
Nervousness,	O
depression,	O
hallucinations,	O
confusion,	O
disorientation.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Vertigo	B-D014717
;	O
light-headedness;	O
paresthesias.	O
Special	O
Senses	O
Transient	O
visual	O
disturbances	O
including	O
blurred	O
vision.	O
Hypersensitivity	B-D006967
Reactions	O
Acute	O
anaphylactic	O
reaction	O
with	O
bronchospasm;	O
angioedema;	O
flushing.	O
Hypersensitivity	B-D006967
vasculitis.	O
Hypersensitivity	B-D006967
syndrome	O
(see	O
PRECAUTIONS).	O
Miscellaneous	O
Asthenia	B-D001247
,	O
edema.	O
Causal	O
Relationship	O
Unknown	O
Other	O
reactions	O
have	O
been	O
reported	O
in	O
clinical	O
trials	O
or	O
since	O
the	O
drug	O
was	O
marketed,	O
but	O
occurred	O
under	O
circumstances	O
where	O
a	O
causal	O
relationship	O
could	O
not	O
be	O
established.	O
However,	O
in	O
these	O
rarely	O
reported	O
events,	O
that	O
possibility	O
cannot	O
be	O
excluded.	O
Therefore,	O
these	O
observations	O
are	O
listed	O
to	O
serve	O
as	O
alerting	O
information	O
to	O
physicians.	O
Respiratory	O
Dyspnea	B-D004417
.	O
Cardiovascular	O
Palpitation,	O
syncope.	O
Musculoskeletal	O
Muscle	O
cramps.	O
Genitourinary	O
Nephrotic	O
syndrome.	O
Special	O
Senses	O
Hearing	B-D006309
loss.	O
Miscellaneous	O
Chest	O
pain.	O
A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
fasciitis,	O
particularly	O
in	O
association	O
with	O
Group	O
A	O
β-hemolytic	O
streptococcus,	O
has	O
been	O
described	O
in	O
persons	O
treated	O
with	O
non-steroidal	O
anti-inflammatory	O
agents,	O
including	O
diflunisal,	O
sometimes	O
with	O
fatal	O
outcome	O
(see	O
also	O
PRECAUTIONS,	O
General).	O
Potential	O
Adverse	O
Effects	O
In	O
addition,	O
a	O
variety	O
of	O
adverse	O
effects	O
not	O
observed	O
with	O
diflunisal	O
in	O
clinical	O
trials	O
or	O
in	O
marketing	O
experience,	O
but	O
reported	O
with	O
other	O
non-steroidal	O
analgesic/anti-inflammatory	O
agents	O
should	O
be	O
considered	O
potential	O
adverse	O
effects	O
of	O
diflunisal.	O
Cardiovascular	O
Risk	B-D012306
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS].	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	O
and	O
WARNINGS].	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
[see	O
WARNINGS].	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
fever,	O
infection,	O
sepsis	O
C	O
ardiovascular	O
System	O
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses	O
:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages	O
:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses	O
:	O
conjunctivitis,	O
hearing	O
impairment	O
BOXED	O
WARNING	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS).	O
Etodolac	B-D017308
capsules	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain*,	O
diarrhea*,	O
flatulence*,	O
nausea*,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise*,	O
dizziness*,	O
depression,	O
nervousness.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
*Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death	O
Cardiovascular	O
system	O
-	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis	O
Hemic	O
and	O
lymphatic	O
system	O
–	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
Cardiovascular	O
Risk	B-D012306
•	O
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS).	O
Indomethacin	B-D007213
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
adverse	O
reactions	O
for	O
indomethacin	O
capsules	O
listed	O
in	O
the	O
following	O
table	O
have	O
been	O
arranged	O
into	O
two	O
groups:	O
(1)	O
incidence	O
greater	O
than	O
1%;	O
and	O
(2)	O
incidence	O
less	O
than	O
1%.	O
The	O
incidence	O
for	O
group	O
(1)	O
was	O
obtained	O
from	O
33	O
double-blind	O
controlled	O
clinical	O
trials	O
reported	O
in	O
the	O
literature	O
(1,092	O
patients).	O
The	O
incidence	O
for	O
group	O
(2)	O
was	O
based	O
on	O
reports	O
in	O
clinical	O
trials,	O
in	O
the	O
literature,	O
and	O
on	O
voluntary	O
reports	O
since	O
marketing.	O
The	O
probability	O
of	O
a	O
causal	O
relationship	O
exists	O
between	O
indomethacin	O
and	O
these	O
adverse	O
reactions,	O
some	O
of	O
which	O
have	O
been	O
reported	O
only	O
rarely.	O
Incidence	B-D015994
greater	O
than	O
1%	O
GASTROINTESTINAL	O
nausea*	O
with	O
or	O
without	O
vomitingdyspepsia*	O
(including	O
indigestion,	O
heartburn	O
and	O
epigastric	O
pain)diarrheaabdominal	O
distress	O
or	O
painconstipation	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
headache	O
(11.7%)dizziness*vertigosomnolencedepression	O
and	O
fatigue	O
(including	O
malaise	O
and	O
listlessness)	O
SPECIAL	O
SENSES	O
tinnitus	O
CARDIOVASCULAR	O
none	O
METABOLIC	O
none	O
INTEGUMENTARY	O
none	O
HEMATOLOGIC	O
none	O
HYPERSENSITIVITY	O
none	O
GENITOURINARY	O
none	O
MISCELLANEOUS	O
none	O
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
indomethacin.	O
(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.)	O
Incidence	B-D015994
less	O
than	O
1%	O
GASTROINTESTINAL	O
anorexiabloating	O
(includes	O
distention)flatulencepeptic	O
ulcergastroenteritisrectal	O
bleedingproctitissingle	O
or	O
multiple	O
ulcerations,	O
including	O
perforation	O
and	O
hemorrhage	O
of	O
the	O
esophagus,	O
stomach,	O
duodenum	O
or	O
small	O
and	O
large	O
intestinesintestinal	O
ulceration	O
associated	O
with	O
stenosis	O
and	O
obstructiongastrointestinal	O
bleeding	O
without	O
obvious	O
ulcer	O
formation	O
and	O
perforation	O
of	O
preexisting	O
sigmoid	O
lesions	O
(diverticulum,	O
carcinoma,	O
etc.)	O
development	O
of	O
ulcerative	O
colitis	O
and	O
regional	O
ileitisulcerative	O
stomatitistoxic	O
hepatitis	O
and	O
jaundice	O
(some	O
fatal	O
cases	O
have	O
been	O
reported)intestinal	O
strictures	O
(diaphragms)	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
anxiety	O
(includes	O
nervousness)muscle	O
weaknessinvoluntary	O
muscle	O
movementsinsomniamuzzinesspsychic	O
disturbances	O
including	O
psychotic	O
episodesmental	O
confusiondrowsinesslight-headednesssyncopeparesthesiaaggravation	O
of	O
epilepsy	O
and	O
parkinsonismdepersonalizationcomaperipheral	O
neuropathyconvulsionsdysarthria	O
SPECIAL	O
SENSES	O
ocular-corneal	O
deposits	O
and	O
retinal	O
disturbances,	O
including	O
those	O
of	O
the	O
macula,	O
have	O
been	O
reported	O
in	O
some	O
patients	O
on	O
prolonged	O
therapy	O
with	O
indomethacinblurred	O
visiondiplopiahearing	O
disturbances,	O
deafness	O
CARDIOVASCULAR	O
congestive	O
heart	O
failurehypertensionhypotensiontachycardiachest	O
painarrhythmia;	O
palpitations	O
METABOLIC	O
edemaweight	O
gainfluid	O
retentionflushing	O
or	O
sweatinghyperglycemiaglycosuriahyperkalemia	O
INTEGUMENTARY	O
pruritusrash;	O
urticariapetechiae	O
or	O
ecchymosisexfoliative	O
dermatitiserythema	O
nodosumloss	O
of	O
hairStevens-Johnson	O
Syndrome	B-D013577
erythema	O
multiformetoxic	O
epidermal	O
necrolysis	O
HEMATOLOGIC	O
leukopeniabone	O
marrow	O
depressionanemia	O
secondary	O
to	O
obvious	O
or	O
occult	O
gastrointestinal	O
bleedingaplastic	O
anemiahemolytic	O
anemiaagranulocytosisthrombocytopenic	O
purpuradisseminated	O
intravascular	O
coagulation	O
HYPERSENSITIVITY	O
acute	O
anaphylaxisacute	O
respiratory	O
distressrapid	O
fall	O
in	O
blood	O
pressure	O
resembling	O
a	O
shock-like	O
stateangioedemadyspneaasthmapurpuraangiitispulmonary	O
edemafever	O
GENITOURINARY	O
hematuriavaginal	O
bleedingproteinuria,	O
nephrotic	O
syndrome,	O
interstitial	O
nephritisBUN	O
elevationrenal	O
insufficiency,	O
including	O
renal	O
failure	O
MISCELLANEOUS	O
epistaxisbreast	O
changes,	O
including	O
enlargement	O
and	O
tenderness,	O
or	O
gynecomastia	O
Causal	O
Relationship	O
Unknown	O
Other	O
reactions	O
have	O
been	O
reported	O
but	O
occurred	O
under	O
circumstances	O
where	O
a	O
causal	O
relationship	O
could	O
not	O
be	O
established.	O
However,	O
in	O
these	O
rarely	O
reported	O
events,	O
the	O
possibility	O
cannot	O
be	O
excluded.	O
Therefore,	O
these	O
observations	O
are	O
being	O
listed	O
to	O
serve	O
as	O
alerting	O
information	O
to	O
physicians:	O
Cardiovascular:	O
thrombophlebitis	O
Hematologic:	O
Although	O
there	O
have	O
been	O
several	O
reports	O
of	O
leukemia,	O
the	O
supporting	O
information	O
is	O
weak.	O
Genitourinary:	O
urinary	O
frequency	O
A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
fasciitis,	O
particularly	O
in	O
association	O
with	O
Group	O
A	O
β-hemolytic	O
streptococcus,	O
has	O
been	O
described	O
in	O
persons	O
treated	O
with	O
non-steroidal	O
anti-inflammatory	O
agents,	O
including	O
indomethacin,	O
sometimes	O
with	O
fatal	O
outcome	O
(see	O
also	O
PRECAUTIONS:	O
General).	O
BOXED	O
WARNING	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(See	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(See	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
As	O
A	O
Whole:fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
And	O
Lymphatic	B-D008208
System	I-D008208
:ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
And	O
Nutritional:weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:asthma,	O
dyspnea	O
Skin	B-D012867
And	O
Appendages:alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
As	O
A	O
Whole:anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
And	O
Lymphatic	B-D008208
System	I-D008208
:agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
And	O
Nutritional:hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
And	O
Appendages:angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.(5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity	O
:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity	O
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions	O
:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
:	O
Celecoxib	B-D000068579
capsules	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions	O
:	O
Discontinue	O
celecoxib	O
capsules	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity	O
:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	O
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
for	O
the	O
celecoxib	O
capsules	O
400mg	O
twice	O
daily	O
and	O
celecoxib	O
capsules	O
200	O
mg	O
twice	O
daily	O
treatment	O
arms	O
compared	O
to	O
placebo.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.7)].	O
A	O
randomized	O
controlled	O
trial	O
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs.	O
Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	O
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	O
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	O
and	O
ibuprofen.	O
Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	O
375	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	O
600	O
to	O
800	O
mg	O
three	O
times	O
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists'	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	O
(including	O
hemorrhagic	O
death),	O
non-fatal	O
myocardial	O
infarction,	O
and	O
non-fatal	O
stroke	O
[See	O
Clinical	O
Studies	O
(14.6)].	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
celecoxib	O
capsules.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	O
anticoagulants;	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.7)].	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	O
capsules	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib	O
capsules,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
capsules	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
capsules	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
discontinue	O
celecoxib	O
capsules	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	O
capsules	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
blood	O
pressure	O
data	O
for	O
celecoxib	O
capsules.	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
celecoxib	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
capsules	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE	O
inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
celecoxib	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
celecoxib	O
capsules.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
celecoxib	O
capsules	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
celecoxib	O
and	O
in	O
patients	O
with	O
aspirin	O
sensitive	O
asthma.	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	O
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	O
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib	O
capsules,	O
including	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(AGEP).	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	O
capsules	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Celecoxib	B-D000068579
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
celecoxib	O
capsules	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
capsules	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
capsules	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	O
SSRIs	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
capsules	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation	O
with	O
use	O
of	O
celecoxib	O
capsules	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	O
and	O
their	O
caregivers	O
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible.	O
6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Cipla	O
Ltd,	O
at	O
1-866-604-3268	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labelling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
capsules	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
capsules	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
capsules	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Celecoxib	B-D000068579
=	O
Celecoxib	B-D000068579
capsules	O
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Celecoxib	B-D000068579
(N=4146)	O
Placebo	O
(N=1864)	O
NAP	O
(N=1366)	O
DCF	O
(N=387)	O
IBU	O
(N=345)	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
capsules	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
capsules	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1%	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
Capsules	B-D002214
(100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
Allergy	O
General:	O
Hypersensitivity	B-D006967
,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional:	O
blood	O
urea	O
nitrogen	O
(BUN)	O
increased,	O
creatine	O
phosphokinase	O
(CPK)	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis	O
ileus	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
,	O
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia	B-D001259
,	O
suicide	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)	O
]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.7)]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
capsules	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
capsules	O
was	O
maintained	O
with	O
or	O
without	O
aspirin	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
twice	O
daily.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
$	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
*Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
capsules	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
capsules	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
capsules	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
capsules	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.7)].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
capsules	O
pre-marketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
capsules	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
Capsules	B-D002214
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib	O
capsules,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
celecoxib	O
capsules.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis	B-D014657
,	O
deep	O
venous	O
thrombosis	O
General:	O
Anaphylactoid	O
reaction,	O
angioedema	O
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	O
hepatitis,	O
jaundice,	O
hepatic	O
failure	O
Hemic	O
and	O
lymphatic	O
Agranulocytosis	B-D000380
,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
Renal	O
Interstitial	O
nephritis	O
Cardiovascular	O
Thrombotic	O
Events	O
•Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
].	O
•Diclofenac	O
sodium	O
delayed-release	O
tablets	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
and	O
Warnings	O
].	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
Diclofenac	B-D004008
Sodium	B-D012964
Delayed-Release	O
Tablets	B-D013607
,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Rising	O
Pharmaceuticals,	O
Inc.	O
at	O
1-866-562-4597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
ADVERSE	O
REACTIONS:	O
The	O
most	O
frequent	O
adverse	O
reactions	O
are	O
drowsiness	O
and	O
dizziness.	O
Less	O
frequent	O
adverse	O
reactions	O
are	O
lightheadedness	O
and	O
gastrointestinal	O
disturbances	O
including	O
nausea,	O
vomiting,	O
and	O
flatulence.	O
Men	B-D008571
tal	O
confusion	O
or	O
depression	O
can	O
occur	O
due	O
to	O
intolerance	O
or	O
overdosage	O
of	O
butalbital	B-C004470
.	O
Several	O
cases	O
of	O
dermatological	O
reactions	O
including	O
toxic	O
epidermal	O
necrolysis	O
and	O
erythema	O
multiforme	O
have	O
been	O
reported.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
potassium	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
718	O
patients	O
treated	O
for	O
shorter	O
periods,	O
i.e.,	O
2	O
weeks	O
or	O
less,	O
with	O
diclofenac	O
tablets,	O
adverse	O
reactions	O
were	O
reported	O
one-half	O
to	O
one-tenth	O
as	O
frequently	O
as	O
by	O
patients	O
treated	O
for	O
longer	O
periods.	O
In	O
a	O
6	O
month,	O
double-blind	O
trial	O
comparing	O
diclofenac	O
potassium	O
tablets	O
(N	O
=	O
196)	O
versus	O
diclofenac	O
sodium	O
delayed-release	O
tablets	O
(N	O
=	O
197)	O
versus	O
ibuprofen	O
(N	O
=	O
197),	O
adverse	O
reactions	O
were	O
similar	O
in	O
nature	O
and	O
frequency.	O
In	O
patients	O
taking	O
diclofenac	O
potassium	O
tablets	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
(GI)	O
events.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
celecoxib.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3–6	O
months,	O
and	O
in	O
about	O
2%–4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants;	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
celecoxib	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
celecoxib	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
celecoxib	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
celecoxib.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
celecoxib	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoadosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
celecoxib	O
and	O
in	O
patients	O
with	O
aspirin	O
sensitive	O
asthma.	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	O
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	O
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib,	O
including	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(AGEP).	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
celecoxib	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs,	O
including	O
celecoxib,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
].	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation	O
with	O
use	O
of	O
celecoxib	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	O
and	O
their	O
caregivers	O
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible.	O
6.	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General	O
:	O
Hypersensitivity	B-D006967
,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional	O
:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia,	O
Psychiatric	O
:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders	O
:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary	O
:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	O
Cardiovascular	O
:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis	O
Gastrointestinal	O
:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death	O
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic	O
:	O
Thrombocytopenia	B-D013921
Nervous	O
:	O
Ataxia	B-D001259
,	O
suicide	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
aspirin	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
twice	O
daily.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kgN=77	O
Celecoxib	B-D000068579
6	O
mg/kgN=82	O
Naproxen	B-D009288
7.5	O
mg/kgN=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
InvestigationsAbnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials	O
,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)N	O
=	O
2285	O
PlaceboN=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders	O
:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth	O
:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders	O
:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders	O
:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
celecoxib.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular	O
:	O
Vasculitis	B-D014657
,	O
deep	O
venous	O
thrombosis	O
General:	O
Anaphylactoid	O
reaction,	O
angioedema	O
Liver	B-D008099
and	O
biliary	O
:	O
Liver	B-D008099
necrosis,	O
hepatitis,	O
jaundice,	O
hepatic	O
failure	O
Hemic	O
and	O
lymphatic:	O
Agranulocytosis	B-D000380
,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous	O
:	O
Aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
Renal	O
:	O
Interstitial	O
nephritis	O
Cardiovascular	O
Risk	B-D012306
NSAIDs1	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS.)	O
Etodolac	B-D017308
extended-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(See	O
WARNINGS.)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS.)	O
1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug.	O
ADVERSE	O
REACTIONS	O
A	O
total	O
of	O
1552	O
patients	O
were	O
exposed	O
to	O
etodolac	O
extended-release	O
tablets	O
in	O
controlled	O
clinical	O
studies	O
of	O
at	O
least	O
4	O
weeks	O
in	O
length	O
and	O
using	O
daily	O
doses	O
in	O
the	O
range	O
of	O
400	O
to	O
1200	O
mg.	O
In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
incidence	O
of	O
events	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	O
extended-release	O
tablets.	O
As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
time	O
with	O
extended	O
therapy.	O
In	O
patients	O
taking	O
NSAIDs,	O
including	O
etodolac	O
extended-release	O
tablets,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain	O
constipation	O
diarrhea	O
dyspepsia	O
flatulence	O
GI	O
ulcers	O
(gastric/duodenal)*	O
gross	O
bleeding/perforation*	O
nausea	O
vomiting	O
other	O
events	O
including:	O
abnormal	O
renal	O
function*	O
anemia*	O
asthenia	O
dizziness	O
edema*	O
elevated	O
liver	O
enzymes*	O
headaches	O
hypertension	O
increased	O
bleeding	O
time*	O
infection	O
pharyngitis	O
pruritus	O
rashes	O
rhinitis	O
tinnitus*	O
*	O
Adverse	O
events	O
that	O
were	O
observed	O
in	O
<	O
1%	O
of	O
patients	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	O
extended-release	O
tablets	O
in	O
clinical	O
trials.	O
Additional	O
NSAID	O
Adverse	O
Experiences	O
Reported	O
Occasionally	O
with	O
NSAIDs	O
or	O
Etodolac	B-D017308
Extended-Release	O
Tablets	B-D013607
Include	O
Body	O
as	O
a	O
whole	O
-	O
allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock),	O
chills,	O
fever,	O
sepsis	O
Cardiovascular	O
system	O
-	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
tachycardia,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic)	O
Digestive	O
system	O
-	O
anorexia,	O
cholestatic	O
hepatitis,	O
cholestatic	O
jaundice,	O
dry	O
mouth,	O
duodenitis,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastric/peptic	O
ulcers,	O
glossitis,	O
hepatic	O
failure,	O
hepatitis,	O
hematemesis,	O
intestinal	O
ulceration,	O
jaundice,	O
liver	O
necrosis,	O
melena,	O
pancreatitis,	O
rectal	O
bleeding,	O
stomatitis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
agranulocytosis,	O
ecchymosis,	O
eosinophilia,	O
hemolytic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia,	O
purpura,	O
thrombocytopenia	O
Metabolic	O
and	O
nutritional	O
-	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients	O
Nervous	O
system	O
-	O
anxiety,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
insomnia,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
asthma,	O
dyspnea,	O
pulmonary	O
infiltration	O
with	O
eosinophilia	O
Skin	B-D012867
and	O
appendages	O
-	O
angioedema,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
erythema	O
multiforme,	O
hyperpigmentation,	O
sweating,	O
urticaria,	O
vesiculobullous	O
rash	O
Special	O
senses	O
-	O
blurred	O
vision,	O
photophobia,	O
transient	O
visual	O
disturbances	O
Urogenital	O
system	O
-	O
dysuria,	O
elevated	O
BUN,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis,	O
serum	O
creatinine	O
increase,	O
urinary	O
frequency	O
Other	O
NSAID	O
Adverse	O
Reactions,	O
Which	O
Occur	O
Rarely	O
Are	O
Body	O
as	O
a	O
whole	O
-	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	O
system	O
-	O
arrhythmia,	O
cerebrovascular	O
accident,	O
hypotension,	O
myocardial	O
infarction	O
Digestive	O
system	O
-	O
colitis,	O
esophagitis	O
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
thirst,	O
ulcerative	O
stomatitis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
aplastic	O
anemia,	O
lymphadenopathy	O
Metabolic	O
and	O
nutritional	O
-	O
change	O
in	O
weight	O
Nervous	O
system	O
-	O
coma,	O
convulsions,	O
hallucinations,	O
meningitis	O
Respiratory	O
-	O
bronchitis,	O
pneumonia,	O
respiratory	O
depression,	O
sinusitis	O
Skin	B-D012867
and	O
appendages	O
-	O
alopecia,	O
exfoliative	O
dermatitis,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrosis	O
Special	O
senses	O
-	O
conjunctivitis,	O
deafness,	O
hearing	O
impairment,	O
taste	O
perversion	O
Urogenital	O
system	O
-	O
cystitis,	O
hematuria,	O
interstitial	O
nephritis,	O
leukorrhea,	O
renal	O
calculus,	O
uterine	O
bleeding	O
irregularities	O
ADVERSE	O
REACTIONS	O
Serious	O
adverse	O
reactions	O
that	O
may	O
be	O
associated	O
with	O
ENDODAN	O
tablet	O
use	O
include	O
respiratory	O
depression,	O
apnea,	O
respiratory	O
arrest,	O
circulatory	O
depression,	O
hypotension,	O
and	O
shock	O
(see	O
OVERDOSAGE).	O
The	O
most	O
frequently	O
observed	O
non-serious	O
adverse	O
reactions	O
include	O
lightheadedness,	O
dizziness,	O
drowsiness	O
or	O
sedation,	O
nausea,	O
and	O
vomiting.	O
These	O
effects	O
seem	O
to	O
be	O
more	O
prominent	O
in	O
ambulatory	O
than	O
in	O
nonambulatory	O
patients,	O
and	O
some	O
of	O
these	O
adverse	O
reactions	O
may	O
be	O
alleviated	O
if	O
the	O
patient	O
lies	O
down.	O
Other	O
adverse	O
reactions	O
include	O
euphoria,	O
dysphoria,	O
constipation	O
and	O
pruritus.	O
Aspirin	B-D001241
may	O
increase	O
the	O
likelihood	O
of	O
hemorrhage	O
due	O
to	O
its	O
effect	O
on	O
the	O
gastric	O
mucosa	O
and	O
platelet	O
function.	O
Furthermore,	O
aspirin	O
has	O
the	O
potential	O
to	O
cause	O
anaphylaxis	O
in	O
hypersensitive	O
patients	O
as	O
well	O
as	O
angioedema	O
especially	O
in	O
patients	O
with	O
chronic	O
urticaria.	O
Other	O
adverse	O
reactions	O
due	O
to	O
aspirin	O
use	O
include	O
anorexia,	O
reversible	O
hepatotoxicity,	O
leukopenia,	O
thrombocytopenia,	O
purpura,	O
decreased	O
plasma	O
iron	O
concentration,	O
and	O
shortened	O
erythrocyte	O
survival	O
time.	O
Other	O
adverse	O
reactions	O
obtained	O
from	O
postmarketing	O
experiences	O
with	O
ENDODAN	O
tablets	O
are	O
listed	O
by	O
organ	O
system	O
and	O
in	O
decreasing	O
order	O
of	O
severity	O
and/or	O
frequency	O
as	O
follows:	O
Body	O
as	O
a	O
Whole	O
allergic	O
reaction,	O
malaise,	O
asthenia,	O
headache,	O
anaphylaxis,	O
fever,	O
hypothermia,	O
thirst,	O
increased	O
sweating,	O
accident,	O
accidental	O
overdose,	O
non-accidental	O
overdose.	O
Cardiovascular	O
tachycardia,	O
dysrhythmias,	O
hypotension,	O
orthostatic	O
hypotension,	O
bradycardia,	O
palpitations	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
stupor,	O
paresthesia,	O
agitation,	O
cerebral	O
edema,	O
coma,	O
confusion,	O
dizziness,	O
headache,	O
subdural	O
or	O
intracranial	O
hemorrhage,	O
lethargy,	O
seizures,	O
anxiety,	O
mental	O
impairment	O
Fluid	O
and	O
Electrolyte	O
dehydration,	O
hyperkalemia,	O
metabolic	O
acidosis,	O
respiratory	O
alkalosis	O
Gastrointestinal	O
hemorrhagic	O
gastric/duodenal	O
ulcer,	O
gastric/peptic	O
ulcer,	O
dyspepsia,	O
abdominal	O
pain,	O
diarrhea,	O
eructation,	O
dry	O
mouth,	O
gastrointestinal	O
bleeding,	O
intestinal	O
perforation,	O
nausea,	O
vomiting,	O
transient	O
elevations	O
of	O
hepatic	O
enzymes,	O
hepatitis,	O
Reye	O
syndrome,	O
pancreatitis,	O
intestinal	O
obstruction,	O
ileus	O
Hearing	B-D006309
and	O
Vestibular	O
hearing	O
loss,	O
tinnitus.	O
Patients	B-D010361
with	O
high	O
frequency	O
loss	O
may	O
have	O
difficulty	O
perceiving	O
tinnitus.	O
In	O
these	O
patients,	O
tinnitus	O
cannot	O
be	O
used	O
as	O
a	O
clinical	O
indicator	O
of	O
salicylism.	O
Hematologic	O
unspecified	O
hemorrhage,	O
purpura,	O
reticulocytosis,	O
prolongation	O
of	O
prothrombin	O
time,	O
disseminated	O
intravascular	O
coagulation,	O
ecchymosis,	O
thrombocytopenia.	O
Hypersensitivity	B-D006967
acute	O
anaphylaxis,	O
angioedema,	O
asthma,	O
bronchospasm,	O
laryngeal	O
edema,	O
urticaria,	O
anaphylactoid	O
reaction	O
Metabolic	O
and	O
Nutritional	O
hypoglycemia,	O
hyperglycemia,	O
acidosis,	O
alkalosis	O
Musculoskeletal	O
rhabdomyolysis	O
Ocular	O
miosis,	O
visual	O
disturbances,	O
red	O
eye.	O
Psychiatric	O
drug	O
dependence,	O
drug	O
abuse,	O
somnolence,	O
depression,	O
nervousness,	O
hallucination	O
Reproductive	O
prolonged	O
pregnancy	O
and	O
labor,	O
stillbirths,	O
lower	O
birth	O
weight	O
infants,	O
antepartum	O
and	O
postpartum	O
bleeding,	O
closure	O
of	O
patent	O
ductus	O
arteriosis	O
Respiratory	B-D012137
System	I-D012137
bronchospasm,	O
dyspnea,	O
hyperpnea,	O
pulmonary	O
edema,	O
tachypnea,	O
aspiration,	O
hypoventilation,	O
laryngeal	O
edema	O
Skin	B-D012867
and	O
Appendages	O
urticaria,	O
rash,	O
flushing	O
Urogenital	O
interstitial	O
nephritis,	O
papillary	O
necrosis,	O
proteinuria,	O
renal	O
insufficiency	O
and	O
failure,	O
urinary	O
retention	O
Cardiovascular	O
Risk	B-D012306
•NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS	O
).	O
•Diclofenac	O
Sodium	B-D012964
Extended-release	O
Tablets	B-D013607
,	O
USP	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
extended-release	O
tablets,	O
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure.	O
Other	O
adverse	O
reactions	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment.	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
Etodolac	B-D017308
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
a	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1,000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain*,	O
diarrhea*,	O
flatulence*,	O
nausea*,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise*,	O
dizziness*,	O
depression,	O
nervousness.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death	O
Cardiovascular	O
system	O
-	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk..	O
(See	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
extended-release	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
inflammation,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(See	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
extended-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
As	O
A	O
Whole:fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
And	O
Lymphatic	B-D008208
System	I-D008208
:ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
And	O
Nutritional:weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:asthma,	O
dyspnea	O
Skin	B-D012867
And	O
Appendages:alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
As	O
A	O
Whole:anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
And	O
Lymphatic	B-D008208
System	I-D008208
:agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
And	O
Nutritional:hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
And	O
Appendages:angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:conjunctivitis,	O
hearing	O
impairment	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS	O
].	O
Ibuprofen	B-D007052
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	O
and	O
WARNINGS	O
].	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
WARNINGS	O
].	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	O
tablets	O
is	O
gastrointestinal.	O
In	O
controlled	O
clinical	O
trials	O
the	O
percentage	O
of	O
patients	O
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%.	O
In	O
controlled	O
studies	O
when	O
ibuprofen	O
tablets	O
were	O
compared	O
to	O
aspirin	O
and	O
indomethacin	O
in	O
equally	O
effective	O
doses,	O
the	O
overall	O
incidence	O
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	O
or	O
indomethacin-treated	O
patients.	O
Adverse	O
reactions	O
observed	O
during	O
controlled	O
clinical	O
trials	O
at	O
an	O
incidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table.	O
Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	O
in	O
approximately	O
3,000	O
patients.	O
More	O
than	O
500	O
of	O
these	O
patients	O
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks.	O
Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	O
clinical	O
trials	O
and	O
from	O
marketing	O
experience.	O
These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	O
tablets	O
where	O
the	O
probability	O
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	O
tablets	O
has	O
not	O
been	O
established.	O
Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	O
trials	O
of	O
patients	O
with	O
rheumatoid	O
arthritis.	O
The	O
increases	O
in	O
incidence	O
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table.	O
Incidence	B-D015994
Greater	O
Than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
ibuprofen	O
tablets.	O
(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.)	O
**	O
Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related.	O
Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met.	O
GASTROINTESTINAL	O
Nausea	B-D009325
*,	O
epigastric	O
pain*,	O
heartburn*,	O
diarrhea,	O
abdominal	O
distress,	O
nausea	O
and	O
vomiting,	O
indigestion,	O
constipation,	O
abdominal	O
cramps	O
or	O
pain,	O
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	O
Gastric	O
or	O
duodenal	O
ulcer	O
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	O
hemorrhage,	O
melena,	O
gastritis,	O
hepatitis,	O
jaundice,	O
abnormal	O
liver	O
function	O
tests;	O
pancreatitis	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
Dizziness	B-D004244
*,	O
headache,	O
nervousness	O
Depression	B-D003863
,	O
insomnia,	O
confusion,	O
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	O
with	O
fever	O
and	O
coma	O
[see	O
PRECAUTIONS	O
]	O
Paresthesia	B-D010292
s,	O
hallucinations,	O
dream	O
abnormalities,	O
pseudotumor	O
cerebri	O
DERMATOLOGIC	O
Rash*	O
(including	O
maculopapular	O
type),	O
pruritus	O
Vesiculobullous	O
eruptions,	O
urticaria,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome,	O
alopecia	O
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	O
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D006309
loss,	O
amblyopia	O
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	O
and/or	O
changes	O
in	O
color	O
vision)	O
[see	O
PRECAUTIONS	O
]	O
Conjunctivitis	B-D003231
,	O
diplopia,	O
optic	O
neuritis,	O
cataracts	O
HEMATOLOGIC	O
Neutropenia	B-D009503
,	O
agranulocytosis,	O
aplastic	O
anemia,	O
hemolytic	O
anemia	O
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	O
with	O
or	O
without	O
purpura,	O
eosinophilia,	O
decreases	O
in	O
hemoglobin	O
and	O
hematocrit	O
[see	O
PRECAUTIONS	O
]	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	O
menorrhagia)	O
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	O
Gynecomastia	B-D006177
,	O
hypoglycemic	O
reaction,	O
acidosis	O
CARDIOVASCULAR	O
Edema	B-D004487
,	O
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS	O
)	O
Congestive	O
heart	O
failure	O
in	O
patients	O
with	O
marginal	O
cardiac	O
function,	O
elevated	O
blood	O
pressure,	O
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	O
sinus	O
bradycardia)	O
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	O
pain,	O
fever,	O
chills,	O
nausea	O
and	O
vomiting;	O
anaphylaxis;	O
bronchospasm	O
[see	O
CONTRAINDICATIONS	O
]	O
Serum	B-D044967
sickness,	O
lupus	O
erythematosus	O
syndrome.	O
Henoch-Schonlein	O
vasculitis,	O
angioedema	O
RENAL	O
Acute	O
renal	O
failure	O
[see	O
PRECAUTIONS	O
],	O
decreased	O
creatinine	O
clearance,	O
polyuria,	O
azotemia,	O
cystitis,	O
hematuria	O
Renal	O
papillary	O
necrosis	O
MISCELLANEOUS	O
Dry	O
eyes	O
and	O
mouth,	O
gingival	O
ulcer,	O
rhinitis	O
tests	O
Cardiovascular	O
Risk	B-D012306
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
•	O
Diflunisal	B-D004061
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
adverse	O
reactions	O
observed	O
in	O
controlled	O
clinical	O
trials	O
encompass	O
observations	O
in	O
2,427	O
patients.	O
Listed	O
below	O
are	O
the	O
adverse	O
reactions	O
reported	O
in	O
the	O
1,314	O
of	O
these	O
patients	O
who	O
received	O
treatment	O
in	O
studies	O
of	O
two	O
weeks	O
or	O
longer.	O
Five	O
hundred	O
thirteen	O
patients	O
were	O
treated	O
for	O
at	O
least	O
24	O
weeks,	O
255	O
patients	O
were	O
treated	O
for	O
at	O
least	O
48	O
weeks,	O
and	O
46	O
patients	O
were	O
treated	O
for	O
96	O
weeks.	O
In	O
general,	O
the	O
adverse	O
reactions	O
listed	O
below	O
were	O
2	O
to	O
14	O
times	O
less	O
frequent	O
in	O
the	O
1,113	O
patients	O
who	O
received	O
short-term	O
treatment	O
for	O
mild	O
to	O
moderate	O
pain.	O
Incidence	B-D015994
Greater	O
Than	O
1%	O
Gastrointestinal	O
The	O
most	O
frequent	O
types	O
of	O
adverse	O
reactions	O
occurring	O
with	O
diflunisal	O
are	O
gastrointestinal:	O
these	O
include	O
nausea*,	O
vomiting,	O
dyspepsia*,	O
gastrointestinal	O
pain*,	O
diarrhea*,	O
constipation,	O
and	O
flatulence.	O
Psychiatric	O
Somnolence,	O
insomnia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Dizziness	B-D004244
.	O
Special	O
Senses	O
Tinnitus	B-D014012
.	O
Dermatologic	O
Rash*.	O
Miscellaneous	O
Headache	B-D006261
*,	O
fatigue/tiredness.	O
*	O
Incidence	B-D015994
between	O
3%	O
and	O
9%.	O
Those	O
reactions	O
occurring	O
in	O
1%	O
to	O
3%	O
are	O
not	O
marked	O
with	O
an	O
asterisk.	O
Incidence	B-D015994
Less	O
Than	O
1	O
in	O
100	O
The	O
following	O
adverse	O
reactions,	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100,	O
were	O
reported	O
in	O
clinical	O
trials	O
or	O
since	O
the	O
drug	O
was	O
marketed.	O
The	O
probability	O
exists	O
of	O
a	O
causal	O
relationship	O
between	O
diflunisal	O
and	O
these	O
adverse	O
reactions.	O
Dermatologic	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis,	O
urticaria,	O
pruritus,	O
sweating,	O
dry	O
mucous	O
membranes,	O
stomatitis,	O
photosensitivity.	O
Gastrointestinal	O
Peptic	O
ulcer,	O
gastrointestinal	O
bleeding,	O
anorexia,	O
eructation,	O
gastrointestinal	O
perforation,	O
gastritis.	O
Liver	B-D008099
function	O
abnormalities;	O
jaundice,	O
sometimes	O
with	O
fever;	O
cholestasis;	O
hepatitis.	O
Hematologic	O
Thrombocytopenia	B-D013921
;	O
agranulocytosis;	O
hemolytic	O
anemia.	O
Genitourinary	O
Dysuria	B-D053159
;	O
renal	O
impairment,	O
including	O
renal	O
failure;	O
interstitial	O
nephritis;	O
hematuria;	O
proteinuria.	O
Psychiatric	O
Nervousness,	O
depression,	O
hallucinations,	O
confusion,	O
disorientation.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Vertigo	B-D014717
;	O
light-headedness;	O
paresthesias.	O
Special	O
Senses	O
Transient	O
visual	O
disturbances	O
including	O
blurred	O
vision.	O
Hypersensitivity	B-D006967
Reactions	O
Acute	O
anaphylactic	O
reaction	O
with	O
bronchospasm;	O
angioedema;	O
flushing.	O
Hypersensitivity	B-D006967
vasculitis.	O
Hypersensitivity	B-D006967
syndrome	O
(see	O
PRECAUTIONS).	O
Miscellaneous	O
Asthenia	B-D001247
,	O
edema.	O
Causal	O
Relationship	O
Unknown	O
Other	O
reactions	O
have	O
been	O
reported	O
in	O
clinical	O
trials	O
or	O
since	O
the	O
drug	O
was	O
marketed,	O
but	O
occurred	O
under	O
circumstances	O
where	O
a	O
causal	O
relationship	O
could	O
not	O
be	O
established.	O
However,	O
in	O
these	O
rarely	O
reported	O
events,	O
that	O
possibility	O
cannot	O
be	O
excluded.	O
Therefore,	O
these	O
observations	O
are	O
listed	O
to	O
serve	O
as	O
alerting	O
information	O
to	O
physicians.	O
Respiratory	O
Dyspnea	B-D004417
.	O
Cardiovascular	O
Palpitation,	O
syncope.	O
Musculoskeletal	O
Muscle	O
cramps.	O
Genitourinary	O
Nephrotic	O
syndrome.	O
Special	O
Senses	O
Hearing	B-D006309
loss.	O
Miscellaneous	O
Chest	O
pain.	O
A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
fasciitis,	O
particularly	O
in	O
association	O
with	O
Group	O
A	O
β-hemolytic	O
streptococcus,	O
has	O
been	O
described	O
in	O
persons	O
treated	O
with	O
non-steroidal	O
anti-inflammatory	O
agents,	O
including	O
diflunisal,	O
sometimes	O
with	O
fatal	O
outcome	O
(see	O
also	O
PRECAUTIONS,	O
General).	O
Potential	O
Adverse	O
Effects	O
In	O
addition,	O
a	O
variety	O
of	O
adverse	O
effects	O
not	O
observed	O
with	O
diflunisal	O
in	O
clinical	O
trials	O
or	O
in	O
marketing	O
experience,	O
but	O
reported	O
with	O
other	O
non-steroidal	O
analgesic/anti-inflammatory	O
agents	O
should	O
be	O
considered	O
potential	O
adverse	O
effects	O
of	O
diflunisal.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages	O
:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses	O
:	O
conjunctivitis,	O
hearing	O
impairment	O
BOXED	O
WARNING	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(See	O
WARNINGS	O
).	O
Etodolac	B-D017308
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(See	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
a	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain*,	O
diarrhea*,	O
flatulence*,	O
nausea*,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise*,	O
dizziness*,	O
depression,	O
nervousness.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death	O
Cardiovascular	O
system	O
-	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
Cardiovascular	O
Risk	B-D012306
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
.	O
•	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)]	O
.	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
.	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Cardiovascular	O
Risk	B-D012306
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
(5.1)	O
•	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
Gastrointestinal	O
Risk	B-D012306
(4,	O
5.1)	O
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs),	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
The	O
lowest	O
possible	O
dose	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
should	O
be	O
used	O
in	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
(5.1)	O
•NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
be	O
prescribed	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
(5.2)	O
•Elevation	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
diclofenac.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
be	O
discontinued	O
immediately	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen.	O
(5.3)	O
•Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
at	O
greatest	O
risk	O
of	O
this	O
reaction,	O
including	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors.	O
(5.6)	O
•Hypertension	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
gel.	O
(5.4)	O
•Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
(5.5)	O
•Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
or	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
should	O
be	O
discontinued	O
immediately	O
if	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
(5.7)	O
•NSAIDs	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
be	O
discontinued	O
if	O
rash	O
or	O
other	O
signs	O
of	O
local	O
skin	O
reaction	O
occur.	O
(5.8)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
NSAIDs,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAIDs	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
NSAIDs	O
such	O
as	O
diclofenac,	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
.Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)]	O
.	O
5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAIDs	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
possible	O
duration.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
diclofenac	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
5.3	O
Hepatic	O
Effects	O
Elevations	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
diclofenac	O
sodium.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy.	O
Borderline	O
elevations	O
(i.e.	O
less	O
than	O
3	O
times	O
the	O
ULN	O
[ULN	O
=	O
the	O
upper	O
limit	O
of	O
normal	O
range])	O
or	O
greater	O
elevations	O
of	O
transaminases	O
occurred	O
in	O
about	O
15%	O
of	O
diclofenac-treated	O
patients.	O
Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	O
injury.In	O
clinical	O
trials,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(GOT)	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment.	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
for	O
2-6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
patients	O
and	O
included	O
marked	O
elevations	O
(i.e.,	O
more	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3-8	O
times	O
the	O
ULN),	O
and	O
marked	O
(>8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.Physicians	O
should	O
measure	O
transaminases	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
should	O
be	O
discontinued	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
physicians	O
should	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
“flu-like”	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
patients	O
should	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Caution	O
should	O
be	O
exercised	O
in	O
prescribing	O
diclofenac	O
sodium	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
cardiovascular	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
not	O
recommended	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
diclofenac	O
sodium	O
topical	O
gel	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
gel.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)]..	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations,	O
and	O
the	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
not	O
be	O
applied	O
to	O
open	O
skin	O
wounds,	O
infections,	O
inflammations,	O
or	O
exfoliative	O
dermatitis,	O
as	O
it	O
may	O
affect	O
absorption	O
and	O
tolerability	O
of	O
the	O
drug.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
should	O
not	O
be	O
allowed	O
to	O
come	O
into	O
contact	O
with	O
the	O
eyes	O
or	O
with	O
mucous	O
membranes.The	O
effect	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
under	O
occlusive	O
dressings	O
has	O
not	O
been	O
evaluated,	O
and	O
should	O
be	O
avoided.	O
5.9	O
Pregnancy	B-D011247
As	O
with	O
other	O
NSAIDs,	O
diclofenac	O
sodium	O
topical	O
gel	O
should	O
be	O
avoided	O
in	O
late	O
pregnancy,	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
5.10	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.12	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoeisis.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration,	O
and	O
reversible.	O
Patients	B-D010361
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alteration	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants	O
should	O
be	O
carefully	O
monitored.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
non-steroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
diclofenac	O
sodium	O
topical	O
gel	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
areas	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light	O
induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
with	O
eyes	O
and	O
mucosa,	O
although	O
not	O
studied,	O
should	O
be	O
avoided.	O
Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
eye	O
contact	O
occurs,	O
they	O
should	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
diclofenac	O
sodium	O
topical	O
gel	O
should	O
be	O
discontinued.	O
6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
greater	O
than	O
placebo)	O
are	O
application	O
site	O
reactions,	O
including	O
dermatitis.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sand	B-D000080463
oz	O
Inc.	O
at	O
1-800-398-5876	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.During	O
clinical	O
development,	O
913	O
patients	O
were	O
exposed	O
to	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
randomized,	O
double-blind,	O
multicenter,	O
vehicle-controlled,	O
parallel-group	O
studies	O
in	O
osteoarthritis	O
of	O
the	O
superficial	O
joints	O
of	O
the	O
extremities.	O
Of	O
these,	O
513	O
patients	O
received	O
diclofenac	O
sodium	O
topical	O
gel	O
for	O
osteoarthritis	O
of	O
the	O
knee	O
and	O
400	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
the	O
hand.	O
Additionally,	O
583	O
patients	O
were	O
exposed	O
to	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
an	O
uncontrolled,	O
open-label,	O
long-term	O
safety	O
trial	O
in	O
osteoarthritis	O
of	O
the	O
knee.	O
Of	O
these,	O
355	O
patients	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
1	O
knee	O
and	O
228	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
both	O
knees.	O
Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
safety	O
trial.	O
Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel:	O
Non-serious	O
adverse	O
reactions	O
that	O
were	O
reported	O
during	O
the	O
short-term	O
placebo-controlled	O
studies	O
comparing	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
placebo	O
(vehicle	O
gel)	O
over	O
study	O
periods	O
of	O
8	O
to	O
12	O
weeks	O
(16	O
g	O
per	O
day),	O
were	O
application	O
site	O
reactions.	O
These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>1%	O
of	O
treated	O
patients	O
with	O
a	O
greater	O
frequency	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
gel	O
group	O
(7%)	O
than	O
the	O
placebo	O
group	O
(2%).	O
Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported.	O
Application	O
site	O
dermatitis	O
was	O
the	O
most	O
frequent	O
type	O
of	O
application	O
site	O
reaction	O
and	O
was	O
reported	O
by	O
4%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
compared	O
to	O
1%	O
of	O
placebo	O
patients.	O
Table	O
1:	O
Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
Patients	B-D010361
)	O
–	O
Short-term	O
Controlled	O
Trials	O
Adverse	O
Reaction†	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
N=913	O
Placebo	O
(vehicle)	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
dermatitis	O
32	O
(4)	O
6	O
(<1)	O
Application	O
site	O
pruritus	O
7	O
(<1)	O
1	O
(<1)	O
Application	O
site	O
erythema	O
6	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
paresthesia	O
5	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
dryness	O
4	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
vesicles	O
3	O
(<1)	O
0	O
Application	O
site	O
irritation	O
2	O
(<1)	O
0	O
Application	O
site	O
papules	O
1	O
(<1)	O
0	O
†	O
Preferred	O
Term	O
according	O
to	O
MedDRA	O
9.1.	O
In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
and	O
3%	O
for	O
patients	O
in	O
the	O
placebo	O
group.	O
Application	O
site	O
reactions,	O
including	O
application	O
site	O
dermatitis,	O
were	O
the	O
most	O
frequent	O
reason	O
for	O
treatment	O
discontinuation.	O
Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
safety	O
study,	O
distribution	O
of	O
adverse	O
reactions	O
was	O
similar	O
to	O
that	O
in	O
the	O
placebo-controlled	O
studies.	O
In	O
this	O
study,	O
where	O
patients	O
were	O
treated	O
for	O
up	O
to	O
1	O
year	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
up	O
to	O
32	O
g	O
per	O
day,	O
application	O
site	O
dermatitis	O
was	O
observed	O
in	O
11%	O
of	O
patients.	O
Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
patients.	O
The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
dermatitis,	O
which	O
was	O
experienced	O
by	O
6%	O
of	O
patients.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional	O
:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages	O
:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses	O
:	O
conjunctivitis,	O
hearing	O
impairment	O
Boxed	O
warning	O
Cardiovascular	O
Thrombotic	O
Events	O
-	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
...	O
Cardiovascular	O
Thrombotic	O
Events	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
].	O
Etodolac	B-D017308
extended-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
and	O
Warnings	O
and	O
Precautions	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions].	O
Adverse	O
Reactions	O
A	O
total	O
of	O
1552	O
patients	O
were	O
exposed	O
to	O
etodolac	O
extended-release	O
tablets	O
in	O
controlled	O
clinical	O
studies	O
of	O
at	O
least	O
4	O
weeks	O
in	O
length	O
and	O
using	O
daily	O
doses	O
in	O
the	O
range	O
of	O
400	O
to	O
1200	O
mg.	O
In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
incidence	O
of	O
events	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	O
extended-release	O
tablets.	O
As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
time	O
with	O
extended	O
therapy.	O
In	O
patients	O
taking	O
NSAIDs,	O
including	O
etodolac	O
extended-release	O
tablets,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including	O
abdominal	O
pain	O
constipation	O
Diarrhea	B-D003967
dyspepsia	O
flatulence	O
GI	O
ulcers	O
(gastric/duodenal)*	O
gross	O
bleeding/perforation*	O
nausea	O
Vomiting	B-D014839
Other	O
events	O
including:	O
*	O
Adverse	O
events	O
that	O
were	O
observed	O
in	O
<	O
1%	O
of	O
patients	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	O
extended-release	O
tablets	O
in	O
clinical	O
trials.	O
abnormal	O
renal	O
function*	O
Anemia	B-D000740
*	O
asthenia	O
dizziness	O
edema*	O
elevated	O
liver	O
enzymes*	O
headaches	O
hypertension	O
increased	O
bleeding	O
time*	O
infection	O
pharyngitis	O
pruritus	O
rashes	O
rhinitis	O
tinnitus*	O
Additional	O
NSAID	O
Adverse	O
Experiences	O
Reported	O
Occasionally	O
with	O
NSAIDs	O
or	O
Etodolac	B-D017308
Extended-release	O
Tablets	B-D013607
Include	O
Body	O
as	O
a	O
whole	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock),	O
chills,	O
fever,	O
sepsis	O
Cardiovascular	O
system	O
Congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
tachycardia,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic)	O
Digestive	O
system	O
Anorexia	B-D000855
,	O
cholestatic	O
hepatitis,	O
cholestatic	O
jaundice,	O
dry	O
mouth,	O
duodenitis,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastric/peptic	O
ulcers,	O
glossitis,	O
hepatic	O
failure,	O
hepatitis,	O
hematemesis,	O
intestinal	O
ulceration,	O
jaundice,	O
liver	O
necrosis,	O
melena,	O
pancreatitis,	O
rectal	O
bleeding,	O
stomatitis	O
Hemic	O
and	O
lymphatic	O
system	O
Agranulocytosis	B-D000380
,	O
ecchymosis,	O
eosinophilia,	O
hemolytic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia,	O
purpura,	O
thrombocytopenia	O
Metabolic	O
and	O
nutritional	O
Hyperglycemia	B-D006943
in	O
previously	O
controlled	O
diabetic	O
patients	O
Nervous	O
system	O
Anxiety	B-D001007
,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
insomnia,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
Asthma	B-D001249
,	O
dyspnea,	O
pulmonary	O
infiltration	O
with	O
eosinophilia	O
Skin	B-D012867
and	O
appendages	O
Angioedema	B-D000799
,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
erythema	O
multiforme,	O
hyperpigmentation,	O
sweating,	O
urticaria,	O
vesiculobullous	O
rash	O
Special	O
senses	O
Blurred	O
vision,	O
photophobia,	O
transient	O
visual	O
disturbances	O
Urogenital	O
system	O
Dysuria	B-D053159
,	O
elevated	O
BUN,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis,	O
serum	O
creatinine	O
increase,	O
urinary	O
frequency	O
Other	O
NSAID	O
Adverse	O
Reactions,	O
Which	O
Occur	O
Rarely	O
Are	O
Body	O
as	O
a	O
whole	O
Anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	O
system	O
Arrhythmia,	O
cerebrovascular	O
accident,	O
hypotension,	O
myocardial	O
infarction	O
Digestive	O
system	O
Colitis	B-D003092
,	O
esophagitis	O
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
thirst,	O
ulcerative	O
stomatitis	O
Hemic	O
and	O
lymphatic	O
system	O
Aplastic	O
anemia,	O
lymphadenopathy	O
Metabolic	O
and	O
nutritional	O
Change	O
in	O
weight	O
Nervous	O
system	O
Coma	B-D003128
,	O
convulsions,	O
hallucinations,	O
meningitis	O
Respiratory	O
Bronchitis	B-D001991
,	O
pneumonia,	O
respiratory	O
depression,	O
sinusitis	O
Skin	B-D012867
and	O
appendages	O
Alopecia	B-D000505
,	O
exfoliative	O
dermatitis,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrosis	O
Special	O
senses	O
Conjunctivitis	B-D003231
,	O
deafness,	O
hearing	O
impairment,	O
taste	O
perversion	O
Urogenital	O
system	O
Cystitis	B-D003556
,	O
hematuria,	O
interstitial	O
nephritis,	O
leukorrhea,	O
renal	O
calculus,	O
uterine	O
bleeding	O
irregularities	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
•	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
•	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop.	O
(5.3)	O
•	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure.	O
(5.4,	O
7)	O
•	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure.	O
(5.5)	O
•	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function.	O
(5.6)	O
•	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
(5.7)	O
•	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity).	O
(5.8)	O
•	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity.	O
(5.9)	O
•	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation.	O
(5.10,	O
8.1)	O
•	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia.	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
•Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
•Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
•Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
•Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
•If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
•In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials,	O
of	O
oral	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
sodium	O
for	O
2-6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3-8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactoid	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
areas	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light	O
induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
with	O
eyes	O
and	O
mucosa,	O
although	O
not	O
studied,	O
should	O
be	O
avoided.	O
Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
eye	O
contact	O
occurs,	O
they	O
should	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea,	O
and	O
hemoglobin.	O
Do	O
not	O
use	O
combination	O
therapy	O
with	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
•Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
•Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
•Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
•Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
•Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
patients	O
treated	O
with	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
and	O
greater	O
than	O
placebo)	O
are	O
application	O
site	O
reactions,	O
including	O
dermatitis.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
GlaxoSmithKline	O
Consumer	O
Health	B-D006262
care	O
at	O
1-855-297-3031	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
During	O
clinical	O
development,	O
913	O
patients	O
were	O
exposed	O
to	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
in	O
randomized,	O
double-blind,	O
multicenter,	O
vehicle-controlled,	O
parallel-group	O
studies	O
in	O
osteoarthritis	O
of	O
the	O
superficial	O
joints	O
of	O
the	O
extremities.	O
Of	O
these,	O
513	O
patients	O
received	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
for	O
osteoarthritis	O
of	O
the	O
knee	O
and	O
400	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
the	O
hand.	O
Additionally,	O
583	O
patients	O
were	O
exposed	O
to	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
in	O
an	O
uncontrolled,	O
open-label,	O
long-term	O
safety	O
trial	O
in	O
osteoarthritis	O
of	O
the	O
knee.	O
Of	O
these,	O
355	O
patients	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
1	O
knee	O
and	O
228	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
both	O
knees.	O
Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
safety	O
trial.	O
Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
patients	O
treated	O
with	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL:	O
Non-serious	O
adverse	O
reactions	O
that	O
were	O
reported	O
during	O
the	O
short-term	O
placebo-controlled	O
studies	O
comparing	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
and	O
placebo	O
(vehicle	O
gel)	O
over	O
study	O
periods	O
of	O
8	O
to	O
12	O
weeks	O
(16	O
g	O
per	O
day),	O
were	O
application	O
site	O
reactions.	O
These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>1%	O
of	O
treated	O
patients	O
with	O
a	O
greater	O
frequency	O
in	O
the	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
group	O
(7%)	O
than	O
the	O
placebo	O
group	O
(2%).	O
Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported.	O
Application	O
site	O
dermatitis	O
was	O
the	O
most	O
frequent	O
type	O
of	O
application	O
site	O
reaction	O
and	O
was	O
reported	O
by	O
4%	O
of	O
patients	O
treated	O
with	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL,	O
compared	O
to	O
1%	O
of	O
placebo	O
patients.	O
Table	O
1.	O
Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
Patients	B-D010361
)	O
–	O
Short-term	O
Controlled	O
Trials	O
†Preferred	O
Term	O
according	O
to	O
MedDRA	O
9.1	O
Adverse	O
Reaction†	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
N=913	O
Placebo	O
(Vehicle)	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
dermatitis	O
32	O
(4)	O
6	O
(<1)	O
Application	O
site	O
pruritus	O
7	O
(<1)	O
1	O
(<1)	O
Application	O
site	O
erythema	O
6	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
paresthesia	O
5	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
dryness	O
4	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
vesicles	O
3	O
(<1)	O
0	O
Application	O
site	O
irritation	O
2	O
(<1)	O
0	O
Application	O
site	O
papules	O
1	O
(<1)	O
0	O
In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
patients	O
treated	O
with	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL,	O
and	O
3%	O
for	O
patients	O
in	O
the	O
placebo	O
group.	O
Application	O
site	O
reactions,	O
including	O
application	O
site	O
dermatitis,	O
were	O
the	O
most	O
frequent	O
reason	O
for	O
treatment	O
discontinuation.	O
Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:In	O
the	O
open-label,	O
long-term	O
safety	O
study,	O
distribution	O
of	O
adverse	O
reactions	O
was	O
similar	O
to	O
that	O
in	O
the	O
placebo-controlled	O
studies.	O
In	O
this	O
study,	O
where	O
patients	O
were	O
treated	O
for	O
up	O
to	O
1	O
year	O
with	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
GEL	O
up	O
to	O
32	O
g	O
per	O
day,	O
application	O
site	O
dermatitis	O
was	O
observed	O
in	O
11%	O
of	O
patients.	O
Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
patients.	O
The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
dermatitis,	O
which	O
was	O
experienced	O
by	O
6%	O
of	O
patients.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
).	O
•Diclofenac	O
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS	O
).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS	O
)	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
•Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
•Hypertension	O
(see	O
WARNINGS	O
)	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
•Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
•Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
•Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses	O
conjunctivitis,	O
hearing	O
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Rising	O
Pharmaceuticals,	O
Inc.	O
1-866-562-4597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
thrombocyte	O
aggregation	O
(5.1)	O
Delayed	O
healing	O
(5.2)	O
Cornea	B-D003315
l	O
effects	O
including	O
keratitis	O
(5.3)	O
5.1	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
With	O
some	O
NSAIDs,	O
including	O
NEVANAC	O
0.1%,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
thrombocyte	O
aggregation.	O
There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
NSAIDs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
tissues	O
(including	O
hyphema)	O
in	O
conjunction	O
with	O
ocular	O
surgery.	O
It	O
is	O
recommended	O
that	O
NEVANAC	O
0.1%	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
known	O
bleeding	O
tendencies,	O
or	O
who	O
are	O
receiving	O
other	O
medications,	O
which	O
may	O
prolong	O
bleeding	O
time.	O
5.2	O
Delayed	O
Healing	O
Topical	O
NSAIDs,	O
including	O
NEVANAC	O
0.1%,	O
may	O
slow	O
or	O
delay	O
healing.	O
Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing.	O
Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
steroids	O
may	O
increase	O
the	O
potential	O
for	O
healing	O
problems.	O
5.3	O
Cornea	B-D003315
l	O
Effects	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
keratitis.	O
In	O
some	O
susceptible	O
patients,	O
continued	O
use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
epithelial	O
breakdown,	O
corneal	O
thinning,	O
corneal	O
erosion,	O
corneal	O
ulceration,	O
or	O
corneal	O
perforation.	O
These	O
events	O
may	O
be	O
sight	O
threatening.	O
Patients	B-D010361
with	O
evidence	O
of	O
corneal	O
epithelial	O
breakdown	O
should	O
immediately	O
discontinue	O
use	O
of	O
topical	O
NSAIDs,	O
including	O
NEVANAC	O
0.1%,	O
and	O
should	O
be	O
closely	O
monitored	O
for	O
corneal	O
health.	O
Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
patients	O
with	O
complicated	O
ocular	O
surgeries,	O
corneal	O
denervation,	O
corneal	O
epithelial	O
defects,	O
diabetes	O
mellitus,	O
ocular	O
surface	O
diseases	O
(e.g.,	O
dry	O
eye	O
syndrome),	O
rheumatoid	O
arthritis,	O
or	O
repeat	O
ocular	O
surgeries	O
within	O
a	O
short	O
period	O
of	O
time	O
may	O
be	O
at	O
increased	O
risk	O
for	O
corneal	O
adverse	O
events,	O
which	O
may	O
become	O
sight	O
threatening.	O
Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients.	O
Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
1	O
day	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
post-surgery	O
may	O
increase	O
patient	O
risk	O
and	O
severity	O
of	O
corneal	O
adverse	O
events.	O
5.4	O
Contact	O
Lens	O
Wear	O
NEVANAC*	O
0.1%	O
should	O
not	O
be	O
administered	O
while	O
using	O
contact	O
lenses.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
labeling:	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Delayed	O
Healing	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Cornea	B-D003315
l	O
Effects	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Most	O
common	O
adverse	O
reactions	O
(5%	O
to	O
10%)	O
are	O
capsular	O
opacity,	O
decreased	O
visual	O
acuity,	O
foreign	O
body	O
sensation,	O
increased	O
intraocular	O
pressure	O
(IOP)	O
and	O
sticky	O
sensation.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Alcon	O
Laboratories	B-D007753
,	O
Inc.	O
at	O
1-800-757-9195	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
the	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
most	O
frequently	O
reported	O
ocular	O
adverse	O
reactions	O
following	O
cataract	O
surgery	O
were	O
capsular	O
opacity,	O
decreased	O
visual	O
acuity,	O
foreign	O
body	O
sensation,	O
increased	O
intraocular	O
pressure	O
(IOP),	O
and	O
sticky	O
sensation.	O
These	O
reactions	O
occurred	O
in	O
approximately	O
5%	O
to	O
10%	O
of	O
patients.	O
Other	O
ocular	O
adverse	O
reactions	O
occurring	O
at	O
an	O
incidence	O
of	O
approximately	O
1%	O
to	O
5%	O
included	O
conjunctival	O
edema,	O
corneal	O
edema,	O
dry	O
eye,	O
lid	O
margin	O
crusting,	O
ocular	O
discomfort,	O
ocular	O
hyperemia,	O
ocular	O
pain,	O
ocular	O
pruritus,	O
photophobia,	O
tearing,	O
and	O
vitreous	O
detachment.	O
Some	O
of	O
these	O
reactions	O
may	O
be	O
the	O
consequence	O
of	O
the	O
cataract	O
surgical	O
procedure.	O
Non-ocular	O
adverse	O
reactions	O
reported	O
at	O
an	O
incidence	O
of	O
1%	O
to	O
4%	O
included	O
headache,	O
hypertension,	O
nausea/vomiting,	O
and	O
sinusitis.	O
BOXED	O
WARNING	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	O
capsules	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	O
capsules	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	O
capsules	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
CLINICAL	O
STUDIES	O
(14.6)].	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[seeWARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
CONTRAINDICATIONS	O
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
celecoxib	O
capsules.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants;	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
CLINICAL	O
STUDIES	O
(14.6)].	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	O
capsules	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib	O
capsules,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
capsules	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
capsules	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
celecoxib	O
capsules	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	O
capsules	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib	O
capsules,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[see	O
CLINICAL	O
STUDIES	O
(14.6)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
celecoxib	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
In	O
the	O
CLASS	O
study	O
[see	O
CLINICAL	O
STUDIES	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
celecoxib	O
capsules	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
celecoxib	O
capsules	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
celecoxib	O
capsules.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
celecoxib	O
capsules	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoadosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
celecoxib	O
and	O
in	O
patients	O
with	O
aspirin	O
sensitive	O
asthma.	O
Celecoxib	B-D000068579
capsules	O
are	O
sulfonamides	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	O
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
CONTRAINDICATIONS	O
(4)	O
AND	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
CONTRAINDICATIONS	O
(4)].	O
When	O
celecoxib	O
capsules	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	O
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib	O
capsules,	O
including	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(AGEP).	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	O
capsules	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Celecoxib	B-D000068579
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[seeCONTRAINDICATIONS	O
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
USE	O
IN	O
SPECIFIC	O
POPULATIONS	O
(8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
celecoxib	O
capsules	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
capsules	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation	O
with	O
use	O
of	O
celecoxib	O
capsules	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	O
and	O
their	O
caregivers	O
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)]	O
Hepatotoxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.3)]	O
Hypertension	B-D006973
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp.	O
at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CXB	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
Injury-Accidental	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CXB	O
=	O
celecoxib	O
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
In	O
placebo	O
-	O
or	O
active	O
-	O
controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
celecoxib	O
capsules.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis	B-D014657
,	O
deep	O
venous	O
thrombosis	O
General:	O
Anaphylactoid	O
reaction,	O
angioedema	O
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	O
hepatitis,	O
jaundice,	O
hepatic	O
failure	O
Hemic	O
and	O
lymphatic:	O
Agranulocytosis	B-D000380
,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
Renal:	O
Interstitial	O
nephritis	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
VIVLODEX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
VIVLODEX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
.	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
VIVLODEX	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
VIVLODEX	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
VIVLODEX	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
VIVLODEX	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
meloxicam,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
VIVLODEX	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
VIVLODEX	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
meloxicam,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
VIVLODEX.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
for	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
high	O
risk	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
VIVLODEX	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
meloxicam.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flulike"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
VIVLODEX	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
VIVLODEX,	O
can	O
lead	O
to	O
new	O
onset	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
meloxicam	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
VIVLODEX	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
VIVLODEX	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
VIVLODEX	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
VIVLODEX	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
pre-existing	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
VIVLODEX.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
VIVLODEX	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
VIVLODEX	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
VIVLODEX	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Meloxicam	B-D000077239
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
meloxicam	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
VIVLODEX	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
VIVLODEX	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
meloxicam,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
VIVLODEX	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
VIVLODEX	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Meloxicam	B-D000077239
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
VIVLODEX,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
VIVLODEX	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
VIVLODEX,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Concomitant	O
use	O
of	O
warfarin	O
and	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
and	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
VIVLODEX	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
].	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥2%	O
in	O
controlled	O
clinical	O
trials	O
of	O
VIVLODEX	O
5	O
mg	O
or	O
10	O
mg	O
group)	O
are	O
diarrhea,	O
nausea,	O
abdominal	O
discomfort.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Iroko	O
Pharmaceuticals,	O
LLC	O
at	O
1-877-757-0676	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Adverse	O
Reactions	O
in	O
Patients	B-D010361
with	O
Osteoarthritis	B-D010003
Pain	B-D010146
Eight	O
hundred	O
sixty-eight	O
(868)	O
patients	O
with	O
osteoarthritis	O
pain,	O
ranging	O
in	O
age	O
from	O
40	O
–	O
87	O
years,	O
were	O
enrolled	O
in	O
two	O
Phase	O
3	O
clinical	O
trials	O
and	O
received	O
VIVLODEX	O
5	O
mg	O
or	O
10	O
mg	O
once	O
daily.	O
Fifty	O
percent	O
(50%)	O
of	O
patients	O
were	O
aged	O
61	O
years	O
or	O
older.	O
Two	O
hundred	O
sixty-nine	O
(269)	O
patients	O
received	O
VIVLODEX	O
5	O
mg	O
or	O
10	O
mg	O
once	O
daily	O
in	O
the	O
12-week,	O
double-blind,	O
placebo-controlled,	O
clinical	O
trial	O
of	O
osteoarthritis	O
pain	O
of	O
the	O
knee	O
or	O
hip.	O
The	O
most	O
frequent	O
adverse	O
reactions	O
in	O
this	O
study	O
are	O
summarized	O
in	O
Table	O
1.	O
Table	O
1	O
Summary	O
of	O
Adverse	O
Reactions	O
(≥2%)	O
–	O
12-Week	O
Phase	O
3	O
Study	O
in	O
Patients	B-D010361
With	O
Osteoarthritis	B-D010003
Pain	B-D010146
Adverse	O
Reactions	O
VIVLODEX	O
5	O
mg	O
or	O
10	O
mg	O
N=269	O
Placebo	O
N=133	O
Diarrhea	B-D003967
3%	O
1%	O
Nausea	B-D009325
2%	O
0	O
Abdominal	O
Discomfort	O
2%	O
0	O
Six	O
hundred	O
(600)	O
patients	O
received	O
VIVLODEX	O
10	O
mg	O
once	O
daily	O
in	O
a	O
52-week,	O
open-label,	O
clinical	O
trial	O
in	O
osteoarthritis	O
pain	O
of	O
the	O
knee	O
or	O
hip.	O
Of	O
these,	O
390	O
(65%)	O
patients	O
completed	O
the	O
trial.	O
The	O
most	O
frequent	O
adverse	O
reactions	O
in	O
this	O
study	O
are	O
summarized	O
in	O
Table	O
2.	O
Table	O
2	O
Summary	O
of	O
Adverse	O
Reactions	O
(≥2%)	O
–	O
52-Week	O
Open-Label	O
Study	O
in	O
Patients	B-D010361
With	O
Osteoarthritis	B-D010003
Pain	B-D010146
Adverse	O
Reactions	O
VIVLODEX	O
10	O
mg	O
N=600	O
Arthralgia	B-D018771
6%	O
Urinary	B-D014551
Tract	I-D014551
Infection	O
6%	O
Osteoarthritis	B-D010003
5%	O
Hypertension	B-D006973
4%	O
Diarrhea	B-D003967
4%	O
Headache	B-D006261
4%	O
Upper	O
Respiratory	O
Tract	O
Infection	O
4%	O
Back	B-D001416
Pain	I-D001416
4%	O
Nasopharyngitis	B-D009304
4%	O
Bronchitis	B-D001991
3%	O
Sinusitis	B-D012852
3%	O
Constipation	B-D003248
3%	O
Dyspepsia	B-D004415
3%	O
Nausea	B-D009325
2%	O
Edema	B-D004487
Peripheral	O
2%	O
Pain	B-D010146
in	O
Extremity	O
2%	O
Additional	O
adverse	O
reactions	O
reported	O
for	O
meloxicam:	O
Body	O
as	O
a	O
Whole	O
allergic	O
reaction,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
malaise,	O
syncope,	O
weight	O
decrease,	O
weight	O
increase	O
Cardiovascular	O
angina	O
pectoris,	O
cardiac	O
failure,	O
hypertension,	O
hypotension,	O
myocardial	O
infarction,	O
vasculitis	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
convulsions,	O
paresthesia,	O
tremor,	O
vertigo	O
Gastrointestinal	O
colitis,	O
dry	O
mouth,	O
duodenal	O
ulcer,	O
eructation,	O
esophagitis,	O
gastric	O
ulcer,	O
gastritis,	O
gastroesophageal	O
reflux,	O
gastrointestinal	O
hemorrhage,	O
hematemesis,	O
hemorrhagic	O
duodenal	O
ulcer,	O
hemorrhagic	O
gastric	O
ulcer,	O
intestinal	O
perforation,	O
melena,	O
pancreatitis,	O
perforated	O
duodenal	O
ulcer,	O
perforated	O
gastric	O
ulcer,	O
stomatitis	O
ulcerative	O
Heart	B-D006339
Rate	I-D006339
and	O
Rhythm	O
arrhythmia,	O
palpitation,	O
tachycardia	O
Hematologic	O
agranulocytosis,	O
leukopenia,	O
purpura,	O
thrombocytopenia	O
Immune	B-D007107
System	I-D007107
anaphylactoid	O
reactions	O
(including	O
shock)	O
Liver	B-D008099
and	O
Biliary	O
System	O
ALT	O
increased,	O
AST	O
increased,	O
bilirubinemia,	O
GGT	O
increased,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Metabolic	O
and	O
Nutritional	O
dehydration	O
Psychiatric	O
abnormal	O
dreaming,	O
alterations	O
in	O
mood	O
(such	O
as	O
mood	O
elevation),	O
anxiety,	O
appetite	O
increased,	O
confusion,	O
depression,	O
nervousness,	O
somnolence,	O
Respiratory	O
asthma,	O
bronchospasm,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
alopecia,	O
angioedema,	O
bullous	O
eruption,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
sweating	O
increased,	O
urticaria	O
Special	O
Senses	O
abnormal	O
vision,	O
conjunctivitis,	O
taste	O
perversion,	O
tinnitus	O
Urinary	O
System	O
albuminuria,	O
acute	O
urinary	O
retention,	O
BUN	O
increased,	O
creatinine	O
increased,	O
hematuria,	O
interstitial	O
nephritis,	O
renal	O
failure,	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS).	O
•	O
Diclofenac	B-D004008
potassium	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
•Hepatotoxicity	O
(see	O
WARNINGS)	O
•Hypertension	O
(see	O
WARNINGS)	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
•Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
•Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
•Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
718	O
patients	O
treated	O
for	O
shorter	O
periods,	O
i.e.,	O
2	O
weeks	O
or	O
less,	O
with	O
diclofenac	O
potassium	O
tablets,	O
adverse	O
reactions	O
were	O
reported	O
one-half	O
to	O
one-tenth	O
as	O
frequently	O
as	O
by	O
patients	O
treated	O
for	O
longer	O
periods.	O
In	O
a	O
6-month,	O
double-blind	O
trial	O
comparing	O
diclofenac	O
potassium	O
tablets	O
(N	O
=	O
196)	O
versus	O
diclofenac	O
sodium	O
delayed-release	O
tablets	O
(N	O
=	O
197)	O
versus	O
ibuprofen	O
(N	O
=	O
197),	O
adverse	O
reactions	O
were	O
similar	O
in	O
nature	O
and	O
frequency.	O
In	O
patients	O
taking	O
diclofenac	O
potassium	O
tablets	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(5.1)	O
FLECTOR	O
PATCH	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
FLECTOR	O
PATCH	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)•	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
FLECTOR	O
PATCH	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
FLECTOR	O
PATCH	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
FLECTOR	O
PATCH	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials	O
of	O
oral	O
diclofenac	O
containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
sodium	O
for	O
2-6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3-8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
FLECTOR	O
PATCH	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
FLECTOR	O
PATCH	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
FLECTOR	O
PATCH,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
FLECTOR	O
PATCH	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
FLECTOR	O
PATCH,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
FLECTOR	O
PATCH	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
pre-existing	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
FLECTOR	O
PATCH.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
FLECTOR	O
PATCH	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
FLECTOR	O
PATCH	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
FLECTOR	O
PATCH	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
FLECTOR	O
PATCH,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
FLECTOR	O
PATCH	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
FLECTOR	O
PATCH,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
FLECTOR	O
PATCH	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
].	O
5.14	O
Accidental	O
Exposure	O
in	O
Child	B-D002648
ren	O
Even	O
a	O
used	O
Flector	O
Patch	O
contains	O
a	O
large	O
amount	O
of	O
diclofenac	O
epolamine	B-C104862
(as	O
much	O
as	O
170	O
mg).	O
The	O
potential	O
therefore	O
exists	O
for	O
a	O
small	O
child	O
or	O
pet	O
to	O
suffer	O
serious	O
adverse	O
effects	O
from	O
chewing	O
or	O
ingesting	O
a	O
new	O
or	O
used	O
Flector	O
Patch.	O
It	O
is	O
important	O
for	O
patients	O
to	O
store	O
and	O
dispose	O
of	O
Flector	O
Patch	O
out	O
of	O
the	O
reach	O
of	O
children	O
and	O
pets.	O
5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Flector	O
Patch	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Do	O
not	O
use	O
combination	O
therapy	O
with	O
Flector	O
Patch	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
are	O
application	O
site	O
conditions,	O
occurring	O
in	O
11%	O
and	O
12%,	O
respectively,	O
of	O
FLECTOR	O
PATCH	O
and	O
Placebo	O
Patch-treated	O
patients	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
Inc.	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
controlled	O
trials	O
during	O
the	O
premarketing	O
development	O
of	O
FLECTOR	O
PATCH,	O
approximately	O
600	O
patients	O
with	O
minor	O
sprains,	O
strains,	O
and	O
contusions	O
were	O
treated	O
with	O
FLECTOR	O
PATCH	O
for	O
up	O
to	O
two	O
weeks.	O
Adverse	O
Events	O
Lead	B-D007854
ing	O
to	O
Discontinuation	O
of	O
Treatment	O
In	O
the	O
controlled	O
trials,	O
3%	O
of	O
patients	O
in	O
both	O
the	O
FLECTOR	O
PATCH	O
and	O
placebo	O
patch	O
groups	O
discontinued	O
treatment	O
due	O
to	O
an	O
adverse	O
event.	O
The	O
most	O
common	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
were	O
application	O
site	O
reactions,	O
occurring	O
in	O
2%	O
of	O
both	O
the	O
FLECTOR	O
PATCH	O
and	O
placebo	O
patch	O
groups.	O
Application	O
site	O
reactions	O
leading	O
to	O
dropout	O
included	O
pruritus,	O
dermatitis,	O
and	O
burning.	O
Common	O
Adverse	O
Events	O
Localized	O
Reactions	O
Overall	B-D016424
,	O
the	O
most	O
common	O
adverse	O
events	O
associated	O
with	O
FLECTOR	O
PATCH	O
treatment	O
were	O
skin	O
reactions	O
at	O
the	O
site	O
of	O
treatment.	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥	O
1%	O
of	O
patients	O
in	O
controlled	O
trials	O
of	O
FLECTOR	O
PATCH.	O
A	O
majority	O
of	O
patients	O
treated	O
with	O
FLECTOR	O
PATCH	O
had	O
adverse	O
events	O
with	O
a	O
maximum	O
intensity	O
of	O
"mild"	O
or	O
"moderate."	O
Table	O
1.	O
Common	O
Adverse	O
Events	O
(by	O
body	O
system	O
and	O
preferred	O
term)	O
in	O
≥	O
1%	O
of	O
Patients	B-D010361
treated	O
with	O
FLECTOR	O
PATCH	O
or	O
Placebo	O
Patch	O
The	O
table	O
lists	O
adverse	O
events	O
occurring	O
in	O
placebo-treated	O
patients	O
because	O
the	O
placebo-patch	O
was	O
comprised	O
of	O
the	O
same	O
ingredients	O
as	O
FLECTOR	O
PATCH	O
except	O
for	O
diclofenac.	O
Adverse	O
events	O
in	O
the	O
placebo	O
group	O
may	O
therefore	O
reflect	O
effects	O
of	O
the	O
non-active	O
ingredients.	O
Category	O
Diclofenac	B-D004008
N=572	O
Placebo	O
N=564	O
N	O
Percent	O
N	O
Percent	O
Application	O
Site	O
Conditions	O
64	O
11	O
70	O
12	O
Pruritus	B-D011537
31	O
5	O
44	O
8	O
Dermatitis	B-D003872
9	O
2	O
3	O
<1	O
Burning	O
2	O
<1	O
8	O
1	O
OtherIncludes:	O
application	O
site	O
dryness,	O
irritation,	O
erythema,	O
atrophy,	O
discoloration,	O
hyperhidriosis,	O
and	O
vesicles.	O
22	O
4	O
15	O
3	O
Gastrointestinal	O
Disorders	O
49	O
9	O
33	O
6	O
Nausea	B-D009325
17	O
3	O
11	O
2	O
Dysgeusia	B-D004408
10	O
2	O
3	O
<1	O
Dyspepsia	B-D004415
7	O
1	O
8	O
1	O
OtherIncludes:	O
gastritis,	O
vomiting,	O
diarrhea,	O
constipation,	O
upper	O
abdominal	O
pain,	O
and	O
dry	O
mouth.	O
15	O
3	O
11	O
2	O
Nervous	B-D009420
System	I-D009420
Disorders	O
13	O
2	O
18	O
3	O
Headache	B-D006261
7	O
1	O
10	O
2	O
Paresthesia	B-D010292
6	O
1	O
8	O
1	O
Somnolence	O
4	O
1	O
6	O
1	O
Other	O
Includes:	O
hypoesthesia,	O
dizziness,	O
and	O
hyperkinesias.	O
4	O
1	O
3	O
<1	O
Foreign	O
labeling	O
describes	O
that	O
dermal	O
allergic	O
reactions	O
may	O
occur	O
with	O
FLECTOR	O
PATCH	O
treatment.	O
Additionally,	O
the	O
treated	O
area	O
may	O
become	O
irritated	O
or	O
develop	O
itching,	O
erythema,	O
edema,	O
vesicles,	O
or	O
abnormal	O
sensation.	O
CONTRAINDICATIONS	O
AND	O
WARNINGS	O
ARTHROTEC®	O
CONTAINS	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL.	O
ADMINISTRATION	O
OF	O
MISOPROSTOL	O
TO	O
WOMEN	O
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
OR	O
BIRTH	O
DEFECTS.	O
UTERINE	O
RUPTURE	O
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	O
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	O
WOMEN	O
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O
BEYOND	O
THE	O
EIGHTH	O
WEEK	O
OF	O
PREGNANCY	O
(see	O
also	O
PRECAUTIONS	O
).	O
ARTHROTEC	O
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	O
WOMEN	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS	O
and	O
PRECAUTIONS	O
).	O
PATIENTS	O
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS.ARTHROTEC	O
should	O
not	O
be	O
used	O
in	O
women	O
of	O
childbearing	O
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	O
of	O
developing	O
gastric	O
or	O
duodenal	O
ulceration	O
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	O
ulcers	O
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID	O
(see	O
WARNINGS	O
).	O
In	O
such	O
patients,	O
ARTHROTEC	O
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
has	O
had	O
a	O
negative	O
serum	O
pregnancy	O
test	O
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy.	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures.	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	O
the	O
risk	O
of	O
possible	O
contraception	O
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	O
of	O
childbearing	O
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake.	O
will	O
begin	O
ARTHROTEC	O
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	O
period.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS	O
).	O
ARTHROTEC	O
is	O
contraindicated	O
for	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
Adverse	O
reactions	O
associated	O
with	O
ARTHROTEC	O
Adverse	O
reaction	O
information	O
for	O
ARTHROTEC	O
is	O
derived	O
from	O
Phase	O
III	O
multinational	O
controlled	O
clinical	O
trials	O
in	O
over	O
2,000	O
patients	O
receiving	O
ARTHROTEC	O
50	O
or	O
ARTHROTEC	O
75,	O
as	O
well	O
as	O
from	O
blinded,	O
controlled	O
trials	O
of	O
Voltaren®	O
Delayed-Release	O
tablets	O
(diclofenac)	O
and	O
Cytotec®	O
tablets	O
(misoprostol).	O
Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
incidence	O
of	O
adverse	O
events	O
for	O
patients	O
receiving	O
ARTHROTEC.	O
These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
patients	O
on	O
ARTHROTEC	O
and	O
5%	O
of	O
patients	O
on	O
diclofenac.	O
For	O
GI	O
ulcer	O
rates,	O
see	O
CLINICAL	O
STUDIES—Upper	O
gastrointestinal	O
safety	O
.	O
GI	O
disorder	O
ARTHROTEC	O
Diclofenac	B-D004008
Abdominal	O
pain	O
21%	O
15%	O
Diarrhea	B-D003967
19%	O
11%	O
Dyspepsia	B-D004415
14%	O
11%	O
Nausea	B-D009325
11%	O
6%	O
Flatulence	B-D005414
9%	O
4%	O
ARTHROTEC	O
can	O
cause	O
more	O
abdominal	O
pain,	O
diarrhea,	O
and	O
other	O
GI	O
symptoms	O
than	O
diclofenac	O
alone.	O
Diarrhea	B-D003967
and	O
abdominal	O
pain	O
developed	O
early	O
in	O
the	O
course	O
of	O
therapy,	O
and	O
were	O
usually	O
self-limited	O
(resolved	O
after	O
2	O
to	O
7	O
days).	O
Rare	O
instances	O
of	O
profound	O
diarrhea	O
leading	O
to	O
severe	O
dehydration	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
misoprostol.	O
Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
disease,	O
or	O
those	O
in	O
whom	O
dehydration,	O
were	O
it	O
to	O
occur,	O
would	O
be	O
dangerous,	O
should	O
be	O
monitored	O
carefully	O
if	O
ARTHROTEC	O
is	O
prescribed.	O
The	O
incidence	O
of	O
diarrhea	O
can	O
be	O
minimized	O
by	O
administering	O
ARTHROTEC	O
with	O
food	O
and	O
by	O
avoiding	O
coadministration	O
with	O
magnesium-containing	O
antacids.	O
Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
misoprostol	O
use	O
have	O
also	O
been	O
reported	O
for	O
women	O
receiving	O
ARTHROTEC	O
(see	O
below).	O
Postmenopausal	O
vaginal	O
bleeding	O
may	O
be	O
related	O
to	O
administration	O
of	O
ARTHROTEC.	O
If	O
it	O
occurs,	O
diagnostic	O
workup	O
should	O
be	O
undertaken	O
to	O
rule	O
out	O
gynecological	O
pathology	O
(see	O
boxed	O
CONTRAINDICATIONS	O
AND	O
WARNINGS	O
).	O
Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
safety	O
profile	O
of	O
ARTHROTEC	O
in	O
over	O
500	O
patients	O
65	O
years	O
of	O
age	O
or	O
older	O
compared	O
with	O
younger	O
patients.	O
Other	O
adverse	O
experiences	O
reported	O
occasionally	O
or	O
rarely	O
with	O
ARTHROTEC,	O
diclofenac	O
or	O
other	O
NSAIDs,	O
or	O
misoprostol	O
are:	O
Body	O
as	O
a	O
whole:	O
Asthenia	B-D001247
,	O
death,	O
fatigue,	O
fever,	O
infection,	O
malaise,	O
sepsis,	O
chills.	O
Cardiovascular	O
system:	O
Arrhythmia,	O
atrial	O
fibrillation,	O
congestive	O
heart	O
failure,	O
hypertension,	O
hypotension,	O
increased	O
CPK,	O
increased	O
LDH,	O
myocardial	O
infarction,	O
palpitations,	O
phlebitis,	O
premature	O
ventricular	O
contractions,	O
syncope,	O
tachycardia,	O
vasculitis.	O
Central	O
and	O
peripheral	O
nervous	O
system:	O
Coma	B-D003128
,	O
convulsions,	O
dizziness,	O
drowsiness,	O
headache,	O
hyperesthesia,	O
hypertonia,	O
hypoesthesia,	O
insomnia,	O
meningitis,	O
migraine,	O
neuralgia,	O
paresthesia,	O
somnolence,	O
tremor,	O
vertigo.	O
Digestive:	O
Anorexia	B-D000855
,	O
appetite	O
changes,	O
constipation,	O
dry	O
mouth,	O
dysphagia,	O
enteritis,	O
esophageal	O
ulceration,	O
esophagitis,	O
eructation,	O
gastritis,	O
gastroesophageal	O
reflux,	O
GI	O
bleeding,	O
GI	O
neoplasm	O
benign,	O
glossitis,	O
heartburn,	O
hematemesis,	O
hemorrhoids,	O
intestinal	O
perforation,	O
peptic	O
ulcer,	O
stomatitis	O
and	O
ulcerative	O
stomatitis,	O
tenesmus,	O
vomiting.	O
Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940
pain,	O
dysmenorrhea,	O
intermenstrual	O
bleeding,	O
leukorrhea,	O
menstrual	O
disorder,	O
menorrhagia,	O
vaginal	O
hemorrhage.	O
Hemic	O
and	O
lymphatic	O
system:	O
Agranulocytosis	B-D000380
,	O
anemia,	O
aplastic	O
anemia,	O
coagulation	O
time	O
increased,	O
ecchymosis,	O
eosinophilia,	O
epistaxis,	O
hemolytic	O
anemia,	O
leukocytosis,	O
leukopenia,	O
lymphadenopathy,	O
melena,	O
pancytopenia,	O
pulmonary	O
embolism,	O
purpura,	O
rectal	O
bleeding,	O
thrombocythemia,	O
thrombocytopenia.	O
Hypersensitivity	B-D006967
:	O
Angioedema	B-D000799
,	O
laryngeal/pharyngeal	O
edema,	O
urticaria.	O
Liver	B-D008099
and	O
biliary	O
system:	O
Abnormal	O
hepatic	O
function,	O
bilirubinemia,	O
hepatitis,	O
jaundice,	O
liver	O
failure,	O
pancreatitis.	O
Male	B-D008297
reproductive	O
disorders:	O
Impotence,	O
perineal	O
pain.	O
Metabolic	O
and	O
nutritional:	O
Alkaline	O
phosphatase	O
increased,	O
BUN	O
increased,	O
dehydration,	O
glycosuria,	O
gout,	O
hypercholesterolemia,	O
hyperglycemia,	O
hyperuricemia,	O
hypoglycemia,	O
hyponatremia,	O
periorbital	O
edema,	O
porphyria,	O
weight	O
changes.	O
Musculoskeletal	O
system:	O
Arthralgia	B-D018771
,	O
myalgia.	O
Psychiatric:	O
Anxiety	B-D001007
,	O
concentration	O
impaired,	O
confusion,	O
depression,	O
disorientation,	O
dream	O
abnormalities,	O
hallucinations,	O
irritability,	O
nervousness,	O
paranoia,	O
psychotic	O
reaction.	O
Respiratory	O
system:	O
Asthma	B-D001249
,	O
coughing,	O
dyspnea,	O
hyperventilation,	O
pneumonia,	O
respiratory	O
depression.	O
Skin	B-D012867
and	O
appendages:	O
Acne,	O
alopecia,	O
bruising,	O
eczema,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
pemphigoid	O
reaction,	O
photosensitivity,	O
pruritus,	O
pruritus	O
ani,	O
rash,	O
skin	O
ulceration,	O
Stevens-Johnson	O
syndrome,	O
sweating	O
increased,	O
toxic	O
epidermal	O
necrolysis.	O
Special	O
senses:	O
Hearing	B-D006309
impairment,	O
taste	O
loss,	O
taste	O
perversion,	O
tinnitus.	O
Urinary	O
system:	O
Cystitis	B-D003556
,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
micturition	O
frequency,	O
nocturia,	O
nephrotic	O
syndrome,	O
oliguria/polyuria,	O
papillary	O
necrosis,	O
proteinuria,	O
renal	O
failure,	O
urinary	O
tract	O
infection.	O
Vision:	O
Amblyopia	B-D000550
,	O
blurred	O
vision,	O
conjunctivitis,	O
diplopia,	O
glaucoma,	O
iritis,	O
lacrimation	O
abnormal,	O
night	O
blindness,	O
vision	O
abnormal.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(5.1)	O
DAYPRO	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
DAYPRO	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
DAYPRO	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
DAYPRO	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
DAYPRO	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
DAYPRO	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
oxaprozin,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
DAYPRO	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
DAYPRO	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
DAYPRO,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients,	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy,	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-times	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
DAYPRO	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
alanine	O
aminotransferase	O
(ALT)	O
or	O
aspartate	O
aminotransferase	O
(AST)	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
oxaprozin.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
discontinue	O
DAYPRO	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
DAYPRO,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
oxaprozin	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
DAYPRO	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
DAYPRO	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
DAYPRO	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
DAYPRO	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
DAYPRO.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
DAYPRO	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
DAYPRO	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
DAYPRO	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Oxaprozin	B-D000077431
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
oxaprozin	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
DAYPRO	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
DAYPRO	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
oxaprozin,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
DAYPRO	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
DAYPRO	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Oxaprozin	B-D000077431
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
DAYPRO,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
DAYPRO	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
DAYPRO,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	O
SSRIs,	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
DAYPRO	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
complete	O
blood	O
count	O
(CBC)	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
].	O
5.14	O
Photosensitivity	O
Oxaprozin	B-D000077431
has	O
been	O
associated	O
with	O
rash	O
and/or	O
mild	O
photosensitivity	O
in	O
dermatologic	O
testing.	O
An	O
increased	O
incidence	O
of	O
rash	O
on	O
sun-exposed	O
skin	O
was	O
seen	O
in	O
some	O
patients	O
in	O
the	O
clinical	O
trials.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(>3	O
%)	O
are:	O
constipation,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
rash	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Adverse	O
reaction	O
data	O
were	O
derived	O
from	O
patients	O
who	O
received	O
DAYPRO	O
in	O
multidose,	O
controlled,	O
and	O
open-label	O
clinical	O
trials.	O
Rates	O
for	O
events	O
from	O
clinical	O
trial	O
experience	O
are	O
based	O
on	O
2253	O
patients	O
who	O
took	O
1200	O
mg	O
to	O
1800	O
mg	O
DAYPRO	O
per	O
day	O
in	O
clinical	O
trials.	O
Of	O
these,	O
1721	O
patients	O
were	O
treated	O
for	O
at	O
least	O
1	O
month,	O
971	O
patients	O
for	O
at	O
least	O
3	O
months,	O
and	O
366	O
patients	O
for	O
more	O
than	O
1	O
year.	O
Incidence	B-D015994
Greater	O
than	O
1%:	O
In	O
clinical	O
trials	O
of	O
DAYPRO	O
or	O
in	O
patients	O
taking	O
other	O
NSAIDs,	O
the	O
following	O
adverse	O
reactions	O
occurred	O
at	O
an	O
incidence	O
greater	O
than	O
1%.	O
Cardiovascular	O
system:	O
edema.	O
Digestive	O
system:	O
abdominal	O
pain/distress,	O
anorexia,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gastrointestinal	O
ulcers	O
(gastric/duodenal),	O
gross	O
bleeding/perforation,	O
heartburn,	O
liver	O
enzyme	O
elevations,	O
nausea,	O
vomiting.	O
Hematologic	O
system:	O
anemia,	O
increased	O
bleeding	O
time.	O
Nervous	O
system:	O
CNS	O
inhibition	O
(depression,	O
sedation,	O
somnolence,	O
or	O
confusion),	O
disturbance	O
of	O
sleep,	O
dizziness,	O
headache.	O
Skin	B-D012867
and	O
appendages:	O
pruritus,	O
rash.	O
Special	O
senses:	O
tinnitus.	O
Urogenital	O
system:	O
abnormal	O
renal	O
function,	O
dysuria	O
or	O
frequency.	O
Incidence	B-D015994
Greater	O
than	O
1%:	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
clinical	O
trials	O
or	O
in	O
patients	O
taking	O
other	O
NSAIDs.	O
Body	O
as	O
a	O
whole:	O
appetite	O
changes,	O
death,	O
drug	O
hypersensitivity	O
reactions	O
including	O
anaphylaxis,	O
fever,	O
infection,	O
sepsis.	O
Cardiovascular	O
system:	O
arrhythmia,	O
blood	O
pressure	O
changes,	O
congestive	O
heart	O
failure,	O
hypertension,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
tachycardia,	O
syncope,	O
vasculitis.	O
Digestive	O
system:	O
alteration	O
in	O
taste,	O
dry	O
mouth,	O
eructation,	O
esophagitis,	O
gastritis,	O
glossitis,	O
hematemesis,	O
jaundice,	O
liver	O
function	O
abnormalities	O
including	O
liver	O
failure,	O
stomatitis,	O
hemorrhoidal	O
or	O
rectal	O
bleeding.	O
Hematologic	O
system:	O
aplastic	O
anemia,	O
ecchymoses,	O
eosinophilia,	O
hemolytic	O
anemia,	O
lymphadenopathy,	O
melena,	O
purpura,	O
thrombocytopenia,	O
leukopenia.	O
Metabolic	O
system:	O
hyperglycemia,	O
weight	O
changes.	O
Nervous	O
system:	O
anxiety,	O
asthenia,	O
coma,	O
convulsions,	O
dream	O
abnormalities,	O
drowsiness,	O
hallucinations,	O
insomnia,	O
malaise,	O
meningitis,	O
nervousness,	O
paresthesia,	O
tremors,	O
vertigo,	O
weakness.	O
Respiratory	O
system:	O
asthma,	O
dyspnea,	O
pulmonary	O
infections,	O
pneumonia,	O
sinusitis,	O
symptoms	O
of	O
upper	O
respiratory	O
tract	O
infection,	O
respiratory	O
depression.	O
Skin	B-D012867
:	O
alopecia,	O
angioedema,	O
urticaria,	O
photosensitivity,	O
sweat.	O
Special	O
senses:	O
blurred	O
vision,	O
conjunctivitis,	O
hearing	O
decrease.	O
Urogenital:	O
cystitis,	O
hematuria,	O
increase	O
in	O
menstrual	O
flow,	O
oliguria/	O
polyuria,	O
proteinuria,	O
renal	O
insufficiency,	O
decreased	O
menstrual	O
flow.	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
DAYPRO.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
whole:	O
serum	O
sickness.	O
Digestive	O
system:	O
hepatitis,	O
pancreatitis.	O
Hematologic	O
system:	O
agranulocytosis,	O
pancytopenia.	O
Skin	B-D012867
:	O
pseudoporphyria,	O
exfoliative	O
dermatitis,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
(Lyell's	O
syndrome).	O
Urogenital:	O
acute	O
interstitial	O
nephritis,	O
nephrotic	O
syndrome,	O
acute	O
renal	O
failure.	O
WARNING:	O
RISK	O
OF	O
UTERINE	O
RUPTURE,	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
BIRTH	O
DEFECTS;	O
AND	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
CONTAIN	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL.	O
ADMINISTRATION	O
OF	O
MISOPROSTOL	O
TO	O
WOMEN	O
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
OR	O
BIRTH	O
DEFECTS.	O
UTERINE	O
RUPTURE	O
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	O
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	O
WOMEN	O
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O
BEYOND	O
THE	O
EIGHTH	O
WEEK	O
OF	O
PREGNANCY.	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	O
WOMEN	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.10),	O
and	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
PATIENTS	O
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS.	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
should	O
not	O
be	O
used	O
in	O
women	O
of	O
childbearing	O
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	O
of	O
developing	O
gastric	O
or	O
duodenal	O
ulceration	O
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	O
ulcers	O
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID.	O
In	O
such	O
patients,	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
●	O
has	O
had	O
a	O
negative	O
serum	O
pregnancy	O
test	O
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy.	O
●	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures.	O
●	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	O
the	O
risk	O
of	O
possible	O
contraception	O
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	O
of	O
childbearing	O
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake.	O
●	O
will	O
begin	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	O
period	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.3)].	O
Cardiovascular	O
Thrombotic	O
Events	O
●	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
●	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4),	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
●	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
RISK	O
OF	O
UTERINE	O
RUPTURE,	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
BIRTH	O
DEFECTS;	O
AND	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
CONTAINS	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL.	O
ADMINISTRATION	O
OF	O
MISOPROSTOL	O
TO	O
WOMEN	O
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
OR	O
BIRTH	O
DEFECTS.	O
UTERINE	O
RUPTURE	O
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	O
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	O
WOMEN	O
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O
BEYOND	O
THE	O
EIGHTH	O
WEEK	O
OF	O
PREGNANCY.	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	O
WOMEN	O
(	O
4	O
,	O
5.10	O
,	O
8.1	O
).	O
PATIENTS	O
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS.	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
should	O
not	O
be	O
used	O
in	O
women	O
of	O
childbearing	O
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	O
of	O
developing	O
gastric	O
or	O
duodenal	O
ulceration	O
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	O
ulcers	O
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID.	O
In	O
such	O
patients,	O
d	O
iclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
•	O
has	O
had	O
a	O
negative	O
serum	O
pregnancy	O
test	O
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy	O
(	O
8.3	O
).	O
•	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures.	O
•	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	O
the	O
risk	O
of	O
possible	O
contraception	O
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	O
of	O
childbearing	O
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake.	O
•	O
will	O
begin	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	O
period.	O
Cardiovascular	O
Thrombotic	O
Events	O
Risk	B-D012306
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(	O
5.1	O
).	O
•	O
Di	O
clofenac	O
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(	O
4	O
,	O
5.1	O
).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(	O
5.2	O
).	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnancy.	O
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
diclofenac	O
sodium	O
and	O
misoprostol	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
●	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.●	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.●	O
Avoid	O
use	O
in	O
patients	O
at	O
high	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.●	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.●	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	O
sodium	O
and	O
misoprostol	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.●	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
meaningful	O
elevation	O
of	O
ALT	O
(SGPT,	O
more	O
than	O
3	O
times	O
the	O
ULN	O
[ULN	O
=	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range])	O
occurred	O
in	O
1.6%	O
of	O
2,184	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
and	O
in	O
1.4%	O
of	O
1,691	O
patients	O
treated	O
with	O
diclofenac	O
sodium.	O
These	O
increases	O
were	O
generally	O
transient,	O
and	O
enzyme	O
levels	O
returned	O
to	O
within	O
the	O
normal	O
range	O
upon	O
discontinuation	O
of	O
therapy	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets.	O
The	O
misoprostol	O
component	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
does	O
not	O
appear	O
to	O
exacerbate	O
the	O
hepatic	O
effects	O
caused	O
by	O
the	O
diclofenac	O
sodium	O
component.	O
In	O
clinical	O
trials	O
of	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
sodium	O
for	O
2	O
to	O
6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
patients	O
and	O
included	O
marked	O
elevations	O
(i.e.,	O
greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
are	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
pre-existing	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
diclofenac	O
sodium	O
and	O
misoprostol.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
/misoprostol	O
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac/misoprostol	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
diclofenac	O
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
are	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
pregnant	O
women.	O
Advise	O
pregnant	O
women	O
of	O
the	O
potential	O
risk	O
to	O
a	O
fetus.	O
Verify	O
the	O
pregnancy	O
status	O
of	O
females	O
of	O
reproductive	O
potential	O
prior	O
to	O
initiation	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol.	O
Advise	O
females	O
of	O
reproductive	O
potential	O
to	O
use	O
effective	O
contraception	O
during	O
treatment	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(	O
8.1	O
,	O
8.3	O
)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin	O
and	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
and	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
,	O
5.6	O
)].	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
greater	O
than	O
2%	O
from	O
clinical	O
trials)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
flatulence,	O
gastritis,	O
vomiting,	O
constipation,	O
headache,	O
dizziness,	O
alanine	O
aminotransferase	O
increased,	O
hematocrit	O
decreased	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Adverse	O
reaction	O
information	O
for	O
diclofenac	O
sodium	O
and	O
misoprostol	O
is	O
derived	O
from	O
Phase	O
III	O
multinational	O
controlled	O
clinical	O
trials	O
in	O
over	O
2,000	O
patients	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets,	O
50	O
mg/0.2	O
mg	O
or	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets,	O
75	O
mg/0.2	O
mg,	O
as	O
well	O
as	O
from	O
blinded,	O
controlled	O
trials	O
of	O
diclofenac	O
delayed-release	O
tablets	O
and	O
misoprostol	O
tablets.	O
Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
incidence	O
of	O
adverse	O
events	O
for	O
patients	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol.	O
These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
patients	O
on	O
diclofenac	O
sodium	O
and	O
misoprostol	O
and	O
5%	O
of	O
patients	O
on	O
diclofenac.	O
For	O
GI	O
ulcer	O
rates,	O
[see	O
Clinical	O
Studies	O
(14)	O
].	O
GI	O
disorder	O
Diclofenac	B-D004008
Sodium	B-D012964
and	O
Misoprostol	B-D016595
Diclofenac	B-D004008
Abdominal	O
pain	O
21%	O
15%	O
Diarrhea	B-D003967
19%	O
11%	O
Dyspepsia	B-D004415
14%	O
11%	O
Nausea	B-D009325
11%	O
6%	O
Flatulence	B-D005414
9%	O
4%	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
can	O
cause	O
more	O
abdominal	O
pain,	O
diarrhea,	O
and	O
other	O
GI	O
symptoms	O
than	O
diclofenac	O
alone.	O
Diarrhea	B-D003967
and	O
abdominal	O
pain	O
developed	O
early	O
in	O
the	O
course	O
of	O
therapy,	O
and	O
were	O
usually	O
self-limited	O
(resolved	O
after	O
2	O
to	O
7	O
days).	O
Rare	O
instances	O
of	O
profound	O
diarrhea	O
leading	O
to	O
severe	O
dehydration	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
misoprostol.	O
Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
disease,	O
or	O
those	O
in	O
whom	O
dehydration,	O
were	O
it	O
to	O
occur,	O
would	O
be	O
dangerous,	O
should	O
be	O
monitored	O
carefully	O
if	O
diclofenac	O
sodium	O
and	O
misoprostol	O
is	O
prescribed.	O
The	O
incidence	O
of	O
diarrhea	O
can	O
be	O
minimized	O
by	O
administering	O
diclofenac	O
sodium	O
and	O
misoprostol	O
with	O
food	O
and	O
by	O
avoiding	O
coadministration	O
with	O
magnesium-containing	O
antacids.	O
Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
misoprostol	O
use	O
have	O
also	O
been	O
reported	O
for	O
women	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol	O
(see	O
below).	O
Postmenopausal	O
vaginal	O
bleeding	O
may	O
be	O
related	O
to	O
administration	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol.	O
If	O
it	O
occurs,	O
diagnostic	O
workup	O
should	O
be	O
undertaken	O
to	O
rule	O
out	O
gynecological	O
pathology	O
[see	O
Boxed	O
Warnings	O
,	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5)	O
].	O
Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
safety	O
profile	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
over	O
500	O
patients	O
65	O
years	O
of	O
age	O
or	O
older	O
compared	O
with	O
younger	O
patients.	O
Other	O
adverse	O
experiences	O
reported	O
occasionally	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
diclofenac	O
or	O
other	O
NSAIDs,	O
or	O
misoprostol	O
are:	O
Body	O
as	O
a	O
whole:	O
asthenia,	O
fatigue,	O
malaise.	O
Central	O
and	O
peripheral	O
nervous	O
system:	O
dizziness,	O
drowsiness,	O
headache,	O
insomnia,	O
paresthesia,	O
vertigo.	O
Digestive:	O
anorexia,	O
appetite	O
changes,	O
constipation,	O
dry	O
mouth,	O
dysphagia,	O
esophageal	O
ulceration,	O
oesophagitis,	O
eructation,	O
gastritis,	O
gastroesophageal	O
reflux,	O
GI	O
neoplasm	O
benign,	O
peptic	O
ulcer,	O
tenesmus,	O
vomiting.	O
Female	B-D005260
reproductive	O
disorders:	O
breast	O
pain,	O
dysmenorrhea,	O
menstrual	O
disorder,	O
menorrhagia,	O
vaginal	O
hemorrhage.	O
Hemic	O
and	O
lymphatic	O
system:	O
epistaxis,	O
leukopenia,	O
melena,	O
purpura,	O
decreased	O
hematocrit.	O
Metabolic	O
and	O
nutritional:	O
alanine	O
aminotransferase	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
aspartate	O
aminotransferase	O
increased,	O
dehydration,	O
hyponatremia.	O
Musculoskeletal	O
system:	O
arthralgia,	O
myalgia.	O
Psychiatric:	O
anxiety,	O
concentration	O
impaired,	O
depression,	O
irritability.	O
Respiratory	O
system:	O
asthma,	O
coughing,	O
hyperventilation.	O
Skin	B-D012867
and	O
appendages:	O
alopecia,	O
eczema,	O
pemphigoid	O
reaction,	O
photosensitivity,	O
sweating	O
increased,	O
pruritus.	O
Special	O
senses:	O
taste	O
perversion,	O
tinnitus.	O
Renal	O
and	O
urinary	O
disorders:	O
dysuria,	O
nocturia,	O
polyuria,	O
proteinuria,	O
urinary	O
tract	O
infection.	O
Vision:	O
diplopia.	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
diclofenac	O
or	O
misoprostol.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliable	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
whole:	O
death,	O
fever,	O
infection,	O
sepsis,	O
chills,	O
edema.	O
Cardiovascular	O
system:	O
arrhythmia,	O
atrial	O
fibrillation,	O
congestive	O
heart	O
failure,	O
hypertension,	O
hypotension,	O
increased	O
CPK,	O
increased	O
LDH,	O
myocardial	O
infarction,	O
palpitations,	O
phlebitis,	O
premature	O
ventricular	O
contractions,	O
syncope,	O
tachycardia,	O
vasculitis.	O
Central	O
and	O
peripheral	O
nervous	O
system:	O
coma,	O
convulsions,	O
hyperesthesia,	O
hypertonia,	O
hypoesthesia,	O
meningitis,	O
migraine,	O
neuralgia,	O
somnolence,	O
stroke,	O
tremor.	O
Congenital,	O
familial	O
and	O
genetic	O
disorders:	O
birth	O
defects.	O
Digestive:	O
enteritis,	O
GI	O
bleeding,	O
glossitis,	O
heartburn,	O
hematemesis,	O
hemorrhoids,	O
intestinal	O
perforation,	O
stomatitis	O
and	O
ulcerative	O
stomatitis.	O
Female	B-D005260
reproductive	O
disorders:	O
intermenstrual	O
bleeding,	O
leukorrhea,	O
vaginitis,	O
uterine	O
cramping,	O
uterine	O
hemorrhage.	O
Hemic	O
and	O
lymphatic	O
system:	O
agranulocytosis,	O
anemia,	O
aplastic	O
anemia,	O
coagulation	O
time	O
increased,	O
ecchymosis,	O
eosinophilia,	O
hemolytic	O
anemia,	O
leukocytosis,	O
lymphadenopathy,	O
pancytopenia,	O
pulmonary	O
embolism,	O
rectal	O
bleeding,	O
thrombocythemia,	O
thrombocytopenia.	O
Hypersensitivity	B-D006967
:	O
angioedema,	O
laryngeal/pharyngeal	O
edema,	O
urticaria.	O
Liver	B-D008099
and	O
biliary	O
system:	O
abnormal	O
hepatic	O
function,	O
bilirubinemia,	O
liver	O
failure,	O
pancreatitis,	O
hepatitis,	O
jaundice.	O
Male	B-D008297
reproductive	O
disorders:	O
impotence,	O
perineal	O
pain.	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
glycosuria,	O
gout,	O
hypercholesterolemia,	O
hyperglycemia,	O
hyperuricemia,	O
hypoglycemia,	O
periorbital	O
edema,	O
porphyria,	O
weight	O
changes,	O
fluid	O
retention.	O
Pregnancy	B-D011247
,	O
puerperium	O
and	O
perinatal	O
conditions:	O
abnormal	O
uterine	O
contractions,	O
uterine	O
rupture/perforation,	O
retained	O
placenta,	O
amniotic	O
fluid	O
embolism,	O
incomplete	O
abortion,	O
premature	O
birth,	O
fetal	O
death.	O
Psychiatric:	O
confusion,	O
disorientation,	O
dream	O
abnormalities,	O
hallucinations,	O
nervousness,	O
paranoia,	O
psychotic	O
reaction.	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
female	O
fertility	O
decreased.	O
Respiratory	O
system:	O
dyspnea,	O
pneumonia,	O
respiratory	O
depression.	O
Skin	B-D012867
and	O
appendages:	O
acne,	O
bruising,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
pruritus	O
ani,	O
rash,	O
skin	O
ulceration,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis,	O
cutaneous	O
reactions	O
(bullous	O
eruption).	O
Special	O
senses:	O
hearing	O
impairment,	O
taste	O
loss.	O
Renal	O
and	O
urinary	O
disorders:	O
cystitis,	O
hematuria,	O
interstitial	O
nephritis,	O
micturition	O
frequency,	O
nephrotic	O
syndrome,	O
oliguria,	O
papillary	O
necrosis,	O
renal	O
failure,	O
glomerulonephritis	O
membranous,	O
glomerulonephritis	O
minimal	O
lesion,	O
glomerulohephritis.	O
Vision:	O
amblyopia,	O
blurred	O
vision,	O
conjunctivitis,	O
glaucoma,	O
iritis,	O
lacrimation	O
abnormal,	O
night	O
blindness,	O
vision	O
abnormal.	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
•	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
•	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(5.4)	O
Cardiovascular	O
Risk	B-D012306
•	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
•	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.4)	O
5.WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(5.1,	O
14.6,	O
17.2).	O
•Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
(5.4,	O
8.5,	O
14.6,	O
17.3).	O
•Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
CELEBREX	O
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen	O
(5.5,	O
17.4).	O
•New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
CELEBREX	O
(5.2,	O
7.4,	O
17.2).	O
•Fluid	O
retention	O
and	O
edema.	O
CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure	O
(5.3,	O
17.6).	O
•Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
CELEBREX	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6).	O
•Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
CELEBREX	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(5.7,	O
10,	O
17.7).	O
•Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions	O
(5.8,	O
17.5).	O
5.1Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
CELEBREX	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
CELEBREX,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
CELEBREX	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.2Hypertension	O
As	O
with	O
all	O
NSAIDs,	O
CELEBREX	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
CELEBREX,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
CELEBREX	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
CELEBREX,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
5.3Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
CELEBREX	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
CELEBREX,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
CELEBREX	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
Celebrex	O
is	O
contraindicated	O
in	O
patients	O
with	O
active	O
GI	O
bleeding.	O
5.5Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
CELEBREX	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
controlled	O
clinical	O
trials	O
of	O
CELEBREX,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
CELEBREX	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
CELEBREX	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
CELEBREX.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
CELEBREX	O
should	O
be	O
discontinued.	O
5.6Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
CELEBREX	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
CELEBREX	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
CELEBREX	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
CELEBREX.	O
In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
CELEBREX.	O
CELEBREX	O
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8Skin	O
Reactions	O
CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9Pregnancy	O
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
CELEBREX	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.10	O
Corticosteroid	O
Treatment	O
CELEBREX	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
CELEBREX.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
CELEBREX	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
CELEBREX	O
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
CELEBREX	O
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
CELEBREX	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
CELEBREX	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
CELEBREX	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
CELEBREX	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6.ADVERSE	O
REACTIONS	O
Of	O
the	O
CELEBREX-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
CELEBREX	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
CELEBREX	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
CELEBREX	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CBX	O
=	O
CELEBREX	O
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
CELEBREX	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
CELEBREX	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	O
treated	O
with	O
CELEBREX	O
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS,	O
or	O
hypersensitivity	O
syndrome)	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
CELEBREX	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
CELEBREX	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
CELEBREX	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
CELEBREX	O
pre-marketing	O
controlled	O
arthritis	O
trials	O
,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
CELEBREX	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
CELEBREX	O
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
CELEBREX,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	O
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
for	O
the	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
treatment	O
arms	O
compared	O
to	O
placebo.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.7)	O
].	O
A	O
randomized	O
controlled	O
trial	O
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs.	O
Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	O
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	O
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	O
and	O
ibuprofen.	O
Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	O
375	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	O
600	O
to	O
800	O
mg	O
three	O
times	O
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists’	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	O
(including	O
hemorrhagic	O
death),	O
non-fatal	O
myocardial	O
infarction,	O
and	O
non-fatal	O
stroke	O
[See	O
Clinical	O
Studies	O
(14.6)	O
].	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
celecoxib.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	O
anticoagulants;	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.4%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.7)	O
].	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O
.	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
“flu-like”	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
discontinue	O
celecoxib	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
blood	O
pressure	O
data	O
for	O
celecoxib.	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-­fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
celecoxib	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE	O
inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
celecoxib	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
celecoxib.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
celecoxib	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
celecoxib	O
and	O
in	O
patients	O
with	O
aspirin	O
sensitive	O
asthma.	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	O
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	O
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib,	O
including	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(AGEP).	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
celecoxib	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs,	O
including	O
celecoxib,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	O
SSRIs	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
].	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation	O
with	O
use	O
of	O
celecoxib	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	O
and	O
their	O
caregivers	O
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible.	O
6.	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Aurobindo	O
Pharma	O
USA,	O
Inc.	O
at	O
1-866-850-2876	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%5.6%	O
8.8%	O
2.2%	O
3.5%	O
2.8%	O
3.8%	O
6.2%	O
1%	O
4.2%	O
7.7%	O
5.3%	O
12.2%	O
3.6%6%	O
9%9.3%10.9%4.1%3.4%	O
9%5.8%12.8%3.5%6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%2.1%2.9%	O
3.6%1.1%2.3%	O
2.2%2.1%3%	O
2.6%1%2.6%	O
0.9%3.5%3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
Headache	B-D006261
2%15.8%	O
1.7%20.2%	O
2.6%14.5%	O
1.3%15.5%	O
2.3%15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
Rhinitis	B-D012220
Sinusitis	B-D012852
Upper	O
Respiratory	O
Infection	O
2.3%2%5%8.1%	O
1.1%1.3%4.3%6.7%	O
1.7%2.4%4%9.9%	O
1.6%2.3%5.4%9.8%	O
2.6%0.6%5.8%9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1%	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular	O
:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General:	O
Hypersensitivity	B-D006967
,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
blood	O
urea	O
nitrogen	O
(BUN)	O
increased,	O
creatine	O
phosphokinase	O
(CPK)	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia,	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	O
Cardiovascular	O
:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
General	O
:	O
Sepsis	B-D018805
,	O
sudden	O
death	O
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia	B-D001259
,	O
suicide	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Clinical	O
Studies	O
(14.7)	O
]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
aspirin	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
twice	O
daily.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
*	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
All	O
Doses	O
Twice	O
Daily	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.7)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning,	O
and	O
procedural	O
c	O
omplications:	O
Epicondylitis,	O
tendon	O
rupture	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
celecoxib.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis	B-D014657
,	O
deep	O
venous	O
thrombosis	O
General:	O
Anaphylactoid	O
reaction,	O
angioedema	O
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	O
hepatitis,	O
jaundice,	O
hepatic	O
failure	O
Hemic	O
and	O
lymphatic:	O
Agranulocytosis	B-D000380
,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
Renal:	O
Interstitial	O
nephritis	O
WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
RISK	O
EVALUATION	O
AND	O
MITIGATION	O
STRATEGY	O
(REMS);	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION;	O
ACCIDENTAL	O
INGESTION;	O
NEONATAL	O
OPIOID	O
WITHDRAWAL	O
SYNDROME;	O
CYTOCHROME	O
P450	O
3A4	O
INTERACTION;	O
RISKS	O
FROM	O
CONCOMITANT	O
USE	O
WITH	O
BENZODIAZEPINES	O
OR	O
OTHER	O
CNS	O
DEPRESSANTS;	O
and	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
Hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	O
tablets	O
expose	O
patients	O
and	O
other	O
users	O
to	O
the	O
risks	O
of	O
opioid	O
addiction,	O
abuse,	O
and	O
misuse,	O
which	O
can	O
lead	O
to	O
overdose	O
and	O
death.	O
Assess	O
each	O
patient’s	O
risk	O
prior	O
to	O
prescribing	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
tablets,	O
and	O
monitor	O
all	O
patients	O
regularly	O
for	O
the	O
development	O
of	O
these	O
behaviors	O
and	O
conditions	O
(see	O
WARNINGS:	O
Addiction,	O
Abuse,	O
and	O
Misuse).	O
Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS):	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
REMS	O
for	O
these	O
products	O
[	O
see	O
Warnings]	O
.	O
Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
education	O
programs	O
available	O
to	O
healthcare	O
providers.	O
Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
complete	O
a	O
REMS-compliant	O
education	O
program,	O
counsel	O
patients	O
and/or	O
their	O
caregivers,	O
with	O
every	O
prescription,	O
on	O
safe	O
use,	O
serious	O
risks,	O
storage,	O
and	O
disposal	O
of	O
these	O
products,	O
emphasize	O
to	O
patients	O
and	O
their	O
caregivers	O
the	O
importance	O
of	O
reading	O
the	O
Medication	O
Guide	O
every	O
time	O
it	O
is	O
provided	O
by	O
their	O
pharmacist,	O
and	O
consider	O
other	O
tools	O
to	O
improve	O
patient,	O
household,	O
and	O
community	O
safety	O
L	O
ife-Threatening	O
Respiratory	O
Depression	B-D003863
S	O
er	O
ious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
may	O
occur	O
with	O
use	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
tablets.	O
Monitor	O
for	O
respiratory	O
depression,	O
especially	O
during	O
initiation	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
tablets	O
or	O
following	O
a	O
dose	O
increase	O
(	O
see	O
WARNINGS:	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
).	O
Accidental	O
Ingestion	O
Accidental	O
ingestion	O
of	O
even	O
one	O
dose	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
tablets,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
a	O
fatal	O
overdose	O
of	O
hydrocodone	O
(	O
see	O
WARNINGS:	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
).	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
tablets	O
during	O
pregnancy	O
can	O
result	O
in	O
neonatal	O
opioid	O
withdrawal	O
syndrome,	O
which	O
may	O
be	O
life-threatening	O
if	O
not	O
recognized	O
and	O
treated,	O
and	O
requires	O
management	O
according	O
to	O
protocols	O
developed	O
by	O
neonatology	O
experts.	O
If	O
opioid	O
use	O
is	O
required	O
for	O
a	O
prolonged	O
period	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available	O
(	O
see	O
WARNINGS:	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
).	O
Cytochrome	O
P450	O
3A4	O
Interaction	O
The	O
concomitant	O
use	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
tablets	O
with	O
all	O
cytochrome	O
P450	O
3A4	O
inhibitors	O
may	O
result	O
in	O
an	O
increase	O
in	O
hydrocodone	O
plasma	O
concentrations,	O
which	O
may	O
cause	O
potentially	O
fatal	O
respiratory	O
depression.	O
In	O
addition,	O
discontinuation	O
of	O
a	O
concomitantly	O
used	O
cytochrome	O
P450	O
3A4	O
inducer	O
may	O
result	O
in	O
an	O
increase	O
in	O
hydrocodone	O
plasma	O
concentration.	O
Monitor	O
patients	O
taking	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
tablets	O
and	O
any	O
CYP3A4	O
inhibitor	O
or	O
upon	O
discontinuation	O
of	O
a	O
CYP3A4	O
inducer	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation	O
(see	O
WARNINGS:	O
Risk	B-D012306
s	O
of	O
Concomitant	O
Use	O
or	O
Discontinuation	O
of	O
Cytochrome	O
P450	O
3A4	O
Inhibitors	O
and	O
Inducers,	O
PRECAUTIONS:	O
Drug	B-D004347
Interactions	I-D004347
).	O
Risk	B-D012306
s	O
From	O
Concomitant	O
Use	O
With	O
Benzodiazepines	B-D001569
Or	O
Other	O
CNS	O
Depressants	O
Concomitant	O
use	O
of	O
opioids	O
with	O
benzodiazepines	O
or	O
other	O
central	O
nervous	O
system	O
(CNS)	O
depressants,	O
including	O
alcohol,	O
may	O
result	O
in	O
profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death	O
(see	O
WARNINGS:	O
Risk	B-D012306
s	O
from	O
Concomitant	O
Use	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants,	O
PRECAUTIONS:	O
Drug	B-D004347
Interactions	I-D004347
).	O
Reserve	O
concomitant	O
prescribing	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
tablets	O
and	O
b	O
e	O
n	O
z	O
odiazepines	O
or	O
other	O
CNS	O
depressants	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
t	O
r	O
e	O
atment	O
options	O
are	O
inadequate.	O
L	O
imit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required.	O
F	O
ollow	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(	O
see	O
WARNINGS:	O
Cardiovascular	O
Thrombotic	O
Events).	O
Hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS:	O
Cardiovascular	O
Thrombotic	O
Events).	O
G	O
astrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS:	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
described	O
below	O
and	O
elsewhere	O
in	O
the	O
labeling	O
including	O
the	O
WARNINGS	O
section.	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Interactions	O
with	O
Cytochrome	O
P450	O
3A4	O
Inhibitors	O
and	O
Inducers	O
Interactions	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
Adrenal	B-D000309
Insufficiency	I-D000309
Severe	O
Hypotension	B-D007022
Seizures	B-D012640
Withdrawal	O
Cardiovascular	O
Thrombotic	O
Events	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Hepatotoxicity	O
Hypertension	B-D006973
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Anaphylactic	O
Reactions	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
Serious	O
Skin	B-D012867
Reactions	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Hematologic	O
Toxicity	O
Aseptic	O
Meningitis	B-D008581
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	O
tablets	O
was	O
administered	O
to	O
approximately	O
300	O
pain	O
patients	O
in	O
a	O
safety	O
study	O
that	O
employed	O
dosages	O
and	O
a	O
duration	O
of	O
treatment	O
sufficient	O
to	O
encompass	O
the	O
recommended	O
usage	O
(see	O
DOSAGE	O
AND	O
ADMINISTRATION).	O
Adverse	O
event	O
rates	O
generally	O
increased	O
with	O
increasing	O
daily	O
dose.	O
The	O
event	O
rates	O
reported	O
below	O
are	O
from	O
approximately	O
150	O
patients	O
who	O
were	O
in	O
a	O
group	O
that	O
received	O
one	O
tablet	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
tablets	O
an	O
average	O
of	O
three	O
to	O
four	O
times	O
daily.	O
The	O
overall	O
incidence	O
rates	O
of	O
adverse	O
experiences	O
in	O
the	O
trials	O
were	O
fairly	O
similar	O
for	O
this	O
patient	O
group	O
and	O
those	O
who	O
received	O
the	O
comparison	O
treatment,	O
acetaminophen	O
600	O
mg	O
with	O
codeine	O
60	O
mg.	O
The	O
following	O
lists	O
adverse	O
events	O
that	O
occurred	O
with	O
an	O
incidence	O
of	O
1%	O
or	O
greater	O
in	O
clinical	O
trials	O
of	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
tablets,	O
without	O
regard	O
to	O
the	O
causal	O
relationship	O
of	O
the	O
events	O
to	O
the	O
drug.	O
To	O
distinguish	O
different	O
rates	O
of	O
occurrence	O
in	O
clinical	O
studies,	O
the	O
adverse	O
events	O
are	O
listed	O
as	O
follows:	O
name	O
of	O
adverse	O
event	O
=	O
less	O
than	O
3%	O
adverse	O
events	O
marked	O
with	O
an	O
asterisk	O
*	O
=	O
3%	O
to	O
9%	O
adverse	O
event	O
rates	O
over	O
9%	O
are	O
in	O
parentheses.	O
B	O
ody	O
as	O
a	O
Whole	O
Abdominal	O
pain*;	O
Asthenia	B-D001247
*;	O
Fever	B-D005334
;	O
Flu	O
syndrome;	O
Headache	B-D006261
(27%);	O
Infection*;	O
Pain	B-D010146
.	O
Cardiovascular	O
Palpitations;	O
Vasodilation	B-D014664
.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Anxiety	B-D001007
*;	O
Confusion	B-D003221
;	O
Dizziness	B-D004244
(14%);	O
Hypertonia;	O
Insomnia*;	O
Nervousness*;	O
Paresthesia	B-D010292
;	O
Somnolence	O
(22%);	O
Thinking	B-D013850
abnormalities.	O
Digestive	O
Anorexia	B-D000855
;	O
Constipation	B-D003248
(22%);	O
Diarrhea	B-D003967
*;	O
Dry	O
mouth*;	O
Dyspepsia	B-D004415
(12%);	O
Flatulence	B-D005414
*;	O
Gastritis	B-D005756
;	O
Melena	B-D008551
;	O
Mouth	B-D009055
ulcers;	O
Nausea	B-D009325
(21%);	O
Thirst	B-D013894
;	O
Vomiting	B-D014839
*.	O
Metabolic	O
and	O
Nutritional	O
Disorders	O
Edema	B-D004487
*.	O
Respiratory	O
Dyspnea	B-D004417
;	O
Hiccup	B-D006606
s;	O
Pharyngitis	B-D010612
;	O
Rhinitis	B-D012220
.	O
Skin	B-D012867
and	O
Appendages	O
Pruritus	B-D011537
*;	O
Sweating	B-D013546
*.	O
Special	O
Senses	O
Tinnitus	B-D014012
.	O
Urogenital	O
Urinary	O
frequency.	O
Incidence	B-D015994
less	O
than	O
1%	O
Body	O
as	O
a	O
Whole	O
Allergic	O
reaction.	O
Cardiovascular	O
Arrhythmia;	O
Hypotension	B-D007022
;	O
Tachycardia	B-D013610
.	O
C	O
e	O
ntral	O
Nervous	B-D009420
System	I-D009420
Agitation;	O
Abnormal	O
dreams;	O
Decreased	O
libido;	O
Depression	B-D003863
;	O
Euphoria	B-D005059
;	O
Mood	O
changes;	O
Neuralgia	B-D009437
;	O
Slurred	O
speech;	O
Tremor	B-D014202
,	O
Vertigo	B-D014717
.	O
Digestive	O
Chalky	O
stool;	O
"Clenching	O
teeth";	O
Dysphagia;	O
Esophageal	O
spasm;	O
Esophagitis	B-D004941
;	O
Gastroenteritis	B-D005759
;	O
Glossitis	B-D005928
;	O
Liver	B-D008099
enzyme	O
elevation.	O
Me	O
tabolic	O
and	O
Nutritional	O
Weight	O
decrease.	O
M	O
usculoskeletal	O
Arthralgia	B-D018771
;	O
Myalgia	B-D063806
.	O
Respiratory	O
Asthma	B-D001249
;	O
Bronchitis	B-D001991
;	O
Hoarseness	B-D006685
;	O
Increased	O
cough;	O
Pulmonary	O
congestion;	O
Pneumonia	B-D011014
;	O
Shallow	O
breathing;	O
Sinusitis	B-D012852
.	O
Skin	B-D012867
and	O
Appendages	O
Rash;	O
Urticaria	B-D014581
.	O
Special	O
Senses	O
Altered	O
vision;	O
Bad	O
taste;	O
Dry	O
eyes.	O
Urogenital	O
Cystitis	B-D003556
;	O
Glycosuria	B-D006029
;	O
Impotence;	O
Urinary	O
incontinence;	O
Urinary	O
retention.	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
hydrocodone.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
S	O
er	O
otonin	O
syndrome:	O
Cases	O
of	O
serotonin	O
syndrome,	O
a	O
potentially	O
life-threatening	O
condition,	O
have	O
been	O
reported	O
during	O
concomitant	O
use	O
of	O
opioids	O
with	O
serotonergic	O
drugs.	O
Adrenal	O
insufficiency:	O
Cases	O
of	O
adrenal	O
insufficiency	O
have	O
been	O
reported	O
with	O
opioid	O
use,	O
more	O
often	O
following	O
greater	O
than	O
one	O
month	O
of	O
use.	O
Anaphylaxis	B-D000707
:	O
Anaphylaxis	B-D000707
has	O
been	O
reported	O
with	O
ingredients	O
contained	O
in	O
hydrocodone	O
bitartrate	O
and	O
ibuprofen	O
tablets.	O
Androgen	O
deficiency:	O
Cases	O
of	O
androgen	O
deficiency	O
have	O
occurred	O
with	O
chronic	O
use	O
of	O
opioids	O
(see	O
CLINICAL	O
PHARMACOLOGY:	O
Pharmacodynamics).	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS	O
).	O
•	O
Diflunisal	B-D004061
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATION	O
and	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
The	O
adverse	O
reactions	O
observed	O
in	O
controlled	O
clinical	O
trials	O
encompass	O
observations	O
in	O
2,427	O
patients.	O
Listed	O
below	O
are	O
the	O
adverse	O
reactions	O
reported	O
in	O
the	O
1,314	O
of	O
these	O
patients	O
who	O
received	O
treatment	O
in	O
studies	O
of	O
two	O
weeks	O
or	O
longer.	O
Five	O
hundred	O
thirteen	O
patients	O
were	O
treated	O
for	O
at	O
least	O
24	O
weeks,	O
255	O
patients	O
were	O
treated	O
for	O
at	O
least	O
48	O
weeks,	O
and	O
46	O
patients	O
were	O
treated	O
for	O
96	O
weeks.	O
In	O
general,	O
the	O
adverse	O
reactions	O
listed	O
below	O
were	O
2	O
to	O
14	O
times	O
less	O
frequent	O
in	O
the	O
1,113	O
patients	O
who	O
received	O
short-term	O
treatment	O
for	O
mild	O
to	O
moderate	O
pain.	O
Incidence	B-D015994
Greater	O
Than	O
1%	O
Gastrointestinal	O
The	O
most	O
frequent	O
types	O
of	O
adverse	O
reactions	O
occurring	O
with	O
diflunisal	O
are	O
gastrointestinal:	O
these	O
include	O
nausea*,	O
vomiting,	O
dyspepsia*,	O
gastrointestinal	O
pain*,	O
diarrhea*,	O
constipation,	O
and	O
flatulence.	O
Psychiatric	O
Somnolence,	O
insomnia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Dizziness	B-D004244
.	O
Special	O
Senses	O
Tinnitus	B-D014012
.	O
Dermatologic	O
Rash*.	O
Miscellaneous	O
Headache	B-D006261
*,	O
fatigue/tiredness.	O
*	O
Incidence	B-D015994
between	O
3%	O
and	O
9%.	O
Those	O
reactions	O
occurring	O
in	O
1%	O
to	O
3%	O
are	O
not	O
marked	O
with	O
an	O
asterisk.	O
Incidence	B-D015994
Less	O
Than	O
1	O
in	O
100	O
The	O
following	O
adverse	O
reactions,	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100,	O
were	O
reported	O
in	O
clinical	O
trials	O
or	O
since	O
the	O
drug	O
was	O
marketed.	O
The	O
probability	O
exists	O
of	O
a	O
causal	O
relationship	O
between	O
diflunisal	O
and	O
these	O
adverse	O
reactions.	O
Dermatologic	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis,	O
urticaria,	O
pruritus,	O
sweating,	O
dry	O
mucous	O
membranes,	O
stomatitis,	O
photosensitivity.	O
Gastrointestinal	O
Peptic	O
ulcer,	O
gastrointestinal	O
bleeding,	O
anorexia,	O
eructation,	O
gastrointestinal	O
perforation,	O
gastritis.	O
Liver	B-D008099
function	O
abnormalities;	O
jaundice,	O
sometimes	O
with	O
fever;	O
cholestasis;	O
hepatitis.	O
Hematologic	O
Thrombocytopenia	B-D013921
;	O
agranulocytosis;	O
hemolytic	O
anemia.	O
Genitourinary	O
Dysuria	B-D053159
;	O
renal	O
impairment,	O
including	O
renal	O
failure;	O
interstitial	O
nephritis;	O
hematuria;	O
proteinuria.	O
Psychiatric	O
Nervousness,	O
depression,	O
hallucinations,	O
confusion,	O
disorientation.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Vertigo	B-D014717
;	O
light-headedness;	O
paresthesias.	O
Special	O
Senses	O
Transient	O
visual	O
disturbances	O
including	O
blurred	O
vision.	O
Hypersensitivity	B-D006967
Reactions	O
Acute	O
anaphylactic	O
reaction	O
with	O
bronchospasm;	O
angioedema;	O
flushing.	O
Hypersensitivity	B-D006967
vasculitis.	O
Hypersensitivity	B-D006967
syndrome	O
(see	O
PRECAUTIONS	O
).	O
Miscellaneous	O
Asthenia	B-D001247
,	O
edema.	O
Causal	O
Relationship	O
Unknown	O
Other	O
reactions	O
have	O
been	O
reported	O
in	O
clinical	O
trials	O
or	O
since	O
the	O
drug	O
was	O
marketed,	O
but	O
occurred	O
under	O
circumstances	O
where	O
a	O
causal	O
relationship	O
could	O
not	O
be	O
established.	O
However,	O
in	O
these	O
rarely	O
reported	O
events,	O
that	O
possibility	O
cannot	O
be	O
excluded.	O
Therefore,	O
these	O
observations	O
are	O
listed	O
to	O
serve	O
as	O
alerting	O
information	O
to	O
physicians.	O
Respiratory	O
Dyspnea	B-D004417
.	O
Cardiovascular	O
Palpitation,	O
syncope.	O
Musculoskeletal	O
Muscle	O
cramps.	O
Genitourinary	O
Nephrotic	O
syndrome.	O
Special	O
Senses	O
Hearing	B-D006309
loss.	O
Miscellaneous	O
Chest	O
pain.	O
A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
fasciitis,	O
particularly	O
in	O
association	O
with	O
Group	O
A	O
β-hemolytic	O
streptococcus,	O
has	O
been	O
described	O
in	O
persons	O
treated	O
with	O
non-steroidal	O
anti-inflammatory	O
agents,	O
including	O
diflunisal,	O
sometimes	O
with	O
fatal	O
outcome	O
(see	O
also	O
PRECAUTIONS,	O
General	O
).	O
Potential	O
Adverse	O
Effects	O
In	O
addition,	O
a	O
variety	O
of	O
adverse	O
effects	O
not	O
observed	O
with	O
diflunisal	O
in	O
clinical	O
trials	O
or	O
in	O
marketing	O
experience,	O
but	O
reported	O
with	O
other	O
non-steroidal	O
analgesic/anti-inflammatory	O
agents	O
should	O
be	O
considered	O
potential	O
adverse	O
effects	O
of	O
diflunisal.	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Rising	O
Pharmaceuticals	O
at	O
1-866-562-4597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
for	O
ketorolac	O
tromethamine	O
ophthalmic	O
solution	O
occurring	O
in	O
approximately	O
1	O
to	O
5%	O
of	O
the	O
overall	O
study	O
population	O
were	O
conjunctival	O
hyperemia,	O
corneal	O
infiltrates,	O
headache,	O
ocular	O
edema	O
and	O
ocular	O
pain.	O
The	O
most	O
frequent	O
adverse	O
events	O
reported	O
with	O
the	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
have	O
been	O
transient	O
stinging	O
and	O
burning	O
on	O
instillation.	O
These	O
events	O
were	O
reported	O
by	O
20%	O
-	O
40%	O
of	O
patients	O
participating	O
in	O
these	O
other	O
clinical	O
trials.	O
Other	O
adverse	O
events	O
occurring	O
approximately	O
1%	O
-	O
10%	O
of	O
the	O
time	O
during	O
treatment	O
with	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
included	O
allergic	O
reactions,	O
corneal	O
edema,	O
iritis,	O
ocular	O
inflammation,	O
ocular	O
irritation,	O
ocular	O
pain,	O
superficial	O
keratitis,	O
and	O
superficial	O
ocular	O
infections.	O
Clinical	O
Practice	O
The	O
following	O
events	O
have	O
been	O
identified	O
during	O
postmarketing	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
in	O
clinical	O
practice.	O
Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size,	O
estimates	O
of	O
frequency	O
cannot	O
be	O
made.	O
The	O
events,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions,	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
corneal	O
erosion,	O
corneal	O
perforation,	O
corneal	O
thinning	O
and	O
epithelial	O
breakdown	O
(see	O
PRECAUTIONS,	O
General).	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(5.1)	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(	O
4,	O
5.1	O
)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
naproxen,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
naproxen,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
naproxen.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
,	O
can	O
lead	O
to	O
new	O
onset	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
naproxen	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Naproxen	B-D009288
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
naproxen	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
naproxen	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Naproxen	B-D009288
sodium	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Naproxen	B-D009288
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
The	O
most	O
frequent	O
adverse	O
events	O
were	O
headache	O
(15%),	O
followed	O
by	O
dyspepsia	O
(14%),	O
and	O
flu	O
syndrome	O
(10%).	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Alvogen,	O
Inc.	O
at	O
1-866-770-3024	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
As	O
with	O
all	O
drugs	O
in	O
this	O
class,	O
the	O
frequency	O
and	O
severity	O
of	O
adverse	O
events	O
depends	O
on	O
several	O
factors:	O
the	O
dose	O
of	O
the	O
drug	O
and	O
duration	O
of	O
treatment;	O
the	O
age,	O
the	O
sex,	O
physical	O
condition	O
of	O
the	O
patient;	O
any	O
concurrent	O
medical	O
diagnoses	O
or	O
individual	O
risk	O
factors.	O
The	O
following	O
adverse	O
reactions	O
are	O
divided	O
into	O
three	O
parts	O
based	O
on	O
frequency	O
and	O
whether	O
or	O
not	O
the	O
possibility	O
exists	O
of	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
these	O
adverse	O
events.	O
In	O
those	O
reactions	O
listed	O
as	O
“Probable	O
Causal	O
Relationship”	O
there	O
is	O
at	O
least	O
one	O
case	O
for	O
each	O
adverse	O
reaction	O
where	O
there	O
is	O
evidence	O
to	O
suggest	O
that	O
there	O
is	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
the	O
reported	O
event.	O
The	O
adverse	O
reactions	O
reported	O
were	O
based	O
on	O
the	O
results	O
from	O
two	O
double-blind	O
controlled	O
clinical	O
trials	O
of	O
three	O
months	O
duration	O
with	O
an	O
additional	O
nine	O
month	O
open-label	O
extension.	O
A	O
total	O
of	O
542	O
patients	O
received	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
either	O
in	O
the	O
double-blind	O
period	O
or	O
in	O
the	O
nine	O
month	O
open-label	O
extension.	O
Of	O
these	O
542	O
patients,	O
232	O
received	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
,	O
167	O
were	O
initially	O
treated	O
with	O
Naprosyn®	O
and	O
143	O
were	O
initially	O
treated	O
with	O
placebo.	O
Adverse	O
reactions	O
reported	O
by	O
patients	O
who	O
received	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
shown	O
by	O
body	O
system.	O
Those	O
adverse	O
reactions	O
observed	O
with	O
naproxen	O
but	O
not	O
reported	O
in	O
controlled	O
trials	O
with	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
italicized.	O
The	O
most	O
frequent	O
adverse	O
events	O
from	O
the	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
were	O
headache	O
(15%),	O
followed	O
by	O
dyspepsia	O
(14%),	O
and	O
flu	O
syndrome	O
(10%).	O
The	O
incidence	O
of	O
other	O
adverse	O
events	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
the	O
patients	O
are	O
marked	O
with	O
an	O
asterisk.	O
Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.	O
Incidence	B-D015994
greater	O
than	O
1%	O
(probable	O
causal	O
relationship)	O
Body	O
as	O
a	O
Whole—Pain	O
(back)*,	O
pain*,	O
infection*,	O
fever,	O
injury	O
(accident),	O
asthenia,	O
pain	O
chest,	O
headache	O
(15%),	O
flu	O
syndrome	O
(10%).	O
Gastrointestinal—Nausea*,	O
diarrhea*,	O
constipation*,	O
abdominal	O
pain*,	O
flatulence,	O
gastritis,	O
vomiting,	O
dysphagia,	O
dyspepsia	O
(14%),	O
heartburn*,	O
stomatitis.	O
Hematologic—Anemia,	O
ecchymosis.	O
Respiratory—Pharyngitis*,	O
rhinitis*,	O
sinusitis*,	O
bronchitis,	O
cough	O
increased.	O
Renal—Urinary	O
tract	O
infection*,	O
cystitis.	O
Dermatologic—Skin	O
rash*,	O
skin	O
eruptions*,	O
ecchymoses*,	O
purpura.	O
Metabolic	O
and	O
Nutrition—Peripheral	O
edema,	O
hyperglycemia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Dizziness,	O
paresthesia,	O
insomnia,	O
drowsiness*,	O
lightheadedness.	O
Cardiovascular—Hypertension,	O
edema*,	O
dyspnea*,	O
palpitations.	O
Musculoskeletal—Cramps	O
(leg),	O
myalgia,	O
arthralgia,	O
joint	O
disorder,	O
tendon	O
disorder.	O
Special	O
Senses—Tinnitus*,	O
hearing	O
disturbances,	O
visual	O
disturbances.	O
General—Thirst.	O
Incidence	B-D015994
less	O
than	O
1%	O
(probable	O
causal	O
relationship)	O
Body	O
as	O
a	O
Whole—Abscess,	O
monilia,	O
neck	O
rigid,	O
pain	O
neck,	O
abdomen	O
enlarged,	O
carcinoma,	O
cellulitis,	O
edema	O
general,	O
LE	O
syndrome,	O
malaise,	O
mucous	O
membrane	O
disorder,	O
allergic	O
reaction,	O
pain	O
pelvic.	O
Gastrointestinal—Anorexia,	O
cholecystitis,	O
cholelithiasis,	O
eructation,	O
GI	O
hemorrhage,	O
rectal	O
hemorrhage,	O
stomatitis	O
aphthous,	O
stomatitis	O
ulcer,	O
ulcer	O
mouth,	O
ulcer	O
stomach,	O
periodontal	O
abscess,	O
cardiospasm,	O
colitis,	O
esophagitis,	O
gastroenteritis,	O
GI	O
disorder,	O
rectal	O
disorder,	O
tooth	O
disorder,	O
hepatosplenomegaly,	O
liver	O
function	O
abnormality,	O
melena,	O
ulcer	O
esophagus,	O
hematemesis,	O
jaundice,	O
pancreatitis,	O
necrosis.	O
Renal—Dysmenorrhea,	O
dysuria,	O
kidney	O
function	O
abnormality,	O
nocturia,	O
prostate	O
disorder,	O
pyelonephritis,	O
carcinoma	O
breast,	O
urinary	O
incontinence,	O
kidney	O
calculus,	O
kidney	O
failure,	O
menorrhagia,	O
metrorrhagia,	O
neoplasm	O
breast,	O
nephrosclerosis,	O
hematuria,	O
pain	O
kidney,	O
pyuria,	O
urine	O
abnormal,	O
urinary	O
frequency,	O
urinary	O
retention,	O
uterine	O
spasm,	O
vaginitis,	O
glomerular	O
nephritis,	O
hyperkalemia,	O
interstitial	O
nephritis,	O
nephrotic	O
syndrome,	O
renal	O
disease,	O
renal	O
failure,	O
renal	O
papillary	O
necrosis.	O
Hematologic—Leukopenia,	O
bleeding	O
time	O
increased,	O
eosinophilia,	O
abnormal	O
RBC,	O
abnormal	O
WBC,	O
thrombocytopenia,	O
agranulocytosis,	O
granulocytopenia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Depression,	O
anxiety,	O
hypertonia,	O
nervousness,	O
neuralgia,	O
neuritis,	O
vertigo,	O
amnesia,	O
confusion,	O
co-ordination,	O
abnormal	O
diplopia,	O
emotional	O
lability,	O
hematoma	O
subdural,	O
paralysis,	O
dream	O
abnormalities,	O
inability	O
to	O
concentrate,	O
muscle	O
weakness.	O
Dermatologic:	O
Angiodermatitis,	O
herpes	O
simplex,	O
dry	O
skin,	O
sweating,	O
ulcer	O
skin,	O
acne,	O
alopecia,	O
dermatitis	O
contact,	O
eczema,	O
herpes	O
zoster,	O
nail	O
disorder,	O
skin	O
necrosis,	O
subcutaneous	O
nodule,	O
pruritus,	O
urticaria,	O
neoplasm	O
skin,	O
photosensitive	O
dermatitis,	O
photosensitivity	O
reactions	O
resembling	O
porphyria	O
cutaneous	O
tarda,	O
epidermolysis	O
bullosa.	O
Special	O
Senses—Amblyopia,	O
scleritis,	O
cataract,	O
conjunctivitis,	O
deaf,	O
ear	O
disorder,	O
keratoconjunctivitis,	O
lacrimation	O
disorder,	O
otitis	O
media,	O
pain	O
eye.	O
Cardiovascular—Angina	O
pectoris,	O
coronary	O
artery	O
disease,	O
myocardial	O
infarction,	O
deep	O
thrombophlebitis,	O
vasodilation,	O
vascular	O
anomaly,	O
arrhythmia,	O
bundle	O
branch	O
block,	O
abnormal	O
ECG,	O
heart	O
failure	O
right,	O
hemorrhage,	O
migraine,	O
aortic	O
stenosis,	O
syncope,	O
tachycardia,	O
congestive	O
heart	O
failure.	O
Respiratory—Asthma,	O
dyspnea,	O
lung	O
edema,	O
laryngitis,	O
lung	O
disorder,	O
epistaxis,	O
pneumonia,	O
respiratory	O
distress,	O
respiratory	O
disorder,	O
eosinophilic	O
pneumonitis.	O
Musculoskeletal—Myasthenia,	O
bone	O
disorder,	O
spontaneous	O
bone	O
fracture,	O
fibrotendinitis,	O
bone	O
pain,	O
ptosis,	O
spasm	O
general,	O
bursitis.	O
Metabolic	O
and	O
Nutrition—Creatinine	O
increase,	O
glucosuria,	O
hypercholesteremia,	O
albuminuria,	O
alkalosis,	O
BUN	O
increased,	O
dehydration,	O
edema,	O
glucose	O
tolerance	O
decrease,	O
hyperuricemia,	O
hypokalemia,	O
SGOT	O
increase,	O
SGPT	O
increase,	O
weight	O
decrease.	O
General—Anaphylactoid	O
reactions,	O
angioneurotic	O
edema,	O
menstrual	O
disorders,	O
hypoglycemia,	O
pyrexia	O
(chills	O
and	O
fevers).	O
Incidence	B-D015994
less	O
than	O
1%	O
(causal	O
relationship	O
unknown)	O
Other	O
adverse	O
reactions	O
listed	O
in	O
the	O
naproxen	O
package	O
label,	O
but	O
not	O
reported	O
by	O
those	O
who	O
received	O
Naproxen	B-D009288
Sodium	B-D012964
Controlled-Release	O
Tablets	B-D013607
are	O
shown	O
in	O
italics.	O
These	O
observations	O
are	O
being	O
listed	O
as	O
alerting	O
information	O
to	O
the	O
physician.	O
Hematologic—Aplastic	O
anemia,	O
hemolytic	O
anemia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Aseptic	O
meningitis,	O
cognitive	O
dysfunction.	O
Dermatologic—Epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome.	O
Gastrointestinal—Non-peptic	O
GI	O
ulceration,	O
ulcerative	O
stomatitis.	O
Cardiovascular—Vasculitis.	O
Cardiovascular	O
Thrombotic	O
Events	O
•Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
•Diflunisal	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
adverse	O
reactions	O
observed	O
in	O
controlled	O
clinical	O
trials	O
encompass	O
observations	O
in	O
2,427	O
patients.	O
Listed	O
below	O
are	O
the	O
adverse	O
reactions	O
reported	O
in	O
the	O
1,314	O
of	O
these	O
patients	O
who	O
received	O
treatment	O
in	O
studies	O
of	O
two	O
weeks	O
or	O
longer.	O
Five	O
hundred	O
thirteen	O
patients	O
were	O
treated	O
for	O
at	O
least	O
24	O
weeks,	O
255	O
patients	O
were	O
treated	O
for	O
at	O
least	O
48	O
weeks,	O
and	O
46	O
patients	O
were	O
treated	O
for	O
96	O
weeks.	O
In	O
general,	O
the	O
adverse	O
reactions	O
listed	O
below	O
were	O
2	O
to	O
14	O
times	O
less	O
frequent	O
in	O
the	O
1,113	O
patients	O
who	O
received	O
short-term	O
treatment	O
for	O
mild	O
to	O
moderate	O
pain.	O
Incidence	B-D015994
Greater	O
Than	O
1%	O
Gastrointestinal	O
The	O
most	O
frequent	O
types	O
of	O
adverse	O
reactions	O
occurring	O
with	O
diflunisal	O
are	O
gastrointestinal:	O
these	O
include	O
nausea*,	O
vomiting,	O
dyspepsia*,	O
gastrointestinal	O
pain*,	O
diarrhea*,	O
constipation,	O
and	O
flatulence.	O
Psychiatric	O
Somnolence,	O
insomnia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Dizziness	B-D004244
.	O
Special	O
Senses	O
Tinnitus	B-D014012
.	O
Dermatologic	O
Rash*.	O
Miscellaneous	O
Headache	B-D006261
*,	O
fatigue/tiredness.	O
*	O
Incidence	B-D015994
between	O
3%	O
and	O
9%.	O
Those	O
reactions	O
occurring	O
in	O
1%	O
to	O
3%	O
are	O
not	O
marked	O
with	O
an	O
asterisk.	O
Incidence	B-D015994
Less	O
Than	O
1	O
in	O
100	O
The	O
following	O
adverse	O
reactions,	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100,	O
were	O
reported	O
in	O
clinical	O
trials	O
or	O
since	O
the	O
drug	O
was	O
marketed.	O
The	O
probability	O
exists	O
of	O
a	O
causal	O
relationship	O
between	O
diflunisal	O
and	O
these	O
adverse	O
reactions.	O
Dermatologic	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis,	O
urticaria,	O
pruritus,	O
sweating,	O
dry	O
mucous	O
membranes,	O
stomatitis,	O
photosensitivity.	O
Gastrointestinal	O
Peptic	O
ulcer,	O
gastrointestinal	O
bleeding,	O
anorexia,	O
eructation,	O
gastrointestinal	O
perforation,	O
gastritis.	O
Liver	B-D008099
function	O
abnormalities;	O
jaundice,	O
sometimes	O
with	O
fever;	O
cholestasis;	O
hepatitis.	O
Hematologic	O
Thrombocytopenia	B-D013921
;	O
agranulocytosis;	O
hemolytic	O
anemia.	O
Genitourinary	O
Dysuria	B-D053159
;	O
renal	O
impairment,	O
including	O
renal	O
failure;	O
interstitial	O
nephritis;	O
hematuria;	O
proteinuria.	O
Psychiatric	O
Nervousness,	O
depression,	O
hallucinations,	O
confusion,	O
disorientation.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Vertigo	B-D014717
;	O
light-headedness;	O
paresthesias.	O
Special	O
Senses	O
Transient	O
visual	O
disturbances	O
including	O
blurred	O
vision.	O
Hypersensitivity	B-D006967
Reactions	O
Acute	O
anaphylactic	O
reaction	O
with	O
bronchospasm;	O
angioedema;	O
flushing.	O
Hypersensitivity	B-D006967
vasculitis.	O
Hypersensitivity	B-D006967
syndrome	O
(see	O
PRECAUTIONS).	O
Miscellaneous	O
Asthenia	B-D001247
,	O
edema.	O
Causal	O
Relationship	O
Unknown	O
Other	O
reactions	O
have	O
been	O
reported	O
in	O
clinical	O
trials	O
or	O
since	O
the	O
drug	O
was	O
marketed,	O
but	O
occurred	O
under	O
circumstances	O
where	O
a	O
causal	O
relationship	O
could	O
not	O
be	O
established.	O
However,	O
in	O
these	O
rarely	O
reported	O
events,	O
that	O
possibility	O
cannot	O
be	O
excluded.	O
Therefore,	O
these	O
observations	O
are	O
listed	O
to	O
serve	O
as	O
alerting	O
information	O
to	O
physicians.	O
Respiratory	O
Dyspnea	B-D004417
.	O
Cardiovascular	O
Palpitation,	O
syncope.	O
Musculoskeletal	O
Muscle	O
cramps.	O
Genitourinary	O
Nephrotic	O
syndrome.	O
Special	O
Senses	O
Hearing	B-D006309
loss.	O
Miscellaneous	O
Chest	O
pain.	O
A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
fasciitis,	O
particularly	O
in	O
association	O
with	O
Group	O
A	O
β-hemolytic	O
streptococcus,	O
has	O
been	O
described	O
in	O
persons	O
treated	O
with	O
non-steroidal	O
anti-inflammatory	O
agents,	O
including	O
diflunisal,	O
sometimes	O
with	O
fatal	O
outcome	O
(see	O
also	O
PRECAUTIONS,	O
General).	O
Potential	O
Adverse	O
Effects	O
In	O
addition,	O
a	O
variety	O
of	O
adverse	O
effects	O
not	O
observed	O
with	O
diflunisal	O
in	O
clinical	O
trials	O
or	O
in	O
marketing	O
experience,	O
but	O
reported	O
with	O
other	O
non-steroidal	O
analgesic/anti-inflammatory	O
agents	O
should	O
be	O
considered	O
potential	O
adverse	O
effects	O
of	O
diflunisal.	O
Cardiovascular	O
Thrombotic	O
Events	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
].	O
Etodolac	B-D017308
extended-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
and	O
Warnings	O
and	O
Precautions	O
]	O
.	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions].	O
ADVERSE	O
REACTIONS	O
A	O
total	O
of	O
1552	O
patients	O
were	O
exposed	O
to	O
etodolac	O
extended-release	O
tablets	O
in	O
controlled	O
clinical	O
studies	O
of	O
at	O
least	O
4	O
weeks	O
in	O
length	O
and	O
using	O
daily	O
doses	O
in	O
the	O
range	O
of	O
400	O
to	O
1200	O
mg.	O
In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
incidence	O
of	O
events	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	O
extended-release	O
tablets.	O
As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
time	O
with	O
extended	O
therapy.	O
In	O
patients	O
taking	O
NSAIDs,	O
including	O
etodolac	O
extended-release	O
tablets,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including	O
abdominal	O
pain	O
constipation	O
Diarrhea	B-D003967
dyspepsia	O
flatulence	O
GI	O
ulcers	O
(gastric/duodenal)*	O
gross	O
bleeding/perforation	O
*	O
nausea	O
Vomiting	B-D014839
Other	O
events	O
including:	O
abnormal	O
renal	O
function	O
Adverse	O
events	O
that	O
were	O
observed	O
in	O
<	O
1%	O
of	O
patients	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	O
extended-release	O
tablets	O
in	O
clinical	O
trials.	O
Anemia	B-D000740
asthenia	O
dizziness	O
edema	O
elevated	O
liver	O
enzymes	O
headaches	O
hypertension	O
increased	O
bleeding	O
time	O
infection	O
pharyngitis	O
pruritus	O
rashes	O
rhinitis	O
tinnitus	O
Additional	O
NSAID	O
Adverse	O
Experiences	O
Reported	O
Occasionally	O
with	O
NSAIDs	O
or	O
Etodolac	B-D017308
Extended-release	O
Tablets	B-D013607
Include	O
Body	O
as	O
a	O
whole	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock),	O
chills,	O
fever,	O
sepsis	O
Cardiovascular	O
system	O
Congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
tachycardia,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic)	O
Digestive	O
system	O
Anorexia	B-D000855
,	O
cholestatic	O
hepatitis,	O
cholestatic	O
jaundice,	O
dry	O
mouth,	O
duodenitis,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastric/peptic	O
ulcers,	O
glossitis,	O
hepatic	O
failure,	O
hepatitis,	O
hematemesis,	O
intestinal	O
ulceration,	O
jaundice,	O
liver	O
necrosis,	O
melena,	O
pancreatitis,	O
rectal	O
bleeding,	O
stomatitis	O
Hemic	O
and	O
lymphatic	O
system	O
Agranulocytosis	B-D000380
,	O
ecchymosis,	O
eosinophilia,	O
hemolytic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia,	O
purpura,	O
thrombocytopenia	O
Metabolic	O
and	O
nutritional	O
Hyperglycemia	B-D006943
in	O
previously	O
controlled	O
diabetic	O
patients	O
Nervous	O
system	O
Anxiety	B-D001007
,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
insomnia,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
Asthma	B-D001249
,	O
dyspnea,	O
pulmonary	O
infiltration	O
with	O
eosinophilia	O
Skin	B-D012867
and	O
appendages	O
Angioedema	B-D000799
,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
erythema	O
multiforme,	O
hyperpigmentation,	O
sweating,	O
urticaria,	O
vesiculobullous	O
rash	O
Special	O
senses	O
Blurred	O
vision,	O
photophobia,	O
transient	O
visual	O
disturbances	O
Urogenital	O
system	O
Dysuria	B-D053159
,	O
elevated	O
BUN,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis,	O
serum	O
creatinine	O
increase,	O
urinary	O
frequency	O
Other	O
NSAID	O
Adverse	O
Reactions,	O
Which	O
Occur	O
Rarely	O
Are	O
Body	O
as	O
a	O
whole	O
Anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	O
system	O
Arrhythmia,	O
cerebrovascular	O
accident,	O
hypotension,	O
myocardial	O
infarction	O
Digestive	O
system	O
Colitis	B-D003092
,	O
esophagitis	O
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
thirst,	O
ulcerative	O
stomatitis	O
Hemic	O
and	O
lymphatic	O
system	O
Aplastic	O
anemia,	O
lymphadenopathy	O
Metabolic	O
and	O
nutritional	O
Change	O
in	O
weight	O
Nervous	O
system	O
Coma	B-D003128
,	O
convulsions,	O
hallucinations,	O
meningitis	O
Respiratory	O
Bronchitis	B-D001991
,	O
pneumonia,	O
respiratory	O
depression,	O
sinusitis	O
Skin	B-D012867
and	O
appendages	O
Alopecia	B-D000505
,	O
exfoliative	O
dermatitis,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrosis	O
Special	O
senses	O
Conjunctivitis	B-D003231
,	O
deafness,	O
hearing	O
impairment,	O
taste	O
perversion	O
Urogenital	O
system	O
Cystitis	B-D003556
,	O
hematuria,	O
interstitial	O
nephritis,	O
leukorrhea,	O
renal	O
calculus,	O
uterine	O
bleeding	O
irregularities	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
in	O
the	O
perioperative	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)].	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDS)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1)	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.2)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
Use	O
the	O
lowest	O
effective	O
dose	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
(5.1)	O
NSAIDs	O
can	O
cause	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation.	O
Prescribe	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
(5.2)	O
Elevation	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
NSAIDs.	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen.	O
(5.3)	O
Hypertension	B-D006973
can	O
occur	O
with	O
NSAID	O
treatment.	O
Monitor	O
blood	O
pressure	O
closely	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
treatment.	O
(5.4)	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
(5.5)	O
Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
at	O
greatest	O
risk	O
of	O
this	O
reaction,	O
including	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors.	O
(5.6)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
or	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution.	O
(5.7)	O
NSAIDs	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
(5.8)	O
Not	O
for	O
use	O
during	O
pregnancy.	O
(5.9)	O
Do	O
not	O
administer	O
to	O
patients	O
with	O
aspirin	O
sensitive	O
asthma	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
(5.10)	O
Avoid	O
exposure	O
of	O
treated	O
knee(s)	O
to	O
natural	O
or	O
artificial	O
sunlight.	O
(5.11)	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
(5.12)	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs.	O
(5.13)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
oral	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
COX-2	O
selective	O
and	O
nonselective	O
orally	O
administered	O
NSAIDs,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Inform	O
patients	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
an	O
orally	O
administered	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
NSAIDS,	O
such	O
as	O
diclofenac,	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Prescribe	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore,	O
use	O
special	O
care	O
when	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
diclofencac	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs.	O
5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
[ULN]	O
range)	O
or	O
greater	O
elevations	O
of	O
transaminases	O
occurred	O
in	O
about	O
15%	O
of	O
oral	O
diclofenac-treated	O
patients	O
in	O
clinical	O
trials	O
of	O
indications	O
other	O
than	O
acute	O
pain.	O
Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	O
injury.	O
In	O
clinical	O
trials	O
of	O
an	O
oral	O
diclofenac	O
–	O
misoprostol	O
combination	O
product,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
for	O
2	O
to	O
6	O
months,	O
patients	O
with	O
oral	O
diclofenac	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(>8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
this	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(>8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
test	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
oral	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
sever	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
oral	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Measure	O
transaminases	O
(ALT	O
and	O
AST)	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
monitor	O
transaminases	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flulike"	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
to	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver-related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
certain	O
antibiotics,	O
antiepileptics).	O
Caution	O
patients	O
to	O
avoid	O
taking	O
unprescribed	O
acetaminophen	O
while	O
using	O
diclofenac	O
sodium	O
topical	O
solution.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac,	O
can	O
lead	O
to	O
new	O
onset	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Use	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Monitor	O
blood	O
pressure	O
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
Patients	B-D010361
taking	O
ACE-inhibitors,	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution.	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
considerable	O
dehydration.	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
is	O
not	O
recommended	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
diclofenac	O
sodium	O
topical	O
solution	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution.	O
Do	O
not	O
prescribe	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.10)].	O
Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Do	O
not	O
apply	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
open	O
skin	O
wounds,	O
infections,	O
inflammations,	O
or	O
exfoliative	O
dermatitis,	O
as	O
it	O
may	O
affect	O
absorption	O
and	O
tolerability	O
of	O
the	O
drug.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations,	O
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
should	O
not	O
be	O
used	O
by	O
pregnant	O
or	O
nursing	O
women	O
or	O
those	O
intending	O
to	O
become	O
pregnant.	O
5.10	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross-reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
do	O
not	O
administer	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.11	O
Sun	O
Exposure	O
Instruct	O
patients	O
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
knee(s)	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light-induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.13	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	O
and	O
conduct	O
periodic	O
laboratory	O
evaluations.	O
5.14	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-response	O
illness.	O
For	O
patients	O
on	O
prolonged	O
corticosteroid	O
therapy,	O
taper	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Hematological	O
Effects	O
The	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	O
subjects	O
administered	O
80	O
drops	O
four	O
times	O
a	O
day	O
for	O
7	O
days.	O
There	O
was	O
no	O
significant	O
change	O
in	O
platelet	O
aggregation	O
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)].	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
Check	O
hemoglobin	O
or	O
hematocrit	O
of	O
patients	O
on	O
diclofenac	O
sodium	O
topical	O
solution	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration	O
and	O
reversible.	O
Carefully	O
monitor	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alteration	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants.	O
5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms	O
in	O
patients	O
taking	O
NSAIDs,	O
monitor	O
patients	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Check	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
in	O
patients	O
on	O
long-term	O
treatment	O
with	O
NSAIDs.	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
if	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen.	O
6.	O
ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
are	O
application	O
site	O
reactions.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
IGI	O
Laboratories	B-D007753
,	O
Inc.	O
at	O
1-856-697-1441,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trial	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution	O
of	O
911	O
patients	O
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	O
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	O
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	O
treated	O
for	O
at	O
least	O
12	O
months.	O
The	O
population	O
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	O
were	O
Caucasians,	O
64%	O
were	O
females,	O
and	O
all	O
patients	O
had	O
primary	O
osteoarthritis.	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies.	O
Application	O
site	O
reactions:	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment	O
related	O
adverse	O
events	O
in	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
Application	O
site	O
reactions	O
were	O
characterized	O
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	O
induration,	O
vesicles,	O
paresthesia,	O
pruritus,	O
vasodilation,	O
acne,	O
and	O
urticaria.	O
The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	O
(32%),	O
contact	O
dermatitis	O
characterized	O
by	O
skin	O
erythema	O
and	O
induration	O
(9%),	O
contact	O
dermatitis	O
with	O
vescicles	O
(2%)	O
and	O
pruritus	O
(4%).	O
In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	O
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac.	O
In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	O
study,	O
contact	O
dermatitis	O
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	O
with	O
vesicles	O
in	O
10%	O
of	O
patients,	O
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	O
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%.	O
Adverse	O
events	O
common	O
to	O
the	O
NSAID	O
class:	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
flatulence,	O
abdominal	O
pain,	O
edema;	O
see	O
Table	O
1).	O
The	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac,	O
compared	O
to	O
oral	O
diclofenac	O
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	O
(3%	O
vs.	O
less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	O
(12%	O
vs.	O
7%),	O
urea	O
(20%	O
vs.	O
12%),	O
and	O
hemoglobin	O
(13%	O
vs.	O
9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	O
transaminases.	O
Table	O
1:	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
osteoarthritis.	O
Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	O
trials.	O
Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
SolutionN=911	O
Topical	O
PlaceboN=332	O
Adverse	O
ReactionPreferred	O
Term	O
according	O
to	O
COSTART	O
N(%)	O
N(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non	O
–	O
U.S.	O
postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
Whole:	O
abdominal	O
pain,	O
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	O
back	O
pain,	O
body	O
odor,	O
chest	O
pain,	O
edema,	O
face	O
edema,	O
halitosis,	O
headache,	O
lack	O
of	O
drug	O
effect,	O
neck	O
rigidity,	O
pain	O
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	O
dry	O
mouth,	O
dyspepsia,	O
gastroenteritis,	O
decreased	O
appetite,	O
mouth	O
ulceration,	O
nausea,	O
rectal	O
hemorrhage,	O
ulcerative	O
stomatitis	O
Metabolic	O
and	O
Nutritional:	O
creatinine	O
increased	O
Musculoskeletal:	O
leg	O
cramps,	O
myalgia	O
Nervous:	O
depression,	O
dizziness,	O
drowsiness,	O
lethargy,	O
paresthesia,	O
paresthesia	O
at	O
application	O
site	O
Respiratory:	O
asthma,	O
dyspnea,	O
laryngismus,	O
laryngitis,	O
pharyngitis	O
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	O
contact	O
dermatitis	O
with	O
vesicles,	O
dry	O
skin,	O
pruritus,	O
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	O
rash,	O
pruritus,	O
skin	O
discoloration,	O
urticaria	O
Special	O
senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	O
ear	O
pain,	O
eye	O
disorder,	O
eye	O
pain,	O
taste	O
perversion	O
BOXED	O
WARNING	O
SECTION	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
423	O
patients	O
evaluable	O
for	O
safety	O
in	O
adequate	O
and	O
well-controlled	O
trials,	O
211	O
were	O
treated	O
with	O
diclofenac	O
sodium	O
gel,	O
3%	O
drug	O
product	O
and	O
212	O
were	O
treated	O
with	O
a	O
vehicle	O
gel.	O
Eighty-seven	O
percent	O
(87%)	O
of	O
the	O
diclofenac	O
sodium	O
gel,	O
3%-treated	O
patients	O
(183	O
patients)	O
and	O
84%	O
of	O
the	O
vehicle-treated	O
patients	O
(178	O
patients)	O
experienced	O
one	O
or	O
more	O
adverse	O
events	O
(AEs)	O
during	O
the	O
studies.	O
The	O
majority	O
of	O
these	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
upon	O
discontinuation	O
of	O
therapy.	O
Of	O
the	O
211	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
gel,	O
3%,	O
172	O
(82%)	O
experienced	O
AEs	O
involving	O
skin	O
and	O
the	O
application	O
site	O
compared	O
to	O
160	O
(75%)	O
vehicle-treated	O
patients.	O
Application	O
site	O
reactions	O
(ASRs)	O
were	O
the	O
most	O
frequent	O
AEs	O
in	O
both	O
diclofenac	O
sodium	O
gel,	O
3%-and	O
vehicle-treated	O
groups.	O
Of	O
note,	O
four	O
reactions,	O
contact	O
dermatitis,	O
rash,	O
dry	O
skin	O
and	O
exfoliation	O
(scaling)	O
were	O
significantly	O
more	O
prevalent	O
in	O
the	O
diclofenac	O
sodium	O
gel,	O
3%	O
group	O
than	O
in	O
the	O
vehicle-treated	O
patients.	O
Eighteen	O
percent	O
of	O
diclofenac	O
sodium	O
gel,	O
3%-treated	O
patients	O
and	O
4%	O
of	O
vehicle-treated	O
patients	O
discontinued	O
from	O
the	O
clinical	O
trials	O
due	O
to	O
adverse	O
events	O
(whether	O
considered	O
related	O
to	O
treatment	O
or	O
not).	O
These	O
discontinuations	O
were	O
mainly	O
due	O
to	O
skin	O
irritation	O
or	O
related	O
cutaneous	O
adverse	O
reactions.	O
Table	O
1	O
below	O
presents	O
the	O
AEs	O
reported	O
at	O
an	O
incidence	O
of	O
>1%	O
for	O
patients	O
treated	O
with	O
either	O
diclofenac	O
sodium	O
gel,	O
3%	O
or	O
vehicle	O
(60-	O
and	O
90-day	O
treatment	O
groups)	O
during	O
the	O
phase	O
3	O
studies.	O
Table	O
1.	O
Adverse	O
Events	O
Reported	O
(>1%	O
in	O
Any	O
Treatment	O
Group)	O
During	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
Phase	O
3	O
Clinical	B-D016430
Trial	I-D016430
s	O
Incidence	B-D015994
s	O
for	O
60-Day	O
and	O
90-Day	O
Treatments	O
60-day	O
Treatment	O
90-day	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
(%)	O
N=48	O
Gel	O
Vehicle	O
(%)	O
N=49	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
(%)	O
N=114	O
Gel	O
Vehicle	O
(%)	O
N=114	O
BODY	O
AS	O
A	O
WHOLE	O
21	O
20	O
20	O
18	O
Abdominal	B-D015746
Pain	I-D015746
2	O
0	O
1	O
0	O
Accidental	O
Injury	O
0	O
0	O
4	O
2	O
Allergic	O
Reaction	O
0	O
0	O
1	O
3	O
Asthenia	B-D001247
0	O
0	O
2	O
0	O
Back	B-D001416
Pain	I-D001416
4	O
0	O
2	O
2	O
Chest	B-D002637
Pain	I-D002637
2	O
0	O
1	O
0	O
Chills	B-D023341
0	O
2	O
0	O
0	O
Flu	O
Syndrome	B-D013577
10	O
6	O
1	O
4	O
Headache	B-D006261
0	O
6	O
7	O
6	O
Infection	O
4	O
6	O
4	O
5	O
Neck	B-D019547
Pain	I-D019547
0	O
0	O
2	O
0	O
Pain	B-D010146
2	O
0	O
2	O
2	O
CARDIOVASCULAR	O
SYSTEM	O
2	O
4	O
3	O
1	O
Hypertension	B-D006973
2	O
0	O
1	O
0	O
Migraine	O
0	O
2	O
1	O
0	O
Phlebitis	B-D010689
0	O
2	O
0	O
0	O
DIGESTIVE	O
SYSTEM	O
4	O
0	O
6	O
8	O
Constipation	B-D003248
0	O
0	O
0	O
2	O
Diarrhea	B-D003967
2	O
0	O
2	O
3	O
Dyspepsia	B-D004415
2	O
0	O
3	O
4	O
METABOLICS	O
AND	O
NUTRITIONAL	O
DISORDERS	O
2	O
8	O
7	O
2	O
Creatine	B-D003401
Phosphokinase	O
Increased	O
0	O
0	O
4	O
1	O
Creatinine	B-D003404
Increased	O
2	O
2	O
0	O
1	O
Edema	B-D004487
0	O
2	O
0	O
0	O
Hypercholesteremia	O
0	O
2	O
1	O
0	O
Hyperglycemia	B-D006943
0	O
2	O
1	O
0	O
SGOT	O
Increased	O
0	O
0	O
3	O
0	O
SGPT	O
Increased	O
0	O
0	O
2	O
0	O
MUSCULOSKELETAL	O
SYSTEM	O
4	O
0	O
3	O
4	O
Arthralgia	B-D018771
2	O
0	O
0	O
2	O
Art	B-D001154
hrosis	O
2	O
0	O
0	O
0	O
Myalgia	B-D063806
2	O
0	O
3	O
1	O
NERVOUS	O
SYSTEM	O
2	O
2	O
2	O
5	O
Anxiety	B-D001007
0	O
2	O
0	O
1	O
Dizziness	B-D004244
0	O
0	O
0	O
4	O
Hypokinesia	B-D018476
2	O
0	O
0	O
0	O
RESPIRATORY	O
SYSTEM	O
8	O
8	O
7	O
6	O
Asthma	B-D001249
2	O
0	O
0	O
0	O
Dyspnea	B-D004417
2	O
0	O
2	O
0	O
Pharyngitis	B-D010612
2	O
8	O
2	O
4	O
Pneumonia	B-D011014
2	O
0	O
0	O
1	O
Rhinitis	B-D012220
2	O
2	O
2	O
2	O
Sinusitis	B-D012852
0	O
0	O
2	O
0	O
SKIN	O
AND	O
APPENDAGES	O
75	O
86	O
86	O
71	O
Acne	O
0	O
2	O
0	O
1	O
Application	O
Site	O
Reaction	O
75	O
71	O
84	O
70	O
Acne	O
0	O
4	O
1	O
0	O
Alopecia	B-D000505
2	O
0	O
1	O
1	O
Contact	O
Dermatitis	B-D003872
19	O
4	O
33	O
4	O
Dry	O
Skin	B-D012867
27	O
12	O
25	O
17	O
Edema	B-D004487
4	O
0	O
3	O
0	O
Exfoliation	O
6	O
4	O
24	O
13	O
Hyperesthesia	B-D006941
0	O
0	O
3	O
1	O
Pain	B-D010146
15	O
22	O
26	O
30	O
Paresthesia	B-D010292
8	O
4	O
20	O
20	O
Photosensitivity	O
Reaction	O
0	O
2	O
3	O
0	O
Pruritus	B-D011537
31	O
59	O
52	O
45	O
Rash	O
35	O
20	O
46	O
17	O
Vesiculobullous	O
Rash	O
0	O
0	O
4	O
1	O
Contact	O
Dermatitis	B-D003872
2	O
0	O
0	O
0	O
Dry	O
Skin	B-D012867
0	O
4	O
3	O
0	O
Herpes	B-D006561
Simplex	I-D006561
0	O
2	O
0	O
0	O
Maculopapular	O
Rash	O
0	O
2	O
0	O
0	O
Pain	B-D010146
2	O
2	O
1	O
0	O
Pruritus	B-D011537
4	O
6	O
4	O
1	O
Rash	O
2	O
10	O
4	O
0	O
Skin	B-D012867
Carcinoma	B-D002277
0	O
6	O
2	O
2	O
Skin	B-D012867
Nodule	O
0	O
2	O
0	O
0	O
Skin	B-D012883
Ulcer	I-D012883
2	O
0	O
1	O
0	O
SPECIAL	O
SENSES	O
2	O
0	O
4	O
2	O
Conjunctivitis	B-D003231
2	O
0	O
4	O
1	O
Eye	B-D058447
Pain	I-D058447
0	O
2	O
2	O
0	O
UROGENITAL	O
SYSTEM	O
0	O
0	O
4	O
5	O
Hematuria	B-D006417
0	O
0	O
2	O
1	O
OTHER	O
0	O
0	O
0	O
3	O
Procedure	O
0	O
0	O
0	O
3	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Events	O
Reported	O
for	O
diclofenac	O
sodium	O
gel,	O
3%	O
at	O
Less	O
Than	O
1%	O
Incidence	B-D015994
in	O
the	O
Phase	O
3	O
Studies:	O
skin	O
hypertrophy,	O
paresthesia,	O
seborrhea,	O
urticaria,	O
application	O
site	O
reactions	O
(skin	O
carcinoma,	O
hypertonia,	O
skin	O
hypertrophy	O
lacrimation	O
disorder,	O
maculopapular	O
rash,	O
purpuric	O
rash,	O
vasodilation).	O
Adverse	O
Reactions	O
Reported	O
for	O
Oral	O
Diclofenac	B-D004008
Dosage	O
Form	B-D020478
(not	O
topical	O
diclofenac	O
sodium	O
gel,	O
3%):	O
*Incidence	O
Greater	O
than	O
1%	O
marked	O
with	O
asterisk.	O
Body	O
as	O
a	O
Whole:	O
abdominal	O
pain	O
or	O
cramps*,	O
headache*,	O
fluid	O
retention*,	O
abdominal	O
distention*,	O
malaise,	O
swelling	O
of	O
lips	O
and	O
tongue,	O
photosensitivity,	O
anaphylaxis,	O
anaphylactoid	O
reactions,	O
chest	O
pain.	O
Cardiovascular:	O
hypertension,	O
congestive	O
heart	O
failure,	O
palpitations,	O
flushing,	O
tachycardia,	O
premature	O
ventricular	O
contractions,	O
myocardial	O
infarction,	O
hypotension.	O
Digestive:	O
diarrhea*,	O
indigestion*,	O
nausea*,	O
constipation*,	O
flatulence*,	O
liver	O
test	O
abnormalities*,	O
PUB*,	O
i.e.,	O
peptic	O
ulcer,	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
or	O
bleeding	O
without	O
ulcer,	O
vomiting,	O
jaundice,	O
melena,	O
esophageal	O
lesions,	O
aphthous	O
stomatitis,	O
dry	O
mouth	O
and	O
mucous	O
membranes,	O
bloody	O
diarrhea,	O
hepatitis,	O
hepatic	O
necrosis,	O
cirrhosis,	O
hepatorenal	O
syndrome,	O
appetite	O
change,	O
pancreatitis	O
with	O
or	O
without	O
concomitant	O
hepatitis,	O
colitis,	O
intestinal	O
perforation.	O
Hemic	O
and	O
Lymph	B-D008196
atic:	O
hemoglobin	O
decrease,	O
leukopenia,	O
thrombocytopenia,	O
eosinophilia,	O
hemolytic,	O
anemia,	O
aplastic	O
anemia,	O
agranulocytosis,	O
purpura,	O
allergic	O
purpura,	O
bruising.	O
Metabolic	O
and	O
Nutritional	O
Disorders:	O
azotemia,	O
hypoglycemia,	O
weight	O
loss.	O
Nervous	B-D009420
System	I-D009420
:	O
dizziness*,	O
insomnia,	O
drowsiness,	O
depression,	O
diplopia,	O
anxiety,	O
irritability,	O
aseptic	O
meningitis,	O
convulsions,	O
paresthesia,	O
memory	O
disturbance,	O
nightmares,	O
tremor,	O
tic,	O
abnormal	O
coordination,	O
disorientation,	O
psychotic	O
reaction.	O
Respiratory:	O
epistaxis,	O
asthma,	O
laryngeal	O
edema,	O
dyspnea,	O
hyperventilation,	O
edema	O
of	O
pharynx.	O
Skin	B-D012867
and	O
Appendages:	O
rash*,	O
pruritus*,	O
alopecia,	O
urticaria,	O
eczema,	O
dermatitis,	O
bullous	O
eruption,	O
erythema	O
multiforme	O
major,	O
angioedema,	O
Stevens-Johnson	O
syndrome,	O
excess	O
perspiration,	O
exfoliative	O
dermatitis.	O
Special	O
Senses:	O
tinnitus*,	O
blurred	O
vision,	O
taste	O
disorder,	O
reversible	O
and	O
irreversible	O
hearing	O
loss,	O
scotoma,	O
vitreous	O
floaters,	O
night	O
blindness,	O
amblyopia.	O
Urogenital:	O
nephrotic	O
syndrome,	O
proteinuria,	O
oliguria,	O
interstitial	O
nephritis,	O
papillary	O
necrosis,	O
acute	O
renal	O
failure,	O
urinary	O
frequency,	O
nocturia,	O
hematuria,	O
impotence,	O
vaginal	O
bleeding.	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
adverse	O
reactions	O
are	O
drowsiness	O
and	O
dizziness.	O
Less	O
frequent	O
adverse	O
reactions	O
are	O
lightheadedness	O
and	O
gastrointestinal	O
disturbances	O
including	O
nausea,	O
vomiting,	O
and	O
flatulence.	O
A	O
single	O
incidence	O
of	O
bone	O
marrow	O
suppression	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
and	O
caffeine	O
capsules.	O
Several	O
cases	O
of	O
dermatological	O
reactions	O
including	O
toxic	O
epidermal	O
necrolysis	O
and	O
erythema	O
multiforme	O
have	O
been	O
reported.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS	O
.)	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
Diclofenac	B-D004008
Sodium	B-D012964
Delayed-release	O
Tablets	B-D013607
,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Unique	O
Pharmaceutical	O
Laboratories	B-D007753
toll-free	O
at	O
(800)	O
521-5340	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
Boxed	O
Warning	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
FULL	O
PRESCRIBING	O
INFORMATION	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)].	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	O
(4)and	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)].	O
Warnings	O
and	O
Precautions	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
CONTRAINDICATIONS	O
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	O
sodium	O
topical	O
gel	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials,	O
of	O
oral	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
sodium	O
for	O
2	O
to	O
6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
topical	O
gel	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
topical	O
gel	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
topical	O
gel	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edem	O
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
diclofenac	O
sodium	O
topical	O
gel.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactoid	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[seeCONTRAINDICATIONS	O
(4)	O
and	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
CONTRAINDICATIONS	O
(4)].	O
When	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
CONTRAINDICATIONS	O
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
USE	O
IN	O
SPECIFIC	O
POPULATIONS	O
(8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2,	O
5.3,	O
5.6)].	O
5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
areas	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light	O
induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
with	O
eyes	O
and	O
mucosa,	O
although	O
not	O
studied,	O
should	O
be	O
avoided.	O
Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
eye	O
contact	O
occurs,	O
they	O
should	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk.	O
Adverse	O
Reactions	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)]	O
Hepatotoxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.11)]	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
During	O
clinical	O
development,	O
913	O
patients	O
were	O
exposed	O
to	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
randomized,	O
double-blind,	O
multicenter,	O
vehicle-controlled,	O
parallel-group	O
studies	O
in	O
osteoarthritis	O
of	O
the	O
superficial	O
joints	O
of	O
the	O
extremities.	O
Of	O
these,	O
513	O
patients	O
received	O
diclofenac	O
sodium	O
topical	O
gel	O
for	O
osteoarthritis	O
of	O
the	O
knee	O
and	O
400	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
the	O
hand.	O
Additionally,	O
583	O
patients	O
were	O
exposed	O
to	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
an	O
uncontrolled,	O
open-label,	O
long-term	O
safety	O
trial	O
in	O
osteoarthritis	O
of	O
the	O
knee.	O
Of	O
these,	O
355	O
patients	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
1	O
knee	O
and	O
228	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
both	O
knees.	O
Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
safety	O
trial.	O
Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel:	O
Non-serious	O
adverse	O
reactions	O
that	O
were	O
reported	O
during	O
the	O
short-term	O
placebo-controlled	O
studies	O
comparing	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
placebo	O
(vehicle	O
gel)	O
over	O
study	O
periods	O
of	O
8	O
to	O
12	O
weeks	O
(16	O
g	O
per	O
day),	O
were	O
application	O
site	O
reactions.	O
These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
1%	O
of	O
treated	O
patients	O
with	O
a	O
greater	O
frequency	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
gel	O
group	O
(7%)	O
than	O
the	O
placebo	O
group	O
(2%).	O
Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported.	O
Application	O
site	O
dermatitis	O
was	O
the	O
most	O
frequent	O
type	O
of	O
application	O
site	O
reaction	O
and	O
was	O
reported	O
by	O
4%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
compared	O
to	O
1%	O
of	O
placebo	O
patients.	O
Adverse	O
Reaction†	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
Placebo	O
(vehicle)	O
N=913	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction.	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
dermatitis	O
32	O
(4)	O
6	O
(˂1)	O
Application	O
site	O
pruritus	O
7	O
(˂1)	O
1	O
(˂1)	O
Application	O
site	O
erythema	O
6	O
(˂1)	O
3	O
(˂1)	O
Application	O
site	O
paresthesia	O
5	O
(˂1)	O
3	O
(˂1)	O
Application	O
site	O
dryness	O
4	O
(˂1)	O
3	O
(˂1)	O
Application	O
site	O
vesicles	O
3	O
(˂1)	O
0	O
Application	O
site	O
irritation	O
2	O
(˂1)	O
0	O
Application	O
site	O
papules	O
1	O
(˂1)	O
0	O
†Preferred	O
Term	O
according	O
to	O
MedDRA	O
9.1	O
In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
and	O
3%	O
for	O
patients	O
in	O
the	O
placebo	O
group.	O
Application	O
site	O
reactions,	O
including	O
application	O
site	O
dermatitis,	O
were	O
the	O
most	O
frequent	O
reason	O
for	O
treatment	O
discontinuation.	O
Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
safety	O
study,	O
distribution	O
of	O
adverse	O
reactions	O
was	O
similar	O
to	O
that	O
in	O
the	O
placebo-controlled	O
studies.	O
In	O
this	O
study,	O
where	O
patients	O
were	O
treated	O
for	O
up	O
to	O
1	O
year	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
up	O
to	O
32	O
g	O
per	O
day,	O
application	O
site	O
dermatitis	O
was	O
observed	O
in	O
11%	O
of	O
patients.	O
Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
patients.	O
The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
dermatitis,	O
which	O
was	O
experienced	O
by	O
6%	O
of	O
patients.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS	O
.)	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/	O
polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
BOXED	O
WARNING	O
WARNING	O
Ketorolac	B-D020910
tromethamine,	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID),	O
is	O
indicated	O
for	O
the	O
short-term	O
(up	O
to	O
5	O
days	O
in	O
adults)	O
management	O
of	O
moderately	O
severe	O
acute	O
pain	O
that	O
requires	O
analgesia	O
at	O
the	O
opioid	O
level.	O
Oral	O
ketorolac	O
tromethamine	O
is	O
indicated	O
only	O
as	O
continuation	O
treatment	O
following	O
intravenous	O
or	O
intramuscular	O
dosing	O
of	O
ketorolac	O
tromethamine,	O
if	O
necessary.	O
The	O
total	O
combined	O
duration	O
of	O
use	O
of	O
oral	O
ketorolac	O
tromethamine	O
and	O
ketorolac	O
tromethamine	O
injection	O
should	O
not	O
exceed	O
5	O
days.	O
Ketorolac	B-D020910
tromethamine	O
is	O
not	O
indicated	O
for	O
use	O
in	O
pediatric	O
patients	O
and	O
it	O
is	O
NOT	O
indicated	O
for	O
minor	O
or	O
chronic	O
painful	O
conditions.	O
Increasing	O
the	O
dose	O
of	O
ketorolac	O
tromethamine	O
beyond	O
the	O
label	O
recommendations	O
will	O
not	O
provide	O
better	O
efficacy	O
but	O
will	O
increase	O
the	O
risk	O
of	O
developing	O
serious	O
adverse	O
events.	O
GASTROINTESTINAL	O
RISK	O
Ketorolac	B-D020910
tromethamine	O
can	O
cause	O
peptic	O
ulcers,	O
gastrointestinal	O
bleeding	O
and/or	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Therefore,	O
ketorolac	O
tromethamine	O
is	O
CONTRAINDICATED	O
in	O
patients	O
with	O
active	O
peptic	O
ulcer	O
disease,	O
in	O
patients	O
with	O
recent	O
gastrointestinal	O
bleeding	O
or	O
perforation,	O
and	O
in	O
patients	O
with	O
a	O
history	O
of	O
peptic	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS).	O
CARDIOVASCULAR	O
THROMBOTIC	O
EVENTS	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
Ketorolac	B-D020910
tromethamine	O
is	O
CONTRAINDICATED	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
RENAL	O
RISK	O
Ketorolac	B-D020910
tromethamine	O
is	O
CONTRAINDICATED	O
in	O
patients	O
with	O
advanced	O
renal	O
impairment	O
and	O
in	O
patients	O
at	O
risk	O
for	O
renal	O
failure	O
due	O
to	O
volume	O
depletion	O
(see	O
WARNINGS).	O
RISK	O
OF	O
BLEEDING	O
Ketorolac	B-D020910
tromethamine	O
inhibits	O
platelet	O
function	O
and	O
is,	O
therefore,	O
CONTRAINDICATED	O
in	O
patients	O
with	O
suspected	O
or	O
confirmed	O
cerebrovascular	O
bleeding,	O
patients	O
with	O
hemorrhagic	O
diathesis,	O
incomplete	O
hemostasis	O
and	O
those	O
at	O
high	O
risk	O
of	O
bleeding	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
Ketorolac	B-D020910
tromethamine	O
is	O
CONTRAINDICATED	O
as	O
prophylactic	O
analgesic	O
before	O
any	O
major	O
surgery.	O
HYPERSENSITIVITY	O
Hypersensitivity	B-D006967
reactions,	O
ranging	O
from	O
bronchospasm	O
to	O
anaphylactic	O
shock,	O
have	O
occurred	O
and	O
appropriate	O
counteractive	O
measures	O
must	O
be	O
available	O
when	O
administering	O
the	O
first	O
dose	O
of	O
ketorolac	O
tromethamine	O
injection	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Ketorolac	B-D020910
tromethamine	O
is	O
CONTRAINDICATED	O
in	O
patients	O
with	O
previously	O
demonstrated	O
hypersensitivity	O
to	O
ketorolac	O
tromethamine	O
or	O
allergic	O
manifestations	O
to	O
aspirin	O
or	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs).	O
INTRATHECAL	O
OR	O
EPIDURAL	O
ADMINISTRATION	O
Ketorolac	B-D020910
tromethamine	O
is	O
CONTRAINDICATED	O
for	O
intrathecal	O
or	O
epidural	O
administration	O
due	O
to	O
its	O
alcohol	O
content.	O
RISK	O
DURING	O
LABOR	O
AND	O
DELIVERY	O
The	O
use	O
of	O
ketorolac	O
tromethamine	O
in	O
labor	O
and	O
delivery	O
is	O
CONTRAINDICATED	O
because	O
it	O
may	O
adversely	O
affect	O
fetal	O
circulation	O
and	O
inhibit	O
uterine	O
contractions.	O
CONCOMITANT	O
USE	O
WITH	O
NSAIDs	O
Ketorolac	B-D020910
tromethamine	O
is	O
CONTRAINDICATED	O
in	O
patients	O
currently	O
receiving	O
aspirin	O
or	O
NSAIDs	O
because	O
of	O
the	O
cumulative	O
risk	O
of	O
inducing	O
serious	O
NSAID-related	O
side	O
effects.	O
SPECIAL	O
POPULATIONS	O
Dosage	O
should	O
be	O
adjusted	O
for	O
patients	O
65	O
years	O
or	O
older,	O
for	O
patients	O
under	O
50	O
kg	O
(110	O
lbs.)	O
of	O
body	O
weight	O
(see	O
DOSAGE	O
AND	O
ADMINISTRATION)	O
and	O
for	O
patients	O
with	O
moderately	O
elevated	O
serum	O
creatinine	O
(see	O
WARNINGS).	O
Doses	O
of	O
ketorolac	O
tromethamine	O
injection	O
are	O
not	O
to	O
exceed	O
60	O
mg	O
(total	O
dose	O
per	O
day)	O
in	O
these	O
patients.	O
DOSAGE	O
AND	O
ADMINISTRATION	O
Ketorolac	B-D020911
Tromethamine	I-D020911
Tablets	B-D013607
Ketorolac	B-D020910
tromethamine	O
tablets	O
are	O
indicated	O
only	O
as	O
continuation	O
therapy	O
to	O
ketorolac	O
tromethamine	O
injection,	O
and	O
the	O
combined	O
duration	O
of	O
use	O
of	O
ketorolac	O
tromethamine	O
injection	O
and	O
ketorolac	O
tromethamine	O
tablets	O
is	O
not	O
to	O
exceed	O
5	O
(five)	O
days,	O
because	O
of	O
the	O
increased	O
risk	O
of	O
serious	O
adverse	O
events.	O
The	O
recommended	O
total	O
daily	O
dose	O
of	O
ketorolac	O
tromethamine	O
tablets	O
(maximum	O
40	O
mg)	O
is	O
significantly	O
lower	O
than	O
for	O
ketorolac	O
tromethamine	O
injection	O
(maximum	O
120	O
mg)	O
(see	O
DOSAGE	O
AND	O
ADMINISTRATION).	O
ADVERSE	O
REACTIONS	O
Systemic:	O
Adverse	O
experiences	O
following	O
the	O
administration	O
of	O
lidocaine	O
are	O
similar	O
in	O
nature	O
to	O
those	O
observed	O
with	O
other	O
amide	O
local	O
anesthetic	O
agents.	O
These	O
adverse	O
experiences	O
are,	O
in	O
general,	O
dose-related	O
and	O
may	O
result	O
from	O
high	O
plasma	O
levels	O
caused	O
by	O
excessive	O
dosage,	O
rapid	O
absorption	O
or	O
inadvertent	O
intravascular	O
injection,	O
or	O
may	O
result	O
from	O
a	O
hypersensitivity,	O
idiosyncrasy	O
or	O
diminished	O
tolerance	O
on	O
the	O
part	O
of	O
the	O
patient.	O
Serious	O
adverse	O
experiences	O
are	O
generally	O
systemic	O
in	O
nature.	O
The	O
following	O
types	O
are	O
those	O
most	O
commonly	O
reported:	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
CNS	O
manifestations	O
are	O
excitatory	O
and/or	O
depressant	O
and	O
may	O
be	O
characterized	O
by	O
lightheadedness,	O
nervousness,	O
apprehension,	O
euphoria,	O
confusion,	O
dizziness,	O
drowsiness,	O
tinnitus,	O
blurred	O
or	O
double	O
vision,	O
vomiting,	O
sensations	O
of	O
heat,	O
cold	O
or	O
numbness,	O
twitching,	O
tremors,	O
convulsions,	O
unconsciousness,	O
respiratory	O
depression	O
and	O
arrest.	O
The	O
excitatory	O
manifestations	O
may	O
be	O
very	O
brief	O
or	O
may	O
not	O
occur	O
at	O
all,	O
in	O
which	O
case	O
the	O
first	O
manifestation	O
of	O
toxicity	O
may	O
be	O
drowsiness	O
merging	O
into	O
unconsciousness	O
and	O
respiratory	O
arrest.	O
Drowsiness	O
following	O
the	O
administration	O
of	O
lidocaine	O
is	O
usually	O
an	O
early	O
sign	O
of	O
a	O
high	O
blood	O
level	O
of	O
the	O
drug	O
and	O
may	O
occur	O
as	O
a	O
consequence	O
of	O
rapid	O
absorption.	O
Cardiovascular	B-D002319
System	I-D002319
:	O
Cardiovascular	O
manifestations	O
are	O
usually	O
depressant	O
and	O
are	O
characterized	O
by	O
bradycardia,	O
hypotension,	O
and	O
cardiovascular	O
collapse,	O
which	O
may	O
lead	O
to	O
cardiac	O
arrest.	O
Allergic:	O
Allergic	O
reactions	O
are	O
characterized	O
by	O
cutaneous	O
lesions,	O
urticaria,	O
edema	O
or	O
anaphylactoid	O
reactions.	O
Allergic	O
reactions	O
may	O
occur	O
as	O
a	O
result	O
of	O
sensitivity	O
either	O
to	O
local	O
anesthetic	O
agents	O
or	O
to	O
the	O
methylparaben	B-C015358
used	O
as	O
a	O
preservative	O
in	O
multiple	O
dose	O
vials.	O
Allergic	O
reactions	O
as	O
a	O
result	O
of	O
sensitivity	O
to	O
lidocaine	O
are	O
extremely	O
rare	O
and,	O
if	O
they	O
occur,	O
should	O
be	O
managed	O
by	O
conventional	O
means.	O
The	O
detection	O
of	O
sensitivity	O
by	O
skin	O
testing	O
is	O
of	O
doubtful	O
value.	O
Neurologic:	O
The	O
incidences	O
of	O
adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
local	O
anesthetics	O
may	O
be	O
related	O
to	O
the	O
total	O
dose	O
of	O
local	O
anesthetic	O
administered	O
and	O
are	O
also	O
dependent	O
upon	O
the	O
particular	O
drug	O
used,	O
the	O
route	O
of	O
administration	O
and	O
the	O
physical	O
status	O
of	O
the	O
patient.	O
In	O
a	O
prospective	O
review	O
of	O
10,440	O
patients	O
who	O
received	O
lidocaine	O
for	O
spinal	O
anesthesia,	O
the	O
incidences	O
of	O
adverse	O
reactions	O
were	O
reported	O
to	O
be	O
about	O
3	O
percent	O
each	O
for	O
positional	O
headaches,	O
hypotension	O
and	O
backache;	O
2	O
percent	O
for	O
shivering;	O
and	O
less	O
than	O
1	O
percent	O
each	O
for	O
peripheral	O
nerve	O
symptoms,	O
nausea,	O
respiratory	O
inadequacy	O
and	O
double	O
vision.	O
Many	O
of	O
these	O
observations	O
may	O
be	O
related	O
to	O
local	O
anesthetic	O
techniques,	O
with	O
or	O
without	O
a	O
contribution	O
from	O
the	O
local	O
anesthetic.	O
In	O
the	O
practice	O
of	O
caudal	O
or	O
lumbar	O
epidural	O
block,	O
occasional	O
unintentional	O
penetration	O
of	O
the	O
subarachnoid	O
space	O
by	O
the	O
catheter	O
may	O
occur.	O
Subsequent	O
adverse	O
effects	O
may	O
depend	O
partially	O
on	O
the	O
amount	O
of	O
drug	O
administered	O
subdurally.	O
These	O
may	O
include	O
spinal	O
block	O
of	O
varying	O
magnitude	O
(including	O
total	O
spinal	O
block),	O
hypotension	O
secondary	O
to	O
spinal	O
block,	O
loss	O
of	O
bladder	O
and	O
bowel	O
control,	O
and	O
loss	O
of	O
perineal	O
sensation	O
and	O
sexual	O
function.	O
Persistent	O
motor,	O
sensory	O
and/or	O
autonomic	O
(sphincter	O
control)	O
deficit	O
of	O
some	O
lower	O
spinal	O
segments	O
with	O
slow	O
recovery	O
(several	O
months)	O
or	O
incomplete	O
recovery	O
have	O
been	O
reported	O
in	O
rare	O
instances	O
when	O
caudal	O
or	O
lumbar	O
epidural	O
block	O
has	O
been	O
attempted.	O
Back	B-D001415
ache	O
and	O
headache	O
have	O
also	O
been	O
noted	O
following	O
use	O
of	O
these	O
anesthetic	O
procedures.	O
There	O
have	O
been	O
reported	O
cases	O
of	O
permanent	O
injury	O
to	O
extraocular	O
muscles	O
requiring	O
surgical	O
repair	O
following	O
retrobulbar	O
administration.	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
•	O
Diflunisal	B-D004061
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS).	O
Adverse	O
Reactions	O
The	O
adverse	O
reactions	O
observed	O
in	O
controlled	O
clinical	O
trials	O
encompass	O
observations	O
in	O
2,427	O
patients.	O
Listed	O
below	O
are	O
the	O
adverse	O
reactions	O
reported	O
in	O
the	O
1,314	O
of	O
these	O
patients	O
who	O
received	O
treatment	O
in	O
studies	O
of	O
two	O
weeks	O
or	O
longer.	O
Five	O
hundred	O
thirteen	O
patients	O
were	O
treated	O
for	O
at	O
least	O
24	O
weeks,	O
255	O
patients	O
were	O
treated	O
for	O
at	O
least	O
48	O
weeks,	O
and	O
46	O
patients	O
were	O
treated	O
for	O
96	O
weeks.	O
In	O
general,	O
the	O
adverse	O
reactions	O
listed	O
below	O
were	O
2	O
to	O
14	O
times	O
less	O
frequent	O
in	O
the	O
1,113	O
patients	O
who	O
received	O
short-term	O
treatment	O
for	O
mild	O
to	O
moderate	O
pain.	O
Incidence	B-D015994
Greater	O
Than	O
1%	O
Gastrointestinal	O
The	O
most	O
frequent	O
types	O
of	O
adverse	O
reactions	O
occurring	O
with	O
diflunisal	O
are	O
gastrointestinal:	O
these	O
include	O
nausea*,	O
vomiting,	O
dyspepsia*,	O
gastrointestinal	O
pain*,	O
diarrhea*,	O
constipation,	O
and	O
flatulence.	O
Psychiatric	O
Somnolence,	O
insomnia.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Dizziness	B-D004244
.	O
Special	O
Senses	O
Tinnitus	B-D014012
.	O
Dermatologic	O
Rash*.	O
Miscellaneous	O
Headache	B-D006261
*,	O
fatigue/tiredness.	O
*	O
Incidence	B-D015994
between	O
3%	O
and	O
9%.	O
Those	O
reactions	O
occurring	O
in	O
1%	O
to	O
3%	O
are	O
not	O
marked	O
with	O
an	O
asterisk.	O
Incidence	B-D015994
Less	O
Than	O
1	O
in	O
100	O
The	O
following	O
adverse	O
reactions,	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100,	O
were	O
reported	O
in	O
clinical	O
trials	O
or	O
since	O
the	O
drug	O
was	O
marketed.	O
The	O
probability	O
exists	O
of	O
a	O
causal	O
relationship	O
between	O
diflunisal	O
and	O
these	O
adverse	O
reactions.	O
Dermatologic	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis,	O
urticaria,	O
pruritus,	O
sweating,	O
dry	O
mucous	O
membranes,	O
stomatitis,	O
photosensitivity.	O
Gastrointestinal	O
Peptic	O
ulcer,	O
gastrointestinal	O
bleeding,	O
anorexia,	O
eructation,	O
gastrointestinal	O
perforation,	O
gastritis.	O
Liver	B-D008099
function	O
abnormalities;	O
jaundice,	O
sometimes	O
with	O
fever;	O
cholestasis;	O
hepatitis.	O
Hematologic	O
Thrombocytopenia	B-D013921
;	O
agranulocytosis;	O
hemolytic	O
anemia.	O
Genitourinary	O
Dysuria	B-D053159
;	O
renal	O
impairment,	O
including	O
renal	O
failure;	O
interstitial	O
nephritis;	O
hematuria;	O
proteinuria.	O
Psychiatric	O
Nervousness,	O
depression,	O
hallucinations,	O
confusion,	O
disorientation.	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Vertigo	B-D014717
;	O
light-headedness;	O
paresthesias.	O
Special	O
Senses	O
Transient	O
visual	O
disturbances	O
including	O
blurred	O
vision.	O
Hypersensitivity	B-D006967
Reactions	O
Acute	O
anaphylactic	O
reaction	O
with	O
bronchospasm;	O
angioedema;	O
flushing.	O
Hypersensitivity	B-D006967
vasculitis.	O
Hypersensitivity	B-D006967
syndrome	O
(see	O
PRECAUTIONS).	O
Miscellaneous	O
Asthenia	B-D001247
,	O
edema.	O
Causal	O
Relationship	O
Unknown	O
Other	O
reactions	O
have	O
been	O
reported	O
in	O
clinical	O
trials	O
or	O
since	O
the	O
drug	O
was	O
marketed,	O
but	O
occurred	O
under	O
circumstances	O
where	O
a	O
causal	O
relationship	O
could	O
not	O
be	O
established.	O
However,	O
in	O
these	O
rarely	O
reported	O
events,	O
that	O
possibility	O
cannot	O
be	O
excluded.	O
Therefore,	O
these	O
observations	O
are	O
listed	O
to	O
serve	O
as	O
alerting	O
information	O
to	O
physicians.	O
Respiratory	O
Dyspnea	B-D004417
.	O
Cardiovascular	O
Palpitation,	O
syncope.	O
Musculoskeletal	O
Muscle	O
cramps.	O
Genitourinary	O
Nephrotic	O
syndrome.	O
Special	O
Senses	O
Hearing	B-D006309
loss.	O
Miscellaneous	O
Chest	O
pain.	O
A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
fasciitis,	O
particularly	O
in	O
association	O
with	O
Group	O
A	O
β-hemolytic	O
streptococcus,	O
has	O
been	O
described	O
in	O
persons	O
treated	O
with	O
non-steroidal	O
anti-inflammatory	O
agents,	O
including	O
diflunisal,	O
sometimes	O
with	O
fatal	O
outcome	O
(see	O
also	O
PRECAUTIONS,	O
General).	O
Potential	O
Adverse	O
Effects	O
In	O
addition,	O
a	O
variety	O
of	O
adverse	O
effects	O
not	O
observed	O
with	O
diflunisal	O
in	O
clinical	O
trials	O
or	O
in	O
marketing	O
experience,	O
but	O
reported	O
with	O
other	O
non-steroidal	O
analgesic/anti-inflammatory	O
agents	O
should	O
be	O
considered	O
potential	O
adverse	O
effects	O
of	O
diflunisal.	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
nonsteroidal	O
antiinflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.4)	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
CardiovascularRisk	O
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(5.4)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(5.1,	O
14.6,	O
17.2).	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
(5.4,	O
8.5,	O
14.6,	O
17.3).	O
Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
celecoxibimmediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen	O
(5.5,	O
17.4).	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
duringtreatment	O
with	O
celecoxib	O
(5.2,	O
7.4,	O
17.2).	O
Fluid	O
retention	O
and	O
edema.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retentionor	O
heart	O
failure	O
(5.3,	O
17.6).	O
Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
celecoxib	O
with	O
caution	O
inthe	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6).	O
Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
celecoxib	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(5.7,	O
10,	O
17.7).	O
Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
evenwithout	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions	O
(5.8,	O
17.5).	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
to	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
to	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
celecoxib,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
Development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
celecoxib	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
Individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
celecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
Patients	B-D010361
,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)].	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
Carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
celecoxib	O
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
celecoxib	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
celecoxib.	O
In	O
postmarketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
celecoxib.	O
Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
antiinflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
celecoxib	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sydon	O
Labs,	O
LLC	O
at	O
1	O
866-487-4695	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
>2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4,	O
146	O
Placebo	O
N=1,	O
864	O
NAP	O
N=1,	O
366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%5.6%8.8%2.2%3.5%	O
2.8%3.8%6.2%1%4.2%	O
7.7%5.3%12.2%3.6%6%	O
9%9.3%10.9%4.1%3.4%	O
9%5.8%12.8%3.5%6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%2.1%2.9%	O
3.6%1.1%2.3%	O
2.2%2.1%3%	O
2.6%1%2.6%	O
0.9%3.5%3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
Headache	B-D006261
2%15.8%	O
1.7%20.2%	O
2.6%14.5%	O
1.3%15.5%	O
2.3%15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
Rhinitis	B-D012220
Sinusitis	B-D012852
Upper	O
Respiratory	O
Infection	O
2.3%2%5%8.1%	O
1.1%1.3%4.3%6.7%	O
1.7%2.4%4%9.9%	O
1.6%2.3%5.4%9.8%	O
2.6%0.6%5.8%9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,aplastic	O
anemia,pancytopenia,	O
leucopenia	O
Metabolic	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-	O
Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
General	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
>5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
doubleblind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
>5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
Abdominal	O
pain	O
upper	O
Vomiting	B-D014839
NOS	O
Diarrhea	B-D003967
NOS	O
Nausea	B-D009325
4	O
8	O
3	O
5	O
7	O
7	O
6	O
6	O
4	O
4	O
7	O
10	O
11	O
8	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
Dizziness	B-D004244
(excl	O
vertigo)	O
13	O
1	O
10	O
1	O
16	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
postdental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
premarketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
premarketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2,285	O
Placebo	O
N=1,303	O
Diarrhea	B-D003967
10.5%	O
7%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
>0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders	O
:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
arteryatherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
bloodtestosterone	O
decreased	O
Injury,	O
poisoning	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
in	O
the	O
perioperative	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)]	O
.	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDS)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(	O
5.1)	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(	O
4)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(	O
5.2)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
Use	O
the	O
lowest	O
effective	O
dose	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
(	O
5.1)	O
NSAIDs	O
can	O
cause	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation.	O
Prescribe	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
(	O
5.2)	O
Elevation	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
NSAIDs.	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen.	O
(	O
5.3)	O
Hypertension	B-D006973
can	O
occur	O
with	O
NSAID	O
treatment.	O
Monitor	O
blood	O
pressure	O
closely	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
treatment.	O
(	O
5.4)	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
(	O
5.5)	O
Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
at	O
greatest	O
risk	O
of	O
this	O
reaction,	O
including	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors.	O
(	O
5.6)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
or	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution.	O
(	O
5.7)	O
NSAIDs	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
(	O
5.8)	O
Not	O
for	O
use	O
during	O
pregnancy.	O
(	O
5.9)	O
Do	O
not	O
administer	O
to	O
patients	O
with	O
aspirin	O
sensitive	O
asthma	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
(	O
5.10)	O
Avoid	O
exposure	O
of	O
treated	O
knee(s)	O
to	O
natural	O
or	O
artificial	O
sunlight.	O
(	O
5.11)	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
(	O
5.12)	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs.	O
(	O
5.13)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
oral	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
COX-2	O
selective	O
and	O
nonselective	O
orally	O
administered	O
NSAIDs,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Inform	O
patients	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
an	O
orally	O
administered	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
NSAIDS,	O
such	O
as	O
diclofenac,	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Prescribe	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore,	O
use	O
special	O
care	O
when	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
diclofencac	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs.	O
5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
[ULN]	O
range)	O
or	O
greater	O
elevations	O
of	O
transaminases	O
occurred	O
in	O
about	O
15%	O
of	O
oral	O
diclofenac-treated	O
patients	O
in	O
clinical	O
trials	O
of	O
indications	O
other	O
than	O
acute	O
pain.	O
Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	O
injury.	O
In	O
clinical	O
trials	O
of	O
an	O
oral	O
diclofenac	O
–	O
misoprostol	O
combination	O
product,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
for	O
2	O
to	O
6	O
months,	O
patients	O
with	O
oral	O
diclofenac	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(>8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
this	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(>8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
test	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
oral	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
sever	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
oral	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Measure	O
transaminases	O
(ALT	O
and	O
AST)	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
monitor	O
transaminases	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flulike"	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
to	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver-related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
certain	O
antibiotics,	O
antiepileptics).	O
Caution	O
patients	O
to	O
avoid	O
taking	O
unprescribed	O
acetaminophen	O
while	O
using	O
diclofenac	O
sodium	O
topical	O
solution.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac,	O
can	O
lead	O
to	O
new	O
onset	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Use	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Monitor	O
blood	O
pressure	O
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
Patients	B-D010361
taking	O
ACE-inhibitors,	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution.	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
considerable	O
dehydration.	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
is	O
not	O
recommended	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
diclofenac	O
sodium	O
topical	O
solution	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution.	O
Do	O
not	O
prescribe	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.10)].	O
Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Do	O
not	O
apply	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
open	O
skin	O
wounds,	O
infections,	O
inflammations,	O
or	O
exfoliative	O
dermatitis,	O
as	O
it	O
may	O
affect	O
absorption	O
and	O
tolerability	O
of	O
the	O
drug.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations,	O
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
should	O
not	O
be	O
used	O
by	O
pregnant	O
or	O
nursing	O
women	O
or	O
those	O
intending	O
to	O
become	O
pregnant.	O
5.10	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross-reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
do	O
not	O
administer	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.11	O
Sun	O
Exposure	O
Instruct	O
patients	O
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
knee(s)	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light-induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.13	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	O
and	O
conduct	O
periodic	O
laboratory	O
evaluations.	O
5.14	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-response	O
illness.	O
For	O
patients	O
on	O
prolonged	O
corticosteroid	O
therapy,	O
taper	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Hematological	O
Effects	O
The	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	O
subjects	O
administered	O
80	O
drops	O
four	O
times	O
a	O
day	O
for	O
7	O
days.	O
There	O
was	O
no	O
significant	O
change	O
in	O
platelet	O
aggregation	O
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)].	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
Check	O
hemoglobin	O
or	O
hematocrit	O
of	O
patients	O
on	O
diclofenac	O
sodium	O
topical	O
solution	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration	O
and	O
reversible.	O
Carefully	O
monitor	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alteration	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants.	O
5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms	O
in	O
patients	O
taking	O
NSAIDs,	O
monitor	O
patients	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Check	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
in	O
patients	O
on	O
long-term	O
treatment	O
with	O
NSAIDs.	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
if	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen.	O
6.	O
ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
are	O
application	O
site	O
reactions.	O
(	O
6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Teligent	O
Pharma,	O
Inc.	O
at	O
1-856-697-1441,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trial	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution	O
of	O
911	O
patients	O
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	O
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	O
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	O
treated	O
for	O
at	O
least	O
12	O
months.	O
The	O
population	O
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	O
were	O
Caucasians,	O
64%	O
were	O
females,	O
and	O
all	O
patients	O
had	O
primary	O
osteoarthritis.	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies.	O
Application	O
site	O
reactions:	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment	O
related	O
adverse	O
events	O
in	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
Application	O
site	O
reactions	O
were	O
characterized	O
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	O
induration,	O
vesicles,	O
paresthesia,	O
pruritus,	O
vasodilation,	O
acne,	O
and	O
urticaria.	O
The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	O
(32%),	O
contact	O
dermatitis	O
characterized	O
by	O
skin	O
erythema	O
and	O
induration	O
(9%),	O
contact	O
dermatitis	O
with	O
vescicles	O
(2%)	O
and	O
pruritus	O
(4%).	O
In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	O
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac.	O
In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	O
study,	O
contact	O
dermatitis	O
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	O
with	O
vesicles	O
in	O
10%	O
of	O
patients,	O
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	O
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%.	O
Adverse	O
events	O
common	O
to	O
the	O
NSAID	O
class:	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
flatulence,	O
abdominal	O
pain,	O
edema;	O
see	O
Table	O
1).	O
The	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac,	O
compared	O
to	O
oral	O
diclofenac	O
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	O
(3%	O
vs.	O
less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	O
(12%	O
vs.	O
7%),	O
urea	O
(20%	O
vs.	O
12%),	O
and	O
hemoglobin	O
(13%	O
vs.	O
9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	O
transaminases.	O
Table	O
1:	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
=1%	O
of	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
osteoarthritis.	O
Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
=1%	O
of	O
patients	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	O
trials.	O
Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
N=911	O
Topical	O
Placebo	O
N=332	O
Adverse	O
Reaction	O
Preferred	O
Term	O
according	O
to	O
COSTART	O
N(%)	O
N(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non	O
–	O
U.S.	O
postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
Whole:	O
abdominal	O
pain,	O
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	O
back	O
pain,	O
body	O
odor,	O
chest	O
pain,	O
edema,	O
face	O
edema,	O
halitosis,	O
headache,	O
lack	O
of	O
drug	O
effect,	O
neck	O
rigidity,	O
pain	O
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	O
dry	O
mouth,	O
dyspepsia,	O
gastroenteritis,	O
decreased	O
appetite,	O
mouth	O
ulceration,	O
nausea,	O
rectal	O
hemorrhage,	O
ulcerative	O
stomatitis	O
Metabolic	O
and	O
Nutritional:	O
creatinine	O
increased	O
Musculoskeletal:	O
leg	O
cramps,	O
myalgia	O
Nervous:	O
depression,	O
dizziness,	O
drowsiness,	O
lethargy,	O
paresthesia,	O
paresthesia	O
at	O
application	O
site	O
Respiratory:	O
asthma,	O
dyspnea,	O
laryngismus,	O
laryngitis,	O
pharyngitis	O
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	O
contact	O
dermatitis	O
with	O
vesicles,	O
dry	O
skin,	O
pruritus,	O
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	O
rash,	O
pruritus,	O
skin	O
discoloration,	O
urticaria	O
Special	O
senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	O
ear	O
pain,	O
eye	O
disorder,	O
eye	O
pain,	O
taste	O
perversion	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
•	O
Solaraze	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
423	O
patients	O
evaluable	O
for	O
safety	O
in	O
adequate	O
and	O
well-controlled	O
trials,	O
211	O
were	O
treated	O
with	O
Solaraze®	O
drug	O
product	O
and	O
212	O
were	O
treated	O
with	O
a	O
vehicle	O
gel.	O
Eighty-seven	O
percent	O
(87%)	O
of	O
the	O
Solaraze®-treated	O
patients	O
(183	O
patients)	O
and	O
84%	O
of	O
the	O
vehicle-treated	O
patients	O
(178	O
patients)	O
experienced	O
one	O
or	O
more	O
adverse	O
events	O
(AEs)	O
during	O
the	O
studies.	O
The	O
majority	O
of	O
these	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
upon	O
discontinuation	O
of	O
therapy.	O
Of	O
the	O
211	O
patients	O
treated	O
with	O
Solaraze®,	O
172	O
(82%)	O
experienced	O
AEs	O
involving	O
skin	O
and	O
the	O
application	O
site	O
compared	O
to	O
160	O
(75%)	O
vehicle-treated	O
patients.	O
Application	O
site	O
reactions	O
(ASRs)	O
were	O
the	O
most	O
frequent	O
AEs	O
in	O
both	O
Solaraze®-and	O
vehicle-treated	O
groups.	O
Of	O
note,	O
four	O
reactions,	O
contact	O
dermatitis,	O
rash,	O
dry	O
skin	O
and	O
exfoliation	O
(scaling)	O
were	O
significantly	O
more	O
prevalent	O
in	O
the	O
Solaraze®	O
group	O
than	O
in	O
the	O
vehicle-treated	O
patients.	O
Eighteen	O
percent	O
of	O
Solaraze®-treated	O
patients	O
and	O
4%	O
of	O
vehicle-treated	O
patients	O
discontinued	O
from	O
the	O
clinical	O
trials	O
due	O
to	O
adverse	O
events	O
(whether	O
considered	O
related	O
to	O
treatment	O
or	O
not).	O
These	O
discontinuations	O
were	O
mainly	O
due	O
to	O
skin	O
irritation	O
or	O
related	O
cutaneous	O
adverse	O
reactions.	O
Table	O
1	O
below	O
presents	O
the	O
AEs	O
reported	O
at	O
an	O
incidence	O
of	O
>1%	O
for	O
patients	O
treated	O
with	O
either	O
Solaraze®	O
Gel	O
or	O
vehicle	O
(60-	O
and	O
90-day	O
treatment	O
groups)	O
during	O
the	O
phase	O
3	O
studies.	O
Table	O
1.	O
Adverse	O
Events	O
Reported	O
(>1%	O
in	O
Any	O
Treatment	O
Group)	O
During	O
Solaraze®	O
Phase	O
3	O
Clinical	B-D016430
Trial	I-D016430
s	O
Incidence	B-D015994
s	O
for	O
60-Day	O
and	O
90-Day	O
Treatments	O
60-day	O
Treatment	O
90-day	O
Treatment	O
Solaraze®	O
(%)	O
Gel	O
Vehicle	O
(%)	O
Solaraze®	O
(%)	O
Gel	O
Vehicle	O
(%)	O
N=48	O
N=49	O
N=114	O
N=114	O
BODY	O
AS	O
A	O
WHOLE	O
21	O
20	O
20	O
18	O
Abdominal	B-D015746
Pain	I-D015746
2	O
0	O
1	O
0	O
Accidental	O
Injury	O
0	O
0	O
4	O
2	O
Allergic	O
Reaction	O
0	O
0	O
1	O
3	O
Asthenia	B-D001247
0	O
0	O
2	O
0	O
Back	B-D001416
Pain	I-D001416
4	O
0	O
2	O
2	O
Chest	B-D002637
Pain	I-D002637
2	O
0	O
1	O
0	O
Chills	B-D023341
0	O
2	O
0	O
0	O
Flu	O
Syndrome	B-D013577
10	O
6	O
1	O
4	O
Headache	B-D006261
0	O
6	O
7	O
6	O
Infection	O
4	O
6	O
4	O
5	O
Neck	B-D019547
Pain	I-D019547
0	O
0	O
2	O
0	O
Pain	B-D010146
2	O
0	O
2	O
2	O
CARDIOVASCULAR	O
SYSTEM	O
2	O
4	O
3	O
1	O
Hypertension	B-D006973
2	O
0	O
1	O
0	O
Migraine	O
0	O
2	O
1	O
0	O
Phlebitis	B-D010689
0	O
2	O
0	O
0	O
DIGESTIVE	O
SYSTEM	O
4	O
0	O
6	O
8	O
Constipation	B-D003248
0	O
0	O
0	O
2	O
Diarrhea	B-D003967
2	O
0	O
2	O
3	O
Dyspepsia	B-D004415
2	O
0	O
3	O
4	O
METABOLIC	O
AND	O
NUTRITIONAL	O
DISORDERS	O
2	O
8	O
7	O
2	O
Creatine	B-D003401
Phosphokinase	O
Increased	O
0	O
0	O
4	O
1	O
Creatinine	B-D003404
Increased	O
2	O
2	O
0	O
1	O
Edema	B-D004487
0	O
2	O
0	O
0	O
Hypercholesteremia	O
0	O
2	O
1	O
0	O
Hyperglycemia	B-D006943
0	O
2	O
1	O
0	O
SGOT	O
Increased	O
0	O
0	O
3	O
0	O
SGPT	O
Increased	O
0	O
0	O
2	O
0	O
MUSCULOSKELETAL	O
SYSTEM	O
4	O
0	O
3	O
4	O
Arthralgia	B-D018771
2	O
0	O
0	O
2	O
Art	B-D001154
hrosis	O
2	O
0	O
0	O
0	O
Myalgia	B-D063806
2	O
0	O
3	O
1	O
NERVOUS	O
SYSTEM	O
2	O
2	O
2	O
5	O
Anxiety	B-D001007
0	O
2	O
0	O
1	O
Dizziness	B-D004244
0	O
0	O
0	O
4	O
Hypokinesia	B-D018476
2	O
0	O
0	O
0	O
RESPIRATORY	O
SYSTEM	O
8	O
8	O
7	O
6	O
Asthma	B-D001249
2	O
0	O
0	O
0	O
Dyspnea	B-D004417
2	O
0	O
2	O
0	O
Pharyngitis	B-D010612
2	O
8	O
2	O
4	O
Pneumonia	B-D011014
2	O
0	O
0	O
1	O
Rhinitis	B-D012220
2	O
2	O
2	O
2	O
Sinusitis	B-D012852
0	O
0	O
2	O
0	O
SKIN	O
AND	O
APPENDAGES	O
75	O
86	O
86	O
71	O
Acne	O
0	O
2	O
0	O
1	O
Application	O
Site	O
Reaction	O
75	O
71	O
84	O
70	O
Acne	O
0	O
4	O
1	O
0	O
Alopecia	B-D000505
2	O
0	O
1	O
1	O
Contact	O
Dermatitis	B-D003872
19	O
4	O
33	O
4	O
Dry	O
Skin	B-D012867
27	O
12	O
25	O
17	O
Edema	B-D004487
4	O
0	O
3	O
0	O
Exfoliation	O
6	O
4	O
24	O
13	O
Hyperesthesia	B-D006941
0	O
0	O
3	O
1	O
Pain	B-D010146
15	O
22	O
26	O
30	O
Paresthesia	B-D010292
8	O
4	O
20	O
20	O
Photosensitivity	O
Reaction	O
0	O
2	O
3	O
0	O
Pruritus	B-D011537
31	O
59	O
52	O
45	O
Rash	O
35	O
20	O
46	O
17	O
Vesiculobullous	O
Rash	O
0	O
0	O
4	O
1	O
Contact	O
Dermatitis	B-D003872
2	O
0	O
0	O
0	O
Dry	O
Skin	B-D012867
0	O
4	O
3	O
0	O
Herpes	B-D006561
Simplex	I-D006561
0	O
2	O
0	O
0	O
Maculopapular	O
Rash	O
0	O
2	O
0	O
0	O
Pain	B-D010146
2	O
2	O
1	O
0	O
Pruritus	B-D011537
4	O
6	O
4	O
1	O
Rash	O
2	O
10	O
4	O
0	O
Skin	B-D012867
Carcinoma	B-D002277
0	O
6	O
2	O
2	O
Skin	B-D012867
Nodule	O
0	O
2	O
0	O
0	O
Skin	B-D012883
Ulcer	I-D012883
2	O
0	O
1	O
0	O
SPECIAL	O
SENSES	O
2	O
0	O
4	O
2	O
Conjunctivitis	B-D003231
2	O
0	O
4	O
1	O
Eye	B-D058447
Pain	I-D058447
0	O
2	O
2	O
0	O
UROGENITAL	O
SYSTEM	O
0	O
0	O
4	O
5	O
Hematuria	B-D006417
0	O
0	O
2	O
1	O
OTHER	O
0	O
0	O
0	O
3	O
Procedure	O
0	O
0	O
0	O
3	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Events	O
Reported	O
for	O
Solaraze	O
®	O
at	O
Less	O
Than	O
1%	O
Incidence	B-D015994
in	O
the	O
Phase	O
3	O
Studies:	O
skin	O
hypertrophy,	O
paresthesia,	O
seborrhea,	O
urticaria,	O
application	O
site	O
reactions	O
(skin	O
carcinoma,	O
hypertonia,	O
skin	O
hypertrophy	O
lacrimation	O
disorder,	O
maculopapular	O
rash,	O
purpuric	O
rash,	O
vasodilation).	O
Adverse	O
Reactions	O
Reported	O
for	O
Oral	O
Diclofenac	B-D004008
Dosage	O
Form	B-D020478
(not	O
topical	O
Solaraze	O
®	O
Gel):	O
*Incidence	O
Greater	O
than	O
1%	O
marked	O
with	O
asterisk.	O
Body	O
as	O
a	O
Whole:	O
abdominal	O
pain	O
or	O
cramps*,	O
headache*,	O
fluid	O
retention*,	O
abdominal	O
distention*,	O
malaise,	O
swelling	O
of	O
lips	O
and	O
tongue,	O
photosensitivity,	O
anaphylaxis,	O
anaphylactoid	O
reactions,	O
chest	O
pain.	O
Cardiovascular:	O
hypertension,	O
congestive	O
heart	O
failure,	O
palpitations,	O
flushing,	O
tachycardia,	O
premature	O
ventricular	O
contractions,	O
myocardial	O
infarction,	O
hypotension.	O
Digestive:	O
diarrhea*,	O
indigestion*,	O
nausea*,	O
constipation*,	O
flatulence*,	O
liver	O
test	O
abnormalities*,	O
PUB*,	O
i.e.,	O
peptic	O
ulcer,	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
or	O
bleeding	O
without	O
ulcer,	O
vomiting,	O
jaundice,	O
melena,	O
esophageal	O
lesions,	O
aphthous	O
stomatitis,	O
dry	O
mouth	O
and	O
mucous	O
membranes,	O
bloody	O
diarrhea,	O
hepatitis,	O
hepatic	O
necrosis,	O
cirrhosis,	O
hepatorenal	O
syndrome,	O
appetite	O
change,	O
pancreatitis	O
with	O
or	O
without	O
concomitant	O
hepatitis,	O
colitis,	O
intestinal	O
perforation.	O
Hemic	O
and	O
Lymph	B-D008196
atic:	O
hemoglobin	O
decrease,	O
leukopenia,	O
thrombocytopenia,	O
eosinophilia,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
agranulocytosis,	O
purpura,	O
allergic	O
purpura,	O
bruising.	O
Metabolic	O
and	O
Nutritional	O
Disorders:	O
azotemia,	O
hypoglycemia,	O
weight	O
loss.	O
Nervous	B-D009420
System	I-D009420
:	O
dizziness*,	O
insomnia,	O
drowsiness,	O
depression,	O
diplopia,	O
anxiety,	O
irritability,	O
aseptic	O
meningitis,	O
convulsions,	O
paresthesia,	O
memory	O
disturbance,	O
nightmares,	O
tremor,	O
tic,	O
abnormal	O
coordination,	O
disorientation,	O
psychotic	O
reaction.	O
Respiratory:	O
epistaxis,	O
asthma,	O
laryngeal	O
edema,	O
dyspnea,	O
hyperventilation,	O
edema	O
of	O
pharynx.	O
Skin	B-D012867
and	O
Appendages:	O
rash*,	O
pruritus*,	O
alopecia,	O
urticaria,	O
eczema,	O
dermatitis,	O
bullous	O
eruption,	O
erythema	O
multiforme	O
major,	O
angioedema,	O
Stevens-Johnson	O
syndrome,	O
excess	O
perspiration,	O
exfoliative	O
dermatitis.	O
Special	O
Senses:	O
tinnitus*,	O
blurred	O
vision,	O
taste	O
disorder,	O
reversible	O
and	O
irreversible	O
hearing	O
loss,	O
scotoma,	O
vitreous	O
floaters,	O
night	O
blindness,	O
amblyopia.	O
Urogenital:	O
nephrotic	O
syndrome,	O
proteinuria,	O
oliguria,	O
interstitial	O
nephritis,	O
papillary	O
necrosis,	O
acute	O
renal	O
failure,	O
urinary	O
frequency,	O
nocturia,	O
hematuria,	O
impotence,	O
vaginal	O
bleeding.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS.)	O
Diclofenac	B-D004008
sodium	O
extended-release	O
tablets,	O
USP	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
extended-release	O
tablets,	O
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure.	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment.	O
WARNING:	O
RISK	O
OF	O
UTERINE	O
RUPTURE,	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
BIRTH	O
DEFECTS;	O
AND	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
CONTAIN	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL.	O
ADMINISTRATION	O
OF	O
MISOPROSTOL	O
TO	O
WOMEN	O
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
OR	O
BIRTH	O
DEFECTS.	O
UTERINE	O
RUPTURE	O
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	O
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	O
WOMEN	O
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O
BEYOND	O
THE	O
EIGHTH	O
WEEK	O
OF	O
PREGNANCY.	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	O
WOMEN	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.10),	O
and	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
PATIENTS	O
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS.	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
should	O
not	O
be	O
used	O
in	O
women	O
of	O
childbearing	O
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	O
of	O
developing	O
gastric	O
or	O
duodenal	O
ulceration	O
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	O
ulcers	O
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID.	O
In	O
such	O
patients,	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
●	O
has	O
had	O
a	O
negative	O
serum	O
pregnancy	O
test	O
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy.	O
●	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures.	O
●	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	O
the	O
risk	O
of	O
possible	O
contraception	O
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	O
of	O
childbearing	O
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake.	O
●	O
will	O
begin	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	O
period	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.3)].	O
Cardiovascular	O
Thrombotic	O
Events	O
●	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
●	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4),	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
●	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
RISK	O
OF	O
UTERINE	O
RUPTURE,	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
BIRTH	O
DEFECTS;	O
AND	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
CONTAINS	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL.	O
ADMINISTRATION	O
OF	O
MISOPROSTOL	O
TO	O
WOMEN	O
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
OR	O
BIRTH	O
DEFECTS.	O
UTERINE	O
RUPTURE	O
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	O
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	O
WOMEN	O
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O
BEYOND	O
THE	O
EIGHTH	O
WEEK	O
OF	O
PREGNANCY.	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL	O
DELAYED-RELEASE	O
TABLETS	O
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	O
WOMEN	O
(	O
4	O
,	O
5.10	O
,	O
8.1	O
).	O
PATIENTS	O
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS.	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
should	O
not	O
be	O
used	O
in	O
women	O
of	O
childbearing	O
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	O
of	O
developing	O
gastric	O
or	O
duodenal	O
ulceration	O
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	O
ulcers	O
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID.	O
In	O
such	O
patients,	O
d	O
iclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
•	O
has	O
had	O
a	O
negative	O
serum	O
pregnancy	O
test	O
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy	O
(	O
8.3	O
).	O
•	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures.	O
•	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	O
the	O
risk	O
of	O
possible	O
contraception	O
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	O
of	O
childbearing	O
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake.	O
•	O
will	O
begin	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	O
period.	O
Cardiovascular	O
Thrombotic	O
Events	O
Risk	B-D012306
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(	O
5.1	O
).	O
•	O
Di	O
clofenac	O
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(	O
4	O
,	O
5.1	O
).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(	O
5.2	O
).	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(	O
5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(	O
5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(	O
5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(	O
5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(	O
5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(	O
5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnancy.	O
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(	O
5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
diclofenac	O
sodium	O
and	O
misoprostol	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
●	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
●	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
●	O
Avoid	O
use	O
in	O
patients	O
at	O
high	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
●	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
●	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	O
sodium	O
and	O
misoprostol	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
●	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
meaningful	O
elevation	O
of	O
ALT	O
(SGPT,	O
more	O
than	O
3	O
times	O
the	O
ULN	O
[ULN	O
=	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range])	O
occurred	O
in	O
1.6%	O
of	O
2,184	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
and	O
in	O
1.4%	O
of	O
1,691	O
patients	O
treated	O
with	O
diclofenac	O
sodium.	O
These	O
increases	O
were	O
generally	O
transient,	O
and	O
enzyme	O
levels	O
returned	O
to	O
within	O
the	O
normal	O
range	O
upon	O
discontinuation	O
of	O
therapy	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets.	O
The	O
misoprostol	O
component	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
does	O
not	O
appear	O
to	O
exacerbate	O
the	O
hepatic	O
effects	O
caused	O
by	O
the	O
diclofenac	O
sodium	O
component.	O
In	O
clinical	O
trials	O
of	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
sodium	O
for	O
2	O
to	O
6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
patients	O
and	O
included	O
marked	O
elevations	O
(i.e.,	O
greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
are	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
pre-existing	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
diclofenac	O
sodium	O
and	O
misoprostol.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
/misoprostol	O
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac/misoprostol	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
diclofenac	O
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
are	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
is	O
contraindicated	O
in	O
pregnant	O
women.	O
Advise	O
pregnant	O
women	O
of	O
the	O
potential	O
risk	O
to	O
a	O
fetus.	O
Verify	O
the	O
pregnancy	O
status	O
of	O
females	O
of	O
reproductive	O
potential	O
prior	O
to	O
initiation	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol.	O
Advise	O
females	O
of	O
reproductive	O
potential	O
to	O
use	O
effective	O
contraception	O
during	O
treatment	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(	O
8.1	O
,	O
8.3	O
)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin	O
and	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
and	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
,	O
5.6	O
)].	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
greater	O
than	O
2%	O
from	O
clinical	O
trials)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
flatulence,	O
gastritis,	O
vomiting,	O
constipation,	O
headache,	O
dizziness,	O
alanine	O
aminotransferase	O
increased,	O
hematocrit	O
decreased	O
(	O
6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
AvKARE,	O
Inc.	O
1-855-361-3993	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Adverse	O
reaction	O
information	O
for	O
diclofenac	O
sodium	O
and	O
misoprostol	O
is	O
derived	O
from	O
Phase	O
III	O
multinational	O
controlled	O
clinical	O
trials	O
in	O
over	O
2,000	O
patients	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets,	O
50	O
mg/0.2	O
mg	O
or	O
diclofenac	O
sodium	O
and	O
misoprostol	O
delayed-release	O
tablets,	O
75	O
mg/0.2	O
mg,	O
as	O
well	O
as	O
from	O
blinded,	O
controlled	O
trials	O
of	O
diclofenac	O
delayed-release	O
tablets	O
and	O
misoprostol	O
tablets.	O
Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
incidence	O
of	O
adverse	O
events	O
for	O
patients	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol.	O
These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
patients	O
on	O
diclofenac	O
sodium	O
and	O
misoprostol	O
and	O
5%	O
of	O
patients	O
on	O
diclofenac.	O
For	O
GI	O
ulcer	O
rates,	O
[see	O
Clinical	O
Studies	O
(14)	O
].	O
GI	O
disorder	O
Diclofenac	B-D004008
Sodium	B-D012964
and	O
Misoprostol	B-D016595
Diclofenac	B-D004008
Abdominal	O
pain	O
21%	O
15%	O
Diarrhea	B-D003967
19%	O
11%	O
Dyspepsia	B-D004415
14%	O
11%	O
Nausea	B-D009325
11%	O
6%	O
Flatulence	B-D005414
9%	O
4%	O
Diclofenac	B-D004008
sodium	O
and	O
misoprostol	O
can	O
cause	O
more	O
abdominal	O
pain,	O
diarrhea,	O
and	O
other	O
GI	O
symptoms	O
than	O
diclofenac	O
alone.	O
Diarrhea	B-D003967
and	O
abdominal	O
pain	O
developed	O
early	O
in	O
the	O
course	O
of	O
therapy,	O
and	O
were	O
usually	O
self-limited	O
(resolved	O
after	O
2	O
to	O
7	O
days).	O
Rare	O
instances	O
of	O
profound	O
diarrhea	O
leading	O
to	O
severe	O
dehydration	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
misoprostol.	O
Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
disease,	O
or	O
those	O
in	O
whom	O
dehydration,	O
were	O
it	O
to	O
occur,	O
would	O
be	O
dangerous,	O
should	O
be	O
monitored	O
carefully	O
if	O
diclofenac	O
sodium	O
and	O
misoprostol	O
is	O
prescribed.	O
The	O
incidence	O
of	O
diarrhea	O
can	O
be	O
minimized	O
by	O
administering	O
diclofenac	O
sodium	O
and	O
misoprostol	O
with	O
food	O
and	O
by	O
avoiding	O
coadministration	O
with	O
magnesium-containing	O
antacids.	O
Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
misoprostol	O
use	O
have	O
also	O
been	O
reported	O
for	O
women	O
receiving	O
diclofenac	O
sodium	O
and	O
misoprostol	O
(see	O
below).	O
Postmenopausal	O
vaginal	O
bleeding	O
may	O
be	O
related	O
to	O
administration	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol.	O
If	O
it	O
occurs,	O
diagnostic	O
workup	O
should	O
be	O
undertaken	O
to	O
rule	O
out	O
gynecological	O
pathology	O
[see	O
Boxed	O
Warnings	O
,	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5)	O
].	O
Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
safety	O
profile	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol	O
in	O
over	O
500	O
patients	O
65	O
years	O
of	O
age	O
or	O
older	O
compared	O
with	O
younger	O
patients.	O
Other	O
adverse	O
experiences	O
reported	O
occasionally	O
with	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
diclofenac	O
or	O
other	O
NSAIDs,	O
or	O
misoprostol	O
are:	O
Body	O
as	O
a	O
whole:	O
asthenia,	O
fatigue,	O
malaise.	O
Central	O
and	O
peripheral	O
nervous	O
system:	O
dizziness,	O
drowsiness,	O
headache,	O
insomnia,	O
paresthesia,	O
vertigo.	O
Digestive:	O
anorexia,	O
appetite	O
changes,	O
constipation,	O
dry	O
mouth,	O
dysphagia,	O
esophageal	O
ulceration,	O
oesophagitis,	O
eructation,	O
gastritis,	O
gastroesophageal	O
reflux,	O
GI	O
neoplasm	O
benign,	O
peptic	O
ulcer,	O
tenesmus,	O
vomiting.	O
Female	B-D005260
reproductive	O
disorders:	O
breast	O
pain,	O
dysmenorrhea,	O
menstrual	O
disorder,	O
menorrhagia,	O
vaginal	O
hemorrhage.	O
Hemic	O
and	O
lymphatic	O
system:	O
epistaxis,	O
leukopenia,	O
melena,	O
purpura,	O
decreased	O
hematocrit.	O
Metabolic	O
and	O
nutritional:	O
alanine	O
aminotransferase	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
aspartate	O
aminotransferase	O
increased,	O
dehydration,	O
hyponatremia.	O
Musculoskeletal	O
system:	O
arthralgia,	O
myalgia.	O
Psychiatric:	O
anxiety,	O
concentration	O
impaired,	O
depression,	O
irritability.	O
Respiratory	O
system:	O
asthma,	O
coughing,	O
hyperventilation.	O
Skin	B-D012867
and	O
appendages:	O
alopecia,	O
eczema,	O
pemphigoid	O
reaction,	O
photosensitivity,	O
sweating	O
increased,	O
pruritus.	O
Special	O
senses:	O
taste	O
perversion,	O
tinnitus.	O
Renal	O
and	O
urinary	O
disorders:	O
dysuria,	O
nocturia,	O
polyuria,	O
proteinuria,	O
urinary	O
tract	O
infection.	O
Vision:	O
diplopia.	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
of	O
diclofenac	O
sodium	O
and	O
misoprostol,	O
diclofenac	O
or	O
misoprostol.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliable	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
whole:	O
death,	O
fever,	O
infection,	O
sepsis,	O
chills,	O
edema.	O
Cardiovascular	O
system:	O
arrhythmia,	O
atrial	O
fibrillation,	O
congestive	O
heart	O
failure,	O
hypertension,	O
hypotension,	O
increased	O
CPK,	O
increased	O
LDH,	O
myocardial	O
infarction,	O
palpitations,	O
phlebitis,	O
premature	O
ventricular	O
contractions,	O
syncope,	O
tachycardia,	O
vasculitis.	O
Central	O
and	O
peripheral	O
nervous	O
system:	O
coma,	O
convulsions,	O
hyperesthesia,	O
hypertonia,	O
hypoesthesia,	O
meningitis,	O
migraine,	O
neuralgia,	O
somnolence,	O
stroke,	O
tremor.	O
Congenital,	O
familial	O
and	O
genetic	O
disorders:	O
birth	O
defects.	O
Digestive:	O
enteritis,	O
GI	O
bleeding,	O
glossitis,	O
heartburn,	O
hematemesis,	O
hemorrhoids,	O
intestinal	O
perforation,	O
stomatitis	O
and	O
ulcerative	O
stomatitis.	O
Female	B-D005260
reproductive	O
disorders:	O
intermenstrual	O
bleeding,	O
leukorrhea,	O
vaginitis,	O
uterine	O
cramping,	O
uterine	O
hemorrhage.	O
Hemic	O
and	O
lymphatic	O
system:	O
agranulocytosis,	O
anemia,	O
aplastic	O
anemia,	O
coagulation	O
time	O
increased,	O
ecchymosis,	O
eosinophilia,	O
hemolytic	O
anemia,	O
leukocytosis,	O
lymphadenopathy,	O
pancytopenia,	O
pulmonary	O
embolism,	O
rectal	O
bleeding,	O
thrombocythemia,	O
thrombocytopenia.	O
Hypersensitivity	B-D006967
:	O
angioedema,	O
laryngeal/pharyngeal	O
edema,	O
urticaria.	O
Liver	B-D008099
and	O
biliary	O
system:	O
abnormal	O
hepatic	O
function,	O
bilirubinemia,	O
liver	O
failure,	O
pancreatitis,	O
hepatitis,	O
jaundice.	O
Male	B-D008297
reproductive	O
disorders:	O
impotence,	O
perineal	O
pain.	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
glycosuria,	O
gout,	O
hypercholesterolemia,	O
hyperglycemia,	O
hyperuricemia,	O
hypoglycemia,	O
periorbital	O
edema,	O
porphyria,	O
weight	O
changes,	O
fluid	O
retention.	O
Pregnancy	B-D011247
,	O
puerperium	O
and	O
perinatal	O
conditions:	O
abnormal	O
uterine	O
contractions,	O
uterine	O
rupture/perforation,	O
retained	O
placenta,	O
amniotic	O
fluid	O
embolism,	O
incomplete	O
abortion,	O
premature	O
birth,	O
fetal	O
death.	O
Psychiatric:	O
confusion,	O
disorientation,	O
dream	O
abnormalities,	O
hallucinations,	O
nervousness,	O
paranoia,	O
psychotic	O
reaction.	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
female	O
fertility	O
decreased.	O
Respiratory	O
system:	O
dyspnea,	O
pneumonia,	O
respiratory	O
depression.	O
Skin	B-D012867
and	O
appendages:	O
acne,	O
bruising,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
pruritus	O
ani,	O
rash,	O
skin	O
ulceration,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis,	O
cutaneous	O
reactions	O
(bullous	O
eruption).	O
Special	O
senses:	O
hearing	O
impairment,	O
taste	O
loss.	O
Renal	O
and	O
urinary	O
disorders:	O
cystitis,	O
hematuria,	O
interstitial	O
nephritis,	O
micturition	O
frequency,	O
nephrotic	O
syndrome,	O
oliguria,	O
papillary	O
necrosis,	O
renal	O
failure,	O
glomerulonephritis	O
membranous,	O
glomerulonephritis	O
minimal	O
lesion,	O
glomerulohephritis.	O
Vision:	O
amblyopia,	O
blurred	O
vision,	O
conjunctivitis,	O
glaucoma,	O
iritis,	O
lacrimation	O
abnormal,	O
night	O
blindness,	O
vision	O
abnormal.	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS	O
).	O
Etodolac	B-D017308
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
a	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1,000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain*,	O
diarrhea*,	O
flatulence*,	O
nausea*,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise*,	O
dizziness*,	O
depression,	O
nervousness,	O
fatigue.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
Musculoskeletal	O
-	O
Arthralgia	B-D018771
*Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis	O
,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
fatal	O
fulminant	O
hepatitis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation	O
,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
leukocytoclastic	O
vasculitis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.	O
Musculoskeletal	O
-	O
Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death	O
Cardiovascular	O
system	O
-	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis	O
Hemic	O
and	O
lymphatic	O
system	O
–	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
contact	O
AvKARE,	O
Inc.	O
at	O
1-855-361-3993;	O
email	O
drugsafety@avkare.com	O
;	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Events	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
Diclofenac	B-D004008
Sodium	B-D012964
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
].	O
Diclofenac	B-D004008
Sodium	B-D012964
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008
sodium	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
diclofenac	O
sodium	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
Exposure	O
to	O
light:	O
Avoid	O
exposure	O
of	O
treated	O
knee(s)	O
to	O
natural	O
or	O
artificial	O
sunlight.	O
(5.14)	O
Eye	B-D005123
Contact:	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
with	O
eyes	O
and	O
mucosa.	O
(5.15)	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs:	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs.	O
(5.16)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAIDtreated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
diclofenac	O
sodium	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2	O
%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	O
sodium	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials,	O
of	O
oral	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
for	O
2	O
to	O
6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
then	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver-related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
antibiotics,	O
antiepileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension,	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotension	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Monitor	O
blood	O
pressure	O
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebotreated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
diclofenac	O
sodium	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
diclofenac	O
sodium	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
diclofenac	O
sodium.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
diclofenac	O
sodium	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
diclofenac	O
sodium	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac	O
and	O
in	O
patients	O
with	O
aspirinsensitive	O
asthma	O
(see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
diclofenac	O
sodium	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
diclofenac	O
sodium	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	O
sodium	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Diclofenac	B-D004008
sodium	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Do	O
not	O
apply	O
diclofenac	O
sodium	O
to	O
open	O
skin	O
wounds,	O
infections,	O
inflammations,	O
or	O
exfoliative	O
dermatitis,	O
as	O
it	O
may	O
affect	O
absorption	O
and	O
tolerability	O
of	O
the	O
drug.	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
diclofenac	O
sodium,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
diclofenac	O
sodium	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
diclofenac	O
sodium,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
The	O
effects	O
of	O
diclofenac	O
sodium	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	O
subjects	O
administered	O
80	O
drops	O
four	O
times	O
a	O
day	O
for	O
7	O
days.	O
There	O
was	O
no	O
significant	O
change	O
in	O
platelet	O
aggregation	O
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
longterm	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
].	O
5.14	O
Sun	O
Exposure	O
Instruct	O
patients	O
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
knee(s)	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light-induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	O
sodium	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	O
sodium	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	O
and	O
conduct	O
periodic	O
laboratory	O
evaluations.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
The	O
most	O
common	O
adverse	O
reactions	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
are	O
application	O
site	O
reactions.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Taro	O
Pharmaceuticals	O
U.S.A.,	O
Inc.	O
at	O
1-866-923-4914	O
or	O
the	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution	O
of	O
911	O
patients	O
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	O
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	O
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	O
treated	O
for	O
at	O
least	O
12	O
months.	O
The	O
population	O
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	O
were	O
Caucasians,	O
64%	O
were	O
females,	O
and	O
all	O
patients	O
had	O
primary	O
osteoarthritis.	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies.	O
Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
Application	O
site	O
reactions	O
were	O
characterized	O
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	O
induration,	O
vesicles,	O
paresthesia,	O
pruritus,	O
vasodilation,	O
acne,	O
and	O
urticaria.	O
The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	O
(32%),	O
contact	O
dermatitis	O
characterized	O
by	O
skin	O
erythema	O
and	O
induration	O
(9%),	O
contact	O
dermatitis	O
with	O
vesicles	O
(2%)	O
and	O
pruritus	O
(4%).	O
In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	O
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac.	O
In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	O
study,	O
contact	O
dermatitis	O
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	O
with	O
vesicles	O
in	O
10%	O
of	O
patients,	O
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	O
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%.	O
Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
flatulence,	O
abdominal	O
pain,	O
edema;	O
see	O
Table	O
1	O
).	O
The	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac,	O
compared	O
to	O
oral	O
diclofenac	O
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	O
(3%	O
vs.	O
less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	O
(12%	O
vs.	O
7%),	O
urea	O
(20%	O
vs.	O
12%),	O
and	O
hemoglobin	O
(13%	O
vs.	O
9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	O
transaminases.	O
Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
osteoarthritis.	O
Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
placebo	O
and	O
oral	O
diclofenaccontrolled	O
trials.	O
Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
SolutionN=911	O
TopicalPlaceboN=332	O
Adverse	O
ReactionPreferred	O
Term	O
according	O
to	O
COSTART	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-U.S.	O
postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
Whole:	O
abdominal	O
pain,	O
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	O
back	O
pain,	O
body	O
odor,	O
chest	O
pain,	O
edema,	O
face	O
edema,	O
halitosis,	O
headache,	O
lack	O
of	O
drug	O
effect,	O
neck	O
rigidity,	O
pain	O
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	O
dry	O
mouth,	O
dyspepsia,	O
gastroenteritis,	O
decreased	O
appetite,	O
mouth	O
ulceration,	O
nausea,	O
rectal	O
hemorrhage,	O
ulcerative	O
stomatitis	O
Metabolic	O
and	O
Nutritional:	O
creatinine	O
increased	O
Musculoskeletal:	O
leg	O
cramps,	O
myalgia	O
Nervous:	O
depression,	O
dizziness,	O
drowsiness,	O
lethargy,	O
paresthesia,	O
paresthesia	O
at	O
application	O
site	O
Respiratory:	O
asthma,	O
dyspnea,	O
laryngismus,	O
laryngitis,	O
pharyngitis	O
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	O
contact	O
dermatitis	O
with	O
vesicles,	O
dry	O
skin,	O
pruritus,	O
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	O
rash,	O
pruritus,	O
skin	O
discoloration,	O
urticaria	O
Special	O
Senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	O
ear	O
pain,	O
eye	O
disorder,	O
eye	O
pain,	O
taste	O
perversion	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Aspirin	B-D001241
and	O
extended-release	O
dipyridamole	O
capsules	O
increase	O
the	O
risk	O
of	O
bleeding	O
(5.1)	O
Avoid	O
use	O
in	O
patients	O
with	O
severe	O
hepatic	O
or	O
renal	O
insufficiency	O
(5.2,	O
5.3)	O
5.1	O
Risk	B-D012306
of	O
Bleeding	O
Aspirin	B-D001241
and	O
extended-release	O
dipyridamole	O
capsules	O
increase	O
the	O
risk	O
of	O
bleeding.	O
Risk	B-D012306
factors	O
for	O
bleeding	O
include	O
the	O
use	O
of	O
other	O
drugs	O
that	O
increase	O
the	O
risk	O
of	O
bleeding	O
(e.g.	O
anticoagulants,	O
antiplatelet	O
agents,	O
heparin,	O
anagrelide	B-C021139
,	O
fibrinolytic	O
therapy,	O
and	O
chronic	O
use	O
of	O
NSAIDs)	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)].	O
Intracranial	O
Hemorrhage	B-D006470
In	O
Europe	B-D005060
an	O
Stroke	B-D020521
Prevention	O
Study-2	O
(ESPS2),	O
the	O
annualized	O
event	O
rate	O
for	O
intracranial	O
hemorrhage	O
was	O
0.39%/year	O
in	O
the	O
aspirin	O
and	O
extended-release	O
dipyridamole	O
capsules	O
group,	O
0.26%/year	O
in	O
the	O
extended-release	O
dipyridamole	O
(ER-DP)	O
group,	O
0.24%/year	O
in	O
the	O
aspirin	O
(ASA)	O
group	O
and	O
0.29%/year	O
in	O
the	O
placebo	O
groups.	O
Gastrointestinal	O
(GI)	O
Side	O
Effects	O
GI	O
side	O
effects	O
include	O
stomach	O
pain,	O
heartburn,	O
nausea,	O
vomiting,	O
and	O
gross	O
GI	O
bleeding.	O
Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
dyspepsia,	O
are	O
common	O
and	O
can	O
occur	O
anytime	O
during	O
therapy,	O
physicians	O
should	O
remain	O
alert	O
for	O
signs	O
of	O
ulceration	O
and	O
bleeding,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
GI	O
symptoms.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
GI	O
side	O
effects	O
and	O
what	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
In	O
ESPS2,	O
the	O
annualized	O
event	O
rate	O
for	O
gastrointestinal	O
bleeding	O
was	O
2.97%/year	O
in	O
the	O
aspirin	O
and	O
extended-release	O
dipyridamole	O
capsules	O
group,	O
1.58%/year	O
in	O
the	O
extendedrelease	O
dipyridamole	O
group,	O
2.06%/year	O
in	O
the	O
aspirin	O
group,	O
and	O
1.40%/year	O
in	O
the	O
placebo	O
groups.	O
Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
Avoid	O
using	O
aspirin	O
in	O
patients	O
with	O
a	O
history	O
of	O
active	O
peptic	O
ulcer	O
disease,	O
which	O
can	O
cause	O
gastric	O
mucosal	O
irritation	O
and	O
bleeding.	O
Alcohol	O
Warning	O
Because	O
aspirin	O
and	O
extended-release	O
dipyridamole	O
capsules	O
contain	O
aspirin,	O
counsel	O
patients	O
who	O
consume	O
three	O
or	O
more	O
alcoholic	O
drinks	O
every	O
day	O
about	O
the	O
bleeding	O
risks	O
involved	O
with	O
chronic,	O
heavy	O
alcohol	O
use	O
while	O
taking	O
aspirin.	O
5.2	O
Renal	O
Failure	O
Avoid	O
aspirin	O
in	O
patients	O
with	O
severe	O
renal	O
failure	O
(glomerular	O
filtration	O
rate	O
less	O
than	O
10	O
mL/minute)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.6)	O
and	O
Clinical	O
Pharmacology	B-D010600
(12.3)].	O
5.3	O
Hepatic	B-D048550
Insufficiency	I-D048550
Elevations	O
of	O
hepatic	O
enzymes	O
and	O
hepatic	O
failure	O
have	O
been	O
reported	O
in	O
association	O
with	O
dipyridamole	O
administration	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.6)	O
and	O
Clinical	O
Pharmacology	B-D010600
(12.3)].	O
5.4	O
Coronary	B-D003324
Artery	I-D003324
Disease	I-D003324
Dipyridamole	B-D004176
has	O
a	O
vasodilatory	O
effect.	O
Chest	O
pain	O
may	O
be	O
precipitated	O
or	O
aggravated	O
in	O
patients	O
with	O
underlying	O
coronary	O
artery	O
disease	O
who	O
are	O
receiving	O
dipyridamole.	O
For	O
stroke	O
or	O
TIA	O
patients	O
for	O
whom	O
aspirin	O
is	O
indicated	O
to	O
prevent	O
recurrent	O
myocardial	O
infarction	O
(MI)	O
or	O
angina	O
pectoris,	O
the	O
aspirin	O
in	O
this	O
product	O
may	O
not	O
provide	O
adequate	O
treatment	O
for	O
the	O
cardiac	O
indications.	O
5.5	O
Hypotension	B-D007022
Dipyridamole	B-D004176
produces	O
peripheral	O
vasodilation,	O
which	O
can	O
exacerbate	O
pre-existing	O
hypotension.	O
5.6	O
General	O
Aspirin	B-D001241
and	O
extended-release	O
dipyridamole	O
capsules	O
are	O
not	O
interchangeable	O
with	O
the	O
individual	O
components	O
of	O
aspirin	O
and	O
dipyridamole	O
tablets.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(>10%	O
and	O
greater	O
than	O
placebo)	O
were	O
headache,	O
dyspepsia,	O
abdominal	O
pain,	O
nausea,	O
and	O
diarrhea	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Zydus	O
Pharmaceuticals	O
USA	O
Inc.	O
at	O
1-877-993-8779	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Hypersensitivity	B-D006967
[see	O
Contraindications	B-D000075202
(4.1)	O
].	O
Allergy	O
[see	O
Contraindications	B-D000075202
(4.2)	O
].	O
Risk	B-D012306
of	O
Bleeding	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
efficacy	O
and	O
safety	O
of	O
aspirin	O
and	O
extended-release	O
dipyridamole	O
capsules	O
was	O
established	O
in	O
the	O
Europe	B-D005060
an	O
Stroke	B-D020521
Prevention	O
Study-2	O
(ESPS2).	O
ESPS2	O
was	O
a	O
double-blind,	O
placebo	O
controlled	O
study	O
that	O
evaluated	O
6602	O
patients	O
over	O
the	O
age	O
of	O
18	O
years	O
who	O
had	O
a	O
previous	O
ischemic	O
stroke	O
or	O
transient	O
ischemic	O
attack	O
within	O
ninety	O
days	O
prior	O
to	O
entry.	O
Patients	B-D010361
were	O
randomized	O
to	O
either	O
aspirin	O
and	O
extended-release	O
dipyridamole	O
capsules,	O
aspirin,	O
ER-DP,	O
or	O
placebo	O
[see	O
Clinical	O
Studies	O
(14)];	O
primary	O
endpoints	O
included	O
stroke	O
(fatal	O
or	O
nonfatal)	O
and	O
death	O
from	O
all	O
causes.	O
This	O
24-month,	O
multicenter,	O
double-blind,	O
randomized	O
study	O
(ESPS2)	O
was	O
conducted	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
aspirin	O
and	O
extended-release	O
dipyridamole	O
capsules	O
with	O
placebo,	O
extended-release	O
dipyridamole	O
alone	O
and	O
aspirin	O
alone.	O
The	O
study	O
was	O
conducted	O
in	O
a	O
total	O
of	O
6602	O
male	O
and	O
female	O
patients	O
who	O
had	O
experienced	O
a	O
previous	O
ischemic	O
stroke	O
or	O
transient	O
ischemia	O
of	O
the	O
brain	O
within	O
three	O
months	O
prior	O
to	O
randomization.	O
Table	O
1	O
presents	O
the	O
annualized	O
event	O
rate	O
for	O
adverse	O
events	O
that	O
occurred	O
in	O
1%/year	O
or	O
more	O
of	O
patients	O
treated	O
with	O
aspirin	O
and	O
extended-release	O
dipyridamole	O
capsules	O
where	O
the	O
incidence	O
was	O
also	O
at	O
least	O
1%/year	O
greater	O
than	O
in	O
those	O
patients	O
treated	O
with	O
placebo.	O
There	O
is	O
no	O
clear	O
benefit	O
of	O
the	O
dipyridamole/aspirin	O
combination	O
over	O
aspirin	O
with	O
respect	O
to	O
safety.	O
Table	O
1	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
in	O
ESPS2a	O
a	O
Reported	O
by	O
≥1%/year	O
of	O
patients	O
during	O
aspirin	O
and	O
extended-release	O
dipyridamole	O
capsules	O
treatment	O
where	O
the	O
incidence	O
was	O
atleast	O
1%/year	O
greater	O
than	O
in	O
those	O
treated	O
with	O
placebo.	O
b	O
Annual	O
event	O
rate	O
per	O
100pt-years=	O
100*	O
number	O
of	O
subjects	O
with	O
event/subject-years.	O
Subject-years	O
is	O
defined	O
as	O
cumulative	O
number	O
of	O
days	O
on	O
treatment	O
divided	O
by	O
365.25.	O
Note:	O
ER-DP	O
=	O
extended-release	O
dipyridamole	O
200	O
mg;	O
ASA	O
=	O
aspirin	O
25	O
mg.	O
The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O
NOS	O
=	O
not	O
otherwise	O
specified.	O
Individual	O
Treatment	O
Group	O
Body	O
System/Preferred	O
Term	O
Aspirin	B-D001241
and	O
Extended-release	O
Dipyridamole	B-D004176
Capsules	B-D002214
n	O
(%/year)b	O
ER-DP	O
Alone	O
n	O
(%/year)b	O
ASA	O
Alone	O
n	O
(%/year)b	O
Placebo	O
n	O
(%/year)b	O
Total	O
Number	O
of	O
Patients	B-D010361
1650	O
1654	O
1649	O
1649	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Disorders	O
Headache	B-D006261
647	O
(28.25)	O
634	O
(27.91)	O
558	O
(22.10)	O
543	O
(22.29)	O
Gastrointestinal	O
System	O
Disorders	O
Dyspepsia	B-D004415
303	O
(13.23)	O
288	O
(12.68)	O
299	O
(11.84)	O
275	O
(11.29)	O
Abdominal	B-D015746
Pain	I-D015746
289	O
(12.62)	O
255	O
(11.22)	O
262	O
(10.38)	O
239	O
(9.81)	O
Nausea	B-D009325
264	O
(11.53)	O
254	O
(11.18)	O
210	O
(8.32)	O
232	O
(9.53)	O
Diarrhea	B-D003967
210	O
(9.17)	O
257	O
(11.31)	O
112	O
(4.44)	O
161	O
(6.61)	O
Vomiting	B-D014839
138	O
(6.03)	O
129	O
(5.68)	O
101	O
(4.00)	O
118	O
(4.84)	O
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders	O
Hemorrhage	B-D006470
NOS	O
52	O
(2.27)	O
24	O
(1.06)	O
46	O
(1.82)	O
24	O
(0.99)	O
Discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
ESPS2	O
was	O
25%	O
for	O
aspirin	O
and	O
extended-release	O
dipyridamole	O
capsules,	O
25%	O
for	O
extended-release	O
dipyridamole,	O
19%	O
for	O
aspirin,	O
and	O
21%	O
for	O
placebo	O
(refer	O
to	O
Table	O
2)	O
Table	O
2	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
that	O
Led	O
to	O
the	O
Discontinuation	O
of	O
Treatmenta	O
a	O
Reported	O
by	O
≥1%/year	O
of	O
patients	O
during	O
aspirin	O
and	O
extended-release	O
dipyridamole	O
capsules	O
treatment	O
where	O
the	O
incidence	O
was	O
atleast	O
1%/year	O
greater	O
than	O
in	O
those	O
treated	O
with	O
placebo.	O
b	O
Annual	O
event	O
rate	O
per	O
100pt-years=	O
100*	O
number	O
of	O
subjects	O
with	O
event/subject-years.	O
Subject-years	O
is	O
defined	O
as	O
cumulative	O
number	O
of	O
days	O
on	O
treatment	O
divided	O
by	O
365.25.	O
Note:	O
ER-DP	O
=	O
extended-release	O
dipyridamole	O
200	O
mg;	O
ASA	O
=	O
aspirin	O
25	O
mg.	O
The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O
Headache	B-D006261
was	O
most	O
notable	O
in	O
the	O
first	O
month	O
of	O
treatment.	O
Treatment	O
Groups	O
Aspirin	B-D001241
and	O
Extended-release	O
Dipyridamole	B-D004176
Capsules	B-D002214
n(%/year)b	O
ER-DP	O
n(%/year)b	O
ASA	O
n(%/year)b	O
Placebo	O
n(%/year)b	O
Total	O
Number	O
of	O
Patients	B-D010361
1650	O
1654	O
1649	O
1649	O
Patients	B-D010361
with	O
at	O
least	O
one	O
Adverse	O
Event	O
that	O
led	O
to	O
treatment	O
discontinuation	O
417	O
(18.21)	O
419	O
(18.44)	O
318	O
(12.59)	O
352	O
(14.45)	O
Headache	B-D006261
165	O
(7.20)	O
166	O
(7.31)	O
57	O
(2.26)	O
69	O
(2.83)	O
Nausea	B-D009325
91	O
(3.97)	O
95	O
(4.18)	O
51	O
(2.02)	O
53	O
(2.18)	O
Abdominal	B-D015746
Pain	I-D015746
74	O
(3.23)	O
64	O
(2.82)	O
56	O
(2.22)	O
52	O
(2.13)	O
Vomiting	B-D014839
53	O
(2.31)	O
52	O
(2.29)	O
28	O
(1.11)	O
24	O
(0.99)	O
Headache	B-D006261
was	O
most	O
notable	O
in	O
the	O
first	O
month	O
of	O
treatment.	O
6.2	O
Post	O
Marketing	B-D040541
Experience	O
The	O
following	O
is	O
a	O
list	O
of	O
additional	O
adverse	O
reactions	O
that	O
have	O
been	O
reported	O
either	O
in	O
the	O
literature	O
or	O
are	O
from	O
post-marketing	O
spontaneous	O
reports	O
for	O
either	O
dipyridamole	O
or	O
aspirin.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
estimate	O
reliably	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Decisions	O
to	O
include	O
these	O
reactions	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
reaction,	O
(2)	O
frequency	O
of	O
reporting,	O
or	O
(3)	O
strength	O
of	O
causal	O
connection	O
to	O
aspirin	O
and	O
extended-release	O
dipyridamole	O
capsules.	O
Body	O
as	O
a	O
Whole	O
Hypothermia	B-D007035
,	O
chest	O
pain,	O
allergic	O
reaction,	O
syncope	O
Cardiovascular	O
Angina	O
pectoris,	O
hypotension	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Cerebral	O
edema,	O
dizziness,	O
cerebral	O
hemorrhage,	O
intracranial	O
hemorrhage,	O
subarachnoid	O
hemorrhage	O
Fluid	O
and	O
Electrolyte	O
Hyperkalemia	B-D006947
,	O
metabolic	O
acidosis,	O
respiratory	O
alkalosis,	O
hypokalemia	O
Gastrointestinal	O
Pancreatitis	B-D010195
,	O
Reye	O
syndrome,	O
hematemesis,	O
gastritis,	O
ulceration	O
and	O
perforation,	O
hemorrhage	O
rectum,	O
melena,	O
GI	O
hemorrhage	O
Heart	B-D006339
Rate	I-D006339
and	O
Rhythm	O
Disorders	O
Tachycardia	B-D013610
,	O
palpitation	O
Hearing	B-D006309
and	O
Vestibular	O
Disorders	O
Hearing	B-D006309
loss	O
Immune	B-D007107
System	I-D007107
Disorders	O
Hypersensitivity	B-D006967
,	O
acute	O
anaphylaxis,	O
laryngeal	O
edema	O
Liver	B-D008099
and	O
Biliary	O
System	O
Disorders	O
Hepatitis	B-D006505
,	O
hepatic	O
failure,	O
cholelithiasis,	O
jaundice,	O
hepatic	O
function	O
abnormal	O
Musculoskeletal	O
Rhabdomyolysis	B-D012206
,	O
myalgia	O
Metabolic	O
and	O
Nutritional	O
Disorders	O
Hypoglycemia	B-D007003
,	O
dehydration	O
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders	O
Prolongation	O
of	O
the	O
prothrombin	O
time,	O
disseminated	O
intravascular	O
coagulation,	O
coagulopathy,	O
thrombocytopenia,	O
hematoma,	O
gingival	O
bleeding,	O
epistaxis,	O
purpura	O
Psychiatric	O
Disorders	O
Confusion	B-D003221
,	O
agitation	O
Respiratory	O
Tachypnea	B-D059246
,	O
dyspnea,	O
hemoptysis	O
Skin	B-D012867
and	O
Appendages	O
Disorders	O
Rash,	O
alopecia,	O
angioedema,	O
Stevens-Johnson	O
syndrome,	O
skin	O
hemorrhages	O
such	O
as	O
bruising,	O
ecchymosis,	O
and	O
hematoma,	O
pruritus,	O
urticaria	O
Urogenital	O
Interstitial	O
nephritis,	O
papillary	O
necrosis,	O
proteinuria,	O
renal	O
insufficiency	O
and	O
failure,	O
hematuria	O
Vascular	O
(Extracardiac)	O
Disorders	O
Allergic	O
vasculitis,	O
flushing	O
Other	O
Adverse	O
Events	O
Anorexia	B-D000855
,	O
aplastic	O
anemia,	O
migraine,	O
pancytopenia,	O
thrombocytosis.	O
WARNING	O
If	O
persistent	O
skin	O
irritation	O
develops,	O
discontinue	O
use	O
of	O
product	O
and	O
consult	O
your	O
physician	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Increased	O
risk	O
of	O
bleeding.	O
(5.1)	O
DURLAZA	O
can	O
cause	O
gastric	O
mucosal	O
irritation	O
and	O
bleeding.	O
Patients	B-D010361
with	O
a	O
history	O
of	O
active	O
peptic	O
ulcer	O
disease	O
are	O
at	O
particular	O
risk.	O
(5.2)	O
DURLAZA	O
can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman.	O
(5.3,	O
8.1)	O
5.1	O
Risk	B-D012306
of	O
Bleeding	O
DURLAZA	O
increases	O
the	O
risk	O
of	O
bleeding.	O
Risk	B-D012306
factors	O
for	O
bleeding	O
include	O
the	O
use	O
of	O
other	O
drugs	O
that	O
increase	O
the	O
risk	O
of	O
bleeding	O
(e.g.,	O
anticoagulants,	O
antiplatelet	O
agents,	O
and	O
chronic	O
use	O
of	O
NSAIDs)	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.2	O
Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
DURLAZA	O
may	O
cause	O
gastric	O
ulceration	O
and	O
bleeding.	O
Avoid	O
DURLAZA	O
in	O
patients	O
with	O
active	O
peptic	O
ulcer	O
disease.	O
5.3	O
Fetal	O
Toxicity	O
DURLAZA	O
can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman.	O
Maternal	O
aspirin	O
use	O
during	O
later	O
stages	O
of	O
pregnancy	O
may	O
cause	O
low	O
birth	O
weight,	O
increased	O
incidence	O
for	O
intracranial	O
hemorrhage	O
in	O
premature	O
infants,	O
stillbirths	O
and	O
neonatal	O
death.	O
Because	O
NSAIDs	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus,	O
avoid	O
DURLAZA	O
in	O
the	O
third	O
trimester	O
of	O
pregnancy	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
are	O
Gastrointestinal	O
(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
New	O
Haven	O
Pharmaceuticals	O
at	O
(877)	O
824-2483	O
or	O
www.newhavenpharma.com	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
The	O
following	O
is	O
a	O
list	O
of	O
adverse	O
reactions	O
that	O
have	O
been	O
reported	O
in	O
the	O
literature	O
for	O
products	O
containing	O
low	O
dose	O
aspirin	O
[see	O
Warnings	O
and	O
Precautions	O
(5)].	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Agitation,	O
cerebral	O
edema,	O
coma,	O
confusion,	O
dizziness,	O
headache,	O
lethargy,	O
seizures.	O
Fluid	O
and	O
Electrolyte:	O
Hyperkalemia	B-D006947
,	O
metabolic	O
acidosis,	O
respiratory	O
alkalosis.	O
Gastrointestinal:	O
Dyspepsia	B-D004415
,	O
hepatic	O
enzyme	O
elevation,	O
hepatitis,	O
Reye's	O
Syndrome	B-D013577
.	O
Renal:	O
Interstitial	O
nephritis,	O
papillary	O
necrosis,	O
proteinuria,	O
renal	O
insufficiency	O
and	O
failure.	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
The	O
risk	O
of	O
GI	O
bleeding	O
is	O
increased,	O
especially	O
in	O
patients	O
who	O
are	O
heavy	O
alcohol	O
users,	O
have	O
a	O
history	O
of	O
peptic	O
ulcer,	O
or	O
have	O
coagulation	O
abnormalities	O
due	O
to	O
liver	O
disease	O
or	O
vitamin	O
K	O
deficiency	O
(5.1)	O
As	O
with	O
other	O
antiplatelets,	O
there	O
is	O
a	O
risk	O
of	O
intracranial	O
hemorrhage	O
(5.1)	O
Avoid	O
use	O
in	O
patients	O
with	O
severe	O
hepatic	O
or	O
renal	O
insufficiency	O
(5.2,	O
5.3)	O
Can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman,	O
especially	O
in	O
the	O
third	O
trimester	O
(5.4)	O
5.1	O
Risk	B-D012306
of	O
Bleeding	O
Intracranial	O
Hemorrhage	B-D006470
In	O
ESPS2	O
the	O
incidence	O
of	O
intracranial	O
hemorrhage	O
was	O
0.6%	O
in	O
the	O
AGGRENOX	O
group,	O
0.5%	O
in	O
the	O
extended-release	O
dipyridamole	O
(ER-DP)	O
group,	O
0.4%	O
in	O
the	O
aspirin	O
(ASA)	O
group	O
and	O
0.4%	O
in	O
the	O
placebo	O
groups.	O
Coagulation	O
Abnormalities	O
Even	O
low	O
doses	O
of	O
aspirin	O
can	O
inhibit	O
platelet	O
function	O
leading	O
to	O
an	O
increase	O
in	O
bleeding	O
time.	O
This	O
can	O
adversely	O
affect	O
patients	O
with	O
inherited	O
or	O
acquired	O
(liver	O
disease	O
or	O
vitamin	O
K	O
deficiency)	O
bleeding	O
disorders	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.4)	O
].	O
Gastrointestinal	O
(GI)	O
Side	O
Effects	O
GI	O
side	O
effects	O
include	O
stomach	O
pain,	O
heartburn,	O
nausea,	O
vomiting,	O
and	O
gross	O
GI	O
bleeding.	O
Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
dyspepsia,	O
are	O
common	O
and	O
can	O
occur	O
anytime	O
during	O
therapy,	O
physicians	O
should	O
remain	O
alert	O
for	O
signs	O
of	O
ulceration	O
and	O
bleeding,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
GI	O
symptoms.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
GI	O
side	O
effects	O
and	O
what	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
In	O
ESPS2	O
the	O
incidence	O
of	O
gastrointestinal	O
bleeding	O
was	O
4.1%	O
in	O
the	O
AGGRENOX	O
group,	O
2.2%	O
in	O
the	O
extended-release	O
dipyridamole	O
group,	O
3.2%	O
in	O
the	O
aspirin	O
group,	O
and	O
2.1%	O
in	O
the	O
placebo	O
groups.	O
Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
Avoid	O
using	O
aspirin	O
in	O
patients	O
with	O
a	O
history	O
of	O
active	O
peptic	O
ulcer	O
disease,	O
which	O
can	O
cause	O
gastric	O
mucosal	O
irritation	O
and	O
bleeding.	O
Alcohol	O
Warning	O
Because	O
AGGRENOX	O
contains	O
aspirin,	O
counsel	O
patients	O
who	O
consume	O
three	O
or	O
more	O
alcoholic	O
drinks	O
every	O
day	O
about	O
the	O
bleeding	O
risks	O
involved	O
with	O
chronic,	O
heavy	O
alcohol	O
use	O
while	O
taking	O
aspirin.	O
5.2	O
Renal	O
Failure	O
Avoid	O
aspirin	O
in	O
patients	O
with	O
severe	O
renal	O
failure	O
(glomerular	O
filtration	O
rate	O
less	O
than	O
10	O
mL/minute)	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.6)	O
and	O
Clinical	O
Pharmacology	B-D010600
(12.3)	O
].	O
5.3	O
Hepatic	B-D048550
Insufficiency	I-D048550
Elevations	O
of	O
hepatic	O
enzymes	O
and	O
hepatic	O
failure	O
have	O
been	O
reported	O
in	O
association	O
with	O
dipyridamole	O
administration	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.6)	O
and	O
Clinical	O
Pharmacology	B-D010600
(12.3)	O
].	O
5.4	O
Pregnancy	B-D011247
Because	O
AGGRENOX	O
contains	O
aspirin,	O
AGGRENOX	O
can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman.	O
Maternal	O
aspirin	O
use	O
during	O
later	O
stages	O
of	O
pregnancy	O
may	O
cause	O
low	O
birth	O
weight,	O
increased	O
incidence	O
for	O
intracranial	O
hemorrhage	O
in	O
premature	O
infants,	O
stillbirths	O
and	O
neonatal	O
death.	O
Because	O
of	O
the	O
above	O
and	O
because	O
of	O
the	O
known	O
effects	O
of	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
on	O
the	O
fetal	O
cardiovascular	O
system	O
(closure	O
of	O
the	O
ductus	O
arteriosus),	O
avoid	O
AGGRENOX	O
in	O
the	O
third	O
trimester	O
of	O
pregnancy	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
Aspirin	B-D001241
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
rats	O
(spina	O
bifida,	O
exencephaly,	O
microphthalmia	O
and	O
coelosomia)	O
and	O
rabbits	O
(congested	O
fetuses,	O
agenesis	O
of	O
skull	O
and	O
upper	O
jaw,	O
generalized	O
edema	O
with	O
malformation	O
of	O
the	O
head,	O
and	O
diaphanous	O
skin)	O
at	O
oral	O
doses	O
of	O
330	O
mg/kg/day	O
and	O
110	O
mg/kg/day,	O
respectively.	O
These	O
doses,	O
which	O
also	O
resulted	O
in	O
a	O
high	O
resorption	O
rate	O
in	O
rats	O
(63%	O
of	O
implantations	O
versus	O
5%	O
in	O
controls),	O
are,	O
on	O
a	O
mg/m2	O
basis,	O
about	O
66	O
and	O
44	O
times,	O
respectively,	O
the	O
dose	O
of	O
aspirin	O
contained	O
in	O
the	O
maximum	O
recommended	O
daily	O
human	O
dose	O
of	O
AGGRENOX.	O
Reproduction	B-D012098
studies	O
with	O
dipyridamole	O
have	O
been	O
performed	O
in	O
mice,	O
rabbits	O
and	O
rats	O
at	O
oral	O
doses	O
of	O
up	O
to	O
125	O
mg/kg,	O
40	O
mg/kg	O
and	O
1000	O
mg/kg,	O
respectively	O
(about	O
1½,	O
2	O
and	O
25	O
times	O
the	O
maximum	O
recommended	O
daily	O
human	O
oral	O
dose,	O
respectively,	O
on	O
a	O
mg/m2	O
basis)	O
and	O
have	O
revealed	O
no	O
evidence	O
of	O
harm	O
to	O
the	O
fetus	O
due	O
to	O
dipyridamole.	O
When	O
330	O
mg	O
aspirin/kg/day	O
was	O
combined	O
with	O
75	O
mg	O
dipyridamole/kg/day	O
in	O
the	O
rat,	O
the	O
resorption	O
rate	O
approached	O
100%,	O
indicating	O
potentiation	O
of	O
aspirin-related	O
fetal	O
toxicity.	O
There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
of	O
the	O
use	O
of	O
AGGRENOX	O
in	O
pregnant	O
women.	O
If	O
AGGRENOX	O
is	O
used	O
during	O
pregnancy,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
AGGRENOX,	O
inform	O
the	O
patient	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus.	O
5.5	O
Coronary	B-D003324
Artery	I-D003324
Disease	I-D003324
Dipyridamole	B-D004176
has	O
a	O
vasodilatory	O
effect.	O
Chest	O
pain	O
may	O
be	O
precipitated	O
or	O
aggravated	O
in	O
patients	O
with	O
underlying	O
coronary	O
artery	O
disease	O
who	O
are	O
receiving	O
dipyridamole.	O
For	O
stroke	O
or	O
TIA	O
patients	O
for	O
whom	O
aspirin	O
is	O
indicated	O
to	O
prevent	O
recurrent	O
myocardial	O
infarction	O
(MI)	O
or	O
angina	O
pectoris,	O
the	O
aspirin	O
in	O
this	O
product	O
may	O
not	O
provide	O
adequate	O
treatment	O
for	O
the	O
cardiac	O
indications.	O
5.6	O
Hypotension	B-D007022
Dipyridamole	B-D004176
produces	O
peripheral	O
vasodilation,	O
which	O
can	O
exacerbate	O
pre-existing	O
hypotension.	O
5.7	O
General	O
AGGRENOX	O
capsules	O
are	O
not	O
interchangeable	O
with	O
the	O
individual	O
components	O
of	O
aspirin	O
and	O
dipyridamole	O
tablets.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Hypersensitivity	B-D006967
[	O
see	O
Contraindications	B-D000075202
(4.1)	O
].	O
Allergy	O
[	O
see	O
Contraindications	B-D000075202
(4.2)	O
].	O
Risk	B-D012306
of	O
Bleeding	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(>10%	O
and	O
greater	O
than	O
placebo)	O
were	O
headache,	O
dyspepsia,	O
abdominal	O
pain,	O
nausea,	O
and	O
diarrhea	O
(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Boehringer	O
Ingelheim	O
Pharmaceuticals,	O
Inc.	O
at	O
(800)	O
542-6257	O
or	O
(800)	O
459-9906	O
TTY	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
efficacy	O
and	O
safety	O
of	O
AGGRENOX	O
was	O
established	O
in	O
the	O
Europe	B-D005060
an	O
Stroke	B-D020521
Prevention	O
Study-2	O
(ESPS2).	O
ESPS2	O
was	O
a	O
double-blind,	O
placebo	O
controlled	O
study	O
that	O
evaluated	O
6602	O
patients	O
over	O
the	O
age	O
of	O
18	O
years	O
who	O
had	O
a	O
previous	O
ischemic	O
stroke	O
or	O
transient	O
ischemic	O
attack	O
within	O
ninety	O
days	O
prior	O
to	O
entry.	O
Patients	B-D010361
were	O
randomized	O
to	O
either	O
AGGRENOX,	O
aspirin,	O
ER-DP,	O
or	O
placebo	O
[	O
see	O
Clinical	O
Studies	O
(14)	O
];	O
primary	O
endpoints	O
included	O
stroke	O
(fatal	O
or	O
nonfatal)	O
and	O
death	O
from	O
all	O
causes.	O
This	O
24-month,	O
multicenter,	O
double-blind,	O
randomized	O
study	O
(ESPS2)	O
was	O
conducted	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
AGGRENOX	O
with	O
placebo,	O
extended-release	O
dipyridamole	O
alone	O
and	O
aspirin	O
alone.	O
The	O
study	O
was	O
conducted	O
in	O
a	O
total	O
of	O
6602	O
male	O
and	O
female	O
patients	O
who	O
had	O
experienced	O
a	O
previous	O
ischemic	O
stroke	O
or	O
transient	O
ischemia	O
of	O
the	O
brain	O
within	O
three	O
months	O
prior	O
to	O
randomization.	O
Table	O
1	O
presents	O
the	O
incidence	O
of	O
adverse	O
events	O
that	O
occurred	O
in	O
1%	O
or	O
more	O
of	O
patients	O
treated	O
with	O
AGGRENOX	O
where	O
the	O
incidence	O
was	O
also	O
greater	O
than	O
in	O
those	O
patients	O
treated	O
with	O
placebo.	O
There	O
is	O
no	O
clear	O
benefit	O
of	O
the	O
dipyridamole/aspirin	O
combination	O
over	O
aspirin	O
with	O
respect	O
to	O
safety.	O
Table	O
1	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
in	O
ESPS2*	O
Individual	O
Treatment	O
Group	O
Body	O
System/Preferred	O
Term	O
AGGRENOX	O
ER-DP	O
Alone	O
ASA	O
Alone	O
Placebo	O
*	O
Reported	O
by	O
≥1%	O
of	O
patients	O
during	O
AGGRENOX	O
treatment	O
where	O
the	O
incidence	O
was	O
greater	O
than	O
in	O
those	O
treated	O
with	O
placebo.	O
Note:	O
ER-DP	O
=	O
extended-release	O
dipyridamole	O
200	O
mg;	O
ASA	O
=	O
aspirin	O
25	O
mg.	O
The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BIDNOS	O
=	O
not	O
otherwise	O
specified.	O
Total	O
Number	O
of	O
Patients	B-D010361
1650	O
1654	O
1649	O
1649	O
Total	O
Number	O
(%)	O
of	O
Patients	B-D010361
With	O
at	O
Least	O
One	O
On-Treatment	O
Adverse	O
Event	O
1319	O
(80%)	O
1305	O
(79%)	O
1323	O
(80%)	O
1304	O
(79%)	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Disorders	O
Headache	B-D006261
647	O
(39%)	O
634	O
(38%)	O
558	O
(34%)	O
543	O
(33%)	O
Convulsions	O
28	O
(2%)	O
15	O
(1%)	O
28	O
(2%)	O
26	O
(2%)	O
Gastrointestinal	O
System	O
Disorders	O
Dyspepsia	B-D004415
303	O
(18%)	O
288	O
(17%)	O
299	O
(18%)	O
275	O
(17%)	O
Abdominal	B-D015746
Pain	I-D015746
289	O
(18%)	O
255	O
(15%)	O
262	O
(16%)	O
239	O
(14%)	O
Nausea	B-D009325
264	O
(16%)	O
254	O
(15%)	O
210	O
(13%)	O
232	O
(14%)	O
Diarrhea	B-D003967
210	O
(13%)	O
257	O
(16%)	O
112	O
(7%)	O
161	O
(10%)	O
Vomiting	B-D014839
138	O
(8%)	O
129	O
(8%)	O
101	O
(	O
6%)	O
118	O
(7%)	O
Hemorrhage	B-D006470
Rectum	B-D012007
26	O
(2%)	O
22	O
(1%)	O
16	O
(1%)	O
13	O
(1%)	O
Melena	B-D008551
31	O
(2%)	O
10	O
(1%)	O
20	O
(1%)	O
13	O
(1%)	O
Hemorrhoids	B-D006484
16	O
(1%)	O
13	O
(1%)	O
10	O
(1%)	O
10	O
(1%)	O
GI	O
Hemorrhage	B-D006470
20	O
(1%)	O
5	O
(0%)	O
15	O
(1%)	O
7	O
(0%)	O
Body	O
as	O
a	O
Whole	O
-	O
General	O
Disorders	O
Pain	B-D010146
105	O
(6%)	O
88	O
(5%)	O
103	O
(6%)	O
99	O
(6%)	O
Fatigue	B-D005221
95	O
(6%)	O
93	O
(6%)	O
97	O
(6%)	O
90	O
(5%)	O
Back	B-D001416
Pain	I-D001416
76	O
(5%)	O
77	O
(5%)	O
74	O
(4%)	O
65	O
(4%)	O
Accidental	O
Injury	O
42	O
(3%)	O
24	O
(1%)	O
51	O
(3%)	O
37	O
(2%)	O
Malaise	O
27	O
(2%)	O
23	O
(1%)	O
26	O
(2%)	O
22	O
(1%)	O
Asthenia	B-D001247
29	O
(2%)	O
19	O
(1%)	O
17	O
(1%)	O
18	O
(1%)	O
Syncope	B-D013575
17	O
(1%)	O
13	O
(1%)	O
16	O
(1%)	O
8	O
(0%)	O
Psychiatric	O
Disorders	O
Amnesia	B-D000647
39	O
(2%)	O
40	O
(2%)	O
57	O
(3%)	O
34	O
(2%)	O
Confusion	B-D003221
18	O
(1%)	O
9	O
(1%)	O
22	O
(1%)	O
15	O
(1%)	O
Anorexia	B-D000855
19	O
(1%)	O
17	O
(1%)	O
10	O
(1%)	O
15	O
(1%)	O
Somnolence	O
20	O
(1%)	O
13	O
(1%)	O
18	O
(1%)	O
9	O
(1%)	O
Musculoskeletal	B-D009141
System	I-D009141
Disorders	O
Arthralgia	B-D018771
91	O
(6%)	O
75	O
(5%)	O
91	O
(6%)	O
76	O
(5%)	O
Arthritis	B-D001168
34	O
(2%)	O
25	O
(2%)	O
17	O
(1%)	O
19	O
(1%)	O
Art	B-D001154
hrosis	O
18	O
(1%)	O
22	O
(1%)	O
13	O
(1%)	O
14	O
(1%)	O
Myalgia	B-D063806
20	O
(1%)	O
16	O
(1%)	O
11	O
(1%)	O
11	O
(1%)	O
Respiratory	B-D012137
System	I-D012137
Disorders	O
Cough	B-D003371
ing	O
25	O
(2%)	O
18	O
(1%)	O
32	O
(2%)	O
21	O
(1%)	O
Upper	O
Respiratory	O
Tract	O
Infection	O
16	O
(1%)	O
9	O
(1%)	O
16	O
(1%)	O
14	O
(1%)	O
Cardiovascular	O
Disorders,	O
General	O
Cardia	B-D002299
c	O
Failure	O
26	O
(2%)	O
17	O
(1%)	O
30	O
(2%)	O
25	O
(2%)	O
Platelet,	O
Bleeding	O
&	O
Clotting	O
Disorders	O
Hemorrhage	B-D006470
NOS	O
52	O
(3%)	O
24	O
(1%)	O
46	O
(3%)	O
24	O
(1%)	O
Epistaxis	B-D004844
39	O
(2%)	O
16	O
(1%)	O
45	O
(3%)	O
25	O
(2%)	O
Purpura	B-D011693
23	O
(1%)	O
8	O
(0%)	O
9	O
(1%)	O
7	O
(0%)	O
Neoplasm	O
Neoplasm	O
NOS	O
28	O
(2%)	O
16	O
(1%)	O
23	O
(1%)	O
20	O
(1%)	O
Red	O
Blood	B-D001769
Cell	O
Disorders	O
Anemia	B-D000740
27	O
(2%)	O
16	O
(1%)	O
19	O
(1%)	O
9	O
(1%)	O
Discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
ESPS2	O
was	O
25%	O
for	O
AGGRENOX,	O
25%	O
for	O
extended-release	O
dipyridamole,	O
19%	O
for	O
aspirin,	O
and	O
21%	O
for	O
placebo	O
(refer	O
to	O
Table	O
2)	O
Table	O
2	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
that	O
Led	O
to	O
the	O
Discontinuation	O
of	O
Treatment:	O
Adverse	O
Events	O
with	O
an	O
Incidence	B-D015994
of≥1%	O
in	O
the	O
AGGRENOX	O
Group	O
Treatment	O
Groups	O
AGGRENOX	O
ER-DP	O
ASA	O
Placebo	O
Note:	O
ER-DP	O
=	O
extended-release	O
dipyridamole	O
200	O
mg;	O
ASA	O
=	O
aspirin	O
25	O
mg.	O
The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O
Total	O
Number	O
of	O
Patients	B-D010361
1650	O
1654	O
1649	O
1649	O
Patients	B-D010361
with	O
at	O
least	O
one	O
Adverse	O
Eventthat	O
led	O
to	O
treatment	O
discontinuation	O
417	O
(25%)	O
419	O
(25%)	O
318	O
(19%)	O
352	O
(21%)	O
Headache	B-D006261
165	O
(10%)	O
166	O
(10%)	O
57	O
(3%)	O
69	O
(4%)	O
Dizziness	B-D004244
85	O
(5%)	O
97	O
(6%)	O
69	O
(4%)	O
68	O
(4%)	O
Nausea	B-D009325
91	O
(6%)	O
95	O
(6%)	O
51	O
(3%)	O
53	O
(3%)	O
Abdominal	B-D015746
Pain	I-D015746
74	O
(4%)	O
64	O
(4%)	O
56	O
(3%)	O
52	O
(3%)	O
Dyspepsia	B-D004415
59	O
(4%)	O
61	O
(4%)	O
49	O
(3%)	O
46	O
(3%)	O
Vomiting	B-D014839
53	O
(3%)	O
52	O
(3%)	O
28	O
(2%)	O
24	O
(1%)	O
Diarrhea	B-D003967
35	O
(2%)	O
41	O
(2%)	O
9	O
(<1%)	O
16	O
(<1%)	O
Stroke	B-D020521
39	O
(2%)	O
48	O
(3%)	O
57	O
(3%)	O
73	O
(4%)	O
Transient	O
Ischemic	O
Attack	O
35	O
(2%)	O
40	O
(2%)	O
26	O
(2%)	O
48	O
(3%)	O
Angina	B-D000787
Pectoris	I-D000787
23	O
(1%)	O
20	O
(1%)	O
16	O
(<1%)	O
26	O
(2%)	O
Headache	B-D006261
was	O
most	O
notable	O
in	O
the	O
first	O
month	O
of	O
treatment.	O
Other	O
Adverse	O
Events	O
Adverse	O
reactions	O
that	O
occurred	O
in	O
less	O
than	O
1%	O
of	O
patients	O
treated	O
with	O
AGGRENOX	O
in	O
the	O
ESPS2	O
study	O
and	O
that	O
were	O
medically	O
judged	O
to	O
be	O
possibly	O
related	O
to	O
either	O
dipyridamole	O
or	O
aspirin	O
are	O
listed	O
below.	O
Body	O
as	O
a	O
Whole	O
:	O
Allergic	O
reaction,	O
fever	O
Cardiovascular	O
:	O
Hypotension	B-D007022
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Coma	B-D003128
,	O
dizziness,	O
paresthesia,	O
cerebral	O
hemorrhage,	O
intracranial	O
hemorrhage,	O
subarachnoid	O
hemorrhage	O
Gastrointestinal	O
:	O
Gastritis	B-D005756
,	O
ulceration	O
and	O
perforation	O
Hearing	B-D006309
and	O
Vestibular	O
Disorders	O
:	O
Tinnitus	B-D014012
,	O
and	O
deafness.	O
Patients	B-D010361
with	O
high	O
frequency	O
hearing	O
loss	O
may	O
have	O
difficulty	O
perceiving	O
tinnitus.	O
In	O
these	O
patients,	O
tinnitus	O
cannot	O
be	O
used	O
as	O
a	O
clinical	O
indicator	O
of	O
salicylism	O
Heart	B-D006339
Rate	I-D006339
and	O
Rhythm	O
Disorders	O
:	O
Tachycardia	B-D013610
,	O
palpitation,	O
arrhythmia,	O
supraventricular	O
tachycardia	O
Liver	B-D008099
and	O
Biliary	O
System	O
Disorders	O
:	O
Cholelithiasis	B-D002769
,	O
jaundice,	O
hepatic	O
function	O
abnormal	O
Metabolic	O
and	O
Nutritional	O
Disorders	O
:	O
Hyperglycemia	B-D006943
,	O
thirst	O
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders	O
:	O
Hematoma	B-D006406
,	O
gingival	O
bleeding	O
Psychiatric	O
Disorders	O
:	O
Agitation	O
Reproductive	O
:	O
Uterine	O
hemorrhage	O
Respiratory	O
:	O
Hyperpnea,	O
asthma,	O
bronchospasm,	O
hemoptysis,	O
pulmonary	O
edema	O
Special	O
Senses	O
Other	O
Disorders	O
:	O
Taste	B-D013649
loss	O
Skin	B-D012867
and	O
Appendages	O
Disorders	O
:	O
Pruritus	B-D011537
,	O
urticaria	O
Urogenital	O
:	O
Renal	O
insufficiency	O
and	O
failure,	O
hematuria	O
Vascular	O
(Extracardiac)	O
Disorders	O
:	O
Flushing	B-D005483
Laboratory	O
Changes	O
Over	O
the	O
course	O
of	O
the	O
24-month	O
study	O
(ESPS2),	O
patients	O
treated	O
with	O
AGGRENOX	O
showed	O
a	O
decline	O
(mean	O
change	O
from	O
baseline)	O
in	O
hemoglobin	O
of	O
0.25	O
g/dL,	O
hematocrit	O
of	O
0.75%,	O
and	O
erythrocyte	O
count	O
of	O
0.13x106/mm3.	O
6.2	O
Post-Marketing	O
Experience	O
The	O
following	O
is	O
a	O
list	O
of	O
additional	O
adverse	O
reactions	O
that	O
have	O
been	O
reported	O
either	O
in	O
the	O
literature	O
or	O
are	O
from	O
post-marketing	O
spontaneous	O
reports	O
for	O
either	O
dipyridamole	O
or	O
aspirin.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
estimate	O
reliably	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Decisions	O
to	O
include	O
these	O
reactions	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
reaction,	O
(2)	O
frequency	O
of	O
reporting,	O
or	O
(3)	O
strength	O
of	O
causal	O
connection	O
to	O
AGGRENOX.	O
Body	O
as	O
a	O
Whole	O
:	O
Hypothermia	B-D007035
,	O
chest	O
pain	O
Cardiovascular	O
:	O
Angina	O
pectoris	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Cerebral	O
edema	O
Fluid	O
and	O
Electrolyte	O
:	O
Hyperkalemia	B-D006947
,	O
metabolic	O
acidosis,	O
respiratory	O
alkalosis,	O
hypokalemia	O
Gastrointestinal	O
:	O
Pancreatitis	B-D010195
,	O
Reye	O
syndrome,	O
hematemesis	O
Hearing	B-D006309
and	O
Vestibular	O
Disorders	O
:	O
Hearing	B-D006309
loss	O
Immune	B-D007107
System	I-D007107
Disorders	O
:	O
Hypersensitivity	B-D006967
,	O
acute	O
anaphylaxis,	O
laryngeal	O
edema	O
Liver	B-D008099
and	O
Biliary	O
System	O
Disorders	O
:	O
Hepatitis	B-D006505
,	O
hepatic	O
failure	O
Musculoskeletal	O
:	O
Rhabdomyolysis	B-D012206
Metabolic	O
and	O
Nutritional	O
Disorders	O
:	O
Hypoglycemia	B-D007003
,	O
dehydration	O
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders	O
:	O
Prolongation	O
of	O
the	O
prothrombin	O
time,	O
disseminated	O
intravascular	O
coagulation,	O
coagulopathy,	O
thrombocytopenia	O
Reproductive	O
:	O
Prolonged	O
pregnancy	O
and	O
labor,	O
stillbirths,	O
lower	O
birth	O
weight	O
infants,	O
antepartum	O
and	O
postpartum	O
bleeding	O
Respiratory	O
:	O
Tachypnea	B-D059246
,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
Disorders	O
:	O
Rash,	O
alopecia,	O
angioedema,	O
Stevens-Johnson	O
syndrome,	O
skin	O
hemorrhages	O
such	O
as	O
bruising,	O
ecchymosis,	O
and	O
hematoma	O
Urogenital	O
:	O
Interstitial	O
nephritis,	O
papillary	O
necrosis,	O
proteinuria	O
Vascular	O
(Extracardiac	O
Disorders)	O
:	O
Allergic	O
vasculitis	O
Other	O
adverse	O
events	O
:	O
anorexia,	O
aplastic	O
anemia,	O
migraine,	O
pancytopenia,	O
thrombocytosis.	O
WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
RISK	O
EVALUATION	O
AND	O
MITIGATION	O
STRATEGY	O
(REMS);	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION;	O
ACCIDENTAL	O
INGESTION;	O
RISKS	O
FROM	O
CONCOMITANT	O
USE	O
WITH	O
BENZODIAZEPINES	O
OR	O
OTHER	O
CNS	O
DEPRESSANTS;	O
ULTRA-RAPID	O
METABOLISM	O
OF	O
CODEINE	O
AND	O
OTHER	O
RISK	O
FACTORS	O
FOR	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION	O
IN	O
CHILDREN;	O
NEONATAL	O
OPIOID	O
WITHDRAWAL	O
SYNDROME;	O
and	O
INTERACTIONS	O
WITH	O
DRUGS	O
AFFECTING	O
CYTOCHROME	O
P450	O
ISOENZYMES	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
exposes	O
patients	O
and	O
other	O
users	O
to	O
the	O
risks	O
of	O
opioid	O
addiction,	O
abuse,	O
and	O
misuse,	O
which	O
can	O
lead	O
to	O
overdose	O
and	O
death.	O
Assess	O
each	O
patient’s	O
risk	O
prior	O
to	O
prescribing	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP,	O
and	O
monitor	O
all	O
patients	O
regularly	O
for	O
the	O
development	O
of	O
these	O
behaviors	O
and	O
conditions	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)].	O
Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
REMS	O
for	O
these	O
products	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)].	O
Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
education	O
programs	O
available	O
to	O
healthcare	O
providers.	O
Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
complete	O
a	O
REMS-compliant	O
education	O
program,	O
counsel	O
patients	O
and/or	O
their	O
caregivers,	O
with	O
every	O
prescription,	O
on	O
safe	O
use,	O
serious	O
risks,	O
storage,	O
and	O
disposal	O
of	O
these	O
products,	O
emphasize	O
to	O
patients	O
and	O
their	O
caregivers	O
the	O
importance	O
of	O
reading	O
the	O
Medication	O
Guide	O
every	O
time	O
it	O
is	O
provided	O
by	O
their	O
pharmacist,	O
and	O
consider	O
other	O
tools	O
to	O
imp	O
r	O
ove	O
patient,	O
household,	O
and	O
community	O
safety.	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
may	O
occur	O
with	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP.	O
Monitor	O
for	O
respiratory	O
depression,	O
especially	O
during	O
initiation	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
or	O
following	O
a	O
dose	O
increase	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
.	O
Accidental	O
Ingestion	O
Accidental	O
ingestion	O
of	O
even	O
one	O
dose	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
a	O
fatal	O
overdose	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)].	O
Risk	B-D012306
s	O
From	O
Concomitant	O
Use	O
With	O
Benzodiazepines	B-D001569
Or	O
Other	O
CNS	O
Depressants	O
Concomitant	O
use	O
of	O
opioids	O
with	O
benzodiazepines	O
or	O
other	O
central	O
nervous	O
system	O
(CNS)	O
depressants,	O
including	O
alcohol,	O
may	O
result	O
in	O
profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
,	O
5.8	O
),	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
Reserve	O
concomitant	O
prescribing	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
and	O
benzodiazepines	O
or	O
other	O
CNS	O
depressants	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
treatment	O
options	O
are	O
inadequate.	O
Limit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required.	O
Follow	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
and	O
death	O
have	O
occurred	O
in	O
children	O
who	O
received	O
codeine.	O
Most	O
of	O
the	O
reported	O
cases	O
occurred	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy,	O
and	O
many	O
of	O
the	O
children	O
had	O
evidence	O
of	O
being	O
an	O
ultra-rapid	O
metabolizer	O
of	O
codeine	O
due	O
to	O
a	O
CYP2D6	O
polymorphism	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)].	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
is	O
contraindicated	O
in	O
children	O
younger	O
than	O
12	O
years	O
of	O
age	O
and	O
in	O
children	O
younger	O
than	O
18	O
years	O
of	O
age	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy	O
[see	O
Contraindications	B-D000075202
(	O
4	O
)].	O
Avoid	O
the	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
in	O
adolescents	O
12	O
to	O
18	O
years	O
of	O
age	O
who	O
have	O
other	O
risk	O
factors	O
that	O
may	O
increase	O
their	O
sensitivity	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine.	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
during	O
pregnancy	O
can	O
result	O
in	O
neonatal	O
opioid	O
withdrawal	O
syndrome,	O
which	O
may	O
be	O
life-threatening	O
if	O
not	O
recognized	O
and	O
treated,	O
and	O
requires	O
management	O
according	O
to	O
protocols	O
developed	O
by	O
neonatology	O
experts.	O
If	O
opioid	O
use	O
is	O
required	O
for	O
a	O
prolonged	O
period	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)].	O
Interactions	O
with	O
Drugs	O
Affect	B-D000339
ing	O
Cytochrome	O
P450	O
Isoenzymes	B-D007527
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
codeine	O
are	O
complex.	O
Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
requires	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
codeine,	O
and	O
the	O
active	O
metabolite,	O
morphine	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
,	O
5.8	O
),	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
RISK	O
EVALUATION	O
AND	O
MITIGATION	O
STRATEGY	O
(REMS);	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION;	O
ACCIDENTAL	O
INGESTION;	O
RISKS	O
FROM	O
CONCOMITANT	O
USE	O
WITH	O
BENZODIAZEPINES	O
OR	O
OTHER	O
CNS	O
DEPRESSANTS;	O
ULTRA-RAPID	O
METABOLISM	O
OF	O
CODEINE	O
AND	O
OTHER	O
RISK	O
FACTORS	O
FOR	O
LIFE-THREATENING	O
RESPIRATORY	O
DEPRESSION	O
IN	O
CHILDREN;	O
NEONATAL	O
OPIOID	O
WITHDRAWAL	O
SYNDROME;	O
and	O
INTERACTIONS	O
WITH	O
DRUGS	O
AFFECTING	O
CYTOCHROME	O
P450	O
ISOENZYMES	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
exposes	O
users	O
to	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse,	O
which	O
can	O
lead	O
to	O
overdose	O
and	O
death.	O
Assess	O
patient’s	O
risk	O
before	O
prescribing	O
and	O
monitor	O
regularly	O
for	O
these	O
behaviors	O
and	O
conditions.	O
(	O
5.1	O
)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opio	O
i	O
d	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
for	O
these	O
products	O
.	O
(	O
5.2	O
)	O
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
may	O
occur	O
.	O
Monitor	O
closely,	O
especially	O
upon	O
initiation	O
or	O
following	O
a	O
dose	O
increase	O
.	O
(	O
5.3	O
)	O
Accidental	O
ingestion	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
fatal	O
overdose	O
.	O
(	O
5.3	O
)	O
Concomitant	O
use	O
of	O
opioids	O
or	O
a	O
barbiturate	O
with	O
benzodiazepines	O
or	O
other	O
central	O
nervous	O
system	O
(CNS)	O
depressants,	O
including	O
alcohol,	O
may	O
result	O
in	O
profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death.	O
Reserve	O
concomitant	O
prescribing	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
treatment	O
options	O
are	O
inadequate;	O
limit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required;	O
and	O
follow	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
(	O
5.4	O
,	O
5.8	O
,	O
7	O
)	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
and	O
death	O
have	O
occurred	O
in	O
children	O
who	O
received	O
codeine;	O
most	O
cases	O
followed	O
tonsillectomy	O
and/or	O
adenoidectomy,	O
and	O
many	O
of	O
the	O
children	O
had	O
evidence	O
of	O
being	O
an	O
ultra-rapid	O
metabolizer	O
of	O
codeine	O
due	O
to	O
a	O
CYP2D6	O
polymorphism.	O
(	O
5.5	O
)	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
is	O
contraindicated	O
in	O
children	O
younger	O
than	O
12	O
years	O
of	O
age	O
and	O
in	O
children	O
younger	O
than	O
18	O
years	O
of	O
age	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy	O
.	O
(	O
4	O
)	O
Avoid	O
the	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
in	O
adolescents	O
12	O
to	O
18	O
years	O
of	O
age	O
who	O
have	O
other	O
risk	O
factors	O
that	O
may	O
increase	O
their	O
sensitivity	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine.	O
Prolonged	O
use	O
during	O
pregnancy	O
can	O
result	O
in	O
neonatal	O
opioid	O
withdrawal	O
syndrome,	O
which	O
may	O
be	O
life-threatening	O
if	O
not	O
recognized	O
and	O
treated.	O
If	O
prolonged	O
opioid	O
use	O
is	O
required	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available.	O
(	O
5.6	O
)	O
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibi	O
tors	O
with	O
codeine	O
are	O
complex.	O
Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
requires	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
codeine,	O
and	O
the	O
active	O
metabolite,	O
morphine.	O
(	O
5.7	O
,	O
5.8	O
,	O
7	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
or	O
in	O
Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
:	O
Monitor	O
closely,	O
particularly	O
during	O
initiation	O
and	O
titration.	O
(5.8)	O
Adrenal	B-D000309
Insufficiency	I-D000309
:	O
If	O
diagnosed,	O
treat	O
with	O
physiologic	O
replacement	O
of	O
corticosteroids,	O
and	O
wean	O
patient	O
off	O
the	O
opioid.	O
(5.10)	O
Severe	O
Hypotensi	O
on:	O
Monitor	O
during	O
dose	O
initiation	O
and	O
titration.	O
Avoid	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
in	O
patients	O
with	O
circulatory	O
shock.	O
(5.11)	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Increased	O
Intracranial	B-D007427
Pressure	I-D007427
,	O
Brain	B-D001921
Tumors,	O
Head	B-D006257
Injury,	O
or	O
Impaired	O
Consciousness	B-D003243
:	O
Monitor	O
for	O
sedation	O
and	O
respiratory	O
depression.	O
Avoid	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
in	O
patients	O
with	O
impaired	O
consciousness	O
or	O
coma.	O
(5.12)	O
5.	O
1	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
contain	O
codeine.	O
Codeine	B-D003061
in	O
combination	O
with	O
butalbital	B-C004470
,	O
aspirin,	O
and	O
caffeine	O
is	O
a	O
Schedule	O
III	O
controlled	O
substance.	O
As	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
contain	O
butalbital	B-C004470
and	O
codeine,	O
it	O
exposes	O
users	O
to	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse	O
[see	O
Drug	O
Abuse	O
and	O
Dependence	O
(	O
9	O
)].	O
Although	O
the	O
risk	O
of	O
addiction	O
in	O
any	O
individual	O
is	O
unknown,	O
it	O
can	O
occur	O
in	O
patients	O
appropriately	O
prescribed	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP.	O
Addiction	O
can	O
occur	O
at	O
recommended	O
dosages	O
and	O
if	O
the	O
drug	O
is	O
misused	O
or	O
abused.	O
Assess	O
each	O
patient’s	O
risk	O
for	O
addiction,	O
abuse,	O
or	O
misuse	O
prior	O
to	O
prescribing	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP,	O
and	O
monitor	O
all	O
patients	O
receiving	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
for	O
the	O
development	O
of	O
these	O
behaviors	O
and	O
conditions.	O
Risk	B-D012306
s	O
are	O
increased	O
in	O
patients	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
substance	O
abuse	O
(including	O
drug	O
or	O
alcohol	O
abuse	O
or	O
addiction)	O
or	O
mental	O
illness	O
(e.g.,	O
major	O
depression).	O
The	O
potential	O
for	O
these	O
risks	O
should	O
not,	O
however,	O
prevent	O
the	O
proper	O
management	O
of	O
pain	O
in	O
any	O
given	O
patient.	O
Patients	B-D010361
at	O
increased	O
risk	O
may	O
be	O
prescribed	O
opioids	O
such	O
as	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP,	O
but	O
use	O
in	O
such	O
patients	O
necessitates	O
intensive	O
counseling	O
about	O
the	O
risks	O
and	O
proper	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
along	O
with	O
intensive	O
monitoring	O
for	O
signs	O
of	O
addiction,	O
abuse,	O
and	O
misuse.	O
Opioids	O
and	O
barbiturates	O
are	O
sought	O
by	O
drug	O
abusers	O
and	O
people	O
with	O
addiction	O
disorders	O
and	O
are	O
subject	O
to	O
criminal	O
diversion.	O
Consider	O
these	O
risks	O
when	O
prescribing	O
or	O
dispensing	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP.	O
Strategies	O
to	O
reduce	O
these	O
risks	O
include	O
prescribing	O
the	O
drug	O
in	O
the	O
smallest	O
appropriate	O
quantity	O
and	O
advising	O
the	O
patient	O
on	O
the	O
proper	O
disposal	O
of	O
unused	O
drug	O
[see	O
Patient	O
Counseling	B-D003376
Information	O
(	O
17	O
)].	O
Contact	O
local	O
state	O
professional	O
licensing	O
board	O
or	O
state	O
controlled	O
substances	O
authority	O
for	O
information	O
on	O
how	O
to	O
prevent	O
and	O
detect	O
abuse	O
or	O
diversion	O
of	O
this	O
product.	O
5.2	O
Opio	O
i	O
d	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
analgesics	O
outweigh	O
the	O
risks	O
of	O
addiction,	O
abuse,	O
and	O
misuse,	O
the	O
Food	B-D005502
and	O
Drug	O
Administration	O
(FDA)	O
has	O
required	O
a	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
for	O
these	O
products.	O
Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
education	O
programs	O
available	O
to	O
healthcare	O
providers.	O
Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
do	O
all	O
of	O
the	O
following:	O
•	O
Complete	O
a	O
REMS-compliant	O
education	O
program	O
offered	O
by	O
an	O
accredited	O
provider	O
of	O
continuing	O
education	O
(CE)	O
or	O
another	O
education	O
program	O
that	O
includes	O
all	O
the	O
elements	O
of	O
the	O
FDA	O
Education	B-D004493
Blueprint	O
for	O
Health	B-D006262
care	O
Providers	O
Involved	O
in	O
the	O
Management	O
or	O
Support	O
of	O
Patients	B-D010361
with	O
Pain	B-D010146
.	O
•	O
Discuss	O
the	O
safe	O
use,	O
serious	O
risks,	O
and	O
proper	O
storage	O
and	O
disposal	O
of	O
opioid	O
analgesics	O
with	O
patients	O
and/or	O
their	O
caregivers	O
every	O
time	O
these	O
medicines	O
are	O
prescribed.	O
The	O
Patient	O
Counseling	B-D003376
Guide	O
(PCG)	O
can	O
be	O
obtained	O
at	O
this	O
link:	O
www.fda.gov/OpioidAnalgesicREMSPCG.	O
•	O
Emphasize	O
to	O
patients	O
and	O
their	O
caregivers	O
the	O
importance	O
of	O
reading	O
the	O
Medication	O
Guide	O
that	O
they	O
will	O
receive	O
from	O
their	O
pharmacist	O
every	O
time	O
an	O
opioid	O
analgesic	O
is	O
dispensed	O
to	O
them.	O
•	O
Consider	O
using	O
other	O
tools	O
to	O
improve	O
patient,	O
household,	O
and	O
community	O
safety,	O
such	O
as	O
patient-prescriber	O
agreements	O
that	O
reinforce	O
patient-prescriber	O
responsibilities.	O
To	O
obtain	O
further	O
information	O
on	O
the	O
opioid	O
analgesic	O
REMS	O
and	O
for	O
a	O
list	O
of	O
accredited	O
REMS	O
CME/CE,	O
call	O
1-800-503-0784,	O
or	O
log	O
on	O
to	O
www.opioidanalgesicrems.com.	O
The	O
FDA	O
Blueprint	O
can	O
be	O
found	O
at	O
www.fda.gov/OpioidAnalgesicREMSBlueprint.	O
5.	O
3	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
opioids,	O
even	O
when	O
used	O
as	O
recommended.	O
Respiratory	O
depression,	O
if	O
not	O
immediately	O
recognized	O
and	O
treated,	O
may	O
lead	O
to	O
respiratory	O
arrest	O
and	O
death.	O
Management	O
of	O
respiratory	O
depression	O
may	O
include	O
close	O
observation,	O
supportive	O
measures,	O
and	O
use	O
of	O
opioid	O
antagonists,	O
depending	O
on	O
the	O
patient’s	O
clinical	O
status	O
[see	O
Overdosage	O
(	O
10	O
)].	O
Carbon	B-D002244
dioxide	O
(CO2)	O
retention	O
from	O
opioid-induced	O
respiratory	O
depression	O
can	O
exacerbate	O
the	O
sedatin	B-C493049
g	O
effects	O
of	O
opioids.	O
While	O
serious,	O
life-threatening,	O
or	O
fatal	O
respiratory	O
depression	O
can	O
occur	O
at	O
any	O
time	O
during	O
the	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP,	O
the	O
risk	O
is	O
greatest	O
during	O
the	O
initiation	O
of	O
therapy	O
or	O
following	O
a	O
dosage	O
increase.	O
Monitor	O
patients	O
closely	O
for	O
respiratory	O
depression,	O
especially	O
within	O
the	O
first	O
24-72	O
hours	O
of	O
initiating	O
therapy	O
with	O
and	O
following	O
dosage	O
increases	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP.	O
To	O
reduce	O
the	O
risk	O
of	O
respiratory	O
depression,	O
proper	O
dosing	O
and	O
titration	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
are	O
essential	O
[see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)].	O
Overestimating	O
the	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
dosage	O
when	O
converting	O
patients	O
from	O
another	O
opioid	O
product	O
can	O
result	O
in	O
a	O
fatal	O
overdose	O
with	O
the	O
first	O
dose.	O
Accidental	O
ingestion	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP,	O
especially	O
by	O
children,	O
can	O
result	O
in	O
respiratory	O
depression	O
and	O
death	O
due	O
to	O
an	O
overdose	O
of	O
codeine	O
and	O
butalbital	B-C004470
.	O
Opioids	O
can	O
cause	O
sleep-related	O
breathing	O
disorders	O
including	O
central	O
sleep	O
apnea	O
(CSA)	O
and	O
sleep-related	O
hypoxemia.	O
Opioid	O
use	O
increases	O
the	O
risk	O
of	O
CSA	O
in	O
a	O
dose-dependent	O
fashion.	O
In	O
patients	O
who	O
present	O
with	O
CSA,	O
consider	O
decreasing	O
the	O
opioid	O
dosage	O
using	O
best	O
practices	O
for	O
opioid	O
taper	O
[see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)].	O
5.	O
4	O
Risk	B-D012306
s	O
from	O
Concomitant	O
Use	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
Profound	O
sedation,	O
respiratory	O
depression,	O
coma,	O
and	O
death	O
may	O
result	O
from	O
the	O
concomitant	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
with	O
benzodiazepines	O
or	O
other	O
CNS	O
depressants	O
(e.g.,	O
non-benzodiazepine	O
sedatives/hypnotics,	O
anxiolytics,	O
tranquilizers,	O
muscle	O
relaxants,	O
general	O
anesthetics,	O
antipsychotics,	O
other	O
opioids,	O
alcohol).	O
Because	O
of	O
these	O
risks,	O
reserve	O
concomitant	O
prescribing	O
of	O
these	O
drugs	O
for	O
use	O
in	O
patients	O
for	O
whom	O
alternative	O
treatment	O
options	O
are	O
inadequate.	O
Observation	B-D019370
al	O
studies	O
have	O
demonstrated	O
that	O
concomitant	O
use	O
of	O
opioid	O
analgesics	O
and	O
benzodiazepines	O
increases	O
the	O
risk	O
of	O
drug-related	O
mortality	O
compared	O
to	O
use	O
of	O
opioid	O
analgesics	O
alone.	O
Because	O
of	O
similar	O
pharmacological	O
properties,	O
it	O
is	O
reasonable	O
to	O
expect	O
similar	O
risk	O
with	O
the	O
concomitant	O
use	O
of	O
other	O
CNS	O
depressant	O
drugs	O
with	O
opioid	O
analgesics	O
[	O
s	O
e	O
e	O
Drug	O
I	O
nt	O
e	O
ra	O
c	O
tions	O
(	O
7	O
)	O
].	O
If	O
the	O
decision	O
is	O
made	O
to	O
prescribe	O
a	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant	O
concomitantly	O
with	O
an	O
opioid	O
analgesic,	O
prescribe	O
the	O
lowest	O
effective	O
dosages	O
and	O
minimum	O
durations	O
of	O
concomitant	O
use.	O
In	O
patients	O
already	O
receiving	O
an	O
opioid	O
analgesic,	O
prescribe	O
a	O
lower	O
initial	O
dose	O
of	O
the	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant	O
than	O
indicated	O
in	O
the	O
absence	O
of	O
an	O
opioid,	O
and	O
titrate	O
based	O
on	O
clinical	O
response.	O
If	O
an	O
opioid	O
analgesic	O
is	O
initiated	O
in	O
a	O
patient	O
already	O
taking	O
a	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant,	O
prescribe	O
a	O
lower	O
initial	O
dose	O
of	O
the	O
opioid	O
analgesic,	O
and	O
titrate	O
based	O
on	O
clinical	O
response.	O
Follow	O
patients	O
closely	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
and	O
sedation.	O
Advise	O
both	O
patients	O
and	O
caregivers	O
about	O
the	O
risks	O
of	O
respiratory	O
depression	O
and	O
sedation	O
when	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
are	O
used	O
with	O
benzodiazepines	O
or	O
other	O
CNS	O
depressants	O
(including	O
alcohol	O
and	O
illicit	O
drugs).	O
Advise	O
patients	O
not	O
to	O
drive	O
or	O
operate	O
heavy	O
machinery	O
until	O
the	O
effects	O
of	O
concomitant	O
use	O
of	O
the	O
benzodiazepine	O
or	O
other	O
CNS	O
depressant	O
have	O
been	O
determined.	O
Screen	O
patients	O
for	O
risk	O
of	O
substance	O
use	O
disorders,	O
including	O
opioid	O
abuse	O
and	O
misuse,	O
and	O
warn	O
them	O
of	O
the	O
risk	O
for	O
overdose	O
and	O
death	O
associated	O
with	O
the	O
use	O
of	O
additional	O
CNS	O
depressants	O
including	O
alcohol	O
and	O
illicit	O
drugs	O
[	O
s	O
e	O
e	O
Drug	O
I	O
nt	O
e	O
r	O
a	O
c	O
tions	O
(	O
7	O
)	O
and	O
Pati	O
e	O
nt	O
C	O
ouns	O
e	O
ling	O
I	O
nformation	O
(	O
17	O
)	O
].	O
5.	O
5	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
and	O
death	O
have	O
occurred	O
in	O
children	O
who	O
received	O
codeine.	O
Codeine	B-D003061
is	O
subject	O
to	O
variability	O
in	O
metabolism	O
based	O
upon	O
CYP2D6	O
genotype	O
(described	O
below),	O
which	O
can	O
lead	O
to	O
an	O
increased	O
exposure	O
to	O
the	O
active	O
metabolite	O
morphine.	O
Based	O
upon	O
postmarketing	O
reports,	O
children	O
younger	O
than	O
12	O
years	O
old	O
appear	O
to	O
be	O
more	O
susceptible	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine,	O
particularly	O
if	O
there	O
are	O
risk	O
factors	O
for	O
respiratory	O
depression.	O
For	O
example,	O
many	O
reported	O
cases	O
of	O
death	O
occurred	O
in	O
the	O
post-	O
operative	O
period	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy,	O
and	O
many	O
of	O
the	O
children	O
had	O
evidence	O
of	O
being	O
ultra-rapid	O
metabolizers	O
of	O
codeine.	O
Furthermore,	O
children	O
with	O
obstructive	O
sleep	O
apnea	O
who	O
are	O
treated	O
with	O
codeine	O
for	O
post-tonsillectomy	O
and/or	O
adenoidectomy	O
pain	O
may	O
be	O
particularly	O
sensitive	O
to	O
its	O
respiratory	O
depressant	O
effect.	O
Because	O
of	O
the	O
risk	O
of	O
life-threatening	O
respiratory	O
depression	O
and	O
death:	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
are	O
contraindicated	O
for	O
all	O
children	O
younger	O
than	O
12	O
years	O
of	O
age	O
[see	O
Contraindications	B-D000075202
(	O
4	O
)].	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
are	O
contraindicated	O
for	O
post-operative	O
management	O
in	O
pediatric	O
patients	O
younger	O
than	O
18	O
years	O
of	O
age	O
following	O
tonsillectomy	O
and/or	O
adenoidectomy	O
[see	O
Contraindications	B-D000075202
(	O
4	O
)].	O
Avoid	O
the	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
in	O
adolescents	O
12	O
to	O
18	O
years	O
of	O
age	O
who	O
have	O
other	O
risk	O
factors	O
that	O
may	O
increase	O
their	O
sensitivity	O
to	O
the	O
respiratory	O
depressant	O
effects	O
of	O
codeine	O
unless	O
the	O
benefits	O
outweigh	O
the	O
risks.	O
Risk	B-D012306
factors	O
include	O
conditions	O
associated	O
with	O
hypoventilation,	O
such	O
as	O
postoperative	O
status,	O
obstructive	O
sleep	O
apnea,	O
obesity,	O
severe	O
pulmonary	O
disease,	O
neuromuscular	O
disease,	O
and	O
concomitant	O
use	O
of	O
other	O
medications	O
that	O
cause	O
respiratory	O
depression.	O
As	O
with	O
adults,	O
when	O
prescribing	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
for	O
adolescents,	O
healthcare	O
providers	O
should	O
choose	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
period	O
of	O
time	O
and	O
inform	O
patients	O
and	O
caregivers	O
about	O
these	O
risks	O
and	O
the	O
signs	O
of	O
morphine	O
overdose	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(	O
8.4	O
),	O
Overd	O
osag	O
e	O
(	O
10	O
)].	O
N	O
ursing	O
M	O
oth	O
e	O
rs	O
At	O
least	O
one	O
death	O
was	O
reported	O
in	O
a	O
nursing	O
infant	O
who	O
was	O
exposed	O
to	O
high	O
levels	O
of	O
morphine	O
in	O
breast	O
milk	O
because	O
the	O
mother	O
was	O
an	O
ultra-rapid	O
metabolizer	O
of	O
codeine.	O
Breast	B-D001940
feeding	O
is	O
not	O
recommended	O
during	O
treatment	O
with	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
[s	O
e	O
e	O
Use	O
in	O
S	O
p	O
ec	O
ific	O
Population	B-D011153
s	O
(	O
8.2	O
)].	O
C	O
Y	O
P2D6	O
G	O
e	O
n	O
e	O
tic	O
Variabilit	O
y	O
:	O
Ultra	O
-	O
rapid	O
m	O
e	O
taboliz	O
e	O
r	O
Some	O
individuals	O
may	O
be	O
ultra-rapid	O
metabolizers	O
because	O
of	O
a	O
specific	O
CYP2D6	O
genotype	O
(gene	O
duplications	O
denoted	O
as	O
*1/*1xN	O
or	O
*1/*2xN).	O
The	O
prevalence	O
of	O
this	O
CYP2D6	O
phenotype	O
varies	O
widely	O
and	O
has	O
been	O
estimated	O
at	O
1	O
to	O
10%	O
for	O
Whites	O
(European,	O
North	B-D009656
America	I-D009656
n),	O
3	O
to	O
4%	O
for	O
Blacks	O
(African	O
Americans),	O
1	O
to	O
2%	O
for	O
East	O
Asia	B-D001208
ns	O
(Chinese,	O
Japan	B-D007564
ese,	O
Korea	B-D007723
n),	O
and	O
may	O
be	O
greater	O
than	O
10%	O
in	O
certain	O
racial/ethnic	O
groups	O
(i.e.,	O
Oceania	B-D044349
n,	O
Northern	O
Africa	B-D000349
n,	O
Middle	B-D008877
East	I-D008877
ern,	O
Ashkenazi	O
Jews	B-D007585
,	O
Puerto	O
Rican).	O
These	O
individuals	O
convert	O
codeine	O
into	O
its	O
active	O
metabolite,	O
morphine,	O
more	O
rapidly	O
and	O
completely	O
than	O
other	O
people.	O
This	O
rapid	O
conversion	O
results	O
in	O
higher	O
than	O
expected	O
serum	O
morphine	O
levels.	O
Even	O
at	O
labeled	O
dosage	O
regimens,	O
individuals	O
who	O
are	O
ultra-rapid	O
metabolizers	O
may	O
have	O
life-threatening	O
or	O
fatal	O
respiratory	O
depression	O
or	O
experience	O
signs	O
of	O
overdose	O
(such	O
as	O
extreme	O
sleepiness,	O
confusion,	O
or	O
shallow	O
breathing)	O
[	O
s	O
ee	O
Ove	O
rdosage	O
(	O
10	O
)].	O
Therefore,	O
individuals	O
who	O
are	O
ultra-rapid	O
metabolizers	O
should	O
not	O
use	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP.	O
5.	O
6	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
during	O
pregnancy	O
can	O
result	O
in	O
withdrawal	O
in	O
the	O
neonate.	O
Neon	B-D009356
atal	O
opioid	O
withdrawal	O
syndrome,	O
unlike	O
opioid	O
withdrawal	O
syndrome	O
in	O
adults,	O
may	O
be	O
life-threatening	O
if	O
not	O
recognized	O
and	O
treated,	O
and	O
requires	O
management	O
according	O
to	O
protocols	O
developed	O
by	O
neonatology	O
experts.	O
Observe	O
newborns	O
for	O
signs	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
manage	O
accordingly.	O
Advise	O
pregnant	O
women	O
using	O
opioids	O
for	O
a	O
prolonged	O
period	O
of	O
the	O
risk	O
of	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
and	O
ensure	O
that	O
appropriate	O
treatment	O
will	O
be	O
available	O
[s	O
e	O
e	O
Use	O
in	O
Sp	O
e	O
c	O
ific	O
Po	O
p	O
ulations	O
(	O
8.1	O
,	O
8.2	O
)	O
,	O
Pati	O
e	O
nt	O
C	O
ouns	O
e	O
ling	O
I	O
nformatio	O
n	O
(	O
17	O
)	O
].	O
5.	O
7	O
Risk	B-D012306
s	O
of	O
Interactions	O
with	O
Drugs	O
Affect	B-D000339
ing	O
Cytochrome	O
P450	O
Isoenzymes	B-D007527
The	O
effects	O
of	O
concomitant	O
use	O
or	O
discontinuation	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
codeine	O
are	O
complex.	O
Use	O
of	O
cytochrome	O
P450	O
3A4	O
inducers,	O
3A4	O
inhibitors,	O
or	O
2D6	O
inhibitors	O
with	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
requires	O
careful	O
consideration	O
of	O
the	O
effects	O
on	O
codeine	O
and	O
the	O
active	O
metabolite,	O
morphine.	O
Cytochrome	O
P450	O
3A4	O
Interaction	O
The	O
concomitant	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
with	O
all	O
cytochrome	O
P450	O
3A4	O
inhibitors,	O
such	O
as	O
macrolide	O
antibiotics	O
(e.g.,	O
erythromycin),	O
azole-antifungal	O
agents	O
(e.g.,	O
ketoconazole),	O
and	O
protease	O
inhibitors	O
(e.g.,	O
ritonavir)	O
or	O
discontinuation	O
of	O
a	O
cytochrome	O
P450	O
3A4	O
inducer	O
such	O
as	O
rifampin,	O
carbamazepine,	O
and	O
phenytoin,	O
may	O
result	O
in	O
an	O
increase	O
in	O
codeine	O
plasma	O
concentrations	O
with	O
subsequently	O
greater	O
metabolism	O
by	O
cytochrome	O
P450	O
2D6,	O
resulting	O
in	O
greater	O
morphine	O
levels,	O
which	O
could	O
increase	O
or	O
prolong	O
adverse	O
reactions	O
and	O
may	O
cause	O
potentially	O
fatal	O
respiratory	O
depression.	O
The	O
concomitant	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
with	O
all	O
cytochrome	O
P450	O
3A4	O
inducers	O
or	O
discontinuation	O
of	O
a	O
cytochrome	O
P450	O
3A4	O
inhibitor	O
may	O
result	O
in	O
lower	O
codeine	O
levels,	O
greater	O
norcodeine	B-C010414
levels,	O
and	O
less	O
metabolism	O
via	O
2D6	O
with	O
resultant	O
lower	O
morphine	O
levels.	O
This	O
may	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
efficacy,	O
and	O
in	O
some	O
patients,	O
may	O
result	O
in	O
signs	O
and	O
symptoms	O
of	O
opioid	O
withdrawal.	O
Follow	O
patients	O
receiving	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
and	O
any	O
CYP3A4	O
inhibitor	O
or	O
inducer	O
for	O
signs	O
and	O
symptoms	O
that	O
may	O
reflect	O
opioid	O
toxicity	O
and	O
opioid	O
withdrawal	O
when	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
is	O
used	O
in	O
conjunction	O
with	O
inhibitors	O
and	O
inducers	O
of	O
CYP3A4.	O
If	O
concomitant	O
use	O
of	O
a	O
CYP3A4	O
inhibitor	O
is	O
necessary	O
or	O
if	O
a	O
CYP3A4	O
inducer	O
is	O
discontinued,	O
consider	O
dosage	O
reduction	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
until	O
stable	O
drug	O
effects	O
are	O
achieved.	O
Monitor	O
patients	O
for	O
respiratory	O
depression	O
and	O
sedation	O
at	O
frequent	O
intervals.	O
If	O
concomitant	O
use	O
of	O
a	O
CYP3A4	O
inducer	O
is	O
necessary	O
or	O
if	O
a	O
CYP3A4	O
inhibitor	O
is	O
discontinued,	O
consider	O
increasing	O
the	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
dosage	O
until	O
stable	O
drug	O
effects	O
are	O
achieved.	O
Monitor	O
for	O
signs	O
of	O
opioid	O
withdrawal	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
Risk	B-D012306
s	O
of	O
Concomitant	O
Use	O
or	O
Discontinuation	O
of	O
Cytochrome	O
P450	O
2D6	O
Inhibitors	O
The	O
concomitant	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
with	O
all	O
cytochrome	O
P450	O
2D6	O
inhibitors	O
(e.g.,	O
amiodarone,	O
quinidine)	O
may	O
result	O
in	O
an	O
increase	O
in	O
codeine	O
plasma	O
concentrations	O
and	O
a	O
decrease	O
in	O
active	O
metabolite	O
morphine	O
plasma	O
concentration	O
which	O
could	O
result	O
in	O
an	O
analgesic	O
efficacy	O
reduction	O
or	O
symptoms	O
of	O
opioid	O
withdrawal.	O
Discontinuation	O
of	O
a	O
concomitantly	O
used	O
cytochrome	O
P450	O
2D6	O
inhibitor	O
may	O
result	O
in	O
a	O
decrease	O
in	O
codeine	O
plasma	O
concentration	O
and	O
an	O
increase	O
in	O
active	O
metabolite	O
morphine	O
plasma	O
concentration	O
which	O
could	O
increase	O
or	O
prolong	O
adverse	O
reactions	O
and	O
may	O
cause	O
potentially	O
fatal	O
respiratory	O
depression.	O
Follow	O
patients	O
receiving	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
and	O
any	O
CYP2D6	O
inhibitor	O
for	O
signs	O
and	O
symptoms	O
that	O
may	O
reflect	O
opioid	O
toxicity	O
and	O
opioid	O
withdrawal	O
when	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
are	O
used	O
in	O
conjunction	O
with	O
inhibitors	O
of	O
CYP2D6.	O
If	O
concomitant	O
use	O
with	O
a	O
CYP2D6	O
inhibitor	O
is	O
necessary,	O
follow	O
the	O
patient	O
for	O
signs	O
of	O
reduced	O
efficacy	O
or	O
opioid	O
withdrawal	O
and	O
consider	O
increasing	O
the	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
dosage.	O
After	O
stopping	O
use	O
of	O
a	O
CYP2D6	O
inhibitor,	O
consider	O
reducing	O
the	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
dosage	O
and	O
follow	O
the	O
patient	O
for	O
signs	O
and	O
symptoms	O
of	O
respiratory	O
depression	O
or	O
sedation	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
5.	O
8	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
or	O
in	O
Elderly,	O
Cachectic,	O
or	O
Debilitated	O
Patients	B-D010361
The	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
in	O
patients	O
with	O
acute	O
or	O
severe	O
bronchial	O
asthma	O
in	O
an	O
unmonitored	O
setting	O
or	O
in	O
the	O
absence	O
of	O
resuscitative	O
equipment	O
is	O
contraindicated.	O
Patients	B-D010361
with	O
Chronic	O
Pulmonary	O
Disease	B-D004194
:	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
-treated	O
patients	O
with	O
significant	O
chronic	O
obstructive	O
pulmonary	O
disease	O
or	O
cor	O
pulmonale,	O
and	O
those	O
with	O
a	O
substantially	O
decreased	O
respiratory	O
reserve,	O
hypoxia,	O
hypercapnia,	O
or	O
pre-existing	O
respiratory	O
depression	O
are	O
at	O
increased	O
risk	O
of	O
decreased	O
respiratory	O
drive	O
including	O
apnea,	O
even	O
at	O
recommended	O
dosages	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)].	O
Elderly,	O
Cachectic	O
,	O
or	O
Debilitated	O
Patients	B-D010361
:	O
Life	B-D019369
-threatening	O
respiratory	O
depression	O
is	O
more	O
likely	O
to	O
occur	O
in	O
elderly,	O
cachectic,	O
or	O
debilitated	O
patients	O
because	O
they	O
may	O
have	O
altered	O
pharmacokinetics	O
or	O
altered	O
clearance	O
compared	O
to	O
younger,	O
healthier	O
patients	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)].	O
Monitor	O
such	O
patients	O
closely,	O
particularly	O
when	O
initiating	O
and	O
titrating	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
and	O
when	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
are	O
given	O
concomitantly	O
with	O
other	O
drugs	O
that	O
depress	O
respiration	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)].	O
Alternatively,	O
consider	O
the	O
use	O
of	O
non-opioid	O
analgesics	O
in	O
these	O
patients.	O
5.	O
9	O
Interaction	O
with	O
Monoamine	B-D008996
Oxidase	I-D008996
Inhibitors	I-D008996
Monoamine	O
oxidase	O
inhibitors	O
(MAOIs)	O
may	O
potentiate	O
the	O
effects	O
of	O
morphine,	O
codeine’s	O
active	O
metabolite,	O
including	O
respiratory	O
depression,	O
coma,	O
and	O
confusion.	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
should	O
not	O
be	O
used	O
in	O
patients	O
taking	O
MAOIs	O
or	O
within	O
14	O
days	O
of	O
stopping	O
such	O
treatment.	O
5.	O
10	O
Adrenal	B-D000309
Insufficiency	I-D000309
Cases	O
of	O
adrenal	O
insufficiency	O
have	O
been	O
reported	O
with	O
opioid	O
use,	O
more	O
often	O
following	O
greater	O
than	O
one	O
month	O
of	O
use.	O
Presentation	O
of	O
adrenal	O
insufficiency	O
may	O
include	O
non-specific	O
symptoms	O
and	O
signs	O
including	O
nausea,	O
vomiting,	O
anorexia,	O
fatigue,	O
weakness,	O
dizziness,	O
and	O
low	O
blood	O
pressure.	O
If	O
adrenal	O
insufficiency	O
is	O
suspected,	O
confirm	O
the	O
diagnosis	O
with	O
diagnostic	O
testing	O
as	O
soon	O
as	O
possible.	O
If	O
adrenal	O
insufficiency	O
is	O
diagnosed,	O
treat	O
with	O
physiologic	O
replacement	O
doses	O
of	O
corticosteroids.	O
Wean	O
the	O
patient	O
off	O
of	O
the	O
opioid	O
to	O
allow	O
adrenal	O
function	O
to	O
recover	O
and	O
continue	O
corticosteroid	O
treatment	O
until	O
adrenal	O
function	O
recovers.	O
Other	O
opioids	O
may	O
be	O
tried	O
as	O
some	O
cases	O
reported	O
use	O
of	O
a	O
different	O
opioid	O
without	O
recurrence	O
of	O
adrenal	O
insufficiency.	O
The	O
information	O
available	O
does	O
not	O
identify	O
any	O
particular	O
opioids	O
as	O
being	O
more	O
likely	O
to	O
be	O
associated	O
with	O
adrenal	O
insufficiency.	O
5.	O
1	O
1	O
Severe	O
Hypotension	B-D007022
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
may	O
cause	O
severe	O
hypotension	O
including	O
orthostatic	O
hypotension	O
and	O
syncope	O
in	O
ambulatory	O
patients.	O
There	O
is	O
increased	O
risk	O
in	O
patients	O
whose	O
ability	O
to	O
maintain	O
blood	O
pressure	O
has	O
already	O
been	O
compromised	O
by	O
a	O
reduced	O
blood	O
volume	O
or	O
concurrent	O
administration	O
of	O
certain	O
CNS	O
depressant	O
drugs	O
(e.g.,	O
phenothiazine	B-C031637
s	O
or	O
general	O
anesthetics)	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)].	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
hypotension	O
after	O
initiating	O
or	O
titrating	O
the	O
dosage	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP.	O
In	O
patients	O
with	O
circulatory	O
shock,	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
may	O
cause	O
vasodilation	O
that	O
can	O
further	O
reduce	O
cardiac	O
output	O
and	O
blood	O
pressure.	O
Avoid	O
the	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
in	O
patients	O
with	O
circulatory	O
shock.	O
5.	O
1	O
2	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Increased	O
Intracranial	B-D007427
Pressure	I-D007427
,	O
Brain	B-D001921
Tumors,	O
Head	B-D006257
Injury,	O
or	O
Impaired	O
Consciousness	B-D003243
In	O
patients	O
who	O
may	O
be	O
susceptible	O
to	O
the	O
intracranial	O
effects	O
of	O
CO2	O
retention	O
(e.g.,	O
those	O
with	O
evidence	O
of	O
increased	O
intracranial	O
pressure	O
or	O
brain	O
tumors),	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
may	O
reduce	O
respiratory	O
drive,	O
and	O
the	O
resultant	O
CO2	O
retention	O
can	O
further	O
increase	O
intracranial	O
pressure.	O
Monitor	O
such	O
patients	O
for	O
signs	O
of	O
sedation	O
and	O
respiratory	O
depression,	O
particularly	O
when	O
initiating	O
therapy	O
with	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP.	O
Opioids	O
may	O
also	O
obscure	O
the	O
clinical	O
course	O
in	O
a	O
patient	O
with	O
a	O
head	O
injury.	O
Avoid	O
the	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
in	O
patients	O
with	O
impaired	O
consciousness	O
or	O
coma.	O
5.	O
1	O
3	O
Risk	B-D012306
s	O
of	O
Use	O
in	O
Patients	B-D010361
with	O
Gastrointestinal	O
Conditions	O
Including	O
Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
are	O
contraindicated	O
in	O
patients	O
with	O
known	O
or	O
suspected	O
gastrointestinal	O
obstruction,	O
including	O
paralytic	O
ileus.	O
The	O
codeine	O
in	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
may	O
cause	O
spasm	O
of	O
the	O
sphincter	O
of	O
Oddi.	O
Opioids	O
may	O
cause	O
increases	O
in	O
serum	O
amylase.	O
Monitor	O
patients	O
with	O
biliary	O
tract	O
disease,	O
including	O
acute	O
pancreatitis	O
for	O
worsening	O
symptoms.	O
Patients	B-D010361
with	O
a	O
history	O
of	O
active	O
peptic	O
ulcer	O
disease	O
should	O
avoid	O
using	O
aspirin,	O
which	O
can	O
cause	O
gastric	O
mucosal	O
irritation	O
and	O
bleeding.	O
The	O
aspirin	O
in	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
can	O
cause	O
GI	O
side	O
effects	O
including	O
stomach	O
pain,	O
heartburn,	O
nausea,	O
vomiting,	O
and	O
gross	O
GI	O
bleeding.	O
Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
dyspepsia,	O
are	O
common	O
and	O
can	O
occur	O
anytime	O
during	O
therapy,	O
physicians	O
should	O
remain	O
alert	O
for	O
signs	O
of	O
ulceration	O
and	O
bleeding,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
GI	O
symptoms.	O
Physicians	B-D010820
should	O
inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
GI	O
side	O
effects	O
and	O
what	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
5.	O
1	O
4	O
Increased	O
Risk	B-D012306
of	O
Seizures	B-D012640
in	O
Patients	B-D010361
with	O
Seizure	O
Disorders	O
The	O
codeine	O
in	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
may	O
increase	O
the	O
frequency	O
of	O
seizures	O
in	O
patients	O
with	O
seizure	O
disorders,	O
and	O
may	O
increase	O
the	O
risk	O
of	O
seizures	O
occurring	O
in	O
other	O
clinical	O
settings	O
associated	O
with	O
seizures.	O
Monitor	O
patients	O
with	O
a	O
history	O
of	O
seizure	O
disorders	O
for	O
worsened	O
seizure	O
control	O
during	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
therapy.	O
5.	O
1	O
5	O
Withdrawal	O
Do	O
not	O
abruptly	O
discontinue	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
in	O
a	O
patient	O
physically	O
dependent	O
on	O
opioids.	O
Rapid	O
tapering	O
of	O
butalbital	B-C004470
,	O
aspirin,	O
caffeine,	O
and	O
codeine	O
phosphate	O
capsules	O
in	O
a	O
patient	O
physically	O
dependent	O
on	O
opioids	O
may	O
lead	O
to	O
a	O
withdrawal	O
syndrome	O
and	O
return	O
of	O
pain	O
[see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
),	O
Drug	O
Abuse	O
and	O
Dependence	O
(	O
9.3	O
)].	O
Additionally,	O
avoid	O
the	O
use	O
of	O
mixed	O
agonist/antagonist	O
(e.g.,	O
pentazocine,	O
nalbuphine,	O
and	O
butorphan	B-C520649
ol)	O
or	O
partial	O
agonist	O
(e.g.,	O
buprenorphine)	O
analgesics	O
in	O
patients	O
who	O
are	O
receiving	O
a	O
full	O
opioid	O
agonist	O
analgesic,	O
including	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP.	O
In	O
these	O
patients,	O
mixed	O
agonist/antagonist	O
and	O
partial	O
agonist	O
analgesics	O
may	O
reduce	O
the	O
analgesic	O
effect	O
and/or	O
precipitate	O
withdrawal	O
symptoms.	O
When	O
discontinuing	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
in	O
a	O
physically	O
dependent	O
patient,	O
gradually	O
taper	O
the	O
dosage	O
[see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)].	O
Abrupt	O
discontinuation	O
of	O
butalbital	B-C004470
can	O
cause	O
seizures	O
[see	O
Drug	O
Abuse	O
and	O
Dependence	O
(	O
9.3	O
)].	O
5.	O
1	O
6	O
Risk	B-D012306
s	O
of	O
Driving	O
and	O
Operating	O
Machinery	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
may	O
impair	O
the	O
mental	O
or	O
physical	O
abilities	O
needed	O
to	O
perform	O
potentially	O
hazardous	O
activities	O
such	O
as	O
driving	O
a	O
car	O
or	O
operating	O
machinery.	O
Warn	O
patients	O
not	O
to	O
drive	O
or	O
operate	O
dangerous	O
machinery	O
unless	O
they	O
are	O
tolerant	O
to	O
the	O
effects	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
and	O
know	O
how	O
they	O
will	O
react	O
to	O
the	O
medication.	O
5.1	O
7	O
Coagulation	O
Abnormalities	O
and	O
Bleeding	O
Risk	B-D012306
s	O
Even	O
low	O
doses	O
of	O
aspirin	O
can	O
inhibit	O
platelet	O
function	O
leading	O
to	O
an	O
increase	O
in	O
bleeding	O
time.	O
This	O
can	O
adversely	O
affect	O
patients	O
with	O
inherited	O
(i.e.	O
hemophilia)	O
or	O
acquired	O
(i.e.	O
liver	O
disease	O
or	O
vitamin	O
K	O
deficiency)	O
bleeding	O
disorders.	O
Aspirin	B-D001241
is	O
contraindicated	O
in	O
patients	O
with	O
hemophilia.	O
Aspirin	B-D001241
administered	O
pre-operatively	O
may	O
prolong	O
the	O
bleeding	O
time.	O
Patients	B-D010361
who	O
consume	O
three	O
or	O
more	O
alcoholic	O
drinks	O
every	O
day	O
should	O
be	O
counseled	O
about	O
the	O
bleeding	O
risks	O
involved	O
with	O
chronic,	O
heavy	O
alcohol	O
use	O
while	O
taking	O
aspirin.	O
5.1	O
8	O
Reye’s	O
Syndrome	B-D013577
Aspirin	B-D001241
should	O
not	O
be	O
used	O
in	O
children	O
or	O
teenagers	O
for	O
viral	O
infections,	O
with	O
or	O
without	O
fever,	O
because	O
of	O
the	O
risk	O
of	O
Reye’s	O
syndrome	O
with	O
concomitant	O
use	O
of	O
aspirin	O
in	O
certain	O
viral	O
illnesses.	O
5.1	O
9	O
Allergy	O
Aspirin	B-D001241
is	O
contraindicated	O
in	O
patients	O
with	O
known	O
allergy	O
to	O
nonsteroidal	O
anti-inflammatory	O
drug	O
products	O
(NSAIDs)	O
and	O
in	O
patients	O
with	O
the	O
syndrome	O
of	O
asthma,	O
rhinitis,	O
and	O
nas	B-C015378
al	O
polyps.	O
Aspirin	B-D001241
may	O
cause	O
severe	O
urticaria,	O
angioedema,	O
or	O
bronchospasm	O
(asthma).	O
5.	O
20	O
Drug/Laboratory	O
Test	O
Interactions	O
Aspirin	B-D001241
:	O
Aspirin	B-D001241
may	O
interfere	O
with	O
the	O
following	O
laboratory	O
determinations	O
in	O
blood:	O
serum	O
amylase,	O
fasting	O
blood	O
glucose,	O
cholesterol,	O
protein,	O
serum	O
glutamic-oxalacetic	O
transaminase	O
(SGOT),	O
uric	O
acid,	O
prothrombin	O
time	O
and	O
bleeding	O
time.	O
Aspirin	B-D001241
may	O
interfere	O
with	O
the	O
following	O
laboratory	O
determinations	O
in	O
urine:	O
glucose,	O
5-hydroxy-indoleacetic	O
acid,	O
Gerhardt	O
ketone,	O
vanillylmandelic	O
acid	O
(VMA),	O
uric	O
acid,	O
diacetic	O
acid,	O
and	O
spectrophotometric	O
detection	O
of	O
barbiturates.	O
Codeine	B-D003061
:	O
Codeine	B-D003061
may	O
increase	O
serum	O
amylase	O
levels.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described,	O
or	O
described	O
in	O
greater	O
detail,	O
in	O
other	O
sections:	O
Addiction,	O
Abuse,	O
and	O
Misuse	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
Interactions	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
Ultra-Rapid	O
Metabolism	B-D008660
of	O
Codeine	B-D003061
and	O
Other	O
Risk	B-D012307
Factors	I-D012307
for	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
in	O
Child	B-D002648
ren	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)]	O
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)]	O
Adrenal	B-D000309
Insufficiency	I-D000309
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.10	O
)]	O
Severe	O
Hypotension	B-D007022
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.11	O
)]	O
Gastrointestinal	O
Adverse	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.13	O
)]	O
Seizures	B-D012640
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.14	O
)]	O
Withdrawal	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.15	O
)]	O
Coagulation	O
Abnormalities	O
and	O
Bleeding	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.17	O
)]	O
Reye’s	O
Syndrome	B-D013577
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.18	O
)]	O
Allergy	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.19	O
)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
1%)	O
are	O
nausea	O
and/or	O
abdominal	O
pain,	O
drowsiness,	O
and	O
dizziness.	O
(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
Incidence	B-D015994
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
s	O
The	O
following	O
table	O
summarizes	O
the	O
incidence	O
rates	O
of	O
the	O
adverse	O
events	O
reported	O
by	O
at	O
least	O
1%	O
of	O
the	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
treated	O
patients	O
in	O
controlled	O
clinical	O
trials	O
comparing	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
to	O
placebo,	O
and	O
provides	O
a	O
comparison	O
to	O
the	O
incidence	O
rates	O
reported	O
by	O
the	O
placebo-treated	O
patients.	O
The	O
prescriber	O
should	O
be	O
aware	O
that	O
these	O
figures	O
cannot	O
be	O
used	O
to	O
predict	O
the	O
incidence	O
of	O
side	O
effects	O
in	O
the	O
course	O
of	O
usual	O
medical	O
practice	O
where	O
patient	O
characteristics	O
and	O
other	O
factors	O
differ	O
from	O
those	O
that	O
prevailed	O
in	O
the	O
clinical	O
trials.	O
Similarly,	O
the	O
cited	O
frequencies	O
cannot	O
be	O
compared	O
with	O
figures	O
obtained	O
from	O
other	O
clinical	O
investigations	O
involving	O
different	O
treatments,	O
uses,	O
and	O
investigators.	O
Adverse	O
Events	O
Reported	O
by	O
at	O
Least	O
1%	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
Treated	O
Patients	B-D010361
During	O
Placebo	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
s	O
Incidence	B-D015994
Rate	O
of	O
Adverse	O
Events	O
Body	O
System/Adverse	O
Event	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
(N=382)	O
Placebo	O
(N	O
=377)	O
Central	O
Nervous	O
Drowsiness	O
2.4%	O
0.5%	O
Dizziness	B-D004244
/Lightheadedness	O
2.6%	O
0.5%	O
Intoxicated	O
Feeling	O
1.0%	O
0%	O
Gastrointestinal	O
Nausea	B-D009325
/Abdominal	O
Pain	B-D010146
3.7%	O
0.8%	O
Othe	O
r	O
Advers	O
e	O
Event	O
s	O
Reporte	O
d	O
Durin	O
g	O
Controlle	O
d	O
Clinica	O
l	O
Trials	O
The	O
listing	O
that	O
follows	O
represents	O
the	O
proportion	O
of	O
the	O
382	O
patients	O
exposed	O
to	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP	O
while	O
participating	O
in	O
the	O
controlled	O
clinical	O
trials	O
who	O
reported,	O
on	O
at	O
least	O
one	O
occasion,	O
an	O
adverse	O
event	O
of	O
the	O
type	O
cited.	O
All	O
reported	O
adverse	O
events,	O
except	O
those	O
already	O
presented	O
in	O
the	O
previous	O
table,	O
are	O
included.	O
It	O
is	O
important	O
to	O
emphasize	O
that,	O
although	O
the	O
adverse	O
events	O
reported	O
did	O
occur	O
while	O
the	O
patient	O
was	O
receiving	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP,	O
the	O
adverse	O
events	O
were	O
not	O
necessarily	O
caused	O
by	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP.	O
Adverse	O
events	O
are	O
classified	O
by	O
body	O
system	O
and	O
frequency.	O
“Frequent”	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
which	O
occurred	O
in	O
at	O
least	O
1/100	O
(1%)	O
of	O
the	O
patients;	O
all	O
adverse	O
events	O
listed	O
in	O
the	O
previous	O
table	O
are	O
frequent.	O
“Infrequent”	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
that	O
occurred	O
in	O
less	O
than	O
1/100	O
patients	O
but	O
at	O
least	O
1/1000	O
patients.	O
All	O
adverse	O
events	O
tabulated	O
below	O
are	O
classified	O
as	O
infrequent.	O
Centra	O
l	O
Nervous:	O
headache,	O
shaky	O
feeling,	O
tingling,	O
agitation,	O
fainting,	O
fatigue,	O
heavy	O
eyelids,	O
high	O
energy,	O
hot	O
spells,	O
numbness,	O
and	O
sluggishness.	O
Autonomic	O
Nervous:	O
dry	O
mouth	O
and	O
hyperhidrosis.	O
Gastrointestinal:	O
vomiting,	O
difficulty	O
swallowing,	O
and	O
heartburn.	O
Cardiovascular:	O
tachycardia.	O
Musculoskeletal:	O
leg	O
pain	O
and	O
muscle	O
fatigue.	O
Genitourinary:	O
diuresis.	O
Miscellaneous:	O
pruritus,	O
fever,	O
earache,	O
nas	B-C015378
al	O
congestion,	O
and	O
tinnitus.	O
The	O
following	O
adverse	O
drug	O
reactions	O
have	O
been	O
reported	O
with	O
the	O
components	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP.	O
Potential	O
effects	O
of	O
high	O
dosage	O
are	O
listed	O
in	O
the	O
[	O
O	O
verdosage	O
(	O
10	O
)]	O
section	O
of	O
this	O
insert.	O
Aspirin	B-D001241
:	O
occult	O
blood	O
loss,	O
hemolytic	O
anemia,	O
iron	O
deficiency	O
anemia,	O
gastric	O
distress,	O
heartburn,	O
nausea,	O
peptic	O
ulcer,	O
prolonged	O
bleeding	O
time,	O
acute	O
airway	O
obstruction,	O
renal	O
toxicity	O
when	O
taken	O
in	O
high	O
doses	O
for	O
prolonged	O
periods,	O
impaired	O
urate	O
excretion,	O
hepatitis.	O
Caffeine	B-D002110
:	O
cardiac	O
stimulation,	O
irritability,	O
tremor,	O
dependence,	O
nephrotoxicity,	O
hyperglycemia.	O
Codeine	B-D003061
:	O
nausea,	O
vomiting,	O
drowsiness,	O
lightheadedness,	O
constipation,	O
pruritus.	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Centra	O
l	O
Nervous:	O
abuse,	O
addiction,	O
anxiety,	O
depression,	O
disorientation,	O
hallucination,	O
hyperactivity,	O
insomnia,	O
libido	O
decrease,	O
nervousness,	O
neuropathy,	O
psychosis,	O
sedation,	O
sexual	O
activity	O
increase,	O
slurred	O
speech,	O
twitching,	O
unconsciousness,	O
vertigo.	O
Autonomic	O
Nervous:	O
epistaxis,	O
flushing,	O
miosis,	O
salivation.	O
Gastrointestinal:	O
anorexia,	O
appetite	O
increased,	O
constipation,	O
diarrhea,	O
esophagitis,	O
gastroenteritis,	O
gastrointestinal	O
spasm,	O
hiccup,	O
mouth	O
burning,	O
pyloric	O
ulcer.	O
Cardiovascular:	O
chest	O
pain,	O
hypotensive	O
reaction,	O
palpitations,	O
syncope.	O
Skin	B-D012867
:	O
erythema,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
hives,	O
rash,	O
toxic	O
epidermal	O
necrolysis.	O
Urinary:	O
kidney	O
impairment,	O
urinary	O
difficulty.	O
Miscellaneous:	O
allergic	O
reaction,	O
anaphylactic	O
shock,	O
cholangiocarcinoma,	O
drug	O
interaction	O
with	O
erythromycin	O
(stomach	O
upset),	O
edema.	O
Serotonin	B-D012701
syndrome:	O
Cases	O
of	O
serotonin	O
syndrome,	O
a	O
potentially	O
life-threatening	O
condition,	O
have	O
been	O
reported	O
during	O
concomitant	O
use	O
of	O
opioids	O
with	O
serotonergic	O
drugs.	O
Adrenal	O
insufficiency:	O
Cases	O
of	O
adrenal	O
insufficiency	O
have	O
been	O
reported	O
with	O
opioid	O
use,	O
more	O
often	O
following	O
greater	O
than	O
one	O
month	O
of	O
use.	O
Anaphylaxis	B-D000707
:	O
Anaphylaxis	B-D000707
has	O
been	O
reported	O
with	O
ingredients	O
contained	O
in	O
Butalbital,	O
Aspirin	B-D001241
,	O
Caffeine	B-D002110
,	O
and	O
Codeine	B-D003061
Phosphate	O
Capsules	B-D002214
,	O
USP.	O
Androgen	O
deficiency:	O
Cases	O
of	O
androgen	O
deficiency	O
have	O
occurred	O
with	O
chronic	O
use	O
of	O
opioids	O
[see	O
Clinical	O
Pharmacology	B-D010600
(	O
12.2	O
)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
).	O
•	O
NAPROXEN,	O
EC-NAPROXEN,	O
NAPROXEN	O
SODIUM	O
and/	O
NAPROXEN	O
SODIUM	O
DS	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS	O
).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS	O
)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
Hypertension	B-D006973
(see	O
WARNINGS	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Adverse	O
reactions	O
reported	O
in	O
controlled	O
clinical	O
trials	O
in	O
960	O
patients	O
treated	O
for	O
rheumatoid	O
arthritis	O
or	O
osteoarthritis	O
are	O
listed	O
below.	O
In	O
general,	O
reactions	O
in	O
patients	O
treated	O
chronically	O
were	O
reported	O
2	O
to	O
10	O
times	O
more	O
frequently	O
than	O
they	O
were	O
in	O
short-term	O
studies	O
in	O
the	O
962	O
patients	O
treated	O
for	O
mild	O
to	O
moderate	O
pain	O
or	O
for	O
dysmenorrhea.	O
The	O
most	O
frequent	O
complaints	O
reported	O
related	O
to	O
the	O
gastrointestinal	O
tract.	O
A	O
clinical	O
study	O
found	O
gastrointestinal	O
reactions	O
to	O
be	O
more	O
frequent	O
and	O
more	O
severe	O
in	O
rheumatoid	O
arthritis	O
patients	O
taking	O
daily	O
doses	O
of	O
1500	O
mg	O
naproxen	O
compared	O
to	O
those	O
taking	O
750	O
mg	O
naproxen	O
(see	O
CLINICAL	O
PHARMACOLOGY	O
).	O
In	O
controlled	O
clinical	O
trials	O
with	O
about	O
80	O
pediatric	O
patients	O
and	O
in	O
well-monitored,	O
open-label	O
studies	O
with	O
about	O
400	O
pediatric	O
patients	O
with	O
juvenile	O
arthritis	O
treated	O
with	O
naproxen,	O
the	O
incidence	O
of	O
rash	O
and	O
prolonged	O
bleeding	O
times	O
were	O
increased,	O
the	O
incidence	O
of	O
gastrointestinal	O
and	O
central	O
nervous	O
system	O
reactions	O
were	O
about	O
the	O
same,	O
and	O
the	O
incidence	O
of	O
other	O
reactions	O
were	O
lower	O
in	O
pediatric	O
patients	O
than	O
in	O
adults.	O
In	O
patients	O
taking	O
naproxen	O
in	O
clinical	O
trials,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
(GI)	O
Experiences	O
,	O
i	O
ncluding:	O
heartburn*,	O
abdominal	O
pain*,	O
nausea*,	O
constipation*,	O
diarrhea,	O
dyspepsia,	O
stomatitis	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
headache*,	O
dizziness*,	O
drowsiness*,	O
lightheadedness,	O
vertigo	O
Dermatologic:	O
pruritus	O
(itching)*,	O
skin	O
eruptions*,	O
ecchymoses*,	O
sweating,	O
purpura	O
Special	O
Senses:	O
tinnitus*,	O
visual	O
disturbances,	O
hearing	O
disturbances	O
Cardiovascular:	O
edema*,	O
palpitations	O
General:	O
dyspnea*,	O
thirst	O
*Incidence	O
of	O
reported	O
reaction	O
between	O
3%	O
and	O
9%.	O
Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked.	O
In	O
patients	O
taking	O
NSAIDs,	O
the	O
following	O
adverse	O
experiences	O
have	O
also	O
been	O
reported	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients.	O
Gastrointestinal	O
(GI)	O
Experiences	O
,	O
i	O
ncluding:	O
flatulence,	O
gross	O
bleeding/perforation,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting	O
General:	O
abnormal	O
renal	O
function,	O
anemia,	O
elevated	O
liver	O
enzymes,	O
increased	O
bleeding	O
time,	O
rashes	O
The	O
following	O
are	O
additional	O
adverse	O
experiences	O
reported	O
in	O
<1%	O
of	O
patients	O
taking	O
naproxen	O
during	O
clinical	O
trials	O
and	O
through	O
postmarketing	O
reports.	O
Those	O
adverse	O
reactions	O
observed	O
through	O
postmarketing	O
reports	O
are	O
italicized.	O
Body	O
as	O
a	O
Whole:	O
anaphylactoid	O
reactions,	O
angioneurotic	O
edema,	O
menstrual	O
disorders,	O
pyrexia	O
(chills	O
and	O
fever)	O
Cardiovascular:	O
congestive	O
heart	O
failure,	O
vasculitis	O
,	O
hypertension,	O
pulmonary	O
edema	O
Gastrointestinal:	O
inflammation,	O
bleeding	O
(sometimes	O
fatal,	O
particularly	O
in	O
the	O
elderly),	O
ulceration,	O
perforation	O
and	O
obstruction	O
of	O
the	O
upper	O
or	O
lower	O
gastrointestinal	O
tract.	O
E	O
sophagitis	O
,	O
stomatitis	O
,	O
hematemesis,	O
pancreatitis,	O
vomiting,	O
colitis,	O
exacerbation	O
of	O
inflammatory	O
bowel	O
disease	O
(ulcerative	O
colitis,	O
Crohn’s	O
disease)	O
.	O
Hepatobiliary:	O
jaundice,	O
abnormal	O
liver	O
function	O
tests,	O
hepatitis	O
(some	O
cases	O
have	O
been	O
fatal)	O
Hemic	O
and	O
L	O
ymphatic:	O
eosinophilia,	O
leucopenia,	O
melena,	O
thrombocytopenia,	O
agranulocytosis,	O
granulocytopenia,	O
hemolytic	O
anemia,	O
aplastic	O
anemia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia,	O
hypoglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
inability	O
to	O
concentrate,	O
depression,	O
dream	O
abnormalities,	O
insomnia,	O
malaise,	O
myalgia,	O
muscle	O
weakness,	O
aseptic	O
meningitis,	O
cognitive	O
dysfunction	O
,	O
convulsions	O
Respiratory:	O
eosinophilic	O
pneumonitis	O
,	O
asthma	O
Dermatologic:	O
alopecia,	O
urticaria,	O
skin	O
rashes,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
erythema	O
nodosum,	O
fixed	O
drug	O
eruption,	O
lichen	O
planus,	O
pustular	O
reaction,	O
systemic	O
lupus	O
erythematoses,	O
bullous	O
reactions,	O
including	O
Stevens-Johnson	O
syndrome,	O
photosensitive	O
dermatitis,	O
photosensitivity	O
reactions,	O
including	O
rare	O
cases	O
resembling	O
porphyria	O
cutanea	O
tarda	O
(pseudoporphyria)	O
or	O
epidermolysis	O
bullosa.	O
If	O
skin	O
fragility,	O
blistering	O
or	O
other	O
symptoms	O
suggestive	O
of	O
pseudoporphyria	O
occur,	O
treatment	O
should	O
be	O
discontinued	O
and	O
the	O
patient	O
monitored.	O
Special	O
Senses:	O
hearing	O
impairment	O
,	O
corneal	O
opacity,	O
papillitis,	O
retrobulbar	O
optic	O
neuritis,	O
papilledema	O
Urogenital:	O
glomerular	O
nephritis,	O
hematuria,	O
hyperkalemia,	O
interstitial	O
nephritis,	O
nephrotic	O
syndrome,	O
renal	O
disease,	O
renal	O
failure,	O
renal	O
papillary	O
necrosis	O
,	O
raised	O
serum	O
creatinine	O
Reproduction	B-D012098
(female):	O
infertility	O
In	O
patients	O
taking	O
NSAIDs,	O
the	O
following	O
adverse	O
experiences	O
have	O
also	O
been	O
reported	O
in	O
<1%	O
of	O
patients.	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis,	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular:	O
hypertension,	O
tachycardia,	O
syncope,	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction	O
Gastrointestinal:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
glossitis,	O
eructation	O
Hepatobiliary:	O
hepatitis,	O
liver	O
failure	O
Hemic	O
and	O
L	O
ymphatic:	O
rectal	O
bleeding,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
convulsions,	O
coma,	O
hallucinations	O
Respiratory:	O
asthma,	O
respiratory	O
depression,	O
pneumonia	O
Dermatologic:	O
exfoliative	O
dermatitis	O
Special	O
Senses:	O
blurred	O
vision,	O
conjunctivitis	O
Urogenital:	O
cystitis,	O
dysuria,	O
oliguria/polyuria,	O
proteinuria	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
Hypertension	B-D006973
(see	O
WARNINGS	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuriarenal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
EVENTS,	O
contact	O
Actavis	O
at	O
1-800-432-8534	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
http://www.fda.gov/	O
for	O
voluntary	O
reporting	O
of	O
adverse	O
reactions.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
Hypertension	B-D006973
(see	O
WARNINGS	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuriarenal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
EVENTS,	O
contact	O
Actavis	O
at	O
1-800-432-8534	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
http://www.fda.gov/	O
for	O
voluntary	O
reporting	O
of	O
adverse	O
reactions.	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O
.	O
Etodolac	B-D017308
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
a	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1,000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain*,	O
diarrhea*,	O
flatulence*,	O
nausea*,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise*,	O
dizziness*,	O
depression,	O
nervousness.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation	O
,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
hyperpigmentation	O
,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death	O
Cardiovascular	O
system	O
-	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Sulfite	O
Allergic	O
Reactions	O
(5.1)	O
Slow	O
or	O
Delayed	O
Healing	O
(5.2)	O
Potential	O
for	O
cross-sensitivity	O
(5.3)	O
Increase	O
bleeding	O
of	O
ocular	O
tissues	O
(5.4)	O
Cornea	B-D003315
l	O
effects	O
including	O
keratitis	O
(5.5)	O
Contact	O
Lens	O
Wear	O
(5.6)	O
5.1	O
Sulfite	O
Allergic	O
Reactions	O
Contains	O
sodium	B-C025026
sulfite	I-C025026
,	O
a	O
sulfite	O
that	O
may	O
cause	O
allergic-type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people.	O
The	O
overall	O
prevalence	O
of	O
sulfite	O
sensitivity	O
in	O
the	O
general	O
population	O
is	O
unknown	O
and	O
probably	O
low.	O
Sulfite	O
sensitivity	O
is	O
seen	O
more	O
frequently	O
in	O
asthmatic	O
than	O
in	O
non-asthmatic	O
people.	O
5.2	O
Slow	O
or	O
Delayed	O
Healing	O
All	O
topical	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
slow	O
or	O
delay	O
healing.	O
Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing.	O
Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
steroids	O
may	O
increase	O
the	O
potential	O
for	O
healing	O
problems	O
5.3	O
Potential	O
for	O
Cross-Sensitivity	O
There	O
is	O
the	O
potential	O
for	O
cross-sensitivity	O
to	O
acetylsalicylic	O
acid,	O
phenylacetic	B-C025136
acid	I-C025136
derivatives,	O
and	O
other	O
NSAIDs.	O
Therefore,	O
caution	O
should	O
be	O
used	O
when	O
treating	O
individuals	O
who	O
have	O
previously	O
exhibited	O
sensitivities	O
to	O
these	O
drugs.	O
5.4	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
With	O
some	O
NSAIDs,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
platelet	O
aggregation.	O
There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
NSAIDs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
tissues	O
(including	O
hyphemas)	O
in	O
conjunction	O
with	O
ocular	O
surgery.	O
It	O
is	O
recommended	O
that	O
Bromday	O
ophthalmic	O
solution	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
known	O
bleeding	O
tendencies	O
or	O
who	O
are	O
receiving	O
other	O
medications	O
which	O
may	O
prolong	O
bleeding	O
time.	O
5.5	O
Keratitis	B-D007634
and	O
Cornea	B-D003315
l	O
Reactions	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
keratitis.	O
In	O
some	O
susceptible	O
patients,	O
continued	O
use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
epithelial	O
breakdown,	O
corneal	O
thinning,	O
corneal	O
erosion,	O
corneal	O
ulceration	O
or	O
corneal	O
perforation.	O
These	O
events	O
may	O
be	O
sight	O
threatening.	O
Patients	B-D010361
with	O
evidence	O
of	O
corneal	O
epithelial	O
breakdown	O
should	O
immediately	O
discontinue	O
use	O
of	O
topical	O
NSAIDs	O
and	O
should	O
be	O
closely	O
monitored	O
for	O
corneal	O
health.	O
Post-marketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
patients	O
with	O
complicated	O
ocular	O
surgeries,	O
corneal	O
denervation,	O
corneal	O
epithelial	O
defects,	O
diabetes	O
mellitus,	O
ocular	O
surface	O
diseases	O
(e.g.,	O
dry	O
eye	O
syndrome),	O
rheumatoid	O
arthritis,	O
or	O
repeat	O
ocular	O
surgeries	O
within	O
a	O
short	O
period	O
of	O
time	O
may	O
be	O
at	O
increased	O
risk	O
for	O
corneal	O
adverse	O
events	O
which	O
may	O
become	O
sight	O
threatening.	O
Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients.	O
Post-marketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
24	O
hours	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
post	O
surgery	O
may	O
increase	O
patient	O
risk	O
for	O
the	O
occurrence	O
and	O
severity	O
of	O
corneal	O
adverse	O
events.	O
5.6	O
Contact	O
Lens	O
Wear	O
Bromday	O
should	O
not	O
be	O
administered	O
while	O
wearing	O
contact	O
lenses.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
in	O
2-7%	O
of	O
patients	O
were	O
abnormal	O
sensation	O
in	O
eye,	O
conjunctival	O
hyperemia	O
and	O
eye	O
irritation	O
(including	O
burning/stinging)	O
(6.1)	O
.	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
ISTA	O
Pharmaceuticals,	O
Inc.	O
at	O
1-877-788-2020,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
Experience	O
The	O
most	O
commonly	O
reported	O
adverse	O
experiences	O
reported	O
following	O
use	O
of	O
bromfenac	B-C053083
after	O
cataract	O
surgery	O
include:	O
abnormal	O
sensation	O
in	O
eye,	O
conjunctival	O
hyperemia,	O
eye	O
irritation	O
(including	O
burning/stinging),	O
eye	O
pain,	O
eye	O
pruritus,	O
eye	O
redness,	O
headache,	O
and	O
iritis.	O
These	O
events	O
were	O
reported	O
in	O
2-7%	O
of	O
patients.	O
6.2	O
Post-Marketing	O
Experience	O
The	O
following	O
events	O
have	O
been	O
identified	O
during	O
post-marketing	O
use	O
of	O
bromfenac	B-C053083
ophthalmic	O
solution	O
0.09%	O
in	O
clinical	O
practice.	O
Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size,	O
estimates	O
of	O
frequency	O
cannot	O
be	O
made.	O
The	O
events,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
bromfenac	B-C053083
ophthalmic	O
solution	O
0.09%	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
corneal	O
erosion,	O
corneal	O
perforation,	O
corneal	O
thinning,	O
and	O
epithelial	O
breakdown.	O
[see	O
Warnings	O
and	O
Precautions	O
(5)]	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs	O
1)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(See	O
WARNINGS).	O
•	O
Etodolac	B-D017308
capsules	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(See	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(See	O
WARNINGS).	O
1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
nonsteroidal	O
anti-inflammatory	O
drug.	O
Adverse	O
Reactions	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
capsules	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
or	O
Equal	O
to	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain*,	O
diarrhea*,	O
flatulence*,	O
nausea*,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise*,	O
dizziness*,	O
depression,	O
nervousness,	O
fatigue.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
Musculoskeletal	O
-	O
Arthralgia	B-D018771
.	O
*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
leukocytoclastic	O
vasculitis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.	O
Musculoskeletal	O
-	O
Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death.	O
Cardiovascular	O
system	O
-	O
Tachycardia	B-D013610
.	O
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Lymphadenopathy	B-D000072281
.	O
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo.	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia.	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(5.1)	O
Piroxicam	B-D010894
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Piroxicam	B-D010894
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
piroxicam	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
piroxicam	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Piroxicam	B-D010894
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
piroxicam	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
piroxicam,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
piroxicam	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
piroxicam	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
piroxicam,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
piroxicam	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
alanine	O
aminotransferase	O
(ALT)	O
or	O
aspartate	O
aminotransferase	O
(AST)	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
piroxicam.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
discontinue	O
piroxicam	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
piroxicam,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
piroxicam	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
piroxicam	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
piroxicam	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
piroxicam	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
piroxicam	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
piroxicam.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
piroxicam	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
piroxicam	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
piroxicam	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Piroxicam	B-D010894
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
piroxicam	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
piroxicam	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
piroxicam	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
piroxicam,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
piroxicam	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
piroxicam	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Piroxicam	B-D010894
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
piroxicam,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
piroxicam	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
piroxicam,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	O
SSRIs,	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
piroxicam	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
complete	O
blood	O
count	O
(CBC)	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
5.14	O
Ophthalmologic	O
Effects	O
Because	O
of	O
reports	O
of	O
adverse	O
eye	O
findings	O
with	O
nonsteroidal	O
anti-inflammatory	O
agents,	O
it	O
is	O
recommended	O
that	O
patients	O
who	O
develop	O
visual	O
complaints	O
during	O
treatment	O
with	O
piroxicam	O
have	O
ophthalmic	O
evaluations.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
from	O
clinical	O
trials)	O
are:	O
nausea,	O
constipation,	O
flatulence,	O
abdominal	O
pain,	O
diarrhea,	O
headache,	O
dizziness,	O
edema,	O
rash.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Greenstone	O
LLC	O
Professional	O
Information	B-D007255
Services	I-D007255
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
piroxicam	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Cardiovascular	B-D002319
System	I-D002319
:	O
Edema	B-D004487
Digestive	B-D004064
System	I-D004064
:	O
Anorexia	B-D000855
,	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
flatulence,	O
nausea,	O
vomiting	O
Nervous	B-D009420
System	I-D009420
:	O
Dizziness	B-D004244
,	O
headache,	O
vertigo	O
Skin	B-D012867
and	O
Appendages:	O
Pruritus	B-D011537
,	O
rash	O
Special	O
Senses:	O
Tinnitus	B-D014012
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Cardiovascular	B-D002319
System	I-D002319
:	O
Palpitations	O
Digestive	B-D004064
System	I-D004064
:	O
Stomatitis	B-D013280
Nervous	B-D009420
System	I-D009420
:	O
Drowsiness	O
Special	O
Senses:	O
Blurred	O
vision	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
piroxicam.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
As	O
a	O
Whole:	O
Fever	B-D005334
,	O
infection,	O
sepsis,	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death,	O
flu-like	O
syndrome,	O
pain	O
(colic),	O
serum	O
sickness	O
Cardiovascular	B-D002319
System	I-D002319
:	O
Congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope,	O
arrhythmia,	O
exacerbation	O
of	O
angina,	O
hypotension,	O
myocardial	O
infarction,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
Dyspepsia	B-D004415
,	O
elevated	O
liver	O
enzymes,	O
gross	O
bleeding/perforation,	O
heartburn,	O
ulcers	O
(gastric/duodenal),	O
dry	O
mouth,	O
esophagitis,	O
gastritis,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice,	O
melena,	O
rectal	O
bleeding,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
Anemia	B-D000740
,	O
increased	O
bleeding	O
time,	O
ecchymosis,	O
eosinophilia,	O
epistaxis,	O
leukopenia,	O
purpura,	O
petechial	O
rash,	O
thrombocytopenia,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Hypersensitivity	B-D006967
:	O
Positive	O
ANA	O
Metabolic	O
and	O
Nutritional:	O
Weight	O
changes,	O
Fluid	O
retention,	O
hyperglycemia,	O
hypoglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
Anxiety	B-D001007
,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
akathisia,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
mood	O
alterations	O
Respiratory	B-D012137
System	I-D012137
:	O
Asthma	B-D001249
,	O
dyspnea,	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
Alopecia	B-D000505
,	O
bruising,	O
desquamation,	O
erythema,	O
photosensitivity,	O
sweat,	O
angioedema,	O
toxic	O
epidermal	O
necrosis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
onycholysis,	O
Stevens	O
Johnson	O
Syndrome	B-D013577
,	O
urticaria,	O
vesiculobullous	O
reaction	O
Special	O
Senses:	O
Conjunctivitis	B-D003231
,	O
hearing	O
impairment,	O
swollen	O
eyes	O
Urogenital	B-D014566
System	I-D014566
:	O
Abnormal	O
renal	O
function,	O
cystitis,	O
dysuria,	O
hematuria,	O
hyperkalemia,	O
interstitial	O
nephritis,	O
nephrotic	O
syndrome,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure,	O
glomerulonephritis	O
Reproductive	O
System	O
and	O
Breast	B-D001940
Disorders:	O
Female	B-D005260
fertility	O
decreased	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
•	O
Non-Steroidal	O
Anti-Inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(	O
5.1)	O
•	O
NALFON	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(	O
4,	O
5.1)	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(	O
5.2)	O
Cardiovascular	O
Thrombic	O
Events	O
•	O
Non-Steroidal	O
Anti-Inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
].	O
•	O
NALFON	O
®	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
precautions	O
(	O
5.1)	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
].	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(	O
5.3)	O
•	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(	O
5.4,	O
7)	O
•	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
NALFON	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(	O
5.5)	O
•	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
NALFON	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(	O
5.6)	O
•	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7)	O
•	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
NALFON	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(	O
5.8)	O
•	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
NALFON	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(	O
5.9)	O
•	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(	O
5.10,	O
8.1)	O
•	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(	O
5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
fenoprofen,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
NALFON	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
NALFON,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDS.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
of	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
for	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
:	O
•Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
•Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
•Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
theincreased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GIbleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
•Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
•If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
NALFON	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
•In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
fenoprofen.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
NALFON	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
NALFON,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
fenoprofen	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
NALFON	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
NALFON	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
NALFON	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
pre-existing	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
NALFON.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
NALFON	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
NALFON	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Fenoprofen	B-D005279
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
fenoprofen	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
NALFON	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
].	O
When	O
NALFON	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
fenoprop	B-C009264
fen,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
NALFON	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
NALFON	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Fenoprofen	B-D005279
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
NALFON,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(	O
8.1)	O
].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
NALFON	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
NALFON,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
NALFON	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2,	O
5.3,	O
5.6)	O
].	O
5.14	O
Ocular	O
Effects	O
Studies	O
to	O
date	O
have	O
not	O
shown	O
changes	O
in	O
the	O
eyes	O
attributable	O
to	O
the	O
administration	O
of	O
NALFON.	O
However,	O
adverse	O
ocular	O
effects	O
have	O
been	O
observed	O
with	O
other	O
anti-inflammatory	O
drugs.	O
Eye	B-D005123
examinations,	O
therefore,	O
should	O
be	O
performed	O
if	O
visual	O
disturbances	O
occur	O
in	O
patients	O
taking	O
NALFON.	O
5.15	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Caution	O
should	O
be	O
exercised	O
by	O
patients	O
whose	O
activities	O
require	O
alertness	O
if	O
they	O
experience	O
CNS	O
side	O
effects	O
while	O
taking	O
NALFON.	O
5.16	O
Impact	O
on	O
Hearing	B-D006309
Since	O
the	O
safety	O
of	O
NALFON	O
has	O
not	O
been	O
established	O
in	O
patients	O
with	O
impaired	O
hearing,	O
these	O
patients	O
should	O
have	O
periodic	O
tests	O
of	O
auditory	O
function	O
during	O
prolonged	O
therapy	O
with	O
NALFON.	O
6.	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
•Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
•Hypertension	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
•Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
•Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
•Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
5%)	O
are	O
Dyspepsia	B-D004415
,	O
headache,	O
somnolence,	O
nausea,	O
dizziness,	O
constipation,	O
nervousness,	O
asthenia,	O
and	O
peripheral	O
edema.	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Xspire	O
Pharma	O
at	O
1-601-990-9497	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
During	O
clinical	O
studies	O
for	O
rheumatoid	O
arthritis,	O
osteoarthritis,	O
or	O
mild	O
to	O
moderate	O
pain	O
and	O
studies	O
of	O
pharmacokinetics,	O
complaints	O
were	O
compiled	O
from	O
a	O
checklist	O
of	O
potential	O
adverse	O
reactions,	O
and	O
the	O
following	O
data	O
emerged.	O
These	O
encompass	O
observations	O
in	O
6,786	O
patients,	O
including	O
188	O
observed	O
for	O
at	O
least	O
52	O
weeks.	O
For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
patients	O
who	O
received	O
placebo	O
in	O
these	O
same	O
trials.	O
During	O
short-term	O
studies	O
for	O
analgesia,	O
the	O
incidence	O
of	O
adverse	O
reactions	O
was	O
markedly	O
lower	O
than	O
that	O
seen	O
in	O
longer-term	O
studies.	O
Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
>1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—	O
During	O
clinical	O
trials	O
with	O
Nalfon,	O
the	O
most	O
common	O
adverse	O
reactions	O
were	O
gastrointestinal	O
in	O
nature	O
and	O
occurred	O
in	O
20.8%	O
of	O
patients	O
receiving	O
Nalfon	O
as	O
compared	O
to	O
16.9%	O
of	O
patients	O
receiving	O
placebo.	O
In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
dyspepsia	O
(10.3%	O
Nalfon	O
vs.	O
2.3%	O
placebo),	O
nausea	O
(7.7%	O
vs.	O
7.1%),	O
constipation	O
(7%	O
vs.	O
1.5%),	O
vomiting	O
(2.6%	O
vs.	O
1.9%),	O
abdominal	O
pain	O
(2%	O
vs.	O
1.1%),	O
and	O
diarrhea	O
(1.8%	O
vs.	O
4.1%).	O
The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
patients	O
during	O
premarketing	O
studies.	O
Nervous	B-D009420
System	I-D009420
—	O
The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
headache	O
(8.7%	O
vs.	O
7.5%)	O
and	O
somnolence	O
(8.5%	O
vs.	O
6.4%).	O
Dizziness	B-D004244
(6.5%	O
vs.	O
5.6%),	O
tremor	O
(2.2%	O
vs.	O
0.4%),	O
and	O
confusion	O
(1.4%	O
vs.	O
none)	O
were	O
noted	O
less	O
frequently.	O
Nalfon	O
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
patients	O
because	O
of	O
these	O
side	O
effects	O
during	O
premarketing	O
studies.	O
Skin	B-D012867
and	O
Appendages—	O
Increased	O
sweating	O
(4.6%	O
vs.	O
0.4%),	O
pruritus	O
(4.2%	O
vs.	O
0.8%),	O
and	O
rash	O
(3.7%	O
vs.	O
0.4%)	O
were	O
reported.	O
Nalfon	O
was	O
discontinued	O
in	O
about	O
1%	O
of	O
patients	O
because	O
of	O
an	O
adverse	O
effect	O
related	O
to	O
the	O
skin	O
during	O
premarketing	O
studies.	O
Special	O
Senses	O
—	O
Tinnitus	B-D014012
(4.5%	O
vs.	O
0.4%),	O
blurred	O
vision	O
(2.2%	O
vs.	O
none),	O
and	O
decreased	O
hearing	O
(1.6%	O
vs.	O
none)	O
were	O
reported.	O
Nalfon	O
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
patients	O
because	O
of	O
adverse	O
effects	O
related	O
to	O
the	O
special	O
senses	O
during	O
premarketing	O
studies.	O
Cardiovascular	O
—	O
Palpitations	O
(2.5%	O
vs.	O
0.4%).	O
Nalfon	O
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
patients	O
because	O
of	O
adverse	O
cardiovascular	O
reactions	O
during	O
premarketing	O
studies.	O
Miscellaneous	O
—	O
Nervousness	O
(5.7%	O
vs.	O
1.5%),	O
asthenia	O
(5.4%	O
vs.	O
0.4%),	O
peripheral	O
edema	O
(5.0%	O
vs.	O
0.4%),	O
dyspnea	O
(2.8%	O
vs.	O
none),	O
fatigue	O
(1.7%	O
vs.	O
1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs.	O
5.6%),	O
and	O
nas	B-C015378
opharyngitis	O
(1.2%	O
vs.	O
none).	O
Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—Gastritis,	O
peptic	O
ulcer	O
with/without	O
perforation,	O
gastrointestinal	O
hemorrhage,	O
anorexia,	O
flatulence,	O
dry	O
mouth,	O
and	O
blood	O
in	O
the	O
stool.	O
Increases	O
in	O
alkaline	O
phosphatase,	O
LDH,	O
SGOT,	O
jaundice,	O
and	O
cholestatic	O
hepatitis,	O
aphthous	O
ulcerations	O
of	O
the	O
buccal	O
mucosa,	O
metallic	O
taste,	O
and	O
pancreatitis.	O
Cardiovascular—Atrial	O
fibrillation,	O
pulmonary	O
edema,	O
electrocardiographic	O
changes,	O
and	O
supraventricular	O
tachycardia.	O
Genitourinary	O
Tract—Renal	O
failure,	O
dysuria,	O
cystitis,	O
hematuria,	O
oliguria,	O
azotemia,	O
anuria,	O
interstitial	O
nephritis,	O
nephrosis,	O
and	O
papillary	O
necrosis.	O
Hypersensitivity	B-D006967
—Angioedema	O
(angioneurotic	O
edema).	O
Hematologic—Purpura,	O
bruising,	O
hemorrhage,	O
thrombocytopenia,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
agranulocytosis,	O
and	O
pancytopenia.	O
Nervous	B-D009420
System	I-D009420
—Depression,	O
disorientation,	O
seizures,	O
and	O
trigeminal	O
neuralgia.	O
Special	O
Senses—Burning	O
tongue,	O
diplopia,	O
and	O
optic	O
neuritis.	O
Skin	B-D012867
and	O
Appendages—Exfoliative	O
dermatitis,	O
toxic	O
epidermal	O
necrolysis,	O
Stevens-Johnson	O
syndrome,	O
and	O
alopecia.	O
Miscellaneous—Anaphylaxis,	O
urticaria,	O
malaise,	O
insomnia,	O
tachycardia,	O
personality	O
change,	O
lymphadenopathy,	O
mastodynia,	O
and	O
fever.	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(5.4)	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
CardiovascularRisk	O
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(5.4)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
knownCV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(5.1,	O
14.6,	O
17.2).	O
•	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
diseaseor	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
thesepatients	O
(5.4,	O
8.5,	O
14.6,	O
17.3).	O
•	O
Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
celecoxibimmediately	O
if	O
abnormal	O
liver	O
enzymespersist	O
or	O
worsen	O
(5.5,	O
17.4).	O
•	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
duringtreatment	O
with	O
celecoxib	O
(5.2,	O
7.4,	O
17.2).	O
•	O
Fluid	O
retention	O
and	O
edema.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retentionor	O
heart	O
failure	O
(5.3,	O
17.6).	O
•	O
Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
celecoxib	O
with	O
caution	O
inthe	O
elderly,	O
those	O
with	O
impairedrenal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists(5.6,	O
7.4,	O
8.7,	O
17.6).	O
•	O
Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
celecoxib	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(5.7,	O
10,	O
17.7).	O
•	O
Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
evenwithout	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
ofrash	O
or	O
skin	O
reactions	O
(5.8,	O
17.5).	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovasculardeath,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
to	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
to	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
celecoxib,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
celecoxib	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
celecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)].	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
celecoxib	O
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
celecoxib	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
celecoxib.	O
In	O
postmarketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
celecoxib.	O
Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
antiinflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
celecoxib	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sydon	O
Labs,	O
LLC	O
at	O
1	O
866-487-4695	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
>2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4,	O
146	O
Placebo	O
N=1,	O
864	O
NAP	O
N=1,	O
366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%5.6%8.8%2.2%3.5%	O
2.8%3.8%6.2%1%4.2%	O
7.7%5.3%12.2%3.6%6%	O
9%9.3%10.9%4.1%3.4%	O
9%5.8%12.8%3.5%6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%2.1%2.9%	O
3.6%1.1%2.3%	O
2.2%2.1%3%	O
2.6%1%2.6%	O
0.9%3.5%3.2%	O
Central,	O
Peripheral	O
Nervous	O
systemDizzinessHeadache	O
2%15.8%	O
1.7%20.2%	O
2.6%14.5%	O
1.3%15.5%	O
2.3%15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
Rhinitis	B-D012220
Sinusitis	B-D012852
Upper	O
Respiratory	O
Infection	O
2.3%2%5%8.1%	O
1.1%1.3%4.3%6.7%	O
1.7%2.4%4%9.9%	O
1.6%2.3%5.4%9.8%	O
2.6%0.6%5.8%9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatmentgroups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophagealreflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinineincreased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
alymphatic:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
StevensJohnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
doubleblind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
>5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
ClassPreferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kgN=77	O
Celecoxib	B-D000068579
6	O
mg/kgN=82	O
Naproxen	B-D009288
7.5mg/kgN=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
36	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
postdental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
premarketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
premarketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N=2,285	O
Placebo	O
N=1,303	O
Diarrhea	B-D003967
10.5%	O
7%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
>0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
arteryatherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
bloodtestosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)]	O
.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(	O
5.1)	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(	O
4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(	O
5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(	O
5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(	O
5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(	O
5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(	O
5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(	O
5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
gel	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(	O
5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation.	O
(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(	O
5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	O
sodium	O
topical	O
gel	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
]	O
.	O
5.3	O
Hepatic	O
Effects	O
In	O
clinical	O
trials,	O
of	O
oral	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
sodium	O
for	O
2-6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3-8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
topical	O
gel	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
topical	O
gel	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
topical	O
gel	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
antibiotics,	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
]	O
.	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	O
interactions	O
(	O
7)	O
]	O
.	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
diclofenac	O
sodium	O
topical	O
gel.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
]	O
.	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactoid	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.8)	O
]	O
.	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O
.	O
When	O
diclofenac	O
sodium	O
topical	O
gel	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Diclofenac	B-D004008
sodium	O
topical	O
gel	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O
.	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(	O
8.1)	O
].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
gel,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
]	O
.	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2,	O
5.3,	O
5.6)	O
].	O
5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
areas	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light	O
induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
with	O
eyes	O
and	O
mucosa,	O
although	O
not	O
studied,	O
should	O
be	O
avoided.	O
Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
eye	O
contact	O
occurs,	O
they	O
should	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
greater	O
than	O
placebo)	O
are	O
application	O
site	O
reactions,	O
including	O
dermatitis.	O
(	O
6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
GlaxoSmithKline	O
Consumer	O
Health	B-D006262
care	O
at	O
1	O
-855-297-3031	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
During	O
clinical	O
development,	O
913	O
patients	O
were	O
exposed	O
to	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
randomized,	O
double-blind,	O
multicenter,	O
vehicle-controlled,	O
parallel-group	O
studies	O
in	O
osteoarthritis	O
of	O
the	O
superficial	O
joints	O
of	O
the	O
extremities.	O
Of	O
these,	O
513	O
patients	O
received	O
diclofenac	O
sodium	O
topical	O
gel	O
for	O
osteoarthritis	O
of	O
the	O
knee	O
and	O
400	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
the	O
hand.	O
Additionally,	O
583	O
patients	O
were	O
exposed	O
to	O
diclofenac	O
sodium	O
topical	O
gel	O
in	O
an	O
uncontrolled,	O
open-label,	O
long-term	O
safety	O
trial	O
in	O
osteoarthritis	O
of	O
the	O
knee.	O
Of	O
these,	O
355	O
patients	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
1	O
knee	O
and	O
228	O
were	O
treated	O
for	O
osteoarthritis	O
of	O
both	O
knees.	O
Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
safety	O
trial.	O
Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel:	O
Non-serious	O
adverse	O
reactions	O
that	O
were	O
reported	O
during	O
the	O
short-term	O
placebo-controlled	O
studies	O
comparing	O
diclofenac	O
sodium	O
topical	O
gel	O
and	O
placebo	O
(vehicle	O
gel)	O
over	O
study	O
periods	O
of	O
8	O
to	O
12	O
weeks	O
(16	O
g	O
per	O
day),	O
were	O
application	O
site	O
reactions.	O
These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>1%	O
of	O
treated	O
patients	O
with	O
a	O
greater	O
frequency	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
gel	O
group	O
(7%)	O
than	O
the	O
placebo	O
group	O
(2%).	O
Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported.	O
Application	O
site	O
dermatitis	O
was	O
the	O
most	O
frequent	O
type	O
of	O
application	O
site	O
reaction	O
and	O
was	O
reported	O
by	O
4%	O
of	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
compared	O
to	O
1%	O
of	O
placebo	O
patients.	O
Table	O
1.	O
Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
Patients	B-D010361
)	O
–	O
Short-term	O
Controlled	O
Trials	O
†	O
Preferred	O
Term	O
according	O
to	O
MedDRA	O
9.1.	O
Adverse	O
Reaction	O
†	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
N=913	O
Placebo	O
(vehicle)	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
dermatitis	O
32	O
(4)	O
6	O
(<1)	O
Application	O
site	O
pruritus	O
7	O
(<1)	O
1	O
(<1)	O
Application	O
site	O
erythema	O
6	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
paresthesia	O
5	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
dryness	O
4	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
vesicles	O
3	O
(<1)	O
0	O
Application	O
site	O
irritation	O
2	O
(<1)	O
0	O
Application	O
site	O
papules	O
1	O
(<1)	O
0	O
In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
gel,	O
and	O
3%	O
for	O
patients	O
in	O
the	O
placebo	O
group.	O
Application	O
site	O
reactions,	O
including	O
application	O
site	O
dermatitis,	O
were	O
the	O
most	O
frequent	O
reason	O
for	O
treatment	O
discontinuation.	O
Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
safety	O
study,	O
distribution	O
of	O
adverse	O
reactions	O
was	O
similar	O
to	O
that	O
in	O
the	O
placebo-controlled	O
studies.	O
In	O
this	O
study,	O
where	O
patients	O
were	O
treated	O
for	O
up	O
to	O
1	O
year	O
with	O
diclofenac	O
sodium	O
topical	O
gel	O
up	O
to	O
32	O
g	O
per	O
day,	O
application	O
site	O
dermatitis	O
was	O
observed	O
in	O
11%	O
of	O
patients.	O
Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
patients.	O
The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
dermatitis,	O
which	O
was	O
experienced	O
by	O
6%	O
of	O
patients.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4	O
,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
(GI)	O
events.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	O
capsules	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	O
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
for	O
the	O
celecoxib	O
capsules	O
400	O
mg	O
twice	O
daily	O
and	O
celecoxib	O
capsules	O
200	O
mg	O
twice	O
daily	O
treatment	O
arms	O
compared	O
to	O
placebo.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.7)].	O
A	O
randomized	O
controlled	O
trial	O
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs.	O
Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	O
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	O
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	O
and	O
ibuprofen.	O
Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	O
375	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	O
600	O
to	O
800	O
mg	O
three	O
times	O
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists’	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	O
(including	O
hemorrhagic	O
death),	O
non-fatal	O
myocardial	O
infarction,	O
and	O
non-fatal	O
stroke	O
[See	O
Clinical	O
Studies	O
(14.6)].	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
celecoxib	O
capsules.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants;	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.7)].	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	O
capsules	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib	O
capsules,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
capsules	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
capsules	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
celecoxib	O
capsules	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
blood	O
pressure	O
data	O
for	O
celecoxib	O
capsules.	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
celecoxib	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
celecoxib	O
capsules	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
celecoxib	O
capsules	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
celecoxib	O
capsules.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
celecoxib	O
capsules	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
celecoxib	O
and	O
in	O
patients	O
with	O
aspirin	O
sensitive	O
asthma.	O
Celecoxib	B-D000068579
capsules	O
are	O
sulfonamides	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	O
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
celecoxib	O
capsules	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	O
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib	O
capsules,	O
including	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(AGEP).	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	O
capsules	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Celecoxib	B-D000068579
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
celecoxib	O
capsules	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2	O
,	O
5.3	O
,	O
5.6)].	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
capsules	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation	O
with	O
use	O
of	O
celecoxib	O
capsules	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	O
and	O
their	O
caregivers	O
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp.	O
at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CBX	O
=	O
celecoxib	O
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General:	O
Hypersensitivity	B-D006967
,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia	B-D001259
,	O
suicide	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Clinical	O
Studies	O
(14.7)]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
aspirin	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
twice	O
daily.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Celecoxib	B-D000068579
3	O
mg/kg	O
Celecoxib	B-D000068579
6	O
mg/kg	O
Naproxen	B-D009288
7.5	O
mg/kg	O
Preferred	O
Term	O
N=77	O
N=82	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl.	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-	O
controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.7)].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
Placebo	O
N=	O
2285	O
N=	O
1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
celecoxib	O
capsules.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis	B-D014657
,	O
deep	O
venous	O
thrombosis	O
General:	O
Anaphylactoid	O
reaction,	O
angioedema	O
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	O
hepatitis,	O
jaundice,	O
hepatic	O
failure	O
Hemic	O
and	O
lymphatic:	O
Agranulocytosis	B-D000380
,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
Renal:	O
Interstitial	O
nephritis	O
CONTRAINDICATIONS	O
AND	O
WARNINGS	O
ARTHROTEC®	O
CONTAINS	O
DICLOFENAC	O
SODIUM	O
AND	O
MISOPROSTOL.	O
ADMINISTRATION	O
OF	O
MISOPROSTOL	O
TO	O
WOMEN	O
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	O
BIRTH,	O
OR	O
BIRTH	O
DEFECTS.	O
UTERINE	O
RUPTURE	O
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	O
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	O
WOMEN	O
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O
BEYOND	O
THE	O
EIGHTH	O
WEEK	O
OF	O
PREGNANCY	O
(see	O
also	O
PRECAUTIONS	O
).	O
ARTHROTEC	O
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	O
WOMEN	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS	O
and	O
PRECAUTIONS	O
).	O
PATIENTS	O
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS.	O
ARTHROTEC	O
should	O
not	O
be	O
used	O
in	O
women	O
of	O
childbearing	O
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	O
of	O
developing	O
gastric	O
or	O
duodenal	O
ulceration	O
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	O
ulcers	O
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID	O
(see	O
WARNINGS	O
).	O
In	O
such	O
patients,	O
ARTHROTEC	O
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
has	O
had	O
a	O
negative	O
serum	O
pregnancy	O
test	O
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy.	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures.	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	O
the	O
risk	O
of	O
possible	O
contraception	O
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	O
of	O
childbearing	O
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake.	O
will	O
begin	O
ARTHROTEC	O
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	O
period.	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS	O
).	O
ARTHROTEC	O
is	O
contraindicated	O
for	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
Adverse	O
reactions	O
associated	O
with	O
ARTHROTEC	O
Adverse	O
reaction	O
information	O
for	O
ARTHROTEC	O
is	O
derived	O
from	O
Phase	O
III	O
multinational	O
controlled	O
clinical	O
trials	O
in	O
over	O
2,000	O
patients	O
receiving	O
ARTHROTEC	O
50	O
or	O
ARTHROTEC	O
75,	O
as	O
well	O
as	O
from	O
blinded,	O
controlled	O
trials	O
of	O
Voltaren®	O
Delayed-Release	O
tablets	O
(diclofenac)	O
and	O
Cytotec®	O
tablets	O
(misoprostol).	O
Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
incidence	O
of	O
adverse	O
events	O
for	O
patients	O
receiving	O
ARTHROTEC.	O
These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
patients	O
on	O
ARTHROTEC	O
and	O
5%	O
of	O
patients	O
on	O
diclofenac.	O
For	O
GI	O
ulcer	O
rates,	O
see	O
CLINICAL	O
STUDIES—Upper	O
gastrointestinal	O
safety	O
.	O
GI	O
disorder	O
ARTHROTEC	O
Diclofenac	B-D004008
Abdominal	O
pain	O
21%	O
15%	O
Diarrhea	B-D003967
19%	O
11%	O
Dyspepsia	B-D004415
14%	O
11%	O
Nausea	B-D009325
11%	O
6%	O
Flatulence	B-D005414
9%	O
4%	O
ARTHROTEC	O
can	O
cause	O
more	O
abdominal	O
pain,	O
diarrhea,	O
and	O
other	O
GI	O
symptoms	O
than	O
diclofenac	O
alone.	O
Diarrhea	B-D003967
and	O
abdominal	O
pain	O
developed	O
early	O
in	O
the	O
course	O
of	O
therapy,	O
and	O
were	O
usually	O
self-limited	O
(resolved	O
after	O
2	O
to	O
7	O
days).	O
Rare	O
instances	O
of	O
profound	O
diarrhea	O
leading	O
to	O
severe	O
dehydration	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
misoprostol.	O
Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
disease,	O
or	O
those	O
in	O
whom	O
dehydration,	O
were	O
it	O
to	O
occur,	O
would	O
be	O
dangerous,	O
should	O
be	O
monitored	O
carefully	O
if	O
ARTHROTEC	O
is	O
prescribed.	O
The	O
incidence	O
of	O
diarrhea	O
can	O
be	O
minimized	O
by	O
administering	O
ARTHROTEC	O
with	O
food	O
and	O
by	O
avoiding	O
coadministration	O
with	O
magnesium-containing	O
antacids.	O
Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
misoprostol	O
use	O
have	O
also	O
been	O
reported	O
for	O
women	O
receiving	O
ARTHROTEC	O
(see	O
below).	O
Postmenopausal	O
vaginal	O
bleeding	O
may	O
be	O
related	O
to	O
administration	O
of	O
ARTHROTEC.	O
If	O
it	O
occurs,	O
diagnostic	O
workup	O
should	O
be	O
undertaken	O
to	O
rule	O
out	O
gynecological	O
pathology	O
(see	O
boxed	O
CONTRAINDICATIONS	O
AND	O
WARNINGS	O
).	O
Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
safety	O
profile	O
of	O
ARTHROTEC	O
in	O
over	O
500	O
patients	O
65	O
years	O
of	O
age	O
or	O
older	O
compared	O
with	O
younger	O
patients.	O
Other	O
adverse	O
experiences	O
reported	O
occasionally	O
or	O
rarely	O
with	O
ARTHROTEC,	O
diclofenac	O
or	O
other	O
NSAIDs,	O
or	O
misoprostol	O
are:	O
Body	O
as	O
a	O
whole:	O
Asthenia	B-D001247
,	O
death,	O
fatigue,	O
fever,	O
infection,	O
malaise,	O
sepsis,	O
chills.	O
Cardiovascular	O
system:	O
Arrhythmia,	O
atrial	O
fibrillation,	O
congestive	O
heart	O
failure,	O
hypertension,	O
hypotension,	O
increased	O
CPK,	O
increased	O
LDH,	O
myocardial	O
infarction,	O
palpitations,	O
phlebitis,	O
premature	O
ventricular	O
contractions,	O
syncope,	O
tachycardia,	O
vasculitis.	O
Central	O
and	O
peripheral	O
nervous	O
system:	O
Coma	B-D003128
,	O
convulsions,	O
dizziness,	O
drowsiness,	O
headache,	O
hyperesthesia,	O
hypertonia,	O
hypoesthesia,	O
insomnia,	O
meningitis,	O
migraine,	O
neuralgia,	O
paresthesia,	O
somnolence,	O
stroke,	O
tremor,	O
vertigo.	O
Digestive:	O
Anorexia	B-D000855
,	O
appetite	O
changes,	O
constipation,	O
dry	O
mouth,	O
dysphagia,	O
enteritis,	O
esophageal	O
ulceration,	O
esophagitis,	O
eructation,	O
gastritis,	O
gastroesophageal	O
reflux,	O
GI	O
bleeding,	O
GI	O
neoplasm	O
benign,	O
glossitis,	O
heartburn,	O
hematemesis,	O
hemorrhoids,	O
intestinal	O
perforation,	O
peptic	O
ulcer,	O
stomatitis	O
and	O
ulcerative	O
stomatitis,	O
tenesmus,	O
vomiting.	O
Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940
pain,	O
dysmenorrhea,	O
intermenstrual	O
bleeding,	O
leukorrhea,	O
menstrual	O
disorder,	O
menorrhagia,	O
vaginal	O
hemorrhage.	O
Hemic	O
and	O
lymphatic	O
system:	O
Agranulocytosis	B-D000380
,	O
anemia,	O
aplastic	O
anemia,	O
coagulation	O
time	O
increased,	O
ecchymosis,	O
eosinophilia,	O
epistaxis,	O
hemolytic	O
anemia,	O
leukocytosis,	O
leukopenia,	O
lymphadenopathy,	O
melena,	O
pancytopenia,	O
pulmonary	O
embolism,	O
purpura,	O
rectal	O
bleeding,	O
thrombocythemia,	O
thrombocytopenia.	O
Hypersensitivity	B-D006967
:	O
Angioedema	B-D000799
,	O
laryngeal/pharyngeal	O
edema,	O
urticaria.	O
Liver	B-D008099
and	O
biliary	O
system:	O
Abnormal	O
hepatic	O
function,	O
bilirubinemia,	O
hepatitis,	O
jaundice,	O
liver	O
failure,	O
pancreatitis.	O
Male	B-D008297
reproductive	O
disorders:	O
Impotence,	O
perineal	O
pain.	O
Metabolic	O
and	O
nutritional:	O
Alanine	B-D000409
aminotransferase	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
aspartate	O
aminotransferase	O
increased,	O
BUN	O
increased,	O
dehydration,	O
glycosuria,	O
gout,	O
hypercholesterolemia,	O
hyperglycemia,	O
hyperuricemia,	O
hypoglycemia,	O
hyponatremia,	O
periorbital	O
edema,	O
porphyria,	O
weight	O
changes.	O
Musculoskeletal	O
system:	O
Arthralgia	B-D018771
,	O
myalgia.	O
Psychiatric:	O
Anxiety	B-D001007
,	O
concentration	O
impaired,	O
confusion,	O
depression,	O
disorientation,	O
dream	O
abnormalities,	O
hallucinations,	O
irritability,	O
nervousness,	O
paranoia,	O
psychotic	O
reaction.	O
Respiratory	O
system:	O
Asthma	B-D001249
,	O
coughing,	O
dyspnea,	O
hyperventilation,	O
pneumonia,	O
respiratory	O
depression.	O
Skin	B-D012867
and	O
appendages:	O
Acne,	O
alopecia,	O
bruising,	O
eczema,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
pemphigoid	O
reaction,	O
photosensitivity,	O
pruritus,	O
pruritus	O
ani,	O
rash,	O
skin	O
ulceration,	O
Stevens-Johnson	O
syndrome,	O
sweating	O
increased,	O
toxic	O
epidermal	O
necrolysis.	O
Special	O
senses:	O
Hearing	B-D006309
impairment,	O
taste	O
loss,	O
taste	O
perversion,	O
tinnitus.	O
Urinary	O
system:	O
Cystitis	B-D003556
,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
micturition	O
frequency,	O
nocturia,	O
nephrotic	O
syndrome,	O
oliguria/polyuria,	O
papillary	O
necrosis,	O
proteinuria,	O
renal	O
failure,	O
urinary	O
tract	O
infection.	O
Vision:	O
Amblyopia	B-D000550
,	O
blurred	O
vision,	O
conjunctivitis,	O
diplopia,	O
glaucoma,	O
iritis,	O
lacrimation	O
abnormal,	O
night	O
blindness,	O
vision	O
abnormal.	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
·	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS).	O
·	O
Ibuprofen	B-D007052
Tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	O
tablets	O
is	O
gastrointestinal.	O
In	O
controlled	O
clinical	O
trials	O
the	O
percentage	O
of	O
patients	O
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%.	O
In	O
controlled	O
studies	O
when	O
ibuprofen	O
tablets	O
were	O
compared	O
to	O
aspirin	O
and	O
indomethacin	O
in	O
equally	O
effective	O
doses,	O
the	O
overall	O
incidence	O
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin	O
or	O
indomethacin-treated	O
patients.	O
Adverse	O
reactions	O
observed	O
during	O
controlled	O
clinical	O
trials	O
at	O
an	O
incidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table.	O
Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	O
in	O
approximately	O
3,000	O
patients.	O
More	O
than	O
500	O
of	O
these	O
patients	O
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks.	O
Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	O
clinical	O
trials	O
and	O
from	O
marketing	O
experience.	O
These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	O
tablets	O
where	O
the	O
probability	O
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	O
tablets	O
has	O
not	O
been	O
established.	O
Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	O
trials	O
of	O
patients	O
with	O
rheumatoid	O
arthritis.	O
The	O
increases	O
in	O
incidence	O
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table.	O
Incidence	B-D015994
Greater	O
than	O
1%(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea	B-D009325
*,	O
epigastric	O
pain*,	O
heartburn*,	O
diarrhea,	O
abdominal	O
distress,	O
nausea	O
and	O
vomiting,	O
indigestion,	O
constipation,	O
abdominal	O
cramps	O
or	O
pain,	O
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	O
Gastric	O
or	O
duodenal	O
ulcer	O
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	O
hemorrhage,	O
melena,	O
gastritis,	O
hepatitis,	O
jaundice,	O
abnormal	O
liver	O
function	O
tests;	O
pancreatitis	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
Dizziness	B-D004244
*,	O
headache,	O
nervousness	O
Depression	B-D003863
,	O
insomnia,	O
confusion,	O
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	O
with	O
fever	O
and	O
coma	O
(see	O
PRECAUTIONS)	O
Paresthesia	B-D010292
s,	O
hallucinations,	O
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	O
DERMATOLOGIC	O
Rash*,	O
(including	O
maculopapular	O
type),	O
pruritus	O
Vesiculobullous	O
eruptions,	O
urticaria,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome,	O
alopecia	O
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	O
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D006309
loss,	O
amblyopia	O
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	O
and	O
/or	O
changes	O
in	O
color	O
vision)	O
(see	O
PRECAUTIONS)	O
Conjunctivitis	B-D003231
,	O
diplopia,	O
optic	O
neuritis,	O
cataracts	O
HEMATOLOGIC	O
Neutropenia	B-D009503
,	O
agranulocytosis,	O
aplastic	O
anemia,	O
hemolytic	O
anemia	O
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	O
with	O
or	O
without	O
purpura,	O
eosinophilia,	O
decreases	O
in	O
hemoglobin	O
and	O
hematocrit	O
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	O
menorrhagia)	O
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	O
Gynecomastia	B-D006177
,	O
hypoglycemic	O
reaction,	O
acidosis	O
CARDIOVASCULAR	O
Edema	B-D004487
,	O
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	O
failure	O
in	O
patients	O
with	O
marginal	O
cardiac	O
function,	O
elevate	O
blood	O
pressure,	O
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	O
sinus	O
bradycardia)	O
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	O
pain,	O
fever,	O
chills,	O
nausea	O
and	O
vomiting;	O
anaphylaxis;	O
bronchospasm	O
(see	O
CONTRAINDICATIONS)	O
Serum	B-D044967
sickness,	O
lupus	O
erythematosus	O
syndrome.	O
Henoch-Schonlein	O
vasculitis,	O
angioedema	O
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	O
clearance,	O
poliuria,	O
azotemia,	O
cystitis,	O
hematuria	O
Renal	O
papillary	O
necrosis	O
MISCELLANEOUS	O
Dry	O
eyes	O
and	O
mouth,	O
gingival	O
ulcer,	O
rhinitis	O
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
ibuprofen.	O
(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked).	O
**Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related.	O
Reactions	O
are	O
classified	O
under	O
“CausalRelationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Indomethacin	B-D007213
may	O
mask	O
the	O
usual	O
signs	O
of	O
infection.	O
(5.1)	O
Monitor	O
for	O
signs	O
of	O
hepatic	O
reactions.	O
Indomethacin	B-D007213
for	O
Injection	O
may	O
need	O
to	O
be	O
discontinued.	O
(5.2)	O
Indomethacin	B-D007213
for	O
Injection	O
may	O
inhibit	O
platelet	O
aggregation.	O
(5.3)	O
Gastrointestinal	O
Effects:	O
Monitor	O
neonates	O
for	O
blood	O
in	O
stool.	O
(5.4)	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects:	O
Monitor	O
neonates	O
for	O
intraventricular	O
hemorrhage.	O
(5.5)	O
Renal	O
Effects:	O
Monitor	O
renal	O
function	O
and	O
serum	O
electrolytes.	O
(5.6)	O
5.1	O
Infection	O
Indomethacin	B-D007213
may	O
mask	O
the	O
usual	O
signs	O
and	O
symptoms	O
of	O
infection.	O
Therefore,	O
the	O
physician	O
must	O
be	O
continually	O
on	O
the	O
alert	O
for	O
this	O
and	O
should	O
use	O
the	O
drug	O
with	O
extra	O
care	O
in	O
the	O
presence	O
of	O
existing	O
controlled	O
infection.	O
5.2	O
Hepatic	O
Reactions	O
Severe	O
hepatic	O
reactions	O
have	O
been	O
reported	O
in	O
adults	O
treated	O
chronically	O
with	O
oral	O
indomethacin	O
for	O
arthritic	O
disorders.	O
[For	O
further	O
information,	O
see	O
package	O
insert	O
for	O
oral	O
indomethacin].	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop	O
in	O
the	O
neonate,	O
or	O
if	O
systemic	O
manifestations	O
occur,	O
discontinue	O
Indomethacin	B-D007213
for	O
Injection.	O
5.3	O
Platelet	B-D010974
Aggregation	I-D010974
Indomethacin	B-D007213
for	O
Injection	O
may	O
inhibit	O
platelet	O
aggregation.	O
In	O
one	O
small	O
study,	O
platelet	O
aggregation	O
was	O
grossly	O
abnormal	O
after	O
indomethacin	O
therapy	O
(given	O
orally	O
to	O
premature	O
infants	O
to	O
close	O
the	O
ductus	O
arteriosus).	O
Platelet	O
aggregation	O
returned	O
to	O
normal	O
by	O
the	O
tenth	O
day.	O
Observe	O
premature	O
infants	O
for	O
signs	O
of	O
bleeding.	O
5.4	O
Gastrointestinal	O
Effects	O
In	O
the	O
collaborative	O
study,	O
major	O
gastrointestinal	O
bleeding	O
was	O
no	O
more	O
common	O
in	O
neonates	O
receiving	O
indomethacin	O
than	O
in	O
neonates	O
on	O
placebo.	O
However,	O
minor	O
gastrointestinal	O
bleeding	O
(i.e.,	O
chemical	O
detection	O
of	O
blood	O
in	O
the	O
stool)	O
was	O
more	O
commonly	O
noted	O
in	O
neonates	O
treated	O
with	O
indomethacin.	O
Severe	O
gastrointestinal	O
effects	O
have	O
been	O
reported	O
in	O
adults	O
with	O
various	O
arthritic	O
disorders	O
treated	O
chronically	O
with	O
oral	O
indomethacin.	O
[For	O
further	O
information,	O
see	O
package	O
insert	O
for	O
oral	O
indomethacin].	O
5.5	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Prema	B-C070504
turity	O
per	O
se	O
is	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
spontaneous	O
intraventricular	O
hemorrhage.	O
Because	O
indomethacin	O
may	O
inhibit	O
platelet	O
aggregation,	O
the	O
potential	O
for	O
intraventricular	O
bleeding	O
may	O
be	O
increased.	O
However,	O
in	O
the	O
large	O
multicenter	O
study	O
of	O
Indomethacin	B-D007213
for	O
Injection,	O
the	O
incidence	O
of	O
intraventricular	O
hemorrhage	O
in	O
neonates	O
treated	O
with	O
Indomethacin	B-D007213
for	O
Injection	O
was	O
not	O
significantly	O
higher	O
than	O
in	O
the	O
control	O
neonates.	O
5.6	O
Renal	O
Effects	O
Indomethacin	B-D007213
for	O
Injection	O
may	O
cause	O
significant	O
reduction	O
in	O
urine	O
output	O
(50	O
percent	O
or	O
more)	O
with	O
concomitant	O
elevations	O
of	O
blood	O
urea	O
nitrogen	O
and	O
creatinine,	O
and	O
reductions	O
in	O
glomerular	O
filtration	O
rate	O
and	O
creatinine	O
clearance.	O
These	O
effects	O
in	O
most	O
neonates	O
are	O
transient,	O
disappearing	O
with	O
cessation	O
of	O
therapy	O
with	O
Indomethacin	B-D007213
for	O
Injection.	O
However,	O
because	O
adequate	O
renal	O
function	O
can	O
depend	O
upon	O
renal	O
prostaglandin	O
synthesis,	O
Indomethacin	B-D007213
for	O
Injection	O
may	O
precipitate	O
renal	O
insufficiency,	O
including	O
acute	O
renal	O
failure,	O
especially	O
in	O
neonates	O
with	O
other	O
conditions	O
that	O
may	O
adversely	O
affect	O
renal	O
function	O
(e.g.,	O
extracellular	O
volume	O
depletion	O
from	O
any	O
cause,	O
congestive	O
heart	O
failure,	O
sepsis,	O
concomitant	O
use	O
of	O
any	O
nephrotoxic	O
drug,	O
hepatic	O
dysfunction).	O
When	O
significant	O
suppression	O
of	O
urine	O
volume	O
occurs	O
after	O
a	O
dose	O
of	O
Indomethacin	B-D007213
for	O
Injection,	O
do	O
not	O
give	O
additional	O
doses	O
until	O
urine	O
output	O
returns	O
to	O
normal	O
levels.	O
Indomethacin	B-D007213
for	O
Injection	O
in	O
pre-term	O
infants	O
may	O
suppress	O
water	O
excretion	O
to	O
a	O
greater	O
extent	O
than	O
sodium	O
excretion.	O
When	O
this	O
occurs,	O
a	O
significant	O
reduction	O
in	O
serum	O
sodium	O
values	O
(i.e.,	O
hyponatremia)	O
may	O
result.	O
Monitor	O
renal	O
function	O
and	O
serum	O
electrolyte	O
levels	O
during	O
therapy	O
with	O
Indomethacin	B-D007213
for	O
Injection	O
[see	O
Dosage	O
and	O
Administration	O
(2)]	O
.	O
5.7	O
Administration	O
Administer	O
Indomethacin	B-D007213
for	O
Injection	O
carefully	O
to	O
avoid	O
extravascular	O
injection	O
or	O
leakage	O
as	O
the	O
solution	O
may	O
be	O
irritating	O
to	O
tissue.	O
6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
are	O
bleeding	O
problems,	O
higher	O
incidence	O
of	O
transient	O
oliguria	O
and	O
elevations	O
of	O
serum	O
creatinine.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Fresenius	O
Kabi	O
USA,	O
LLC	O
at	O
1-800-551-7176	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
In	O
a	O
double-blind,	O
placebo-controlled	O
trial	O
of	O
405	O
premature	O
infants	O
weighing	O
less	O
than	O
or	O
equal	O
to	O
1,750	O
g	O
with	O
evidence	O
of	O
large	O
ductal	O
shunting,	O
in	O
those	O
neonates	O
treated	O
with	O
indomethacin	O
(n=206),	O
there	O
was	O
a	O
statistically	O
significantly	O
greater	O
incidence	O
of	O
bleeding	O
problems,	O
including	O
gross	O
or	O
microscopic	O
bleeding	O
into	O
the	O
gastrointestinal	O
tract,	O
oozing	O
from	O
the	O
skin	O
after	O
needle	O
stick,	O
pulmonary	O
hemorrhage,	O
and	O
disseminated	O
intravascular	O
coagulopathy.	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
treatment	O
groups	O
in	O
intracranial	O
hemorrhage.	O
The	O
neonates	O
treated	O
with	O
Indomethacin	B-D007213
for	O
Injection	O
had	O
a	O
significantly	O
higher	O
incidence	O
of	O
transient	O
oliguria	O
and	O
elevations	O
of	O
serum	O
creatinine	O
(greater	O
than	O
or	O
equal	O
to	O
1.8	O
mg/dL)	O
than	O
did	O
the	O
neonates	O
treated	O
with	O
placebo.	O
The	O
incidences	O
of	O
retrolental	O
fibroplasia	O
(grades	O
III	O
and	O
IV)	O
and	O
pneumothorax	O
in	O
neonates	O
treated	O
with	O
Indomethacin	B-D007213
for	O
Injection	O
were	O
no	O
greater	O
than	O
in	O
placebo	O
controls	O
and	O
were	O
statistically	O
significantly	O
lower	O
than	O
in	O
surgically-treated	O
neonates.	O
The	O
following	O
additional	O
adverse	O
reactions	O
in	O
neonates	O
have	O
been	O
reported	O
from	O
the	O
collaborative	O
study,	O
anecdotal	O
case	O
reports,	O
from	O
other	O
studies	O
using	O
rectal,	O
oral,	O
or	O
intravenous	O
indomethacin	O
for	O
treatment	O
of	O
patent	O
ductus	O
arteriosus	O
or	O
in	O
marketed	O
use.	O
The	O
rates	O
are	O
calculated	O
from	O
a	O
database	O
that	O
contains	O
experience	O
of	O
849	O
indomethacin-treated	O
neonates	O
reported	O
in	O
the	O
medical	O
literature,	O
regardless	O
of	O
the	O
route	O
of	O
administration.	O
One	O
year	O
follow-up	O
is	O
available	O
on	O
175	O
neonates	O
and	O
shows	O
no	O
long-term	O
sequelae	O
that	O
could	O
be	O
attributed	O
to	O
indomethacin.	O
In	O
controlled	O
clinical	O
studies,	O
only	O
electrolyte	O
imbalance	O
and	O
renal	O
dysfunction	O
(of	O
the	O
reactions	O
listed	O
below)	O
occurred	O
statistically	O
significantly	O
more	O
frequently	O
after	O
Indomethacin	B-D007213
for	O
Injection	O
than	O
after	O
placebo.	O
Reactions	O
marked	O
with	O
a	O
single	O
asterisk	O
(*)	O
occurred	O
in	O
3	O
to	O
9	O
percent	O
of	O
indomethacin-treated	O
neonates;	O
those	O
marked	O
with	O
a	O
double	O
asterisk	O
(**)	O
occurred	O
in	O
3	O
to	O
9	O
percent	O
of	O
both	O
indomethacin-	O
and	O
placebo-treated	O
neonates.	O
Unmarked	O
reactions	O
occurred	O
in	O
less	O
than	O
3	O
percent	O
of	O
neonates.	O
Renal:	O
renal	O
failure,	O
renal	O
dysfunction	O
in	O
41	O
percent	O
of	O
neonates,	O
including	O
one	O
or	O
more	O
of	O
the	O
following:	O
reduced	O
urinary	O
output;	O
reduced	O
urine	O
sodium,	O
chloride,	O
or	O
potassium,	O
urine	O
osmolality,	O
free	O
water	O
clearance,	O
or	O
glomerular	O
filtration	O
rate;	O
elevated	O
serum	O
creatinine	O
or	O
BUN;	O
uremia.	O
Cardiovascular:	O
intracranial	O
bleeding**,	O
pulmonary	O
hypertension.	O
Gastrointestinal:	O
gastrointestinal	O
bleeding*,	O
vomiting,	O
abdominal	O
distention,	O
transient	O
ileus,	O
gastric	O
perforation,	O
localized	O
perforation(s)	O
of	O
the	O
small	O
and/or	O
large	O
intestine,	O
necrotizing	O
enterocolitis.	O
Metabolic:	O
hyponatremia*,	O
elevated	O
serum	O
potassium*,	O
reduction	O
in	O
blood	O
sugar,	O
including	O
hypoglycemia,	O
increased	O
weight	O
gain	O
(fluid	O
retention).	O
Coagulation:	O
decreased	O
platelet	O
aggregation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
.	O
The	O
following	O
adverse	O
reactions	O
have	O
also	O
been	O
reported	O
in	O
neonates	O
treated	O
with	O
indomethacin,	O
however,	O
a	O
causal	O
relationship	O
to	O
therapy	O
with	O
Indomethacin	B-D007213
for	O
Injection	O
has	O
not	O
been	O
established:	O
Cardiovascular:	O
bradycardia.	O
Respiratory:	O
apnea,	O
exacerbation	O
of	O
pre-existing	O
pulmonary	O
infection.	O
Metabolic:	O
acidosis/alkalosis.	O
Hematologic:	O
disseminated	O
intravascular	O
coagulation,	O
thrombocytopenia.	O
Ophthalmic:	O
retrolental	O
fibroplasia.**	O
A	O
variety	O
of	O
additional	O
adverse	O
experiences	O
have	O
been	O
reported	O
in	O
adults	O
treated	O
with	O
oral	O
indomethacin	O
for	O
moderate	O
to	O
severe	O
rheumatoid	O
arthritis,	O
osteoarthritis,	O
ankylosing	O
spondylitis,	O
acute	O
painful	O
shoulder	O
and	O
acute	O
gouty	O
arthritis	O
(see	O
package	O
insert	O
for	O
oral	O
indomethacin	O
for	O
additional	O
information	O
concerning	O
adverse	O
reactions	O
and	O
other	O
cautionary	O
statements).	O
Their	O
relevance	O
to	O
the	O
pre-term	O
infant	O
receiving	O
indomethacin	O
for	O
patent	O
ductus	O
arteriosus	O
is	O
unknown,	O
however,	O
the	O
possibility	O
exists	O
that	O
these	O
experiences	O
may	O
be	O
associated	O
with	O
the	O
use	O
of	O
Indomethacin	B-D007213
for	O
Injection	O
in	O
pre-term	O
infants.	O
BOXED	O
WARNING	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(See	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(See	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
As	O
A	O
Whole:fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
And	O
Lymphatic	B-D008208
System	I-D008208
:ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
And	O
Nutritional:weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:asthma,	O
dyspnea	O
Skin	B-D012867
And	O
Appendages:alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
As	O
A	O
Whole:anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
And	O
Lymphatic	B-D008208
System	I-D008208
:agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
And	O
Nutritional:hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
And	O
Appendages:angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
4.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
5.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4	O
,	O
5.1)	O
6.	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
1.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
2.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
1.	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
10.	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
11.	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
12.	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
13.	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
14.	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
15.	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
16.	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	O
capsules	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
17.	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,	O
8.1)	O
18.	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	O
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
for	O
the	O
celecoxib	O
capsules	O
400	O
mg	O
twice	O
daily	O
and	O
celecoxib	O
capsules	O
200	O
mg	O
twice	O
daily	O
treatment	O
arms	O
compared	O
to	O
placebo.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.7)].	O
A	O
randomized	O
controlled	O
trial	O
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs.	O
Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	O
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	O
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	O
and	O
ibuprofen.	O
Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	O
375	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	O
600	O
to	O
800	O
mg	O
three	O
times	O
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists’	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	O
(including	O
hemorrhagic	O
death),	O
non-fatal	O
myocardial	O
infarction,	O
and	O
non-fatal	O
stroke	O
[See	O
Clinical	O
Studies	O
(14.6)].	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
celecoxib	O
capsules.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	O
anticoagulants;	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.7)].	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
1.Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
2.Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
3.Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
4.Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
5.If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	O
capsules	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
6.In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib	O
capsules,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
capsules	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
capsules	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
discontinue	O
celecoxib	O
capsules	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
blood	O
pressure	O
data	O
for	O
celecoxib	O
capsules.	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
celecoxib	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
celecoxib	O
capsules	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE	O
inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
celecoxib	O
capsules	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
celecoxib	O
capsules.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
celecoxib	O
capsules	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
celecoxib	O
and	O
in	O
patients	O
with	O
aspirin	O
sensitive	O
asthma.	O
Celecoxib	B-D000068579
capsules	O
are	O
sulfonamides	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	O
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
celecoxib	O
capsules	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	O
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib	O
capsules,	O
including	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(AGEP).	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	O
capsules	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Celecoxib	B-D000068579
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
celecoxib	O
capsules	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	O
SSRIs	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2	O
,	O
5.3,	O
5.6)].	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
capsules	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation	O
with	O
use	O
of	O
celecoxib	O
capsules	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	O
and	O
their	O
caregivers	O
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
1.Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
2.GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
3.Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
4.Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
5.Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
6.Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
7.Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
8.Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
9.Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp.	O
at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CBX	O
=	O
celecoxib	O
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
%	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General:	O
Hypersensitivity	B-D006967
,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
blood	O
urea	O
nitrogen	O
(BUN)	O
increased,	O
creatine	O
phosphokinase	O
(CPK)	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia,	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia	B-D001259
,	O
suicide	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Clinical	O
Studies	O
(	O
14.7	O
)]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
aspirin	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
twice	O
daily.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Celecoxib	B-D000068579
3	O
mg/kg	O
Celecoxib	B-D000068579
6	O
mg/kg	O
Naproxen	B-D009288
7.5	O
mg/kg	O
Preferred	O
Term	O
N=77	O
N=82	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-	O
controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.7)].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
Placebo	O
N=	O
2285	O
N=	O
1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning,	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
celecoxib	O
capsules.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis	B-D014657
,	O
deep	O
venous	O
thrombosis	O
General:	O
Anaphylactoid	O
reaction,	O
angioedema	O
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	O
hepatitis,	O
jaundice,	O
hepatic	O
failure	O
Hemic	O
and	O
lymphatic:	O
Agranulocytosis	B-D000380
,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
Renal:	O
Interstitial	O
nephritis	O
ADVERSE	O
REACTIONS	O
SECTION	O
Ocular	O
Transient	O
burning	O
and	O
stinging	O
were	O
reported	O
in	O
approximately	O
15%	O
of	O
patients	O
across	O
studies	O
with	O
the	O
use	O
of	O
Voltaren	O
Ophthalmic.	O
In	O
cataract	O
surgery	O
studies,	O
keratitis	O
was	O
reported	O
in	O
up	O
to	O
28%	O
of	O
patients	O
receiving	O
Voltaren	O
Ophthalmic,	O
although	O
in	O
many	O
of	O
these	O
cases	O
keratitis	O
was	O
initially	O
noted	O
prior	O
to	O
the	O
initiation	O
of	O
treatment.	O
Elevated	O
intraocular	O
pressure	O
following	O
cataract	O
surgery	O
was	O
reported	O
in	O
approximately	O
15%	O
of	O
patients	O
undergoing	O
cataract	O
surgery.	O
Lacrimation	O
complaints	O
were	O
reported	O
in	O
approximately	O
30%	O
of	O
case	O
studies	O
undergoing	O
incisional	O
refractive	O
surgery.	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
approximately	O
10%	O
or	O
less	O
of	O
patients:	O
abnormal	O
vision,	O
acute	O
elevated	O
IOP,	O
blurred	O
vision,	O
conjunctivitis,	O
corneal	O
deposits,	O
corneal	O
edema,	O
corneal	O
opacity,	O
corneal	O
lesions,	O
discharge,	O
eyelid	O
swelling,	O
eye	O
pain,	O
injection	O
(redness),	O
iritis,	O
irritation,	O
itching,	O
lacrimation	O
disorder,	O
and	O
ocular	O
allergy.	O
Systemic	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
3%	O
or	O
less	O
of	O
patients:	O
abdominal	O
pain,	O
asthenia,	O
chills,	O
dizziness,	O
facial	O
edema,	O
fever,	O
headache,	O
insomnia,	O
nausea,	O
pain,	O
rhinitis,	O
viral	O
infection,	O
and	O
vomiting.	O
Clinical	O
Practice	O
The	O
following	O
reactions	O
have	O
been	O
identified	O
during	O
postmarketing	O
use	O
of	O
topical	O
diclofenac	O
sodium	O
ophthalmic	O
solution,	O
0.1%	O
in	O
clinical	O
practice.	O
Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size,	O
estimates	O
of	O
frequency	O
cannot	O
be	O
made.	O
The	O
reactions,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
diclofenac	O
sodium	O
ophthalmic	O
solution,	O
0.1%,	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
corneal	O
erosion,	O
corneal	O
infiltrates,	O
corneal	O
perforation,	O
corneal	O
thinning,	O
corneal	O
ulceration	O
and	O
epithelial	O
breakdown,	O
(see	O
PRECAUTIONS,	O
General).	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
Cardiovascular	O
Risk	B-D012306
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
•	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
contraindicated	O
in	O
the	O
perioperative	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)].	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Cardiovascular	O
Risk	B-D012306
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1)	O
•	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
Use	O
the	O
lowest	O
effective	O
dose	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
(5.1)	O
•NSAIDs	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation.	O
Prescribe	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
(5.2)	O
•Elevation	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
during	O
therapy	O
with	O
NSAIDs.	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen.	O
(5.3)	O
•Hypertension	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
Monitor	O
blood	O
pressure	O
closely	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
treatment.	O
(5.4)	O
•Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
(5.5)	O
•Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
at	O
greatest	O
risk	O
of	O
this	O
reaction,	O
including	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors.	O
(5.6)	O
•Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
or	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution.	O
(5.7)	O
•NSAIDs	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
(5.8)	O
•Not	O
for	O
use	O
during	O
pregnancy.	O
(5.9)	O
•Do	O
not	O
administer	O
to	O
patients	O
with	O
aspirin	O
sensitive	O
asthma	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
(5.10)	O
•Avoid	O
exposure	O
of	O
treated	O
knee(s)	O
to	O
natural	O
or	O
artificial	O
sunlight.	O
(5.11)	O
•Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
(5.12)	O
•Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs.	O
(5.13)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
oral	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
COX-2	O
selective	O
and	O
nonselective	O
orally	O
administered	O
NSAIDs,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Inform	O
patients	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
an	O
orally	O
administered	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
NSAIDs,	O
such	O
as	O
diclofenac,	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
Prescribe	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore,	O
use	O
special	O
care	O
when	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
diclofenac	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs.	O
5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
[ULN]	O
range)	O
or	O
greater	O
elevations	O
of	O
transaminases	O
occurred	O
in	O
about	O
15%	O
of	O
oral	O
diclofenac-treated	O
patients	O
in	O
clinical	O
trials	O
of	O
indications	O
other	O
than	O
acute	O
pain.	O
Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	O
injury.	O
In	O
clinical	O
trials	O
of	O
an	O
oral	O
diclofenac-misoprostol	O
combination	O
product,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
for	O
2	O
to	O
6	O
months,	O
patients	O
with	O
oral	O
diclofenac	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(>8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
this	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(>8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
oral	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
oral	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Measure	O
transaminases	O
(ALT	O
and	O
AST)	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
monitor	O
transaminases	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
immediately.	O
To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
to	O
take	O
if	O
these	O
signs	O
and	O
symptoms	O
appear.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver-related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
certain	O
antibiotics,	O
antiepileptics).	O
Caution	O
patients	O
to	O
avoid	O
taking	O
unprescribed	O
acetaminophen	O
while	O
using	O
diclofenac	O
sodium	O
topical	O
solution.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac,	O
can	O
lead	O
to	O
new	O
onset	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Use	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Monitor	O
blood	O
pressure	O
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
Patients	B-D010361
taking	O
ACE-inhibitors,	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution.	O
Use	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
considerable	O
dehydration.	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE-inhibitors,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
is	O
not	O
recommended	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
diclofenac	O
sodium	O
topical	O
solution	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
without	O
prior	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution.	O
Do	O
not	O
prescribe	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.10)].	O
Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Do	O
not	O
apply	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
open	O
skin	O
wounds,	O
infections,	O
inflammations,	O
or	O
exfoliative	O
dermatitis,	O
as	O
it	O
may	O
affect	O
absorption	O
and	O
tolerability	O
of	O
the	O
drug.	O
NSAIDs,	O
including	O
diclofenac	O
sodium	O
topical	O
solution,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations,	O
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
should	O
not	O
be	O
used	O
by	O
pregnant	O
or	O
nursing	O
women	O
or	O
those	O
intending	O
to	O
become	O
pregnant.	O
5.10	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross-reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
do	O
not	O
administer	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.11	O
Sun	O
Exposure	O
Instruct	O
patients	O
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
knee(s)	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light-induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.13	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	O
and	O
conduct	O
periodic	O
laboratory	O
evaluations.	O
5.14	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
sodium	O
topical	O
solution	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-response	O
illness.	O
For	O
patients	O
on	O
prolonged	O
corticosteroid	O
therapy,	O
taper	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Hematological	O
Effects	O
The	O
effects	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	O
subjects	O
administered	O
80	O
drops	O
four	O
times	O
a	O
day	O
for	O
7	O
days.	O
There	O
was	O
no	O
significant	O
change	O
in	O
platelet	O
aggregation	O
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)].	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
Check	O
hemoglobin	O
or	O
hematocrit	O
of	O
patients	O
on	O
diclofenac	O
sodium	O
topical	O
solution	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs	O
inhibit	O
platelet	O
aggregation	O
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
some	O
patients.	O
Unlike	O
aspirin,	O
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration	O
and	O
reversible.	O
Carefully	O
monitor	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
who	O
may	O
be	O
adversely	O
affected	O
by	O
alterations	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	O
receiving	O
anticoagulants.	O
5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms	O
in	O
patients	O
taking	O
NSAIDs,	O
monitor	O
patients	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Check	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
in	O
patients	O
on	O
long-term	O
treatment	O
with	O
NSAIDs.	O
Discontinue	O
diclofenac	O
sodium	O
topical	O
solution	O
if	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
are	O
application	O
site	O
reactions.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
the	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	O
sodium	O
topical	O
solution	O
of	O
911	O
patients	O
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	O
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	O
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	O
treated	O
for	O
at	O
least	O
12	O
months.	O
The	O
population	O
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	O
were	O
Caucasians,	O
64%	O
were	O
females,	O
and	O
all	O
patients	O
had	O
primary	O
osteoarthritis.	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies.	O
Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
Application	O
site	O
reactions	O
were	O
characterized	O
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	O
induration,	O
vesicles,	O
paresthesia,	O
pruritus,	O
vasodilation,	O
acne,	O
and	O
urticaria.	O
The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	O
(32%),	O
contact	O
dermatitis	O
characterized	O
by	O
skin	O
erythema	O
and	O
induration	O
(9%),	O
contact	O
dermatitis	O
with	O
vesicles	O
(2%)	O
and	O
pruritus	O
(4%).	O
In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	O
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac.	O
In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	O
study,	O
contact	O
dermatitis	O
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	O
with	O
vesicles	O
in	O
10%	O
of	O
patients,	O
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	O
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%.	O
Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
flatulence,	O
abdominal	O
pain,	O
edema;	O
see	O
Table	O
1	O
).	O
The	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac,	O
compared	O
to	O
oral	O
diclofenac	O
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	O
(3%	O
vs.	O
less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	O
(12%	O
vs.	O
7%),	O
urea	O
(20%	O
vs.	O
12%),	O
and	O
hemoglobin	O
(13%	O
vs.	O
9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	O
transaminases.	O
Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
osteoarthritis.	O
Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	O
trials.	O
Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
N=911	O
Topical	O
Placebo	O
N=332	O
Adverse	O
Reaction	O
Preferred	O
Term	O
according	O
to	O
COSTART	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-U.S.	O
postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	O
sodium	O
topical	O
solution.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
Whole:	O
abdominal	O
pain,	O
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	O
back	O
pain,	O
body	O
odor,	O
chest	O
pain,	O
edema,	O
face	O
edema,	O
halitosis,	O
headache,	O
lack	O
of	O
drug	O
effect,	O
neck	O
rigidity,	O
pain	O
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	O
dry	O
mouth,	O
dyspepsia,	O
gastroenteritis,	O
decreased	O
appetite,	O
mouth	O
ulceration,	O
nausea,	O
rectal	O
hemorrhage,	O
ulcerative	O
stomatitis	O
Metabolic	O
and	O
Nutritional:	O
creatinine	O
increased	O
Musculoskeletal:	O
leg	O
cramps,	O
myalgia	O
Nervous:	O
depression,	O
dizziness,	O
drowsiness,	O
lethargy,	O
paresthesia,	O
paresthesia	O
at	O
application	O
site	O
Respiratory:	O
asthma,	O
dyspnea,	O
laryngismus,	O
laryngitis,	O
pharyngitis	O
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	O
contact	O
dermatitis	O
with	O
vesicles,	O
dry	O
skin,	O
pruritus,	O
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	O
rash,	O
pruritus,	O
skin	O
discoloration,	O
urticaria	O
Special	O
Senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	O
ear	O
pain,	O
eye	O
disorder,	O
eye	O
pain,	O
taste	O
perversion	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
).	O
•Diclofenac	O
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS	O
).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS	O
)	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
•Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
•Hypertension	O
(see	O
WARNINGS	O
)	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
•Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
•Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
•Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses	O
conjunctivitis,	O
hearing	O
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Rising	O
Pharmaceuticals,	O
Inc.	O
1-866-562-4597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
5.1	O
General	O
There	O
are	O
no	O
long-term	O
evaluations	O
of	O
the	O
infants	O
treated	O
with	O
ibuprofen	O
at	O
durations	O
greater	O
than	O
the	O
36	O
weeks	O
post-conceptual	O
age	O
observation	O
period.	O
Ibuprofen	B-D007052
’s	O
effects	O
on	O
neurodevelopmental	O
outcome	O
and	O
growth	O
as	O
well	O
as	O
disease	O
processes	O
associated	O
with	O
prematurity	O
(such	O
as	O
retinopathy	O
of	O
prematurity	O
and	O
chronic	O
lung	O
disease)	O
have	O
not	O
been	O
assessed.	O
5.2	O
Infection	O
NeoProfen	O
may	O
alter	O
the	O
usual	O
signs	O
of	O
infection.	O
The	O
physician	O
must	O
be	O
continually	O
on	O
the	O
alert	O
and	O
should	O
use	O
the	O
drug	O
with	O
extra	O
care	O
in	O
the	O
presence	O
of	O
controlled	O
infection	O
and	O
in	O
infants	O
at	O
risk	O
of	O
infection.	O
5.3	O
Platelet	B-D010974
Aggregation	I-D010974
NeoProfen,	O
like	O
other	O
non-steroidal	O
anti-inflammatory	O
agents,	O
can	O
inhibit	O
platelet	O
aggregation.	O
Preterm	O
infants	O
should	O
be	O
observed	O
for	O
signs	O
of	O
bleeding.	O
Ibuprofen	B-D007052
has	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
(but	O
within	O
the	O
normal	O
range)	O
in	O
normal	O
adult	O
subjects.	O
This	O
effect	O
may	O
be	O
exaggerated	O
in	O
patients	O
with	O
underlying	O
hemostatic	O
defects	O
(see	O
CONTRAINDICATIONS).	O
5.4	O
Bilirubin	B-D001663
Displacement	O
Ibuprofen	B-D007052
has	O
been	O
shown	O
to	O
displace	O
bilirubin	O
from	O
albumin	O
binding-sites;	O
therefore,	O
it	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
elevated	O
total	O
bilirubin.	O
5.5	O
Administration	O
NeoProfen	O
should	O
be	O
administered	O
carefully	O
to	O
avoid	O
extravascular	O
injection	O
or	O
leakage,	O
as	O
solution	O
may	O
be	O
irritating	O
to	O
tissue.	O
NeoProfen	O
has	O
not	O
been	O
assessed	O
for	O
neurodevelopmental	O
outcome	O
and	O
growth	O
(5.1)	O
NeoProfen	O
may	O
alter	O
the	O
usual	O
signs	O
of	O
infection	O
(5.2)	O
NeoProfen	O
can	O
inhibit	O
platelet	O
aggregation,	O
and	O
has	O
been	O
shown	O
to	O
prolong	O
bleeding	O
time	O
in	O
normal	O
adult	O
subjects	O
(5.3)	O
Ibuprofen	B-D007052
has	O
been	O
shown	O
to	O
displace	O
bilirubin	O
from	O
albumin	O
binding-sites	O
(5.4)	O
NeoProfen	O
should	O
be	O
administered	O
carefully	O
to	O
avoid	O
extravascular	O
injection	O
or	O
leakage	O
(5.5)	O
6	O
ADVERSE	O
REACTIONS	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
The	O
most	O
frequently	O
reported	O
adverse	O
events	O
with	O
NeoProfen	O
were	O
as	O
shown	O
in	O
Table	O
1.	O
6.2	O
Renal	O
Function	O
Compared	O
to	O
placebo,	O
there	O
was	O
a	O
small	O
decrease	O
in	O
urinary	O
output	O
in	O
the	O
ibuprofen	O
group	O
on	O
days	O
2-6	O
of	O
life,	O
with	O
a	O
compensatory	O
increase	O
in	O
urine	O
output	O
on	O
day	O
9.	O
In	O
other	O
studies,	O
adverse	O
events	O
classified	O
as	O
renal	O
insufficiency	O
including	O
oliguria,	O
elevated	O
BUN,	O
elevated	O
creatinine,	O
or	O
renal	O
failure	O
were	O
reported	O
in	O
ibuprofen	O
treated	O
infants.	O
6.3	O
Additional	O
Adverse	O
Events	O
The	O
adverse	O
events	O
reported	O
in	O
the	O
multicenter	O
study	O
and	O
of	O
unknown	O
association	O
include	O
tachycardia,	O
cardiac	O
failure,	O
abdominal	O
distension,	O
gastroesophageal	O
reflux,	O
gastritis,	O
ileus,	O
inguinal	O
hernia,	O
injection	O
site	O
reactions,	O
cholestasis,	O
various	O
infections,	O
feeding	O
problems,	O
convulsions,	O
jaundice,	O
hypotension,	O
and	O
various	O
laboratory	O
abnormalities	O
including	O
neutropenia,	O
thrombocytopenia,	O
and	O
hyperglycemia.	O
6.4	O
Post-marketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
from	O
spontaneous	O
post-marketing	O
reports	O
or	O
published	O
literature:	O
gastrointestinal	O
perforation,	O
necrotizing	O
enterocolitis,	O
and	O
pulmonary	O
hypertension.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency,	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Most	O
common	O
adverse	O
reactions	O
(≥10%)	O
are	O
sepsis,	O
anemia,	O
intraventricular	O
bleeding,	O
apnea,	O
gastrointestinal	O
disorders,	O
impaired	O
renal	O
function,	O
respiratory	O
infection,	O
skin	O
lesions,	O
hypoglycemia,	O
hypocalcemia,	O
respiratory	O
failure.	O
(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Recordati	O
Rare	B-D035583
Diseases	I-D035583
at	O
1-888-575-8344,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
Table	O
1	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
].	O
•	O
Etodolac	B-D017308
tablets,	O
400	O
mg	O
and	O
500	O
mg	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
and	O
Warnings	O
].	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(See	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
capsules	O
and	O
tablets	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
capsules	O
and	O
tablets	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain1,	O
diarrhea1,	O
flatulence1,	O
nausea1,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise1,	O
dizziness1,	O
depression,	O
nervousness,	O
fatigue.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
Musculoskeletal—Arthralgia.	O
________________________________	O
1	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/	O
anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis	O
,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis	O
,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia	O
,	O
neutropenia	O
,	O
pancytopenia	O
.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura	O
,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis	O
,	O
leukocytoclastic	O
vasculitis	O
,	O
hyperpigmentation,	O
erythema	O
multiforme	O
.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.	O
Musculoskeletal—Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death	O
Cardiovascular	O
system	O
–	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis	O
Hemic	O
and	O
lymphatic	O
system	O
–	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
WARNING;	O
LIMITATIONS	O
OF	O
USE,	O
GASTROINTESTINAL,	O
BLEEDING,	O
CARDIOVASCULAR,	O
and	O
RENAL	O
RISK	O
Limitations	O
of	O
Use	O
SPRIX	O
(ketorolac	O
tromethamine),	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID),	O
is	O
indicated	O
for	O
short-term	O
(up	O
to	O
5	O
days	O
in	O
adults)	O
management	O
of	O
moderate	O
to	O
moderately	O
severe	O
pain	O
that	O
requires	O
analgesia	O
at	O
the	O
opioid	O
level.	O
Do	O
not	O
exceed	O
a	O
total	O
combined	O
duration	O
of	O
use	O
of	O
SPRIX	O
and	O
other	O
ketorolac	O
formulations	O
(IM/IV	O
or	O
oral)	O
of	O
5	O
days	O
[see	O
Dosage	O
and	O
Administration,	O
(2.1)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
SPRIX	O
is	O
not	O
indicated	O
for	O
use	O
in	O
pediatric	O
patients	O
and	O
it	O
is	O
not	O
indicated	O
for	O
minor	O
or	O
chronic	O
painful	O
conditions.	O
Gastrointestinal	O
Risk	B-D012306
Ketorolac	B-D020910
tromethamine,	O
including	O
SPRIX,	O
can	O
cause	O
peptic	O
ulcers,	O
gastrointestinal	O
bleeding	O
and/or	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Therefore,	O
SPRIX	O
is	O
contraindicated	O
in	O
patients	O
with	O
active	O
peptic	O
ulcer	O
disease,	O
in	O
patients	O
with	O
recent	O
gastrointestinal	O
bleeding	O
or	O
perforation,	O
and	O
in	O
patients	O
with	O
a	O
history	O
of	O
peptic	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Bleeding	O
Risk	B-D012306
Ketorolac	B-D020910
tromethamine	O
inhibits	O
platelet	O
function	O
and	O
is,	O
therefore,	O
contraindicated	O
in	O
patients	O
with	O
suspected	O
or	O
confirmed	O
cerebrovascular	O
bleeding,	O
patients	O
with	O
hemorrhagic	O
diathesis,	O
incomplete	O
hemostasis	O
and	O
those	O
at	O
high	O
risk	O
of	O
bleeding	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.3)].	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
[see	O
Warnings	O
and	O
Precautions	O
(5.6)].	O
SPRIX	O
Nasal	O
spray	O
is	O
contraindicated	O
for	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)].	O
Renal	O
Risk	B-D012306
SPRIX	O
is	O
contraindicated	O
in	O
patients	O
with	O
advanced	O
renal	O
impairment	O
and	O
in	O
patients	O
at	O
risk	O
for	O
renal	O
failure	O
due	O
to	O
volume	O
depletion	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.4)].	O
WARNING:	O
LIMITATIONS	O
OF	O
USE,	O
GASTROINTESTINAL,	O
BLEEDING,	O
CARDIOVASCULAR,	O
and	O
RENAL	O
RISK	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Limitations	O
of	O
Use	O
–	O
The	O
total	O
duration	O
of	O
use	O
of	O
SPRIX	O
and	O
other	O
ketorolac	O
formulations	O
should	O
not	O
exceed	O
5	O
days.	O
(2.1)	O
Gastrointestinal	O
(GI)	O
Risk	B-D012306
–	O
Ketorolac	B-D020910
can	O
cause	O
peptic	O
ulcers,	O
GI	O
bleeding,	O
and/or	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
SPRIX	O
is	O
CONTRAINDICATED	O
in	O
patients	O
with	O
peptic	O
ulcer	O
disease	O
or	O
history	O
of	O
GI	O
bleeding.	O
(4)	O
Bleeding	O
Risk	B-D012306
–	O
SPRIX	O
inhibits	O
platelet	O
function	O
and	O
is	O
CONTRAINDICATED	O
in	O
patients	O
with	O
suspected	O
or	O
confirmed	O
cerebrovascular	O
bleeding,	O
hemorrhagic	O
diathesis,	O
incomplete	O
hemostasis,	O
or	O
high	O
risk	O
of	O
bleeding.	O
(4)	O
Cardiovascular	O
(CV)	O
Risk	B-D012306
–	O
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.6)	O
SPRIX	O
is	O
CONTRAINDICATED	O
for	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4)	O
Renal	O
risk	O
–	O
SPRIX	O
is	O
CONTRAINDICATED	O
in	O
patients	O
with	O
advanced	O
renal	O
impairment	O
and	O
in	O
patients	O
at	O
risk	O
for	O
renal	O
failure	O
due	O
to	O
volume	O
depletion.	O
(4)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
SPRIX	O
should	O
not	O
be	O
used	O
concomitantly	O
with	O
IM/IV	O
or	O
oral	O
ketorolac,	O
aspirin,	O
or	O
other	O
NSAIDs.	O
(5.1)	O
Ketorolac	B-D020910
can	O
cause	O
serious	O
GI	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation.	O
SPRIX	O
should	O
be	O
prescribed	O
with	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(4,	O
5.2)	O
NSAIDs	O
affect	O
platelet	O
aggregation	O
and	O
may	O
cause	O
bleeding	O
complications.	O
SPRIX	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
who	O
have	O
coagulation	O
disorders	O
or	O
are	O
on	O
therapy	O
that	O
affects	O
hemostasis.	O
Do	O
not	O
use	O
SPRIX	O
in	O
patients	O
for	O
whom	O
hemostasis	O
is	O
critical.	O
(4,	O
5.3)	O
Ketorolac	B-D020910
can	O
cause	O
renal	O
injury.	O
SPRIX	O
should	O
not	O
be	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
or	O
patients	O
at	O
risk	O
for	O
renal	O
failure	O
due	O
to	O
volume	O
depletion,	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
diuretics	O
or	O
ACE	O
inhibitors.	O
(4,	O
5.4,	O
12.4)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
with	O
or	O
without	O
a	O
history	O
of	O
allergic	O
reactions	O
to	O
aspirin	O
or	O
NSAIDs.	O
SPRIX	O
should	O
be	O
discontinued	O
immediately	O
in	O
patients	O
with	O
allergic	O
reactions.	O
(4,	O
5.5,	O
5.7,	O
5.11)	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke	O
can	O
occur	O
with	O
NSAID	O
treatment.	O
(5.6)	O
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
patients	O
taking	O
NSAIDs.	O
SPRIX	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
cardiac	O
decompensation	O
or	O
similar	O
conditions.	O
(5.4,	O
5.6)	O
NSAIDs	O
can	O
cause	O
serious	O
dermatologic	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
and	O
toxic	O
epidermal	O
necrolysis,	O
which	O
can	O
be	O
fatal.	O
SPRIX	O
should	O
be	O
discontinued	O
immediately	O
in	O
patients	O
with	O
skin	O
reactions.	O
(4,	O
5.7)	O
During	O
pregnancy,	O
use	O
of	O
SPRIX	O
beyond	O
30	O
weeks	O
gestation	O
can	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus,	O
resulting	O
in	O
fetal	O
harm.	O
(5.8)	O
5.1	O
Limitations	O
of	O
Use	O
The	O
total	O
duration	O
of	O
use	O
of	O
SPRIX	O
alone	O
or	O
sequentially	O
with	O
other	O
forms	O
of	O
ketorolac	O
is	O
not	O
to	O
exceed	O
5	O
days.	O
SPRIX	O
must	O
not	O
be	O
used	O
concomitantly	O
with	O
other	O
forms	O
of	O
ketorolac	O
or	O
other	O
NSAIDs	O
[see	O
Dosage	O
and	O
Administration	O
(2.1)].	O
5.2	O
Gastrointestinal	O
(GI)	O
Effects	O
-	O
Risk	B-D012306
of	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
SPRIX	O
is	O
contraindicated	O
in	O
patients	O
with	O
previously	O
documented	O
peptic	O
ulcers	O
and/or	O
GI	O
bleeding	O
[see	O
Contraindications	B-D000075202
(4)].	O
Ketorolac	B-D020910
tromethamine	O
can	O
cause	O
serious	O
GI	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
ketorolac.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Minor	O
upper	O
GI	O
problems,	O
such	O
as	O
dyspepsia,	O
are	O
common	O
and	O
may	O
also	O
occur	O
at	O
any	O
time	O
during	O
NSAID	O
therapy.	O
The	O
incidence	O
and	O
severity	O
of	O
GI	O
complications	O
increases	O
with	O
increasing	O
dose	O
of,	O
and	O
duration	O
of	O
treatment	O
with,	O
ketorolac.	O
Even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
In	O
addition	O
to	O
past	O
history	O
of	O
ulcer	O
disease,	O
other	O
factors	O
that	O
increase	O
the	O
risk	O
for	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients,	O
and	O
therefore,	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
possible	O
duration.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy,	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
This	O
should	O
include	O
discontinuation	O
of	O
SPRIX	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
For	O
high	O
risk	O
patients,	O
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs.	O
Use	O
great	O
care	O
when	O
giving	O
SPRIX	O
to	O
patients	O
with	O
a	O
history	O
of	O
inflammatory	O
bowel	O
disease	O
(ulcerative	O
colitis,	O
Crohn's	O
disease)	O
as	O
their	O
condition	O
may	O
be	O
exacerbated.	O
5.3	O
Hematological	O
Effects	O
Because	O
prostaglandins	O
play	O
an	O
important	O
role	O
in	O
hemostasis	O
and	O
NSAIDs	O
affect	O
platelet	O
aggregation	O
as	O
well,	O
use	O
caution	O
with	O
use	O
of	O
ketorolac	O
tromethamine	O
in	O
patients	O
who	O
have	O
coagulation	O
disorders,	O
and	O
monitor	O
these	O
patients	O
carefully.	O
The	O
effects	O
of	O
NSAIDs	O
other	O
than	O
aspirin	O
on	O
platelet	O
function	O
are	O
reversible.	O
Patients	B-D010361
on	O
therapeutic	O
doses	O
of	O
anticoagulants	O
(e.g.,	O
heparin	O
or	O
dicumarol	O
derivatives)	O
have	O
an	O
increased	O
risk	O
of	O
bleeding	O
complications	O
if	O
given	O
ketorolac	O
tromethamine	O
concurrently;	O
therefore,	O
administer	O
such	O
concomitant	O
therapy	O
only	O
with	O
extreme	O
caution.	O
The	O
concurrent	O
use	O
of	O
ketorolac	O
tromethamine	O
and	O
therapy	O
that	O
affects	O
hemostasis,	O
including	O
prophylactic	O
low	O
dose	O
heparin	O
(2500	O
to	O
5000	O
units	O
q12h),	O
warfarin	O
and	O
dextrans,	O
has	O
not	O
been	O
studied	O
extensively,	O
but	O
may	O
also	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
bleeding.	O
Until	O
data	O
from	O
such	O
studies	O
are	O
available,	O
carefully	O
weigh	O
the	O
benefits	O
against	O
the	O
risks	O
and	O
use	O
such	O
concomitant	O
therapy	O
in	O
these	O
patients	O
only	O
with	O
extreme	O
caution.	O
Monitor	O
patients	O
receiving	O
therapy	O
that	O
affects	O
hemostasis	O
closely.	O
In	O
clinical	O
trials,	O
serious	O
adverse	O
events	O
related	O
to	O
bleeding	O
were	O
more	O
common	O
in	O
patients	O
treated	O
with	O
SPRIX	O
than	O
placebo.	O
In	O
clinical	O
trials	O
and	O
in	O
postmarketing	O
experience	O
with	O
ketorolac	O
IV	O
and	O
IM	O
dosing,	O
postoperative	O
hematomas	O
and	O
other	O
signs	O
of	O
wound	O
bleeding	O
have	O
been	O
reported	O
in	O
association	O
with	O
peri-operative	O
use.	O
Therefore,	O
use	O
SPRIX	O
with	O
caution	O
in	O
the	O
postoperative	O
setting	O
when	O
hemostasis	O
is	O
critical.	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
NSAIDs.	O
This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	O
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis.	O
Do	O
not	O
use	O
SPRIX	O
in	O
patients	O
for	O
whom	O
hemostasis	O
is	O
critical	O
[see	O
Contraindications	B-D000075202
(4),	O
Drug	B-D004347
Interactions	I-D004347
(7.1,	O
7.2,	O
7.10)].	O
5.4	O
Renal	O
Effects	O
Ketorolac	B-D020910
and	O
its	O
metabolites	O
are	O
eliminated	O
primarily	O
by	O
the	O
kidneys.	O
Patients	B-D010361
with	O
reduced	O
creatinine	O
clearance	O
will	O
have	O
diminished	O
clearance	O
of	O
the	O
drug	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)].	O
SPRIX	O
is	O
contraindicated	O
in	O
patients	O
with	O
advanced	O
renal	O
impairment	O
[see	O
Contraindications	B-D000075202
(4)].	O
In	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Decreased	O
intravascular	O
volume	O
such	O
as	O
when	O
oral	O
intake	O
is	O
poor	O
increases	O
the	O
risks	O
of	O
renal	O
toxicity	O
with	O
NSAIDs.	O
Therefore,	O
patients	O
treated	O
with	O
SPRIX	O
should	O
be	O
adequately	O
hydrated.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Use	O
SPRIX	O
with	O
caution	O
in	O
patients	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
or	O
ACE	O
inhibitors,	O
and	O
the	O
elderly.	O
Assess	O
the	O
risks	O
and	O
benefits	O
prior	O
to	O
giving	O
SPRIX	O
to	O
these	O
patients,	O
and	O
follow	O
these	O
patients	O
closely	O
during	O
SPRIX	O
therapy.	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
such	O
as	O
interstitial	O
nephritis	O
and	O
nephrotic	O
syndrome.	O
5.5	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	O
with	O
or	O
without	O
a	O
history	O
of	O
allergic	O
reactions	O
to	O
aspirin	O
or	O
NSAIDs	O
and	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
ketorolac.	O
SPRIX	O
should	O
be	O
discontinued	O
immediately	O
in	O
patients	O
with	O
allergic	O
reactions.	O
SPRIX	O
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.11)].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.6	O
Cardiovascular	O
Effects	O
Cardiovascular	O
(CV)	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events,	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
an	O
NSAID,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID	O
increases	O
the	O
risk	O
of	O
serious	O
GI	O
events.	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.2),	O
Drug	B-D004347
Interactions	I-D004347
(7.2,	O
7.3,	O
7.7)].	O
Hypertension	B-D006973
NSAIDs	O
can	O
lead	O
to	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.3)].	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention,	O
edema,	O
retention	O
of	O
NaCl,	O
oliguria,	O
and	O
elevations	O
of	O
serum	O
urea	O
nitrogen	O
and	O
creatinine	O
have	O
been	O
reported	O
in	O
clinical	O
trials	O
with	O
ketorolac.	O
Therefore,	O
only	O
use	O
SPRIX	O
very	O
cautiously	O
in	O
patients	O
with	O
cardiac	O
decompensation	O
or	O
similar	O
conditions.	O
5.7	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
ketorolac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations,	O
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.8	O
Pregnancy	B-D011247
Starting	O
at	O
30	O
weeks	O
gestation,	O
SPRIX	O
can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
due	O
to	O
an	O
increased	O
risk	O
of	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
If	O
SPRIX	O
is	O
used	O
at	O
or	O
after	O
30	O
weeks	O
gestation,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
a	O
fetus	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.9	O
Hepatic	O
Effects	O
Use	O
SPRIX	O
with	O
caution	O
in	O
patients	O
with	O
impaired	O
hepatic	O
function	O
or	O
a	O
history	O
of	O
liver	O
disease.	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver	O
tests	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
including	O
ketorolac.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
In	O
addition,	O
rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice,	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure,	O
some	O
of	O
them	O
with	O
fatal	O
outcomes,	O
have	O
been	O
reported	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4,	O
5.6),Clinical	O
Pharmacology	B-D010600
(12.4)].	O
Evaluate	O
patients	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
SPRIX.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
SPRIX.	O
5.10	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
SPRIX	O
in	O
reducing	O
inflammation	O
and	O
fever	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.11	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
do	O
not	O
administer	O
SPRIX	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity,	O
and	O
use	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.5)].	O
5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
SPRIX	O
with	O
the	O
eyes.	O
If	O
eye	O
contact	O
occurs,	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline,	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Gastrointestinal	O
effects	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hemorrhage	B-D006470
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Renal	O
effects	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Anaphylactoid	O
reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Cardiovascular	O
thrombotic	O
events	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Congestive	O
heart	O
failure	O
and	O
edema	O
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Serious	O
skin	O
reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Hepatic	O
effects	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
were	O
related	O
to	O
local	O
symptoms,	O
i.e.,	O
nas	B-C015378
al	O
discomfort	O
or	O
irritation.	O
These	O
reactions	O
were	O
generally	O
mild	O
and	O
transient	O
in	O
nature.	O
The	O
most	O
common	O
drug-related	O
adverse	O
events	O
leading	O
to	O
premature	O
discontinuation	O
were	O
nas	B-C015378
al	O
discomfort	O
or	O
nas	B-C015378
al	O
pain	O
(rhinalgia).	O
The	O
most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
2%)	O
in	O
patients	O
treated	O
with	O
SPRIX	O
and	O
occurring	O
at	O
a	O
rate	O
at	O
least	O
twice	O
that	O
of	O
placebo	O
are	O
nas	B-C015378
al	O
discomfort,	O
rhinalgia,	O
increased	O
lacrimation,	O
throat	O
irritation,	O
oliguria,	O
rash,	O
bradycardia,	O
decreased	O
urine	O
output,	O
increased	O
ALT	O
and/or	O
AST,	O
hypertension,	O
and	O
rhinitis.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
American	O
Regent,	O
Inc.	O
at	O
1-800-734-9236	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Experience	O
from	O
SPRIX	O
Clinical	O
Studies	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
SPRIX	O
in	O
patients	O
enrolled	O
in	O
placebo-controlled	O
efficacy	O
studies	O
of	O
acute	O
pain	O
following	O
major	O
surgery.	O
The	O
studies	O
enrolled	O
828	O
patients	O
(183	O
men,	O
645	O
women)	O
ranging	O
from	O
18	O
years	O
to	O
over	O
75	O
years	O
of	O
age.	O
The	O
patients	O
in	O
the	O
postoperative	O
pain	O
studies	O
had	O
undergone	O
major	O
abdominal,	O
orthopedic,	O
gynecologic,	O
or	O
other	O
surgery;	O
455	O
patients	O
received	O
SPRIX	O
(31.5	O
mg)	O
three	O
or	O
four	O
times	O
a	O
day	O
for	O
up	O
to	O
5	O
days,	O
and	O
245	O
patients	O
received	O
placebo.	O
Most	O
patients	O
were	O
receiving	O
concomitant	O
opioids,	O
primarily	O
PCA	O
morphine.	O
Table	O
1.	O
Post-operative	O
Patients	B-D010361
with	O
Adverse	O
Reactions	O
Observed	O
at	O
a	O
rate	O
of	O
2%	O
or	O
more	O
and	O
at	O
least	O
twice	O
the	O
incidence	O
of	O
the	O
placebo	O
group.	O
SPRIX	O
(N=455)	O
Placebo	O
(N=	O
245)	O
Nasal	O
discomfort	O
15%	O
2%	O
Rhinalgia	O
13%	O
<1%	O
Lacrimation	O
increased	O
5%	O
0%	O
Throat	O
irritation	O
4%	O
<1%	O
Oliguria	B-D009846
3%	O
1%	O
Rash	O
3%	O
<1%	O
Bradycardia	B-D001919
2%	O
<1%	O
Urine	B-D014556
output	O
decreased	O
2%	O
<1%	O
ALT	O
and/or	O
AST	O
increased	O
2%	O
1%	O
Hypertension	B-D006973
2%	O
1%	O
Rhinitis	B-D012220
2%	O
<1%	O
In	O
controlled	O
clinical	O
trials	O
in	O
major	O
surgery,	O
primarily	O
knee	O
and	O
hip	O
replacements	O
and	O
abdominal	O
hysterectomies,	O
seven	O
patients	O
(N=455,	O
1.5%)	O
treated	O
with	O
SPRIX	O
experienced	O
serious	O
adverse	O
events	O
of	O
bleeding	O
(4	O
patients)	O
or	O
hematoma	O
(3	O
patients)	O
at	O
the	O
operative	O
site	O
versus	O
one	O
patient	O
(N=245,	O
0.4%)	O
treated	O
with	O
placebo	O
(hematoma).	O
Six	O
of	O
the	O
seven	O
patients	O
treated	O
with	O
SPRIX	O
underwent	O
a	O
surgical	O
procedure	O
and/or	O
blood	O
transfusion	O
and	O
the	O
placebo	O
patient	O
subsequently	O
required	O
a	O
blood	O
transfusion.	O
6.2	O
Adverse	O
Reactions	O
Reported	O
in	O
Clinical	B-D016430
Trial	I-D016430
s	O
with	O
Other	O
Dosage	B-D004304
Forms	I-D004304
of	O
Ketorolac	B-D020910
or	O
Other	O
NSAIDs	O
Adverse	O
reaction	O
rates	O
increase	O
with	O
higher	O
doses	O
of	O
ketorolac.	O
It	O
is	O
necessary	O
to	O
remain	O
alert	O
for	O
the	O
severe	O
complications	O
of	O
treatment	O
with	O
ketorolac,	O
such	O
as	O
GI	O
ulceration,	O
bleeding,	O
and	O
perforation,	O
postoperative	O
bleeding,	O
acute	O
renal	O
failure,	O
anaphylactic	O
and	O
anaphylactoid	O
reactions,	O
and	O
liver	O
failure.	O
These	O
complications	O
can	O
be	O
serious	O
in	O
certain	O
patients	O
for	O
whom	O
ketorolac	O
is	O
indicated,	O
especially	O
when	O
the	O
drug	O
is	O
used	O
inappropriately.	O
In	O
patients	O
taking	O
ketorolac	O
or	O
other	O
NSAIDs	O
in	O
clinical	O
trials,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
(GI)	O
experiences	O
including:	O
*Incidence	O
greater	O
than	O
10%	O
abdominal	O
pain	O
constipation/diarrhea	O
dyspepsia	O
flatulence	O
GI	O
fullness	O
GI	O
ulcers	O
(gastric/duodenal)	O
gross	O
bleeding/perforation	O
heartburn	O
nausea*	O
stomatitis	O
vomiting	O
Other	O
experiences:	O
abnormal	O
renal	O
function	O
anemia	O
dizziness	O
drowsiness	O
edema	O
elevated	O
liver	O
enzymes	O
headache*	O
hypertension	O
increased	O
bleeding	O
time	O
injection	O
site	O
pain	O
pruritus	O
purpura	O
rash	O
tinnitus	O
sweating	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
(<1%	O
in	O
patients	O
taking	O
ketorolac	O
or	O
other	O
NSAIDs	O
in	O
clinical	O
trials)	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
palpitation,	O
pallor,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
anorexia,	O
dry	O
mouth,	O
eructation,	O
esophagitis,	O
excessive	O
thirst,	O
gastritis,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
increased	O
appetite,	O
jaundice,	O
melena,	O
rectal	O
bleeding	O
Hemic	O
and	O
Lymph	B-D008196
atic:	O
ecchymosis,	O
eosinophilia,	O
epistaxis,	O
leukopenia,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
change	O
Nervous	B-D009420
System	I-D009420
:	O
abnormal	O
dreams,	O
abnormal	O
thinking,	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
euphoria,	O
extrapyramidal	O
symptoms,	O
hallucinations,	O
hyperkinesis,	O
inability	O
to	O
concentrate,	O
insomnia,	O
nervousness,	O
paresthesia,	O
somnolence,	O
stupor,	O
tremors,	O
vertigo,	O
malaise	O
Respiratory:	O
asthma,	O
dyspnea,	O
pulmonary	O
edema,	O
rhinitis	O
Special	O
Senses:	O
abnormal	O
taste,	O
abnormal	O
vision,	O
blurred	O
vision,	O
hearing	O
loss	O
Urogenital:	O
cystitis,	O
dysuria,	O
hematuria,	O
increased	O
urinary	O
frequency,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure,	O
urinary	O
retention	O
6.3	O
Adverse	O
Reactions	O
from	O
Postmarketing	O
Experience	O
with	O
Other	O
Dosage	B-D004304
Forms	I-D004304
of	O
Ketorolac	B-D020910
or	O
Other	O
NSAIDs	O
Other	O
observed	O
reactions	O
(reported	O
from	O
postmarketing	O
experience	O
in	O
patients	O
taking	O
ketorolac	O
or	O
other	O
NSAIDs)	O
are:	O
Body	O
as	O
a	O
Whole:	O
angioedema,	O
death,	O
hypersensitivity	O
reactions	O
such	O
as	O
anaphylaxis,	O
anaphylactoid	O
reaction,	O
laryngeal	O
edema,	O
tongue	O
edema,	O
myalgia	O
Cardiovascular:	O
arrhythmia,	O
bradycardia,	O
chest	O
pain,	O
flushing,	O
hypotension,	O
myocardial	O
infarction,	O
vasculitis	O
Dermatologic:	O
exfoliative	O
dermatitis,	O
erythema	O
multiforme,	O
Lye	B-D008191
ll's	O
syndrome,	O
bullous	O
reactions	O
including	O
Stevens-Johnson	O
syndrome	O
and	O
toxic	O
epidermal	O
necrolysis	O
Gastrointestinal:	O
acute	O
pancreatitis,	O
liver	O
failure,	O
ulcerative	O
stomatitis,	O
exacerbation	O
of	O
inflammatory	O
bowel	O
disease	O
(ulcerative	O
colitis,	O
Crohn's	O
disease)	O
Hemic	O
and	O
Lymph	B-D008196
atic:	O
agranulocytosis,	O
aplastic	O
anemia,	O
hemolytic	O
anemia,	O
lymphadenopathy,	O
pancytopenia,	O
postoperative	O
wound	O
hemorrhage	O
(rarely	O
requiring	O
blood	O
transfusion)	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia,	O
hyperkalemia,	O
hyponatremia	O
Nervous	B-D009420
System	I-D009420
:	O
aseptic	O
meningitis,	O
convulsions,	O
coma,	O
psychosis	O
Respiratory:	O
bronchospasm,	O
respiratory	O
depression,	O
pneumonia	O
Special	O
Senses:	O
conjunctivitis	O
Urogenital:	O
flank	O
pain	O
with	O
or	O
without	O
hematuria	O
and/or	O
azotemia,	O
hemolytic	O
uremic	O
syndrome	O
ADVERSE	O
REACTIONS	O
Transient	O
burning	O
and	O
stinging	O
upon	O
instillation	O
and	O
other	O
minor	O
symptoms	O
of	O
ocular	O
irritation	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
Flurbiprofen	B-D005480
Sodium	B-D012964
Ophthalmic	O
Solution.	O
Other	O
adverse	O
reactions	O
reported	O
with	O
the	O
use	O
of	O
Flurbiprofen	B-D005480
Sodium	B-D012964
Ophthalmic	O
Solution	O
include:	O
fibrosis,	O
hyphema,	O
miosis,	O
mydriasis,	O
and	O
ocular	O
hyperemia.	O
Increased	O
bleeding	O
tendency	O
of	O
ocular	O
tissues	O
in	O
conjunction	O
with	O
ocular	O
surgery	O
has	O
also	O
been	O
reported	O
(see	O
Warnings).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Bausch	O
+	O
Lomb,	O
a	O
division	O
of	O
Valeant	O
Pharmaceuticals	O
North	B-D009656
America	I-D009656
LLC,	O
at	O
1-800-321-4576	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
Cardiovascular	O
Risk	B-D012306
•	O
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS).	O
•	O
Diclofenac	B-D004008
potassium	O
immediate-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(See	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
718	O
patients	O
treated	O
for	O
shorter	O
periods,	O
i.e.,	O
2	O
weeks	O
or	O
less,	O
with	O
diclofenac	O
potassium	O
immediate-release	O
tablets,	O
adverse	O
reactions	O
were	O
reported	O
one-half	O
to	O
one-tenth	O
as	O
frequently	O
as	O
by	O
patients	O
treated	O
for	O
longer	O
periods.	O
In	O
a	O
6-month,	O
double-blind	O
trial	O
comparing	O
diclofenac	O
potassium	O
immediate-release	O
tablets	O
(N=196)	O
versus	O
diclofenac	O
sodium	O
delayed-release	O
tablets	O
(N=197)	O
versus	O
ibuprofen	O
(N=197),	O
adverse	O
reactions	O
were	O
similar	O
in	O
nature	O
and	O
frequency.	O
In	O
patients	O
taking	O
diclofenac	O
potassium	O
immediate-release	O
tablets	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)].	O
Diclofenac	B-D004008
sodium	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	O
(4)	O
and	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Events	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
Diclofenac	B-D004008
sodium	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity	O
:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity	O
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
diclofenac	O
sodium	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions	O
:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
:	O
Diclofenac	B-D004008
sodium	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions	O
:	O
Discontinue	O
diclofenac	O
sodium	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity	O
:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
Exposure	O
to	O
light	O
:	O
Avoid	O
exposure	O
of	O
treated	O
knee(s)	O
to	O
natural	O
or	O
artificial	O
sunlight.	O
(5.14)	O
Eye	B-D005123
Contact	O
:	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
with	O
eyes	O
and	O
mucosa.	O
(5.15)	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs	O
:	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs.	O
(5.16)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NASAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
CONTRAINDICATIONS	O
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
diclofenac	O
sodium	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	O
sodium	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials,	O
of	O
oral	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
for	O
2	O
to	O
6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
diclofenac	O
sodium	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
diclofenac	O
sodium	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver-related	O
event	O
in	O
patients	O
treated	O
with	O
diclofenac	O
sodium,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	O
sodium	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
antibiotics,	O
antiepileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac	O
sodium,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension,	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
diclofenac	O
sodium	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	O
sodium	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
diclofenac	O
sodium	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
diclofenac	O
sodium.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
diclofenac	O
sodium	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
Avoid	O
the	O
use	O
of	O
diclofenac	O
sodium	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
diclofenac	O
sodium	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
CONTRAINDICATIONS	O
(4)	O
and	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
diclofenac	O
sodium	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
CONTRAINDICATIONS	O
(4)].	O
When	O
diclofenac	O
sodium	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	O
sodium	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Diclofenac	B-D004008
sodium	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
CONTRAINDICATIONS	O
(4)].	O
Do	O
not	O
apply	O
diclofenac	O
sodium	O
topical	O
solution	O
to	O
open	O
skin	O
wounds,	O
infections,	O
inflammations,	O
or	O
exfoliative	O
dermatitis,	O
as	O
it	O
may	O
affect	O
absorption	O
and	O
tolerability	O
of	O
the	O
drug.	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
diclofenac	O
sodium,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
USE	O
IN	O
SPECIFIC	O
POPULATIONS	O
(8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
diclofenac	O
sodium	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
diclofenac	O
sodium,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
DRUG	O
INTERACTIONS	O
(7)].	O
The	O
effects	O
of	O
diclofenac	O
sodium	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	O
subjects	O
administered	O
80	O
drops	O
four	O
times	O
a	O
day	O
for	O
7	O
days.	O
There	O
was	O
no	O
significant	O
change	O
in	O
platelet	O
aggregation	O
following	O
one	O
week	O
of	O
treatment	O
[see	O
CLINICAL	O
PHARMACOLOGY	O
(12.4)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	O
sodium	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2,	O
5.3,	O
5.6)].	O
5.14	O
Sun	O
Exposure	O
Instruct	O
patients	O
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
knee(s)	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light-induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
diclofenac	O
sodium	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	O
sodium	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	O
sodium	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	O
sodium	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	O
and	O
conduct	O
periodic	O
laboratory	O
evaluations.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)]	O
Hepatotoxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.3)]	O
Hypertension	B-D006973
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(	O
)	O
with	O
diclofenac	O
sodium	O
topical	O
solution	O
are	O
application	O
site	O
reactions.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Lupin	O
Pharmaceuticals	O
Inc.	O
at	O
1-800-399-2561	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	O
sodium	O
of	O
911	O
patients	O
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	O
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	O
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	O
treated	O
for	O
at	O
least	O
12	O
months.	O
The	O
population	O
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	O
were	O
Caucasians,	O
64%	O
were	O
females,	O
and	O
all	O
patients	O
had	O
primary	O
osteoarthritis.	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	O
sodium	O
were	O
application	O
site	O
skin	O
reactions.	O
These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies.	O
Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution	O
were	O
application	O
site	O
skin	O
reactions.	O
Application	O
site	O
reactions	O
were	O
characterized	O
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	O
induration,	O
vesicles,	O
paresthesia,	O
pruritus,	O
vasodilation,	O
acne,	O
and	O
urticaria.	O
The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	O
(32%),	O
contact	O
dermatitis	O
characterized	O
by	O
skin	O
erythema	O
and	O
induration	O
(9%),	O
contact	O
dermatitis	O
with	O
vesicles	O
(2%)	O
and	O
pruritus	O
(4%).	O
In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	O
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac.	O
In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	O
study,	O
contact	O
dermatitis	O
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	O
with	O
vesicles	O
in	O
10%	O
of	O
patients,	O
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	O
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%.	O
Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	O
sodium	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
flatulence,	O
abdominal	O
pain,	O
edema;	O
see	O
Table	O
1).	O
The	O
combination	O
of	O
diclofenac	O
sodium	O
topical	O
solution	O
and	O
oral	O
diclofenac,	O
compared	O
to	O
oral	O
diclofenac	O
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	O
(3%	O
vs.	O
less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	O
(12%	O
vs.	O
7%),	O
urea	O
(20%	O
vs.	O
12%),	O
and	O
hemoglobin	O
(13%	O
vs.	O
9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	O
transaminases.	O
Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
receiving	O
diclofenac	O
sodium	O
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	O
sodium	O
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
osteoarthritis.	O
Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution,	O
1.5%	O
w/w	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	O
trials.	O
Treatment	O
Group	O
:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
,	O
1	O
.	O
5	O
%	O
w	O
/	O
w	O
Topical	O
Placebo	O
N	O
=	O
911	O
N	O
=	O
332	O
Adverse	O
Reaction	O
Preferred	O
Term	O
according	O
to	O
COSTART	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-U.S.	O
postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	O
sodium.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
Whole	O
Abdominal	O
pain,	O
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	O
back	O
pain,	O
body	O
odor,	O
chest	O
pain,	O
edema,	O
face	O
edema,	O
halitosis,	O
headache,	O
lack	O
of	O
drug	O
effect,	O
neck	O
rigidity,	O
pain	O
Cardiovascular	O
Palpitation,	O
cardiovascular	O
disorder	O
Digestive	O
Diarrhea	B-D003967
,	O
dry	O
mouth,	O
dyspepsia,	O
gastroenteritis,	O
decreased	O
appetite,	O
mouth	O
ulceration,	O
nausea,	O
rectal	O
hemorrhage,	O
ulcerative	O
stomatitis	O
Metabolic	O
and	O
Nutritional	O
Creatinine	B-D003404
increased	O
Musculoskeletal	O
Leg	B-D007866
cramps,	O
myalgia	O
Nervous	O
Depression	B-D003863
,	O
dizziness,	O
drowsiness,	O
lethargy,	O
paresthesia,	O
paresthesia	O
at	O
application	O
site	O
Respiratory	O
Asthma	B-D001249
,	O
dyspnea,	O
laryngismus,	O
laryngitis,	O
pharyngitis	O
Skin	B-D012867
and	O
Appendages	O
At	O
the	O
Application	O
Site:	O
Contact	O
dermatitis,	O
contact	O
dermatitis	O
with	O
vesicles,	O
dry	O
skin,	O
pruritus,	O
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
Eczema	B-D004485
,	O
rash,	O
pruritus,	O
skin	O
discoloration,	O
urticaria	O
Special	O
Senses	O
Abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	O
ear	O
pain,	O
eye	O
disorder,	O
eye	O
pain,	O
taste	O
perversion	O
ADVERSE	O
REACTIONS	O
Transient	O
burning	O
and	O
stinging	O
upon	O
instillation	O
and	O
other	O
minor	O
symptoms	O
of	O
ocular	O
irritation	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
flurbiprofen	O
sodium	O
ophthalmic	O
solution.	O
Other	O
adverse	O
reactions	O
reported	O
with	O
the	O
use	O
of	O
flurbiprofen	O
sodium	O
ophthalmic	O
solution	O
include:	O
fibrosis,	O
miosis,	O
and	O
mydriasis.	O
Increased	O
bleeding	O
tendency	O
of	O
ocular	O
tissues	O
in	O
conjunction	O
with	O
ocular	O
surgery	O
has	O
also	O
been	O
reported.	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Delayed	O
healing	O
(5.1)	O
Cross-sensitivity	O
or	O
hypersensitivity	O
(5.2)	O
Increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
thrombocyte	O
aggregation	O
(5.3)	O
Cornea	B-D003315
l	O
effects	O
including	O
keratitis	O
(5.4)	O
5.1	O
Delayed	O
Healing	O
Topical	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
slow	O
or	O
delay	O
healing.	O
Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing.	O
Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
steroids	O
may	O
increase	O
the	O
potential	O
for	O
healing	O
problems.	O
5.2	O
Cross-Sensitivity	O
or	O
Hypersensitivity	B-D006967
There	O
is	O
the	O
potential	O
for	O
cross-sensitivity	O
to	O
acetylsalicylic	O
acid,	O
phenylacetic	B-C025136
acid	I-C025136
derivatives,	O
and	O
other	O
NSAIDs.	O
There	O
have	O
been	O
reports	O
of	O
bronchospasm	O
or	O
exacerbation	O
of	O
asthma	O
associated	O
with	O
the	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solution	O
in	O
patients	O
who	O
have	O
either	O
a	O
known	O
hypersensitivity	O
to	O
aspirin/non-steroidal	O
anti-inflammatory	O
drugs	O
or	O
a	O
past	O
medical	O
history	O
of	O
asthma.	O
Therefore,	O
caution	O
should	O
be	O
used	O
when	O
treating	O
individuals	O
who	O
have	O
previously	O
exhibited	O
sensitivities	O
to	O
these	O
drugs.	O
5.3	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
With	O
some	O
NSAIDs,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
bleeding	O
time	O
due	O
to	O
interference	O
with	O
thrombocyte	O
aggregation.	O
There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
tissues	O
(including	O
hyphemas)	O
in	O
conjunction	O
with	O
ocular	O
surgery.	O
It	O
is	O
recommended	O
that	O
ACULAR	O
LS	O
®	O
ophthalmic	O
solution	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
known	O
bleeding	O
tendencies	O
or	O
who	O
are	O
receiving	O
other	O
medications,	O
which	O
may	O
prolong	O
bleeding	O
time.	O
5.4	O
Cornea	B-D003315
l	O
Effects	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
keratitis.	O
In	O
some	O
susceptible	O
patients,	O
continued	O
use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
epithelial	O
breakdown,	O
corneal	O
thinning,	O
corneal	O
erosion,	O
corneal	O
ulceration,	O
or	O
corneal	O
perforation.	O
These	O
events	O
may	O
be	O
sight	O
threatening.	O
Patients	B-D010361
with	O
evidence	O
of	O
corneal	O
epithelial	O
breakdown	O
should	O
immediately	O
discontinue	O
use	O
of	O
topical	O
NSAIDs	O
and	O
should	O
be	O
closely	O
monitored	O
for	O
corneal	O
health.	O
Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
patients	O
with	O
complicated	O
ocular	O
surgeries,	O
corneal	O
denervation,	O
corneal	O
epithelial	O
defects,	O
diabetes	O
mellitus,	O
ocular	O
surface	O
diseases	O
(e.g.,	O
dry	O
eye	O
syndrome),	O
rheumatoid	O
arthritis,	O
or	O
repeat	O
ocular	O
surgeries	O
within	O
a	O
short	O
period	O
of	O
time	O
may	O
be	O
at	O
increased	O
risk	O
for	O
corneal	O
adverse	O
events	O
which	O
may	O
become	O
sight	O
threatening.	O
Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients.	O
Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
1	O
day	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
post-surgery	O
may	O
increase	O
patient	O
risk	O
for	O
the	O
occurrence	O
and	O
severity	O
of	O
corneal	O
adverse	O
events.	O
5.5	O
Contact	O
Lens	O
Wear	O
ACULAR	O
LS	O
®	O
should	O
not	O
be	O
administered	O
while	O
wearing	O
contact	O
lenses.	O
6	O
A	O
DVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
elsewhere	O
in	O
the	O
labeling:	O
Delayed	O
Healing	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Cross-Sensitivity	O
or	O
Hypersensitivity	B-D006967
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Cornea	B-D003315
l	O
Effects[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
The	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
1	O
-	O
5%	O
of	O
patients	O
included	O
conjunctival	O
hyperemia,	O
corneal	O
infiltrates,	O
headache,	O
ocular	O
edema	O
and	O
ocular	O
pain.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Allergan	O
at	O
1-800-433-8871	O
or	O
the	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
for	O
ACULAR	O
LS	O
®	O
ophthalmic	O
solution	O
occurring	O
in	O
approximately	O
1	O
to	O
5%	O
of	O
the	O
overall	O
study	O
population	O
were	O
conjunctival	O
hyperemia,	O
corneal	O
infiltrates,	O
headache,	O
ocular	O
edema,	O
and	O
ocular	O
pain.	O
The	O
most	O
frequent	O
adverse	O
reactions	O
reported	O
with	O
the	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
have	O
been	O
transient	O
stinging	O
and	O
burning	O
on	O
instillation.	O
These	O
reactions	O
were	O
reported	O
by	O
up	O
to	O
40%	O
of	O
patients	O
participating	O
in	O
clinical	O
trials.	O
Other	O
adverse	O
reactions	O
occurring	O
approximately	O
in	O
1	O
to	O
10%	O
of	O
the	O
time	O
during	O
treatment	O
with	O
other	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
included	O
allergic	O
reactions,	O
corneal	O
edema,	O
iritis,	O
ocular	O
inflammation,	O
ocular	O
irritation,	O
superficial	O
keratitis,	O
and	O
superficial	O
ocular	O
infections.	O
Other	O
adverse	O
reactions	O
reported	O
rarely	O
with	O
the	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
included:	O
corneal	O
ulcer,	O
eye	O
dryness,	O
and	O
visual	O
disturbance	O
(blurry	O
vision).	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postmarketing	O
use	O
of	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
in	O
clinical	O
practice.	O
Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size,	O
estimates	O
of	O
frequency	O
cannot	O
be	O
made.	O
The	O
reactions,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
ketorolac	O
tromethamine	O
ophthalmic	O
solutions	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
bronchospasm	O
or	O
exacerbation	O
of	O
asthma,	O
corneal	O
erosion,	O
corneal	O
perforation,	O
corneal	O
thinning	O
and	O
corneal	O
melt,	O
and	O
epithelial	O
breakdown	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
,	O
5.4	O
)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
4.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
5.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4	O
,	O
5.1)	O
6.	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
1.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
2.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
1.	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
10.	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
11.	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
12.	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
13.	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
14.	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
15.	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
16.	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	O
capsules	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
17.	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,	O
8.1)	O
18.	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	O
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
for	O
the	O
celecoxib	O
capsules	O
400	O
mg	O
twice	O
daily	O
and	O
celecoxib	O
capsules	O
200	O
mg	O
twice	O
daily	O
treatment	O
arms	O
compared	O
to	O
placebo.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.7)].	O
A	O
randomized	O
controlled	O
trial	O
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs.	O
Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	O
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	O
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	O
and	O
ibuprofen.	O
Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	O
375	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	O
600	O
to	O
800	O
mg	O
three	O
times	O
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists’	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	O
(including	O
hemorrhagic	O
death),	O
non-fatal	O
myocardial	O
infarction,	O
and	O
non-fatal	O
stroke	O
[See	O
Clinical	O
Studies	O
(14.6)].	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
celecoxib	O
capsules.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	O
anticoagulants;	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.7)].	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
1.Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
2.Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
3.Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
4.Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
5.If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	O
capsules	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
6.In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib	O
capsules,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
capsules	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
capsules	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash),	O
discontinue	O
celecoxib	O
capsules	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
blood	O
pressure	O
data	O
for	O
celecoxib	O
capsules.	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
celecoxib	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
celecoxib	O
capsules	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE	O
inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
celecoxib	O
capsules	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
celecoxib	O
capsules.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
celecoxib	O
capsules	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
capsules	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
celecoxib	O
capsules	O
are	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
celecoxib	O
and	O
in	O
patients	O
with	O
aspirin	O
sensitive	O
asthma.	O
Celecoxib	B-D000068579
capsules	O
are	O
sulfonamides	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	O
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
celecoxib	O
capsules	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	O
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib	O
capsules,	O
including	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(AGEP).	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	O
capsules	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Celecoxib	B-D000068579
capsules	O
are	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
celecoxib	O
capsules	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs,	O
including	O
celecoxib	O
capsules,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	O
SSRIs	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2	O
,	O
5.3,	O
5.6)].	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
capsules	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation	O
with	O
use	O
of	O
celecoxib	O
capsules	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	O
and	O
their	O
caregivers	O
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
1.Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
2.GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
3.Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
4.Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
5.Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
6.Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
7.Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
8.Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
9.Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp.	O
at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CBX	O
=	O
celecoxib	O
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
%	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General:	O
Hypersensitivity	B-D006967
,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
blood	O
urea	O
nitrogen	O
(BUN)	O
increased,	O
creatine	O
phosphokinase	O
(CPK)	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia,	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia	B-D001259
,	O
suicide	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Clinical	O
Studies	O
(	O
14.7	O
)]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
aspirin	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
twice	O
daily.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Celecoxib	B-D000068579
3	O
mg/kg	O
Celecoxib	B-D000068579
6	O
mg/kg	O
Naproxen	B-D009288
7.5	O
mg/kg	O
Preferred	O
Term	O
N=77	O
N=82	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-	O
controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.7)].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
Placebo	O
N=	O
2285	O
N=	O
1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning,	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
celecoxib	O
capsules.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis	B-D014657
,	O
deep	O
venous	O
thrombosis	O
General:	O
Anaphylactoid	O
reaction,	O
angioedema	O
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	O
hepatitis,	O
jaundice,	O
hepatic	O
failure	O
Hemic	O
and	O
lymphatic:	O
Agranulocytosis	B-D000380
,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
Renal:	O
Interstitial	O
nephritis	O
Cardiovascular	O
Thrombotic	O
Events	O
•Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS	O
).	O
•Etodolac	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	O
and	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse	O
reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
post-marketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
mg	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
mg/day	O
to	O
1000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
Whole:	O
Chills	B-D023341
and	O
fever.	O
Digestive	B-D004064
System	I-D004064
:	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain1,	O
diarrhea2,	O
flatulence3,	O
nausea4,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	B-D009420
System	I-D009420
:	O
Asthenia	B-D001247
/malaise5,	O
dizziness6,	O
depression,	O
nervousness,	O
fatigue.	O
Skin	B-D012867
and	O
Appendages:	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
Senses:	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	B-D014566
System	I-D014566
:	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
Musculoskeletal:	O
Arthralgia	B-D018771
1Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
2Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
3Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
4Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
5Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
6Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
post-marketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
Whole:	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	B-D002319
System	I-D002319
:	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	B-D004064
System	I-D004064
:	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
Nutritional:	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	B-D009420
System	I-D009420
:	O
Insomnia,	O
somnolence.	O
Respiratory	B-D012137
System	I-D012137
:	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
Appendages:	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
leukocytoclastic	O
vasculitis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
Senses:	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	B-D014566
System	I-D014566
:	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
Whole:	O
Infection,	O
headache.	O
Cardiovascular	B-D002319
System	I-D002319
:	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	B-D004064
System	I-D004064
:	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.	O
Metabolic	O
and	O
Nutritional:	O
Change	O
in	O
weight.	O
Nervous	B-D009420
System	I-D009420
:	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.	O
Respiratory	B-D012137
System	I-D012137
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
Appendages:	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
Senses:	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.	O
Urogenital	B-D014566
System	I-D014566
:	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.	O
Musculoskeletal:	O
Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
Whole:	O
Sepsis	B-D018805
,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
Tachycardia	B-D013610
Digestive	B-D004064
System	I-D004064
:	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
Lymphadenopathy	B-D000072281
Nervous	B-D009420
System	I-D009420
:	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
Respiratory	O
depression,	O
pneumonia	O
Urogenital	B-D014566
System	I-D014566
:	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(5.4)	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.4)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(5.1,	O
14.6,	O
17.2).	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
(5.4,	O
8.5,	O
14.6,	O
17.3).	O
Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
celecoxib	O
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen	O
(5.5,	O
17.4).	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
celecoxib	O
(5.2,	O
7.4,	O
17.2).	O
Fluid	O
retention	O
and	O
edema.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure	O
(5.3,	O
17.6).	O
Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
celecoxib	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6).	O
Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
celecoxib	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(5.7,	O
10,	O
17.7).	O
Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions	O
(5.8,	O
17.5).	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
celecoxib,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
celecoxib	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
celecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
active	O
GI	O
bleeding.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
celecoxib	O
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
celecoxib	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
celecoxib.	O
In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
celecoxib.	O
Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
celecoxib	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Lupin	O
Pharmaceuticals,	O
Inc.	O
at	O
1-800-399-2561	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General	O
:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional	O
:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia,	O
Psychiatric	O
:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders	O
:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary	O
:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular	O
:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal	O
:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic	O
:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous	O
:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
drug	O
rash	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS,	O
or	O
hypersensitivity	O
syndrome)	O
General	O
:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events	O
:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kgN=77	O
Celecoxib	B-D000068579
6	O
mg/kgN=82	O
Naproxen	B-D009288
7.5	O
mg/kgN=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
InvestigationsAbnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials	O
,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)N	O
=	O
2285	O
PlaceboN=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders	O
:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth	O
:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders	O
:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders	O
:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
Cardiovascular	O
Risk	B-D012306
•NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS	O
).	O
•Etodolac	O
capsules	O
USP,	O
200	O
mg	O
and	O
300	O
mg,	O
and	O
Etodolac	B-D017308
tablets	O
USP,	O
400	O
mg	O
and	O
500	O
mg	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(See	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
capsules	O
and	O
tablets,	O
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
capsules	O
and	O
tablets	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
painDrug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.,	O
diarrhea,	O
flatulence,	O
nausea,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise,	O
dizziness,	O
depression,	O
nervousness,	O
fatigue.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
Musculoskeletal—Arthralgia.	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
leukocytoclastic	O
vasculitis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.	O
Musculoskeletal—Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death	O
Cardiovascular	O
system	O
-	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(5.1)	O
ZORVOLEX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
ZORVOLEX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
ZORVOLEX	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
ZORVOLEX	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
ZORVOLEX	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
ZORVOLEX	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
ZORVOLEX	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
ZORVOLEX	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
ZORVOLEX	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials	O
of	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
sodium	O
for	O
2-6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
patients	O
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3-8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
then	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
ZORVOLEX,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
ZORVOLEX	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
ZORVOLEX	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver	O
related	O
event	O
in	O
patients	O
treated	O
with	O
ZORVOLEX,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
ZORVOLEX	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
antibiotics,	O
and	O
anti-epileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
ZORVOLEX,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
ZORVOLEX	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
ZORVOLEX	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
ZORVOLEX	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
ZORVOLEX	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
ZORVOLEX.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
ZORVOLEX	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
ZORVOLEX	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
ZORVOLEX	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
ZORVOLEX	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
ZORVOLEX	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
ZORVOLEX	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
ZORVOLEX	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
ZORVOLEX,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
ZORVOLEX	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
ZORVOLEX,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions,	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
ZORVOLEX	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
].	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥2%)	O
are	O
edema,	O
nausea,	O
headache,	O
dizziness,	O
vomiting,	O
constipation,	O
pruritus,	O
diarrhea,	O
flatulence,	O
pain	O
in	O
extremity,	O
abdominal	O
pain,	O
sinusitis,	O
alanine	O
aminotransferase	O
increased,	O
blood	O
creatinine	O
increased,	O
hypertension,	O
and	O
dyspepsia.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Iroko	O
Pharmaceuticals,	O
LLC	O
at	O
1-877-757-0676	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice.	O
Adverse	O
Reactions	O
in	O
Patients	B-D010361
with	O
Acute	B-D059787
Pain	I-D059787
Two-hundred	O
sixteen	O
(216)	O
patients	O
received	O
ZORVOLEX	O
in	O
the	O
completed,	O
48-hour,	O
double-blind,	O
placebo-controlled,	O
clinical	O
trial	O
of	O
acute	O
pain	O
following	O
bunionectomy.	O
The	O
most	O
frequent	O
adverse	O
reactions	O
in	O
this	O
study	O
are	O
summarized	O
in	O
Table	O
1.	O
Table	O
1	O
Summary	O
of	O
Adverse	O
Reactions	O
(≥2%	O
in	O
ZORVOLEX	O
18	O
mg	O
or	O
35	O
mg	O
group)	O
–	O
Phase	O
3	O
Study	O
in	O
Patients	B-D010361
With	O
Postsurgical	O
Pain	B-D010146
Adverse	O
Reactions	O
ZORVOLEX	O
18	O
mg	O
or	O
35	O
mg	O
three	O
times	O
dailyOne	O
tablet	O
of	O
hydrocodone/acetaminophen	O
10	O
mg/325	O
mg	O
was	O
permitted	O
every	O
4	O
to	O
6	O
hours	O
as	O
rescue	O
medication	O
for	O
pain	O
management.	O
There	O
was	O
a	O
greater	O
use	O
of	O
concomitant	O
opioid	O
rescue	O
medication	O
in	O
placebo-treated	O
patients	O
than	O
in	O
ZORVOLEX-treated	O
patients.	O
About	O
82%	O
of	O
patients	O
in	O
the	O
ZORVOLEX	O
35	O
mg	O
group,	O
85%	O
of	O
the	O
patients	O
in	O
the	O
ZORVOLEX	O
18	O
mg	O
group,	O
and	O
97%	O
of	O
patients	O
in	O
the	O
placebo	O
group	O
took	O
rescue	O
medication	O
for	O
pain	O
management	O
during	O
the	O
study.	O
N	O
=	O
216	O
Placebo	O
N	O
=	O
106	O
Edema	B-D004487
33%	O
32%	O
Nausea	B-D009325
27%	O
37%	O
Headache	B-D006261
13%	O
15%	O
Dizziness	B-D004244
10%	O
16%	O
Vomiting	B-D014839
9%	O
12%	O
Constipation	B-D003248
8%	O
4%	O
Pruritus	B-D011537
7%	O
6%	O
Flatulence	B-D005414
3%	O
2%	O
Pain	B-D010146
in	O
Extremity	O
3%	O
1%	O
Dyspepsia	B-D004415
2%	O
1%	O
Adverse	O
Reactions	O
in	O
Patients	B-D010361
with	O
Osteoarthritis	B-D010003
Pain	B-D010146
Two-hundred	O
two	O
(202)	O
patients	O
received	O
ZORVOLEX	O
in	O
the	O
completed,	O
12-week,	O
double-blind,	O
placebo-controlled,	O
clinical	O
trial	O
of	O
osteoarthritis	O
pain	O
of	O
the	O
knee	O
or	O
hip.	O
The	O
most	O
frequent	O
adverse	O
reactions	O
in	O
this	O
study	O
are	O
summarized	O
in	O
Table	O
2.	O
Table	O
2	O
Summary	O
of	O
Adverse	O
Reactions	O
(≥2%)	O
–	O
12-week	O
Phase	O
3	O
Study	O
in	O
Patients	B-D010361
With	O
Osteoarthritis	B-D010003
Pain	B-D010146
Adverse	O
reactions	O
that	O
occurred	O
in	O
≥2%	O
of	O
patients	O
treated	O
with	O
ZORVOLEX	O
and	O
occurred	O
more	O
frequently	O
than	O
in	O
patients	O
treated	O
with	O
placebo	O
Adverse	O
Reactions	O
ZORVOLEX	O
35	O
mgN=202	O
PlaceboN=103	O
Nausea	B-D009325
7%	O
2%	O
Diarrhea	B-D003967
6%	O
3%	O
Headache	B-D006261
4%	O
3%	O
Abdominal	B-D015746
Pain	I-D015746
Upper	O
3%	O
1%	O
Sinusitis	B-D012852
3%	O
1%	O
Vomiting	B-D014839
3%	O
1%	O
Alanine	B-D000409
Aminotransferase	O
Increased	O
2%	O
0	O
Blood	B-D001769
Creatinine	B-D003404
Increased	O
2%	O
0	O
Dyspepsia	B-D004415
2%	O
1%	O
Flatulence	B-D005414
2%	O
0	O
Hypertension	B-D006973
2%	O
1%	O
Six-hundred	O
one	O
(601)	O
patients	O
received	O
ZORVOLEX	O
35	O
mg	O
either	O
twice	O
or	O
three	O
times	O
daily	O
in	O
a	O
52-week,	O
open-label,	O
clinical	O
trial	O
in	O
osteoarthritis	O
pain	O
of	O
the	O
knee	O
or	O
hip.	O
Of	O
those,	O
360	O
(60%)	O
patients	O
completed	O
the	O
trial.	O
The	O
most	O
frequent	O
adverse	O
reactions	O
in	O
this	O
study	O
are	O
summarized	O
in	O
Table	O
3.	O
Table	O
3	O
Summary	O
of	O
Adverse	O
Reactions	O
(≥2%)	O
–	O
52-week	O
Open-label	O
Study	O
in	O
Patients	B-D010361
with	O
Osteoarthritis	B-D010003
Pain	B-D010146
Adverse	O
Reactions	O
ZORVOLEX	O
35	O
mgN=601	O
Upper	O
respiratory	O
tract	O
infection	O
8%	O
Headache	B-D006261
8%	O
Urinary	O
tract	O
infection	O
7%	O
Diarrhea	B-D003967
6%	O
Nasopharyngitis	B-D009304
6%	O
Nausea	B-D009325
6%	O
Constipation	B-D003248
5%	O
Sinusitis	B-D012852
5%	O
Osteoarthritis	B-D010003
5%	O
Cough	B-D003371
4%	O
Alanine	B-D000409
aminotransferase	O
increased	O
4%	O
Back	B-D001415
pain	O
3%	O
Dyspepsia	B-D004415
3%	O
Procedural	O
pain	O
3%	O
Bronchitis	B-D001991
3%	O
Hypertension	B-D006973
3%	O
Abdominal	O
pain	O
upper	O
3%	O
Influenza	O
3%	O
Arthralgia	B-D018771
3%	O
Contusion	O
3%	O
Vomiting	B-D014839
3%	O
Abdominal	O
discomfort	O
2%	O
Aspartate	O
aminotransferase	O
increased	O
2%	O
Dizziness	B-D004244
2%	O
Fall	O
2%	O
Abdominal	O
pain	O
2%	O
Adverse	O
reactions	O
reported	O
for	O
diclofenac	O
and	O
other	O
NSAIDs:	O
In	O
patients	O
taking	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
reactions	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS:	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
Hypertension	B-D006973
(see	O
WARNINGS	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendages:	O
alopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuriarenal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
:	O
colitis,	O
eructation,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
liver	O
failure,	O
liver	O
necrosis,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	O
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendages:	O
angioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Senses:	O
conjunctivitis,	O
hearing	O
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
EVENTS,	O
contact	O
Actavis	O
at	O
1-800-432-8534	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
http://www.fda.gov/	O
for	O
voluntary	O
reporting	O
of	O
adverse	O
reactions.	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
•	O
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(5.4)	O
Cardiovascular	O
Risk	B-D012306
•	O
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
celecoxib,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.4)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(5.1,	O
14.6,	O
17.2).	O
•Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
(5.4,	O
8.5,	O
14.6,	O
17.3).	O
•Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
celecoxib	O
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen	O
(5.5,	O
17.4).	O
•New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
celecoxib	O
(5.2,	O
7.4,	O
17.2).	O
•Fluid	O
retention	O
and	O
edema.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure	O
(5.3,	O
17.6).	O
•Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
celecoxib	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6).	O
•Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
celecoxib	O
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(5.7,	O
10,	O
17.7).	O
•Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions	O
(5.8,	O
17.5).	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
celecoxib,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
celecoxib	O
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
celecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
].	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
celecoxib	O
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
celecoxib	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
celecoxib.	O
In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
celecoxib.	O
Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
celecoxib	O
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6.	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp.	O
at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CXB	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CXB	O
=	O
celecoxib	O
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials	O
,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
BOXED	O
WARNING	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction	O
(MI),	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(See	O
WARNINGS).Etodolac	O
capsules	O
USP,	O
200	O
mg	O
and	O
300	O
mg,	O
and	O
Etodolac	B-D017308
tablets	O
USP,	O
400	O
mg	O
and	O
500	O
mg	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(See	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(See	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
etodolac	O
capsules	O
and	O
tablets,	O
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal),	O
vomiting.	O
Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritis,	O
rashes,	O
tinnitus.	O
Adverse-reaction	O
information	O
for	O
etodolac	O
was	O
derived	O
from	O
2,629	O
arthritic	O
patients	O
treated	O
with	O
etodolac	O
capsules	O
and	O
tablets	O
in	O
double-blind	O
and	O
open-label	O
clinical	O
trials	O
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies.	O
In	O
clinical	O
trials,	O
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient.	O
The	O
discontinuation	O
rate	O
in	O
controlled	O
clinical	O
trials,	O
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	O
treated	O
with	O
etodolac.	O
New	O
patient	O
complaints	O
(with	O
an	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system.	O
The	O
incidences	O
were	O
determined	O
from	O
clinical	O
trials	O
involving	O
465	O
patients	O
with	O
osteoarthritis	O
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	O
b.i.d.	O
(i.e.,	O
600	O
to	O
1000	O
mg/day).	O
Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever.	O
Digestive	O
system	O
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	O
pain1,	O
diarrhea1,	O
flatulence1,	O
nausea1,	O
abdominal	O
distension,	O
epigastric	O
pain,	O
abnormal	O
stools,	O
constipation,	O
gastritis,	O
melena,	O
vomiting.	O
Nervous	O
system	O
-	O
Asthenia	B-D001247
/malaise1,	O
dizziness1,	O
depression,	O
nervousness,	O
fatigue.	O
Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash.	O
Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus.	O
Urogenital	O
system	O
-	O
Dysuria	B-D053159
,	O
urinary	O
frequency.	O
Musculoskeletal—Arthralgia.	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.	O
1Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
etodolac.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	O
trials,	O
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock).	O
Cardiovascular	O
system	O
-	O
Hypertension	B-D006973
,	O
congestive	O
heart	O
failure,	O
flushing,	O
palpitations,	O
syncope,	O
vasculitis	O
(including	O
necrotizing	O
and	O
allergic).	O
Digestive	O
system	O
-	O
Thirst	B-D013894
,	O
dry	O
mouth,	O
ulcerative	O
stomatitis,	O
anorexia,	O
eructation,	O
elevated	O
liver	O
enzymes,	O
cholestatic	O
hepatitis,	O
hepatitis,	O
cholestatic	O
jaundice,	O
duodenitis,	O
jaundice,	O
hepatic	O
failure,	O
liver	O
necrosis,	O
peptic	O
ulcer	O
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	O
pancreatitis.	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Ecchymosis	B-D004438
,	O
anemia,	O
thrombocytopenia,	O
bleeding	O
time	O
increased,	O
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
leukopenia,	O
neutropenia,	O
pancytopenia.	O
Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
serum	O
creatinine	O
increase,	O
hyperglycemia	O
in	O
previously	O
controlled	O
diabetic	O
patients.	O
Nervous	O
system	O
-	O
Insomnia,	O
somnolence.	O
Respiratory	O
system	O
-	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
eosinophilia.	O
Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
sweating,	O
urticaria,	O
exfoliative	O
dermatitis,	O
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	O
with	O
purpura,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
,	O
toxic	O
epidermal	O
necrolysis,	O
leukocytoclastic	O
vasculitis,	O
hyperpigmentation,	O
erythema	O
multiforme.	O
Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.	O
Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	O
insufficiency,	O
renal	O
papillary	O
necrosis.	O
Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	O
is	O
uncertain.	O
These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	O
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache.	O
Cardiovascular	O
system	O
-	O
Arrhythmias,	O
myocardial	O
infarction,	O
cerebrovascular	O
accident.	O
Digestive	O
system	O
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	O
GI	O
discomfort,	O
burning	O
sensation,	O
blood	O
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort.	O
Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight.	O
Nervous	O
system	O
-	O
Paresthesia	B-D010292
,	O
confusion,	O
irritability.	O
Respiratory	O
system	O
-	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
dyspnea,	O
pharyngitis,	O
rhinitis,	O
sinusitis.	O
Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
skin	O
peeling.	O
Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
deafness,	O
taste	O
perversion,	O
loss	O
of	O
taste.	O
Urogenital	O
system	O
-	O
Cystitis	B-D003556
,	O
hematuria,	O
leukorrhea,	O
renal	O
calculus,	O
interstitial	O
nephritis,	O
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment.	O
Musculoskeletal—Muscle	O
pain.	O
Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
death	O
Cardiovascular	O
system	O
-	O
Tachycardia	B-D013610
Digestive	O
system	O
-	O
Gastric	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis	O
Hemic	O
and	O
lymphatic	O
system	O
-	O
Lymphadenopathy	B-D000072281
Nervous	O
system	O
-	O
Anxiety	B-D001007
,	O
dream	O
abnormalities,	O
convulsions,	O
coma,	O
hallucinations,	O
meningitis,	O
tremors,	O
vertigo	O
Respiratory	O
system	O
-	O
Respiratory	O
depression,	O
pneumonia	O
Urogenital	O
system	O
-	O
Oliguria	B-D009846
/polyuria,	O
proteinuria	O
BOXED	O
WARNING	O
Cardiovascular	O
Risk	B-D012306
1.NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascularthrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
ofuse.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
forcardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(See	O
WARNINGS	O
).	O
1.IBU	O
tablets	O
are	O
contraindicated	O
for	O
treatment	O
of	O
peri-operativepain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)surgery	O
(See	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
1.NSAIDS	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinaladverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforationof	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
eventscan	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinalevents.	O
(See	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
withIbuprofen	O
tablets	O
is	O
gastrointestinal.	O
In	O
controlled	O
clinical	O
trials	O
thepercentage	O
of	O
patients	O
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaintsranged	O
from	O
4%	O
to	O
16%.	O
In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	O
were	O
compared	O
toaspirin	O
and	O
indomethacin	O
in	O
equally	O
effective	O
doses,	O
the	O
overall	O
incidenceof	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
eitherthe	O
aspirin-	O
or	O
indomethacin-treated	O
patients.	O
Adverse	O
reactions	O
observed	O
during	O
controlled	O
clinical	O
trials	O
at	O
anincidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table.	O
Those	O
reactions	O
listedin	O
Column	O
one	O
encompass	O
observations	O
in	O
approximately	O
3,000patients.	O
More	O
than	O
500	O
of	O
these	O
patients	O
were	O
treated	O
for	O
periods	O
ofat	O
least	O
54	O
weeks.	O
Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
werereported	O
in	O
controlled	O
clinical	O
trials	O
and	O
from	O
marketing	O
experience.These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
twoof	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	O
wherethe	O
probability	O
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
inColumn	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	O
has	O
notbeen	O
established.	O
Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
thanat	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	O
trials	O
of	O
patients	O
withrheumatoid	O
arthritis.	O
The	O
increases	O
in	O
incidence	O
were	O
slight	O
and	O
stillwithin	O
the	O
ranges	O
reported	O
in	O
the	O
table.	O
table	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
In	O
patients	O
taking	O
diclofenac	O
sodium	O
delayed-release	O
tablets,	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	O
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	O
pain,	O
constipation,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
gross	O
bleeding/perforation,	O
heartburn,	O
nausea,	O
GI	O
ulcers	O
(gastric/duodenal)	O
and	O
vomiting.	O
Abnormal	O
renal	O
function,	O
anemia,	O
dizziness,	O
edema,	O
elevated	O
liver	O
enzymes,	O
headaches,	O
increased	O
bleeding	O
time,	O
pruritus,	O
rashes	O
and	O
tinnitus.	O
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Wholefever,	O
infection,	O
sepsis	O
Cardiovascular	B-D002319
System	I-D002319
congestive	O
heart	O
failure,	O
hypertension,	O
tachycardia,	O
syncope	O
Digestive	B-D004064
System	I-D004064
dry	O
mouth,	O
esophagitis,	O
gastric/peptic	O
ulcers,	O
gastritis,	O
gastrointestinal	O
bleeding,	O
glossitis,	O
hematemesis,	O
hepatitis,	O
jaundice	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
ecchymosis,	O
eosinophilia,	O
leukopenia,	O
melena,	O
purpura,	O
rectal	O
bleeding,	O
stomatitis,	O
thrombocytopenia	O
Metabolic	O
and	O
Nutritionalweight	O
changes	O
Nervous	B-D009420
System	I-D009420
anxiety,	O
asthenia,	O
confusion,	O
depression,	O
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	O
somnolence,	O
tremors,	O
vertigo	O
Respiratory	B-D012137
System	I-D012137
asthma,	O
dyspnea	O
Skin	B-D012867
and	O
Appendagesalopecia,	O
photosensitivity,	O
sweating	O
increased	O
Special	O
Sensesblurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
cystitis,	O
dysuria,	O
hematuria,	O
interstitial	O
nephritis,	O
oliguria/polyuria,	O
proteinuria,	O
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Wholeanaphylactic	O
reactions,	O
appetite	O
changes,	O
death	O
Cardiovascular	B-D002319
System	I-D002319
arrhythmia,	O
hypotension,	O
myocardial	O
infarction,	O
palpitations,	O
vasculitis	O
Digestive	B-D004064
System	I-D004064
colitis,	O
eructation,	O
liver	O
failure,	O
pancreatitis	O
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
agranulocytosis,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
lymphadenopathy,	O
pancytopenia	O
Metabolic	O
and	O
Nutritionalhyperglycemia	O
Nervous	B-D009420
System	I-D009420
convulsions,	O
coma,	O
hallucinations,	O
meningitis	O
Respiratory	B-D012137
System	I-D012137
respiratory	O
depression,	O
pneumonia	O
Skin	B-D012867
and	O
Appendagesangioedema,	O
toxic	O
epidermal	O
necrolysis,	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
urticaria	O
Special	O
Sensesconjunctivitis,	O
hearing	O
impairment	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk	O
(see	O
WARNINGS	O
).	O
Ibuprofen	B-D007052
tablets	O
are	O
contraindicated	O
for	O
treatment	O
of	O
perioperative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
).	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS	O
).	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	O
tablets	O
is	O
gastrointestinal.	O
In	O
controlled	O
clinical	O
trials	O
the	O
percentage	O
of	O
patients	O
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%.	O
In	O
controlled	O
studies	O
when	O
ibuprofen	O
tablets	O
were	O
compared	O
to	O
aspirin	O
and	O
indomethacin	O
in	O
equally	O
effective	O
doses,	O
the	O
overall	O
incidence	O
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	O
or	O
indomethacin-treated	O
patients.	O
Adverse	O
reactions	O
observed	O
during	O
controlled	O
clinical	O
trials	O
at	O
an	O
incidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table.	O
Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	O
in	O
approximately	O
3,000	O
patients.	O
More	O
than	O
500	O
of	O
these	O
patients	O
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks.	O
Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	O
clinical	O
trials	O
and	O
from	O
marketing	O
experience.	O
These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	O
tablets	O
where	O
the	O
probability	O
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	O
tablets	O
has	O
not	O
been	O
established.	O
Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	O
trials	O
of	O
patients	O
with	O
rheumatoid	O
arthritis.	O
The	O
increases	O
in	O
incidence	O
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table.	O
Incidence	B-D015994
Greater	O
than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship*	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown*	O
GASTROINTESTINAL	O
Nausea	B-D009325
†,	O
epigastric	O
pain†,	O
heartburn†,	O
diarrhea,	O
abdominal	O
distress,	O
nausea	O
and	O
vomiting,	O
indigestion,	O
constipation,	O
abdominal	O
cramps	O
or	O
Pain	B-D010146
,	O
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	O
Gastric	O
or	O
duodenal	O
ulcer	O
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	O
hemorrhage,	O
melena,	O
gastritis,	O
hepatitis,	O
jaundice,	O
abnormal	O
liver	O
function	O
tests;	O
pancreatitis	O
CENTRAL	O
NERVOUS	O
SYSTEM	O
Dizziness	B-D004244
†,	O
headache,	O
nervousness	O
Depression	B-D003863
,	O
insomnia,	O
confusion,	O
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	O
with	O
fever	O
and	O
coma	O
(see	O
PRECAUTIONS	O
)	O
Paresthesia	B-D010292
s,	O
hallucinations,	O
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	O
DERMATOLOGIC	O
Rash†	O
(including	O
maculopapular	O
type),	O
pruritus	O
Vesiculobullous	O
eruptions,	O
urticaria,	O
erythema	O
multiforme,	O
Stevens-Johnson	O
syndrome,	O
alopecia	O
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	O
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D006309
loss,	O
amblyopia	O
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	O
and/or	O
changes	O
in	O
color	O
vision)	O
(see	O
PRECAUTIONS	O
)	O
Conjunctivitis	B-D003231
,	O
diplopia,	O
optic	O
neuritis,	O
cataracts	O
HEMATOLOGIC	O
Neutropenia	B-D009503
,	O
agranulocytosis,	O
aplastic	O
anemia,	O
hemolytic	O
anemia	O
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	O
with	O
or	O
without	O
purpura,	O
eosinophilia,	O
decreases	O
in	O
hemoglobin	O
and	O
hematocrit	O
(see	O
PRECAUTIONS	O
)	O
Bleeding	O
episodes	O
(eg	O
epistaxis,	O
menorrhagia)	O
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	O
Gynecomastia	B-D006177
,	O
hypoglycemic	O
reaction,	O
acidosis	O
CARDIOVASCULAR	O
Edema	B-D004487
,	O
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS	O
)	O
Congestive	O
heart	O
failure	O
in	O
patients	O
with	O
marginal	O
cardiac	O
function,	O
elevated	O
blood	O
pressure,	O
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	O
sinus	O
bradycardia)	O
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	O
pain,	O
fever,	O
chills,	O
nausea	O
and	O
vomiting;	O
anaphylaxis;	O
bronchospasm	O
(see	O
CONTRAINDICATIONS	O
)	O
Serum	B-D044967
sickness,	O
lupus	O
erythematosus	O
syndrome.	O
Henoch-Schonlein	O
vasculitis,	O
angioedema	O
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS	O
),	O
decreased	O
creatinine	O
clearance,	O
polyuria,	O
azotemia,	O
cystitis,	O
Hematuria	B-D006417
Renal	O
papillary	O
necrosis	O
MISCELLANEOUS	O
Dry	O
eyes	O
and	O
mouth,	O
gingival	O
ulcer,	O
rhinitis	O
*Reactions	O
are	O
classified	O
under	O
"Probable	O
Causal	O
Relationship	O
(PCR)"	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related.	O
Reactions	O
are	O
classified	O
under	O
"Causal	O
Relationship	O
Unknown"	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met.	O
†Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
ibuprofen.	O
(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	O
are	O
unmarked).	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Non-Steroidal	O
Anti-Inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(	O
5.1)	O
NALFON	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(	O
4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(	O
5.2)	O
Cardiovascular	O
Thrombic	O
Events	O
Non-Steroidal	O
Anti-Inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
].	O
NALFON	O
®	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
precautions	O
(	O
5.1)	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
].	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(	O
5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(	O
5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
NALFON	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(	O
5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
NALFON	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(	O
5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
NALFON	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(	O
5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
NALFON	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(	O
5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(	O
5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
fenoprofen,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
NALFON	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
NALFON,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDS.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
of	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
for	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
theincreased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GIbleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
NALFON	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
fenoprofen.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
NALFON	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
NALFON,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
fenoprofen	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
NALFON	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
NALFON	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
NALFON	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
pre-existing	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
NALFON.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
NALFON	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
NALFON	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Fenoprofen	B-D005279
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
fenoprofen	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
NALFON	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
].	O
When	O
NALFON	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
fenoprop	B-C009264
fen,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
NALFON	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
NALFON	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Fenoprofen	B-D005279
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
NALFON,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(	O
8.1)	O
].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
NALFON	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
NALFON,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
NALFON	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2,	O
5.3,	O
5.6)	O
].	O
5.14	O
Ocular	O
Effects	O
Studies	O
to	O
date	O
have	O
not	O
shown	O
changes	O
in	O
the	O
eyes	O
attributable	O
to	O
the	O
administration	O
of	O
NALFON.	O
However,	O
adverse	O
ocular	O
effects	O
have	O
been	O
observed	O
with	O
other	O
anti-inflammatory	O
drugs.	O
Eye	B-D005123
examinations,	O
therefore,	O
should	O
be	O
performed	O
if	O
visual	O
disturbances	O
occur	O
in	O
patients	O
taking	O
NALFON.	O
5.15	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Caution	O
should	O
be	O
exercised	O
by	O
patients	O
whose	O
activities	O
require	O
alertness	O
if	O
they	O
experience	O
CNS	O
side	O
effects	O
while	O
taking	O
NALFON.	O
5.16	O
Impact	O
on	O
Hearing	B-D006309
Since	O
the	O
safety	O
of	O
NALFON	O
has	O
not	O
been	O
established	O
in	O
patients	O
with	O
impaired	O
hearing,	O
these	O
patients	O
should	O
have	O
periodic	O
tests	O
of	O
auditory	O
function	O
during	O
prolonged	O
therapy	O
with	O
NALFON.	O
6.	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
5%)	O
are	O
Dyspepsia	B-D004415
,	O
headache,	O
somnolence,	O
nausea,	O
dizziness,	O
constipation,	O
nervousness,	O
asthenia,	O
and	O
peripheral	O
edema.	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Xspire	O
Pharma	O
at	O
1-601-990-9497	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
During	O
clinical	O
studies	O
for	O
rheumatoid	O
arthritis,	O
osteoarthritis,	O
or	O
mild	O
to	O
moderate	O
pain	O
and	O
studies	O
of	O
pharmacokinetics,	O
complaints	O
were	O
compiled	O
from	O
a	O
checklist	O
of	O
potential	O
adverse	O
reactions,	O
and	O
the	O
following	O
data	O
emerged.	O
These	O
encompass	O
observations	O
in	O
6,786	O
patients,	O
including	O
188	O
observed	O
for	O
at	O
least	O
52	O
weeks.	O
For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
patients	O
who	O
received	O
placebo	O
in	O
these	O
same	O
trials.	O
During	O
short-term	O
studies	O
for	O
analgesia,	O
the	O
incidence	O
of	O
adverse	O
reactions	O
was	O
markedly	O
lower	O
than	O
that	O
seen	O
in	O
longer-term	O
studies.	O
Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
>1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—	O
During	O
clinical	O
trials	O
with	O
Nalfon,	O
the	O
most	O
common	O
adverse	O
reactions	O
were	O
gastrointestinal	O
in	O
nature	O
and	O
occurred	O
in	O
20.8%	O
of	O
patients	O
receiving	O
Nalfon	O
as	O
compared	O
to	O
16.9%	O
of	O
patients	O
receiving	O
placebo.	O
In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
dyspepsia	O
(10.3%	O
Nalfon	O
vs.	O
2.3%	O
placebo),	O
nausea	O
(7.7%	O
vs.	O
7.1%),	O
constipation	O
(7%	O
vs.	O
1.5%),	O
vomiting	O
(2.6%	O
vs.	O
1.9%),	O
abdominal	O
pain	O
(2%	O
vs.	O
1.1%),	O
and	O
diarrhea	O
(1.8%	O
vs.	O
4.1%).	O
The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
patients	O
during	O
premarketing	O
studies.	O
Nervous	B-D009420
System	I-D009420
—	O
The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
headache	O
(8.7%	O
vs.	O
7.5%)	O
and	O
somnolence	O
(8.5%	O
vs.	O
6.4%).	O
Dizziness	B-D004244
(6.5%	O
vs.	O
5.6%),	O
tremor	O
(2.2%	O
vs.	O
0.4%),	O
and	O
confusion	O
(1.4%	O
vs.	O
none)	O
were	O
noted	O
less	O
frequently.	O
Nalfon	O
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
patients	O
because	O
of	O
these	O
side	O
effects	O
during	O
premarketing	O
studies.	O
Skin	B-D012867
and	O
Appendages—	O
Increased	O
sweating	O
(4.6%	O
vs.	O
0.4%),	O
pruritus	O
(4.2%	O
vs.	O
0.8%),	O
and	O
rash	O
(3.7%	O
vs.	O
0.4%)	O
were	O
reported.	O
Nalfon	O
was	O
discontinued	O
in	O
about	O
1%	O
of	O
patients	O
because	O
of	O
an	O
adverse	O
effect	O
related	O
to	O
the	O
skin	O
during	O
premarketing	O
studies.	O
Special	O
Senses	O
—	O
Tinnitus	B-D014012
(4.5%	O
vs.	O
0.4%),	O
blurred	O
vision	O
(2.2%	O
vs.	O
none),	O
and	O
decreased	O
hearing	O
(1.6%	O
vs.	O
none)	O
were	O
reported.	O
Nalfon	O
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
patients	O
because	O
of	O
adverse	O
effects	O
related	O
to	O
the	O
special	O
senses	O
during	O
premarketing	O
studies.	O
Cardiovascular	O
—	O
Palpitations	O
(2.5%	O
vs.	O
0.4%).	O
Nalfon	O
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
patients	O
because	O
of	O
adverse	O
cardiovascular	O
reactions	O
during	O
premarketing	O
studies.	O
Miscellaneous	O
—	O
Nervousness	O
(5.7%	O
vs.	O
1.5%),	O
asthenia	O
(5.4%	O
vs.	O
0.4%),	O
peripheral	O
edema	O
(5.0%	O
vs.	O
0.4%),	O
dyspnea	O
(2.8%	O
vs.	O
none),	O
fatigue	O
(1.7%	O
vs.	O
1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs.	O
5.6%),	O
and	O
nas	B-C015378
opharyngitis	O
(1.2%	O
vs.	O
none).	O
Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—Gastritis,	O
peptic	O
ulcer	O
with/without	O
perforation,	O
gastrointestinal	O
hemorrhage,	O
anorexia,	O
flatulence,	O
dry	O
mouth,	O
and	O
blood	O
in	O
the	O
stool.	O
Increases	O
in	O
alkaline	O
phosphatase,	O
LDH,	O
SGOT,	O
jaundice,	O
and	O
cholestatic	O
hepatitis,	O
aphthous	O
ulcerations	O
of	O
the	O
buccal	O
mucosa,	O
metallic	O
taste,	O
and	O
pancreatitis.	O
Cardiovascular—Atrial	O
fibrillation,	O
pulmonary	O
edema,	O
electrocardiographic	O
changes,	O
and	O
supraventricular	O
tachycardia.	O
Genitourinary	O
Tract—Renal	O
failure,	O
dysuria,	O
cystitis,	O
hematuria,	O
oliguria,	O
azotemia,	O
anuria,	O
interstitial	O
nephritis,	O
nephrosis,	O
and	O
papillary	O
necrosis.	O
Hypersensitivity	B-D006967
—Angioedema	O
(angioneurotic	O
edema).	O
Hematologic—Purpura,	O
bruising,	O
hemorrhage,	O
thrombocytopenia,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
agranulocytosis,	O
and	O
pancytopenia.	O
Nervous	B-D009420
System	I-D009420
—Depression,	O
disorientation,	O
seizures,	O
and	O
trigeminal	O
neuralgia.	O
Special	O
Senses—Burning	O
tongue,	O
diplopia,	O
and	O
optic	O
neuritis.	O
Skin	B-D012867
and	O
Appendages—Exfoliative	O
dermatitis,	O
toxic	O
epidermal	O
necrolysis,	O
Stevens-Johnson	O
syndrome,	O
and	O
alopecia.	O
Miscellaneous—Anaphylaxis,	O
urticaria,	O
malaise,	O
insomnia,	O
tachycardia,	O
personality	O
change,	O
lymphadenopathy,	O
mastodynia,	O
and	O
fever.	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Non-Steroidal	O
Anti-Inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(	O
5.1)	O
Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(	O
4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(	O
5.2)	O
Cardiovascular	O
Thrombic	O
Events	O
Non-Steroidal	O
Anti-Inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
].	O
Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
precautions	O
(	O
5.1)	O
].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
].	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(	O
5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(	O
5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
fenoprofen	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(	O
5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
fenoprofen	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(	O
5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(	O
5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
fenoprofen	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(	O
5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(	O
5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
fenoprofen,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
fenoprofen	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
fenoprofen	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
fenoprofen,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDS.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
of	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
for	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
theincreased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GIbleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
fenoprofen	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
fenoprofen.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
fenoprofen	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
fenoprofen,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
pre-existing	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
fenoprofen	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
Avoid	O
the	O
use	O
of	O
fenoprofen	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
fenoprofen	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
fenoprofen	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
fenoprofen	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
pre-existing	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
fenoprofen.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
fenoprofen	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
Avoid	O
the	O
use	O
of	O
fenoprofen	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
fenoprofen	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Fenoprofen	B-D005279
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
fenoprofen	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
fenoprofen	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
].	O
When	O
fenoprofen	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
fenoprop	B-C009264
fen,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
fenoprofen	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Fenoprofen	B-D005279
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
fenoprofen,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(	O
8.1)	O
].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
fenoprofen	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
fenoprofen,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
fenoprofen	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2,	O
5.3,	O
5.6)	O
].	O
5.14	O
Ocular	O
Effects	O
Studies	O
to	O
date	O
have	O
not	O
shown	O
changes	O
in	O
the	O
eyes	O
attributable	O
to	O
the	O
administration	O
of	O
fenoprofen.	O
However,	O
adverse	O
ocular	O
effects	O
have	O
been	O
observed	O
with	O
other	O
anti-inflammatory	O
drugs.	O
Eye	B-D005123
examinations,	O
therefore,	O
should	O
be	O
performed	O
if	O
visual	O
disturbances	O
occur	O
in	O
patients	O
taking	O
fenoprofen.	O
5.15	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Caution	O
should	O
be	O
exercised	O
by	O
patients	O
whose	O
activities	O
require	O
alertness	O
if	O
they	O
experience	O
CNS	O
side	O
effects	O
while	O
taking	O
fenoprofen.	O
5.16	O
Impact	O
on	O
Hearing	B-D006309
Since	O
the	O
safety	O
of	O
fenoprofen	O
has	O
not	O
been	O
established	O
in	O
patients	O
with	O
impaired	O
hearing,	O
these	O
patients	O
should	O
have	O
periodic	O
tests	O
of	O
auditory	O
function	O
during	O
prolonged	O
therapy	O
with	O
fenoprofen.	O
6.	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
5%)	O
are	O
Dyspepsia	B-D004415
,	O
headache,	O
somnolence,	O
nausea,	O
dizziness,	O
constipation,	O
nervousness,	O
asthenia,	O
and	O
peripheral	O
edema.	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Xspire	O
Pharma	O
at	O
1-601-990-9497	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
During	O
clinical	O
studies	O
for	O
rheumatoid	O
arthritis,	O
osteoarthritis,	O
or	O
mild	O
to	O
moderate	O
pain	O
and	O
studies	O
of	O
pharmacokinetics,	O
complaints	O
were	O
compiled	O
from	O
a	O
checklist	O
of	O
potential	O
adverse	O
reactions,	O
and	O
the	O
following	O
data	O
emerged.	O
These	O
encompass	O
observations	O
in	O
6,786	O
patients,	O
including	O
188	O
observed	O
for	O
at	O
least	O
52	O
weeks.	O
For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
patients	O
who	O
received	O
placebo	O
in	O
these	O
same	O
trials.	O
During	O
short-term	O
studies	O
for	O
analgesia,	O
the	O
incidence	O
of	O
adverse	O
reactions	O
was	O
markedly	O
lower	O
than	O
that	O
seen	O
in	O
longer-term	O
studies.	O
Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
>1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—	O
During	O
clinical	O
trials	O
with	O
fenoprofen,	O
the	O
most	O
common	O
adverse	O
reactions	O
were	O
gastrointestinal	O
in	O
nature	O
and	O
occurred	O
in	O
20.8%	O
of	O
patients	O
receiving	O
fenoprofen	O
as	O
compared	O
to	O
16.9%	O
of	O
patients	O
receiving	O
placebo.	O
In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
dyspepsia	O
(10.3%	O
fenoprofen	O
vs.	O
2.3%	O
placebo),	O
nausea	O
(7.7%	O
vs.	O
7.1%),	O
constipation	O
(7%	O
vs.	O
1.5%),	O
vomiting	O
(2.6%	O
vs.	O
1.9%),	O
abdominal	O
pain	O
(2%	O
vs.	O
1.1%),	O
and	O
diarrhea	O
(1.8%	O
vs.	O
4.1%).	O
The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
patients	O
during	O
premarketing	O
studies.	O
Nervous	B-D009420
System	I-D009420
—	O
The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
headache	O
(8.7%	O
vs.	O
7.5%)	O
and	O
somnolence	O
(8.5%	O
vs.	O
6.4%).	O
Dizziness	B-D004244
(6.5%	O
vs.	O
5.6%),	O
tremor	O
(2.2%	O
vs.	O
0.4%),	O
and	O
confusion	O
(1.4%	O
vs.	O
none)	O
were	O
noted	O
less	O
frequently.	O
Fenoprofen	B-D005279
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
patients	O
because	O
of	O
these	O
side	O
effects	O
during	O
premarketing	O
studies.	O
Skin	B-D012867
and	O
Appendages—	O
Increased	O
sweating	O
(4.6%	O
vs.	O
0.4%),	O
pruritus	O
(4.2%	O
vs.	O
0.8%),	O
and	O
rash	O
(3.7%	O
vs.	O
0.4%)	O
were	O
reported.	O
Fenoprofen	B-D005279
was	O
discontinued	O
in	O
about	O
1%	O
of	O
patients	O
because	O
of	O
an	O
adverse	O
effect	O
related	O
to	O
the	O
skin	O
during	O
premarketing	O
studies.	O
Special	O
Senses	O
—	O
Tinnitus	B-D014012
(4.5%	O
vs.	O
0.4%),	O
blurred	O
vision	O
(2.2%	O
vs.	O
none),	O
and	O
decreased	O
hearing	O
(1.6%	O
vs.	O
none)	O
were	O
reported.	O
Fenoprofen	B-D005279
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
patients	O
because	O
of	O
adverse	O
effects	O
related	O
to	O
the	O
special	O
senses	O
during	O
premarketing	O
studies.	O
Cardiovascular	O
—	O
Palpitations	O
(2.5%	O
vs.	O
0.4%).	O
Fenoprofen	B-D005279
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
patients	O
because	O
of	O
adverse	O
cardiovascular	O
reactions	O
during	O
premarketing	O
studies.	O
Miscellaneous	O
—	O
Nervousness	O
(5.7%	O
vs.	O
1.5%),	O
asthenia	O
(5.4%	O
vs.	O
0.4%),	O
peripheral	O
edema	O
(5.0%	O
vs.	O
0.4%),	O
dyspnea	O
(2.8%	O
vs.	O
none),	O
fatigue	O
(1.7%	O
vs.	O
1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs.	O
5.6%),	O
and	O
nas	B-C015378
opharyngitis	O
(1.2%	O
vs.	O
none).	O
Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—Gastritis,	O
peptic	O
ulcer	O
with/without	O
perforation,	O
gastrointestinal	O
hemorrhage,	O
anorexia,	O
flatulence,	O
dry	O
mouth,	O
and	O
blood	O
in	O
the	O
stool.	O
Increases	O
in	O
alkaline	O
phosphatase,	O
LDH,	O
SGOT,	O
jaundice,	O
and	O
cholestatic	O
hepatitis,	O
aphthous	O
ulcerations	O
of	O
the	O
buccal	O
mucosa,	O
metallic	O
taste,	O
and	O
pancreatitis.	O
Cardiovascular—Atrial	O
fibrillation,	O
pulmonary	O
edema,	O
electrocardiographic	O
changes,	O
and	O
supraventricular	O
tachycardia.	O
Genitourinary	O
Tract—Renal	O
failure,	O
dysuria,	O
cystitis,	O
hematuria,	O
oliguria,	O
azotemia,	O
anuria,	O
interstitial	O
nephritis,	O
nephrosis,	O
and	O
papillary	O
necrosis.	O
Hypersensitivity	B-D006967
—Angioedema	O
(angioneurotic	O
edema).	O
Hematologic—Purpura,	O
bruising,	O
hemorrhage,	O
thrombocytopenia,	O
hemolytic	O
anemia,	O
aplastic	O
anemia,	O
agranulocytosis,	O
and	O
pancytopenia.	O
Nervous	B-D009420
System	I-D009420
—Depression,	O
disorientation,	O
seizures,	O
and	O
trigeminal	O
neuralgia.	O
Special	O
Senses—Burning	O
tongue,	O
diplopia,	O
and	O
optic	O
neuritis.	O
Skin	B-D012867
and	O
Appendages—Exfoliative	O
dermatitis,	O
toxic	O
epidermal	O
necrolysis,	O
Stevens-Johnson	O
syndrome,	O
and	O
alopecia.	O
Miscellaneous—Anaphylaxis,	O
urticaria,	O
malaise,	O
insomnia,	O
tachycardia,	O
personality	O
change,	O
lymphadenopathy,	O
mastodynia,	O
and	O
fever.	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
•Celecoxib	O
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
•Celecoxib	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•NSAIDs,	O
including	O
Celecoxib	B-D000068579
,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
(GI)	O
events.	O
(5.4)	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	O
Cardiovascular	O
Risk	B-D012306
•	O
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
All	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk.	O
This	O
risk	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
Patients	B-D010361
with	O
cardiovascular	O
disease	O
or	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579
,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
gastrointestinal	O
events.	O
(5.4)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke.	O
Patients	B-D010361
with	O
known	O
CV	O
disease/risk	O
factors	O
may	O
be	O
at	O
greater	O
risk	O
(5.1,14.6,	O
17.2).	O
•Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal.	O
The	O
risk	O
is	O
greater	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
GI	O
bleeding,	O
and	O
in	O
patients	O
at	O
high	O
risk	O
for	O
GI	O
events,	O
especially	O
the	O
elderly.	O
Celecoxib	B-D000068579
Capsules	B-D002214
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
(5.4,	O
8.5,14.6,	O
17.3).	O
•Elevated	O
liver	O
enzymes	O
and,	O
rarely,	O
severe	O
hepatic	O
reactions.	O
Discontinue	O
use	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214
immediately	O
if	O
abnormal	O
liver	O
enzymes	O
persist	O
or	O
worsen	O
(5.5,17.4).	O
•New	O
onset	O
or	O
worsening	O
of	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
Celecoxib	B-D000068579
Capsules	B-D002214
(5.2,	O
7.4,	O
17.2).	O
•Fluid	O
retention	O
and	O
edema.	O
Celecoxib	B-D000068579
Capsules	B-D002214
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure	O
(5.3,	O
17.6).	O
•Renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use.	O
Use	O
Celecoxib	B-D000068579
Capsules	B-D002214
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
and	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
or	O
angiotensin	O
II	O
antagonists	O
(5.6,	O
7.4,	O
8.7,17.6).	O
•Anaphylactoid	O
reactions.	O
Do	O
not	O
use	O
Celecoxib	B-D000068579
Capsules	B-D002214
in	O
patients	O
with	O
the	O
aspirin	O
triad	O
(5.7,10,	O
17.7).	O
•Serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy.	O
Discontinue	O
Celecoxib	B-D000068579
Capsules	B-D002214
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	O
reactions	O
(5.8,17.5).	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214
may	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
-	O
8.5)	O
for	O
Celecoxib	B-D000068579
Capsules	B-D002214
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
-	O
7.2)	O
with	O
Celecoxib	B-D000068579
Capsules	B-D002214
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk.	O
Patients	B-D010361
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease	O
may	O
be	O
at	O
greater	O
risk.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	O
treated	O
with	O
Celecoxib	B-D000068579
Capsules	B-D002214
,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
Celecoxib	B-D000068579
Capsules	B-D002214
does	O
increase	O
the	O
risk	O
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)].	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	O
can	O
lead	O
to	O
the	O
onset	O
of	O
new	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
thiazides	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
NSAIDs,	O
including	O
celecoxib,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
hypertension.	O
Blood	B-D001769
pressure	O
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
taking	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
Celecoxib	B-D000068579
Capsules	B-D002214
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
fluid	O
retention	O
or	O
heart	O
failure.	O
5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach,	O
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	O
during	O
the	O
course	O
of	O
therapy.	O
However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.	O
NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
ulcer	O
disease	O
or	O
gastrointestinal	O
bleeding.	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
with	O
neither	O
of	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	O
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	O
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	O
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
celecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected.	O
For	O
high-risk	O
patients,	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered.	O
5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	O
enzymes	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
NSAIDs.	O
These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy.	O
Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	O
and	O
fatal	O
fulminant	O
hepatitis,	O
liver	O
necrosis	O
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	O
outcome)	O
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	O
[see	O
Adverse	O
Reactions	O
(6.1)].	O
In	O
controlled	O
clinical	O
trials	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214
,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
Celecoxib	B-D000068579
Capsules	B-D002214
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
Celecoxib	B-D000068579
Capsules	B-D002214
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	O
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	O
test	O
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
Celecoxib	B-D000068579
Capsules	B-D002214
.	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
Celecoxib	B-D000068579
Capsules	B-D002214
should	O
be	O
discontinued.	O
5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
Clinical	O
trials	O
with	O
Celecoxib	B-D000068579
Capsules	B-D002214
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
Therefore,	O
treatment	O
with	O
celecoxib	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
with	O
advanced	O
renal	O
disease.	O
If	O
celecoxib	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable.	O
5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	O
without	O
known	O
prior	O
exposure	O
to	O
Celecoxib	B-D000068579
Capsules	B-D002214
.	O
In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
Celecoxib	B-D000068579
Capsules	B-D002214
.	O
Celecoxib	B-D000068579
Capsules	B-D002214
should	O
not	O
be	O
given	O
to	O
patients	O
with	O
the	O
aspirin	O
triad.	O
This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	O
patients	O
who	O
experience	O
rhinitis	O
with	O
or	O
without	O
nas	B-C015378
al	O
polyps,	O
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	O
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)].	O
Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs.	O
5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	O
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS)	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN)	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	O
without	O
prior	O
known	O
sulfa	O
allergy.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
manifestations	O
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	O
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency.	O
Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	O
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness.	O
Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids.	O
5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	O
receiving	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
Celecoxib	B-D000068579
Capsules	B-D002214
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579
Capsules	B-D002214
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	O
platelet	O
counts,	O
prothrombin	O
time	O
(PT),	O
or	O
partial	O
thromboplastin	O
time	O
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	O
aggregation	O
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)].	O
5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
Capsules	B-D002214
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation.	O
5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma.	O
The	O
use	O
of	O
aspirin	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal.	O
Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	O
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
Celecoxib	B-D000068579
Capsules	B-D002214
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
preexisting	O
asthma.	O
5.14	O
Laboratory	O
Tests	O
Because	O
serious	O
GI	O
tract	O
ulcerations	O
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	O
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
checked	O
periodically.	O
If	O
abnormal	O
liver	O
tests	O
or	O
renal	O
tests	O
persist	O
or	O
worsen,	O
Celecoxib	B-D000068579
Capsules	B-D002214
should	O
be	O
discontinued.	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
Celecoxib	B-D000068579
Capsules	B-D002214
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	O
conditions.	O
5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	O
of	O
adverse	O
reactions.	O
6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Cipla	O
Ltd,	O
at	O
1-866-604-3268	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
Of	O
the	O
Celecoxib	B-D000068579
Capsules	B-D002214
-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
Celecoxib	B-D000068579
Capsules	B-D002214
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
Celecoxib	B-D000068579
Capsules	B-D002214
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Celecoxib	B-D000068579
=	O
Celecoxib	B-D000068579
Capsules	B-D002214
100	O
-	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
Celecoxib	B-D000068579
(N=4146)	O
Placebo	O
(N=1864)	O
NAP	O
(N=1366)	O
DCF	O
(N=387)	O
IBU	O
(N=345)	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
-	O
1.9%	O
of	O
patients	O
treated	O
with	O
Celecoxib	B-D000068579
Capsules	B-D002214
(100	O
-	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
Allergy	O
General:	O
aggravated,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	O
(cases	O
reported	O
only	O
in	O
postmarketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis,	O
vasculitis,	O
deep	O
venous	O
thrombosis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
,	O
hepatitis,	O
jaundice,	O
liver	O
failure	O
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
,	O
agranulocytosis,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous:	O
Ataxia	B-D001259
,	O
suicide,	O
aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	O
Skin	B-D012867
:	O
Erythema	B-D004890
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome,	O
toxic	O
epidermal	O
necrolysis	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death,	O
anaphylactoid	O
reaction,	O
angioedema	O
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
Celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
Celecoxib	B-D000068579
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579
,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
Celecoxib	B-D000068579
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
Celecoxib	B-D000068579
3	O
mg/kg	O
BID,	O
82	O
patients	O
were	O
treated	O
with	O
Celecoxib	B-D000068579
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
BID.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
Celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
Celecoxib	B-D000068579
6	O
mg/kg	O
BID.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
*Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
Celecoxib	B-D000068579
Capsules	B-D002214
in	O
placebo-	O
and	O
active	O
controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
Celecoxib	B-D000068579
Capsules	B-D002214
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579
Capsules	B-D002214
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
Capsules	B-D002214
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
Celecoxib	B-D000068579
Capsules	B-D002214
,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction,	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
(GI)	O
events.	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
5.	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	O
MI,	O
or	O
stroke	O
was	O
3.4	O
(95%	O
CI	O
1.4	O
to	O
8.5)	O
for	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
to	O
7.2)	O
with	O
celecoxib	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo.	O
Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	O
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment.	O
The	O
increases	O
in	O
both	O
celecoxib	O
dose	O
groups	O
versus	O
placebo-treated	O
patients	O
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	O
clinical	O
trials	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke.	O
NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
celecoxib.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants;	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Complicated	O
and	O
symptomatic	O
ulcer	O
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	O
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA.	O
Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	O
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)	O
].	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	O
in	O
clinical	O
trials.	O
In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	O
liver	O
necrosis,	O
and	O
hepatic	O
failure	O
have	O
been	O
reported.	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	O
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	O
treated	O
with	O
NSAIDs	O
including	O
celecoxib.	O
In	O
controlled	O
clinical	O
trials	O
of	O
celecoxib,	O
the	O
incidence	O
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	O
and	O
less	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	O
associated	O
enzymes	O
was	O
6%	O
for	O
celecoxib	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	O
taking	O
celecoxib	O
and	O
0.3%	O
of	O
patients	O
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
“flu-like”	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
celecoxib	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
The	O
rates	O
of	O
hypertension	O
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	O
ibuprofen	O
and	O
diclofenac-treated	O
patients	O
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	O
[see	O
Clinical	O
Studies	O
(14.6)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two­fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
celecoxib	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
and	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively.	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics,	O
ACE-inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
celecoxib	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
celecoxib.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
celecoxib	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
Avoid	O
the	O
use	O
of	O
celecoxib	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoadosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
celecoxib	O
and	O
in	O
patients	O
with	O
aspirin	O
sensitive	O
asthma.	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	O
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	O
or	O
less	O
severe	O
asthmatic	O
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
].	O
Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
celecoxib	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
When	O
celecoxib	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	O
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib,	O
including	O
erythema	O
multiforme,	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	O
syndrome	O
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	O
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	O
generalized	O
exanthematous	O
pustulosis	O
(AGEP).	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
].	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	O
closure	O
of	O
the	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
].	O
5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
celecoxib	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
In	O
controlled	O
clinical	O
trials	O
the	O
incidence	O
of	O
anemia	O
was	O
0.6%	O
with	O
celecoxib	O
and	O
0.4%	O
with	O
placebo.	O
Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	O
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	O
or	O
blood	O
loss.	O
NSAIDs,	O
including	O
celecoxib,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
].	O
In	O
controlled	O
clinical	O
trials,	O
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
celecoxib	O
compared	O
with	O
patients	O
on	O
placebo.	O
This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	O
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies.	O
The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established.	O
5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	O
of	O
disseminated	O
intravascular	O
coagulation	O
with	O
use	O
of	O
celecoxib	O
in	O
pediatric	O
patients	O
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	O
and	O
their	O
caregivers	O
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible.	O
6.	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	O
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	O
pain,	O
diarrhea,	O
dyspepsia,	O
flatulence,	O
peripheral	O
edema,	O
accidental	O
injury,	O
dizziness,	O
pharyngitis,	O
rhinitis,	O
sinusitis,	O
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1).	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Cambridge	O
Therapeutic	O
Technologies	O
at	O
1-844-810-0004	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
adverse	O
reaction	O
information	O
from	O
clinical	O
trials	O
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates.	O
Of	O
the	O
celecoxib-treated	O
patients	O
in	O
the	O
pre-marketing	O
controlled	O
clinical	O
trials,	O
approximately	O
4,250	O
were	O
patients	O
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	O
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	O
with	O
post-surgical	O
pain.	O
More	O
than	O
8,500	O
patients	O
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily).	O
Approximately	O
3,900	O
patients	O
received	O
celecoxib	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more.	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	O
occurring	O
in	O
≥2%	O
of	O
patients	O
receiving	O
celecoxib	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group.	O
Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	O
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	O
daily.	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%5.6%	O
8.8%	O
2.2%	O
3.5%	O
2.8%	O
3.8%	O
6.2%	O
1%	O
4.2%	O
7.7%	O
5.3%	O
12.2%	O
3.6%6%	O
9%9.3%10.9%4.1%3.4%	O
9%5.8%12.8%3.5%6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%2.1%2.9%	O
3.6%1.1%2.3%	O
2.2%2.1%3%	O
2.6%1%2.6%	O
0.9%3.5%3.2%	O
Central,	O
Peripheral	O
Nervous	O
system	O
Dizziness	B-D004244
Headache	B-D006261
2%15.8%	O
1.7%20.2%	O
2.6%14.5%	O
1.3%15.5%	O
2.3%15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
Rhinitis	B-D012220
Sinusitis	B-D012852
Upper	O
Respiratory	O
Infection	O
2.3%2%5%8.1%	O
1.1%1.3%4.3%6.7%	O
1.7%2.4%4%9.9%	O
1.6%2.3%5.4%9.8%	O
2.6%0.6%5.8%9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	O
receiving	O
celecoxib	O
and	O
6.1%	O
for	O
patients	O
receiving	O
placebo.	O
Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	O
treatment	O
groups	O
were	O
dyspepsia	O
and	O
abdominal	O
pain	O
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	O
patients,	O
respectively).	O
Among	O
patients	O
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	O
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	O
pain.	O
The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
patients	O
treated	O
with	O
celecoxib	O
(100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
diverticulitis,	O
dysphagia,	O
eructation,	O
esophagitis,	O
gastritis,	O
gastroenteritis,	O
gastroesophageal	O
reflux,	O
hemorrhoids,	O
hiatal	O
hernia,	O
melena,	O
dry	O
mouth,	O
stomatitis,	O
tenesmus,	O
vomiting	O
Cardiovascular:	O
Aggravated	O
hypertension,	O
angina	O
pectoris,	O
coronary	O
artery	O
disorder,	O
myocardial	O
infarction	O
General:	O
Hypersensitivity	B-D006967
,	O
allergic	O
reaction,	O
chest	O
pain,	O
cyst	O
NOS,	O
edema	O
generalized,	O
face	O
edema,	O
fatigue,	O
fever,	O
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	O
peripheral	O
pain	O
Central,	O
peripheral	O
nervous	O
system:	O
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	O
vertigo	O
Hearing	B-D006309
and	O
vestibular:	O
Deafness	B-D003638
,	O
tinnitus	O
Heart	B-D006321
rate	O
and	O
rhythm:	O
Palpitation,	O
tachycardia	O
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	O
hyperglycemia,	O
hypokalemia,	O
NPN	O
increased,	O
creatinine	O
increased,	O
alkaline	O
phosphatase	O
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia	B-D018771
,	O
arthrosis,	O
myalgia,	O
synovitis,	O
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis	B-D004438
,	O
epistaxis,	O
thrombocythemia,	O
Psychiatric:	O
Anorexia	B-D000855
,	O
anxiety,	O
appetite	O
increased,	O
depression,	O
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	O
dyspnea,	O
laryngitis,	O
pneumonia	O
Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505
,	O
dermatitis,	O
photosensitivity	O
reaction,	O
pruritus,	O
rash	O
erythematous,	O
rash	O
maculopapular,	O
skin	O
disorder,	O
skin	O
dry,	O
sweating	O
increased,	O
urticaria	O
Application	O
site	O
disorders:	O
Cellulitis	B-D002481
,	O
dermatitis	O
contact	O
Urinary:	O
Albuminuria	B-D000419
,	O
cystitis,	O
dysuria,	O
hematuria,	O
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	O
Cardiovascular:	O
Syncope	B-D013575
,	O
congestive	O
heart	O
failure,	O
ventricular	O
fibrillation,	O
pulmonary	O
embolism,	O
cerebrovascular	O
accident,	O
peripheral	O
gangrene,	O
thrombophlebitis	O
Gastrointestinal:	O
Intestinal	O
obstruction,	O
intestinal	O
perforation,	O
gastrointestinal	O
bleeding,	O
colitis	O
with	O
bleeding,	O
esophageal	O
perforation,	O
pancreatitis,	O
ileus	O
General:	O
Sepsis	B-D018805
,	O
sudden	O
death	O
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	O
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia	B-D001259
,	O
suicide	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)]	O
Hematological	O
Events:	O
The	O
incidence	O
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	O
on	O
celecoxib	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	O
on	O
either	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	O
800	O
mg	O
three	O
times	O
daily	O
1.9%.	O
The	O
lower	O
incidence	O
of	O
events	O
with	O
celecoxib	O
was	O
maintained	O
with	O
or	O
without	O
aspirin	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
].	O
Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	O
diclofenac	O
and	O
ibuprofen	O
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively.	O
Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	O
or	O
felt	O
to	O
be	O
life-threatening	O
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	O
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively).	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	O
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	O
or	O
naproxen;	O
77	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	O
were	O
treated	O
with	O
naproxen	O
7.5	O
mg/kg	O
twice	O
daily.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	O
treated	O
patients	O
were	O
headache,	O
fever	O
(pyrexia),	O
upper	O
abdominal	O
pain,	O
cough,	O
nas	B-C015378
opharyngitis,	O
abdominal	O
pain,	O
nausea,	O
arthralgia,	O
diarrhea	O
and	O
vomiting.	O
The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	O
patients	O
were	O
headache,	O
nausea,	O
vomiting,	O
fever,	O
upper	O
abdominal	O
pain,	O
diarrhea,	O
cough,	O
abdominal	O
pain,	O
and	O
dizziness	O
(Table	O
2).	O
Compared	O
with	O
naproxen,	O
celecoxib	O
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	O
and	O
development	O
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study.	O
There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	O
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.	O
In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	O
were	O
treated	O
with	O
celecoxib	O
6	O
mg/kg	O
twice	O
daily.	O
The	O
incidence	O
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged.	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	O
with	O
events)	O
*	O
Abnormal	O
laboratory	O
tests,	O
which	O
include:	O
Prolonged	O
activated	O
partial	O
thromboplastin	O
time,	O
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	O
phosphokinase	O
increased,	O
Blood	B-D001769
culture	O
positive,	O
Blood	B-D001769
glucose	O
increased,	O
Blood	B-D001769
pressure	O
increased,	O
Blood	B-D001769
uric	O
acid	O
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	O
decreased,	O
Liver	B-D008099
function	O
tests	O
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
All	O
Doses	O
Twice	O
Daily	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	O
pain	O
NOS	O
4	O
7	O
7	O
Abdominal	O
pain	O
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-D009304
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	O
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies	O
:	O
A	O
total	O
of	O
378	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies.	O
Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied.	O
The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies.	O
Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	O
were	O
treated	O
with	O
celecoxib	O
in	O
analgesia	O
and	O
dysmenorrhea	O
studies.	O
All	O
patients	O
in	O
post-oral	O
surgery	O
pain	O
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication.	O
Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	O
and	O
post-orthopedic	O
surgery	O
pain	O
studies.	O
The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	O
and	O
dysmenorrhea	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	O
studies.	O
The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	O
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	O
studies.	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
celecoxib	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
].	O
Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	O
than	O
in	O
the	O
arthritis	O
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	O
pre-marketing	O
controlled	O
arthritis	O
trials,	O
above).	O
The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	O
treated	O
with	O
celecoxib	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	O
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7%	O
Gastroesophageal	O
reflux	O
disease	O
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	O
taking	O
celecoxib,	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	O
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	O
system	O
disorders:	O
Cerebral	O
infarction	O
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	O
hemorrhage	O
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardia	B-D002299
c	O
disorders:	O
Angina	O
unstable,	O
aortic	O
valve	O
incompetence,	O
coronary	O
artery	O
atherosclerosis,	O
sinus	O
bradycardia,	O
ventricular	O
hypertrophy	O
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	O
Reproductive	O
system	O
and	O
breast	O
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	O
increased,	O
blood	O
sodium	O
increased,	O
blood	O
testosterone	O
decreased	O
Injury,	O
poisoning	O
and	O
procedural	O
c	O
omplications	O
:	O
Epicondylitis,	O
tendon	O
rupture	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
celecoxib.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular	O
:	O
Vasculitis	B-D014657
,	O
deep	O
venous	O
thrombosis	O
General:	O
Anaphylactoid	O
reaction,	O
angioedema	O
Liver	B-D008099
and	O
biliary	O
:	O
Liver	B-D008099
necrosis,	O
hepatitis,	O
jaundice,	O
hepatic	O
failure	O
Hemic	O
and	O
lymphatic	O
:	O
Agranulocytosis	B-D000380
,	O
aplastic	O
anemia,	O
pancytopenia,	O
leucopenia	O
Metabolic:	O
Hypoglycemia	B-D007003
,	O
hyponatremia	O
Nervous	O
:	O
Aseptic	O
meningitis,	O
ageusia,	O
anosmia,	O
fatal	O
intracranial	O
hemorrhage	O
Renal	O
:	O
Interstitial	O
nephritis	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)].	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Events	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning.	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.	O
(5.1)	O
DICLOFENAC	O
SODIUM	O
TOPICAL	O
SOLUTION	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery.	O
(4,	O
5.1)	O
NSAIDs,	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events.	O
(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	O
of	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity.	O
Discontinue	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	O
and	O
symptoms	O
of	O
liver	O
disease	O
develop	O
(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs.	O
Monitor	O
blood	O
pressure	O
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
heart	O
failure	O
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia.	O
Avoid	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	O
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
contraindicated	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma.	O
Monitor	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
aspirin	O
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
at	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	O
(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	O
in	O
patients	O
with	O
any	O
signs	O
or	O
lsymptoms	O
of	O
anemia	O
(5.11,	O
7)	O
Exposure	O
to	O
light:	O
Avoid	O
exposure	O
of	O
treated	O
knee(s)	O
to	O
natural	O
or	O
artificial	O
sunlight.	O
(5.14)	O
Eye	B-D005123
Contact:	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
with	O
eyes	O
and	O
mucosa.	O
(5.15)	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs:	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs.	O
(5.16)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	O
trials	O
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
(MI)	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	O
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs.	O
The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
for	O
CV	O
disease.	O
However,	O
patients	O
with	O
known	O
CV	O
disease	O
or	O
risk	O
factors	O
had	O
a	O
higher	O
absolute	O
incidence	O
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate.	O
Some	O
observational	O
studies	O
found	O
that	O
this	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	O
as	O
the	O
first	O
weeks	O
of	O
treatment.	O
The	O
increase	O
in	O
CV	O
thrombotic	O
risk	O
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
CV	O
event	O
in	O
NASAID-treated	O
patients,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Physicians	B-D010820
and	O
patients	O
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms.	O
Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.	O
There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	O
mitigates	O
the	O
increased	O
risk	O
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use.	O
The	O
concurrent	O
use	O
of	O
aspirin	O
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	O
increases	O
the	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)].	O
Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
clinical	O
trials	O
of	O
a	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	O
in	O
the	O
first	O
10	O
-	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	O
of	O
myocardial	O
infarction	O
and	O
stroke	O
[see	O
Contraindications	B-D000075202
(4)].	O
Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	O
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	O
of	O
reinfarction,	O
CV-related	O
death,	O
and	O
all-cause	O
mortality	O
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment.	O
In	O
this	O
same	O
cohort,	O
the	O
incidence	O
of	O
death	O
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	O
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients.	O
Although	O
the	O
absolute	O
rate	O
of	O
death	O
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	O
of	O
death	O
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up.	O
Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
patients	O
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
recurrent	O
CV	O
thrombotic	O
events.	O
If	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
used	O
in	O
patients	O
with	O
a	O
recent	O
MI,	O
monitor	O
patients	O
for	O
signs	O
of	O
cardiac	O
ischemia.	O
5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
esophagus,	O
stomach,	O
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	O
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	O
treated	O
with	O
NSAIDs.	O
Only	O
one	O
in	O
five	O
patients	O
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic.	O
Upper	O
GI	O
ulcers,	O
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	O
treated	O
for	O
3	O
-	O
6	O
months,	O
and	O
in	O
about	O
2	O
%-	O
4%	O
of	O
patients	O
treated	O
for	O
one	O
year.	O
However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk.	O
Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	O
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	O
without	O
these	O
risk	O
factors.	O
Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
GI	O
bleeding	O
in	O
patients	O
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	O
anticoagulants,	O
or	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	O
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	O
status.	O
Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients.	O
Additionally,	O
patients	O
with	O
advanced	O
liver	O
disease	O
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	O
for	O
GI	O
bleeding.	O
Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
patients:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration.	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time.	O
Avoid	O
use	O
in	O
patients	O
at	O
higher	O
risk	O
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
bleeding.	O
For	O
such	O
patients,	O
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs.	O
Remain	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
GI	O
ulceration	O
and	O
bleeding	O
during	O
NSAID	O
therapy.	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out.	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	O
for	O
cardiac	O
prophylaxis,	O
monitor	O
patients	O
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
5.3	O
Hepatotoxicity	O
In	O
clinical	O
trials,	O
of	O
oral	O
diclofenac-containing	O
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	O
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	O
at	O
some	O
time	O
during	O
diclofenac	O
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies).	O
In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	O
treated	O
with	O
oral	O
diclofenac	O
for	O
2-6	O
months,	O
patients	O
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	O
were	O
monitored	O
again	O
at	O
24	O
weeks.	O
Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	O
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients.	O
In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	O
of	O
borderline	O
(less	O
than	O
3	O
times	O
the	O
ULN),	O
moderate	O
(3-8	O
times	O
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	O
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	O
receiving	O
diclofenac	O
when	O
compared	O
to	O
other	O
NSAIDs.	O
Elevations	O
in	O
transaminases	O
were	O
seen	O
more	O
frequently	O
in	O
patients	O
with	O
osteoarthritis	O
than	O
in	O
those	O
with	O
rheumatoid	O
arthritis.	O
Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	O
were	O
detected	O
before	O
patients	O
became	O
symptomatic.	O
Abnormal	O
tests	O
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	O
in	O
42	O
of	O
the	O
51	O
patients	O
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.	O
In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	O
necrosis,	O
jaundice,	O
fulminant	O
hepatitis	O
with	O
and	O
without	O
jaundice,	O
and	O
liver	O
failure.	O
Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	O
transplantation.	O
In	O
a	O
Europe	B-D005060
an	O
retrospective	O
population-based,	O
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	O
associated	O
drug-induced	O
liver	O
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	O
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	O
ratio	O
of	O
liver	O
injury.	O
In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	O
number	O
of	O
10	O
cases	O
of	O
liver	O
injury	O
associated	O
with	O
diclofenac,	O
the	O
adjusted	O
odds	O
ratio	O
increased	O
further	O
with	O
female	O
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
then	O
90	O
days.	O
Physicians	B-D010820
should	O
measure	O
transaminases	O
at	O
baseline	O
and	O
periodically	O
in	O
patients	O
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms.	O
The	O
optimum	O
times	O
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known.	O
Based	O
on	O
clinical	O
trial	O
data	O
and	O
postmarketing	O
experiences,	O
transaminases	O
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac.	O
However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	O
during	O
treatment	O
with	O
diclofenac.	O
If	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
abdominal	O
pain,	O
diarrhea,	O
dark	O
urine,	O
etc.),	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
should	O
be	O
discontinued	O
immediately.	O
Inform	O
patients	O
of	O
the	O
warning	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	O
fatigue,	O
lethargy,	O
diarrhea,	O
pruritus,	O
jaundice,	O
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms).	O
If	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
liver	O
disease	O
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	O
rash,	O
etc.),	O
discontinue	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient.	O
To	O
minimize	O
the	O
potential	O
risk	O
for	O
an	O
adverse	O
liver-related	O
event	O
in	O
patients	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible.	O
Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	O
antibiotics,	O
antiepileptics).	O
5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
,	O
can	O
lead	O
to	O
new	O
onset	O
of	O
hypertension,	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	O
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
CV	O
events.	O
Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	O
or	O
loop	O
diuretics	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Monitor	O
blood	O
pressure	O
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.	O
5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	O
for	O
heart	O
failure	O
in	O
COX-2	O
selective-treated	O
patients	O
and	O
nonselective	O
NSAID-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients.	O
In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	O
with	O
heart	O
failure,	O
NSAID	O
use	O
increased	O
the	O
risk	O
of	O
MI,	O
hospitalization	O
for	O
heart	O
failure,	O
and	O
death.	O
Additionally,	O
fluid	O
retention	O
and	O
edema	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
NSAIDs.	O
Use	O
of	O
diclofenac	O
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	O
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
patients	O
with	O
severe	O
heart	O
failure	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
heart	O
failure.	O
If	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
used	O
in	O
patients	O
with	O
severe	O
heart	O
failure,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
heart	O
failure.	O
5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	O
and	O
other	O
renal	O
injury.	O
Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	O
in	O
whom	O
renal	O
prostaglandins	O
have	O
a	O
compensatory	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
perfusion.	O
In	O
these	O
patients,	O
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	O
and,	O
secondarily,	O
in	O
renal	O
blood	O
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation.	O
Patients	B-D010361
at	O
greatest	O
risk	O
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	O
hypovolemia,	O
heart	O
failure,	O
liver	O
dysfunction,	O
those	O
taking	O
diuretics	O
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly.	O
Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state.	O
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
patients	O
with	O
advanced	O
renal	O
disease.	O
The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	O
with	O
preexisting	O
renal	O
disease.	O
Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	O
prior	O
to	O
initiating	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
.	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	O
failure,	O
dehydration,	O
or	O
hypovolemia	O
during	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	O
of	O
worsening	O
renal	O
function.	O
If	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
used	O
in	O
patients	O
with	O
advanced	O
renal	O
disease,	O
monitor	O
patients	O
for	O
signs	O
of	O
worsening	O
renal	O
function.	O
Hyperkalemia	B-D006947
Increases	O
in	O
serum	O
potassium	O
concentration,	O
including	O
hyperkalemia,	O
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	O
without	O
renal	O
impairment.	O
In	O
patients	O
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state.	O
5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	O
with	O
and	O
without	O
known	O
hypersensitivity	O
to	O
diclofenac	O
and	O
in	O
patients	O
with	O
aspirin-sensitive	O
asthma	O
(see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)].	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs.	O
5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	O
with	O
asthma	O
may	O
have	O
aspirin-sensitive	O
asthma	O
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nas	B-C015378
al	O
polyps;	O
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	O
and	O
other	O
NSAIDs.	O
Because	O
cross-reactivity	O
between	O
aspirin	O
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	O
patients,	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
contraindicated	O
in	O
patients	O
with	O
this	O
form	O
of	O
aspirin	O
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)].	O
When	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
used	O
in	O
patients	O
with	O
preexisting	O
asthma	O
(without	O
known	O
aspirin	O
sensitivity),	O
monitor	O
patients	O
for	O
changes	O
in	O
the	O
signs	O
and	O
symptoms	O
of	O
asthma.	O
5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	O
can	O
cause	O
serious	O
skin	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	O
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal.	O
These	O
serious	O
events	O
may	O
occur	O
without	O
warning.	O
Inform	O
patients	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
skin	O
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
at	O
the	O
first	O
appearance	O
of	O
skin	O
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity.	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
is	O
contraindicated	O
in	O
patients	O
with	O
previous	O
serious	O
skin	O
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)].Do	O
not	O
apply	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
to	O
open	O
skin	O
wounds,	O
infections,	O
inflammations,	O
or	O
exfoliative	O
dermatitis,	O
as	O
it	O
may	O
affect	O
absorption	O
and	O
tolerability	O
of	O
the	O
drug.	O
5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	O
closure	O
of	O
the	O
fetal	O
ductus	O
arteriosus.	O
Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
,	O
in	O
pregnant	O
women	O
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)].	O
5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients.	O
This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	O
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis.	O
If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	O
monitor	O
hemoglobin	O
or	O
hematocrit.	O
NSAIDs,	O
including	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
events.	O
Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	O
other	O
anticoagulants,	O
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk.	O
Monitor	O
these	O
patients	O
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)].	O
The	O
effects	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	O
subjects	O
administered	O
80	O
drops	O
four	O
times	O
a	O
day	O
for	O
7	O
days.	O
There	O
was	O
no	O
significant	O
change	O
in	O
platelet	O
aggregation	O
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)].	O
5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
reducing	O
inflammation,	O
and	O
possibly	O
fever,	O
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections.	O
5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	O
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	O
profile	O
periodically	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)].	O
5.14	O
Sun	O
Exposure	O
Instruct	O
patients	O
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	O
sunlight	O
on	O
treated	O
knee(s)	O
because	O
studies	O
in	O
animals	O
indicated	O
topical	O
diclofenac	O
treatment	O
resulted	O
in	O
an	O
earlier	O
onset	O
of	O
ultraviolet	O
light-induced	O
skin	O
tumors.	O
The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
on	O
skin	O
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	O
are	O
not	O
known.	O
5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
with	O
eyes	O
and	O
mucosa.	O
Advise	O
patients	O
that	O
if	O
eye	O
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	O
with	O
water	O
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour.	O
5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	O
more	O
frequent	O
abnormal	O
creatinine,	O
urea	O
and	O
hemoglobin.	O
Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	O
and	O
conduct	O
periodic	O
laboratory	O
evaluations.	O
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
are	O
application	O
site	O
reactions.	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Teligent	O
Pharma,	O
Inc.	O
at	O
1-856-697-1441	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
of	O
911	O
patients	O
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	O
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	O
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	O
treated	O
for	O
at	O
least	O
12	O
months.	O
The	O
population	O
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	O
were	O
Caucasians,	O
64%	O
were	O
females,	O
and	O
all	O
patients	O
had	O
primary	O
osteoarthritis.	O
The	O
most	O
common	O
adverse	O
events	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
were	O
application	O
site	O
skin	O
reactions.	O
These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies.	O
Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
patients	O
receiving	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
were	O
application	O
site	O
skin	O
reactions.	O
Application	O
site	O
reactions	O
were	O
characterized	O
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	O
induration,	O
vesicles,	O
paresthesia,	O
pruritus,	O
vasodilation,	O
acne,	O
and	O
urticaria.	O
The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	O
(32%),	O
contact	O
dermatitis	O
characterized	O
by	O
skin	O
erythema	O
and	O
induration	O
(9%),	O
contact	O
dermatitis	O
with	O
vesicles	O
(2%)	O
and	O
pruritus	O
(4%).	O
In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	O
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
and	O
oral	O
diclofenac.	O
In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	O
study,	O
contact	O
dermatitis	O
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	O
with	O
vesicles	O
in	O
10%	O
of	O
patients,	O
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	O
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%.	O
Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	O
dyspepsia,	O
nausea,	O
flatulence,	O
abdominal	O
pain,	O
edema;	O
see	O
Table	O
1	O
).	O
The	O
combination	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
and	O
oral	O
diclofenac,	O
compared	O
to	O
oral	O
diclofenac	O
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	O
(3%	O
vs.	O
less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	O
(12%	O
vs.	O
7%),	O
urea	O
(20%	O
vs.	O
12%),	O
and	O
hemoglobin	O
(13%	O
vs.	O
9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	O
transaminases.	O
Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
receiving	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
,	O
where	O
the	O
rate	O
in	O
the	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	O
with	O
osteoarthritis.	O
Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence.	O
Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	O
trials.	O
†Preferred	O
Term	O
according	O
to	O
COSTART	O
Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
N=911	O
Topical	O
Placebo	O
N=332	O
Adverse	O
Reaction†	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-US	O
postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
.	O
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure.	O
Body	O
as	O
a	O
Whole:	O
abdominal	O
pain,	O
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	O
back	O
pain,	O
body	O
odor,	O
chest	O
pain,	O
edema,	O
face	O
edema,	O
halitosis,	O
headache,	O
lack	O
of	O
drug	O
effect,	O
neck	O
rigidity,	O
pain	O
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	O
dry	O
mouth,	O
dyspepsia,	O
gastroenteritis,	O
decreased	O
appetite,	O
mouth	O
ulceration,	O
nausea,	O
rectal	O
hemorrhage,	O
ulcerative	O
stomatitis	O
Metabolic	O
and	O
Nutritional:	O
creatinine	O
increased	O
Musculoskeletal:	O
leg	O
cramps,	O
myalgia	O
Nervous:	O
depression,	O
dizziness,	O
drowsiness,	O
lethargy,	O
paresthesia,	O
paresthesia	O
at	O
application	O
site	O
Respiratory:	O
asthma,	O
dyspnea,	O
laryngismus,	O
laryngitis,	O
pharyngitis	O
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	O
contact	O
dermatitis	O
with	O
vesicles,	O
dry	O
skin,	O
pruritus,	O
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	O
rash,	O
pruritus,	O
skin	O
discoloration,	O
urticaria	O
Special	O
Senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	O
ear	O
pain,	O
eye	O
disorder,	O
eye	O
pain,	O
taste	O
perversion	O
WARNING:	O
RISK	O
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	O
infarction	O
and	O
stroke,	O
which	O
can	O
be	O
fatal.	O
This	O
risk	O
may	O
occur	O
early	O
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS).	O
Diclofenac	B-D004008
sodium	O
delayed-release	O
tablets	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	O
artery	O
bypass	O
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	O
WARNINGS).	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	O
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	O
and	O
perforation	O
of	O
the	O
stomach	O
or	O
intestines,	O
which	O
can	O
be	O
fatal.	O
These	O
events	O
can	O
occur	O
at	O
any	O
time	O
during	O
use	O
and	O
without	O
warning	O
symptoms.	O
Elderly	O
patients	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
peptic	O
ulcer	O
disease	O
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	O
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS).	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
